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1038-9 The Serial intravascular Ultrasound Findings of a New 
Biodegradable Self-Expanding Coronary Stents 
Hldenori Komori, Hide@ Tamai, Keiji Igaki, Eisho Kyo, Kunihiko Kosuga, Tatsuhiko Hata, 
Masaharu Okada, Takuji Nakamura, Takafumi Tsuji, Shlnsaku Take&, Seiichiro 
Motohara, Hiromu Uehata. Shiga Medical Center for Adults, Moriyama, Japan 
Background: The Igaki-Tamai stent is made of poly-I -lactic acid (PLLA) monopolymer 
with self-expanding ability. We reported the safety and efficacy of the Igakl-Tamai stent, 
clinically and anglographically. This is the report of serial mtravascular ultrasound (IVUS) 
findings comparing the Igaki-Tamai stent wth the Radius (self-expanding metallic) stent 
I” human coronary arteries. Methods: IVUS studies were performed immediately after, at 
3 months, 6 months and 12 months using 30MHz IVUS catheter (SCIMED Co.Ltd,) with 
O.Smm/sec motorized pullback. Thirty lesions of the Igaki-Tamai stent and 7 lesions of 
the Radius stent were compared. To evaluate the self-expanding ability of the stents and 
their influence on neointiomal proliferation, we measured the Imean stent cross-sectional 
area (ST-CSA), the mean lumen cross-sectional area (LM-CSA) and the neointimal area 
(NA). Results: The results were shown in the table (*:p<O.O5 compared with immediately 
after, **:p<O.O5 compared with Smonths).ST-CSA was significant greater at 3 months 
than immediately after stents implantation in both stents. Although the Igakl-Tamai stent 
did not expand beyond 3 months. the Radius stent expanded gradually up to 12 months 
NA did not increase in the Igaki-Tamai .stent beyond 6 months,but in the Radius stent it 
tended to proliferate (P=O.O9) fill 12 months. Finally LM-GSA in the Igaki-Tamai stent did 
not decrese beyond 3 months,rather it tended to incease after 6 months(P=O.O8).LM- 
CSA in the Radius stent increased till 12 months. Conclusions: This study suggest that 
the strength of self-expansion of the igaki-Tamai stent weakened beyond 3 monthslt 
might be caused of the degradation of the stent. 
ST-CSA(mmA2) 
IGAKI-TAMAI 
Radius 
NA(mm’2) 
IGAKI-TAMAI 
Radius 
LM-CSA(mmA2) 
IGAKI-TAMAI 
Radius 
POST 3months Gmonths 12months 
7.61+2.85 8.76’&44 8.86e2.60 9.12t2 10 
9 4221.47 10.75’+2.52 11.59**+2 64 12.59”*2.92 
2.33*&65 2.63***2.70 2.51t2.60 
2.38**1 .Ol 2.57+0.55 3.27i1.27 
7.6152.85 6.43*t0.92 6.2420.96 6.61+0.99 
9.4221.47 8.37*&i .89 9.02*2.24 9.32**+2.03 
1038-10 Temporal Effects on Arterial Repair of a Sustained Release 
Formulation of Sirolimus Eluting From a Stent 
Andrew J. Carter, Gregory Kopia, Lynn R. Bailey, Ronald Kolata, Julianne Meister, 
Takeshl Suzuki, Gerard Llanos, Pallassana Narayan, George Papandreou, Robert 
Falotico, Fermin Tio. Sfanford University Medica/ Center, Stanford. CA, University Texas 
San Antonio, San Antonio. TX 
Background: Sirolimus (SIR), a potent ceil-cycle inhibitor and immunosuppressive agent. 
is a promising therapy for the prevention of restenosis. The objective of this study was to 
determine the temporal effects of a sustained release formulation of SIR delivered via a 
stent on arterial rapa~i. Methods: Eighteen mm long stainless steel balloon expandable 
tubular stents (BX Velocity? Cordis, Co.) were coated with a thin layer oi a synthetic 
non-erodable polymer matrix containing 155 mcg (2 2.5%) of SIR and modified to pro- 
long drug release. Thirty-nine stents (metal, n = 19; SIR, n = 20) were implanted at a 
steni to artery ratio of approximately 1.3 to 1 in the coronary arteries of 14 mini-swine. 
After 3 days (metal, n = 10; SIR, n = 10) or 28 days (metal, n = 9; SIR, n = IO), histologl- 
cal analysis of the stented coronary arteries was completed to determine effects on vas- 
cular healing. Results: At 3 days, the neointima was composed of fibrin and platelets with 
rare SMC for both the metal and SIR stents. The neointimal area was similar for the 
metal (0.38 + 0.19 mm2) and SIR stents (0.29 i 0.09 mm2, p = 0.19). The acute inflam- 
mation score was also similar for the metal (1.1 -t 0.2) and the SIR stents (1 .l i 0.1. p = 
0.74). After 28 days, the neointima contained SMC and was substantially less for the SIR 
(1.40 f 0.35 mm2) as compared with the metal stents (2.94 -t 1.28 mm2, p = 0.0019), 
resulting in a 50% reduction of % in-stent stenosis. Chronic inflammation scores were 
low for both the metal (0.1 2 0.3) and the SIR stents (0.3 ? 0.3, p = 0.31). Conclusion: 
The sustained release of sirolimus via a novel non-erodable polymer coated stent pro- 
foundly reduces late in-stent neointimal hyperplasia without adversely impacting early 
reparative events such as f~brinlplatelet deposition. 
1038-l 1 A Platelet Glycoprotein llblllla Receptor Blocker-Coated 
Stent Inhibits Porcine Coronary Stent Thrombosis and 
Restenosis 
Myung Ho Jeong, Kyung Tae Kang, Young Keun Ahn, Jeong Gwan Cho, Jong Chun 
Park, Jung Chaee Kang. Chonnam National University Hospitai, Kwang Ju, South Korea 
A platelet GP Ilb/llla receptor blocker IS known to be effective in the prevention of acute 
thrombosis and restenosis after percutaneous coronary intervention. ReoPro, a platelet 
GP llbillla receptor blocker, was coated on the surface of stem by the method of plasma 
polymerization. Stent overdilation injury was performed with ReoPro-coated stents 
(Group I, n=14), and control bare stents (Group II, n=13). Follow-up quantitative coronary 
angiogram was performed at 4 weeks after stenting and histopathologic assessments 
were compared in both groups. Diameter stenosis measured by QCA was lower in Group 
I than in II (15+/-7% vs. 23+/-5%, P=O.O03). On histopathologic examination, no in-stent 
thrombosis observed. Injury score was not different between two groups. The percent 
area stenosis was significantly higher in Group II (30.5+/-16% vs. 48.1+/-17%, P=O.Ol). 
The area of neolntima was larger in Group II (2.02+/-i.Omm2 vs. 3.29+/-1.2mm2, 
P=O.Oi). The ratio of neointlmaimedia was lower in Group I than in II (0.82+1-O 4 vs. 
1.35+/-0.7, P=O.O2). By wnmunocytochemistry, PCNA index was higher in Group II 
(2.48+/-1.8% vs. 4.22+/-2.1%, P=O.O3). The platelet GP llbillla receptor blocker-coated 
stent is effective to prevent stent thrombosis and neointimal cell proliferation within the 
stent in a porcine stent restenosis model. 
1038-12 VEGF-Eluting Stents Stimulate Endothelial Cell Growth In 
Vitro 
Neil Swanson, Kai Hogrefe, Qamar Javed, Michael A. Azrin, Anthony Gershiick. 
University of Leicesfer; Leicesteer, United Kingdom. University of Connecticut Health 
Centeer; Farmington, CT 
Background: 
Vascular endot- 
helial growth 
factor (VEGF) is 
El” angiogenic 
growth factor 
with high speci- 
ficity for endot- 
helial cells. 
Coronary stent 
use IS still beset 
by the complica- 
tions of throm- 
bosis and, 
particularly, in- 
stent restenosis. 
These compli- 
cations are 
partly due to the 
lack of an endothelial covering over the stents early on after delivery. Methods. Cook 
hydrocarbon polymer coated stents were immersed in 2mgiml VEGF solutions for 48 
hours. The adsorption on the stents was measured by radlalabeling the VEGF. The eiu- 
tion of VEGF from the stents was measured over nine days in a perfusion circuit. Non- 
radiolabelled VEGF was used to coat sterile stents that were then co-cultured wth 
Human Umbilical Vein Endothelial Ceils (HUVECs). One group of stents was washed 
with culture medium for 24 hours prior to HUVEC culture (washed stents). The effects of 
these stents was compared to control, albumin-coated (BSA), stents. HUVEC growth 
was determined wth a PMSIMTS assay depending on mitochondrial activity in the cells 
Results: Adsorption to the stents followed by perfusion demonstrated prolonged eiution 
with persistence of 20% even at 9 daysThe HUVECs cultured with VEGF-coated stents 
showed an 11% increase in growth compared to controls (p<O.OOl). Washed stents 
showed a 10% increase in growth over controls (p=O.O04)(see graph). Conclusions, 
VEGF-eluting, polymer-coated stents will release VEGF gradually over many days. 
Stents are easily loaded and, despite sterilisation of the stents or prior perfusion for 24 
hours. stimulated endothelial growth was .sean around them in vitro. In summary, the 
VEGF stent shows both favourable pharmacokinetics and effectiveness on target cell 
growth in vitro. In viva this effect would speed the re-endothelialisation process and may 
reduce the incidence of stent thrombosis or restenosis. 
1038-13 Stent-Based Delivery is Associated With Marked Spatial 
Variations in Drug Distribution 
Chao-Wei Hwang, David Wu, Elazer R. Edelman.~assachuseft lnsiifufe of Technology 
Cambridge, MA, Brigham and Worn&k Hospital, Boston, MA 
BACKGROUND & METHODS: Proliferative vascular diseases pose an excellent model 
to study issues of local delivery, transport. and biological effect. We therefore sought to 
examine the limitations to drug efficacy imposed by local pharmacokinetics with a quanti- 
tative multidimensional model of stent-based local delivery. We experimentally validated 
our theoretical results by implantmg a fluorescein coated stent into a calf carotid artery ex 
viva and imaging the distribution of fluoresceln in the carotid wall at steady-state. 
RESULTS: We found that stent-based local delivery leads invariably to large concentra- 
tion gradients at steady-state, where drug concentrations range from nearly nil to several 
times the mean tissue concentration over a few microns. These concentration variations 
were a function of the PBclet number, the ratio of convective to diffusive forces, such that 
the overall drug distribution was most uniform within a narrow range around Pe = IO, and 
was increasingly heterogeneous at extremes of this parameter. Uniform versus non-uni- 
form stent expansion was found to signifmntly enhance drug distribution without chang- 
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ing mean tissue concentration Proximity of the coated stent to the tissue alone does not 
ensure adequate targeting. CONCLUSION: As local concentrations and concentration 
gradients are inextricably linked to biological effect, our results provide a potential expla- 
nation for the variable success of stent-based delivery, and demonstrate the importance 
of considering physiological transport forces and drug physicochemical properties in both 
the analysis of local delivery data and the design of local delivery systems. 
1038-14 Influence on Angiographic and Clinical Restenosis of a 
New Biodegradable Stent Coating Releasing Hirudin and 
the Prostacyciin Analogue lloprost 
Josef Dirschinger, Adnan Kastrati, Julinda Mehilli, Franz-Josef Neumann, Helmut 
SchOhlen, Albert Schiimig. Deutsches Herzzentrum, Munich, Germany 1. Med. Klinik 
rechts der lsar der TU MOnchen, Munich, Germany 
Background: A new biodegradable stent coating (BSC+) with a polylactic acid polymer 
releasing hirudin and the prostacyclin analogue iloprost has been shown to inhibit neoin- 
tima formation in 2 animal models (Circulation March 2000). In a pilot trial, we investi- 
gated whether these favorable experimental findings are also valid in the clinical settings. 
Methods: The data from the arm of a recent randomized trial (Circulation May 2000) 
treated with an identical stent type, but without biodegradable coating (BSC-) are shown 
as a control (418 lesions1367 pts). The stent type used for both BSC+ and BSC- groups 
was the gold-plated Inflow stent. The BSC+ group comprised 49 coronary lesions of 35 
consecutive pts with acute or stable coronary syndromes treated with stenting. 
Results: We achieved a 80% reangiography rate at 6 months (42 lesions). Results are 
shown in the table. 
BSC+ BSC- 
Vessel size, mm 3.15*0.54 3.03*0.47 
Stented segment length, mm 20*12 .2&18 
Residual stenosis, % 4.8k6.4 2.3k7.1 
Subacute stem thrombosis, % 2.8 2.5 
Diameter stenosis (DS) at 6 months, % 528133.1 53.3+31.9 
&stenosis (250% DS) rate, % 50.0 49.7 
l-year death or MI, % 11.4 114 
1 -year death, MI or TVR, % 37.1 37.1 
Conclusion: The similar angiographic and clinical results between the BSC+ and BSC- 
groups suggest that the iavorable effect on neointima formation of the biodegradable 
layer releasing hirudin and iloprost which was observed in experiments may not be appli- 
cable to the clinical settings. 
1038-15 Preliminary Findings Using a PTFE-Coated Stent in Patients 
With Saphenous Vein Graft Disease 
Martin 6. Leon, R Strumpf, Maurice Buchbinder, Alexandra J. Lansky, Lowell F. Satler. 
Cardiovascular Research Foundation, New York, NY; Lenox Hi// Heart & Vascular 
Institute, New York, NY 
Background: The treatment of saphenous vein graft (SVG) lesions using conventional 
interventional modalities often results in procedural CK rises due to distal embolization 
and frequent late restenosis (RES). 
Methods & Results: The SYMBIOT (SYM) covered stent system is a self-expanding nit- 
inal stent (4.5-5.5 mm expanded diameter, 31 mm length) encapsulated within two layers 
of ultra-thin polytetrafluoroethylene (PTFE) which utilizes distal-to-proximal sheath 
retraction for deployment. To a?s??s safely and efficacy, SYM was implanted (after pra- 
dilatation) in 25 pts with SVG lesions; mean age-69 years, SVG age . 11.4 years, diabet- 
ics - 40%, CCS class Ill/IV - 64% lesion length 16.9mm, reference diameter - 3.9 mm, 
thrombus - 21%, and 50% diameter stenosis in only one SVG (total occlusion, ?thromo- 
botic). Overall, binary RES frequency was only 6.7%. 
Conclusions: In this Phase 1 registry, the use of the PTFE-covered SYM stent system 
in S/G lesions resulted in (1) high implantation succass, (2) infrequent embolization or 
CK rises (possibly exacerbated by the need for pre-dilatation), (3) occasional subacute 
thrombotic closure (perhaps suggesting the need for long-term thienopyridine therapy), 
and (4) rare late clinical or angiographic recurrence. These encouraging preliminary data 
justify a definitive clinical trial with an improved SYM device (additional smaller diame- 
ters, variable lengths, and improved tip profile for direct stenting) to establish the clinical 
benefit of PTFE-covered stent system in pts with complex SVG disease. 
1038-16 Stents Covered by Autologous Venous Grafts: Beneficial 
Effect in Patients With Acute Coronary Syndromes 
Konstantinos Toutouzas, Chrlstodoulos Stefanadis, Eleftherios Tsiamis, loannis 
Kallikazaros, Castas Stratos, Manolis Vavuranakis, Costas Tentolouris, Pavlos 
Toutouzas. Hippokration Hospital, Athens, Greece 
Previous studies with the autologous venous graft-covered stent (AVGCS) have shown 
favorable results. The aim of this study was to investigate the long-term outcome of this 
technique in human coronary arteries and to compare the long-term results with those of 
uncovered stews. Methods: Metallic conventional stents (Palmaz-SchatzTM and Multi- 
linkTM stents) were covered either completely or only externally by autologous venous 
grafts. Fifty-eight AVGCSs were implanted in 56 patients (pts), including 16 pts with 
acute coronary syndromes (ACS). Additionally, in 114 pts, 138 uncovered stents were 
implanted serving as a control group, including 38 pts with ACS. All pts were examined 
clinically or interviewed by telephone communication at a mean of 50.8 + 12.4 months in 
AVGCS group and 53.8 * 14.2 months in the control group. Results: The procedure was 
successful in all patients. Stent thrombosis was observed in 3 patients of the control 
group and in 1 patient with an AVGCS. The restenosis rate was 13.3% in covered stents 
vs 20.8% in uncovered stents (p=NS). The minimal lumen diameter had a trend to be 
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greater inthe AVGCS group at follow-up (2.22r0.9 vs 2.10i0.9 mm, p=O.O7). The target 
vessel revascularization rate was 14% in the AVGCS group vs 18.5% in the control 
group (p=NS). The event-free survival rate was 84% in the AVGCS vs 78% in the control 
group (p=NS). However, in pts with ACS the minimal luminal diameter was greater in the 
AVGCS group (2.56~0.7 vs 2.01+1 mm, ~~0.01). Also, the event-free survival was 91% 
in AVGCS group vs 74% (~~0.05) (figure). Conclusions: Stents covered by autologous 
venous grafts may be Implanted without late complications, which are related to the tech- 
nique. Thus, the application of this technique may be performed safely for several indica- 
tions. 
1038-17 Influence of Intermittent and Prolonged Administration of 
Methotrexate on Restenosis Rate and Neointimal Growing 
After lntracoronary Stent Treatment: The Methquita Project 
Jose Suarez de Lezo, Dolores Aumente, Antonio Torres, Alfonso Medina, Miguel 
Romero, Manuel Pan, Jose Segura, Jose L. Carrasco, Jose J. PerepBrez. Reina Sofia 
Hospital, Cordoba, Spain, Negrin Hospital. Las Palmaq Spain 
Background: The Methotrexate is a fo!ic-antagonist drug that inhibits the S phase of the 
cellular cycle. This drug has been proved to control the proliferation of a small cell-popu- 
lation and reduces the acute graft-versus-host disease in allogeneic hemopoietic progen- 
itor cells transplantation. In addition, the Methotrexate is a non mutagenic agent which its 
potential toxicity can be reversed with folinic acid. We postulated that a weekly adminis- 
trated low-dose of Methotrexate during a six- month period, could prevent restenosis 
after intracoronary stent treatment. Methods: We designed a prospective, controlled, ran- 
domized and stratified study in 91 patients with single vessel native coronary dtsease 
who were electively treated with stent implantation. All of them were serially (baseline, 
post-stent and follow-up 6rl months later) evaluated by angiography and intracoronary 
ultrasound analysis. patients were randomized in a Z-to-1 fashion to control (group I 
n=61) and Methotrexate (group II n=30). The drug was administered intra- muscular at a 
loading dose of 15 mg/mZ of BSA starting 24 hours after stent implantation and contin- 
ued weekly’through a B-month period at a dose of 10 mglm2. A 24 hour curve of blood 
levels by immunofluorescence technique was obtained in all patients from group II follow- 
ing the first and the last doses. Patients were closely followed and toxicity requiring drug 
discontinuity was observed in 2 (7%). Angiographic restenosis (>50% stenosis) and 
ultrasonic neointimal growing constituted the main end points. Results: The table sum- 
marizes the main findings: 
Reference Initial Late Rest- Ultrasonic Ultrasonic 
vessel (mm) gain loss enosis thickening thickening 
(mm) (mm) rate (mm) (mm21 
Group I 3.2kO.5 2.3kO.5 l.Zr0.9 35% 0.5io.3 3.3il.9 
Group II 3.3tO.5 2.5*0.5 1.1~0.9 28% 0.4kO.3 3.6e2.5 
All differences were non-significant. Conclusion: These preliminary findings do not show 
significant influences of an intermittent and prolonged administration of Methotrexate on 
restenosis and neointimal growing after coronary stent treatment. 
1038-18 Hyperthermia of Arterial Stented Segments by Magnetic 
Force: A New Method to Eliminate lntimal Hyperplasia 
Christodoulos Stefanadis, Konstantinos Toutouzas, Eleftherios Tsiamis, Charalambos 
Vlachopoulos, Dorothea Tsekoura, Pavlos Toutouzas. Hippokration Hospital, Athens 
In vitro and in viva studies have shown that gentle heating eliminates the proliferation of 
smooth muscle ceils. In this study we evaluated the effect of hyperthermia by applying 
magnetic energy in stented segments. Methods: We applied an alternative magnetic field 
(frequency 20 MHz). An electric field from a geqerator is driven to an inductor and an 
alternating magnetic field is created that produces periodically reversing magnetic force 
on the metallic surface of the stent. The energy loss is presented on the metallic surface 
of stent as heat. By this method the stent is heated from a distance without affecting tis- 
sues and thus hyperthermia is induced in the stented arterial wall. Twelve wines were 
used. Metallic stents (MultilinkTM) was implanted in the LAD and immediately after heat 
was delivered by placing the inductor 5-cm above the anterior thoracic surface at the pre- 
caurdial region (heated group). The temperature of the stented segment was monitored 
by a thermography catheter that was designed in our institution. All stented segments 
were heated up to 45°C in a single session of 45 minutes. After the heating procedure, a 
stem (MultilinkTM) was implanted in the LCx artery of the animal (control group). The ani- 
mals were sacrificed after 4 weeks and histomorphometry was performed. Results: The 
procedure was performed successfully without any complication. The temperature of 
45°C was maintained at all stented segments of the heated group. Acute thrombosis was 
not observed by angiography. The maximal intimal thickness was less in the heated 
group compared to the control group (91.3t31.6 vs 187.4~49.2, ~~0.05) and also the dif- 
ference in lumen area did not reach statistical significance (25.9c4.7 vs 22 1~4.7, 
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p=O.O6) Conclusions: External heating of metallic stents by an alternative magnetic field 
is feasible and it seems to have favorable results in intlmai proliferation. Further long- 
term studies to observe any technique-related complications are being performed. 
1038-I 9 improved Local Drug Delivery Using the ELUT Coronary 
Stent 
Huang Yanming, Qiang Bei Ping. Lan Wang, Ivan De Scheerder. Univers~fy Hospitals. 
Leuven, Belgium 
The ELUT stenl (Precision Cutting Systems, Kalken. Belgium) is a balloon expandable 
multicellular endovascuiar prothesis specially designed to allow higher local drug deliv- 
ery. The stent contains laser drilled holes in its metal backbone, taking care of sufficient 
remained radial strength and fatigue. The holes can be filled up with a drug with antlpro- 
liferative characteristics, The system can also be used for local gene delivery. The arm of 
this study was to evaluate the feasibility of loading this stent with methylprednisolone and 
to study the in-vitro drug release. Methods: ELUT stents and control stents were dip- 
coated with 10% (g/g) methylprednisolone impregnated in a polyfluoroalkoxyphosp- 
hazene polymer (PFM-P75). The stents were examined with SEM and in-vitro MP- 
release curves were performed using high-performance liquid chromatography. Results: 
Total methylprednisolone content of the ELUT stent was significantly increased com- 
pared to the control stents (823 + 21 vs 22 + 3 vg (p<O.OOl)). In the control stents, 20% 
of the MP was released after one hour and all MP was released within 48 hours. In the 
ELUT stents the MP-release was significantly prolonged. Twenty percent of the MP was 
released within 10 days and 80% of the MP was released wlthin 100 days. Conclusions: 
The ELUT stent allows significantly higher total drug amount loading and results in a pro- 
longed local drug release. This system could enable better fine tuning of stent mediated 
local drug delivery. 
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1039-20 pH and Lactate Imaging of Atherosclerotic Plaques; 
introducing a 3 F 360 Degree Side-Viewing Near Infrared 
Spectroscopic Catheter to Monitor Metabolic Activity of 
Atherosclerotic Plaque 
Tania Khan, Babs Soiler, Peter Melling. Mohammed Asif, Mohammad Madjid, Ward 
Casscells, Morteza Naghavi. Universify of Texas-Houston, Houston, TX, Unwers~ty of 
Massachusetts, Worchester. MA 
Background: Plaque hypoxia and lschemia have been 
identified for a long time. Activated macrophages. in par- 
,-, =J Y .(I i -jr 
titular those incubated with Ox-LDL, produce enormous 
amounts of lactate and reduce their environmental pH to 
acidic level. We have previously reported marked pH 
heterogeneity of human carotid endarterectomired ath- 
erosclerotic plaques with lower pH in areas with large 
lipid core. We further made similar observations in ath- 
erosclerotic lesions of Watanabe rabbit aorta, and aortic 
lesions of Apo E deficient mice. Hence we planned to develop an intravascular probe for 
measurement of plaque pH and lactate concentration. Methods: Near-infrared spectros- 
copy is one of the few available non-destructive techniques for in viva measurement of 
tissue pH. We have studied spectroscopic characteristics of lactate and pH in human 
carotid atherosclerotic plaques (reported elsewhere). Here we are reporting our first pro- 
totype of a near-infrared fiber optic catheter with the capability to measure reflectance 
spectra from the vessel wall. Results and Conclusion: The catheter is comprised of 39 
low OH polyimide-coated silica fibers stacked in a 1.5 meter length bundle which is 
divided into two groups of fibers. illuminating fibers (13) and receiving fibers (26). A gold- 
coated cone mirror assembly (width 0.5 mm) is placed at the end of the catheter and is 
attached to the fibers. It reflects near infrared light from Illuminating fibers to the side of 
the catheter and collects backscattered light from the vessel wall to the receiving fibers. 
We have developed a phantom model in which the catheter configurations have been 
identified from Monte Carlo calculations to optimize light penetration. The catheter has 
the capability to not only measure pH and lactate of plaque in a uni-axial dimension but 
with the help of speciailzed software also to Image lactate and pH distribution in the 
plaque 
1039-21 Identification of Lipid-Rich Aortic Atherosclerotic Plaques 
in Living Rabbits With a Near Infrared Spectroscopy 
Catheter 
Pedro R Moreno, S. Eric Ryan, David Hopkins, K-Raman Purushothaman, William E. 
Charash, William O’Connor, James E. Muller Umversity of Kentucky Lexingion, KY 
InfraUeDx, Cambridge, MA 
Background: Lipid-rich vulnerable plaques that precipitate acute coronary events can not 
be detected by current diagnostic methods. We have previously demonstrated that near- 
infrared spectroscopy (NIRS) can detect Ilpid-rich plaques in autopsy specimens from 
atherosclerotic rabbits and humans. In the present study, we tested the hypothesis that 
NIRS can be performed with a laser-driven catheter system to identrfy lipid-rich plaques, 
through blood, in living rabbrts with diet-induced atherosclerosis. Methods: Twenty-three 
New Zealand rabbits (1% cholesterol diet for 8 months) and 4 normal rabbits were stud- 
ied. Laser ilght in the near-I!+ wavelength range was delivered by a diode laser attached 
to a 1.5 mm fiberoptic catheter (MedVenture, KY). The catheter directed the light to the 
vessel wall with a 45.degree mirror located at the tip. Reflected photons were detected 
by a lead-sulfide sensor and the resultant signal was transmitted to a computer for analy- 
sis. With this system, NIRS could be performed in the aorta of each rabbit (20 set per 
scan) with brisk blood flow distal to the catheter. After euthanasia, a total of 369 speci- 
mens from each NIRS site were prepared and lipid areas quantified by computerized 
planimetry following H & E and trichrome staining. Histologic data on the 369 scans were 
provided to a chemometrician (DH) to perform a calibration. The spectral data samples 
were averaged into in 21 groups formed at 0.2 mm2 (lipid area) intervals to improve 
noise reduction, and a calibration was performed by partial least squares regression. 
Cross validation, in which each sample is removed and then separately reapplied to the 
calibration, was utilized to determine the legitimacy of the calibration. Results: NIRS 
identified lipid areas above and below 0.75 mm2 with a 78% sensitivity and a 75% speci- 
ficity for lipid-rich versus lipid-poor plaques. Conclusions: This intravascular, catheter 
based-NIRS system was able to differentlate lipid-rich from lipid-poor plaques, through 
blood, in the aorta of living rabbits. With further refinement of catheter design and reduc- 
tion in noise levels, this system may be useful to identify individual lipid-rich plaques in 
the coronary arteries of living patients. 
1039-22 Atherosclerotic Coronary Artery Expansion is Not Simply a 
Function of Percent Stenosis. Calcification, and Lipid Core 
Contribute to Positive Remodeling 
Allen P. Burke, Deena K. Weber, Frank D. Koiodgie, Eric Peterson, Renu Virmani. 
Armed Forces Institute of Pathology: Washington, DC 
Background: Arterial remodeling in atherosclerotic arteries affects iuminal patency, but 
morphologic correlates determining the degree and type of remodeling have not been 
studied extensively. Methods: We measured morphometrically arterial expansion (mea- 
sured IELlpredicted IEL based on references segments and tapering) of 1318 coronary 
segments from 36 hearts of patients dying with severe coronary atherosclerosis. All 
hearts were perfusion fixed, epicardial arteries sectioned at 3-5 mm intervals, and sec- 
tions stained for elastic, fibrous tissue, and calcified matrix. Arterial expansion was 
related to plaque morphology (fibroatheroma, thin-capped atheroma, intraplaque hemor- 
rhage, plaque rupture, healed plaque rupture, plaque erosion, and total occlusions) and 
morphometrically derived parameters of % luminal narrowing, % plaque calcification, % 
lipid core, medial thickness, and adventitial thickness. Results. Plaques with acute rup- 
ture and hemorrhage demonstrated arterial expansion greater than fibroatheromas 
(P<O.OOl), and total occiusions and plaque erosions demonstrated arterial contraction 
(negative remodeling, p=O.O02 vs. fibroatheromas). By multivariate analysis, indepen- 
dent of % luminal narrowing and other parameters measured, calcification (p<.OOOl) and 
lipid core (p=.OOi) were independently associated with plaque expansion at all ranges of 
% stenosis. Adventitial thickness was not associated w!th plaque expansion. Conclusion: 
Arterial expansion is a function of not solely of degree of luminal narrowing, but varies by 
plaque type and composition. Calcification and large lipid cure result in increased arterial 
remodelling. 
1039-23 First Prototype of a 4 French 180 Degree Side-Viewing 
infrared Fiber Optic Catheter for Thermal Imaging of 
Atherosclerotic Plaque 
Mortera Naghavi. Peter Melling, Khawar GUI, Mohammad Madjid, James T. Willerson, 
Ward Casscells. University of Texas-Houston, Houston, TX, Remspec Inc., Boston 
Background: Our group has discovered that inflamed vulnerable atherosclerotic plaques 
can be detected based on their increased temperature We have designed and built an 
infrared angio-thermography catheter for imaging the thermal characteristics of arterial 
walls. Previously, we have presented a 3 mm prototype of a forward-viewing infrared 
fiber optic catheter. Here we describe the first 4 French side-viewing catheter capable of 
imaging temperature of the vessel wall with a 180 degrees scope. Methods: The size of 
the catheter is 4 French for coronary application. Nineteen chalcogenide fibers, each 100 
nxcrons in diameter, are bundled hexagonally with a length of 1.5 meter. At the tip of the 
catheter, there is a 1 mm width wedge-shaped mirror assembly made of zinc selenide. It 
is transparent to infrared radiation and is placed in a way that reflects the temperature 
only from side of the catheter. A guide-wire lumen passes through the bundle. The fiber 
optic catheter is connected to a focal plane array cooled Infrared camera. The system 
has a thermal resolution of 0.01’ C and spatial resolution of 100 microns. A real-time 
image reconstruction software continuously records the linear images obtained through 
the Imm window and processes them into two-dimensional and virtual longitudinal color- 
coded thermographic images of the lumen Results: We have tested the catheter in our 
phantom model simulating blood vessels and hot plaques with continuous flow of nOrmal 
saline in a silicon tube on which multiple hot spots were created. The catheter success 
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tully detected temperature changes along the side of the tube as shown in picture below. 
Conclusion: Side-viewing thermography using 4 French infrared fiber optic bundle cathe- 
ter is feasible and can be used for thermal detection of vulnerable atherosclerotic 
plaques. 
1039-24 Significance of Cyclic Variation of Integrated Backscatter in 
Intravascular Ultrasound Radio-Frequency Signal Analysis 
for Coronary Atherosclerosis 
Nobuyukl Komiyama, Akio Oshima, Matthew L. Kolz, Brian Courtney, Paul G. Yock, 
Peter J. Fitzgerald. Chiba University Hospital, Chtba, Japan> Stanford University Medical 
Center, Stanford, CA 
Background: We already reported that integrated backscatter (16) in intravascular ultra- 
sound (IVUS) radio-frequency [RF) signal analysis is one of useful parameters to distin- 
guish among different histologic subtypes of coronary atherosclerosis. To evaluate the 
significance of IB variation during cardiac cycle in-viva setting, we used an in-vitro pulsa- 
tile perfusion model with a non-fixed coronary artery specimen and analyzed IB from ath- 
erosclerotic plaques. Methods: Ten specimens of human coronary arteries were 
resected from 8 transplant-recipient hearts with atherosclerotic disease. Each non-fixed 
vessel specimen was pulsatilely perfused in a heated (37 degrees Celsius) saline-bath 
system under the same condition of pulsatile frequency and pressure. A 30 MHz IVUS 
catheter was inserted into the vessel specimen. RF signals were continuously sampled 
throughout the pulse cycle from regions of interests (ROls) of non-calcified plaques, 
being monitored on an IVUS video screen, and digitized at 500 MHz in B-bit resolution. IB 
of each ROI was calculated off-line in all frames throughout the pulse cycle. We selected 
the following 2 groups of FiOls without significant changes of both distance from the 
IVUS catheter and angle to the ultrasonIc beam throughout the pulse cycle: Group FF 
consisted of 10 fibrofatty plaques with lower echodensity than adventitia and Group DF 
consisted of 10 dense fibrous plaques with equal or greater echodensity than adventitia 
on the IVUS video images. Change of IB in a pulse cycle was compared between the 2 
groups. Cyclic “aria& of IB (CVIB) was defined as the maximal change of IB in a pulse 
cycle. Results: IB of each ROI showed a cyclic variation following the perfusion pulse in 
both groups. CVIB was significantly greater in Group FF than Group DF (4.9 r 2.9 vs 2.0 
* 1.2 dB; p = 0.022). Conclusion: These preliminary results suggest that CVIB in IVUS 
RF signal analysis may be a new parameter to be used to discriminate among coronary 
atherosclerotic plaque subtypes. 
1039-25 Positive Arterial Remodeling is Associated With Increased 
Temperature of Atherosclerotic Plaques in Patients With 
Acute Coronary Syndromes 
Konstantinos Toutouzas, Christodoulos Stefanadis, Manolis Vavuranakis, Eleftherios 
Tsiamis, loannis Kallikazaros, Charalambos Vlachopoulos, Athanasios Trikas, Sofia 
Vaina, Dorothea Tsekoura, Pavlos Toutouzas. Hippokration Hospitaal, Athens, Greece 
Background: It has been shown, that patients with acute coronary syndromes have a 
positive remodeling of the atherosclerotic plaques. Additionally, an inflammatory process 
is involved in the pathogenesis of acute coronary syndromes, enhancing heat production. 
In this study intracoronary ultrasound was performed, tn order to assess the culprit 
lesions in effort angina and acute coronary syndroms and we correlated these findings 
with the temperature of the atherosclerotic plaque. Methods: We studied 12 coronary 
lesions of patients with acute coronary syndromes and 17 lesions of patients with stable 
angina. We measured lumen and external elastic membrane (EEM) areas at both target 
lesion and proximal reference sites by intracoronary ultrasound before intervention. The 
remodeling index was defined as the ratio of the EEM area at the lesion to that at the 
proximal site. Positive and negative remodeling were defined as indices of >1.05 and 
~0.95, respectively and plaque area as: EEM area-lumen area at the lesion. In addition, 
temperature difference (AT) between the culprit lesion and and the normal vessel wall 
was measured by a thermometer catheter that was developed in our institution. Results: 
There was no difference between the two groups in age, reference vessel size, and per- 
cent diameter stenosis. Positive remodeling was more frequent and AT was increased 
(0.82-+0.2 vs 0.08+0.02 oC) in patients with acute coronary syndromes. Additionally, 
there was a good correlation between remodeling index and AT in patients with acute 
coronary syndromes (P<O.OOl, r=0.68). Conclusions: The present study showed, that 
patients with acute coronary syndromes had extended remodeling and greater plaque 
area in the culprit lesions. The association, however, of remodeling index and plaque 
area with increased AT provides new insights about the involvement of inflammation in 
the pathogenesis of acute coronary syndromes. 
1039-26 Simultaneous Thermal and Morphology Mapping of the 
Coronary Arteries in Vivo. A New Method to Study the 
Atheromatic Plaque, by Means of a Special Catheter That 
Combines Intravascular Ultrasounds With Thermography 
Leonidas D. Diamantopoulos, Glenn Van Langenhove, David Folley, Marcel Van de 
Brand, Pim De Feyter, Patrick W. Serruys lnterventional CardiOlOQy Dept., 
THORAXCENTER, ROTTERDAM, The Netherlands 
Background: Atherosclerotic coronary arteries 
show temperature heterogeneity, which is 
detectable in viva However, plaque tempera- 
ture and morphology have not been reliably i*“mn(nrl 
correlated. Methods: A new catheter-based 
system was developed in our laboratory. This TOIP l,ynal 
system combines intravascular ultrasound and 
multi-point thermography at the same time and 
position. The 3.5F catheter uses 4 very accu- 
cz+:, -+ Connrtlv j ““““*‘“- /~I~ 
rate thermistors to study the temperature at 
3600 of the arterial wall, and an ultrasound 
scanning system for the simultaneous acquisi- 
tion of intravascular images. The catheter can easily be placed in the coronary arteries, 
based on the monorail system. The signals from the catheter are digitized and driven to a 
computer-based main unit, equipped with appropriate software, which is recording, ana- 
lyzing and plotting data. Both on-line and delayed study of the plaque characteristics are 
available The catheter can be easily attached to a retraction system for reliable puil- 
backs. As the catheter crosses the region of interest, the operator can view simulta- 
neously the temperature and morphology of the arterial wall. 2D plots and 30 re- 
constructions are automatically provided. We tested the safety of our system in 10 non- 
atherosclerotic rabbits, performing low-speed (0.5mmisec) retraction of the special cath- 
eter inside the descending aorta. Temperature and morphology data were easily 
obtained during a single pullback. After animal sacrifice, histology and microscopy axam- 
ination of the aorta revealed no endothelial wall damage. Conclusions: The multi-point 
thermal and morphology mapping of the Coronary Arteries in viva using our system IS a 
feasible and fast procedure. The advantage of this method is that it can give information 
concerning both temperature and morphology of the diseased arterial wall. 
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1040-28 The Safety of Abciximab Before Percutaneous Coronary 
Revascularization in Patients With Chronic Renal 
Insufficiency 
Patricia J. M. Best, Ryan Lennon, Henry H. Ting, Malcolm R. Bell, Charanjit S. Rihal, 
David R. Holmes, Jr., Peter B. Berger. Mayo Clinic, Rochester, MN 
Background: Patients (pts) with chronic renal insufficiency (CRI) patients have worse out- 
comes during and following percutaneous coronary interventions (PCI). Glycoprotein llbl 
llla antagonists reduce complications during PCI, but may increase bleeding, particularly 
in pts with CRI, due to associated platelet and coagulation abnormalities. CRI pts were 
excluded from randomised trials evaluating abciximab; there are few data about its safety 
in such pts. Methods: To determine the safety and efficacy of abciximab in pts with CRI, 
we analyzed all patients undergoing PCI at the Mayo Clinic since the availability of abcix- 
lmab (41958199). Major bleeding was defined (similar to TIMI criteria) as femoral, cere- 
brovascular, retroperitoneal or gastrointestinal bleeding, or a drop in hematocrit >15%, or 
need for transfusion due to bleeding. Minor bleeding was defined as a drop in hematocrit 
of >12% or documented hem&ma resulting in a prolonged hospital stay. Pts receiving 
abciximab were analyzed according to whether they had an estimated creatinine clear- 
ance z 70 ccimin (n=649), 50-69 ccimin (n=367) or ~50 ccimin (n=230), estimated by the 
Cockroft-Gault formula. Cox proportional hazards modeling was used to investigate an 
association between creatinine clearance and abciximab and death or myocardial infarc- 
tion. Results: There was no interaction between abciximab and creatinine clearance with 
death or myocardial infarction (risk ratio - 1.05, 95% confidence intervals [l.O,l.l], 
~~0.34). There was also no interaction between creatinine clearance, abciximab, and 
maior bleeding (odds ratio 1.1, [l.O,l.l], p&19), minor bleeding (odds ratio - 1.1, [l.O- 
1 .l], p=O.51), or any bleeding (odds ratio . 1 .l, [I .0-l .l], p=O.39). Conclusions: Abcix- 
imab does not significantly increase bleeding in pts with CRI more than in pts without 
CRI, nor does there appear to be an interaction between the risk reduction of ischemic 
complications and renal function. Abciximab is therefore likely to be beneficial in renal 
failure pts undergoing PCI as it is in pts without renal failure. 
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1040-29 Do Patients Who Proceed lmmediately to Coronary 
Intervention Following Diagnostic Catheterization Have 
Higher Complication Rates? 
E&U!&, Compared to the 
II cardiac system, the DFP 
cardiac system results in 
Sameer Mehta, Andres Hildago, April W. Simon, Lynn G. Tarkington, Salvatore Battagiia, 
Steven D. Culler, Edmund R. Becker. Cedars Medical Center, Miami, FL, Emory 
University Rollins School of Public Health, Atlanta, GA 
a mean dose reduction of ji m olll.“l~ml, ‘,d~-Lm 
31.0% (62.2+11.4 mGy/ I, 
min vs 42.9+19.3 mGy/min 8 c 
Background: Managed care, fiscal policres and patient preferences are changing practice 
patterns in cardiac catheterizatron labs (CCL) As a result, more patients who are admit- 
ted for diagnostic catheterizations (DC) proceed to percutaneous coronary intervention 
(PCI) during the same encounter (DC/PCI). The purpose of this abstract IS to compare 
acute events between elective PCI and DC/PC procedures. Methods. Between 1998 
and 1999, data from 71 CCL’s were collected on 47.880 consecutive patients who under- 
went an elective PCI. Compared to the DC/PC1 group, patients undergoing an elective 
PCI were significantly older (65.1 yrs vs. 63.4 yrs) and more likely to be female (37.7% 
vs. 34.8%). Results: The table reports the acute outcomes for the two groups. The PCI 
group had higher procedural success, less contrast use, less IABP use, and lower mor- 
tality. The two groups did not show a difference in the rates of abrupt closure, emergency 
CABG or ventricular dysrhythmras. Conclusions: Although both groups show high proce- 
dural success rates, patients undergorng DC/PC1 have higher acute complic,ations. 
respectively, p<0.0001) 
Thus corresponds to a 25. 
65% lower dose for EPTs 
of Ii-23cm, and 0.25% 
lower dose for EPTs of 23. 
30cm For an equivalent 
thickness level, the mean 
absolute dose saving IS 
about 19.3f12.3 (O-36.8) 
mGy/min, p<O.OOOl. 
Conclusion: The digital flat panel based cardrac system has the potential to significantly 
decrease the radiation risks linked to fluoroscopy in interventronal cardiovascular proce- 
dures for both patients and laboratory staff. 
DC/PC PCI Onlv o-Value 
Mortality 0.09% 0.04% 0.038 
IABP 1 .OO% 0.83% 0.054 
C0fltM.S Use 257.5 cc 212.4 cc <O.OOl 
SUCCSSS 94.1% 94.6% 0.027 
Patients 26,568 21,312 
1040-30 Women Do Have an Increased Risk of Contrast Media- 
Associated Nephrotoxicity After Coronary Angioplasty 
Christian Mulier, Gerd Biirkle, Heinz J. Buttner, Andre P Perruchoud, Helmut Roskamm. 
Medizimsche Universit~iskfinik, Base/, Switzerland. Hen Zentrum, Bad Krozingen, 
Germany 
Background: The administration of radiographic contrast agents remains an important 
cause of acute renal failure. Previous studies have failed to reveal independent risk fac- 
tors other than renal axsufficrency at baseline. 
Methods: In 1620 patients scheduled for electrve or emergency PTCA serum creatinine 
values were analyzed before as well as 24 and 48 hours after PTCA. An increase in 
serum creatlnine of at least 0.5 mgidl (44 ymol/l) was defined as contrast nephrotoxicity 
(CN). For multrvariate analysis, backward stepwrse logrstic regression analysis was 
used. 
Results: Besides baseline creattnine, female sex was an independent risk factor for CN. 
Age, diabetes mellrtus and contrast volume were no Independent risk factors. 
Multivariate Risk Factors for CN 
B P Odds Ratio (95% Cl) 
Female Sex 1.35 0.002 3.8 (1.8-9.0) 
Baseline Creatinrne 1.95 <0.001 7.0 (3.4-14.4)’ 
*for an increase in baseline creatinine of 1 .O mgldl (88ymol/l) 
The individual risk for CN (Prob (CN)) could be calculated using the followrng equations: 
Prob (CN) = 1 / (1 + e-r) z = -6.0 + 1.35’sex + 1.95?baseline creatinine, sex = O/l for 
menlwomen. 
Conclusions: Women do have an increased risk of contrast media-associated nephrotox- 
icity after coronary angioplasty. 
1040-31 Estimated Patient Dose Reduction in Interventional Cardiac 
Procedures Using a Flat Panel Digital Cardiac Imaging 
System 
Karim Benali, Lionel Desponds, Herve Blanc, Remy Klausz, Pascal Lumbroso. GE 
Medical Systems. BUC, France 
Background: Patient radiation dose received during cardiac interventional procedures 
can be considerable and cause local inturies such as skrn burns The potential carcino- 
genic effects should also be noted. Fully digital cardiovascular itmaging systems based 
on flat panel detector technology have recently been introduced. Since the radiation 
exposure is dependent on the x-ray system design and detector conversion efficiency, 
this study estimates the patient dose using a Digital Fiat Panel (DFP) cardiac system in 
comparison to a conventional Image Intensifier (II) based system. 
F&Shod% Fluoroscopic dose rates were measured on an amorphous silicon DFP car- 
diac system (Innova 2000, GE) and a conventional cardiac system with an II and pick-up 
tube (LC+, GE). Each device was set at an equivalent operating point (7OmGy/min maxi- 
mum skin dose rate). The nominal field of view of each device was 20cm and 22cm. 
respectively. The delivered dose (expressed as air-Kerma rate) was measured for each 
system using a lucrte phantom of varying Equivalent Patient Thickness (EPT) according 
to the actual drstribution of patient thicknesses recorded over 1081 cardiac acquisitions 
(756 diagnostic and 325 interventional). Patient doses for that adult population (BMI= 
26+6 kg/m*) were then estimated. 
1040-32 Reduction in Operator X-Ray Exposure Using a Digital Flat 
Panel Imaging System 
Larry Ong, Raef H. Hajj-Ali, Donna Marchant, Stephen Green, Stanley Katz. Norfh Shore 
University Hospital, Manhasset, NY 
Background: It has been shown that complex percutaneous coronary interventkxxs has 
led to increasing operator and patient X-ray exposure due to the prolonged fluoroscopy 
trme, highly angulated views and image magnification required. The imaging efficiency 
(Modulation Transfer Function) of conventional X-ray systems is limited by the analog 
image intensifier tube. A new imaging technology using a digital flat panel detector, elim- 
inating the image intensifier, has been shown to have a significantly higher MTF com- 
pared to conventional systems with the potential of towering the X-ray dose requrred to 
perform complex coronary interventions. We examined the reduction in X-ray exposure 
using a new digital flat panel imaging system (GE lnnova 2000) compared with a conven- 
tional image intensifier system (GE Advantax LC) in simulated coronary interventions 
with a human phantom and in preliminary clinical experience. 
Methods/Results: Initial phantom studies were performed with an ionization chamber 
placed lm from the phantom. Measurements were performed without shrelding in 6 
angulated views. Significant reduction in fluaroscopy (15?6(sd)mr/h versus 44+17mr/h. 
pc.005) and tine (150+57mr/h versus 399fl74mrih,p<.005)X-ray dose were found. 
Simulated PCI using the phantom with camera angle, fluoroscopy time and tine time 
from 10 consecutive PCI patients were periormed. A digital dosimeter was worn at waist 
level rn the primary operator position with upper and lower shields. Again approximately 
50% reduction in X-ray exposure was achieved with the digital flat panel system (1.28 
i0.7 mR/procedure vs.3.32?- 1.99, p=O.OOZ). Prelimrnary clinical experience reveals sim- 
ilar reductions (0.81 mRiprocedur.s n=6). 
Conclusion: The new digital flat panel X-ray imaging technology can significantly reduce 
X-ray exposure during coronary interventions compared to conventional systems. 
1040-33 Essential Reduction of Radiation Exposure to Operator and 
Staff During Cardiac Interventions by Analysis of Radiation 
Leakages and Improved Lead Shielding 
Eberhard Kuon, Moritz Schmitt, Johannes B. Dahm. Department of lntemal Medicine. 
C/WC Franconian Swifzerland, Ebermannstadt, Germany, Department of Interna! 
Medicine, Ernst-Moritz-Amdt-University, Greifswald, Germany 
Background: Radiatton exposure to patients and staff due to invasive coronary interven- 
tions is high. Methods: Prospectrvely, we analyzed various dose parameters of 330 con- 
secutive coronary procedures. Scatter-Entrance Skin Air Kerma to the operator (S- 
ESAK-0) during fluoroscopy was determined in all standard tube angulations at a 
Fiando-phantom as well as scatter isodosis lines of O”iO”-posterior-anterior angulation. 
Results: Optimized interventional technique provided patient’s dose area products (DAP) 
due to diagnostic catheterization and elective percutaneous transluminal coronary angio- 
plasty of 6.2 and 10.4 Gycn?, reaching 12.4 and 13.1 % of current publications, respec- 
trvely. Dependent on angulation, mean S-ESAK-0 during low-level flucroscopy 
amounted 166 . 2,421 @v/h. Total S-ESAK-0 per applicated DAP could be reduced by 
means of 0.5 and 1 .O mm over- and undercouch shielding from 4,705 to 677 and 277 
nSv par Gycm*, applicated to the patient, respectively. The closure of a hazardous radia- 
tion leakage up to 897 @v/h in operator’s gonadal height (80-105 cm), never described 
so far, was achieved insufficiently by a 1 .O mm lead undercouch-top, but completely by a 
new 1.0 mm lead-flap besides the table down to 47.5 nSv/Gycm*. Additionally. using 0.5 
mm lead apron, collar, glasses, foot switch shield and a 1.0 lead cover around patient’s 
thighs, the operator’s body (O-180 cm) received a mean S-ESAK-0 of 8.5, his forehead. 
eyes, thyreord, chest, gonads and hands 68.2, 1.2, 1.2, 1.2, 0.8 and 58.2 nSv/Gycm*, 
respectively. Conclusions: Improved interventional technique and lead protection contrib- 
utes to a new “state of the art” in invasive cardiology, essenttally reducing radiation haz- 
ard in the operator’s position to 0.87 % of S-ESAK-levels, calculated usual in modern 
catheterization laboratories. 
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1040-34 Percutaneous Interventions of Coronary Bypass Grafts 
Have Doubled Major Adverse Events 
Marco Roffi, Debabrata Mukherjee, Deepak L. Bhatt, Derek P. Chew, Khaled M. Ziada, 
Danielle M. Prosper, Stephen G. Ellis, Eric J. Topol. Cleveland Clinic Foundation, 
Cleveland, OH 
Background: Percutaneous coronary interventions (PCI) of bypass grafts are generally 
considered higher risk than interventions of native coronary arteries. However, data are 
limited because graft interventions are less common and have been frequently excluded 
from the trials. Methods: We performed a pooled analysis of the 30.day outcome of five 
large randomized clinical trials (EPIC, EPILOG, EPISTENT, IMPACT II, and PURSUIT) 
that included PCI of bypass grafts. Results: A total of 627 patients underwent PCI of a 
bypass graft and were compared with 13,158 patients undergoing PCI of native vessels. 
Patients undergoing PCI of a graft were older (mean 64.3r9.53 vs. 59.9+10.81 years), 
were more frequently male, and had higher incidence of hypercholesterolemia and 
hypertension (for all p<O.OOl). Additional baseline parameters are listed in the table. The 
“se of GP llbillla inhibitors was comparable (63.9 % for graft lesions vs. 64.5 % for native 
interventions, p=NS). Graft lesions were more frequently stented than native lesions 
(30.6 % vs. 25.3 "a, p=O.O03). 
Baseline Characteristics Grafts N = 627 Natives N = 13,158 P 
Diabetes 30.2 % 21 .7 % c 0.001 
History of stroke 4.0 % 1.6% 4 0.001 
History of CHF 11.8% 6.1 % < 0.001 
History of PVD 17.8 % 6.5 % c 0.001 
History of Ml 59.6 % 43.4 % < 0.001 
History of angina 92.3 % 80.0 % < 0.001 
At 30 days patients undergoing PCI of bypass grafts had higher mortality (2.1 % vs. 1.0 
%, see Kaplan-Meier curve) and higher incidence of MI (CKMB > 3x normal)(l3.1 % vs. 
7.7 %, P<O.OOl). 
Conclusions: Patients undergoing PCI of bypass grafts have a baseline high-risk profile. 
PCI in this population are associated with a doubling of major adverse outcomes at 30 
days. 
1040-35 Blood Transfusion After Percutaneous Coronary 
Interventions: A Potential Target for Quality Improvement 
Mauro Moscucci, David Share, Eva M. Kline-Rogers, Michael J. O’Donnell, Adam B. 
Greenbaum, William L. Meengs, Ann Maxwell-Eward, Anthony DeFranco, Kim A. Eagle, 
For The Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMCP). 
University of Michigan Health System, Ann Arbor, MI 
The reported incidence of blood transfusions (tx) following percutaneous coronary inter- 
ventions varies between 4% and 8%, but despite this relatively high frequency, them 
have been no large scale studies attempting to analyze transfusion practices following 
PCl’s. The objectives of our study were to identify predictors of tx following PCl’s, and to 
identify potential targets for decreasing their incidence. 
Methods. Data on 9,056 consecutive procedures from a large regional database were 
analyzed. independent predictors of tx were identified-using logistic regression. To evalu- 
ate the potential role of intra-procedure blood losses secondary to longer or more com- 
plex procedures, total fluoroscopy time during the procedure was used as marker of 
procedure duration. 
Results. In this large data set, the overall incidence of tx was 5.2% (range for 6 hospitals 
3.9%-E%, p<O.OOl ). Total fluoroscopy time, multiple procedures during the same hospi- 
talization. and post procedure administration of intravenous heparin were strong univari- 
ate predictors of tx requirement. After adjustment for comorbidities, total fluoroscopy 
time, multiple procedures and post procedure heparin remawed strong independent pre- 
dictors (Table). 
Variable Odds 95% c.i P 
ratio 
Baseline comorbidities Age > 80 years 1.8 1.3-2.5 <O.OOl 
Age 70-79 years 1.5 1.2-l .9 0.001 
Body weight (kg)* 0.83 0.7-0.8 <O.OOl 
Baseline Hb c 10 gidl 6.2 4.4-8.7 <O.OOi 
Female gender 1.5 1.2-l .9 <0.001 
Creatinrne 2 2 mg/dl 2.3 1.6-3.1 <O.OOl 
CHF 1.8 1.4-2.3 <O.OOl 
Presentation Acute Ml 2.5 1.9-3.3 <O.OOl 
Shock 3.4 2.4-4.9 <O.OOl 
Procedure variables Fluoroscopy time (>15 1.9 1.5-2.3 <O.OOl 
min, median) 
Multiple procedures 2.5 1.7-3.7 <O.OOl 
Post procedure heparin 1.7 1.3-2.1 <O.OOi 
llbillla receptor blocker 1.4 1.1-1.7 0.002 
x ucms rat10 per Iv “mt rncrease 
Conclusions. 1) Transfusions are a common complication of PCI. 2) Baseline clinical 
characteristics and procedure variables identify patients at higher risk of tx. 3) The 
observed relationship between procedure variables and tx requirement suggests that 
procedure related blood losses are an important factor in subsequent need of ix, and a 
potential target for quality improvement initiatives. 
1040-36 Prevention of Contrast Media-Associated Nephrotoxicity: 
Randomized Comparison of Two Hydration Regimens in 
1620 Patients Undergoing Elective or Emergency PTCA 
Christian Miiller, Gerd Biirkle, Heinz J. Biittner, Andre P Perruchoud, Helmut Roskamm. 
Medizinische UniversiUtsklinik, Base/, Switzerland, Herz-Zentrum, Bad Krozingen, 
Germany 
Background: The administration of radiographic contrast agents remains an important 
cause of hospital-acquired acute renal failure. Very little is known about effective preven- 
tive strategies. We hypothesized that isotonic hydration may be more effective than half- 
isotonic. 
Methods: Patients scheduled for elective or emergency PTCA were randomly assigned 
to receive isotonic (0.9 percent saline) or half-isotonic (0.45 percent saline plus 5 percent 
glucose) hydration. Serum creatinine values were analyzed before as well as 24 and 48 
hours after PTCA. An increase in serum creatinine concentration of at least 0.5 mgidl (44 
ymol/l) within 48 hours was defined as CN. Secondary endpoints were cardiac and 
peripheral vascular complications. 
Results: In patients undergoing elective procedures (n=656), the incidence of CN was 
significantly reduced with isotonic hydration to 0.6% versus 2.7% (p=O.OZ), whereas in 
patients undergoing emergency procedures (n=964) both regimens were equally effec- 
tive. Two predefined subgroups did benefit in particular from isotonic hydration: women 
(CN 1.0% versus 4.7%, p=O.OZ) and diabetics (CN 0% versus 4.7%, p=O.Ol). The inci- 
dence of cardiac and vascular complications was similar between the two hydration 
groups. 
Conclusions: In patients undergoing elective coronary angioplasty CN is significantly 
reduced with isotonic hydratron. 
POSTER SESSION 
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1041-37 Safety and Efficacy of High Pressure Retrograde Cardiac 
Venous Injection. Implications for Regional Myocardial 
Delivery 
Niall A. Herity, William Fearon, Bonnie L. Hiatt, Mehrdad Rezaee, Takeshi Suzukt, David 
P Lee, Alan C. Yeung, Andrew J. Carter, Peter J. Fitzgerald, Paul G. Yock.. Stanford 
University Medical Center, Stanford, CA 
Background: Percutaneous retrograde injection through selected cardiac veins is an 
emerging modality for local drug or gene delivery to the heart. Existing retroinfusion 
techniques employ an upper pressure limit for safety (peak typically 5 50 mmHg). The 
purpose of this study was to evaluate retrograde venous injection at substantially higher 
pressures in terms of safety and efficacy of myocardial penetration. Methods: In 8 
anesthetized pigs the anterior interventricular vein (AIV) was cannulated with a 7Fr bal- 
loon-tipped catheter. During balloon occlusion, repeated retrograde injections were per- 
formed at progressively increasing flow rates. The effects on tissue penetration by 
radiographic contrast (IO ml per injection) and AIV pressure (n=4) were recorded. 
Results: Radiographically visible myocardial penetration occurred at higher venous 
pressures than conventionally used (Table). No ECG changes, hypotension or venous 
perforations ensued. Conclusion: In this model, high pressure retrograde venous injec- 
tion enhanced myocardial penetration and was well tolerated by the heart. 
Radioqraphic penetration No radiographic penetration 
Number of injections 50 17 
Flow rate (mlimin) 19 (14.30) 19 (9-40) 
Peak AIV pressure (mmHg) 167 (120.181) 75 (46-l 30) 
Mea” AIV pressure (mmHg) 100 (75-l 15) 48 (27-65) 
Median (interquartile range). Pc0.0001 compared with no penetration 
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1041-38 Magnetic Resonance Imaging Assessment of Myocardial 
Drug Distribution Pattern Following lntrapericardial 
Administration 
John D. Gleason, Khanh f? Nguyen, Kraig V. Kissinger, Warren J. Manning, Richard L. 
Verrier. Beth lsrael Deaconess Medical Cenfer, Boston, MA, Massachusetts institute of 
Technology Cambridge, MA 
Background: Novel catheter-based techniques to access the 
Intact pericardial space have increased Interest in this approach 
to target therapy. The distribution of intrapericardially admlnis- 
tered agents may be impacted by the nonuniform distribution of 
oericardial fluid but remains to be studied. The ouroose of this 
study was to investigate myocardial distribution of an MRI con- 
trast agent administered intrapericardially. Methods: Access to the intact pericardiai 
space was gained by percutaneous approach through the right atrial appendage in three 
anesthetized pigs. Infusion catheter (0.038in OD) was advanced near the apex of the 
heart. Gadopentetate dimeglumine [Gd-DTPA] (5 ml, 0.5-M solution) was injected in two 
pigs but no drug in the third animal. The pigs were maintained alive for 3.5 hours. Then 
the heart was excised, the pewarzlium removed, and the heart surface washed with 
saline. The distribution of Gd-DTPA through the epicardial surface was studied by a 
series of short-axis Tl-weighted turbospin-echo images. The depth of contrast agent 
penetration in the right ventricular free wall and in the anterior, lateral and posterior ven- 
tricular myocardium was measured. Results: For animals receiving Gd-DTPA, a rela- 
tively uniform penetration of 3.3kO.2 mm (mean&EM) was found in all free-wall 
measured samples of the ventricles. No contrast enhancement was noted in the inter- 
ventricular septum. in non-Gd-DTPA control, there was no area of contrast enhance- 
ment. Conclusion: lntrapericardial drug administration results in relatively uniform agent 
distribution around the epicardial surfaces of the entire heart. Thus, adequate mixing and 
uniform penetration occur despite the nonuniform distribution of pericardial fluid within 
the sac. While penetration depth will differ with each agent, these results may provide a 
useful framework for understanding the potential actions of intrapericardial agents. 
1041-39 Characterization of ‘251-Recombinant Fibroblast Growth 
Factor 2 Retention and Distribution Following Direct 
lntramyocardial Injection 
Wendy A. Naimark, W. Michael Kavanaugh, Maria Palasis, Zhenguo Han, Susan 
Fischer, P. Michael Grossman, Robert J. Lederman. Boston Scientific Corporation, One 
Boston Scienbfic Place, MA, Unwersity of Michfgan Hea/fb System, Ann Arbor, MI 
Background: Endocardial injection of agents such as angiogenic proteins enable direct, 
localized delivery to compromised myocardial tissue. Understanding agent retention and 
distribution is necessary to develop an effective therapeutic delivery regime. In this study, 
a percutaneous endomyocardial injection catheter was used to deliver “51-rFGF2 (Chi- 
ran Corp.) as a function of injection volume. lntramyocardial deposition and systemic 
uptake of ‘251-recombinant fibroblast growth factor (“51-rFGF2) were examined. 
Methods: Eight pigs (38-43 kg)each received five endocardial injections of “Sl-rFGF2 
via a percutaneous endomyocardial injection catheter. The ammats were divided into two 
groups receiving either 5 x 100 h injections (Group I) or 5 x 20 h injections (Group II). The 
total delivery dose was kept constant at 50 kg of protein for all animals. immediately fol- 
lowing the procedure, animals were sacrificed and organs harvested. Gamma emission 
of “51-labeied rFGF2 was used to quantify protein deposition and systemic uptake. The 
raw data was corrected for catheter adsorption, tissue quenching, and protein-associated 
radioactivity (TCA precipitation). 
Results: Endocardial delivery resulted in 45 + 7% (100 h, 
Group II) and 39 i. 5% (20 h, Group I) retention of the deliv- 
ered dose. Protein deposition traversed the endo- and epicar- 
_. ..,.. /.,,./ 
dial layers. Systemic uptake following injection was 
i’l@ &ii 
distributed throughout the peripheral organs at relatively low 
levels ranging from 1 f 0.2% in spleen (20 h group) to 32 rt 9% in liver (100 h group) 
Conclusions: The overall efficiency of ‘“51-rFGF2 delwery was 42 t 4%; retention was 
not dependent on injection volume. DeposItion occurred well out to the epicardium dem- 
onstrating that a large zone of myocardium is accessible for treatment. Systemic uptake 
of ‘251-rFGF2 was detected in all organs at low levels, most significantly within the liver at 
the higher delivery volume. 
1041-40 Could Plasmid-Mediated Gene Transfer Into the 
Myocardium be Augmented by Left-Ventricular Guided 
Laser Myocardial Injury? 
Shmuel Fuchs, Richard Baffour, Bertrand Schwartz, Didier Branellec, Stephen E. 
Epstein, Ran Kornowski. Cardiovascular Research Institute, Washington, DC, Aventis- 
Gencel, Vitry S/Seine, France 
Background: Prior studies suggest a synergistic affect between mechanical myocardial 
injury and plasmid-based gene transfer. This could be due to enhanced plasmid uptake 
by injured myocardium. We examined whether catheter-based transendocardial laser- 
induced injury enhances transendocardial gene transfer and expression. 
Methods:This concept was tested in pigs in which myocardial ischemia was induced by 
coronary obstruction caused by an ameroid constrictor. Thirteen animals had transcath- 
eteritransendocardial injections of the plasmid containing the luciferase reporter gene. 
Injections (0.5 mg per animal, 50mg per injection site) were divided into 10 sites in the 
ischemic territory. Eight animals underwent prior transendocardial laser injury (2 Joule 
per pulse x 10 sites). In 5, the plasmid was injected between laser channels and in 3 
laser and gene delivery were applied at close proximity (~5 mm). injection sites were 
identified by co-injection of fluorescent beads and luciferase activity was measured at 3 
and 7 days. 
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Results: Luciferase levels I” non-transduced myocardium (background) were low (-100 
pg) but were markedly elevated (P&001), to Similar degrees, following gene injection 
alone or when dispersed between laser channels at day 3 (189.752199.730 vs. 
206,874i77,080 pg luciferase, p=NS), and at day 7 (295,808+142,211 vs. 
144,133?46,407 pg luclferase, p=NS). Similar results were found when plasmid was 
injected in close proximity to the laser channels. Conclusions: With this catheter-based 
approach to combine laser injury and gene delivery in ischemic myocardial sites, high 
levels of gene expression were obtained in the absence of laser-induced injury; however, 
these levels were not further augmented by laser-induced injury of the injected myocar- 
dium. 
1041-41 Stress Echocardiography and Nuclear Perfusion Imaging to 
Assess Response to Angiogenesis Therapy: A Double 
Blind, Placebo Controlled Clinical Trial 
Bradley A. Bart, Charles A. Herzog, Chariene Ft. Boisjolie Kathy Peterson-Norby, 
Timothy D. Henry. Hennepin County Medicai Center, Minneapolis. MN 
Background: Given the significant placebo effect associated with angcogenesis therapy, 
an objective, reproducible, non-invasive means of assessing response to therapy is 
desirable. 
Methods: We compared stress echocardiography (ECHO) and nuclear perfusion imag- 
ing (NUC) on patients (pts) enrolled in VIVA, a multicenter, double-blind, placebo con- 
trolled trial of VEGF protein for the treatment of angina in pts ineligible for 
revascularization. 
Results: Of the 36 pts enrolled at our site, 27 (75%) had prior CABG and 29 (81%) had 3 
vessel CAD. Placebo and VEGF groups had significant improvement?, in treadmill time 
and angina scores at 60 days. The VEGF pts had sustained improvements in treadmill 
time at 120 days. There were not significant improvements in stress ECHO or NUC 
scores in the 27 pts with concurrent ECHO and NUC imaging at 60 days; stress imaging 
was not performed at 120 days. (see Table). 
Conclusion: Despite improvements in treadmill time and angina, stress ECHO and NUC 
did not demonstrate improvements in placebo or VEGF pts at 60 days. Stress ECHO 
and NUC appear to provide similar informatlon with respect to therapeutic response in 
pts with advanced CAD. The optimal timing and assessment of response to anglogene- 
sis therapy has yet to be determined. 
Table Stress ECHO and NUC Scores 
Treatment WMI-R WMI-S SRS sss 
Day0 Day60 Day0 Day60 Day0 Day60 Day0 Day60 
Placebo 1.02 1.02 1.54 1.22 2. 2.3 16.3 10.6 
VEGF 1.42 1.37 1.74 1.73 5. 5.3 20.5 20.3 
*WMI-R and WMI-S = wall motion index at rest and stress by ECHO, respoectively; SRS 
and SSS = summed rest score and summed stress scow, respectively 
1041-42 Outcome Measures in Angiogenesis and Laser Trials: 
Natural history of No-option Patients with lschemic Heart 
Disease Who Are Not Candidates for PTCA or CABG and 
Who Remain Symptomatic on Medical Therapy 
Roger J. Laham, Frank W. Sellke. Donald S. Balm, Michael Simons. B/DMC/Harvard 
medical School, Boston 
Background: The investigation of therapeutic angiogenesis and laser myocardial was- 
cularization (LMR) has been limited by the lack of well defined outcome measures to 
assess the benefit of this treatment strategy. This is partly due to a poor understanding of 
the natural history of medically-refractory patients who are not candidates for CABG or 
PTCA and are considered for these treatments (“no-option patients”). Methods: Patients 
enrolled and screened for enrollment in angiogenesis and LMR studies were studied. 
Clinical follow-up of at least one year was obtained on all patients and averaged 20*8 
months. Results: A total of 244 patients were so studied. 10 patients in phase I VEGF 
study, 24 patients in the basic fibroblast growth factor (FGFB) CABG-plus study, 59 
patients in Phase I-II intracoronary FGF2 study, and 79 patients in percutaneous LMR 
studies. The remaining 72 patients screened out (low EF, renal dysfunction) and had 
high risk PTCA (n=38), CABG (n=4), and continued medical therapy (n=30). The mean 
age was 6&7 years and 8% were women. 50 patients (22%) had diabetes mellitus and 
30 (12.3%) patients had EF<20%. Overall mortality was 5.3% (13 patients died, 5 in the 
screened-out patients, ). 18 patients (7.3%) suffered a myocardial infarction (4 Q-wave 
myocardial infarction, 1.6%), 3 patients (1.2%) had a stroke, and 28 patients (11.4%) had 
repeat revascularization (PTCA in 20 and CABG in 9 patients). 80% of patlents had at 
least a one class improvement in angina (CCS class) and 53% of patients had two or 
more class improvement. There was a significant increase in quality of life assessed by 
Seattle Angina Questionnaire in most patients. Conclusions, “No-option patients” have a 
low overall mortality with a low incidence of major cardiac adverse events. In addition, 
angina class improvement is almost universal irrespective of treatment. Therefore, surro- 
gate outcome measuws are needed for efficacy assessment. In addition, mechanistic 
endpoints are crucial for definitive efficacy. 
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I:45 p.m. 
Mid-(4-Month) and Long-Term (I-Year) QCA and Three- 
Dimensional IVUS Follow-Up After Implantation of 
Sirolimus-Coated Stent in Human Coronary Arteries 
J. Eduardo M. R. Sousa, Marco A. Costa, Alexandre Abizaid, Andrea S. Abizaid, Fausto 
Feres, lbraim M. F. Pinto, Ana C. S&as, Gal0 Maldonado, Luiz A. Mattes, Amanda G. 
M. R. Sousa, Robert Falotico, Judith Jaeger, Jeffrey J. Popma, Patrick W. Serruys. 
institute Dante Pazzanese of Cardiology S&T Paula, Brazil 
Background: Restenosis remains an important limitation of interventional cardiology. 
We aimed to determine the safety, feasibility and neointimal formation after implantatran 
of sirolimus (an antiproliferative agent) coated BX Velocity (stems). Methods: Thirty 
patients with angina pectoris were electively treated with single coronary stenting 
between December 1399 and February 2000. Two different formulations of sirolimus- 
coated stent were used (slow release[SR], n=15 and fast release [FR], n=15). Follow-up 
angiogram and IVUS imaging were scheduled at 4 and 12 months. Data were analyzed 
by independent core laboratories. Results: All stems were successfully delivered and 
patients were discharged without complications. Six-month clinical follow-up was 
obtained in all patients. The IVUS volumetric analysis at 4 months showed minimal 
amount of neointimal hyperplasia in both groups (11 .O f 3.0% in the SR and 10.4 + 3.0% 
in the FR group, p=NS). These findings were corroborated by angiographic data (in-stent 
late loss = 0.08 + 0.2mm [SRI and -0.02 f 0.3mm [FR]; in-lesion late loss = 0.16 i 0.3mm 
[SR] and -0.lr 0.3mm [FR]). No in-stent or edge restenosis (diameter stenosis B 50%) 
was observed. No clinical event (stent thrombosis, repeat revascularization, myocardial 
infarction or death) occurred up to 6 months. One-year data will be available in February 
2001. Conclusion: The implantation of sirolimus-coated BX Velocity stents was safe, 
feasible and elicited only minimal neointimal proliferation. Further large placebo-con- 
trolled trials are required to confirm these promising results. 
2:oo p.m. 
29-3 - The Major Risk Factor for Late Thrombosis Following 
Gamma Radiation for I&tent Restenosis Is New Stent Use 
Richard E. Kuntz, Paul S. T&stein, Kalon K. L. Ho, Brian J. Firth, Steven J. Ellis, David 
Fish, James B. Hermiller, Prabhakar Tripuraneni, Shirish Jani, Martin B. Leon. Brigham 
and Women’s Hospital, Boston, Lenox Hi// Hospital, New York 
Background: Three randomized trials (RCT) have demonstrated that intracoronary 
Gamma irradiation with ‘g21r is highly effective in reducing restenosis following coronary 
intervention for in-stent restenosis (ISR). The incidence of late thrombosis (LT), defined 
as thrombotic occlusion 230 days following irradiation, was 5.3% in the 252 pt GAMMA-l 
RCT, 6.1,% in the 130 pt WRIST RCT, and 0% in the 60 pt SCRIPPS RCT, The potential 
causes of LT were explored by pooling the 3 RCTs. Methods: Late total occlusions were 
determined by angiographic evidence of occlusion at the treatment site, and were broken 
down into symptomatic late thrombosis (SLT) associated with acute myocardial infarc- 
tion, and silent occlusion (SO) due to asymptomatic occlusion at follow-up. Results: The 
independent predictor of SO was reference vessel size (p=O.O38), consistent with SO 
representing chronic occlusion due to proliferative neointima. The independent predictors 
of SLT were radiation treatment (vs. placebo, p=O.O07), and new stent use (p=O.O03), 
consistent with SLT representing acute thrombotic occlusion. The incidence of SLT by 
treatment assignment and new stent use is shown in the table. In patients wlthout new 
stent use (32.4%), the rate of subsequent in-stent restenosis was impressively reduced 
(70.0% treatment effect) compared with placebo. 
Placebo: new stent Placebo: no stent Radiation: new stent Radiation: no stent 
0.7% 1.4% 6.7% 1.2% 
Conclusions: The incidence of late thrombosis following intracoronary Gamma ‘yL’Ir irra- 
diatlon for in-stent restenosis was approximately 6%, and was seen mainly in patients in 
whom new stents were placed. The effectiveness of Gamma “‘lr irradiation for prevent- 
ing restenosis without new strent use is very high (70% treatment effect). The treatment 
of in-stent r&stenosis with Gamma ‘9plr irradiation and non-stent coronary intervention 
should be safe and highly effective in terms of low incidence of late thrombosis and pre- 
vention of restenosis. Extension of anti-platelet therapy with clopldogrel should also help 
to prevent late thrombosis 
29-4 
2:15 pm. 
Patients With Three or More Vessel Disease Treated With 
Percutaneous Interventions Achieved Similar Safety Long 
Term Outcome to Those Treated With Conventional 
Coronary Bypass Surgery: One Year Follow-Up Results 
From the ERACI II Study 
Alfred0 E. Rodriguez, Maximo Rodriguez Alemparte, Victor Bernardi, Julio Baldi. Jose 
Navia, Alejandro Delacasa, Daniel Vogel, Carlos Fernandez Pereira, lgor F. Palacios, 
William 0’ Neill. Otamendi Hospital, Buenos Aires, Argentina, WiNam Beaumont 
Hospital, Royat Oak, MI 
Background: Previous randomized studies comparing balloon angioplasty vs Coronary 
bypass surgery (CABG) have demonstrated equivalent safety results between both tech- 
niques however in many of those studies only minor number of patients (pts) with diffuse 
disease were randomized. Objective: The purpose of the present study was to compare 
percutaneous translumlnal coronary revascularization (PTCR) employing stent implanta- 
tion to conventional CABG in pts with three or more vessel disease. Methods: From 450 
pts randomized in the ERACI II study we analyzed 254 pts with three or more vessel dis- 
ease. Pts with 2 vessel or with left main stenosis were excluded. 181 pts had 3 vessel 
and 73 pts more than three. The primary end point was to compare major adverse events 
(MACE) as death, Q myocardial infarction (AMI) and repeat CABG or PTCR with both 
techniques at 30 days, one, three and five year follow up. In PTCR group 1.5 stems per 
pts and 28% of abciximab infusion were used. Results: Both groups had similar clinical 
demographics and angiographic characteristics: u@abie angina in 85.5%, 43.5% was 
older than 65 years, 23% had concomitant peripheral vascular disease. There were no 
significantly differences III death (1 6% vs. 3.8%) or AMI ( 0.8% vs 5.3%)during the first 
month between PTCR and CABG respectively. At one year of follow up survival was 
95.2% in PTCR vs 94.6% m CABG, p=ns. Freedom from AMI was also similar 97.6% vs 
93.9%, p=O.O96 in PTCR and CABG respectively Requirements for new revasculariza- 
tion procedures were higher in PTCR than CABG (21% vs 1.5%, p=O.OOZ). Freedom 
from MACE was 87% in CABG and 74.4% in PTCR p= 0.059 Conclusion: In pts with 
three or more vessel disease randomized in the ERACI II , PTCR achieved similar sur- 
viva1 and freedom from AMI to those treated with CABG. Repeat revascularizatlon proce- 
dures were higher in PTCR group. 
2:30 p.m. 
29-5 Endothelial Nitric Oxide Synthase Gene 894GT 
Polymorphism Is Associated With an Adverse Outcome 
After Coronary Stenting 
Ollga Gortchakova, Werner Koch, Nicolas van Beckerath, Julinda Mehilli, Albert 
Schijmig, Adnan K&rat!. Deutsches Herzzentrum, Munich, Germany, 1. Med. Klinik 
rechts der lsar der JU Mtinchen, Municf~, Germany 
Background: The endathellal constitutive nitric oxide (NO) synthase (eNOS) produces 
NO which has important vasodilatory, antithrombotic and antiproliferative properties. 
Recently, the eNOS gene 894GT polymorphism (exon 7) has been shown to generate 
protein products with differing susceptibility to cleavage. These data suggest a functional 
effect of this polymorphism on eNOS protein. We investigated whether the 894GT geno- 
type impacts on the long-term outcome after coronary artery stenting. 
Methods: The study included 1850 consecutive patients (pts) with coronary artery dis- 
ease who underwent coronary stenting and were followed-up for 1 year after the proce- 
dure. The primary end point of the study was restenosis defined both angiographically 
(250% diameter stenosis [DS] at follow-up angiography performed in 1556 patients) and 
clinically (target vessel revascularization [TVR]). Secondary end point was the combined 
I-year incidence of death and myocardial infarction (MI). 
Methods: The eNOS 894GT genotype distribution was GG in 865 pts, GT in 792 pts and 
TT in 193 pts. The baseline characteristics were comparable between pts with different 
894GT genotypes except for TT carriers being significantly younger and with a trend 
toward a less frequent history of bypass operation. Despite these baseline differences 
and the absence of significant differences in restenosis (Figure, left panel), TT pts pre- 
sented a higher mortality (4.7% vs 2.2%, P=O.O4) and incidence of Ml (3.6% vs 1.6%, 
P=O.O5) at 1 year after stenting. The combined end point of death and Ml at 1 year was 
reached in 7.8% of the Tr patients and 3.7% of the G allele carriers, P=O.O07 (Figure, 
right panel). 
Conclusion: These data suggest that the eNOS 894GT genotype may serve as a 
genetic risk marker for patients undergoing coronary artery stenting. 
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2:45 p.m. 
Effect of Antibiotic Treatment Against Chlamydia 
pneumoniae With Roxithromycin on Neointima Proliferation 
After Coronary Stent Placement 
Franz-Josef Neumann, Adnan Kastrati, Thomas Miethke, Gisela Pogatsa-Murray, 
Christian Valina, Juiinda Mehiili, Albert Schbmig. 1. Med. K/in/k der Technischen 
iJniversht?t, Muenchen, GermanN lnstitut fij, Medizinische Mikrobiologie der 
Technischen Universitaet, Muenchen. Germany 
Vascular infection with Chiamydia pneumoniae (Cpn) may boost inflammatory responses 
that play a ptvotal role in neointtma formation, the main cause of restenosts after stenting. 
We sought to investigate whether antibtotic treatment of Cpn prevents restenosis after 
coronary stent placement. Our randomized double-blmd trial included 1010 consecutwe 
patients with successful coronary stenttng. Patients received the macrolide antibiotic 
roxithromycin, 300 mg once dally for 28 days or placebo. Primary endpoint was the inci- 
dence of restenosis (diameter stenosis >50%) at follow-up angiography and secondary 
endpoint the rate of target vessel revascularization during 1 year after stenting. We ana- 
lyzed the treatmetlt effect wtth respect to serum Cpn titer by logistic regression wth 
adjustments for major covariables. Angiographic restenosis rate was 30.8% in the 
roxithromycin group and 28.6% in the placebo group (relative risk [95%-confidence inter- 
val]: 1.08 [0.92-l-26]; P=O.43), corresponding to a rate of target vessel revascularization 
of 19.3% or 17.0%, respectively (relative wk: 1.13 [0.95-i 361; P~0.30). The combined l- 
year rates of death and myocardial infarction were 7.1% in the roxithromycin group and 
6.0% in the placebo group (P=O.45). We found a significant tnteraction between treat- 
ment and Cpn antibody titer. At the 4 Cpn titer levels analyzed (negative, 1132, 1118, li 
5121, adjusted odds ratios expresstng the effect of roxithromycin on target vessel revas- 
cularization were 1.51 (l.Ol-2.24), 1.28 (0.90.1.82) 0.78 (0.52-1.18) and 0.11 (0.02 
0.54), respectively (P=O.O04 for the interaction between treatment and titer). Simtlar 
results were obtatned for anglographic restenosis (P~O.015 for the interaction between 
treatment and titer). In conclusion. non-selective use of roxithromycin is inadequate for 
prevention of restenosis after coronary stenting. There is, however, a dtfferential effect 
depending on Cpn titers. In patients with high titers we found a clinically relevant reduc- 
tion in restenosis rate by roxithromycin. 
3:00 p.m. 
29-7 - The Effects of Tirofiban Versus Abciximab Among Diabetic 
Patients Undergoing Stent Placement: The TARGET Trial 
David J. Moliterno, Howard C. Herrmann, Eric R. Powers, Cindy L. Gnnes. Steven J. 
Yakubov, David J. Cohen, H. Graham Parker, Martin J. Frey, Gregg W. Stone, Eric J. 
Topol, for the TARGET Investigators. Cleveland Clinic Foundation, Cleveland, OH 
Background: Diabetic patients are known to be at increased risk for adverse events dur- 
trig coronary stent implantation. In EPISTENT, by using the GP llbillla inhibitor abcw 
imab, BO-day ischemic events (death, Ml, urgent revascularization) were reduced 54% 
among diabetics. Methods: To dacern whether a similar benefit IS extended to diabetic 
patients receiving tirofiban, a prespecified substudy oi the TARGET trial was designed. 
The TARGET tnal was performed in a double-blind, double-dummy fashion so that all 
patients received etther (a) tirofiban bolus (IO ugikg) and 18 to 24.hour infusion (0.15 pgl 
kgimin) with abctximab-placebo bolus and abclximab-placebo infusion or (b) tirofiban- 
placebo bolus plus tirofiban-placebo Infusion with abciximab bolus (0.25 mgikg) and 12. 
hour Infusion (0.125 gikglmin). Results: In the TARGET trial, 4,808 patients undergoing 
stent implantation at 149 centers worldwide were randomized to tirofiban or abciximab. 
Of these, 1 ,I 16 were diabetics and were prospecttvely stratified at randomization. Data 
were collected for ischemic and bleeding outcome events. Conclusion: The 30.day 
results for death. Ml. and urgent revasculariration by treatment assignment will be avail- 
able for presentabon. 
29-8 
3:15 p.m. 
Short-term Outcomes Following Coronary Artery Stenting: 
Higher Mortality and Bypass Surgery Rates in Women 
Compared with Men 
Colin T. Watanabe, Charles Maynard, James L. Ritchie. University of Washington, 
Seattk?, WA, Department oi Veterans Affairs, Seattle, WA, Seattle, WA 
Background: Controversy remains as to whether female gender is an independent pre- 
dictor of in-hospital mortality following percutaneous translumtnal coronary angioplasty 
(PTCA). Furthermore, no study has examined potential gender differences in outcomes 
following PTCA after the widespread dissemination of coronary stenting. This study 
addresses the question of whether compared to men, women have adverse outcomes 
following PTCA and stenting. Methods, Thts study uses information from the Nationwide 
Inpatient Sample, a 20% representation of all U.S. hospital discharges, for the year 1997, 
In 1997. there were 118,548 angioplasties, of which 36% were in women, and 59% which 
involved stents. Outcomes included same-admission mortality and coronary artery 
bypass surgery (CABG). Analyses were performed separately for patients with and with- 
out a principal diagnosis of acute myocardial infarction (AMI). Results: Women in 1997 
had a significant, and roughly two-fold higher mortality than men in every comparison 
group, including conventional PTCA alone, stent. AMI, and no AMI. The mortality rates 
after stenting were 4.0% for women and 2.0% for men in AMI (p<O,OOOi), and 1.1% and 
0.5%, respectively, for p&rents without AMI (pcO.0001). The adjusted odds ratios were 
1.47 (95% Cl, 1.23.1.75), and 1.65 (95% Cl, 1.33.2.04), respectively, Stmiiarly, following 
stenting, women were significantly more likely than men to have same-admission CABG 
in both the AMI (1.6% vs. 1.2% p=O.O25), and no AMI groups (1.5% vs. l.O%, 
p<O.OOOi). After multivartate adjustment, the results retatned significance in the no AMI 
setting, while there was a trend toward significance in the AMI group There was no sig- 
nificant gender difference in CABG rates in the conventtonal PTCA group. Conclusions: 
This study demonstrates that, despite improved outcomes overall in patients receiving 
versus those not receiwng stents, compared with men, women undergoing stentmg had 
htgher rates of mortaltty and same-admission CABG. Additionally, it adds further support 
to previous work showing that female sex is an Independent predictor of mortality follow- 
ing convenhonal PICA. 
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1070-g Direct Coronary Stenting Without Balloon Predilation: 
Immediate and 6 Month Results of a Multicenter Prospective 
Randomized Trial 
Marc Bedossa, Philippe Cammeau. Philippe Brunnel, Martine Gilard, Christian Breut, 
Philippe Geslin, Ashok Tirouvanziam, Luc Maillard, Benoit Moquet, Paul Barragan, 
Patrick Dupouy, Cristophe Leclercq, Herve Le Breton. Dept of Cardiology University 
Hospital, Rennes, France 
This prospective randomized trial was designed to compare dtrect coronary stenttng wtth 
the standard procedure, which includes lesion predilation wtth an angioplasty balloon. 
Background The feasibility and safety of direct stenttng in non-complex coronary 
lesions have been reported in prospective registries. 
Methods All patients ~76 years of age scheduled to undergo angioplasty of a non-com- 
plex, non-calcified lesion in a >3.0 mm coronary artery, who granted their informed con- 
sent, were randomwed into the trial. In group I, the stent was placed without balloon 
predilation, while in group II stent implantation was preceded by balloon predilation. The 
primary endpoint was the angiographic result according to procedure assigned by ran- 
domization. All the pattents were followed at 6 months by phone calls. 
Results Stent implantatton was successful without predilation in 192 of the 197 group I 
patients (97.5%) and with predilatton in 197 of the 199 group II patients (99 %) (ns). No 
in-hospital stent thrombosis or death occurred. Mean overall procedural times, mean flu- 
oroscopy times, and mean volumes of contrast agent administered in group I versus 
group II were 23.50213.54 vs. 27.96115.23 min (p=O.O02), 6.04k4.13 vs. 6.67*3.65 min 
(p=ns), and 135t65 ml vs.157t62 ml (p<O.OOl), respectively. No major adverse cardio- 
vascular event occurred at 30 days. The rates of major cardtovascular events and target 
vessel revascularization were comparable in the two groups at 6 months. 
Conclusions This randomized trial confirmed the feasibility and safety of dtrect stenting 
of non-complex coronary lesions. This technique was as successful as the conventional 
approach, though associated with shorter fluoroscopic exposure and procedural ttmes, 
and the same rate of clintcal 6 month restenosis. 
1070-10 The Impact of Directional Coronary Atherectomy Prior to 
Stenting Versus Stenting Alone on Net Lumen Gain: The 
Paradoxical Role of Vessel Size 
lssam Moussa, Antonto Colombo, Yoshio Kobayashi, Carlo Di Mario, Mtchael Collins, 
Milena Adamian, Edward Kreps, Jeffrey Moses. Lenox Hi// Heart and Vascularlost!tute, 
New York, N): Centro Cuore Columbus, Mi/an. /ta/y 
Background: With 
stenting alone, the - DCA+Stent 
larger the vessel size 
the higher the net 
g n n S t &  
lumen gain at follow-up. 
3 
B 4 
Whether this concept arl 
holds true when di 
tional coronary atherec- 
tomy 
performed 
stentinq has not been 
established. Methods: 
Over a 2 year period 
(1996 - 1998) all pts 
who under&nt DCA 
prior to stentina and 
had angiographic fol- 
low-up (n=132 lesions) 
were matched wtth similar number of pts who underwent stenting alone and had angio- 
graphic FU (n=l32). Matching was performed with respect to diabetes, vessel size, 
lesion length and stent length. All anglograms at baseline and FU were analysed using 
(QCA-CMS version 3.0, MEDIS, Leiden. The Netherlands). Results: As shown tn the fig- 
ure below (simple regression analysis), there was statistically signihcant, albelt moder- 
ate, correlation between vessel size and net lumen gain at FU in the stent group (r=0.34, 
p<O.OOOi). While, there was no correlation between vessel size and net lumen gain in 
the DCA+stent group (r=0.06, p=O.52). Conclusions: The posittve gradient of benefit 
from DCA prior to stenting, compared to stent alone, narrows as vessel size approaches 
3.5 mm. This may be due to less efficient debulking in large vessels These data may 
help select pts who may benefit the most from thts synergistic approach. 
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1070-11 Is Stent Oversizing the Best Strategy to Treat Small 
Vessels? 
Fat&to Feres, Marco A. Costa, Rodolfo Staico, Alexandre Abizaid, lbraim M. F. Pinto, 
Luiz A. P. Mattes, Gala Maldonado, Luiz F. L. Tanajura, Marinella Centernero, Aurea 
Chaves, Andrea S. Abizaid, Ana C. S&as, Angela T. Paes, Amanda G. M. R. Sousa, J. 
Eduardo M. R. Sousa. institute Dan& Pazzanese of Cardiology, Sti, Pm/o, Brazil 
Background: The best strategy to treat small vessel coronary disease has not yet been 
defined. Small vessel stenting usually courses wtth higher restenosis rate. To assess the 
safety and benefity of oversize stenting compared to a less agressive approach for the 
treatment of patients (pts) with small vessel coronary disease. Methods: From 1997 to 
1999, 2085 patients underwent stent implantation in our institution. Of these, 397 pts had 
small vessels with a reference vessel diameter 5 2.5mm. Patients were divided in two 
groups according to the strategy used: largest baloon diameter was < 2.5mm in 170 pts 
(Group l), while in 227 patients an agressive approach (final balloon size >2.5mm) was 
used (Group 2). Stent implantation was performed according to standart practice with 
high pressure balloon inflation in all patients. The decision of agressive or non-agressive 
approach was left to the operator’s preference. Procedural success was defined as 
residual diameter stenosis < 30% without major complications. Clinical follow-up was 
obtained in all patients at 9 months after the procedure. Results: Baseline characteris- 
tics was similar between groups, 
LAD location 
Group 1 (170) Group 2 (227) 
81 (48%) 104 (46%) 
P 
NS 
En/C lesion 104 (61%) 136 (60%) NS 
Stent length (mm) 16.7~65 16.9zk6.3 NS 
Ref. diameter (mm) 2.31+0.3 2.38kO.4 NS 
Final balloon (mm) 2.5kO.2 2.8+0.4 < 0.05 
MLD post (mm) 2.34kO.4 2.62i0.5 c 0.05 
Clinical success 98.5% 97.5% NS 
TVR 36 (21.7%) 28 (12.3%) 0.005 
Conclusions: Treatment of small coronary arteries using an agressive stenting strategy 
was safe and provided superior outome in terms of clinical restenosis compared with a 
more conservative approach. Randomized trials are required to further establish the ben- 
efit of this technique. 
1070-I 2 Cutting-Balloon Versus Balloon Alone for the Treatment of 
In-Stent Restanosis: An Intravascular Ultrasound Study 
Andrea S. Abizaid, Alexandre Abizaid, Alexandre Assad, Fausto Feres, lbraim M. Pinto, 
Luis A. Mat&, Luis F. Tanajura, Aurea Chaves, Marinella Centernero, Rodolfo St&o, 
Ana C. S&as, Amanda G. M. R. Sousa, Eduardo Sousa. lnstituto Dante Pazzanese de 
Cardiologia, Sao PaLdo, Brazil 
Background: In-stent &stenosis (ISR) remains the major limitation of percutaneous 
coronary intervention and its optimal treatment remains to be determined. We compared 
intravascular ultrasound (IVUS) results after cutting balloon (CB) vs. balloo‘n alone @A) 
to treat patients with focal ISR (lesion length 210 mm by operator assessment) in a pro- 
spective randomized study. 
Methods: Twenty-three patients (mean age: 51?4 years) were randomized to CB (n=i 1) 
or BA @=I 2). IVUS was performed pre and post intervention and measurements of mini- 
mum stent cross-sectional area (CSA), lumen CSA, and intimal hyperplasia CSA (Stent- 
Lumen CSA) at the lesion site were obtained. Balloon-to-artery ratio was similar in both 
groups (l.l:l) and final pressure in BA was significantly higher than CB arm (16+2 vs. 
&I, p=) 
Results: There were no differences between CB and BA in baseline clinical and lesion 
characteristics. Procedure success rates and incidence of major in-hospital complica- 
tions were similar between groups. IVUS results are shown in the table: 
CB BA p-value 
Pre-procedure 
Reference lumen CSA (mm’) 8.9i2.2 7.8t2.3 0.24 
Minimum stent CSA (mm*) 9.7+2.4 7.8k2.8 0.06 
MInimum lumen CSA (mm”) 1.9+0.9 1.5ztO.8 6.52 
lntimal hyperplasia CSA (mm’) 7.6k2.7 6.1~2.6 0.28 
Post-procedure 
MinImum stent CSA (mm’) 10&3.1 10.5+3.4 0.83 
Minimum lumen CSA (mm’) 6.9A2.2 6.4r2.6 0.56 
lntimal hyperplasia GSA (mm’) 3.8tl.9 4.0+1.7 0.84 ( 
Changes (post-pre) 
Stent CSA (mm2) 1.1+2.5 2.7+2.8 0.16 
Lumen CSA (mm*) 5.0i2.3 4.9r2.4 0.91 
lntimal hyperplasia CSA (mm’) 3.8~2.4 2.1+2.6 0.21 
Conclusion: Treatment of ISR with CB results in similar acute results compared to BA 
by IVUS. Residual intimal hyperplasia CSA and final lumen dimensions are similar after 
both techniques. A larger randomized trial to evaluate the utility of CB compared to the 
simpler and less costly approach of BA for treatment of focal ISR is warranted. 
1070-13 Vein Thickness Is a New Prognostic Factor for Restenosis 
After the Implantation of Autologous Vein Graft-Covered 
Stents 
Konstantinos Toutouzas, Christodoulos Stefanadis, Eleftherios Tsiamis, Costas Stratos, 
loannis Kallikazaros, Manolis Vavuranakis, Costas Tsioufis, Pavlos Toutouzas. 
Hippokration Hospital, Athens, Greece 
Covered stents by autologous venous grafts are being 
used for the treatment of vessel wall disruptions, such 
as aneurysms and dissections, and in acute coronary 
syndromes. The long-term follow-up and also the proce- 
dure-related factors determining the late outcome 
remain unknown. Methods: Metallic stents were covered 
by autologous venous grafts. Forty-three grafts were 
removed from the anterobrachial region (thicker veins) and 15 from the deltoideopectoral 
sulcus (thinner veins). The stents were covered by the venous grafts. Non-premounted 
(PalmazTM, Palmaz-&h&TM) and premounted stents (MultillnkTM) were used. Fifty- 
eight covered stents were placed in 56 patients (pts). The patients were scheduled for 
follow-up angiography and also they were followed-up clinically. Results: The procedure 
of stent coverage and delivery to the target lesionwas performed without complications. 
In one patient stent thrombosis was observed. The angiographic restenosis rate was 
13.3% and the target lesion revascularization rate was 12%. The event-free survival rate 
at 5 years was 83%. The event-free survival rate was greater in pts with stents covered 
by thicker venous grafts (94% vs 68%, respectively, ~~0.02, figure). In patients in which a 
thicker venous graft (from the deltoideopectoral sulcus) was used a relative risk of 5.8 
was found for a cardiac event (95% confidence interval: 1.2-28.9, p < 0.03). Conclusions: 
The long-term follow-up period after the implantation of venous-graft covered stents is 
favorable and late procedure-related complications were not detected. In addition, the 
thickness of the covering venous graft is a new prognostic factor for the long-term out- 
come. 
1070-14 Comparison of Rotational Atherectomy Versus PTCA With 
or Without Stenting in Cacified Lesions: In-Hospital and 6- 
Month Outcome 
Mandeep Singh, Verghese Mathew, Ryan J. Lennon, John F. Bresnahan, Daniel J. 
Tiede, Charanjit S Rihal. Mayo Clinic, Rochester, MN 
Background: Rotational Atherectomy (RA) IS used for treating calcified lesions. Its 
advantage over PTCA with or without stent is less well known. MethockThe in-hospital 
and long-term outcome of 2065 patients with lesion calcification, treated with PTCA with 
or without stent, were compared with 447 patients treated with RA for lesion calcification, 
since 1993 at Mayo Clinic. Results: 
Baseline, Angiographic characteristics, and In-Hospital Outcomes 
Variable No Rotablator Rotablator (Nz447) P-Value 
(N=2065) (%) (“4 
Age (~0 67.6+11 69.1+10 0.001 
Hypertension 62.7 63.1 0.89 
Diabetes 22.3 24.9 0.223 
Unstable Angina 71.6 68.0 0.13 
Ml l-7 Days 16.9 4.3 co.ooo1 
Prior Ml 48.1 36.1 <0.0001 
EF<0.40 18.2 10.2 0.0025 
Current Smoker 15.4 9.7 0.002 
CHF at Presentation 10.0 6.0 0.009 
Multivessel Disease 75.0 69.7 0.024 
stent use 62.6 46.3 <0.0001 
Definite/Probable Throm- 18.8 1.4 e0.000l 
bus 
Type C Lesion 45.6 65.6 <0.0001 
Mod/Severe Bend 41.8 49.5 0.0008 
Residual Stenosis ~50% 92.7 97.7 <0.0001 
In-Hospital Death 2.0 0.9 0.12 
In-Hospital Death/Ml 8.0 11.2 0.031 
In-Hospital Ml 7.1 10.7 0.0084 
Death/MI/CABG/Redila- 10.9 13.0 0.21 
tion 
RA is associated with higher in-hospital death/Ml, and myocardial infarction despite 
improvement in the angiographic success.After adjusting for significant variables, the use 
of RA is not associated with higher odds of composite in-hospital end point (OR: 
1.2,95%C.l. 0.9-1.6, p=O.25), however, on follow-up (mean 2.7 years) patients with suc- 
cessful procedures had higher risk of death/MIICABGlredilation of the calcified 
lesion.(HR: 1.28, 95%C.l.l.l-1.5, p=O.Ol) Conclusion: RA is associated with improved 
angiographic success. This doesnot translate into improved in-hospital outcome. On fol- 
low-up there is increased incidence of adverse cardiac events in patients successfully 
treated with RA, mainly driven by increased TLR. 
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1070-15 Long Lesion Stenting. Does Covering Relatively Normal 
Segments Affect Outcomes? 
John A. Qrmiston, Mark W. I. Webster, Peter N Ruygrok, Ian T. Meredith, Justin I? 
Ardle. Christopher E. Buller. Donald R. Rrcci, Charles Chan, Gerard f? Devlin, James T 
Stewart. Green Lane Hospital: Auckland, New Zealand 
Background: With regard to subsequent restenosis, it is unclear whether long coronary 
lesions are best treated by a single long stem, or by II/US-gurded multiple “spot” stents. 
“Spot” stenting is expensive. time consuming, and unsupported by randomized trials. If 
covering minimally diseased segments with stent has lrttle effect on restenosis, this 
would argue against “spot” stenting. AIMS To evaluate restenosis of mildly diseased 
5mm segments of long lesions covered by stent. Methods: This multicenter, prospective, 
quantitative angiographic (QCA) trial of long stent deployment enrolled 120 patients with 
de nova native Vessel lesions (length >20mm, diameter >3mm) to be treated with 1 or 
more MultiLInk stents (25 & 35mm). Long lesions were analysed in 5mm segments by 
QCA (CMS Medis) before and after stenting, and at 6 month follow-up in 108 (90%)of 
patients. Results: The mean stented length 135.8 (range 25-95) mm] closely matched 
mean lesion length [33.0 (range 18-99) mm]. Of 716 segments covered by stent, 145 had 
baseline stenosis ~25%. At 6 month QCA, of these 145 segments, only 3 (Z%)had devel- 
oped stenosis of 250% or more and only one of these was a stenosis of >70% or more. 
Summary: When relatively normal segments of long lesion are covered by a long stern 
angiographic restenosrs rarely occurs in those segments arguing for traditional stenting 
of the entire lesion rather than multiple short stent deployment. 
1070-16 Direct Stenting Without Predilatation During Primary 
Angioplasty for Acute Myocardial infarction 
Christian M. Spaulding, Pascal Richard. Faycal Belaouchi, Remain Cador, Jacques 
Monsegu, Antoine Py. Simon Weber. Cochin Hospital, Rene Descartes University, Paris, 
FWRX 
Background: Randomized trials have shown the benefit of stenting in primary angio- 
plasty for acute myocardia infarction (AMI). Direct stenting without predilatation (DS) rn 
non-emergent angiopiasty is cost-effective and reduces procedural time. Its value in 
patients with acute myocardiai infarction has not been tested. Methods: As of June 
1997, direct stenting was performed in our institution during primary angioplasty for AMI 
in patients with non-calcified lesions and no proximal tortuosity, if the distal run-off was 
visible after guide-wire crossing or spontaneously. Results. Between June 1997 and 
August 2000, 398 consecutive patients underwent primary angioplasty for AMI ; DS was 
attempted in 256 and coronary stenting (CS) was performed after pm-dilatation in 122. 
DS failed in 5 patients; stenting was performed safely in all after balloon dilatation. 
Patients rn the CS group were older (66 +/- 12 vs 60 +/- 6, pcO.01) had a greater inci- 
dence of diabetes (21 vs 8%, p<O.Ol) and a smaller reference diameter (2.83 +I- 0.43 vs 
3.1+/- 0.52 mm, p<O.Oi). After stent Implantation, anglographic no-reflow was less fre- 
quent in the DS group (6,5% vs 13% pcO.001). Procedural time was shorter (24+/-12 vs 
32 +/-8 min, p<O.OOl) and procedure-related costs were lower ($1426 +/-312 vs $1672 +/ 
285, p< 0.001) in the DS group. There was no difference in hospital stay duration (5.2 +/ 
- 8 vs 4.9 ci- 6 days) and simrlar in-hospital and six-month revasculariration, reinfarction 
and mortality rates were noted. Conclusions: In selected patients, direct stenting in pri- 
mary angropiasty for AMI is safe, reduces procedural time and costs and may have a 
favorable impact on no-reflow. In-hospital and six-month outcomes are similar. 
1070-17 Evaluation of the Effect of Oversizing on Vascular Injury, 
Thrombogenicity and Neointimal Hyperplasia Using the 
Magic Wallstent in a Porcine Coronary Model 
Qiang Bei Ping, Huang Yanming, Monika Srilard, LIU Xiaoshun, Eric Verbeken, Frans 
Van de Werf, Ivan De Scheerder Urwersity Hospitals, Leuvne, Belgium 
Oversizing of a self-expandable coronary stent results in a continuous pressure on the 
stented vessel wall and has been considered as a continuous stimulator for neointrmal 
growth. Methods: Magic Wallstents (Schneider, Bulach) with a length of 24 mm were ran- 
domly implanted with either an oversizing of +50% (n=28), or an oversizing of +lOO% 
(n=28) in 2.8 crossbred prgs The pigs underwent a control angiogram and were subse- 
quently sacrificed at day 3 (n=4). day 7 (n=4), day 14 (n=6), day 42 (n=lO) and day 84 
(n= 4). QCA was performed using the semi-automated Polytron 10006 system. Mor- 
phometry was performed using a computerized morphometric program. Results: Histo- 
pathology showed significantly more perivasculitis in the high oversizing group 
(1.08+0.17 vs. 0.92+0.16, p<O.OZ). Morphometry showed a similar lumen area at day 3 
and 7. At day 14 the lumen area rn the high oversizing group was significantly smaller 
compared to the low oversizing group (4.70+0.56 vs. 5.70~0.64 mm2, p=O.O16). At day 
42 and 84, however, thrs difference became insignificant. Neointimal hyperplasia was 
also significantly more pronounced at day 14 in the high oversizing group (1.94+0.64 vs 
1.04+0.66 mm2, ~~0.037). At later follow-up neointimal hyperplasra remained increased 
at a non-significant level in the high oversizing group. Conclusion. This study suggests 
that high oversrzing results in an early neointimal overresponse. At longer follow-up, 
however, this continuous vessel overstretching did not result in a significantly more pro- 
nounced neointrmal hyperplasia 
1070-18 Effect of Coronary Plaque Calcification on the Final Lumen 
Dimensions After Stenting Without Rotational Atherectomy: 
An Intravascular Ultrasound Study 
Yoshio Kobayashi, Roxana Mehran, George Dangas, lssam Moussa, Andrea S. Abirad, 
Alexandre Abirad, Mrlena Adamian, Gishel New, Alexandra J. Lansky, Gary S. Roubin, 
Sriram lyer, Gregg W. Stone, Jeffrey W. Moses, Martin B. Leon. Lenox Hi// Heart and 
Vascular Institute, New York, NY 
Background: Impact of calcification of coronary plaques on the final angiographic and 
IVUS results after stenting without prior rotational &here&my is not well established. 
Methods: Pre-intervention rntravascular ultrasound (IVUS) was performed in 366 con- 
secutive lesions, which subsequently underwent stentmg without rotational atherectomy. 
Lesions were classified Into three groups according to the severity of caicrfication as 
measured by IVUS (arc of calcification): 1) no or mild (<150”, n=215), 2) moderate (150. 
249O, n=75). and 3) severe (2250’, n=76). 
Results: 
Measurements: Calcificatron p value 
No or Mild Moderate SWWS 
By angiograhy 
Calcified lesion (%) 27 54 72 <O.Ol 
Ref L diameter (mm) 3.05*0.70 2.97+0.52 3.02+0.55 0.70 
Pre MLD (mm) 0.92+0.49 l.O2i-0.47 0.92_tO.38 0.30 
Post MLD (mm) 3.iOi-0.60 3.16kO.56 3.16+0.47 0.66 
By IVUS: 
Prox ref L CSA (mm*) 8.9k3.2 8.0~2.1 62~2.4 0.20 
Dist ref L CSA (mm’) 8.0~3.3 7.7k2.3 7.0t2.0 0.08 
Pre MLD (mm) 1.5io.3 1.5+0.2 1.5i-0.2 0.12 
Pre L CSA (mm’) 2.4+1 .O 2.4r0.8 2.350.8 0.49 
Final MLD (mm) 2.7io.5 2.6+0.4 2.5eO.5 0.01 
Final L CSA (mm2) 7.4+2.4 6.8t1.6 6.5+2.0 0.02 
% final L CSA >6.0 mm2 71 60 58 0.10 
CSA = cross sectional area; L = lumen; MLD = minimal L diameter 
Conclusions: Arc of calcification in coronary plaques is an important predictor of final 
lumen dimension after stentmg. However, despite severe calcification identified by 
IVUS, stenting alone without rotational atherectomy results in adequate final lumen 
dimensions (>6.0 mm’) for a given reference vessel diameter. 
1070-19 Treatment Effect at Different Levels of Creatinine Clearance 
Following Eptifibatide in Planned Coronary Stent 
Implantation 
Donal N. Reddan, John Conor O’Shea, Kathryn Williams, Todd Lorenz. Michael Kitt, 
Edward Santoian, Glenn Levine, Ian Sarembock, William F Owen, Jr., James E 
Tcheng. Duke Clinica/ Research Institute, Durham: NC 
Background: End-stage renal disease is associated with adverse outcomes in patients 
with coronary artery disease. The role of platelet glycoprotein Ilb/llla inhibrtor therapy in 
patients with mild renal impairment has not been well characterized. We therefore sought 
to explore the relationship of creatinine clearance (CrCl) with eptrfibatide treatment effect 
in percutaneous coronary intervention. 
Methods: In the ESPRIT trial, 2064 patients were randomized to &her placebo or eptifi- 
batide treatment as an adjunct to stent implantation. 48 hour and 30.day outcomes of 
patients were assessed. Serum creatrnine > 4.0 was an exclusion criterion for ESPRIT. 
CrCl was calculated using the Cockcroft and Gault formula. A CrCl < 70 was considered 
abnormal. The effect of CrCl on outcomes was evaluated using logistic regression (unad- 
justed and adjusted for baseline factors). Interactions between level of CrCl and eptifi- 
batide treatment were also included. 
Results: There were 2044 patients included in this analysts. 1537 with CrCl > 70 and 
507 with CrCl < 70. Patients with CrCl c 70 were older, more often female, hypertensive 
and had a higher prevalence of prior CABG, prror stroke and PVD. Patients with CrCl > 
70 were more likely to be smokers and to have hypercholesterolemia. An increase in 
CrCl clearance was associated with a decrease in outcome risk (unadfusted), but no sig 
nificant decrease in risk when adjusted for baseline factors for both 48 hour and 30 day 
outcomes. The interaction of treatment with CrCl was found to be significant (borderline) 
for both outcomes and treatment effects trended towards a greater magnitude in patients 
with lower CrCI. 
CrCl of 70 and 115 correspond to 25th and 75th percentiles 
Outcome Odds 95% Cl 
Ratio 
48 hour Death/Ml/ CrCI: 115 vs 70 lntegrilin 0.95 (0.57, 1.59) 
RevascIThrombotic bail- Placebo 0.65 (0.49, 0.87) 
out. 
lntegrilin vs Placebo CrCl 115 0.74 (0.50, 1.09) 
CrCl70 0.51 (0.35, 0 74) 
30 day DeathlMliRevasc CrCI: 115 vs 70 lntegrilin 0.96 (0.58, 1.60) 
Placebo 0.65 (0.49, 0.87) 
lntegrllin vs Placebo CrCl 115 0.78 (0.53, 1.14) 
CrCi 70 0.53 (0.36, 0.76) 
Conclusion: The treatment effect of eptifibatide is realized regardless of renal function 
but appears greater in patients with mild renal impairment. 
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1071-20 Is the Use of Fractional Flow Reserve to Guide Coronary 
Interventions Cost-Effective? 
William F. Fearon, Alan C. Yeung, Yasuhiro Honda, Paul G. Yock, Paul A. Heidenreich. 
Stanford University Medical Center, Stanford, CA 
Background: Since a majority of patients present to the catheterization lab without prior 
functional tests, the cost-effective management of patients with intermediate coronary 
lesions is a practical challenge. We studled the cost implications of deferring the deci- 
s,on for percutaneous coronary intervention (PCI) in order to obtatn a nuclear stress 
imaging study (NUC Strategy) veraus measuring fractional flow reserve (FFR) at the time 
of angiography to help guide the decision for PCI (Ff?? Strategy). 
Methods: We developed a decision model to compare the long-term costs and benefits 
of the NUC Strategy and the FFR Strategy. Based on the literature, we estimated that 
40% of patients would have ischemia, that 70% of patients treated with PCI, and 30% 
treated medically, would be free of angina after 4 years and that the quality of life adjust- 
ment for living with angina is 0.9 (l.O=perfect health). We estimated the cost of FFR to be 
$600, nuclear stress imaging to be 51,000, and medical treatment for angina to be 
$1,775 per year. The extra cost of splitting the angiogram and PCI as dictated by the 
NUC strategy was $3,900 using hospital cost-accounting data. Sensitivity and threshold 
analyses were performed to determine which variables affected our results and to detect 
when the NUC strategy became financially attractive (<$50,00O/quality-adjusted life year 
or QALY) in relation to other commonly accepted medical interventions. 
Results: The FFR Strategy saved 51,960 per patient compared to the NUC Strategy 
assuming an equal predictwe value for FFR and nuclear stress imaging. The model was 
also used to assess whether the relative accuracy of FFR compared to nuclear stress 
imaging could have an impact on the cost-effectiveness of the NUC Strategy. This anal- 
ysis indicated that the YiJC Strategy would only become financially attractive (<$50,0001 
QALY) if the specificity of nuclear stress imaging was in excess of 33% better than FFR. 
Our results were not altered significantly by changing the other assumptions. 
Conclusion: In patients with an intermediate coronary lesion, measuring FFR to guide 
the decision to perform PCI may lead to significant cost savings compared with using 
nuclear stress imaging. 
1071-21 Higher Doses of lntracoronary Adenosine are Necessary for 
FFR-Based Stent Optimization 
William F. Fearon, Habib Samady, Eric’R. Powers, Ted Feldman, Nabil Dib, E. Murat 
Tuzcu, Michael W. Cleman, Tony M. Chou, David J. Cohen, Atsushi Takagi, Jorge Luna, 
Allen Jeremias, Alan C. Yeung, Morton J. Kern, Paul G. Yock. Stanford University 
Medical Center, Stanford, CA 
Background: Recent experience with measuring fractional flow reserve (FFR) has sug- 
gested that “standard” doses of intracoronary (IC) adenosine may produce incomplete 
hyperemia and result in spuriously normal FFR values. Accordingly, we analyzed the 
impact of IC adenosine dosing on FFR measurements of optimal stent deployment. 
Methods: In the FUSION prqtocol, coronary stenting was performed in stable patients 
starting at 10 atmospheres, and increased serially by 2 atmospheres, until the FFR, mea- 
sured with a coronary pressure we, was Z 0.94 or 16 atmospheres was achieved. IVUS 
was then performed. The suggested dosage of intracoronary adenosine used to measure 
FFR was 15 to 40 ugs, but the exact dosage was left to the operator’s discretion. For this 
retrospective analysis, patients were divided into two groups, low dose adenosine (2 30 
ugs) and high dose adenosine (> 30 ugs), depending on the maximum amount of ade- 
nosine admlnistered during the final measurement of FFR. The diagnostic characteristics 
of FFR to predict optimal stent deployment based on standard IVUS criteria (mean stent 
area > 7 mm’ and/or % area expansion Z 90) were calculated for the two groups. 
Results: In the first 68 patients analyzed, the sensitivity of FFR to predict optimal stent 
deployment, using the best cutpoint of r 0.96, was 33% in the low dose adenosine group 
(n=38) vs. 80% in the high dose group (n=30) (p=O.O7). The specificity of FFR was 53% 
in the low dose group vs. 87% in the high dose group (p<O.O5). The predictive accuracy 
of FFR was 50% in the low dose group vs. 83% in the high dose group (p<O.Ol). The 
positive predictive value of FFR in the low dose group was 18% vs. 86% in the high dose 
group (p=O.O002). No patient suffered an adverse side effect related to adenoslne. 
LOW DOSE ADENOSINE 
Sensitivity 
33% 
Specificity 
53% 
Negative Pre- Positive Predic- Predictive 
dictive Value tive Value Accuracy 
76% 18% 50% 
HIGH DOSE ADENOSINE 
Sensitivity Specificity Negative Pre- Positive Predic- Predictive 
dictive Value tive Value Accuracy 
80% 87% 81% 86% 83% 
Conclusion: In contrast to current usual practice, maximizing hyperemia with higher 
doses of lntracoronary adenosine is critical in order to use fractional flow reserve to opti- 
mize stenting. 
1071-22 Fractional Flow Reserve for Clinical Decision Making in 
Patients With Multivessel Coronary Artery Disease 
Steven A. J. Chamuleau, Rene A. TIO, Care1 C. De Cock, Nice H. J. Pills, Ebo D. De 
Muinck, Gert Jan Laarman, Berthe L. F. Van Eck-Smit, Martijn Meuwissen, Karel T. 
Koch, Jan G. P. Tijssen, Jan J. Piek, on behalf of the ILIAS study group. Academic 
Medical Center, Amsterdam, The Netherlands 
Background: Assessment of functional significance of coronary narrowings in patients 
with multivessel disease is important for clinical declslon making. In this Dutch mult- 
center study, we retrospectively assessed the value of intracoronary pressure derived 
fractional flow reserve (FFR). Methods: A total of 131 patients with stable angina and 
multivessel disease (mean age: 61 yrs; male: 70%) at least 2 coronary lesions (>40% 
diameter stenosis on visual assessment) were eligible for analysis. Dipyridamole 99mTc- 
MIBI SPECT was performed in all patients within 7 days prior to cardiac catheterization. 
Presence or absence of reversible perfusion defects in the region of interest was deter- 
mined by a panel and was decisive for patient management. At angiography, FFR was 
determined distal to 179 lesions following ic administration of adenosine. The FFR of 
co.75 was considered indicative of reversible ischemia. P&ants were followed for 1 year 
to document major cardiac events (PTCA, CABG, myocardial infarction, death), related 
to the target lesion. A retrospective analysis was performed on those lesions, where 
PTCA was deferred. Results: PTCA was deferred in 107 lesions, because no reversible 
perfusion defect was present in the region of interest. Percentage diameter stenosis 
using quantitative coronary angiography ranged from 42.91%. FFR was abnormal in 15 
of these lesions. Clinical follow up after 12 months was completed in all patients. A total 
of 12 events occurred in this group, related to the target lesion. The results for all lesions 
with a normal MIBI SPECT and deferral of PTCA are presented in the table: 
Deferral of PTCA: Events per FFR group 
FFR >= 0.75 
FFR < 0.75 
(* pc0.05) 
n events 95% Cl 
92 8 (8.7%) 4.1 - 16.9’ 
15 4 (26.7%) 8.9 55.2* 
Conclusion: Deferral of PTCA in patients with multivessel disease, because of absense 
of reversible perfusion defects, results in an 3 times higher event rate at 1 year follow up 
in those patients with a FFR ~0.75 compared to those with a FFR x0.75. This study pro- 
vides. accumulative evidence that intracoronary physiological parameters are useful for 
clinical decision making. 
1071-23 Fractional Flow Reserve Versus Stress Test to Assess the 
Functional Severity of Moderate Coronary Artery Stenosis 
Nuri I. Akkus, Surender Sandella, Anil Sharma, Tarif Kannan, Talal T. Abdul-Baki, 
Massoud A. Leesar. University of Louisville, Louisville, KY 
Background: the accuracy of pressure-derived myocardial fractional flow reserve (FFR) 
during coronary angiography is equivalent to that of information provided by noninvasive 
tests. The purpose of this study was to compare the cost, duration of hospitalization, pro- 
cedure time, radiation exposure time, and the amount of contrast media used in the cath- 
eterization laboratory using FFR vs. stress test. Methods: we randomized 35 patients 
during coronary angiography to FFR measured by WaveWire (n=19) or stress test 
(ST)(n=l6); patients were admitted to the hospital with unstable angina and had a mod- 
erate coronary artery disease (40-70% stenosis). The patients in the FFR group who had 
a FFR>0.75 were discharged home on the same or the next day; the ST group under- 
went ST on the next day and were discharged home after the ST revealed no ischemia. 
The total cost of the procedure included cost in the catheterization laboratory (equip- 
ment, supply, registered nurse time, and radiologic technologist time), and that incurred 
with post procedure care (resources used in the transitional care ut,it, the cost of perti- 
nent laboratory and stress tests) until the time of hospital discharge. Results: the total 
cost was $1300 r 52 in the FFR group vs. $1904 i 99 in the ST group, p<O.OOi, The 
duration of hospitalization was 9 ? 2 h in the FFR group vs. 44 f 4 h in the ST group, 
p<O.OOl. The procedure time was 43 + 3 min in the FFR group vs 35 i 3 min in the ST 
group, p = NS. The radiation exposure time was 11 f 1 min in the FFR group vs. 9 i 2 
min in the ST group, p = NS. The amount of contrast media used was 201 2 14 ml in the 
FFR group vs. 168 + 12 ml in the ST group, p = NS Conclusion: 1) Measurement of 
FFR in patients with moderate coronary artery disease is cost-effective and decreases 
the cost approximately by $600. 2) Measurement of FFR shortens the duration of hospi- 
talization by 80%. 3) These benefits are not associated with an increase in procedure 
time, radiation exposure time, and the amount of contrast media used. 
1071-24 Effect of Diabetes Mellitus on Coronary Collateral 
Circulation: Assessment by Pressure-Derived Fractional 
Collateral Blood Flow 
Koichi Tamita, Takashi Akasaka, Tsutomu Takagi, AtsushI Yamamuro, Kazuaki Tanabe, 
Kunihlko Nagai, TomokoTani, Kenji Yamabe, Minako Katayama, Shin Mizoguchi, 
Shigefumi Morioka. Kobe General Hospital, Kobe, Japan, Kawasakf Medical School, 
Kurashiki, Japan 
Background: It has been shown that the development of coronary collateral vessels 
assessed by coronary angiography is poorer in patients (pts) with than without diabetes 
mellitus (DM). It is difficult to evaluate functional collateral circulation with angiographic 
assessment. lntracoronary pressure measurement is a new technique to provide accu- 
rate and quantitative information about the collateral circulation, and it can be easily 
applied during percutaneous, coronary interventions (PCI). We evaluated the relation 
between pressure-derived fractional collateral flow (PDCF) and the effect of DM on coro- 
nary collateral circulation. Methods: The study included 30 pts with DM and 40 pts with- 
out DM who had a single diseased vessel with >50% diameter stenosis (%DS) assessed 
by quantitative coronary angiography (QCA) and underwent elective PCI. Pts with 
JACC February 2001 ABSTRACTS - 
chronic total occlusion were excluded from this study. The minimal lumen diameter 
(MLD) and %DS were evaluated by QCA before PCI. The fractional flow reserve (FFR) 
before PCI was calculated as the ratro of the distal coronary pressure divided by the 
proximal coronary pressure under hyperemia. The PDCF was determined by simulta- 
neous measurement of mean aorta pressure (Pa), distal coronary pressure during the 
balloon occlusion (Poc),and central venous pressure (CVP): PDCF=(Poc-CVP)/(Pa- 
CVP) Resulis : Baseline characteristics were similar between both groups. 
MLD(mm) %DS(%) FFR PDCF 
DM 0.84%0.38 71.9+13.0 0.56iO.20 0.16t0.11* 
nonDM 0.82t0.48 73.4+11 .Q 0.55iO.18 0.24iO.13 
(*P=O.Ol “s non DM) Conclusion: The development of functional collateral circulaiion is 
poorer rn pts with than in pts without DM. DM is thought to be an important factor affect- 
ing coronary collateral circulation. 
1071-25 Cyclic Flow Variation Can Detect Massive Thrombus and 
Predict Abrupt Coronary Occlusion After Successful 
&perfusion Therapy 
Hiroyashi Yamamoto, Atushl Hirayama, Yasunori Ueda, Hrroya Mrzuno, Masahiko 
Shim& Kazuhisa Kodama. Osaka Police Hosp!ta/. Osaka, Japan 
BACKGROUND Cyclrc flow variation (CFV) 
IS the phenomenon known to be present in 
the process of thrombotic arterial occlusion 
and has been demonstrated to be predictive 
of abrupt coronary occlusion (AO) after elec- 
ttve percutaneus transluminal coronary 
angioplasty (PTCA). Therefore, we tested if 
CFV is related with the amount of thrombus 
observed in the culprit lesion or if CFV is pre- 
dictive of A0 in the patients (pts) with acute 
myocardial infarction (AMI) after reperfusion 
by PTCA.METHODS Consecutive 62 pts 
with AMI successfully reperfused by PTCA were prospectively enrolled.’ The amount of 
thrombus at the culprit lesion of AMI was determined as massive or little by the angio- 
scopic observations. After angiographically successful reperfusion by PTCA with or with- 
out stenting, coronary flow velocity was contmuously recorded by doppler guide wire. 
CFV was defined as the gradual decline in the flow velocity >25% followed by abrupt 
recovery. The relation between CFV and the amount of thrombus and A0 was evalu- 
ated.RESULT Stenting was required rn 48 (77%) pts. Massive thrombus was detected 
more frequently (100% vs 36%, p less than 0.05) and A0 occured more frequently 
(100% vs 2%, p less than 0.05) in the pts with CFV ihan without. CFV was detected less 
frequently (2% vs 27%. p less than 0.05) in the pts wiih stenting than without. CONCLU- 
SION CFV was sigmficantly related with massrve thrombus ai the culprit lesion and the 
occurence of A0 after reperfusron in ihe pts with AMI. CFV may be an easy and reliable 
way to detect the presence of massive thrombus after angiographically successful reper- 
fusion therapy and to predict the occurence of AO, which may be prevented by stenting. 
1071-26 The Effect of Lesion Length on FFR: A Study Using 3D-IVUS 
Misao Nakada, Tadanori Arzawa, Hiroshi S&o, Ken Ogasawara, Hajime Kirigaya, 
Kazuyukr Nagashima, Hajime Fujimoto, Yu]i Oikawa, Kimihiko Ishrmura, Long-Tai Fu 
Hiroshi Watanabe. The Cardiovascular Institute, Tokyo, Japan 
Fractional flow reserve (FFR) has been regarded as a valuable parameter for physiologi- 
cal evaluation of coronary stenosis. However, the effects of lesion length(LL) on FFR 
have been unclear, so we studied the effects of LL and coronary stenosis on FFR using 
BD-IVUS. We performed SD-IVUS and measured FFR using a pressure wire in 23 
lesions, rangrng from 70 to 91% in % area stenosis(%AS). We obtained LL of coronary 
stenosis of above 70%AS by counting number of sl1ces(lslice=0.1mm) from SD-h/US. 
FFRs were plotted against LL(Ftg ). This revealed that FFR reduces as the LL gets 
longer(R=0.76, p=O.OOOl). It is clarified that LL can be affected by LL. LL should be con- 
sidered for physrological evaluation of coronary stenosrs as well as %AS 
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1072-28 Local Alcohol Delivery in Coronary Arteries May Prevent 
Repeat In-stent Restenosis 
Ming W. Liu, Francisco Chio, Masroor A. Khan, Jain F. Luo, Diane Alred. University of 
Alabama at Birmingham, Birmingha, AL 
Background: lntimal hyperplasia is the major mechanism of in-stenl restenosis. Local 
deliveries of alcohol solutron in rabbit iliac and pig coronary arteries have been shown to 
reduce rniimal hyperplasia. The purpose of this study was to evaluate the efficacy of 
intramural delivery of 15% alcohol soluiion in preventing repeat in-stent restenosis in 
humans Methods and Results. A total of 46 patrents (pts) with in-stent restenosis were 
enrolled in the study. After successful balloon dilatation of in-stent restenotic lesions, 
InfusaSleeve (LocalMed, Palo Alto, CA), a local delivery device was used to deliver 15% 
alcohol solution to the lesion wrth 3 ml per delivery. Mean ages of pts were 62?llyears; 
28 were males; 15 had diabetes; 38 had hypertension and 34 had hypercholesterolemia. 
Vessel sites lreated were LAD in 21, LCX in 7, RCA in 17 and saphenous vein graft in 1. 
At enrollment, patrents had 1.7rl.2 occurrences of r&stenosis, ranging from 1 to 7. There 
*were 17 pis requiring 2 local deliveries to cover the lesion. Luminal diameter stenosis 
before and after angioplasty /local delivery were 73rlO and 2O-clO % respeciively. 
Lesion type were type A in 5 pts, B1 in 8, BZ in 20 and C in 13. In-hospital outcomes 
included 4 non-Q myocardial infarcttons (MB elevation greater than 5 times upper nor- 
mal) and 1 cardiac death (due to heari failure). Follow-up (F-U) was completed in 44145 
(98%). At F-U of 11.5~1.5 months, there were 1 sudden cardiac death, 2 non-cardiac 
deaths and 10 repeat revascularizaions. Based on the initial length of restenotlc lesion 
before the alcohol delivery, there were 14 pts with lesion length c 10 mm, 13 pts with 
lesion length 10.20 mm and 14 pts with lesion lesion > 20 mm. Target vessel revascular- 
ization rate in these 3 groups were 7% (l/14), 15% (2/13) and 7114 (50%) (p < 0.02). 
Conclusion: In this patient population with an increased rncidence of repeat in-stent rest- 
enosis, local alcohol delivery may reduce the restenosis especially in patients with rest- 
enotic lesions of shorter length. 
1072-29 Can Low Molecular Heparin Dalteparin Inhibit In-Stent 
Neointimal Hyperplasia Following Repeated PTCA to Treat 
In-Stent Restenosis? A Randomized Trial Followed by 
Serial IVUS Analysis 
Jun.ichi Kolani, Shrnsuke Nanto, Tomoki Ohara, Takakazu Morozumr, Tetsuya 
Watanabe, Masashr Fujita, Mayu Nishio, Seiki Nagata. Kansai Rosal Hospital, 
Amagasaki, Japan 
Low molecular heparin (LMH) is reported to attenuate the extent of proliferation of 
smooth muscle cells in vitro. However, there IS no clear consensus as to whether this 
mechanism is effective in the attenuation of in-stent restenosis. The arm of this study was 
to investigate whether neointima formation can be restricted by the local delivery of 
highly concentrated dalteparin sodium (Fragmrn R). Thirty patrents who underwent suc- 
cessful balloon dilatation to treat in-stent restenosis were randomly divided to receive a 
15mrnute local delivery of erther 5ml LMH (1,000 IU/ml) or saline. The local delivery of 
LMH was conducted using a local drug d&very catheter. In-stem neointimal hyperplasia 
and restenosis were assessed by the quantitative coronary ultrasound technique. The 
residual plaque burden inside the stent was assessed rn terms of the difference between 
the stent area (SA) and the lumen area (LA), and neointimal proliferation was assessed 
in terms of the difference between the final SA-LA and SA-LA at B-month follow-up (F/U). 
The results are shown in the table. In conclusion, the infusion of highly concentrated 
dalteoarin was able to not onlv inhibit neointimal orollferation but cause the rearession of 
the residual plaque burden in 6 months. Results: 
Low molecular hepann Saline P value 
Final activated clottmg time 
Final SA (mm2) 
Final SA-LA (mm2) 
F/U SA (mm2) 
F/U SA-LA imm2i 
282+/-42 
iO.l+/-3.23 
2.78+1-l .78 
Io.5+/-0.78 
2.00t/-0.93 
311 J-92 0.423 
12.4+/-2.73 0.086 
3.98+/-1.87 0 176 
Iz.a+/-4.21 0.210 
4.37+/-2.56 0.045 
1072-30 Intra-Coronary Radiaton Therapy With Liquid Radioisotope 
Samarium (153~Sm). Results From a Pilot Phase of a 
Randomized Trial 
Alvaro Moura, Airton Yamada, Cesar Dusilek, Rita Perussolo, Dalton Precoma Nossa 
Sra das Gracas Hospitaal, Curitrba, Brazil, CERMEN, Curitiba, Brazil 
Background: Coronary radiation with beta sources reduces restenosis in patients with 
de nova and restenotic lesions. We have demonstrated that local beta radiation delivered 
by a solution of the beta emitting radroisotope samarium (153.Sm) used to inflate con- 
ventional PTCA balloons inhibits restenosis in the rabbit model. Our objective was to 
present the first cases from the pilot phase of a clinical trral with the liquid radioisotope 
153.Sm. The primary end point was angiographic lumen loss at six months, and second- 
ary end points were additional QCA and clinical outcome at six months. Methods: Fif- 
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teen patients and sixteen l&ions were treated with a radiation dose of 15 Gy at 1 mm 
depth. Radiation was delivered by a single perfusion balloon inflation of 7-l 1 minutes 
filled with 153Sm. Results: There were no deaths, emergency revasculartzations, or MI 
among this group of patients. There was no intra-patient release os isotope, and there 
was no room contamination caused by leakage. Radiation exposure to the operator was 
less than l.SmR/h. At three months, 1115 patient requtred target lesion revascularization 
due to delayed thrombosis. At six months the binary restenosis rate was 3116 (19%), and 
the late-loss index was 0.25 (see table). Conclusions: Coronary radiatton therapy using 
the liquid radioisotope 153.Sm is feasible and can be performed safely. These prelimi- 
nary results of the pilot phase already suggest a significant benefit in treating patents 
with the method. The efficacy of this modality of treatment remains to be estabilished by 
the randomized controlled clinical trial. 
IS Baseline Post 6 months 
ref. diam (mm) 2.7+-0.6 2.8+-0.6 2.71-0.7 
MLD 0.6+-0.2 2.3+-0.4’ 1.9+-0.8*” 
% stenosis 76.9+-l 1.5 14+-12.3’ 31+-26.6’” 
MLD=minimal luminal diameter, *P&O5 vs. baseline, “PxO.05 vs. post 
1072-31 Is 6 Months of Plavix Enough to Prevent Late Total 
Occlusion After Gamma Radiation for In-Stent Restenosis? 
Ron Waksman, Andrew E. Ajam, Han-E&o Kim, Roxana Mehran, Alexandra J. Lansky, 
Regina Deible, Maeve Taaffe, Gary S. Mintz, Lowell F. Satler, Kenneth M. Kent, Augusta 
D. Pichard. Washington Hospifal Center. Washington, DC 
Background: Six months of antiplatelet therapy after treating in-stent restenosis (ISR) 
with gamma radiation demonstrated a redu.ction in the late thrombosis rate. We aimed to 
determine whether 6 months of Plavix therapy was long enough to prevent late total 
occlusion (LTO). 
Methods: In PLAVIX WRIST (Washington Radiatron for In-Stent restenosis Trial with 6 
months of PI&x) 120 patients with ISR underwent PTCA (29% with additional stent) and 
were treated with intracoronary gamma radiation using Iridium-192. Patients were dis- 
charged with 6 months of Plavix (75 mg QD). Angiographic and clinical follow-up was 
continued after 6 months. 
Results: Follow-up angiogram detected 3 patients with LTO while taking Plavix (50, 180, 
and 184 days). At 6 months, 107 patients (89%) completed 6 months of Piavix and then 
were asked to stop the drug. Patients were followed clinically beyond 6 months for car- 
diac events and LTO. Twenty-nine patients continued to take P&ix mainly due to neuro- 
logical events or peripheral vascular disease. None of the patients who continued to take 
Plavix had an event related to LTO. In the remaining 78 patients (73%), Plavix was 
stopped; the mean follow-up from cessation of the drug to the patient contact was 90.4 
days (range 6-191). Two patrents (2.6%) presented with LTO and Q-wave myocardial rnf- 
arction at 19 and 100 days after stopping the Plavix; both patients had angiogram and 
IVUS studies demonstrating patent artery two weeks prior to the event. Overall 5 patients 
(6.4%) had target vessel revascularization (3 not related to LTO) and the major adverse 
cardiac event rate (MACE) was 7.7% (6 pts). 
Conclusions: To date the clinical event rate in patients treated with radiation therapy 
who stopped Plavix after 6 months is low. The optimal duration of Plavix therapy to pre- 
vent LTO remains to be defined based on a longer follow-up. Six-month Plavix free clini- 
cal follow-up of this cohort will be available for presentation. 
1072-32 EndothelinA Receptor Antagonism May Prevent In-Stent 
Restenosis in Humans 
Zenon S. Kyriakides, Dimitrios T. Kremastinos, Michael Georgiades, Stavroula Psychari, 
Theofilos Kolettis, Eleni Voidou, Eftihia SbarQuni, Aias Antoniadis, George K. Karavolias, 
David J Webb. Onassis Cardiac Surgery Center, Athens, Greece, Western General 
Hospital, University of Edinburgh, Edinburgh, United Kingdom 
Background: EndothelinA receptor (ETA) antagonism has been shown to reduce neoint- 
imal hyperplasia in a porcine coronary stent model. However, studies in humans are 
scarce. We examined the effects of 80-123, an ETA antagonist on reducrng in-stent res- 
tenosis in humans. 
Methods: 43 pattents with stable angina undergorng elective angioplasty and stenting for 
single artery lesion were studied post-treatment (post) and at 6 months follow-up (F/U) 
using serial volumetric intravascular ultrasound analysis. All the patients received a steel, 
ACS, stent. Stern, lumen, and intimal hyperplasia (IH=stent-lumen) cross sectional areas 
(A) were measured every lmm of In-stent length. Saline (23 patients) or BQ-123 (20 
patients) was infused in the dilated artery at the rate of 3 mllmin, 300 nmollmin for 20 
min. The time period of drug infusion was from 5 min before the pre-stent balloon inflation 
until 5 min after the end of stent implantation. 
(mean i: SD) BQ, n=ZO Controls, n=23 P 
Post smallest stent A (mmL) 7.5k1.7 7.1+1.2 .49 
F/U smallest stem A (mrne) 7.6~2.1 7.6+1.8 .97 
F/U smallest lumen A (mma) 5.921.3 5.5k2.6 .63 
F/U IH volumes (mm3) 21*25 27r34 .47 
Stenosis (%) 30*15 40+24 .09 
Binary restenosis, n 0 5 .05 
Conclusion: ETA antagonist administration: a) is feasible and safe during angioplasty, 
and b) shows a tendency to decrease IH and in-stent restenosis in humans. 
1072-33 A Novel Drug-Delivery Stent: Intravascular Ultrasound 
Observations From the First Human Experience With the 
QUANAM QuaDS-QP2 Stent System 
Yasuhiro Honda, Eberhard Grube, Luis M. de la Fuente, Paul G. Yock, Peter J. 
Fitzgerald, Simon H. Stertzer. Stanford Universify, Stanford, CA 
Background: The QUANAM QuaDS-QP2 stent (Quanam Medical Corp., Santa Clara, 
CA) is a slotted-tube, 316L statnless steel atent with multiple polymer sleeves that slowly 
release QP-2, a microtubule-inhibitor to prevent neointimal proliferation following stent- 
ing. Preliminary results from a pilot clinical study showed the feasibility and efficacy of 
this new drug-delivery stent. 
Methods: To further characterize the long-term vessel response in the stented segment 
and its edges, we analysed serial IVUS (post-intervention and follow-up: 8.3 months) in 
14 native coronary lesions treated with the QuaDSOP stent. IVUS measurements were 
performed at six cross-sections in each target segment: the tightest cross-sections within 
the stent at baseline and at follow-up; the proximal and the distal stent edges (within 1 
mm of the proximal and distal stent ends): and the proximal and the distal reference 
sites. Cross-sectional narrowing (CSN) was calculated as neointimal area divided by 
stent area. 
Results: At baseline, no significant plaque protrusion or thrombus was detected over the 
stented segment. Mrld incomplete stent apposition and edge tear was observed in one 
and two cases, respectively. Percent expansion of the stent (minimum ?Sent area I aver- 
age reference lumen area) was 95 ri 22%. Serial changes tn quantitative IVUS parame- 
ters were shown in table. 
Baseline Follow-up I p-value 
stent 
Stent area (mma) 8.2 * 1 8 8.5 f 1.8 ns 
Neointimal area (mm’) 0 1.2 + 1.3 <0.0001 
Lumen area (mms) 6.2 r 1.8 7.4 i: 2.0 0.0007 
CSN (“/o) 0 14115 <0.0001 
Reference 
Vessel area (mm? 16.0 i- 5.0 16.6 r 5.6 ns 
Plaque area (mm’) 7.9 f 3.3 9.2 + 4.2 0.04 
Lumen area (mm”) 8.0t2.5 7.5 f 2.7 0.04 
Conclusion: The first human experience with the new drug-delivery stent showed mini- 
mal amount of neointtmal proliferation in the stented segment during the follow-up period. 
Late lumen loss at the reference sites adjacent to the stent was acceptable and predom- 
inantly due to plaque proliferation. 
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1073-34 Angiographic and Clinical Reasons for the Higher Mortality 
of Women With Acute Myocardial Infarction in Comparison 
with Men When Treated With Primary Angioplasty 
Ratil Moreno, Eulogio Garcia, Leopoldo Perez de Isla, Javier Soriano, Manuel Abeytua, 
Rafael Rubio, Esteban Lopez de Sa, Jose L. Lopez-Senddn. Hospifal Greg&o Marafidn, 
Madrid, Spain 
This study aimed to identify the angiographic and clinical reasons for the worse outcome 
of women with acute myocardial infarction (AMI) in comparison with men when treated 
with primary angioplasty (PTCA). Methods: the study population is constituted by 930 
patients with AMI treated with PTCA within 12 hours after symptoms onset. Of them, 111 
(12%) were female, and 819 (88%) male. The angiographic and clinical characteristics, 
as well as the outcome during hospitalization, was compared between men and women. 
Results: The results are summarized on the table. 
WOnlen Men P 
Mortality 19% 10% <O.Ol 
Re-AMI 1 .9% 2.4% NS 
Reocclusion 3.6% 4.4% NS 
Free wall rupture 3.3% 1 .4% 0.08 
Major bleeding 5.7% 2.9% 0.07 
Angio. success 91% 95% 0.06 
No. vessels 1.7kO.8 1.7+0.8 NS 
Proximal occlusion 52% 45% 0.09 
Initial TIMI 2-3 17% 1 1% 0.08 
Ejection fraction 0.44+0 15 0.45t0.14 NS 
Coronary stenting 55% 55% NS 
Ilb/lla inhibitors 1 1% 11% NS 
Age (Y=) 72~11 62+12 40.01 
Killio >l 36% 25% <O.Ol 
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Prior AMI 9% 16% <O.Ol 
Diabetes 39% 17% <O.Ol 
Hypertension 50% 36% co.01 
Smoking 16% 71% <O.Ol 
CO”CtUSlO”: I” patlent WItI, AMI Iraatecl with p I LX, mortality IS h,g,,el ,n women than c,, 
men. Angiographic features, however, are not different between men and women, and 
the worse prognosis of women seems to be mainly due to: 1) A worse clinical profile; 2) A 
higher incidence of left ventricular free wall rupture; 3) A trend to lower angiographic suc- 
cess rate 
1073-35 Variability Among Investigator Sites Within the Dynamic 
Registry: Implications for Interventional Benchmarking 
Javier Jimener, Elizabeth Legowski, Janet Johnston, Sheryl F. Kelsey, Katherine M. 
Detre, Warren K. Laskey, Howard Cohen, David 0. Williams. Rhode /s/andHospita/ and 
Brown university, Providence, RI 
Background: There is a need for monitoring the performance of facilities performing per- 
cutaneous cardiac interventions (XI). Rates of adverse events are typically selected as 
criteria. Knowledge of the range of adverse event rates a$ well a$ the variability of factors 
associated with adverse events according to clinical site is important in developing 
benchmarks. Purpose: To determine 1)the distribution of adverse event rates among 
sites performing PCI; and 2) the variability in prevalence of factors associated with 
adverse events following PCI. Methods: We analyzed the wave 2 (1999 enrollment, 
2024 patients) database of the Dynamic PCI Registry which includes 15 clinical sites. 
Results: In-hospital Percentile Range 
Events 
baseline features of patients Selected for PCI. Such variability needs to be ackno!&dged 
when developing benchmarks for institutional PCI periormance. 
Variable Median 25th 75th Minimum Maximum 
MI 2.6% 0.7% 5.6% 0.0% 1 1 1% 
CABG 0.8% 0.0% 1.7% 0.0% 2.6% 
Death 0.8% 0.0% 2.0% 0.0% 4.2% 
Of factors known to be associated with in-hospital death including age, female gender, 
prior revascularization procedure, prior Ml, renal failure, peripheral vascular disease, dia- 
betes mellitus, CHF, LV function, cardiogenic shock and number of vessels attempted, 
four varied at least 2-fold pavalence between the 25th and 75th percentiles among sites. 
These factors were history of CHF (4.9%-14.6%), EF >,20<.39 (4.4%-9.7%), cardiogenic 
shock (0%.2.5%), 2 vessels attempted (3.1%.12.1%). Conclusions: Considerable vari- 
ability was observed for rates of in-hospital death, MI and CABG among the 15 sites in 
the Dynamic Registry. The prevalence of four baseline factors previously associated with 
in-hospital death varied substantially according to the site. Difference in adverse event 
rates at sites performing PCI may be explained, in part, by the site-to-site variability in the 
1073-37 Pitfalls in Predicting Nonfatal Outcomes of Percutaneous 
Coronary Interventions: Lessons From Large Regional 
Angioplasty Registries 
David J. Malenka, Mauro Moscucc~, David E. Wennberg, Hebe B. Quinton, Winthrop D. 
Piper, Mirle A. Kellet, Andrea Sievers. F. Lee Lucas, Paul D. McGrath, Gerald T. 
O’Connor. Northern New England Cardivascular Study Group, Lebanon, NH, BC/BS of 
Michigan Cardiovacular Consortium. Ann Arbor; MI 
Background: When developing a prediction rule for a combined endpoint it is important 
to insure that the risk factors for this endpoint are similarly related to each of the individ- 
ual components. If not, effect modification is present. The post-angioplasty outcomes of 
nonfatal emergency coronary bypass surgery and nonfatal myocardial infarction are 
often combined and reported as Nonfatal Complications. We examined the relationship 
of age to Nonfatal Complications and its individual components. 
Methods: Data from the Northern New England Cardiovascular Study Group and Blue 
Cross Blue Shield of Michigan Cardiovascular Consortium registries on a total of 20,402 
consecutive procedures performed between 12197.9199 was used. Endpoints were com- 
pared (chi square) across 4 age categories. 
Results: As shown below, the effect of age on emergency bypass surgery and myocar- 
dial infarction differs. While infarctIon rates increase with age, bypass surgery rates do 
not increase with age and there is a trend towards lower rates. These findings were semi- 
lar when each of the reglonal registries was examined separately. 
Conclusions: Increasing age is positively associated with the risk of post-angioplasty 
infarction but not of post-angioplasty emergency bypass surgery. This observation is not 
consistent with the biology of aging, and It supports the possibility that physicrans are 
accepting “controlled infarcts” in older patients rather than proceeding to higher risk 
emergency bypass surgery. These findings suggest that age should not be used to pre- 
dict the combined endpoint of Nonfatal Complications. Rather, &s might best be devel- 
oped for each individual outcome and for patients >80 ver$u$ ~80. 
Percent Incidence of eCABG and MI by Age Group 
< 60 60-69 70-79 >80 p-value 
eCABG 0.6 0.7 0.7 0.4 0.383 
Ml 1.4 2.0 2.4 2.8 < 0.001 
1073-38 isolated Proximal Left Anterior Descending Coronary Artery 
Stenosis: Long-Term Clinical Outcome After Percutaneous 
Interventions. 
Background: Isolated proximal left anterior descending (LAD) artery stenosis is consid- 
ered life-threatening disease because of the large amount of myocardium at risk. Coro- 
Irene Bossi, Catherine Klersy. Christian Jordan, Bibi Fatemeh Hayerizadeh, Fadi Bou 
Aoun, Jean Claude Laborde, Bruno Farah, Bernard Cassagneau, Jean Fajadet. Jean 
Marco. Clinique Pasteur - UC/, 7bulouse, France 
1073-36 Racial Differences in the Use of Invasive Cardiac 
nary angioplasty improves the clinical status and stenting appears to be associated with 
a lower risk of r&stenosis. 
Procedures and I-Year Clinical Outcomes for Non-Q-Wave Methods:We analvzed in-hosaital and lona term results of 224 consecutive ots (57 ” I 
Myocardial infarction Patients Randomized to Invasive vs. females, mean age 63.11-l 1.7 years) undergoing percutaneous lnterventlons for an iso- 
Conservative hlanagement lated proximal LAD de nova lesion between January 1996 and June 1999. Pts with multi- 
Huma Samar, Prabhakara S. Heggunje, Prakash C. Deedwania, Michael J. Wade, Peter 
E. Carson. David R. Ferry, Robert A. O’Rourke, Willlam E. Bode”. Veterans Affairs 
Medical Center, Syracuse, NI: Hartford Hospital, Hartford, CJ 
vessel disease and LAD lesions distal to first septal perforator were excluded. 
Results. Mean lesion length by QCA was 11.5~5.4 mm and reference diameter was 
3.30i0.44 mm. Stenting was done in 178 cases. Mean final MLD was 3.41 ? 0 44 and 
the acute gain was 2.70 + 0.55 mm. In-hospital MACE (death, MI,TLR) occurred in 6 pts 
Background: Prior studies in patients with acute coronary syndromes have shown sig- 
nificant racial differences in the utilization rates of invasive cardiac procedures between 
whites and non-whites, but there are limited data regarding the relationship between pro- 
cedural usage and clinical outcomes among various ethnic groups of patients recovering 
from acute non-Q-wave (NQ) myocardial infarctjon (MI). Methods: We assessed the 
impact of race on utilization rates of invasive cardiac procedures (coronary angiography. 
and myocardial revascularization with CABG surgery or percutaneous coronary interven- 
tion [PCI]), and their effect on l-year clinical outcomes (death or MI) in patients random- 
ized to the Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital (VANQWISH) 
Trial. Results: Among the 683 whites and 207 non-whites (African-American [AA]=l07; 
Hispanics=lOO), almost twice as many whites underwent PCI than non-whites (18% vs. 
10%; P=O.O03). This racial difference was more evident among those assigned to the 
early invasive (INV) strategy (PCI rate in whites=47%; PCI rate in non-whites= 26%, 
P<O.OOl). Of note, at l-year, 23% of whites and 15% of non-whites sustained a trial pri- 
mary endpoint (death or MI), P=O.O25. Even after adjustment for confounding variables. 
non-whites had lower l-year cardiac events (odds ratio [OR]=0.6, P~O.019) and deaths 
(OR=0.5, P=O.O29) than whites. The racial difference in the adjusted l-year event rate 
was more prominent in paiients assigned to the conservative (CON) strategy (O&0.43, 
P=O.O14) than those assigned to the INV strategy (OR=0.67, P=O.279). Among non- 
including: 4 Ml and 3 TLR. 
Long term follow-up, available in 218 pts (median 571 days; range 266-990), showed 
2.7% mortality, 1.3% MI, 16.5% TLR. Non-prox LAD revascularization was needed in 5 
pts. Event-free survival rate were 0.83 (95% Cl 0.77-0.88), 0.80 (95% Cl 0.73-0.85) at 12 
and 24 months respectively. Univariate correlates of long term events are shown in 
Table. 
HR 95% Cl P 
Current smoking 13.39 1.68 - 6.87 0.001 
Ref. Diam. 0.38 0.16 0.89 0.027 
MLD post 0.39 0.18 - 0.83 0.014 
Acute gain 0.31 0.14 0.71 0.006 
Stenting 0.46 0.24 0.99 0.022 
At multivariate logistic regression analysis, stenting showed trend toward less long-term 
clinical events(HR 0.35; 95% Cl 0.1 l-1.09; p&069). 
Conclusion: Long-term prognosis of pts with isolated proximal LAD stenosis treated by 
percutaneous interventions is satisfactory with a low clinical event rate. Stentlng is asso- 
ciated with better long-term outcome 
whites, both AA pts and Hispanics showed similar outcomes. Conclusion: Significant - 
racial differences were $een in the use of PCI (particularly in the INV strategy) in this 1073-39 Gender and Racial Differences in Clinical Outcome After - 
large trial Of NQMI. Importantly, despite the lower rate of PCI, AA and Hispanic pts with Percutaneous Coronary Interventions 
NQMI, cornpared to whites, showed a significant improvement in l-year clinical out- 
comes when managed with a conservative, “lschemia-guided” strategy of non-invasive 
George Dangas, Roxana Mehran, Alexandra J. Lansky, Dmitriy Feldman, David J. 
risk stratification followed by the selective use of coronary Intervention. In such minority 
D’Agate, Lowell F. Satler, Kenneth M. Kent, August0 D. Pichard, Luis Gruberg, Javed M. 
pts. lower rates of PCI do not necessarily portend worse outcomes 
Ahmed, Gregg W. Stone, Martin B. Leon. Cardiovascular Research Foundatfon, New 
York, Washington Hospital Center, Washington, DC 
Background: Several studies have indicated decreased utilization of invasive cardiac 
procedures in African-Am&cans (AA) var$us Caucasian (C) pts. We sought to investi- 
gate the impact of race and gender on in-hospital and l-year outcome after performance 
Of percutaneous coronary interventions (PCI). Methods: A total of 6945 patients (66% C 
man, 26% C women, 5% AA men, 3% AA women) were followed for one year after PC1 
was performed. Independent predictors of in-hospital and late mortality were derived. 
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Results: Compared to men, women were older (67kll vs 63%11, p<O.O5), had greater 
LVEF (48rl3 vs 46kl3, pcO.O5), and had significantly higher frequency (~~0.05) 01 
hypertension, diabetes, hypercholesterolemia, PVD and history of CVA. In-hospital 
results (table): 
African-Americans Caucasians 
Men Women p Men Women p 
Mortality 1 .O% 4.1% 0.006 0.9% 1.2% NS 
Q-wave MI 0.2% 1 .S% 0.037 0.7% 0.4% NS 
MACE 2.4% 6.6% 0.001 2.8% 2.6% NS 
By multivariate logistic regression analysis controlling for baseline imbalances, AA 
female status was an independent predictor of in-hospital mortality: odds ratio 3.4 (1.3. 
9.5), p=O.O16. By Cox proportional hazards method controlling for between-groups 
imbalances, both AA female status: relative risk 1.7 (1 .O-2.9), p=O.O42, and C female sta- 
tus: relative risk 1.3 (1.0-l .7), p=O.O36, were independent predictors of 1 -year mortality. 
Conclusions: Compared to AA man, AA women have worse in-hospital mortality, fre? 
quency of MACE, and lower procedural success rate after PCI. A prospective longitudi- 
nal health care intervention program needs to evaluate these findings. 
1073-40 The Effect of Age on In-Hospital Mortality Following PTCA 
Varies With Sex and Ejection Fraction. Results From the 
National Cardiovascular Network (NCN) 
Emir Veledar, Trevor D. Thompson, Elizabeth M. Mahoney, Joy Burnette, William S. 
Weintraub. Emory University Atlanta, GA, National Cardiovascuiar Network, Atlanta, GA 
Background: Increasing age has been shown to be associated with higher mortality 
among patients undergoing percutaneous coronary intervention (PCI). However, 
whether this age effect is consistent across varying levels of other risk factors remains 
U"CkX 
Methods: We examined the outcomes of 39,316 patients undergoing PCI at 17 U.S. 
centers between 1198 and 6199. Multivariable logistic regression was used to determine 
the independent predictors of in-hospital mortality. Interactions between age and other 
baseline covariates were tested. 
Results: Mean age was 64+12 yrs with 33% female, 63% hypertensive, and 27% 
diabetic. Mean ejection fraction (EF) was 50+12 and 10% presented with an acute MI. 
Increasing age was associated with higher in-hospital mortality after adjusting for base- 
line differences (p<.OOi). However, the relationship between age and mortality was non- 
linear. The age by sex (p=.OOl) and age by EF (p=.OO6) interactions were significant. 
Among younger patients, increasing age had a more harmful effect for female patients 
(Odds ratio for 50 yrs vs. 40 yrs = 3.16, 95% Cl = 1.65-6.06) compared to males (Odds 
ratlo = 1.05, 95% Cl = 0.71-1.55). As age increased, the detrimental effect associated 
with increased age became stronger among males while this effect lessened somewhat 
among females. Among patients over 80, the effect of age was more significant among 
male patients (Odds ratio!or 90 vs. 80 = 2.26, 95% Cl = 1.69-3.02) compared to females 
(Odds ratio = 1 .18, 95% Cl = 37-l .61). The lower the EF, the less significant the impact 
of increased age on mortality. 
Conclusions: While increased age is an independent predictor of in-hospital mortality, 
the age effect is not the same across levels of other risk factors. The age effect is differ- 
ent for females compared to males and this effect is non-linear in both group?.. The age 
effect is also diminished among patients with impaired EF. Patients with low EF are at 
increased risk regardless of age. 
1073-41 Gender Differences Among Patients Undergoing Coronary 
Revascularization. Results from the National 
Cardiovascular Network (NCN) 
Trevor D. Thompson, Elizabeth M. Mahoney, Emir Veledar, Joy Burnette, William S. 
Weintraub. Emory University, Atlanta, GA, National Cardiovascular Nefwork, Atlanta, GA 
Background. Prior studies have reported that women undergoing coronary revascular- 
ization have worse in-hospital outcomes compared to those of men. 
Methods. We examined the clinical profiles and outcomes of women and men in a large 
national database of PTCA and CABG patients. The population consisted of 20,735 
patients (14,397 men and 6,338 women) undergoing CABG and 36,252 patients (24,111 
men and 12,141 women) undergoing PTCA at 21 US. centers between 1198 and 6/99. 
Multivariable logistic regression was used to determme the effect of sex after adjusting 
for differences in baseline and procedural characteristics. 
Results. Women were older with higher ratesof diabetes, hypertension, and history of 
CHF (all p<.OOl). Among PTCA patients, women had slightly lower rates of stenting 
(77% vs. 79%, p<.OOl) and multiple lesions attempted (33% vs. 35%, pc.001) compared 
to men. Emergent PTCAs were performed at similar rates among men and women (35% 
vs. 36% ~~141). Among CABG patients, women were less likely to have an IMA graft 
done (76% vs. 83%, p<.OOl) and had lower rates of 3.vessel or left ma#- disease (61% 
vs. 67%, pc.001). Women were more Ilkely to have an emergent CABG (31% vs. 29% 
pc.001) and had longer bypass (median = 95 vs. 91 min., pc.001) and cross-clamp times 
(63 vs. 60 min., pk.001). In a muliivariable model adusting for baseline and procedural 
differences, female sex remained a significant predictor of in-hospital mortality among 
CABG patients (Odds ratio = 1.32, 95% Cl = 1.08-l 60). Among PTCA patients, sex was 
no longer a significant predIctor of mortality after adjusting (Odds ratio = 0.88, 95% Cl = 
0.68-1.13). 
Conclusion. Women and men undergoing coronary revascularization had different clin- 
ical profiles and procedural characteristics. Female sex was associated with increased 
in-hospital mortality among CABG patients after adjusting for baseline and procedural 
differences. Among PTCA patients, the mortality rates of men and women were similar 
after adjusting for baseline and procedural differences. 
1073-42 In-Hospital Outcome After Stenting in Women Compared to 
Men. Results From the Registry of the Brazilian Society of 
Interventional Cardiology: CENIC 
Amanda G. M. R. Sousa, Luiz A. f? Mat&., Marco A. Costa, Cantideo M. Campos Netto, 
Angela T. Paes, Jamil Saad, Andre Labrunie, Alexandre Abizaid, Roberto Botelho, 
Fionaldo Buena, Eulogio Martinez, Pierre Labrunie, Carlos Gottchall, Costantmo 
Costantini, J. Eduardo M. R. Sousa. Brazilian Society of lntervenfional Cardiology - 
CENIC, Slo Pauio, Brazil, Institute Dante Pazzanese of Cardiology, SBo Paula, Brazrl 
Aims: To assess the clinical characteristics and outcome of women compared to men 
treated with coronary stent implantation. Methods: Between 1997 and 1999, 6 848 
female patients -Group 1 (Gl) and 16 905 males-Group 2 (G2) underwent stent implan- 
tation in 121 hospitals in Brazil participating in a national survey of the Brazilian Society 
of Interventional Cardiology - CENIC. Data were prospectively collected and entered in a 
dedicated database. In-hospital outcome measures included: procedural success (< 50% 
diametbr stenosis with TIMI 3 flow) death, surgery and myocardial infarction. Results: 
Variables Group 1 Group 2 P 
Mean age, SD (years) 63.5 t 10.7 58.9 i 10.9 c 0.001 
Diabetes (%) 21.6 13.8 < 0.0001 
Unstable Angina (%) 23.6 19.9 < 0.0001 
Multivessel disease (%) 39.4 43.4 < 0.0001 
Severe heart failure (%) 3.4 4.0 < 0.05 
LAD lesion (%) 33.5 30.2 < 0.001 
Complex lesion B,/C (%) 60.6 62.9 < 0.001 
Calcium (%) 20.3 16.8 < 0.0001 
Thrombus (%) 14.0 17.3 c 0.0001 
QCAilVUS (%) 37.i 39.0 c 0.05 
Aspirin (%) 88.4 89.1 NS 
Ticlopidine (%) 66.4 87.3 c 0.05 
Abciximab (%) 4.4 4.8 NS 
Technical Success (%) 97.3 97.7 < 0.05 
urgent surgery (%) 0.4 0.3 NS 
Myocardial Infarction (%) 1.5 1.2 NS 
Death (%) 1.8 0.9 < 0.0001 
Female gender was found as an independent predictor of in-hospital death in the multi- 
variate logistic model (p c 0.001). Conclusion: This large, nationally representative sur- 
vey has found that female patients are a subgroup of high-risk patients with worse 
baseline characteristics and higher incidence of complications after stenting as corn- 
pared to men. Even after adjustment for differences in baseline and demographic char- 
acteristics, female gender was retained in the multivariate logistic model as a risk factor 
of in-hospital death. 
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High Shear Stress After Successful Balloon Angioplasty is 
Associated With Restenosis and Target Lesion 
Revascularization 
Attila Thury, Glenn van Langenhove, Stephane G. Carlier, Mariano Albertal, Ken 
Kozuma, Evelyn Regar, Jolanda J. Went& Rob Krams, Cornelis J. Slager, Jan J. Piek, 
Patrick W. Serruys. Department of lnferventional Cardiology, Thoraxcenter, Rotterdam, 
The Netheriands, Laboratory of Hemodynamics, Thoraxcenter, Rotterdam, The 
Netherlands 
Background: Vascular wall shear stress (WSS) has been implied in the pathogenesis of 
atherosclerosis and vascular remodeling. Although, some authors have also suggested a 
role in the genesis of restenosis after coronary intervention, no straightforward evidence 
to sustain this thesis has been provided. 
Methods: In 202 patients included in the DEBATE I trial, values of WSS were calculated 
proximal to, in and distal to the lesion, after angiographically successful balloon angio- 
plasty (BA) with the Hagen-Poiseuille formula (WSS = 4pQ/pi R3). Volumetric blood flow 
(Q) and lumen radius (R) were derived from Doppler velocities and videodensitometric 
cross-sectional areas, respectively. Post-procedural values proximal to (WSSp,,,) and in 
the lesson (WSS,,.Ies,On) in arteries that developed restenosis (defined as a diameter 
stenosis [DS] > 50%, n = 72) were compared with those in arteries that did not develop 
restenosis (n = 130). Uni- and multivariate logistic regression and receiver operator char- 
acterlstic durve (ROC) analysis were applied to establish the prognostic power (odds 
ratio [OR]) and the best cut-off point (where sensitivity equals specificity) of post-proce- 
dural WSS values for restenosis and target lesion revascularization (TLR). 
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Results: WSSprox and WSS,,,.lesion were higher in the restenosis group (1.22 + 0.61 vs. 
1.05 f 0.51 N/m2 and 3.61 i 2.38 vs. 2.46 5 1.39, p&05, respectively). WSS,,.leslon vai- 
ues higher than 2.58 Nfm’were found to be predictive of restenosis (OR = 1.42, pcO.O5), 
whereas WSSp,, was associated with increased incidence of TLR (OR = 2.33, 
p<O.O05). In the multivariate regression model WSSprav was the only independent pre- 
dictor of TLR when entered with other known predictors such as DS and distal coronary 
flow reserve (OR = 2.15, pc0.05). 
Conclusions: WSS,n.les,on after BA is associated with higher Incidence of angiographic 
restenosis. WSSprox has an independent predictive value for TLR. This study opens per- 
spectives for the on-line use of WSS as a combined parameter of anatomy and physiol- 
ogy in the catheterization laboratory to assess necessity of adjunctlve therapy after 
successful BA. 
six-months. Patients and procedural characteristics include 1 or 2 de nova lesions in 
native coronary arteries with a reference dwmeter between 2.2 and 2.7 mm. In the stent 
arm, a small Bestent mounted on a 2.5 mm balloon is deployed and post dilation IS per- 
formed if necessary, with a c 2.75 mm semicompliant balloon. Results: Out of the 426 
patients, 214 were assigned to balloon and 212 to stent. The rate of cross-over in the bal- 
loon and stent arms was 14% and l%, respectively. 
stent Balloon P 
Pre-RVD (mm) 2.32+0.32 2.29439 NS 
Pre-MLD (mm) 0.7&0.34 0.80*0.38 NS 
Pre-DS 66tl4% 65+15% NS 
Post-RVD (mm) 2.64?0 95 2.45t0.71 0.02 
Post-MLD (mm) 2.33t0.86 1.84*0.62 so.01 
Post-DS 12ill% 25il4 NS 
Acute gain (mm) 1.55+0.52 1.04~0.24 <O.Ol 
6mo.MLD (mm) 1.47+0.50 1.31+0.58 0.01 
GmoStenosis 37r20% 44*23% 10.01 
Restenosis rate 27% 37% <o 05 
6mo.Occluslon 1.4% 3.7% <O.Oi 
MACE at 6 mo. 11% 14% NS 
Conclusion: The results of the RAP study demonstrate that coronary stenting reduces 
the rate of restenosis and vessel reocclusion at six-month in small native coronary arter- 
ies. 
sFF2 
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Percutaneous Intervention in ‘Hot’ Plaques is Associated 
With an Unfavorable Outcome: New Insights 
Christodoulos Stefanadis. Hippokration HospIt&, Athens. Greece 
Background. Ex viva and in viva studies 
have shown thermal heterogeneity within “; s. ,,a 
human atherosclerotic plaques. The prog- * * 
nostlc significance of atherosclerotic 1 
; ‘: 
plaque temperature, however, for the , : 
long-term follow-up is unknown. Methods. ’ 
Thus, we prospectively investigated the 
relation between temperature difference 
(Ab) between the atherosclerotic plaque 
and the healthy vessel wall and event-free 
survival among 86 patients with coronary artery disease undergoing successful percuta- 
neous intervention. Temperature was measured by a !hermography catheter previously 
validated. The study population consisted of patients with effort angina (34.5%), unstable 
angina (34.5%) and acute myocardial infarction (30%). Results. iid was increased pro- 
gressively from effort angina to acute myocardial infarction (0.132+0.18”C in effort 
angina, 0.637+0.26’C in unstable angina, 0.942iO.58”C in acute myocardial infarction). ^ 
The median clinical follow-up period was 17.881-7.16 months. A0 was greater in patients ^ 
with adverse cardiac events compared to patients without events (AO: 0.9391;0.49”C; 
95% C.I [intervals 0.72-l ,141 “s 0.428iO.42”C; 95% C.I. [0.33-0.521, P<O.OOOi) (figure). 
Conclusions. Percutaneous intsrventlon in plaques with increased temperature is assoc~- 
ated with an unfavorable outcome. Strategies for stabilization of atherosclerotic plaques 
are required. 
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Cardiac Magnetic Field Mapping at Rest Detects Coronary 
Restenosis in Patients After Percutaneuos Transluminal 
Coronary Angioplasty and Stent Implantation 
Alexander Schirdewan, Andrey Gapelyuk. Damela S&big, Udo Meyerfeldt, Henry 
Schuett. Michail Primin, Frank Uhlich, Juergen Waigand, Fiainer Dietz. Franz l/o/hard 
Hospital, Cbarife. Humboidt University Berlin, Germany 
Background: Noninvasive detection of restenosis in patients after percutaneuos translu- 
mina! coronary angioplasty and stent implantation remains a major clinical problem. The 
value of cardiac magnetic field mapping in detecting restenosis in such patients has not 
been investigated. Methods: Fifty eight patients with single or multiple vessel coronary 
artery disease (62,5% denovo stenosis and 37,5% in-stent restenosis) successfully 
treated with coronary angioplasty and/or stenting were included in a 6 months cllnicai, 
magnetic field mapping and angiographic follow up study, to investigate the ability of the 
magnetic field mapping to detect rester&s (diameter stenosis >50%). Noncontact mag- 
netic field mapping was performed over the anterior chest wall before angioplasty and 
steiiting and 6 months later, prior to control angiography using an axial second order gra- 
diometer SQUID-system. Fourteen isointegral magnetic field maps per study were ana- 
lyzed (11 for QRS and 3 for ST-T intervals). Subtraction maps were calculated to 
estimate differences between first and control maps followed by a forward stepwise dis- 
criminant analysis to select the parameters for revealing patients with restenosls. 
Results: Restenosis was detected in 27 patients by control angiography. Magnetic field 
mapping identified correctly 26127 pts with restenosis. and classified 30/33 pts without 
restenos!s. Three pts were classified false positive. Among them, one patient developed 
a denovo stenosis in a nontreated vessel, one patient showed a subcritical in-stent intima 
proliferation and one patient had a single vessel disease with a large old myocardial inf- 
arction. The patient, classified false negative, showed a 70% stenosis diameter in a for- 
merly occluded vessel The overall sensitivity and specificity for magnetic field mapping 
detecting restenosis after stent implantation was 96,3% and 90.9%. Conclusion: The 
results of this study show a good sensitivity and specificity in detection of restenosis, 
suggesting that magneti! field mapping at rest could become an effective , fast, safe and 
inexpensive approach to follow up patients after coronary angioplasty and stenting. 
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Stent Reduces Restenosis in small Vessels. Results of the 
RAP Study 
Eulogio Garcia, Manuel Gomez-Recio, Raiil Moreno, Javier Pasalodos, Armando 
Bethancourt. Javier Zueco, Andres lfiiguez. Hospital Gregorio Maraiidn, Madrid, Spain 
The RAP study (Restenosis en Arterias PequeRas) is a multicenter prospective random- 
ized trial which compares the results of Bestent implantation versus balloon angioplasty 
!n 426 patients with lesions located in small vessels. The primary end-point of the study is 
anglographIc restenosis at six months. Secondary end-points Include the incidence of 
Major Adverse Cardiac Events (death, Infarction or new revascularlzation procedure) at 
32-5 
5:00 p.m. 
Homocysteine Therapy Improves Clinical Outcome After 
Successful PTCA: The Swiss Heart Study 
Guido Schnyder, Riccardo Pin, Marco Roffi, Yvonne Flammer, Otto M. Hess. 
Swiss Heart Center, Bern, Swtzerland 
Background: We have recently documented an association between elevated plasma 
homocysteine levels (tHcy) and restenosis after coronary angioplasty (PTCA). The effect 
of tHcy lowering on post PTCA outcome has been evaluated in a large single center 
study. Methods: In a prospective double blind randomized study, 553 patients (107 
women, 446 men; mean age 62+11 years) received either a combination of folic acid 
(img), vitamin 612 (4OOpg) & B6 (10mg) [Group 1, n=272] or placebo [Group 2, n=281]. 
Patients were treated for 6 months after successful PTCA (741 treated lesions). Levels of 
tHcy were measured at study entry and at follow-up. The primary endpoint was the com- 
posite rate of death, myocardial infarction (Ml) and target vessel revascularization (TVR). 
Seventy patients (110 lesions) were lost to follow-up or did not comply with the study pro- 
tocol. Results: At 6 months the composite endpoint was significantly lower in Group 1 
(12 0% vs 19.8%: p=o.o2). 
1 
-- 
- l=olic acid< I39 Ez I312 
m-e - Placebo 
Similarly, Group t showed less TVR (10.6% “s 17.4%; p=O.O3) and a trend towards 
lower rates of death and Ml (1.3% “s 2.5%, 0.8% “s 1.7%. respect&y). Baseline tHcy 
levels were similar in both groups (11.4~4.8~moW “s 11.1+4.6pmoVI), while at follow-up 
tHcy levels were significantly lower in Group 1 (7.5i-2.5pmolil “s lO.li4.3~mOlil, 
piO.0001). The use of stents and GP llbillla inhibitors was similar in both groups. Con- 
clusions: Lowering tHcy levels improves ci~iwal outcome after successful PTCA. In 
combination with our previously reported correlation between ttfcy levels and restenosis, 
these results suggest a causal relationship and raise the possibility of a low cost and low 
side effect treatment to decrease event rates after PTCA. 
32-6 
5:15 p.m. 
Influence of Planned 6-Month Follow-Up Angiography on 
Late Outcome After Coronary Angioplasty: a Randomized 
Study 
Jurrien M. ten Berg, Johannes 6. Kelder, Maarten Jan Suttorp, Freek W. A. Verheugt 
Thijs(H) W. M. Plokker. St. Anfonius Hospital, Nieuwegein, The Netherlands 
Background: Whether planned follow-up anglography after coronary angioplasty influ- 
ences late outcome is still largely unknown. Methods: We studied the effect of random- 
ization to planned angiography 6 months aHer coronary angioplasty on late outcome. in 
the Balloon Angioplasty and Anticoagulation Study (BAAS) the effect of pretreatment 
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with coumarins on early and l-year events was studied in 1058 patients. Of these 527 Each wire has 2 sensors located at the maximum curve, 0.5mm apart, allowing monitor- 
patients ware subrandomized to clinical follow-up alone and 531 patients to clinical and mg of T between and within plaques. The catheter also has a central wire with a thermal 
angiographic fOllOW-Up. ReSUltS: The Clinical and anQiOQraphiC baseline characteristics sensor to monitor the blood T simultaneously. The real-time data acquisition software 
were well comparable between the two groups. At i-year, more events occurred in the supports digital transmitters for each channel with a thermal resolution of 0.0025 “C and 
angiOQraphiC fOllOW-Up group than in the group with Clinical follOW-Up alone: 122 (23.2%) a sampling rate of 20 readings per second. It can also display the circumferential and lon- 
versus 88 (16.7%) (p=O.Ol). While the incidence of death or myocardial infarction was gitudinal thermal map of the vessel wall. 
similar at l-year, the difference was due to a higher revascularization rate in the group 
with follow-up angiography: 113 (21.3%) and 67 (12.7%) (relative risk 1.7; 1.3-2.3, 
p=O.O003). Between one and three years of follow-up, there were s.ome more reinterven- 
tions in the clinical follow-up group, but at three years still more events had occurred in 
the angiographic follow-up group (146 (34.5%) versus 114 (26.3%) (p=O.O3)). Angio- 
graphic follow-up was not associated with a reduction of death. But there was a non-sig- 
nificant reduction in myocardial infarctions (7 (1.3%) versus 13 (2.5%), p=O.15) and a 
significantly improved functional class at the end of fo!low-up. The effect of follow-up 
angiography on reintervention rate was similar for stented and non-stented patients. 
Conclusions: Planned, randomized, follow-up angiography to evaluate the late results 
of coronary intervention led to a 1.7 times higher reintervention rate. This effect was sim- 
tlar for stented and non-stented patients. More reinterventions did not improve survival 
but led to a non-significant decrease in myocardial infarctions and a significantly 
improved functional class. 
Results and Conclusion: In our phantom model simulating blood vessels and hot 
plaques, BC showed a T resolution of O.Ol”C capable of detecting T heterogeneity in var- 
ious conditions of blood flow, plaque T and luminal stenosis. We have tested this system 
in 5 in-bred atherosclerotic dogs and 10 Watanabe rabbits. T heterogeneity was detected 
in all. By adding an ultrasound assembly to the BC, we are developing a combined 
Thermo-Elastography ‘system, which m its final prototype, will provide thermal, structural 
and elasticity data for detecting plaques and determination of their functlonal status. 
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1088-13 Blood is a Better Standard Than Adventitia for Ultrasonic 
Backscatter at 30 MegaHertz 
David T. Linker. University of Washington, Seattle, WA 
Background: Backscattered intensity from adventitia has been used as a reference for 
intracoronary ultrasound measurement of plaque characteristics. Blood backscatter 
intensity should be less variable, although the strength of the backscattered signal is 
much less. 
Methods: lntracoronary ultrasound was performed on twelve subjects as part of a study 
on plaque changes with lipid-lowering therapy. Each had a catheterization before initiat- 
ing therapy and after one year of therapy, with collection of one full rotation of raw ultra- 
sound signals from plaque in a non-stenotic vessel at selected points, using an 
intracoranary ultrasound catheter (30 MHz, 2.9 Fr, CVIS). The signal was simultaneously 
digitized at 500 MHz, 8 bit resolution, with two different gain levels, one optimized for tis- 
sue and the other at maximum gain for blood. Images were analyzed if there was blood 
and adventitia at the same depth, to correct for depth-related changes. A total of 52 
areas were analyzed. A custom program allowed selection of the areas for analysis and 
storing of the results. The backscattered power was reported as the integral from 23 to 
37 MHz in relative dB, and also plotted as a function of frequency on a relative dB scale. 
Results: The standard devi- 
ation of the integrated back- 
scatter from adventitia was i; 
9.35dB, while from blood it 
-1 
was 6 4.28 dB (p<O.Oi). The -3 
frequency dependency of -5 
backscatter from blood .7 
showed less variability than 
that from adventitia (see 
wphl. 
Conclusions: We conclude that both integrated backscatter and the frequency depen- 
dency of backscatter from adventitia are more variable than from blood, and therefore 
blood may be a more appropriate standard for normalization of backscatter. The remain- 
ing variability from blood may be due to differences in depth, flow rate, hematocrit, and 
catheter characteristics. 
108814 Coronary Thermosensor Basket Catheter With 
Thermographic Imaging Software for Thermal Detection of 
Vulnerable Atherosclerotic Plaques 
Khawar GUI, Tim O’Brien, Said Siadaty, Mohammad Madjid, Reza Mohammadi, Tarun 
Tewatia, James T. Willerson, Ward Casscells, Mortera Naghavi. University of Texas- 
Houston, H&ton, TX, Temperature Specialist Inc., St. Francis, MN 
Background: Vulnerable atherosclerotic plaques are known to be inflamed and have 
higher temperature (T) than the adjacent areas. We have previously reported the first 
prototype of our intravascular Thermosensor Basket Catheter (EC). Here we report the 
next generation prototype to be used in clinical studies. Methods: The new BC system 
consists of: 1) a 4F catheter with an expandable and externally confrollable basket with 9 
built-in thermosensors, 2) a computer board with special digital transistors for high speed 
sampling, 3) a PC equipped with the board, 4) a custom software for real-time data 
acquisition, tracking, and thermographic imaging, and 5) a circulating microbath for auto- 
matic thermal calibration. The expandable basket at the end of catheter is made of 4-8 
highly flexible hollow wires (lO:O.OOu OD: 0.05”) with 0.001” built-in thermocouples. 
1088-15 Matrix Metalloproteinase-2 Levels and Features of 
Atherosclerotic Plaque Vulnerability. An lntracoronary 
Ultrasound Study 
Manolis Vavouranakis, Kostadinos Toutouzas, Christodoulos Stefanadis, Costadina 
Aggeli, Christina Chrysochou, Dimitris Markou, Emanouil Economou, Sofia Vaina, 
Pavlos Toutouzas. Cardiology Department, Hippokration Hospital Of Athens, Athens, 
GE&X 
Background: Pathological studies in patients with acute coronary syndromes (ACS) 
have shown that a large lipid core with a thin fibrous cap are characteristics of vulnerable 
atherosclerotic plaque (AP). lntracoronary ultrasound (ICUS) permits in viva detection of 
the lipid core as an echolucent area (EA) within the atherosclerotic plaque, but provides 
no information on the biOlOgiCal factors that promote such Changes. Matrix Metallopro- 
teinases-2 (MMP-2) promotes local extracellular matrix destruction and has been found 
to be elevated in serum samples of patients with ACS. Therefore, we measured the dif- 
ference of serum MMP-2 in patients with ACS and stable angina (SA), and detected the 
distinct characteristics of the culprit atherosclerotic plaque by intracoronary ultrasound in 
these patients. Methods: In 15 patients with ACS and 22 patients with SA evaluation of 
the AP of the culprit lesion was performed by ICUS. Serum MMP-2 level was measured 
by one step sandwich enzyme imunoassay technique on admission day. Echolucent 
area within the AP was defined as an area of less than the adventitia echogenicity. 
Plaque burden (PB=vessel area-lumen area), thickness of the fibrous cap (TFC) and the 
ratio EA/PB were measured at the culprit AP. Results: Serum MMP-2 levels were higher 
(443~80 rig/ml vs 313ilOO rig/ml, p=O.O2)in patients with ACS. Patients with ACS have 
more plaques with EA, IO/i5 patients (66.7%) with ACS and in 7R2 patients (31.8%) 
with SA (p=O.O4). TFC was less (ACS:0.2+0.15 mm vs SA:0.8+0.25mm, p=O.O5), and 
EAiPB was greater (ACS:0.11*0.07 vs SA:0.033+0.001, p=O.O02). In addition, the differ- 
ence in serum MMP-2 level between arterial samples of blood taken from the coronary 
ostium and a peripheral vein showed a good correlation EA/PB ratio (r=0.54, p=O.Ol). 
Conclusion: Patients with acute coronary syndromes have higher serum MMP-2 levels 
comparing to patients with stable angina. Echolucent areas are greater wlthin the athero- 
sclerotic plaques in patients with acute coronary syndromes. The correlation between 
MMP-2 levels and EA/PB may provide new insights into the mechanisms of plaque rup- 
ture in acute coronary syndromes. 
1088-16 Intravascular Capacitometry: A New Method to Image Both 
Morphology and Composition of the Coronary Wall by 
Using a Special lntracoronary Catheter 
Leonidas D. Diamantopoulos, Glenn Van Langenhove, David Folley, Pim De Feyter, 
Marcel Van de Brand, Patrick W. Serruys. Interventional Cardiology Dept, 
THORAXCENTER, ROTTERDAM, The Netherlands 
Background: There are currently several feasible and accurate methods to study the 
arterial wall mOrphOlOQy like angiography and intravascular ultrasounds. However, these 
methods have failed to give reliable data on atherosclerotic plaque composition and con- 
sequently on its vulnerability. Methods: The new method that we are proposing is capa- 
ble of imaging the arterial wall by giving information on both morphology and tissue 
composition. It is based on a special 3F intracoronary catheter that can be e&y inserted 
into the target vessel, sliding over a conventional angioplasty guidewire. In its distal tip, 
the catheter is equipped with an array of electrically isolated ultra-thin metallic film rings. 
The rings are connected with thin cables to a connector to the proximal part of the cathe- 
ter. From there, signal is fomarded to an external microprocessor-based unit, capable of 
high-precision measurements of difference in capacitance between the rings and the 
arterial wall. Data are analyzed in frequency domain by dedicated software, and arterial 
wall imaging is performed on screen in the form of real-time video. We tested our system 
in vitro with both atherosclerotic and normal coronary arteries , in an experimental setup 
with both Nacl 0.9% solution and donor blood flow. Still and video images were recorded 
using our new system. Intravascular ultrasound (IVUS) was used also at the same seg- 
ment for purposes of correlation with our method. Then, the samples were sent for histol- 
ogy analysis. Results: Our method have images that correlated perfectly on the plaque 
morphology with the images acquired by IVUS. Additionally, our method was able to dis- 
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tmguish calcrfred areas, areas with fatty content and other trssues. We believe, that our 
method could be useful rn the future to in-viva assess the morphology and tissue compo- 
sitron of the arterial wall and possibly identify vulnerable spots. 
PLL based osciitafor r frequensy mixer 
1088-17 Coronary Artery Distensibility and Plaque Disruption 
Masamichi Takano, Kyoici Mizuno, Ryuta Uemura, Masato Tomimura, Shinya 
Yokoyama, Takayoshi Ohba, Kouii Seimrya, Kentarou Okamatsu. Deparfment of 
medicine, Chiba Hokusoh Hospital, Nippon Medical School, Inba, Chiba, Japan 
Background: Plaque composition is an rmportant determinant of plaque disruption. Yel- 
low plaques have been considerd to be more vulnerable than white plaques, because 
yellow plaques have thin fibrous cap with or without large lipid pool whereas,white 
plaques have thick fibrous cap or are fibrous. Mechanrcal stress also plays an important 
role in plaque disruption. However, it remaines to be determined whether yellow plaques 
are more susceptrble to mechanical stress than white plaques. The purpose of this study 
is to invesiigate the mechanical stress on yellow and white plaques,usrng stiffness 
parameters such as distensibility index and stiffness p. Methods: 38 de now lesions in 
38 patients with ischemic heart disease were examined. The plaques were classified into 
yellow and white,using coronary angioscopy. Intravascular ultrasound imaging with 
simultaneous electrocardiogram and intracoronary pressure recordings were performed 
to measure the coronary distensibility. From the systolic and diastolic lumen cross sec- 
tronal area and intracoronary pulse pressure, distensibility index and stiffness pwere cal- 
culated. %Plaque area was also calculated. Results: 27 yellow plaques and 11 white 
plaques were observed by coronary angiosccpy. Yellow plaques were more frequent in 
acute coronary syndromes than rn stable angina (85% vs 36%; p<O.Oi). Distensibility 
Index in the yellow plaques was significantly greater than in the white plaques (2.7i0.8 vs 
0.7*0.8; p<O.OOOl).whereas, stiffness (j in the white plaques was significantly greater 
than in the yellow plaques (349i16.3 vs 8.7e2.7; pcO.0001). There was no difference of 
%piaque area between the yellow and the white plaques. Conclusion: The yellow 
plaques are more distensible than the white plaques. Repetitive mechanical stress during 
the cardiac cycle may cause mechanical “fatigue” and result in plaque disruption. The 
yellow plaques with high distensibility may be susceptible to mechanical stress. 
1088-18 Evaluation of Plaque instability Using Intravascular 
Ultrasound Images 
Tomokazu Okimoto, Michinori Imazu, Yasuhiko Hayashi, Hitoshi Fujiwara, Hironori 
Ueda, Kotaro Sumir, Mamoru Toyofuku, Kenji Kajiwara, Yoshrto Shimizu, Tomoki 
Shokawa, Shinji Omura. The Second Department of Internal Medicine, Hiroshima 
Unwersity School of Medicine, Hiroshima, Japan, The Division of Cardiology, Jsuchiya 
General Hospital, Hiroshima, Japan 
Background: Macrophages and lymphocytes play a prominent role in atherosclerotic 
plaque formation, progression, and rupture responsible the majority of acute coronary 
syndromes. Therefore, the irmmunohistochemical evaluation of plaque is of prime impor- 
tance. Intravascular ultrasound (IVUS) is a useful in viva technique to evaluate the histo- 
logical character of atherosclerotic plaque Thus study was designed to clarify whether 
the quantitative analysis of IVUS images was useful to predict instability of plaque. Meth- 
ods: Twenty-five coronary lesions in 25 patients who had ultrasound guidance during 
directional coronary atherectomy (DCA) were enrolled. We divided into following two 
groups by the diagnosis (a group of acute coronary syndrome : ACS group and a group 
of stable angina pectoris: SAP group). The lesions retrieved by DCA were analyzed 
inflammatory infiltrates wrth macrophages or lymphocytes. IVUS images were digitized 
using gray-scale levels. The mean of plaque echo levels was divided by the mean of 
adventitia echo levels of the .same section (MPEUMAEL) and the dispersion of plaque 
echo levels (DPEL) were calculated. Results: The pre-DCA DPEL value in the ACS 
group (n = 12) was signrficantly higher than that in the SAP group (n = 13) (22.9 vs. 18.6, 
p = 0.06) while the post-DCA DPLE value showed no significant differences between the 
two groups (20.1 vs. 18.9). And there were no signrficant differences between the two 
groups in ?he pre-DCA MPEUMAEL value (0.62 vs. 0.60) or the post-DCA MPEUMAEL 
value (0.65 vs. 0.61). The proportion of tissues rnfiltrated with macrophage or lymphocyte 
was significantly higher in the ACS group than that in the SAP group (75% vs. 38%, p = 
0.07). Conclusions: Macrophages and lymphocytes are mcreased in coronary atherec- 
tomy tissue from lesions in acute coronary syndromes. The drspersion of plaque echo 
levels, which suggested macrophage or lymphocyte infiltratton into plaque and probably 
reflected plaque activity, might be useful for the prediction of plaque Instability. 
1088-19 Spontaneous Rupture and Ulceration of Atherosclerotic 
Plaques: In Vivo Assessment of the Size of 51 Emptied 
Plaque Cavities and Their Relation With Lesion 
Characteristics 
Clemens van Birgelen, Wolfgang Klinkhart, Gary S. Mintz, Chrtstoph Kaiser, Jorg 
Herrmann, Dietrich Baumgart, Michael Haude, Heinrich Wieneke, Thomas Bartel, Dark 
Bose, Helge Bast, Raimund Erbel. University Essen, Cardio/ogy Department, Essen, 
Germanl: Washington Hospital Center, Washington D.C. 
Background: Aim of this intravascular ultrasound (IVUS) study was to identify any 
potential relation between the size of the emptied plaque cavity and various lesion char- 
acteristics. 
Methods: We prospectively used IVUS to examine a total of 51 ruptured ulcerated coro- 
nary plaques. Cross-sectional area (CSA) measurements comprised lumen, vessel, 
plaque, and emptied plaque cavity. Lumen narrowing was calculated as 1 (lesson lumen 
CSA I reference lumen CSA) x 100%. A remodeling index was calculated as lesion ves- 
sel GSA / reference vessel CSA, and plaques were divided into those with values >I .05 
(group A, compensatory vascular enlargement) and <=1.05 (group B, no compensatory 
vascular enlargement). 
Results: Of the total of 51 plaques, 36 (71%) were assigned to group A and 15 (29%) to 
group B. Both groups showed no significant difference rn reference dimensions and the 
degree of lumen narrowing. But lesion vessel (22.6 + 8.1 mm2 versus 17.5 + 4.3 mme; 
p=O.O06) and plaque areas (15.8 + 6.2 mm2 versus 12.8 & 3.2 mm’; ~~0.03) were larger 
in group A than in B. The cavity inside the plaque measured signrficantly larger in group 
A than in B (2.8 r 1.6 versus 1.8 f 0.9mm’; p=O.O07) and showed a posrtive linear rela- 
tion with lesion and reference vessel size (rzO.58 and 0.56; p<O.OOi), but not wrth lumen 
narrowing. 
Conclusion: The size of the emptied cavrty inside ruptured plaques is on average larger 
in lesions with compensatory vascular enlargement. It shows a linear relation with lesion 
plaque and vessel size. and wrth the reference dimensions, but not with the degree of 
lumen narrowing. 
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1089-20 Lumen Mapping: Pressure Based Algorithms to Define 
lntraluminal Dimensions and Physiologic Characteristics in 
Stenotic Vessels 
Carlo Di Mario, Francesco Liistro, Antonio Colombo, Hylton Miller, Henri Noskowicz, 
Evgeny Shalman, Michael Simkhis. Sf. Retie& Hospital, Milano, itab Tel Aviv Medical 
Center, Tel Aviv, lsrael 
Background: Accurate estimation of lesion length, locatron and severity with angiogra- 
phy is difficult. In this study intracoronary pressure was measured wrth high fidelity 
microtransducers mounted on 0.014” gurde wires in order to provide quantitative data to 
guide vascular intervention and stent placement. Methods: lntralumrnal pressure mea- 
surements acquired during translumrnal pressure guide wire pullback, using an auto- 
matic pullback device at constant speed of 0.5 mm/s, are analyzed by SmartFlowTM 
computational algorithm (Florence Medical LTD). SmartFlowTM processes the raw pres- 
sure signals (Fig.la) resulting in a pressure curve as a functron of axial location (Fig.1 b). 
Based on fluid dynamics considerations, evaluated by extensive use of Computational 
Fluid Dynamics simulations, typical points associated with the stenosis inlet (l),minimal 
lumen diameter (MLD) point (2) and outlet (3) are derived as shown in Fig.1. Results: 
The algorithms were validated using coronary artery in-vitro model incorporatrng pulsatile 
flow in 4 mm reference diameter tube and artificial stenoses having internal diameter of 
1. 1.5, 2 mm and various geometries. The initial clinical experience Includes four patrents 
before percutaneous coronary revascularizatron. Pressure based lesion length was 
13.4~2.1 mm and QCA based length was 15+2.6 mm. Pressure based MLD was 
1.0320.22 mm and QCA derived MLD was 0.91t0.22 mm. Conclusion: Real time trans- 
luminal pullback pressure measurements processed using SmartFlowTM algorithm can 
prowde data on lesion length,location and severity. The method was validated in in-vitro 
phantoms and demonstrated feasible and accurate in the initial human experience. 
1089-21 Impact of Final Coronary Flow Velocity Reserve on Late 
Outcome Following Stent Implantation 
Takahiro Nishida, Carlo Di Mario, Morton J. Kern, Todd J. Anderson, lssam Moussa, 
Raoul Bonan, Toshiya Muramatsu, Abnash Chander Jain, Jose Suarez de Lezo, Seung 
Yun Cho, Ian T. Meredith, Jeffrey W. Moses, Antonio Colombo. Cardiac Catheterization 
Laboratory Centro Cuore Columbus, Milan, ltaiy 
Background: A low coronary flow velocity reserve (CVR) measured after balloon angio- 
plasty predicts a poor outcome and may indrcate the need of subsequent stent implanta- 
tion. Objectives and Methods: To assess whether CVR following stent implantation is 
also predictive of the subsequent need of target lesion revascularization (TLR). The out- 
came of 417 patients enrolled in the multicenter prospective randomized study (DES- 
TINI), who received a successful single vessel stent implantation in native coronary 
arteries and measurement of CVR was examined. Logistic regression analysis and the 
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receiver operator characteristic curve were used to evaluate whether final CVR corre- 
lated with the incidence of TLR. Results: Compared to 358 patlents not requiring TLR, 
59 patients (14%) who underwent TLR were found to have a lower final CVR (2.33kO.87 
vs. 2.48+0.80, ~~0.20) and sm+ar final minimal lumen diameter (2.62+066mm vs. 
2.7320.60, p=O.19), however those differences were not statistically significant. Patlents 
with a CVR of ~2.0 (n=lO9, 26%) exhibited a significantly higher TLR rate than patients 
with a CVR of = or >2.0 (22% vs. ii%, p=O.OlO). This difference remained significant 
(Odds ratio = 2.01, 95% confidence interval = 1.11 to 3.66) after adjustment for other 
variables (hypertension, reference vessel diameter, the use of coil stents and stent 
length) that were also correlated with a higher TLR rate. Conclusion: The presence of a 
final CVR of ~2.0 is an independent predictor of the need for TLR after stent implantation 
in native coronary artery lesions. 
1089-22 Intravascular Ultrasound-Directed Stent Placement in the 
Left Anterior Descending Coronary Artery: Observations 
From AVID 
Robert J. Russo, Michael J. Attubato, Charles J. Davidson, Anthony C. DeFranco, James 
B. Hermiller, Robert A. laffaldano, Frederick S. Ling, Jennifer E. Lucisano, Patricia D. 
Silva, George J. Smith, S. Chiu Wong. Scripps Clinrc, La Jolla, CA 
Background: AVID (Angiography Vs. Intravascular ultrasound [IVUSI-Dlrected stent 
placement] is a multicenter randomized trial to determine the effect of IVUS-directed 
stent placement on clinical outcome. Methods: To determine the vessel-specific 12. 
month clinical event rate after stent placement, cora lab angiographic and IVUS data 
ware analyzed for patients who underwent elective stent placement in the proximal or 
mid portion of the left anterior descending (LAD) coronary artery. Results: At 24 centers, 
269 patients underwent LAD stent placement; 140 were randomized to the IVUS-directed 
group and 129 to the angiography group. Preprocedure angiographic distal reference 
vessel diameter was 2.57r0.53 mm in the IVUS group and 2.62kO.56 mm in the angiog- 
raphy group (p=O.43). Preprocedure angiographic lesion severity was 61i13% in the 
IVUS group and 54116% in the angiography group. In the IVUS group after an optimal 
angiographic result (<IO% stenosis), 40% (561140) required addditional therapy to fulfill 
IVUS criteria for optimal stent placement (~10% area stenosis, apposition and absence 
of dissection)--26% for an underdilated stent with an absolute area gain of 1.18~0.89 
mm2, 13% for stent non-apposition, and 2% for dissection. Final minimum stent area was 
7.05+2.21 mm2 in the IVUS group and 6.52+2.15 mm2 in the angiography group 
(p=O.O5). Final IVUS stent area expansion compared to the distal reference vessel lumen 
was 96?22% in the IVUS group and 88+22% in the angiography group (p=O.OOS). The 
largest balloon used was 3.57i-0.47 mm in the IVUS group and 3.40+0.40 mm in the 
angiography group (p=O.OZ). At 12 months the target lesion revascularization (TLR) rate 
was 11.4% in the IVUS group and 8.5% in the angiography group (p=O.43). For compari- 
son, the 12-month TLR rates in IVUS and angiography groups were 4.0% and 14.3% in 
the right coronary artery (p=O.Oi) and 7.4% and 8.3% in the left circumflex (p=O.85). 
Conclusions: IVUS-directed stent placement in fhe proximal and mid LAD resulted in 
larger acute stent dimensions compared to LAD stent placement guided by angiography 
alone; a result of using larger balloons. However, no improvement was noted in the 12. 
month rate of target lesion revascularization. 
1089-23 Guidance of Long Stent Implantation by Intravascular 
Ultrasound Has a Significantly Better Outcome Compared 
to Implantation Guided by Angiography Alone: Final 
Results of a Randomized Study (The TULIP Study) 
Pranobe V. Oemrawsingh, Martin J. Schalij, Ernst E. van der Wall. Leiden University 
Medical Center, L&den, The Netherlands 
Background: Percutaneous intervention for long coronary lesions has a high rate of res- 
tenosis. In this study we compared the 6 month angiographic results of AVE GFX’XL 
stent implantation in patients with stable angina, after randomization for the use of intra- 
vascular ultrasound (IVUS) guidance vs. angiography alone. Methods: Pts with coronary 
stenoses >20 mm length and a reference diameter (RD) allowing implantation of a stent 
with a RD of at least 3.0 mm were eligible. IVUS criteria for optimal stent placement were 
1) complete stent apposition, 2) Mintmal lumen diameter (MLD) > 80% of the mean of the 
proximal and distal RD, 3) residual minimal lumen area (MLA)> distal reference area. 
Results: In 150 pts (46 female/l04 male; age 58+8 yr.) a total of 187 stems with a length 
of 38~10 mm and a D of 3.3kO.4 mm were implanted. Baseline demographic data of both 
groups were comparable. IVUS was used in 73 (49%) procedures and in 65 (89%) of 
these all IVUS criteria were achieved. Preliminary on-line quantitative coronary anqio- 
graphic data of the first 100 pts are shown in the t&e. 
. 
IVUS+(48) IVUS(52) p-“&E 
PrelPostiFU 
RD mm 2.913.312.7 3.0/3.2/2.8 0.2/0.5/0.4 
MLD mm 0.9/2.9/1.8 0.9/2.9/l .4 0.4/0.9/0.03 
%D stenosis 6611 l/34 69/10/48 0.2/0.6/0.003 
Lesion L mm 31 +9 31 r9 0.4 
AcuteGain mm 1.9io.5 1.910.5 0.7 
Late Loss mm 1.1 f 0.7 1.4kO.5 0.06 
# Restenosis 10 (18%) 18 (36 %) 0.04 
Conclusion: Preliminary data of this randomized study show that the 6-month angio- 
graphic outcome after implantation of AVE GFX XL stents for long coronary stenoses 
guided by IVUS is significantly better compared to implantation guided by angiography 
alone. The final core lab angiographic results of 150 pts will be presented at the meeting. 
1089-24 Neointimal Hyperplasia After Intravascular Ultrasound- 
Guided Stent Placement in a Porcine Model: In Search of 
Optimal Balloon Sizing 
Robert J. Russo, Joseph C. Apostol, Elizabeth Kaback, Patricia D. Silva, Mark Yeager. 
Scripps Clinic, La Jolla, CA, The Scripps Research Institute, La Jolla, CA 
Background: Stents minimize elastic recoil after coronary intervention, however they 
stimulate a proliferative response that may result in restenosis. Methods: A porcine car- 
onary overstretch model was used to determine the effect of varying balloon-to-artery 
(B:A) ratios on neolntimal growth after IVUS (intravascular ult(asound)-guided primary 
stent placement. Vessels were randomly assigned to one of five B:A ratios between 1 .O 
and 1.4:1. IVUS imaging was performed pre- and post-stent placement and at l-month 
follow-up. Quantitative IVUS measurements of diameter and area were made every 1 
mm along the stent length and volumes calculated using Simpson’s rule. Results: A total 
of 47 vessels in 26 animals were treated with coronary stent placement. The mean pre- 
stent vessel diameter by IVUS was 3.1 i&O.34 mm. The mean stent balloon size was 
3.73r0.46 mm. Absolute and relative acute stent recoil were 0.45&0.29 mm and 
11.8t7.8% respectively. At a mean follow-up of 28.9+2.3 days, mean neointimal thick- 
ness was 0.34iO.24 mm. The ratlo of neointimal thickness on the myocardial quadrant of 
the stented vessel compared to the pericardial quadrant was 1.39iO.59 (median 1.17). 
Mean in-stent neointimal volume at follow-up was 51.Ok37.4 mm3. Neointimal volume 
Increased significantly with increasing B:A ratio (R”=0.25, linear regression p<O.OOl) and 
was independent of vessel size. Mean distance of neointimal growth from proximal or 
distal stent edge was 2.58+2.09 mm. Neointimal distance from stent edge increased sig- 
nificantly with increasing B:A ratio (R2=0.20; linear regression p=O.O02) and was inde- 
pendent of vessel size. Based upon linear regression analysis, even minor vessel 
overstretch @:A ratio of l.l:i) resulted in significant neointimal hyperplasia (31% area 
and 17% diameter stenosis by IVUS). Conclusion: In a porcine coronary overstretch 
model of IVUS-guided primary stent placement, in-stent neointimal tissue volume and 
reference vessel neointimal growth are strongly associated with increasing balloonxtery 
ratio and are independent of vessel size. 
1089-25 Clinical, Angiographic, and Intravascular Ultrasound 
Predictors of Target Lesion Revascularization and Late 
Cardiac Events After Stent Implantation in Saphenous Sein 
Grafts 
Javed M. Ahmed, George D. Dangas, Roxana Mehran, Augusto D. Pichard, Lowell F, 
Sailer, Kenneth M. Kent, Mun K. Hong, Gregg W. Stone, Martin 8. Leon. Washington 
Hospital Center, Washington, DC, Cardiovascular Research Foundation, New York, NY 
Background: Stent Implantation in saphenous vein grafts (SVG) has been shown to 
improve procedural results and reduce late restenosis. However, the predictors of target 
lesion revascularization (TLR) and late clinical outcomes after stent implantation in SVG 
are not known. Methods: We studied 740 patients with 1088 SVG lesions treated with a 
variety of stents. Important clinical characteristics included males 78%, unstable angina 
72%, diabetes 29% (insulin treated 14%), chronic renal insufficiency 9%, hypertension 
66%, degenerated grafts 56%, and ostial lesions were 23%. Average graft age was 
104~58 months Results: By quantitative coronary angiography the reference lumen 
diameter was 3.50+0.77mm and diameter stenosis was 6.25t16.8%. Final lumen cross- 
sectional area (CSA) by IVUS was 9.35i-4.22mm2. At one year follow-up the TLR was 
13% and MACE (major adverse cardiac events) rate was 23%. Independent predictors of 
TLR and MACE are shown in the Table. Conclusions: The strongest predictors of TLR 
and MACE in patients after stent implantation in SVG lesions are unstable angina, diabe- 
tes, previous PTCA, and number of stents. Patients with these characteristics should be 
followed very closely after SVG stenting. 
Predictors of TLR OR P 
Patient age 0.81 0.04 
Unstable angina 1.60 0.03 
Diabetes 1.55 0.02 
Previous PTCA 2.2 0.001 
Palmaz-Sch.& stent 1.6 0.007 
Number of stents 1.31 0.05 
Ostial lesion location 1.72 0.01 
Reference diameter 0.08 0.01 
Graft age 1 .Ol 0.05 
Final IVUS lumen GSA 0.72 0.004 
Predictors of MACE 
Unstable angina 2.18 0.0003 
Diabetes 1.71 0.002 
Previous PTCA 1.64 0.05 
Number of stents 1.63 0.0001 
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1089-26 lntracoronary Blood Flow Velocity Analysis of Suboptimal 
Balloon Angioplasty Versus Stent Implantation: A 
Subanalysis of the DEBATE-II Trial 
Jan J. Pick, Michiel Voskuil, Mariano Albertal, Eric Boersma, Bernard de Bruyne, 
Stephane Carlier, Jose Eduardo Soussa, Toshiya Muramatsu, Chris Vrints. Martiln 
Meuwissen, Steven Chamuleau, Patrick W. Serruys. Academfc Medical Center, 
Amsterdam, The Nether/an&, Thoraxcenter, Rotterdam, The Netherlands 
Background: Impaired coronary flow velocity reserve is a frequent finding after PTCA 
due to an enhanced baseline flow velocity secondary to disturbed autoregulation of the 
microvascular bed that may rema,” unaltered after stent implantation. Methods: A total 
of 198 patients with single vessel coronary artery disease and normal left ventricular 
function were randomized to stent implantation or completion of the procedure following 
suboptimal balloon angioplasty (BA) defined as diameter stenosis (DS)>35% and coro- 
nary flow velocity reserve CFRc2.5. Maximum hyperemia was induced by 12-18 micro- 
gram i.c. adenosine to determine target CFR defined as the ratio between hyperemic 
flow velocity (h-APV) and baseline flow velocity (b-APV) and rCFR defined as the ratio 
between CFR of the target vessel and the CFR of the reference vessel. Patients were fol- 
lowed for 12 months to document major adverse clinical events (MACE; death, myocar- 
dial Infarction and target lesion revascularization). Results: Differences between 
suboptimal BA and stent implantation are presented in the table below: 
Balloon (n=86) stent (n=l12) p-value 
CFR 2.0-c/-0.4 2.4+/-0.7 0.001 
b-APV 22+/-i 0 22+/-l 1 09 
h-APV 40+/-15 49+/-26 0.005 
rCFR 0.80+/-0.2! 0.95+/-0.27 0.001 
DS% 22+/-g 8+1-S 0.001 
MACE 23 (27%) 12 (11%) 0.01 
Conclusion: Stent Implantation following suboptimal balloon angioplasty yields in a bet- 
ter clinical outcome in association with a reduced functional residual coronary obstruction 
directly after coronary angioplasty. 
1089-27 Why Do Longer In-Stent Restenosis Lesions Have a Higher 
Recurrence Rate? A Serial Intravascular Ultrasound 
Analysis 
Javed M. Ahmed. Gary S. Mintz, Ron Waksman, Neil J. WeIssman, Lowell F Sailer, 
Kenneth M. I<ent, Augusto D. Pichard. Washington Hospital Center, Washington OC, 
DC 
We used serial (post-intervention and follow-up) intravascular ultrasound (IVUS) analysis 
to understand why longer in-stent restenosis (ISR) lesions have a higher recurrence 
rates compared to shorter ISR lesions. Patients had native artery ISR and were selected 
from the placebo arms of two randomized brachytherapy trials. WRIST (Washington 
Radiation For In-stent &stenosis Trial for lesion lengths IO-47mm, n=40) vs Long 
WRIST (ISR length 36.80mm, “~34). IVUS was performed using automated pullback 
(0.5mm/sec). IVUS measurements included stent, lumen, intimal hyperplasia (lH=stent- 
lumen) cross-sectional areas (GSA) at 2mm intervals. Results. Stent areas were smaller 
in longer lesions; in particular, minimutn stent GSA in Long lesions measured 
5.9+1.6mm2. Post-intervention lumen areas were similar (Table 1). At follow-up there 
was a striking increase I” maximum (Max) IH CSA in the longer lesions resulting in a 
greater heterogeneity in IH distribution (MaxIMin IH CSA). This increased and more vari- 
able proliferative response resulted in smaller follow-up minimum lumen areas. Similarly, 
there was greater axial variability in the distribution of IH postintervention and at follow-up 
in long WRIST lesions resulting in significantly larger maximum IH CSA over the length of 
the lesion. Conclusion. Serial IVUS analysis shows that two main factors contribute to 
recurrent ISR in longer lesions: smaller stent size and a” increased and more variable 
proliferative response. This broloqic difference may explain whv conventional interven- 
tional approaches are less successful in treating these long, diffuse ISR lesions. 
Mean lum CSA(mm2) 6.3i1.7 5.5i2.3 0.11 
Max IH GSA (mm2) 3.94.8 2.5to.77 <0.0001 
MLA @nm2) 4.&1.4 4.521.5 0.39 
Follow-up 
Max IH CSA(mm2) 5 3+1.5 6.2k1.8 0.0243 
Max/Min IH CSA (mm2) 
MLA (mm2) 
Max IH CSA(mm2) 
WRIST Long WRIST p 
Length (mm) 
Post-intervention 
Mean stent CSA (mm2) 
Mean lum CSA(mm2) 
Max IH CSA (mm2) 
MLA (mm2) 
1.9+1.2 4.3i-2.5 <0.0001 
3.lk1.3 1.9tl.O 0.0001 
1.4k1.3 3.7t1.9 <0.0001 
29tl1 54*15 <0.0001 
9.112.5 7.9r2.0 0.0208 
6.351.7 5.5-+2.3 0.11 
3.921.8 2.5r0.77 <0.0001 
4.8r1.4 4.5k1.5 0.39 
Follow-up 
Max IH CSA(mm2) 5.3ti.5 6.2+1.8 0.0243 
MaxIMin IH CSA (mm2) 1.9k1.2 4.3~2.5 <0.0001 
MLA (mm2) 3 li1.3 1.9il .o 0.0001 
Max IH CSA(mm2) 1.4il.3 3.7il.9 <0.0001 
MLA (mm2) -1.7+1.4 -2.6t1.9 0.0273 
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1089-28 Intravascular Ultrasound Findings in Patients With Low 
Fractional Flow Reserve After Stenting 
Hiroshi Ishlmori, Toshlya Muramatsu, Reiko Tsukahara, Mami Ho, Yoshiaki Ito, Naozuml 
Saikl. Kawasaki Social insurance Hospital, Kawasaki, Japan 
Objective: To evaluate intravascular ultrasound (IVUS) findings in patients with low frac- 
tional flow reserve (FFR) after stenting. Subjects and Methods: Patients who had suc- 
cessfully undergone coronary artery stentlng were divided into 2 groups, according to 
FFR (the trans-stenotic pressure ratio at hyperemia induced by injection of 25 kg of ATP 
in the right coronary artery or 50 pg in the left coronary artery, measured using a pres- 
sure guidewlre; Group S (FFRz0.94. 28 lesions, 65kll yrs, 7 female), and Group “S, 
(FFRc0.94, 11 lesions, 64r9 yrs, 2 female). We used IVUS to assess lumen cross-sec- 
tional area (LA), total vessel cross-sectional area (TA), and plaque area (PA) at the 
stenosis site (L), a site (D) 2 mm distal to the stent and a site (P) 2 mm proximal to it. 
There were no differences between the groups with regard to mean reference vessel 
diameter, mean dilatation pressure, or mean stent diameter. Results: 1. No coronary 
dissection was seen by IVUS in either group. 2. LA was 7.1+2.0 in Group S and 6.513.9 
in Group nS at L, 7.9i3.7 in Group S and 6.5i-4.6 in Group nS at D, and 10.6i4.3 in 
Group S and 8.124.5 I” Group nS at P. 3. TA was 17.6+6.3 in Group S and 15.8&9 in 
Group “S at L, 12.1+5.1 in Group S and 12.7+6.8 in Group nS at 0, and 17.0t7.4 in 
Group S and 17.827.5 in Group “S at P. 4. PA was 10514.8 in Group S and 9.3A5.3 in 
Group “S at L, 4.1~2.6 in Group Sand 6.2k3.1 in Group nS (PcO.01) at D, and 6.4+3.8 in 
Group S and 9.7+3.8 in Group nS (P.zO.05) at P. Conclusions: Even when angiographi- 
tally the vessel looked to be well dilated, the IVUS findings suggested the presence of 
residual lesions at sites distal and proximal to the stent in patients with low FFR after 
stent placement. 
1089-29 Is There a Difference in the Mechanisms of Lumen 
Enlargement With Direct Stenting as Compared to Stenting 
With Predilatation? A Three-Dimensional Intravascular 
Ultrasound Analysis 
Gerard Finet. Neil J. Weissman, Lowell F. Satler, Kenneth M. Kent, MarcoT. Castagna, 
August0 D. Pichard. Washington Hospital Center, Washfngton, DC 
Background : While direct stentlng has become routine in some laboratorles, the mech- 
anism by which it causes lumen enlargement is not clear. The purpose of this study is to 
compare the mechanism of lumen enlargement with direct stenting (DS) versus indirect 
stenting with predilatation (IDS). Methods : 30 pts with DS and 30 pts with IDS of de 
nova native coronary lessons treated with the same stent design (Multilink Duet or Tristar) 
and the same stent length (13 mm). Patients were examined by pre- and post-interven- 
tion IVUS using a motorized pullback at 0.5 mmisec. 3-D volumetric IVUS reconstruc- 
tions were performed of the entire treatment area/stent length and 5 mm proximal and 
distal to the treatment area (23 mm total = 450 cross-sectional IVUS images). Lumen, 
vessel, and plaque volumes (L, EEM, P+M vol) were calculated. Results : There was no 
significant difference in patient demographics, target lesion stenosis nor plaque composi- 
tlon prior to coronary Intervention. Both DS and IDS resulted in comparable lumen 
enlargement with comparable mechanisms : 67% of lumen enlargement was due to an 
increased EEM volume (vessel bxpansion) and 23% of lumen enlargement was due to a 
reduced PcM volume (plaque compression and/or emboliration). 
mean&D _ A vol are the difference between prs- and post-intervention values 
Direct stenting Indirect stenting p Value 
Max Balloon Pres- 15.13t3.18 12.4e2.35 0.001 
sure (atm) 
StentiArtery Ratio 1.24& 13 1.23+0.17 “S 
# Balloon lnflatlons 1.9ro 7 3.9*1 .I <O.OOl 
Mean Stent Diame- 3.420.4 3.2r0.4 “$ 
ter (mm) 
A L vol (mm3) 58~25.1 58.41-32.5 “S 
A EEM vol (mm3) 38.83+28.7 40.5k34.8 ns 
A P+M vol (mm3) -19.17+16.1 -17.8+17.6 ns 
Conclusion : With similar stem design and vessel injury , the mechamsms of lumen 
enlargement during stent implantation do not appear to be different in direct stenting ver- 
sus stenting with predilatation. 
1089-30 Intravascular Ultrasound Guided Direct Stenting Without 
Predilatation in Native Coronary Arteries: Procedural 
Results and Late Clinical Outcomes 
Javed M. Ahmed, Augusta D. Pichard, Lowell F. Sat@ Gary S. Mint& John R. Laird, 
Ron Waksman. Kenneth M. Kent. Washington Hospital Center, Washington, DC 
Background: The safety and feasibility of direct stenting (DS: without predilation has 
been well established. However, previous studies have typically used angiographic guid- 
ance for DS. The purpose of the present study was to evaluate procedural and one year 
clinical outcomes alter DS under intravascular ultrasound (IVUS) guidance. Methods: 
Procedural results and one year clinical outcomes ware compared III 319 pts (480 
lesions) treated with IVUS guided DS and 1302 pts (2,336 lesions) treated with IVUS 
guided stenting with predilatlon. Results: Both groups had similar baseline clinical and 
lesion characteristics Including QCA reference lumen diameter (2.98kO.67 mm vs 
2.79t0.77 mm, p=O.lZ), ACCiAHA BP/C lesions type (37% vs 40%, p=O.65) and lesion 
length (14.2+12.0mm vs 14.5-clO.5 mm, p=O.42). Final lesion lumen area by IVUS was 
7.0+2.4mm2 vs 7.0i2.9 mm2 respectively. Procedure time (62*35 vs 79*67 mins, 
p=O.OOOl), flouroscopy time (15.5k12.8 vs 22.8+35.7 mins, p=O.OOOl) and contrast vol- 
ume used (203299 vs 248~118 rnls, p=O.OOOl) were significantly less in the DS group. 
Importantly 16% of lesions with significant calcification identified on preintervention IVUS 
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were not considered suitable for DS. Conclusions: IVUS guided DS in selected lesions and linear effects between BMI and In-hospital outcome were evaluated. Results: The 
is safe and feasible with lower utilization of resources and is associated with similar pro- median age of the cohort was 62 years, 74% were male, 93% were Caucasian and 48% 
cedural and late clinical outcomes (Table) as stenting with predilation. IVUS evaluation had a history of hypertension. A cardiopulmonary event occurred in 28% of the low BMI 
may be helpful: 1) to identify suitable lesions (non-calcified and non-complex) for DS: 2) group, 13% of the normal group, 8% of the overweight and obese groups, and in 9% of 
to achieve optimal stem expansion similar to stenting with predilation. the severely obese group (linear P <O.OOl). Similarly, leaner patients had a higher inci- 
Table: MACE=major adverse cardiac events TLR=target lesion revascularization dence of major event (6%), compared to the normal or overweight (4%), or the obese or 
DS No DS P severely obese groups (2%) (Linear P = 0.02). Local complications were also higher in 
Procedural Success, % 99.0 98.3 0.56 the lean (3%) versus 2% in the normal, 1% in the overweight and obese, and none in the 
In-Hospital MACE % 1.0 1.7 0.98 
very obese (linear P = 0.005). After adjusting for age, gender, race, treated diabetes, 
One TLR, % 
hypertension, congestive heart failure, severe angina, peripheral vascular disease, 
year 7.9 10.1 0.32 smoking, history of malignancy, renal dysfunction, a low BMI remained an independent 
One Year MACE, % 9.7 14.2 0.11 predictor of in-hospital cardiopulmonary events (linear P = O.OOB)with a trend towards 
increased risk of a major in-hospital event(P = 0.07) and local complications (P = 0.08). 
Conclusion: Low BMI appears to be a significant independent predictor of short-term 
POSTER SESSION 
complications in patients undergoing PCI. Operators should be cognizant of the signifi- 
cantly increased risk of early complications in smaller patients. 
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1090-33 CRP Provides Prognostic Value in Addition to ACCYAHA 
Lesion Score Following PCI 
1090-31 Evaluation of Paradoxic Beneficial Effect of Obesity in 
Patients Undergoing Percutaneous Coronary Intervention: 
The Obesity Paradox? 
Luis Gruberg, Roxana Mehran, George Dangas, Lowell F. Satler, Hongsheng Wu, 
Natalie Gevorkian, Rakefet Einav-Gruberg, Asuncion Purser, Augusta D. Pichard, 
Kenneth M. Kent, Ron Waksman. Washington Hospital Center, Washington, DC, 
Cardiovascular Research Foundation, New York, NY 
Background: Previous studies have shown that obesity is an independent predictor of 
coronary artery disease. There is limited data regardmg the effect of obesity on the out- 
come after percutaneous coronary interventions (PCI). The purpose of this study was to 
analyze the relationship between body mass index (BMI) and the short and long-term 
outcomes after PCI, in a large database. 
Methods: BMI was defined as weight in kilograms divided by height in meters squared. 
Patients were divided into three groups: normal (BMI < 24, n= 1,923), overweight 
(BMl=25-29, n=4,813) and obese (BMI 2 30, n= 2,897). 
Results: Patients in the obese group were significantly younger (61ill) than overweight 
(64ill) or normal BMI patients (68?12), pcO.0001. Obese patients also had a higher 
incidence of diabetes, hypertension, smoking, family history of coronary artery disease 
and hyperlipidemia (p<O.OOOl). Procedural and angiographic success, in-hospital mortal- 
ity, myocardial infarction and major complication rates were similar among the three 
groups At 12.month follow-up, target lesion and vessel revascularization rates were sim- 
ilar among the groups, whereas mortality rates were significantly lower in the obese 
group (4.9%) compared to the overweight (5.7%) and normal BMI patients 
(10.6%)(pc0.0001). Analysis by age groups for 12-month mortality, showed that mortality 
rates were still lower in the obese patients compared to overweight and normal BMI 
patients (Figure). 
Derek P. Chew, Mark A. Robbins, Deepak L. Bhatt, Debabrata Mukherjee, Marco Roffi, 
Eric J. Topol, Stephen G. Ellis. Cleveland Ciinic Foundation, Cleveland, OH 
Background: The prognostic implication of inflammation in coronary artery disease has 
been increasingly appreciated. We sought to determine whether an elevated CRP 
imparts additional prognostic significance beyond the accepted ACCIAHA lesson score. 
Methods: As part of an ongoing registry, baseline CRP was routinely measured in all 
patients presenting for PCI. Patients with Ml within the last 7 days were excluded. 
Patients were stratified according to CRP cO.Bmg/dL, 0.3-2.OmgidL and >2.0mg/dL, as 
well as by ACC/AHA lesion score. The incidence of death or Ml (CKMB22xULN) at 30 
days was assessed. A multivariable analysis including the univariate predictors of 30-day 
death or MI (number of diseased vessels, angina class, jeopardy score and LVEF < 40%) 
was also performed. 
Results: In 582 patients, an increase in 30.day death or Ml is evident with increasing 
ACC/AHA lesion score, which is more striking when stratified by CRP level. (table) 
Importantly, an elevated CRP also predicted the endpoint of death alone. (CRP <0.3mg/ 
dL: O%, CRP 0.3-Z.Omg/dL: 1.4%, and CRP>2.0mg/dL, p<O.OOi) On multivariable analy- 
sis, both ACCiAHA lesion score and CRP remain independently prognostic of 30.day 
death or Ml. 
Conclusion: When considering the risk of ischemic events following PCI, the presence 
of an elevated CRP carries substantial negative prognostic significance. In addition to 
ACCiAHA lesion score, CRP may serve as a useful clinical variable for stratifying 
patients presenting for PCI and may potentially help guide the choice of future therapies. 
30-Day Death or MI 
p4.0001 p<0.0001 
40 3X60 a.70 i-70 
CRP <0.3mg/dL CRP 0.3-2.0mg/ CRP >2.Omg/dL p value 
dL 
Type A lesion 0% 0% 0% 
Type Bl lesion 2.6% 6.3% 6.3% 0.597 
Type 82 lesion 3.8% 1?.9% 20.8% 0.118 
Type C lesion 8.3% 15.7% 26.8% 0.013 
Multivariate Analysis Odds Ratio 95% 6.1. p Value 
CRP >O.Smg/dL 2.62 1.24-5.53 0.012 
ACCIAHA lesion score 1.96 1.40-2.75 co.oo1 
LVEF <40% 1.96 1.08-3.54 0.026 
1090-34 Long Term Prognostic Value of Cardiac Troponin T Levels 
Following Percutaneous Coronary Angioplasty 
Manoj R. Mutt@, William H. Matthai, Jorge R. Kizer, Joseph McConnell, Heather 
Nardone, Ali Son& Martin G. Keane, Robert L. Wilensky. Hospital of the University of 
Pennsylvania, Philadelphia, PA 
The relationship of 
cardiac troponin T I o TROPONIN 
- Negerlve 
------- PDSltlYe 
Conclusions: Despite having worse baseline clinical characteristics, obese patients had 
better long-term outcome compared to overweight or normal BMI patients. Nevertheless, 
obese patients underwent PCI seven years earlier, which probably accounts for their bet- 
ter long-term outcome. 
1090-32 The Impact of Body Mass Index (BMI) on Early Outcome 
After Percutaneous Coronary Interventions (PCI) 
Hitinder S. Gurm, Patrick Whitlow, Kevin E. Kip. Cleveland Clinic Foundation, Cleveland, 
OH 
Background: BMI is a clinically useful measure of total body fat and extremes of BMI 
correlate with poor long-term outcome in the general population. Retrospective registry 
data suggest that the very lean or morbidly obese have a worse short-term outcome after 
PCI. Methods: 2,108 patients who received initial PTCA in the BARI randomized series 
and observational registry were evaluated by pre-procedure BMI status: low: ~20 (n=36); 
normal: 20-24.9 (w505); overweight: 25-29.9 (n=994); obese: 30-34.9 (n=427); and 
severely obese: >35 (n=146). Outcome variables defined as per BARI protocol iilcluded 
in-hospital major event (death, MI, stroke, coma), cardiopulmonary events (congestive 
heart failure, pulmonary edema, hypotension requiring treatment, non-fatal cardiac 
arrest, cardiogenic shock and respiratory failure), and local complicationsCategorical 
following PTCA. We 
measured cTnT in 
frozen blood samples 
obtained pre- and o.4 
within 24 hours post- 0 1 2 3 4 5 5 
procedure in 217 Years 
consecutive Pts 
undergoing PTCA in 1994. We excluded 50 pts referred in the setting of acute Ml or wth 
elevated baseline cTnT. Follow-up was obtained in 99% of pts (median 5.7 years). Of the 
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167 patients studied (72% male; median age 60 years), 30 pts (18%) had elevated cTnT 
post-procedure (=O.i pg/L). Overall MACE at foilow up included death (9%) myocardial 
infarction (6.6%). unstable angrna (19.2%) and coronary revascularization (15%). 
Kaplan-Meier analysis (figure) showed a significant tncrease in MACE in those wtth ele- 
vated cTnT (p=O.O16). This was most marked in the short term (1 yr p=O.O06), with con- 
vergence of the curves at the end of follow up. Elevated cTnT was the only factor 
predictive of MACE at 1 y [Hazard Ratio (HR) = 2.4; 95% Cl 1.2 4.61 in a Cox propor- 
tional hazards model including multiple baseline characteristics (age, gender, diabetes, 
multi-vessel disease z-50%, ejection fraction). This association was no longer significant 
by 6 y (cTnT HR 1.3: 0.7 - 2.4), at which time multt-vessel coronary disease (HR 1.4; 1.03 
1.65) and left ventricular ejection fraction (HR 1 6; 1.01 2 67) ware the only significant 
predictors. Conclusion: This is the first study to evaluate the prognostic value of post- 
PTCA cTnT elevations over long-term follow up. Cardiac troponin T is a significant pre- 
dictor of MACE occurrence at one year but is not a predictor of a poor long term out- 
come. Long-term events bear stronger relation to established determinants of outcome in 
coronary atherosclerosis, reflecting the natural history of the disease. 
Atrial fibrillation 13.9 22.8 0.04 
Neuro event 1.2 4.8 0.08 
Time to extubation 3.2t1.5 12.0~13.2 0.0002 
Length of stay (days) 5.7A4.1 8.6t9.1 <O.OOi 
6 Months Angio patency (%) 94.5 96.8 NS 
Conclusion: ~-compared- Slmlar - 
patency at 6 months, (2) shorter hospital stay (by 2.9 days) and extubation time, (3) less 
peri-procedural atrtal fibrillation and (4) marginally lower incidence of neurological 
events. 
1090-37 Do Coronary Interventions Affect Survival in Transplant 
Atherosclerosis? A Comparison With Heart Transplant 
Recipients Free of Coronary Disease 
Khalid H. Ashai, Masood H. Gilani, Leske W. Miller, Robert F. Wilson. Unwersify of 
Minnesota, Minneapolis, MN 
1090-35 Positive Troponin-I Predicts Early and Late Mortality After 
Percutaneous Coronary Intervention 
Andrea S. Abizaid, Roxana Mehran, George Dangas, Shmuel Fuchs, Alexandre Abizaid, 
Alexandra J. Lansky, Ran Kornowski, Ron Waksman, Augusta D. Pichard, Lowell F. 
Satler, Gregg W. Stone, Martin 6. Leon. Cardiovascular Research Foundation, New 
York, NY, Washington Hospital Cenfec Washington, DC 
Background: Biochemical markers of myonecrosis (CK-MB elevation) after percutane- 
ous coronary intervention (PCI) have been associated with early and long-term cardiac 
events. However the prognostic implication of newer biologic markers (Troponin-I, Tnl) 
has not been well elucidated. 
Methods: We analyzed 1872 consecutive pts undergoing PCI with normal baseline CK- 
MB and Tnl. Patients had blood drawings at 8 and 16.24 hrs post procedure, and divided 
them into 2 groups according to peak Tnl: Tnl 2 0.15ngidl n=601 (Tnlc), and Tnl < 
O.l5ng/dl, n=1271 (Tnl-). 
Results: Baseline pt and lesion characteristics were similar in both groups. Overall plate- 
let glycoprotein llbillla inhibitor use was 12.5% and equally distributed between groups. 
In-hospital, SO-day and l-year clinical outcomes are shown in the table: 
Tnl+ Till- P 
CK-MB 2 3x normal (%) 57.0 3.9 0 0001 
CK-MB 7 5x normal (%) 49.6 1.7 0.0001 
In-hospital MACE (%) 4.1 0.7 0.0001 
do-day death/Ml (%) 4.8 2.8 0.03 
1 -year Death (%) 7.5 4.0 0.002 
1 year Ml (%) 6.5 3.4 0.006 
1 -year TLR (%) 12.2 11.4 0.64 
1 -year MACE (%) 16.2 18.8 0.55 
MACE=death, Ml and urgent CABG: TLR=target lesion revascularization 
By multivariate analysis, age (p<O.OOl;OR=l .l), diabetes mellitus (p<0.0001;OR=3.0) 
and Tnl+ (p=0.045;OR=1.7) were independent predictors of l-year mortality. 
Conclusions: Peri-procedural Tnl elevation (>0.15ng/dl) is a strong predictor of early 
(iwhospitali3Oday) and late (l-year) cardiac events along with pt-related co-morbidities 
(age, diabetes). This biological marker of cardiac injury can be useful in risk assessment 
and patient stratrfication. Further studies should investigate its utility both before and 
after PCI and in relation to other prognostic factors. 
Background: Coronary arteriopathy (CAD) occurs progresstvely after heart transplanta- 
tion (TX) and generally connotes a poor prognosis. The extent to which percutaneous 
coronary intervention (PCI) impacts survival in this population is unclear, as is the coinci- 
dence of non-coronary deaths. Methods: We studied the long-term outcome of 36 con- 
secutive adult heart transplant recipients undergoing 118 PCI procedures (TxPCI). We 
compared it to the course of 36 control TX recipients free of CAD (TxCON), matched for 
‘time from TX to first PCI’ and age at transplantation. The follow-up interval was defined 
as the ttme from the first PCI to last follow up or death. The average time from transplan- 
tation to 1st PCI or reference date for control patients was 85 * 40mo (mean * SD) for 
both groups. The duration of follow-up was 48 f 33mo in TxPCl patients and 58 + 37mo 
in TxCON patients. Results: Patients had an average of 3.3i1.8 PCI procedures done in 
the TxPCI. In the follow-up period, 42% (n=l5) TxPCl patients and 20% (n=7) TxCON 
patients died. Average time from PCI to death was 55 i 31mo. Solid tumors contributed 
to 26% (n=4) of deaths in the TxPCl group and none in the TxCON group. During the first 
30mo after PCI, there was no significant difference tn mortality between TxPCl and 
TxCON. TxPCl patients had a greater annual mortality thereafter (see Figure). Conclu- 
sions: This study suggests that PCI may improve survival in TxCAD patients initially, 
comparable to TX patients without CAD. Four years after 1st PCI, however, mortality is 
increased, but a quarter of these deaths is non-cardiac. 
1090-38 
1090-36 Angiographic Patency of LIMA-LAD Anastomosis After 
MIDCAB Compared to Conventional CABG: Results From 
the POEM Trial 
Early and Late Clinical Outcomes After Successful 
Coronary Revascularization in Patients With Moderately 
and Severely Reduced Renal Function 
Masashi Iwabuchi, Hideyuki Nosaka, Takeshi Kimura, Naoya Hamasaki, Hiroyoshi 
Yokoi, Masakiyo Nobuyoshi.Kokura Memorial Hospftal, Kitakyushu, Japan 
Roxana Mehran, Valavanaur Subramanian, Michael Ma& Albert Pfister, Paul Corso, 
lnderjit S. Gill, E. Charles Douville, Trey Brunsting, James Magovern, Robert Matheny, 
Jeffrey W. Moses, Martin B. Leon. Lenox /-fill Heart and Vascular Institute, New York, NL: 
Columbia Hospital and Medical Center, Da//as, TX 
Background: Pts with reduced renal function have an increased risk of peri-procedual 
complications and higher early and late cardiac event rates. Long-term outcomes in pts 
with moderately reduced renal function are unknown. Methods: To evaluate the impact 
of renal dysfunction on the early and late cardiac death(CD), we followed 6388 pts after 
successful coronary revascularization between 1982-1998. Of these, 264pts had moder- 
ately reduced renal function (1.52.0) and 89 pts had end-stage CRF (ESRF) on dialysis. 
Results: Independent multivariate predictors of cardtac death included: poor left ventric- 
ular function (LVEF<O.35)(OR:5.1,p<0.01), CRF (OR:4.8,p<0.01) and left main lesion 
(%stenosis>50%) (OR:2.3,p<0.01). 
Background: Conventional CABG (cardiopulmonary bypass [CPB] + open sternotomy) 
using the internal mammary artery (IMA) as a conduct has been performed for 120 years 
with excellent clinical outcomes. Minimally invasive direct coronary bypass (MIDCAB) is 
a new technique in which the IMA is anastamosed to the LAD under direct visualization 
on a beating heart (no CPB). 
Methods: The Patency, Outcomes, and Economics of MIDCAB (POEM) study is a muk- 
center (9 clinical sites) prospective trial in 310 pts destgned to determine the relative mer- 
Its of the newer MIDCAB procedure compared with conventional CABG. Experienced 
MIDCAB surgeons at each site enrolled pts with IMA-LAD anastamosis into either the 
MIDCAB or conventional CABG arms followed by procedural, in-hospital, and 6 month 
angiographic patentcy (<70% stenosis) at IMA-LAD anastomosis and TIMI 3 flow). 
Results: Baseline pt characteristics were simtlar in both groups. Follow-up angiography 
is available in 60% of pts. 
MIDCAB (n=165) CABG (n=l45) P 
In-hospital (%) 
Death 
Ml 
0 0.7 NS 
0.6 1.4 NS 
ESRF n=89 CRF(Cre>2.0) 1 .S<CRE NRF(Cre<l .O) 
n=144 n=3476 
Early(cGmos)CD(%) 3.4* 10.0’5 2.7* 0.5 
Late(>Gmos)CD (%) 22.3* 19.0’ 10.8*$ 2.6 
5yrs Free From CD (%) 74.3’ 71 .O’ 86.5*$ 96.9 
*p&O5 vs normal renal functton(NRF),$pcO.O5 vs ESRF 
Conclusions: Wtthin six months after procedure. cardiac mortality of pts with CRF was 
higher compared to pts with ESRF, but similar in late phase. Pts with moderately renal 
dysfunction had an increased risk of cardiac death as also as pts wrth CRF and ESRF. 
Because of high incidence of cardiac death after coronary revascularization, careful clini- 
cal follow-up was necessary to the pts with moderately and severely reduced renal dys- 
function. 
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1090-39 Do llblllla Receptor Blockers Improve In-Hospital Outcomes 
in Patients Undergoing Rescue Percutaneous Coronary 
Interventions? 
Julian M. E&ban, Eric Ft. Bates, David Share, Michael J. O’Donnell, Kim A. Eagle, 
Anthony DeFranco, Eva Kline-Rogers, Vivian Clark, Ann Maxwell-Eward, Mauro 
Moscucci, For the Blue Cross Blue Shield of Michigan Cardiovascular Consortium 
(BMCZ). University of Michigan, Ann Arbor, MI 
Background: There is little information on the utility of Ilb/llla receptor blockers in 
patients undergoing rescue percutaneous interventions (PCI) after failed thrombolysis. 
We sought to evaluate the in-hospital outcomes following the use of these agents in res- 
cue PCI. Methods: Data on 416 patients who underwent rescue PCI between July 1997 
and September 1999 ware analyzed from a large multicenter PCI registry. To avoid 
potential treatment bias, the analysis was limited to 353 patients not presenting with car- 
diogenic shock. Of these, 165 patients received a llbillla receptor blocker, and their clini- 
cal characteristics and in-hospital outcomes were compared to those of 188 patients who 
did not. Results: Baselme clinical characteristics were similar between the two groups. 
Hospital outcomes are shown in the table. Angiographic success rate (defined as TIMI 3 
flow and ~50% residual stenosis) was significantly higher in the llbillla receptor blocker 
group. This was however associated with a similar mortality rate and with an increase in 
bleeding complications. 
Variable llbillla No Ilb/llla P 
Angiographic Success 88.5% 77.4% <O.Ol 
Death in the Hospital 4.2% 4.3% ns 
Stroke 2 4% 2.1% “S 
GI Bleeding 5.5% 0.5% 0.025 
Vascular Complication 4.8% 4.8% ns 
GI Bleeding or Vascular Complication 9.1% 5.3% ns 
Conclusions: 1) Rescue PCI for myocardiai infarction not complicated by cardiogenic 
shock is associated with a high in-hospital mortality rate. 2) The addition of a llbllla 
receptor blocker results in a higher angiographic success rate, but it is associated with a 
higher incidence of bleeding complications and it does not appear to result in a survival 
benefit 
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1091-9 Elevated Fasting Blood Glucose in Non-Diabetics Predicts 
Clinical Restenosis: A Prospective Study of 2,246 Patients 
With Severe Coronary Artery Disease 
Chloe A. Allen Maycock, Joseph B. Muhlestein, Dale G. Renlund, Benjamin D. Home, 
Tami L. Bair, Kirti Salunkhe, Farangis Lavasani, Jeffrey L Anderson. LDS Hospital, SaB 
Lake City, UT University of Utah, Salt Lake 0% UT 
Background: Diabetes mellitus is highly predictive of recurrent cardiovascular events 
and restenosis among patients with coronary artery disease (CAD). We have previously 
reported that nondiabetic CAD patients with intermediate glucose levels (1 lo-124 mg/dL) 
exhibit similarly elevated rates of death and myocardial infarction (Ml) as those with 
blood glucose 2125 mg/dL. In this study we evaluated whether nondiabetic patients with 
mildly elevated blood glucose experience similarly increased rates of restenosis. 
Methods: Baseline blood samples, demographic information, and clinical histories were 
obtained from 2,246 nondiabetic patients undergoing coronary angiography. Clinical res- 
tenosis (defined as repeat target lesion revascularization within 6 months of the index 
cardiac procedure) was determined among patients with severe CAD (270% stenosis), 
and index hospitalization fasting blood glucose was determined. 
Results: Patients averaged 64?12 years of age; 77% (n=1,727) male and 23% (n=518) 
female. Overall 6month mortality was 3.3% (n=75), Ml was 3.3% (n=74), and clinical 
restenosis was 12.0% (n=270). Logistic regression controlled for possible confounding 
due to age, gender, smoking, hypertension, hyperlipidemia, family history, number of 
severely disease vessels, and presentation. In multivariate analysis, blood glucose >llO 
mg/dL was significantly and independently predictive of clinical restenosis (pcO.001: 
odds ratio [OR] = 1.6; 95% Cl: Il.2 to 2.01). Elevated blood glucose was also indepen- 
dently predictive of death (p<O.O05; OR = 2.0; Cl: Il.2 to 3.31) and Ml (~~0.034; OR = 
1.7; 95% Cl: [I.0 to 2.71). 
Conclusion: In CAD patients with no previous diagnosis of diabetes, mildly elevated 
blood glucose (>I10 mgidL) predicts six-month clinical restenosis in addition to six- 
month death and Ml. Because these nondiabetics exhibit increased event rates, all 
patients with blood glucose >llO mgidL may be candidates for diabetic treatment regi- 
VX?“S. 
1091-10 Pretreatment with lntragraft Verapamil Prior to 
Percutaneous Coronary Intervention of Saphenous Vein 
Graft Lesions: Results of the Randomized, Controlled 
Vasodilator Prevention of No Reflow (VAPOR) Trial 
Andrew D. Michaels, Kent Dauterman, Fady Malik, Thomas A. Ports, C. M. Gibson, 
Kendrick Shunk, Tony M. Chou. University of California at San Francisco, San Francisco, 
CA 
Background: No-reflow is an occasional serious consequence of percutaneous coro- 
nary intervention (PCI) of saphenous vein grafts (SVG). Verapamil is a long-acting 
vasodilator frequently used to reverse microvascular vasospasm and improve microvas- 
cular perfusion. Methods: The randomized, non-blinded, pilot VAPOR (Vasodilator Pre- 
vention of No-Reflow) trial tested the hypothesis that pretreatment with intragraft 
verapamll may reduce the incidence and severity of no-reflow in patients undergoing 
SVG PCI. Patients were randomized to receive verapamil 200mcg intragraft through the 
guiding catheter or no verapamil prior to wiring the lesion. Results: 21 patients were 
enrolled in VAPOR (verapamil=9, placebo=1 2). The mean age of patients was 71.8+8.7 
years, 86% ware male, and 24% ware diabetic. The mean age of the SVGs was 9.0+5.6 
years, and 95% of patients received glycoproteln Ilb/llla inhibitors prior to PCI. Prior to 
PCI, the placebo group had TIMI 3 flow in 75% and TIMI 2 flow in 25% in the culprit ves- 
sel. After PCI, placebo patients had TIMI 3 in 83% and TIMI 2 in 17%. Prior to PCI. the 
verapam patients had TIMI 3 in 44% and TIMI 2 in 56%. After PCI, TIMI 3 flow was 
present in 100% of verapamil patients (p=NS between groups). Coronary flow improved 
with a decrease in the TIMI frame count by g&32.4% for placebo patients versus 
49.5121 .l% for verapamil patients (p=O.OOS). An increase in the final TIMI frame count 
occurred in 25% of placebo patients compared to none of the verapamil patients after 
PCI No-reflow (defined as a decrease in TIMI flow grade by 1 or more during PCI) 
occurred in 33% of the placebo procedures and none of the verapamil procedures 
(p=O.lO). Cardiac enzymes measured 6-12 hours following PCI were newly elevated 
above the upper limit of normal in two patients in each group (p=NS). No adverse events 
were associated with intragraft verapamil. Conclusion: Pretreatment with intragraft vera- 
pamil prior to SVG PCI reduced the incidence of no reflow and improved the final TIMI 
frame count compared to standard PCI. This promising, simple, and safe preventive 
strategy needs further investigation in larger patient groups and possible comparison to 
other vasodilators and distal protection devices. 
1091-11 Pharmacotherapy Eliminates the Need for Temporary 
Pacemakers During Rotational Atherectomy: Follow-Up of 
the BRAT Study 
Gregory A. Braden, Kevin M. Rankin, Teresa M. Young, Wendy L. Hobbs, Robert J. 
Applegate. Wake For& University School of Medicine, Winsion-Salem, NC 
Background: Bradyarrhythmias (BA), both sinus bradycardia or AV block are common 
during rotational atherectomy (RA), especially of RCA and large CX lesions, therefore 
necessitating the recommendation of temporary pacing during RA in many patients. We 
have previously shown that both adenosine release and vagal stimulation mediate these 
BA’S. 
Methods: We report on a prospective strategy employing pretreatment with Aminophyl- 
line and Atropine to prevent the need for temporary pacing. All RA patients received 
Aminophylline (5 mg/kg over 5-10 min) prior to RA to prevent adenosine mediated BA. 
Patients with resting heart rates of ~60 received 1 mg Atropine and this was supple- 
mented as needed during the procedure to treat BA’s to a total of 3 mg to block vagal 
affects. 
Results: Between 7-l-97 and 6-30-99, 1273 consecutive RA patients were treated using 
this pharmacologic strategy at Wake Forest University. No prophylactic pacers were 
placed in these patients. A total of 2201 lesions were treated, of which 604 (27%) were 
RCA and 486 (22%) were CX lesions. Only 4 patlents (0.3%) developed significant 
bradycardia requiring emergent placement of a temporary pacemaker. All 4 of these 
cases were notable for multivessel disease with moderate to ?.evere LV dysfunction. 
Major hemodynamic complications occurred in these patients from either coronary perfo- 
ration or slow-no-flow necessitating IABP placement. 
Conclusion: Using a pharmacologic strategy blocking adenosine affects and vagal stim- 
ulation, RA can be safely preformed in all patients without the need for prophylactic 
pacemakers. This reduces procedure time, cost, and potential pacemaker related com- 
plications. 
1091-40 Estrogen Induces a Favorable Modulation of Coronary 
Blood Flow and Vasomotor Responses During Atrial Pacing 
in Postmenopausal Women 
loannis Kallikazaros, Constantinos Tsioufis, Panayiotis Zambaras, Christodoulos 
Stefanadis, Anastasios Spanas, K&as Tzioumis, Pavlos Toutouzas. HlfPOKRATlON 
HOSPITAL, ATHENS, Greece 
Background: Short-term administration of 17 p estradiol has been shown to improve 
exercise induced myocardial ischaemia in postmenopausal women with coronary artery 
disease. Methods: In 14 postmenopausal women (aged 6023 yrs) with minimal coronary 
irregularities, as evidenced by angiography or intravascular ultrasound, we evaluated 
coronary reactivity and coronary blood flow (CBF) during incremental atrial pacing (up to 
150 bpm for 3 minutes), before and 20 minutes after the intracoronary infuslon of 75ngl 
ml estradiol which increased coronary sinus estradiol levels from post- to pre-meno- 
pausal levels. The cross sectional area (CSA) and the CBF velocity of the proximal con- 
nary segments were measured with quantitative coronary angiography and with a 
doppler flow wire respectively. Measurements were obtained before, during atrial pacing 
and at 7 mins after pacing. Results: Before estrogen administration, atria pacing 
induced a significant decrease in coronary CSA (from 0.066 to 0.053cm’) and a signifi- 
cant increase in CBF (from 21.5 to 27 mlimin). Furthermore, these changes in CSA and 
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CBF remained 7 mins after pacing. After estrogen admrnistration, at rest the CSA and 
CBF did not change srgnificantly (0.067 cm2 and 22.05 mllmin, respectrvely) but during 
pacing the changes in CSA and CBF were significantly attenuated compared to pacing 
induced changes before estrogen (by 0.003 “s 0.013 cm’; p&O05 and by 10.2 “s 6.2 
mlimin, pcO.005, respectively). These favorable modulations in CSA and CBF remained 
at 7 mins after pacing. In conc!usion, estrogen reduces the degree of pacing-induced 
ischemla by attenuatrng the reduction in coronary CSA and improvrng the increase in 
CBF in postmenopausal women with atherosclerotic coronary arteries. 
1091-41 Effectiveness of Collagen Based Anchor Closure Device in 
the Presence of Potent Anti Platelet Therapy 
Mark A. Grabarczyk, Gregory A. Braden, Kevin M. Rankin, Mrchael A. Kutcher, Lyn R. 
Hardy, William C. Little, Robert J. Applegate. Wake Forest University School of Medicine, 
Winston-Salem, NC 
Background: Activation of collagen based closure devices may be impaired by potent 
anti-platelet therapy, However, initial trials of closure devrces limited enrollment of 
patients on anticoagulants and GP llbillla inhibitors. Thus, the efficacy of collagen based 
closure devices in patients undergoing coronary intervention (PCI) and treated with GP 
ilb/llla inhibitors is uncertain. 
Methods: We studied 2,348 consecutive patients receiving abciximab durrng PCI and 
who had arteriotomy closure with collagen based anchor closure device (Angioseal, 
n=524), or by manual pressure (n=1,824). Femoral arteriograms were performed to 
assess feasrbility of clowre PCI was performed usrng heparin (to achieve target ACT 2 
200) and abciximab (bolus + 12 hr infusion) in standard fashion. Sheaths were removed 
in the lab (Angioseal) or when the ACT was < 170 (manual). By protocol, ambulation 
was begun 2 hours after Angioseal closures and 6-8 hours after hemostasis by manual 
pt?.SSlXe. 
Results: Initial Angloseal success with the 8 Fr device (1X/137; 92.0%) was substan- 
tially improved by use of a “buddy wire” (3891393; 99.0%), p<O.Ol. Procedural and hos- 
prtal vascular complications occurred in 111524 Angioseal patlents (Z.l%), and 52/1,824 
manual patients (2.9%) p=NS; specific outcomes were as follows: 
Failure/ Vascular Maim Large Pseudoaneurysm/ 
Angioseal 
ManlJai 
p value 
Femstop Repair Bleeding HerX&la AV Fistulae 
2.6 0.2 11 0.4 0.8 
3.5 0.8 0.9 1.7 1.3 
0.43 0.21 0.32 0.16 0.80 
No patient died in the Angioseal group while 2 patients died secondary to vascular com- 
plications in the manual group (p=NS). Vascular outcomes were not influenced by 
demographrc or clinical characteristics of the two groups. 
Conclusions: Arteriotomy cloture with Angioseal after PCI can be performed rapidly 
and rmmediately in fully anticoagulated patients treated with the GPllbillla inhibrtor abcix- 
imab with a high success rate and low complication rate. Thus. anchor based closure 
devrces are effective in patients treated with potent anti-platelet therapy, Moreover, in 
addition to reducing time to ambulatron, they may reduce serious vascular complications. 
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Dose-Dependent Reduction in Neointimal Hyperplasia 
Following Coronary Stenting With Halofuginone, a Collagen 
Synthesis Inhibitor 
Paul C. Keelan, LaDonna J. Camrud, Janis Donovan, Krmberiy J. Yuhala, Lior 
Zelikovich, Debra A. Lewis, Robert S. Schwartz. Mayo Clinic and Foundation. Rochester, 
MN, Collgard Biopharmaceuticals, Tel Aviv, Israel 
Background: Increased neointimal hyperplasra 
(NH) occurs foliowir?g coronary stenting com- 119 RI reara, LllrrDiIBCTD”,[l~dlaldD,O,I~ 
pared to cornventional balloon angioplasty. p spkao 
When exaggerated, this response can culminate 
d b<rsi 
i c-c *&+ 
in in-stem restenosis, a major clinical problem. f 
3 
/ 3 ,m 
Collagen and smooth muscle cells (SMC) com- ; &Y 
prise the bulk of NH. In vitro testing confirms that i 
9 
halofuginone potently inhibits collagen synthesis e 
1 
Meal ll l l i Sdlh 
and SMC migration and proliferation. We evalu- 
ated the efficacy of thus drug to limit NH in viva in 
a porcine coronary stent injury model. Methods: We randomised 24 pigs to receive pla- 
cebo, oral halofuginone (O.Pmg/Kg/day) or IV halofugrnone (O.lmg/Kg brd), starting 7 
days before stenting and continuing until euthanasia. All animals underwent oversized 
balloon injury and stent deployment in 2 coronary arteries and were euthanired 28 days 
later. Serum drug levels were drawn at 5 pre-specified time-pornts between stenting and 
sacrifice. Stented arteries were analyzed by hrstomorphometry. NH response was ana- 
lyzed by treatment group and correlated with mean serum drug levels within each group. 
Results: To control for the confounding effect of vessel injury extent on NH, we con- 
structed regression lines for each group, in which neointimal thickness was plotted as a 
function of injury score (fig.). This confirmed a beneficial drug effect in limiting NH, with 
animals in the IV drug group faring best and placebo animals farrng worst. The mean 
eerum drug level was signifwmtly higher m the IV group (Il.lng/ml) than in the oral 
group (3.8ng/ml) (p<O.Ol). Both these levels differed significantly from the placebo 
group, in which no drug was detected (p<O.OOi). Conclusions: Halofuginone appears 
effective in limiting NH following coronary stentmg. The magnitude of thus effect IS closely 
related to serum drug levels. Thus drug may be useful rn attenuating NH following coro- 
nary stenting. 
810-Z 
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Photodynamic Therapy With Local Verteporfin Delivery 
Reduces Stent-induced lntimal Thickening 
Douglas E. Drachman, Gregory S. Toegel, Stefan G. Her&berg, Wrlliam R. Tyrrell, Jr., 
Adam R. Groothuis, Russell G. Hodge, Rrchard T. Choh, Knstina A. Arnold, Campbell 
Rogers. Brigham and Women’s Hospital, Boston. MA, Massachusetts lnst/tute of 
Technology, Cambridge, MA 
Background: Previous attempts to control in-stent restenosis have met with limited suc- 
cess. Photodynamic therapy (PDT) employing locally photoactivated compounds target- 
ing plaque constituents such as smooth muscle cells (SMC) and inflammatory cells has 
been proposed as a primary treatment for atherosclerosis. We hypothesized that PDT 
using local delivery and light-activation of verteporfin would reduce the rate of neointimal 
thickening after stenting, also by virtue of effects on SMC or inflammatory cells 
Methods: Rabbit ilrac arteries (n=45) underwent balloon injury, followed 14 d later by 
stenting. Immediately after stenting, verteporfin or control (5% dextrose solution) was 
delivered locally at the site of stent implantation, followed by catheter-based light-activa- 
tion in the stented lumen. Four drug-treated groups received escalating light doses; 
sham illumination was given in the control group. 
Results: 28 d after stenting and PDT, intimal area and intimamedia area ratio were 
reduced in an illumination-dependent manner. Endothelial regrowth and proliferatwe 
indices were consistent with these data. Late vessel wall healing was examined, and no 
significant difference was seen in inflammation, medial viability, or adventrtial fibrosis. 
Conclusion: PDT using local delivery and local light-activation of verteporfin reduces 
rntimal thickening after stenting. 
Intima:Media Ratio as a Function of PDT with Increasing Light Dose (from 1 to 4) 
Treatment Intima:Media Ratio 
Control (no drug, no light) 5.5 +I- 2.2 
Vertsporfin + light dose 1 4.6 +I- 0.7 
Vertepodin + light dose 2 4.1 +/- 0.8 
Vertepodin + light dose 3 4.5 +/- 1.2 
Vertepadin + lkght dose 4 3.8 ci- 1 .O (~~0.04) 
81 O-3 
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Inhibition of Neointima Formation by the Structural 
Adenosine Analogue 3-Deazaadenosine 
JBrg Kreuzer, Wolfram Hess, Jianwei Fer, Ralf Kinscherf. Christiane Viedt. Unwersit8 
Heidelberg. Heidelberg, Germany 
Background: The anti- inflammatory properties of the structural adenosine analogue 3- 
deazaadenosine (c3Ado) have already been utilized in patients with rheumatoid arthritrs. 
We have recently shown that c3Ado Inhibits atherogenesis in mice. We now wanted to 
study its effect on neointima formation after balloon injury. Methods: Rat smooth muscle 
ceils were incubated with c3Ado (IO to 10 M) and PDGF- dependent activation of extra- 
cellular signal regulated kinase (ERK) was investigated. To study the effect of c3Ado in 
v/w, adult Sprague Dawley rats underwent balloon angioplasty to the left common 
carotid artery. C3Ado was administered orally at a dose of 10 mg/kg BW daily. Each 
group consisted of 12 animals. Treatment was started 5 days prior to balloon rnjury and 
was continued for another 14 days. The neontima and the media were quantrtated by 
computer assisted planimetry. Results: c3Ado inhabited ERK activatron by PDGF in a 
dose and time dependent manner. When c3Ado was used in viva no adverse effects 
were observed and the drug was well tolerated. 14 days after injury the intima/media 
ratio in the treatment group was reduced by 67% (p<O,OOOl). Luminal stenosrs was 
reduced by 50% (p<O,OOOl). Cellular density in the neointima of the treated animals was 
reduced by 25% (pcO,OOl). Another group of animals also received c3Ado for 14 days 
after injury but was sacrificed 3 month after the initial trauma. This group showed a 
reduction of the intimaimedia ratio of 87% (pcO,OOOl). Conclusion: Short term admini- 
startion of C3Ado is capable of inhibiting neointima formation in rats for at least 3 month 
after injury. The effect may be mediated by MAP kinase inhibition. These findings impli- 
cate that c3Ado may be useful as an inhibitor of restenosis formation after balloon angio- 
plasty in humans. 
81 O-4 
IO:00 a.m. 
Local Delivery of Low-Dose Docetaxel, a Novel and Potent 
Anti Microtubular Agent, Reduces Neointimal Hyperplasia 
in a Balloon-Injured Rabbit Iliac Artery Model 
Satoshi Yasuda, Teruo Noguchi, Masahiro Gohda, Takashr Arai, Nobumasa Tsutsui, 
Yasuhide Nakayama, Takehisa Mastuda, Hiroshi Nonogi. Nationai Cardiovascular 
Center, Suita, Osaka, Japan, Tokai Medic& Products, Aichl, Japan 
Background: Docetaxel (DOC) is a novel microtubule polymerizmg agent, with superior 
antiproliferative propertres as compared to taxel. DOC is therefore a potential therapeutic 
tool for the prevention of restenosis following angioplasty. However, DOC has systemic 
toxicrty such as leukocytopenia, which occurs in a dose-dependent manner at plasma 
levels of l-10 micro-g/ml. To mrnimize such adverse effects, we sought local delrvery of 
low-dose DOC directly to the balloon-injured site in the vessels. Methods: The iliac 
artery in New Zealand white rabbits (3 kg) was denuded, and then DOC (2 mg) or control 
vehicle was administered locally over 20 minutes. via a local drug delivery catheter. In 
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pilot studies using this device, the drug permeated into the medial tissues, where it per- 
sisted for at least 24 hours. Results: The plasma levels of DOG did not exceed 
0.20?0.08 [mean+/-SD] micro-g/ml, eliminating hematopoietic side effects. Seven days 
after the local delivery (DOC:n=4, control:n=4), DOC decreased the number of vimentin- 
labeled cells in the intima (DOC:38+/-10 vs control:1 12+/-21 cells/mm2, PcO.O5), indicat- 
ing a decreased proliferative activity. However, immunostaining against endothelial cells 
(CD-20) and macrophages (CD-68) did not differ between the two groups. At 28 days 
(DOC:n=5, control:n=8), computer-assisted morphometric analysis demonstrated that 
DOG significantly reduced the intimal area (DOC: O.lO+/-0.12 vs control: 0.68+1-0.16 
mm2, P&01). There was also a decrease in medial area in the DOC-treated vessels 
(DOC: 0.51+/-0.06 vs control: 1.13+/-0.38 mm2, P<O.Ol). Conclusions: Local delivery of 
DOC, even after a single low-dose administration, effectively inhibits neointimal prolifera- 
tion. Such administration IS assocrated wth a minimal likelihood of systemic adverse 
effects (leukocytopenia), but potentially induces local toxicity of the media due to exten- 
sive injury. 
81 O-5 
IO:15 a.m. 
Therapeutic Ultrasound Can induce Apoptosis in Smooth 
Muscle Cells: A Potential Role for Restenosis Prevention? 
Uri Rosenschein, Hagit Ashush, Michal Blass, Mira Barda-Saad, Ariella Alter, Frida 
Firestein, Leon A. Rozenszajn. Tel Aviv Sourasky Medical Center. Tel AVIV, Israel, Bar 
l/an University; Ramat Gan, lsrael 
Background: It has been suggested that smooth muscle cells (SMC) apoptotic cell 
death is involved in the mechanism of vascular brachytherapy. We have previously 
shown that high power, low frequency therapeutic ultrasound (TUS) can induce in vitro 
dramatic reduction in SMC proliferation, migration and adhesion capacities. We hypothe- 
sized that the underlying effect of TUS irradiation is induction of apoptotic cell death. 
Methods: Pulsed TUS (pulse duration 50 “s duty cycle - 1:25 frequency 750 kHz) 
above the cavitation threshold (52 WlcmP) was delivered using a dedicated external 
transducer (Angiosonics Inc, Morrisville, NC) to different cell cultures (SMC, Ml12 [p53+/ 
+] and K562 [p53-i-1 cell lines). 
Results: Three hours following exposure to TUS typical morphological alterations were 
observed (LM & SEM) including: cell shrinkage, chromatin condensation, nuclear frag- 
mentation and apoptotic body formation. Three to six hours following exposure to TUS, 
viable and apoptotic cells were evaluated by florescence microscopy “sing ethidium bro- 
mide and acridine staining. The TUS-treated SMC exhibited significant proportion of apo- 
ptotic changes, as compared with control (24-1-11 vs 4.4?3.7%, p=O.O05). Significant 
apoptotic changes were observed in both p53 positive (M1/2) and negative (K562) cell 
lines. The genomic DNA single strand breaks characteristic of apoptosis were found in 
sonicated SMC having TUNEL-positive staining. There was neither significant change in 
medium temperature nor production of free radicals by TUS. 
Conclusion: TUS and the resulting cavitation appears to induce apoptosis in SMC. TUS 
has a potential to be an effective modality in the prevention of restenosis. 
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9:15 a.m. 
811-l Acute and Chrbnic Vessel Responses to Direct Stenting vs 
Sfenting With Predilatation: A Serial intravascular 
Ultrasound Study 
Shinichi Shimodozono, Yasuhiro Honda, Ronald F! Caputo, Charles D. O’Shaughnessy, 
Reginald L. Low, Barry D. Rutherford, Patrik C. Zetterlund, Campbell D. K. Rogers, Paul 
G. Yock, Donald S. Bairn, Peter J. Fitzgerald. Stanford University, Stanford, CA, Brigham 
and Womeng Hospital and Harvard Medical School, Boston, MA 
Several observational studies have shown that direct stenting (DS) significantly reduces 
initial costs, radiation exposure, and procedure times. It has also been suggested that DS 
might reduce vessel trauma and subsequent restenosis. Predilatation vs Direct stenting 
In Coronary Treatment (PREDICT) is a multicenter, prospective, randomized trial to eval- 
uate the safety, efficacy and restenosis rates of DS and conventional stenting with predi- 
latation (CS) using the Medtronic AVE 5670 stent. 400 patients with single,de nova 
lesions were enrolled. An intravascular ultrasound (IVUS) substudy (n=68) was per- 
formed to characterize the acute and chronic vessel responses to DS versus CS. Meth- 
ods: In the substudy, IVUS was performed immediately after intervention and at 6.month 
follow-up. 68 baseline and 52 follow-up IVUS cases have been analyzed. Morphometric 
parameters obtained at the tightest cross-section within the stent and at proximal and 
distal references were compared between the two groups. Results: There were no sig- 
nificant differences in baseline clinical and lesion characteristics between DS and CS. At 
baseline post-intervention, no significant differences were observed between the two 
groups, including the average reference lumen area (DS: 8.4+2.7 mm” vs CS: 84~2.8 
mm*) and minimum stent area (DS: 6.&l 9 mm* vs CS: 7.2r2.2 mm’). At 6.month fol- 
low-up, minimum lumen area had significantly decreased in both groups, with no signifi- 
cant differences in intimal area (DS: 3.7k1.9 mn+vs. CS: 4.2e2.1 mm”). minimum lumen 
I  
area (DS: 4.3~1.7 mm’vs CS: 3.9+2.6 mm”), or late lumen loss between the two groups. 
Direct stent Predilatation P 
Reference Lumen Area (mm2) 8.4 zk 2.7 8.4 t 2.8 NS 
Minimum Stent Area 6.8 * 1 .a 7.2 e 2.2 NS 
lntimal Area (at follow up) 3.7 * 1.9 4.2 r 2.1 NS 
Minimum Lumen Area (at follow up) 4.3 t 1.7 3.9 c 2.6 NS 
Conclusion: There are similar acute and long term vessel responses with respect to 
IVUS morphometric parameters to direct stenting and conventional stenting after predila- 
tion. 
9:30 a.m. 
811-Z Intravascular Ultrasound-Guided Provisional Stenting in 
Small Coronary Stenosis 
Alexandre Abizaid, August0 D. Pichard, Roxana Mehran, Gary S. Mintz, Luis Gruberg, 
Javed Ahmed, Gregg W. Stone, Andrea S. Abizaid, Lowell F. Salter, Kenneth M. Kent, 
George Dangas, Martin B. Leon. Cardiovascular Research Foundation, New York, NY 
Washington Hospital Center, Washington, DC 
Background: The strategy of an aggressive balloon angioplasty guided by intravascular 
ultrasound (IVUS) with provisional stenting to treat pts with small vessels stenosis has 
not been tested. 
Methods: To test this hypothesis we performed In/US-guided primary PTCA coupled with 
high pressure inflation pressures to treat 254 pts (286 lesions) with small vessel disease 
(QCA reference diameter < 2.7mm). IVUS lesion media-to-media dimension was used to 
select balloon sizes which were inflated to “high” (>I0 atm) pressures. Pts were crossed 
over to stent implantation if this strategy (1) failed to achieve a final lumen area > 65% of 
the reference lumen areas or (2) resulted in IVUS lumen compromising dissections. 
Results: Ii 6 pts (45%) crossed over to stenting. We than compared this group with 138 
pts ( 155 lesions) that fulfilled IVUS criteria for optimal PTCA and with 413 pts (453 
lesions) that underwent IVUS-guided primary stenting at the same time frame to treat 
small vessel disease (QCA reference diameter c 2.7mm). Balloon-to-artery ratio was 
1.32 and the average balloon inflation was 12+3 atm. Angiographic, IVUS and clinical 
results: 
Provisional Stentinq Elective Stenting P 
PTCA cross-over value 
Final procedural s”ccess 96% 97% 99% 0.71 
QCA: Ref. diameter, mm 2.28i0.31 2.29r0.38 2.35kO.26 0.13 
Final MLD, mm 2.05+_0.48 2.3&0.81 2.44kO.75 0.0001 
Final DS (%) 16.9+16.2 9.2k15.3 8.4A19.4 0.0001 
IVUS: Ref. lumen area, mm2 6.63+2.28 6.78+2.44 6.89Q.38 0.26 
Final lumen area, mm* 4.92A1.61 6.59k2.18 6.64+2.05 0.0001 
I-year FU: TVR 26.1% 27.5% 26.9% 0.18 
Death/Ml 7.8% 8.1% 6.1% 0.65 
MACE 33.5% 34.9% 33.0% 0.91 
Multivariate analysis showed that the only independent predictor of one-year MACE and 
TLR was the IVUS final lumen area (OFb0.825; p=O.O008 and OR: 0.804; p=O.O005 ). 
Conclusion: The strategy of an aggressive IVUS-guided provisional stenting for small 
vessels can be safely performed and yields similar l-year outcome to primary stents. 
However, regardless of treatment strategy, IVUS final result assessment can predict late 
events. 
9:45 a.m. 
811-3 The Efficacy of Post-Deployment Balloon Dilatation for the 
Current Generation Stents: A Serial Volumetric 
Intravascular Ultrasound Study 
Seung-Ho Hur, Katsuhiro Kitamura, Yoshihiro Morino, Yasuhiro Honda, Michael Jones, 
Kenneth S. Kerr, Bernard Reen, Ill, Christopher J. Copper, Gary S. Niess, Leonard 
Christie, Woodrow Corey, John Messenger, Paul G. Yock, Frank Cummins, Peter J. 
Fitzgerald. Sfanford University Stanford, CA 
Background: Recently, post-dilatation following stem deployment is declining in fre- 
quency due to improved stent and delivery systems. However, little data exist to support 
this practice. 
Methods: We evaluated 57 native coronary lesions treated with single stent implantation 
(NIR, nistar or 5670). Serial IVUS was performed following successful stent deployment 
and again after additional high-pressure balloon dilatation (14.6 f 2.8 atm, 1 .l :l .O bal- 
loon to artery ratio). To further investigate the precise expansion characteristics of the 
stents, serial volumetric IVUS analyses were performed in 32 patients with automated 
pullback. 
Results: After additional balloon dilatation, minimum stent area increased significantly 
from 6.33 f 2.12 mm* to 7.23 i 2.11 mm* (p<O.OOl). Volumetric analysis showed a cor- 
responding increase in stent volume (6.53 + 1.62 to 7.41 * 1.86 mm3/mm stent length, 
pcO.001). In the analysis of cross-sections at 1.0 mm axial intervals, the percentage of 
cross-sections where stent area was ~80% of the average reference lumen area 
increased from 51% to 76% (p<O.OOl); similarly, the percentage of cross-sections with 
stent area >=90% of reference increased from 27% to 52% (p<O.OOl) with post dilatation. 
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Conclusion: Post-deployment balloon dilatation improved both minimum stent area and 
volumetric expansion throughout the stented segment. 
IO:00 a.m. 
811-4 intravascular Ultrasound Versus Angiography-Guided Stent 
Implantation: Acute and Long-Term Outcome in 2,883 
Patients 
Alexandre Abizaid, George Dangas, Andrea S. Abizaid, Roxana Mehran, Manuela 
Negolta, Gristian Cioara, Rajshkar Narasimaiah, Augusta D. Pichard, Alexandra J. 
Lansky, Gregg W. Stone, Gary S. Mintz, Martin B. Leon. CardiovascularResearch 
Foundation, New York, NM. Washington Heart Center, Washington, DC 
Background: Although intravascular ultrasound (IVUS) allows in viva tomographic ves- 
sel wall imaging and accurate vessel size measurements, there is still controversy 
whether this method IS superior to angiography to guide stent implaniation. 
Methods: We followed 2883 consecutive pts (3830 lesions) undergoing elective native 
stenl implantation guided by IVUS (n=1839, 2335 lwons) or angiography alone 
(n=l044, 1373 lesions). Pts were contacted at six months, and all events source docu- 
mented and adjudicated. 
Results: Baseline patient characteristics were similar between groups. Angiographic, 
IVUS and clinical follow-up is shown in Ihe table. 
IVIJS-guided Angio-guided P 
QCA: Reference diameter, mm 3.01+0.61 2.95zkO.60 0.07 
Final MLD, mm 2.87kO.66 2.54+0.76 0.0001 
Final diameter stenosis (%) 8il5 13*21 0.0001 
IVUS: Reference lumen GSA, mm2 8.5553 88 8.16+3.24 0.006 
Final lumen CSA, mm’ 8.25+2.05 7.44k2.75 0.0001 
Final area stenosis, % 5i7 15~8 0.0001 
6-month FU: TVR, % 12.3 15.1 0.04 
Death/Ml. % 3.5 4.1 0.20 
MACE, % 15.1 18.4 0.02 
TVA= Target vessel revascularization, MACE= death, Ml, or TVR, MLD= rmnimum 
lumen diameter, GSA= cross sectional area. 
By multivariaie analysis independent predictors of B-month MACE included diabetes 
(OR:l.65; p=O.O07) and IVUS final lumen CSA (OR:0.78; p<O.OOOl). 
Conclusion: Stent implantation guided by IVUS achieves superior angiographic results 
(larger final lumen dimensions) compared to guidance with angiography alone. This is 
translated to improved long-term outcome with IVUS-guided strategy. 
IO:15 a.m. 
811-5 Assessment of Coronary Stent Expansion: Angiographic 
Diameter Versus Intravascular Ultrasound Cross-Sectional 
Area: Observations from AVID 
Robert J. Russo, Michael J. Attubato, Charles J. Davidson, Anthony C DeFranco, Peter 
J. Fiizgerald, James B. Hermiller, Robert A. laffaldano, Frederick S. Lmg, Jennifer E. 
Lucisano, Patricia D. Silva, George J. Smith, S. Chiu Wong. Scripps Clinic, La Jolla, CA 
Background: AVID (Angiography Vs. Intravascular ultrasound [IVUS]-Directed stent 
placement) is a multicenter trial to determine the value of IVUS-dlrecteci stem placement. 
Methods: To evaluate the relationship between angiography and IVUS measurements 
afier elective coronary stent placement, data were compared for 800 patients enrolled in 
AVID. Images were obtained after a final angiographic result (<IO% sienosis and 
absence of dissection). Results: Mean distal reference vessel diameter for all vessels 
was 2.91+0.60 mm by IVUS and 2.9210.58 mm by angiography (~~0.71). Stent diameter 
expansion by angiography was 94.7tl2.8% and was independent of vessel size (Figure 
1). Steni cross-sectIonal area (CSA) expansion by IVUS (compared to the distal refer- 
ence vessel lumen area) was 91.7&0.5% and demonstrated a curvilinear relationship to 
increasing vessel dram&r (Figure 2). By IVUS a 0% CSA stenosis was noted I” vessels 
with a distal reference diameter of 2.6 mm by anglography, 11% CSA stenosis in vessels 
3.0 mm, 18% CSA stenosis in vessels 3.5 mm and 28% CSA stenosis in vessels 4.0 mm. 
Conclusion: After elective coronary stent placement and an optimal angiographic result, 
IVUS demonstrated a residual CSA stenosis for vessels >2.6 mm, which increases sig- 
nlflcantly wth increasing vessel we. 
Angio diameter expansion IVUS area expansion 
0’ 01 
1 2 3 4 5 6 1 2 3 4 5 5 
IVUS distal reference vessel lumen diameter (mm) 
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818-1 
II:00 a.m. 
Prognostic Value of C-Reactive Protein in Patients 
Undergoing Elective PCI 
Gerlind S. Heyde, Robbert J. de Winter, Johan Fischer, Karel T. Koch, Yvonne 
Schouten, Francis M. Wulfert, Jan J. Piek. Academic Medical Center; Amsterdam, Time 
Netherlands 
Background: An abnormal CRP, a sensitive marker of inflammation, has recently 
emerged as a strong independent prognoslic indicator in patients with unstable coronary 
artery disease. Preliminary data suggest that an elevated CRP at the time of percutane- 
ous coronary intervention (PCI) is associated with a poor short and long term outcome in 
patients with unstable angina. Purpose: To evaluate the prognostic value of CRP in 
patients undergoing elective PCI. Methods: Baseline CRP was determined in blood 
samples obtained at the start of elective PCI from 519 consecutive patients (mean age 
61.2 f 11.3 years, males 74,4%). Patients with Braunwald class 3 unstable angina or 
acute MI, were not included. One year follow-up data were obtained by written question- 
aire and telephone. Cardiac events were defined as death, myocardial infarction, CABG 
and repeat PCI. A CRP value above 5 mg/l was considered abnormal (URL Clinical 
Chemistry Lab AMC). Results: One year follow-up was completed in 96% of the study 
population. Patients with an abnormal CRP had a significantly higher incidence of car- 
dlac events as compared to patients with a normal CRP 
Conclusion: This study shows that CRP is a predictor of cardiac events in the patient 
population undergoing elective PTCA as previously shown in patients with unstable 
angina. 
818-Z 
1 I:15 a.m. 
Abciximab Decreases Cytokine Production by Circulating 
Monocytes in Patients With Unstable Angina and Elevated 
Inflammatory Markers 
Antonino Buffon, Giovanna LIUZZO, Dominick J. Angiolillo, Matteo SantamarIa, Simona 
Pelliccioni, Francesca Ginnetti, Antonio G. Rebuzzi. Filippo Crea, Luigi M. Biasucci, 
Attilio Maseri. CathoYc University: Rome, /t&y 
Background: An enhanced production of pro-inflammatory cytokmes by circulating leu- 
kocytes has been shown in patients with unstable angina (UA). Moreover, plasma levels 
of pro-inflammatory cytokines and C-reactive protein (CRP) have been associated with 
short- and long-term occurrence of coronary events. The platelet glycoprotein llbillla 
inhibitor abciximab has been shown to affect leukocyte activation and leukocyte-platelet 
interaction. In this study, we investigated the effect of abcixlmab on monocyte productIon 
of interleukin (IL)-6 following low-grade in vitro stimulation. Methods: We studied 22 
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patients with UA having elevated CRP levels (>3 mg/L, the 90” percentile of normal dis- 
tribution) at the time of hospital admission. Monocyte production of IL-6 was assessed 
after whole blood in vitro stimuiation with 1 ng/mL of lipopolysaccharide (LPS) both in the 
presence or absence of 10 mgimL of abciximab. Resulte: IL-6 production (median, 
range) after 4 hours of stimulation wrth LPS was markedly reduced from baseline 3,391 
pg/mL (range 941- 9,625) to 1,577 pg/mL (range 322-6,745; P<O.Ol) (54% reduction) 
after samples were treated with abciximab. Similar rates of reduction in IL-6 production 
were observed after 24 hours (-48%, from 12,644 pg/mL to 6,591 pg/mL) and 48 hours (- 
36% from 12,291 pg/mL to 7,600 pg/mL) of incubation (all PcO.05). The reduction of IL-6 
production after abciximab compared to baseline was linearly related to plasma levels of 
CRP (r=0.42, P=O.O5). Conclusion: Abciximab markedly reduces monocyte production 
of IL-6 after LPS-challenge in unstable angina patients with elevated CRP levels at the 
time of hospital admission. Modulation of pro-inflammatory cytokine production may con- 
tribute to the favorable effects of abciximab in percutaneous coronary interventions in 
patients with acute coronary syndromes. 
818-3 
11:30 a.m. 
ADP-Antagonists Therapy Added to Aspirin Prior to 
Coronary Intervention Markedly Attenuates the Risk 
Associated With Baseline CRP Status 
Mark A. Robbins, Derek P. Chew, Deepak L. Bhatt, Debabrata Mukerjee, Marco Roffi, 
Jakob P. Schneider, Eric J. Top@ Stephen G. Ellis. Cleveland Clinic Foundation, 
Cleveland, OH 
Background: The negative prognostic significance of elevated CRP in patients undergo- 
ing percutaneous coronary intervention has recently been appreciated. Therapies attenu- 
ating this risk have yet to be defined. 
Methods: Within an ongoing registry of patients presenting for both elective and urgent 
PCI, we studied the impact of pre-treatment with ADP antagonists on 30-day death or Ml 
(CKMB >2x) stratified by CRP (< O.BmgidL, 0.3-2.0mg/dL and >2.0mg/dL). Most patients 
received clopidogrel for 1-3 days prior to PCI. Only patients receiving stents were 
included in this analysis. 
Results: In a total of 473 patients, 19% of patients did not receive pretreatment with ADP 
antagonists. No important differences in baseline characteristics were evident. (No pre- 
treatment vs pretreatment: mean age 66 vs 67, females 28% vs 35%, diabetes 36% vs 
31%, mean EF 52% vs 51%, rest pain/post-infarct angina 8% vs 6%). In patients not 
receiving ADP-antagonist pretreatment, a striking increase in events is observed with 
increasing CRP However, in patients receiving pretreatment with ADP antagonists, 
events associated with increased CRP were dramatically reduced. (Table) On multivari- 
able analysis, only CRP and LVEF remained significant predictors of 30 day death or Ml. 
Conclusion: Pretreatment with ADP antagonists may prove an effective means of atten- 
u,ating the risk of PCI in patients with elevated CRP. 
CRP CRP CRP p-V&E 
No pre ADP-antagonist 
Pre ADP antagonist 
< 0.3mg/dl 0.3 - 2.0mgldl > 2.0mg/dl 
6.5% 13.5 40% 0.006 
6.3% 10.6% 14.1% 0.191 
818-4 
II:45 a.m. 
rPSGL-lg Inhibits In-Stent Restenosis in Porcine Coronary 
Arteries After Double Injury 
Jean-Francois Tanguay, Pascale Geoffroy, Jean-Franc& Theoret, Robert G. Schaub, 
Anjali Kumar, Yahye Merhi. Montreal Heart Institute, Montreal, PQ, Canada, Wyeth/ 
Genetics Institute, Andover, MA 
Background: We have shown that P-selectin antagonism using recombinant P-Selectrn 
Glycoprotein Ligand-lg (rPSGL-lg) inhibits platelet-neutrophii adhesion and reduces rest- 
enosis by compensatory vascular remodeling in a porcine model of repeat carotid angio- 
plasty. Although stents improve the clinical outcome of PTCA. thrombosis and restenosis 
remain major challenges. We investigated the effect of rPSGL-Ig on thrombotic and 
inflammatory reactions and restenosis after stenting porcine coronary arteries injured by 
prior angioplasty. Methods: Two weeks after initial injury to the LAD, LCX and RCA cor- 
onary arteries, stents were implanted at the injury-induced lesion site in 2 randomly 
selected vessels. Vehicle (6 pigs, 12 stents) or rPSGL-Ig (lmg/kg, 5 pigs, 10 stents) was 
administered as a single IV bolus 15 min before stenting. Four weeks later, adhesion of 
51 Cr-platelets, il l In-neutrophils and 1251.fibrinogen was quantified and histo-morpho- 
metric analysis was performed. Results: In reference, non-injured artery segments, vas- 
cular lumen was similar in both control (3.02 mm2) and rPSGL-Ig (2.82 mm2) groups. 
The overall cross sectional area of stented and reference sites was unchanged between 
groups. However, in-stent residual lumen was reduced significantly by 49% to 1.55 * 
0.35 mm2 in control, whereas it remained statistically unchanged in rPSGL-Ig (3.23 + 
0.51 mm2) animals, indicating significant inhibition of restenosis by rPSGL-lg. Neointimal 
area as a percentage of total cross sectional area was reduced by rPSGL-lg treatment 
(66.7 f 2.8 vs 52.4 + 4.9: PcO.05). A 49% inhibition of neutrophil adhesion (P&05), 39% 
reduction in platelet adhesion, and no effect on fibrinogen deposition were also 
observed. Conclusion: Pretreatment with rPSGL-Ig reduces both the thrombo-inflam- 
matory and neointimal proliferative responses, inhibits in-stent restenosis and offers a 
promising therapy to improve the clinical outcome after coronary stenting. 
818-5 
Noon 
Plasma Levels of Hepatocyte growth Factor Is a Useful 
Index of the Restenosis After Percutaneous Coronary 
Intervention 
Jun Tat&hi, Shinzou Waku, Motomaru Masutani, Mitsumasa Ohyanagi, Tadaaki 
Iwasaki. Hyogo CoNege of Medicine, Nishinomiya, Japan 
Background: Hepatocyte growth factor (HGF) is a member of endothelium-specific 
growth factor which mitogenic activity IS the most potent among various growth factors. 
Plasma concentration of HGF have been reported to increase by vascular endothelial 
damage due to various stress such as hypertension. Percutaneous coronary intervention 
(PCI) Injured coronary arterial endothelial cell by the balloon inflation. Rapid regeneration 
of vascular endothelial cells, not accompanied by vascular smooth muscle cells, may 
have therapeutic potential in prevention of abnormal vascular growth such as neointimal 
formation after PCI. Therefore, we hypothesized that plasma HGF concentration can 
serve as a biochemical marker that indicates the coronary renarrowing after PCI. 
Method: Forty-six consecutive patients (64*9 years old, 35 men) who underwent elec- 
tive PCI were enrolled this study. Plasma concentration of HGF was measured by ELISA 
over the time course of four days. Because plasma HGF concentration markdly increase 
by heparin administration, argatroban, thrombin Inhibitor, was administered for anticoag- 
ulation during PCI instead of heparin in this study. We have reported that argatroban did 
not affect plasma HGF concentration. Results: The plasma concentration of HGF was 
0.32iO.13 ngiml before PCI and reached the peak level (0.62+0.20 rig/ml) at 12hr after 
PCI. Thereafter, plasma HGF concentration decreased gradually and restored to the 
control value (0.38iO.14 ngiml) at 48hr after PCI. Follow-up coronary angiogram was 
performed all patients 6 month after PCI. Restenosis was recognized 17 patients (37%). 
AHGF (increment of HGF between before and 12hr after PCI) in patients with restenosis 
(0.39+0.25 nglml) was significantly (p=O.O4) higher than the value in patients without res- 
tenosis (0.23*0.13 ngiml). Odds ratio of AHGF>0.3 ngiml was 3.93 and 95% Cl was 
between 14.2-1.09. Conclusion: These results indicated that plasma concentration of 
HGF transiently increase at 12hr after PCI with argatroban administration. This increment 
of plasma HFG (>0.3 ngiml) may predict the coronary renarrowing after successful PCI. 
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819-I 
ii:00 am. 
Long Lesions Treated Using Sr/ySO Source Trains, a Sub- 
Analysis of RENO: A European Surveillance Registry With 
the NovosteTM Beta-CathTM System 
Antonio Colombo, Goran Stankovic, Patrick Serruys, Thomas Schiele, Eric Eeckhout, 
Sigmund Silber, Raoul Bonan, Philip Urban. EM0 Centro Cuore Columbus, Mi/an, /t&x 
Heart center Rotterdam, Rotterdam, The Netherlands 
The RENO Registry with the NovosteTM Beta-CathTM System has been established to 
keep track of all patients undergoing Beta-C&h brachytherapy not suitable for inclusion 
in any Beta-Cath trial. 477 patients have been included so far in this Registry. In 76 of 
these patients brachytherapy was delivered with the pullback technique due to the length 
of the lesion to be treated. This report presents the acute and follow-up data of these 76 
patients in whom 67 lesions were treated with this technique (1.14 lesion/patient). Mean 
age was 61.78+9.68 years and 63 were male (82.9%). Sixteen patrents (21.3%) had dia- 
betes and 19 (27.9%) had unstable angina One vessel was treated in 66 patients, two 
vessels in 9 patients, and three vessels in 1 patient. 83 lesions were located in native 
coronary arteries and 4 in by-pass grafts. 30 lesions were de nova, 2 were restenotrc, 
and 55 were in-stent restenosis. Reference vessel size was 3.21i0.52 mm and mean 
lesion length was 31.6&l&82 mm. Radiation treatment was performed utilizing a 30 mm 
(25.6% of lesions) or 40 mm (74.6% of lesions) long source train, with a mean dwell time 
of 7.36+2.7 min delivering 17.5k2.4 Gy at 2 mm from the center of the source. Proce- 
dures were successful in 80 lesions (94.1%). Stents were implanted in 52 lesions 
(59.8%). Obvious geographic miss occurred in 8 lesions (9.4%). In-hospital outcome: 
Two patients (2.6%) had myocardial infarction, and two patients (2.6%) had repeat 
PTCA. There were no deaths or CABG. At 6.month follow-up the incidence of MACES 
(including in-hospital events) was 35.1%. 11 patients (29.7%) underwent repeat revascu- 
larization (10 had rePTCA and 1 had CABG). Two patients died (5.4%). Conclusions: 
these preliminary results seem to support the fact that the pullback technique can be 
safely performed with this beta delivery system. The follow-up events appear acceptable 
considering the length of the lesions treated and the high incidence of in-stent restenosis 
in the baseline population. 
819-2 
11:15 a.m. 
The BETTER Trial: 6 Months Restenosis After 
Brachytherapy With a P32 Balloon Source 
Carlo Di Mario, Stefan Verheye, William Wijns, Alexandra Lansky, Remo Albiero, Giorgio 
Gimelli, Eric Eeckhout, Bernard de Bruyne, Guy Heyndrickx Maurice Buchbinder, 
Antonio Colombo. San Raffaele Hospital, M&n, Italy 
Methods: A novel system for intravascular radiation therapy has been developed that 
contains beta emitting P-32 isotope within the balloon membrane of an angioplasty like 
catheter (RDX’. Radiance Medical Systems, Irvine CA). This type of source is capable of 
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delivering very uniform dose patterns lo the vessel wall when compared wrth wire based 
systems. This Study reports cknicai and angiographrc results 6 months after the first 
human application of the RDX system. Results: In 93/99 (93%) patients (mean age 61 
yrs, 87% males) the radioactive balloon could be inserted and maintamed at the site of 
treatment for a mean dwell time of 528 s using cyclic balloon inflatron (75% inflation time) 
to reduce myocardial ischemia. The average dose delivered at 1 mm from balloon mem- 
brane was 19.4 Gy. Reference vessel diameter was 2.83+0.49 mm and mean lesion 
length was 12.315 3 mm De-nova lesions were treated in 70% of cases and restenotrc 
lesions in 30% (27129 restenoses in-stent). All patients received aspirin and clopidogrel 
or ticlopidine for 3 months post procedure, but therapy was continued for 12 months I” 
cases where a new stent was implanted. Clinical and angiographic follow up has been 
completed in 30 patients to date. One patient showed silent total occlusion in the target 
vessel but no signs of earlj, or late stent thromboses were observed in the remaining 
patrents. Angiographic restenosls (>50% diameter stenosis) was present in 12 lesions. 
All restenoses were located at or “ear the edge of the radrated segment. Quantitative 
angiographic analysis of the stented segment, injured segment and radiated segment 
demonstrated that geographic miss was rare (13%) and was absent I” the observed 
cases of restenoses. Conclusions: this novel brachytherapy system appears to signifi- 
cantly restrict intimal hyperplasia at the lesion site. However, restenosrs at the edge of 
the radiated segment remarns the major cause of recurrence. Complete 6 months angio- 
graphic follow-up will be available at the time of presentation 
cal projections surrounded by contrast. Results: Out of 350 edges analysed, 46 were 
excluded due to lack of angiographic follow up and 74 because GM was not interpret- 
able, leaving 230 edges. Out of the latter 84 (36.5%) were balloon edges (BE) and 146 
(63.5%) were stent edges (SE). The incidence of GM at the BE was 33.4% and at the SE 
43.8% The presence of GM at the SE rncreased the incidence of restenosis significantly 
(3.7% vs l&7%, p=O.O03, RR=6.1, Cl 1.6-22.5) compared to individuals with restenosis 
and no GM. The presence of GM at the BE did not signrficantly increase the incrdence of 
n&stenosis (5.4% vs 10.7% p=O.35, RR&l, Cl 0.4-l 1.3). Conclusion: During intracoro- 
nary beta radiatro”, GM caused by stenting is associated with a greater impact on the 
incidence of edge restenosis compared to GM due to ballon angioptasty alone. 
819-5 
NOOIl 
Discordant lntracoronary Brachytherapy Results in Adult 
Mini-Pig Versus Juvenile Farm Pig Restenosis Models: How 
Useful Are These Models for Predicting Safety and Efficacy 
in Man? 
J&g Hausleiter, Alex Li, Kaname Takizawa, Arik Finkeistein, Raj Makkar, Neal Eigler, 
James Whrting. Cedars-Sinai Medical Center, Los Angeles, CA, German Heart Center 
Munich, Munich, Germany 
819-3 
Ii:30 a.m. 
Impact of Gamma and Beta Radiation vs. Placebo on the 
Changing Pattern of In-stent Restenosis: A Matched 
Angiographic Analysis 
Alexandra J. Lansky, Roxana Mehran, Kartik Desai. Costantrno Costantini O., Brian 
Proctor, Terara Conway, Martin Fahy, George Dangas, Gregg W. Stone, Ron Waksman. 
Jeffrey W. Moses, Mark” B. LEO”. Cardiovascular Research Foundation, New York, NY 
Background: The pattern of in-stent restenosis (ISR) is a” important predrctor of long- 
term outcome after treatment of ISR. impact of vascular brachytherapy (VBT) on the pat- 
tern of ISR is not established. 
Methods: We explored the patterns of restenosis I” 772 patients with ISR undergoing 
VBT or placebo (Gamma VBT, n=227, Beta VET, “=177, Placebo, “=226) for treatment 
of native coronary ISA. Angiographic analyses were performed prospectively using con- 
sistent standardized methodology at a central core laboratory at baseline and follow-up 
(9 months). Lesions were matched for ACCiAHA complexrty, lesron length, and vessel 
size. 
Results: See Figure. 
Despite similar lesion 
lengths at baseline. 
Beta and Gamma VBT 
Lesion Lengths 
Promising early clinical results of intracoronary brachytherapy (ICBT) are concordant 
with experimental results in the juvenile farm-pig restenosis model, usrng a variety of 
ICBT devices. However, recent results of long-term studies in the adult mini-pig model 
showed inconsistent results. In this study we investigated the long-term safety and effi- 
cacy of ICBT in a six-month mini-pig stent model. 
Methods. In a blinded and randomized study, intracoronary stent placement was fol- 
lowed by brachytherapy using a (beta-emitting 32P balloon system (20Gy at lmm tissue 
depth, n=lO) or sham treatment (n=8) in 18 Yucatan mini-pigs. Antiplatelet therapy with 
aspirin plus clopidogrel was give” throughout the study. Follow-up angiography and his- 
tology were performed after 6 months. 
Results. Brachytherapy with the 32P system was performed without complications. Dur- 
ing follow-up, one pig died at 98 days after brachytherapy. While the stents in the control 
arteries were diffusely stenosed, the radiated arteries presented with an inconsistent pat- 
tern: some arteries were totally occluded (“=4), some showed with short high-grade 
stenosis (“~3) and others were drffusely Stenosed over the entire stent segment (n=2). 
Neointima area was larger in the radiated arteries, resulting in a significantly smaller 
lumen area after ICBT (I.72 +1.50 vs. 3.41 ?1,66mm2; P=O.O3). The neointima after 
ICBT was characterized by extensive fibrin deposition and more extracellular matrix 
Conclusions. Consistent with previously reported experimental tong-term results of 
other ICBT devices, e.g. the 32P wire or 188Re balloon, ICBT seems not to be effica- 
cious in the Yucatan mini-pig model unlrke the 28.day juvenile farm prg model and unlike 
the promising clrnical results. Total coronary occlusions were not prevented by conbnous 
intensive antiplatelet therapy with aspirin plus clopidogrel I” this model. This raises ques- 
tions about the validity of animal models for predicting safety and efficacy in ma”. result in signrfrcantly 
more focal lesion 
lengths at follow-up 
compared to placebo 
treated patients. 
Reductions in treated 
segment restenosis 
are simrlar with 
Gamma and Beta 
radiation (gamma= 
33.5%, B&=35.0%, 
placebo=50.8%, 
p<O.O001,(30% reduc- 
tion)). 
Conclusions: VBT with Beta and Gamma radiation result I” similar reductions in angio- 
graphic restenosis at 9 months follow-up. Even among treatment failure, both Beta and 
Gamma VBT appear to favorably change the pattern of ISR from diffuse to more focal 
and potentially more treatable lesions. Whether this finding will have a meanrngful impact 
on clinical outcome will require longer-term follow-up. 
819-4 
1 I:45 a.m. 
Geographical Miss: Impact on the Restenosis Rate in 
Relation to the Type of Injury. Insights From the Beta 
Radiation In Europe (BRIE) Study 
Georgios Sianos, Marco Costa, Ken Kozuma, Patrick I. Kay. Stephane G. Carlier, Marie- 
Angeie Morel, Patrick W. Serruys. University Hospital Dijkzgf lnferventionai Cardiology, 
Thoraxcenter, Rotterdam, The Netherlands, Cardialysis BV, Rotterdam, The Netherlands 
Background: lntracoronary beta radiation is limited by the development of stenotic 
lesions at the edges of the effective irradiated segment (EIRS). Geographical miss (GM) 
is the situation in which the radiation source did not fully cover the injured segment. Aims 
of thus study were to evaluate the impact of GM on the restenosis rate in relation to the 
type of injury, balloon or stent, I” patients treated with intracoronary beta radiation after 
percutaneous intervention using the the Novoste Beta-Cath 90Sr / 9OY system, 30mm in 
length (effective radration length 26 mm). Methods: We analysed 175 lesions in 149 
patients enrolled I” the phase I of the BRIE trial. Prescribed dose was 14-18 Gy, at 2mm 
from the centerline of the source axis, based on the reference diameter by quantitatrve 
coronary angiography, measured less than 3.35 mm or more than 3.35 mm, respectively. 
Usrng quantitatwe coronary anglography the EIRS and both edges were studied prior to, 
after intervention and at six months follow-up. The edges that were injured during the 
procedure constituted the GM edges. Restenosrs was defined as diameter stenosis more 
than 50% at six months follow-up. GM was determined by the simultaneous electrocar- 
drographic-matched side-by-side projection of the source and balloons in place, r” rdenti- 
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1122-12 Percutaneous Treatment of Renal Artery Stenosis: The Risk 
of Atheroembolism and the Role of Protection Techniques 
Michel Henry, Christos KLONARIS, lsabelle HENRY, Kyril TZVETANOV, Edmond LE 
BORGNE, Bernard FOLIGUET, Michele HUGEL. fo/yc/vJique d’Essey-/es-Nancy 
ESSEY-LE.5NANCY: France 
Purpose: Percutaneous treatment of atherosclerotrc renal artery stenosis is currently a 
well accepted option of revascularization. However, long-term results demonstrate a 
declrne in renal function in a subset of patients. Atheroembolism during the procedure 
seems to be a” important factor for this outcome. Consequently, protected angioplasty 
techniques could be a reasonable concept. Methods: Protected renal angioplasty and 
stenting was used to treat 32 atherosclerotic stenoses (ostial 29, bilateral 4) I” 28 
patients (males: 18, mea” age 71.3i8.6 y). All were hypertensive, 10 had moderate and 
2 had severe renal dysfunction. The technique consists of crossing the lesson with a Per- 
cuSurge GuardwireTM temporary occlusion balloon-on-a-wire catheter and inflation of 
the protection balloon distal to it. Predilatation and stenting are therefore performed 
under protection, followed by aspiratron of the generated debris with a monorail aspira- 
tion catheter. Deflatron of the protection balloon and anglographic control completes the 
procedure. Results: Immediate technical success was achieved in all cases. Renal 
artery mea” occlusion time was 415i166 set, range 149.797sec. Visible debris was 
extracted from all patients. Number of parttcles varied from 13 to 208 per procedure and 
diameter from 36 to 62061.1, mean diameter 20.5~1OOu.. Creatinrne levels dropped from 
13.4r3.5mg preprocedurally to 12.2236 and 12.4k3.1 at 24 hours and 6 months respec- 
tively.At 6 month follow-up period we observed no renal function deterioratron in any 
patient. Frve patients with baseline renal insufficiency had improvement after the proce- 
dure. Conclusions: Our preliminary results suggest that protected renal artery angio- 
plasty and stenting with the PercuSurge device seems to be a feasible and safe method 
in a” attempt to decrease the risk of renal atheroembolism during the procedure and to 
protect against renal function deterioration. Proper indications and the effectiveness of 
this technique have to be established by larger and randomized studies. 
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1122-13 Angioplasty/Stenting For Post-Transplant Renal Artery 
Stenosis 
Valter C. Lima, Rib&o Garcia, Jose 0. M. Pestana, Jorge E. Amorim. UNIFESP-EPM, 
.%a Paula, Brazil 
Background: Post transplant renal artery stenosis (PTRAS) is an uncommum but seri- 
ous complication as it can cause graft failure not related to rejection and/or refractory 
hypertension. We describe the percutaneaous treatment of this complication. 
Methods: From August/98 to July/2000 we diagnosed 31 patients (pts) (24 males / 7 
females, aged 35?14 years) with PTRAS among 808 transplants pts (3.8%). All pts were 
treated with angioplastylstenting. The indications for the procedure were graft failure (28) 
and refractoiy hypertension (24). 
Results: All procedures were performed through femoral artery (29 homolateral). The 
stenosis location were ostial: 25 and non ostial: 6. The intervention technique was the 
same used for coronary intervention. Stent was implanted in 28 and balloon only was 
used in 3 pts. The pts were given heparin 100 units/Kg IV in bolous and aspirin 200 mg 
PO before and daily after the procedure. There was angiographic success in all pts with 
only one complication (femoral psedoaneurism). The graft function improved [w&nine 
(mg%) - pr& 3.7+1,5; 1 day FU: 2.8+0X; 1 month FU: 23-0.41. Only 4 pts did not reduce 
the number of antihypertensive drugs. Overall, number of antihypertensive drugs 
reduced from 2.26 to 1.58. There has been no clinical restenosis at mean FU of 97fll2 
(7-417) days (median 55). 
Conclusion: Angioplastyistenting for PTRAS is safe and vary effective. Given the rela- 
tively simplicity of the procedure as compared to the surgical option, it must be consid- 
ered the treatemnt of choice. 
1122-14 All Stenoses Are Not Equal: Angiographic Renal Artery 
Stenosis Severity Does Not Predict Trans-Lesional 
Pressure Gradient 
Robert J. Lederman, Stanley J. Chetcuti, Paul M. Grossman, Julian J. Es&ban, Ann 
Luciano, Steven W. Werns, Mauro Moscucci, Eric R. Bates. University of Michigan 
Health System, Ann Arbor, MI 
Background: Stenting effectively relieves renal artery stenosis (RAS) in patients with 
uncontrolled hypertension, however improvement in blood pressure control is variable 
and unpredictable. “Significant” angiographic RAS has been arbitrarily defined as a 
diameter stenosis (DS) ranging between 50-80%. Tans-l&anal pressure gradient IS 
thought to be the etiology of renovascular hypertension, but is not routinely measured 
and has not been compared with DS. Invasive measurement is useful, although cathe- 
ter-measurements may be hazardous or inaccurate. We report quantitative angiography 
(QA) and trans.lesional gradients using a pressure-sensing guidewire. 
Methods: Sixteen patients with uncontrolled hypertension were selected for invasive 
hemodynamic assessment because of angiographically-intermediate atherosclerotic 
RAS. Gradients were measured between a solid-state pressure transducer mounted on 
a 0.014” guidewire (Wavewire, Endosonics) distally and the guiding catheter proximally, 
at baseline and with hyperemia induced by intraarterial acetylcholine 100-1000 kg. 
Lesion severity was determined by quantitative angiography. 
Findings: Angiographic lesion severity did not correlate with pressure gradient either at 
baseline (?=.15) or with hyperemia (&IO). Of lesions having DS>50%, only 701 
(64%) were associated with a peak gradient>20 mm Hg at rest, and only 8/12 (67%) with 
hyperemia. Conversely, 217 (29%) of lesions with D&50% had a significant gradient, 
Conclusion: Angiography does not accurately identify hemodynamically-significant 
RAS. Gradient measurement may be warranted before all clinical renal artery revascular- 
ization procedures. Further study is warranted to determine if trans.lesional gradients 
predict clinical benefit after renal artery stenting. 
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1122-15 Early Improvement in Single Kidney GFR with 
Percutaneous Revascularization Compared to Medical 
Therapy in Renal Artery Stenosis 
Daniel T. Lee, Roberto A. Corpus, Jr., Terry R. Bowers, Simon R. Dixon, William W. 
ONeill, Robert D. Safian. William Beaumont Hospital, Royal Oak, MI 
Background: Previous studies evaluating the efficacy of percutaneous revascularization 
in ischemic nephropathy have yielded conflicting results, which may relate to the use of 
serum creatinine alone as a measure of renal function. Single kidney GFR can be more 
precisely determined by acquiring total GFR using lothalamate and split kidney function 
with Tc-DTPA to estimate fractional flow to each kidney. We report the effect of percuta- 
neous revascularization compared to medical therapy on single kidney GFR in patients 
with ischemic nephropathy. 
Methods: Baseline single kidney GFR was obtained in patients with known renal artery 
stenosis (RAS). Patients with fractional renal blood flow of < 40% to the culprit artery 
underwent percutaneous revascularization, while patients with symmetrical renal blood 
flow were treated medically. Follow up single kidney GFR was performed in both groups. 
Results: Nine patients underwent PTA (stent=lOO%); 10 patients were managed medi- 
cally. There was no statistical difference in baseline GFR between two groups (PTA=20 
ml/min/1.73m2 vs medical 32 mlimin/l.73m2, p=O.O93). Follow-up single kidney GFR 
(mean time for PTA = 3 months:10.3 months for medical therapy) demonstrated an early 
improvement in GFR in the PTA group, while medically treated patients had a progres- 
sive decline in renal function (A GFR -5ml/min/l.73m2 vs. 9 ml/min/l.73m2. p=O.OOi). 
Conclusions: Compared to medical therapy, PTA for renal artery stenosis is associated 
with improvement in single kidney GFR. 
1122-16 The Clinical Role of Intervention on lschemic Nephropathy 
Robin L. Yue, Stephen R. Ram@, Tyrone J. Collins, Stephen J. Jenkins, Allen Chu, 
Christopher J. White. Ochsner Medical Institutions, New Orleans, LA 
Background: Progressive renal artery stenosis (RAS) can cause ischemic nephropathy. 
The clinical benefit of renal artery stent placement (KS) for ischemic nephropathy is con- 
troversial. Method: Renal function was evaluated by all available serial serum creat- 
inines (SCr) before and after RS. Patient selection: 1) Baseline SCr > 2mgidL (the mean 
3.6 +/- 1.5), 2) no angiographic contrast exposure 6 mos before and after RS, 3) >70% 
RAS, 4) dialysis patients excluded We selected 35 patients from 602 patients, who 
underwent successful RS. There are 5 bilateral RAS and 30 unilateral RAS, and the 
mean follow-up (f/u) period was 10 mos Renal function improved or stabilzed (l/S) if f/u 
SCr was no more than +0.1 mm/d1 of baseline and worsened (W) if it rose >i= 0.2 mg/dl. 
The effect of RS on the progression of renal insufficiency was analyzed by comparing 
reciprocal slopes of SCr versus time plots before and after RS. Result: 47 stents were 
placed in 35 patients with 100% sw.xess rate. l/S and W groups were 64% (28144) and 
36% (16144) respectively. The rate of progression of renal insufficiency significantly 
slowed after RS. The mean of the slopes of reciprocal SCr values was 7.1 L/mg.day 
before RS and 0.8 L/mg.day after RS (pcO.001. Conclusion: RS dramatically improves 
renal function in patients with renal insufficiency by improving SCr and decreasing the 
rate of worsening. 
1122-17 Females Demonstrate Improved Renal Function From Renal 
Artery Stenting in Renal Insufficiency 
David J. Kennedy, Mark W. Burket, William J. Thomas, Sadik Khuder, Christopher J. 
Cooper. The Medical College of Ohio, Toledo, OH 
Background: Renal artery stenosis (RAS) is an important cause of renal insufficiency 
(RI) and secondary hypertension. The influence of gender on blood pressure (BP) control 
or renal function, before and late after treatment of RAS, is not known. Methods: To 
date, 232 patients (135 women, 58%), with RAS in 320 vessels have undergone renal 
artery stenting. All patients are followed prospectively at 6 months and annually with BP, 
serum creatinine (Cr), antihypertensive medication usage and cardiovascular events 
assessed. Repeat renal angiography, as clinically indicated, was performed in 56 (25%). 
RI is defined as Cr >1.6 mg/dL. Results: At presentation women have lower incidence of 
RI [28/135 (21%) vs 33197 (34%), p<O.O5], whereas men have lower systolic BP than 
women (1651-29 vs 173+27 mmHg, P<O.O5). In late follow-up (19&O months), BP 
improved with renal stentlng in both males and females, with both genders achieving 
similar control of systolic BP (144r26 vs 1491t28 mmHg, p=O.14). However, the preva- 
lence of RI increased in males at late follow-up while in females it remained unchanged 
[39/84 (46%) vs 28/127 (22%), pcO.O05]. In patients with baseline RI, stepwise multiple 
regression analysis Identified female gender was the most significant factor associated 
with improved creatinine clearance (r2 ~0.16, p = 0.0022). Late renal insufficiency in 
males did not appear to be due to restenosis since, in the angiographically evaluated 
cohort, the incidence of angiographic restenosis was lower in males than females [5/19 
(26%) vs 17/37 (46%), p=.O280]. Conclusion: Whereas renal stenting equalizes late 
blood pressure control between genders, the incidence of late RI increases in men, 
despite a lower incidence of clinically-evident restenosis. Female gender appears to 
have protective effects on renal function, possibly due to the effects of estrogen on the 
endothelium. 
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1122-I 8 Treatment of Relevant Superficial Femoral Artery Stenosis 1123-21 Cost-Effectiveness of Abciximab and Stenting in Acute 
Caused by Transcutaneous Suture Devices Myocardial Infarction: Results From the CADILLAC Trial 
Martin Baumann-Desaga, Gesine Doerr, Katja Riedel, S&fan Dreysse, Juergen Hug, 
Christian Butter, Eckart Fleck. Dept.lnt.Med, Cardiology: Virchow-Klinikum, Char& 
Humboldt University and German Heart Institute: Berlin, Germany 
Background: In 5735 patients who underwent coronary angio-graphy for closure of the 
arterial puncture site transcutaneous suture devices were used. For femoral artery 
access a 7 F sheat was inserted. After finishing the procedure in the catheter laboratory 
the puncture site was closed with Techstar in 2906 (51%) patients and with The Closure 
in 2829 (49%) patients. Bed-rest was 4-6 hours with a pressure dressing. A postpro- 
cedural limb ischemia was diagnosed in 17 patients (n=8 Fon-taine Ilb, n=9 Fontaine Ill). 
None of these patients had preex-isting symptomatic peripheral artery disease. Meth- 
ods: Peripheral angiography was performed in all cases using contra-lateral femoral 
artery access and revealed a unique finding: in all cases the target lesion was 0.5 to 0.7 
cm in the superficial femoral artery after the bifurcation (1 occlusion, 16 subtotal stenosis. 
In 15 patients (0,26%) a PTA in cross-over technique and in two patients a surgical treat- 
ment was per-lormed. After PTA the A primary technical success of PTA was achieved in 
100%. Major complications after PTA (acute reoc-elusion, surgical repair, amputation, 
death) were not observed. In 8 patients stent implantation was necessary (RX Ultra, 
AVE, Multi-Link, Paimaz). The indication for stent implantation was wall Instability or dis- 
section Intrainterve”tionally 10.000 IU Heparin i.v. were administered, puncture site was 
closed with a transcutaneous suture device Clopidogrel (75mg/d, 4 weeks) and concom- 
itant 100mg Aspirin/d were prescribed. Results: All patients ware markedly improved 
postintervention-ally (mean arterial brachial index 0,93~0,11). After 3 months follow-up 
all stents were patent and no restenosis was detected (ultrasound examination). Conclu- 
sion: Superficlai artery stenosis is a rare event (0,26%) of transcutaneous suture 
devices. If it occurs, PTA including stentmg is feasible and safe achieving a satisfactory 
patency rate. 
David J. Cohen, Cindy Grines, David Cox, Thomas Stuckey, John Carroll, JohnGriffin, 
Roberta S. Cosgrove, Louise Githiora, Ronna H. Berezl”, James Tcheng, Gregg Stone, 
CADILLAC Investigators. Beth Israel Deaconess Medical Center, Boston, MA, 
Cardiovascular Data Analysis Center, Boston, MA 
Although primary PTCA is wdely practiced for patients with acute myocardial infarction, 
the incremental value of coronary stenting (CS) and abciximab (AB) as adjuncts to pri- 
mary PTCA remains controversial. Specifically, recent studies have suggested that 
stenting in AMI may increase mortality. Moreover, interventlonal cardiologists may be 
reluctant to use abciximab because of concerns about rare complications as well as addi- 
tional procedural cost. To address these concerns, we performed a prospective eco- 
nomic study alongside the CADILLAC trial. 
Methods: Overall, 2082 patients undergoing primary PTCA within 12 hours of sus- 
pected acute myocardial infarction were randomized to c&nary stenting (vs. balloon 
alone) and to abclximab (vs. conventional anticoagulation) using a 2x2 factorial design. 
Of these, 1703 patients were enrolled at US sites and were included in the economic 
analysis. Catheterization laboratory costs were based on measured resource utilization 
and current unit costs, while all other costs were estimated from hospital charges using 
cost-center specific cost-to-charge ratios. 
Results: Media” patient age was 59 years, 73% were male, 17% had diabetes, and 43% 
were smokers. Multivessel coronary disease was present in 48% of the population. Pre- 
liminary economic data are currently available for 1544 patients (91%) and are displayed 
below. Full cost data through 1 year follow-up and formal cost-effectiveness analysis 
based on clinical outcomes (e.g., death, repeat revascularization, MACE) will be avail- 
able for presentation by March 2001. 
Initial Hospital Charges: 
PTCAINo AB PTCAfAB ST/No AB STIAB 
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1123-20 The Effect of Glycoprotein (GP) Ilb/llla Receptor Inhibitor, 
Tirofiban, on the Microcirculation in Patients Undergoing 
High-Risk Coronary Stenting 
Phllip Wong, Joseph K. Choo, lgnacio Inglessis, C Joon Choi, Stephen N. Oesterle, 
Giorgio Gimelli, Ik-Kyung Jang. Massachwetts Genera/Hospital, Boston, MA 
Background: The mechanisms by which GP llbillla receptor inhibitors benefit patients 
undergoing high risk angioplasty are not fully understood. We evaluated the effect of GP 
Ilb/llla inhibitor, Tirofiban on the rmcrocirculation measured by Doppler coronary flow 
reserve (CFR) in patients undergoing high-risk coronary stenting. 
Methods: 20 patients with acute coronary syndrome within 72 hours or with high risk 
angiographic features were randomized into 2 groups prior to percutaneous intervention. 
Group A received bolus of Tirofiban (IO &g/Kg) before first inflation of a balloon followed 
by a maintenance infusion (0.15 mg/Kglmin). Group 6 received placebo bolus and infu- 
sion. Coronary flow leserve by Doppler wire technique was measured at baseline, post- 
angioplasty and post-stenting. Platelet aggregation was measured at baseline, 10 min- 
utes, 6 hours and 18 hours post-bolus. 
Results: There was no significant difference in the baseline characteristics between the 
groups inciudlng risk factors, clinical presentation and pre-intervention CFR. Post-stent- 
ing CFA was significantly higher in the group pretreated with Tirofiban (Table). The inhi- 
bition of platelet aggregation was 92% at 10 minutes, 96% at 6 hours and 94% at 18 
hours in the Tirofiban group. 
Conclusion: In patients undergoing high risk coronary stenting, Tirofiban significantly 
improved the microcirculation measured by Doppler coronary flow reserve technique. 
This benefit may be due to prevention of distal emboliration by Tirofiban to the microcir- 
culation. 
N 
Length of Stay 
385 391 377 391 
Mean 
Median 
Hospital Charges’ 
4.0 4.4 4.2 3.8 
3 3 3 3 
Mean $24,125 
Median $19,364 
P-value vs. Control** -- 
* Exclusive of drug and stent costs 
$23,305 $22,568 $22,971 
$19,046 $19.733 $19,223 
0.41 0.07 0.18 
** PTCA without AB was considered the control group 
1123-22 How Long Should We Use Antiplatelet Agents in Emergent 
Stenting of Acute Myocardial Infarction ? 
Shinya Yokoyama, Kyoichi Mizuno, Kentaroh Okamatsu, Kouji Seimiya, Masamichi 
Takano, Takayoshi Ohba, Masato Tomimura, Ryuta Uemura, Takeshi Ino. Department 
of Medicine, Chiba Hokusoh Hospital, Nippon Medical School, lmba, Chiba, Japan 
Background: Recently, it was reported that late stent thrombosis (15-360 days) 
occurred even thought ticlopidine was described until 4 weeks aiter elective stenting. 
Thrombi and/or incomplete neointimal coverage of stent are an important determinant of 
thrombolic occlusion. Methods: We performed coronary angioscopy to investigate mor- 
phological characteristics of infarct related lesions, immediately, one and six months after 
emergent stent implantation in 36 patients with acute myocardial infarction. All patients 
were prescribed aspirin and ticlopidine. Thrombi were divided to 3 grade according semi- 
quantitative evaluation: grade 0 (no thrombi), 1 (a little thrombi) and 2 (massive thrombi). 
Neointimal stent coverage was also divided to 5 grade: grade 0 (not covered), 1 (slightly 
covered), 2 (mildly covered), 3 (well covered), 4 (completely covered). Results: Stents 
were successfully deployed with TIMI 3 flow restored in all cases. Immediately after 
stenting, angioscopically visible thrombi were found in 35 (97%) cases and 13 cases 
were grade 2. One and six months after stenting, repeat coronary angioscopy was par- 
formed in 23 cases. One month after stenting, thrombi was observed in 19 cases and 8 
cakes were grade Z(N.S. vs Immediately after stenting). Although “eointimal stent cover- 
age grade become significantly higher compared to immediately after stent- 
ing(pcO.OOOl), no one was covered completely. Six months after stenting, thrombus 
grade become significantly lower compared to 1 month(p<O.OOOl vs one after stenting), 
but thrombc still existed in 3 cases. Neointimal stent coverage was improved(pc0.0001 vs 
one after stenting). Conclusion: Antiplatelet therapy should be continued beyond one 
month after emergent stenting in patient with acute myocardial infarction. I” cases of 
massive thrombi at immediately after stenting, antiplatelet therapy may need until 6 
months. 
1123-23 Late Stent Thrombosis in Humans is Due to Impaired 
lntimal Healing 
Andrew Farb, Renu Virmani. Armed Forces Institute of Pathology, Washington, DC 
Background: Anti-platelet therapy has greatly reduced the incidence of acute coronary 
stent thrombosis. However, late stent thrombosis (LST) has been under-recognized clini- 
cally, and pathologic descriptions are lacking. 
Methods: LST was defined as the presence of a predominately platelet thrombus within 
a stent that had been in place for -30 days. From a registry of 197 human coronary stent 
implants in 157 patients submitted for histology, cases with LST were selected. 
Results: 10 cases of LST (6 me”, 4 women) were identified. The mea” duration from 
implant to thrombosis was 71 r45 days (range 30-l 50 days). Stents deployed were mod- 
els in current use, and 1 stentfartery was placed in all case?,. LST was fatal in 9 cases 
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secondary to sudden cardiac death (n=7) or acute MI (n=Z); 1 patient presented with 
unstable angina and died post-CABG. Thrombi were occlusive or sub-occlusive in all 
cases. The pathologic mechanisms of LST were as follows: 
1. In 3 cases, stent thrombosis was associated with necrotic core prolapse between steni 
struts. The poorly-developed, non-healed neointima was thin and frequently consisted 01 
fragmented, hemorrhagic loose connective tissue with occasional struts uncovered by 
intima. 
2. In 5 arteries, thrombosis was related to arterial branch points. Impaired intimal healing 
was evident characterized by intimal fissures, layered fibrin, incomplete endotheliallza- 
tion, and surface erosion. 
3. The iniima was particularly minimal in 2 patients who were exposed to radiation (exter- 
nal beam radiation therapy for lymphoma in 1 and 32P brachytherapy in the other). The 
vast majority of stent struts had no overlying neointima. 
Notably, underlying in-stent restenosis was present in only 2110 arteries. A contributing 
factor in 2 cases was acute plaque disruption in the arterial segment within 2 mm proxi- 
mal to the stent. 
Conclusion: LST is an uncommon, albeit often fatal, complication of coronary stenting. 
Impaired intimal healing (i.e., the failure to form a compact neointima over stent struts) 
may extend the window during which stents are prone to thrombosis. Plaque prolapse 
between stent struts and neointimal disruption and fissuring appear to precipitate late 
stent thrombosis. 
1123-24 Pathologic Studies of Late Vascular Responses to 
Successful Palmatz-Schatz Stent Implantation 
Katsumi Inoue, Kenji Ando, Shinichi Shirai, Michio Nakanishi, Hiroyoshi Yokoi, Yoshihisa 
Nakagawa, Naoya Hamasaki, Takeshi Kimura, Hideyuki Nosaka, Masakiyo Nobuyoshi. 
Kokura Memorial Hospital, Kitakyushu, Japan 
The long-term efficacy of Palm&z-Schatz stenting (PS) was investigated histologically 
and immunohistochemically. The study population included 30 patients (pts) with 34 
lesions (les) treated with antemortem PS and patent on angiography at 6 months (M). 
The interval between PS and death was distributed as follows: cl year (Y), 10 les: I-ZY, 
11 les: 2-3Y, 8 les; 3-5Y, 3 les; and >5Y, 2 les. Significant proliferation of polymorphic 
smooth muscle cells(SMCs) and increase in extracellular matrix were observed on the 
intimal side of the stented segments 6M after PS. Apparent chronic inflammatory cell 
infiltration, including T lymphocytes (T cells), macrophages (Mf3) and multinucleated 
giant cells, was also observed around the stent struts, despite lack of evidence of rest- 
enosis. In arteries with angiographical late lesion progression more than IY after PS, 
prominent inflammatory cell infiltration and proliferative reaction of SMCs remained 
around the struts. In contrast, arteries with marked lesion regression featured SMCs 
which were spindled-shaped and ordered along the luminal surface, which was com- 
pletely covered by regenerated endothelial cells. In these cases,’ intercellular spaces 
contained dense coliagenous tissue and less significant inflammatory cell infiltration than 
those of progressive lesions. In neointima more than 3Y after PS, SMCs gradually 
became atrophic, and abundant proliferation of collagen fibers was evident. However, 
immunohistochemical studies clearly revealed small numbers of helper / inducer T cells 
and slight Mf3 infiltration adjacent to the stent struts. In arteries more than 5Y after PS, 
heavy infiltration of lipid-laden Mf3 was observed around the struts. These findings sug- 
gest that PS evokes a remarkable inflammatory reaction to the metallic stent as a foreign 
body, and that the degree of inflammation can be a determinant of the extent of neointi- 
mal formation. Furthermore, residual chronic inflammatory cells around the struts may 
induce new and indolent atherosclerotic changes, resulting in plaque vulnerability. 
1123-25 Onset and Extent of Platelet Inhibition by Loading Dose 
Clopidogrel in Patients Undergoing Elective Coronary 
Stenting -The PRONTO (Plavix for Reduction of New 
Thrombus Occurrence) Trial 
Paul A. Gurbel, Charles 6. Cummings, Amanda B. Alford, Andrew F Meister, Victor L. 
Serebruany. Sinai Hospital, Sa/fimore, MD 
Background: Despite the common clinical practice of administering a clopidogrel load- 
ing dose (LD) for coronary stenting, the time dependence and degree of platelet inhibition 
resulting from this therapy have not yet been well defined in this population. Methods: 
Platelet characteristics were assessed by platelet rich plasma aggregation with 5pmol 
ADP (ADP-PA), 1 pgiml collagen (COLL-PA) and 750pmol arachidonic acid (AA-PA); 
whole blood aggregation by 1 pg/mi collagen (WBA); shear-induced closure time (CT); 
contractile force (CF), and expression of 9 surface receptors by flow cytometry in 100 
patients undergoing elective stent placement. Blood samples were obtained at baseline 
and 6 times thereafter over 5 days post-stenting following different clopidogrel loading 
regimens: 300 mg 24 hours before (Group A), 12 hours before (Group B), 3-6 hours 
before (Group C), and 75 mg at the time of intervention (Group D). All patients received 
aspirin (81-325 mgidaily) for at least one week prior to the procedure. None of the 
patients received GP Ilb/llla inhibitors. Results: None of the patients developed stent 
thrombosis. When assessed immediately prior to stenting, ADP-PA, COLL-PA, CT, and 
WBA were reduced by clopidogrel loading. (~~0.05). CF was not affected by clopidogrel. 
Immediately prior to stenting expression of GP llbillla was enhanced in groups A-C 
(pc.O5), whereas PECAM-1 and CD107a expression exhibited marked reduction (pc.05). 
At 2 hours and 2 days post-stenting, platelets, in general, exhibited an increase in activity 
that was most inhibited by LD therapy. After 5 days of clopidogrel therapy profound inhib- 
itory effects on GP lb, PECAM-1, CD 107a, CD 151, and GP llbillla expression were 
observed. Conclusions: Pretreatment with 300 mg ciopidogrel 3-24 hours before stent 
implantation inhibits platelet activity prior to the onset of the procedure. Clopidogrel Inhib- 
its the expression of certain platelet receptors, and is associated with the late inhibition of 
GP Ilb/llla expression. Clopldogrel loading reduces post-stent platelet activity more than 
the administration of 75 mg at the time of the procedure regardless of the time of loading 
before stent placement in this trial. 
1123-26 Accelerated Inhibition of Platelet Activation and 
Aggregation After Administration of Clopidogrel Compared 
to Ticlopidine in Patients Undergoing Coronary Intervention 
Christoph Altmann, Michael Haude, Dirk Welge, Judith Vonnahme, Judith Vonnahme, 
Heinrich Wieneke, Lothar Volbracht, Raimund Erbel. University Hospital Essen, Essen, 
Germany 
Background: Glopidogrel (Clap) and ticlopidine (Ticl) can effectively reduce thrombotic 
complications after percutaneous coronary intervention (PCI). The impact of both drugs 
on platelet activation, aggregation and platelet-leukocyte interactions in the course of PCI 
have not been well described, yet. 
Methods: 50 patients were assigned to receive Clop (300mg loading dose, 75mgid) or 
Ticl (500mg loading dose, 250mgibid) prior to elective PCI. All patients received aspirin 
1OOmgld. Platelet activation, characterized by expression of P-selectin, GP 53, GP lb, 
the activated GP llbillla receptor (PAC.1), the extent of platelet-leukocyte adhesion 
(PLA), and extent of platelet aggregation after in vitro stimulation with ADP and TRAP 
were analyzed prior to and at defined time points after start of antiplatelet therapy. PCI 
was performed 24.72h after start of treatment. 
Results: ADP-Induced platelet aggregation was significantly reduced by both drugs with 
a significantly accelerated inhibition under treatment with Clop (fig.). Expression of P- 
selectin, GP 53, PAC.1 and extent of PLA were also Inhibited by both drugs with a signif- 
icant acceleration under treatment with Clop (not shown). No significant increase of 
platelet activation or aggregation was observed following PCI. After 7 days of treatment 
an equal extent of inhibition was measured irnder both drugs. No acute or subacute 
ischemic events were observed. 
0 
q 
/ r-l 
Oh 6h 24h 72h 7d 
Mean +/- SEM “p<O 05, “p<O 01, tip<0 001 (Clap “s TICI) 
Conclusions: Clop loading dose scheme leads to an accelerated inhibition of platelet 
activation and platelet aggregation compared to Tic1 with a nearly maximal inhibition 
observed already 6 hrs after start of treatment. The extent of inhibition following PCI is 
equal under both drugs. Due to the Improved pharmacokinetics and its fewer adverse 
effects Clop should be preferred to Tic1 in patients undergoing PCI. 
1123-27 Final Angiographic and Intravascular Ultrasound Follow-Up 
Results of Elimination of Restenosis by Stenting After 
Plaque Reduction With Platelet Inhibitor Trial (ESPRIT) 
Etsuo Tsuchikane, Tomoko Kobayashi, Nobuhisa Awata, Satoru Otsuji, Makoto Sakurai, 
Tohru Kobayashi. Osaka Medical Center for Cancer and Cardiovascular Disesaes, 
Osaka, Japan 
Stenting inhibits the remodeling after directional coronary atherectomy (DCA). Cilostazol, 
an antiplatelet agent, is reported to control neointimal proliferation after PTCA. The aim 
of ESPRIT was to evaluate the efficacy of stenting after aggressive DCA followed by 
administration of cilostazol on restenosis reduction. One hundred and seventeen lesions 
successfully dilated by aggressive DCA using intravascular ultrasound (IVUS) were ran- 
domly assigned to the DCA-stent group (58 lesions) or DCA-alone group (59 lesions). 
Single or multiple Multilink stents were implanted in the DCA-stent group. Administration 
of cilostazol, (200mg/day) without aspirin was commenced after the procedure and con- 
tinued until 6 month follow-up (Fu) in both groups. Ticlopidine (200mgiday) was added in 
the DCA-stent group for 1 month. Serial QCA and IVUS examinations were performed at 
the procedure and Fu. No major adverse cardiac events were observed during the hospi- 
tal stay and Fu period in both groups. Eligible Fu angiography was obtained in 112 
lesions (95.7%) 195r48 days after the procedure. Final angiographic and IVUS Fu 
results are shown in the table. Conclusions: Adjunctiue stenting after DCA provides a 
larger immediate lumen compared with DCA alone and a low restenosis rate by the 
administration of cilostazol, However, Fu angiographic outcomes are not significantly dif- 
ferent compared with DCA alone followed by the administration of cilostazol because of 
more accelerated neointimal proliferation after adjunctive stenting. 
DCA-stent DCA-alone P value 
Reference (mm) 3.32kO.32 3.3010.41 NS 
Post Minimal Lumen Diameter (mm) 3.2790.27 2.9220.33 <0.0001 
Post Diameter Stenosis (%) 3.4+7.2 11.5+9.4 <0.0001 
Post Lumen Area (mm2) 10.3+1.9 8.&2.1 <0.0001 
Fu Minimal Lumen Diameter (mm) 2.53+0.59 2.41rt0.69 NS 
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Fu Diameter Stenosis (%) 23.&i 6 6 ze.2t17.5 NS 
Fu Lumen Area (mm2) 6.5i1.9 7 123.1 NS 
Neointima Area (mm2) 4.2i2.4 1.522.8 <0.0001 
Restenosis Rate (%) 5.4% (3156) 8.9% (5156) NS 
1123-28 Platelet-Monocyte Complex Formation: Effect of PSGL-1 
Blockade With KPL-1 in Coronary Stenting With GP Ilb/llla 
Antagonism. 
Laura S Fernandes, Jeffrey A. Klem, Shiba Mathew, Ian Conde-Pozzl, Geoffrey S. 
Kansas, Karen R. Snapp, C. Wayne Smith, Christie M. Ballantyne, Kelly J. Maresh, Neal 
S. Kleiman. Baylor Co//ege of Medicine, Housfon, TX, Northwestern University Chicago, 
IL 
Platelet (pit) P-selectin bind- 
ing to PSGL-I an initial signal 
for monocyte stimulation may 
play a central role in the 
development of acute coro- 
nary syndromes and compli- 
cations afte1 PCI. we 
investigated ex-viva blockade 
of PSGL-I and MAC-1 / alone 
and in combination, in pts 
who underwent coronary 
stenting. Dual label flow 
cytometry was used to detect 
plateI&monocyte complex 
(PMC) formation in whole blood samples of 10 pts who received GP llb/llla blockade with 
either eptifibatide or abciximab. Blood was collected at baseline (BL), 2h, and 24h post 
steni. PSGL-1 was blocked with antibody, KPL-1 and MAC-1 with antibody 2LPM19C. 
PMC formation was stimulated with platelet agonists TRAP and ADP before and after 
blockade of PSGL-1. PSGL-1 blockade significantly prevented PMC formation, prior to 
iIt stimulation with either agonist at each time point, p<O.OOl, p<O.OOl, pcO.001. Addi- 
tional blockade of MAC-1 did not lead to a further decrease in PMC formation, compared 
with PSGL-1 blockade alone, p=O.46 NS. Even after pit stimulation, addition of KPL-1 
was associated with a low PMC percentage, implying displacement of P-s&&tin from 
PSGL-I and disaggregation of PMCs. 
Conclusion: PSGL-1 blockade by KPL-1 alone is sufficient to block PMC interaction fol- 
1123-30 Pretreatment With Ticlopidine or Clopidogrel Improves the 
Safety Profile of Stenting: An Analysis of 3037 Patients 
Steven P Marso, Cathryn A. Carroll, Michael M. Coen. Peter N. Tadros, Daniel L. Lips, 
Warren L. Johnson, Lee V. Giorgi, Barry D. Rutherford. MidAmerica Heart Institufe, 
Kansas City 
Background: The efficacy of pretreatment with ticlopldlne (T) or clopidogrel (6) is 
unknown, pending the results of CREDO. Methods: Consecutive patients from 1197.121 
99 who underwent PCI and admitted 24 hours prior to PCI in order to track pharmacy 
charge data were included. The mafin endpoint was inhospital death, MI or urgent revas- 
cularization. Study groups included treatment with T or C day prior to PCI, day of PCI, or 
day following PCI. Results: 3037 patients (972 day prior, 1701 day of, 364 day following 
PCI) were identified. The day prior group was higher risk’ they were older, had greater 
number of diseased vessels, higher incidence of CHF but less likely had recent MI. In- 
hospital MACE rates listed in Table. Given the baseline differences among study groups, 
a multiple logistic regression analysis was performed including the following variables, 
age, creatinine, EF, acute MI, number of diseased vessels and TIC treatment patterns. 
Sigmficant predictors of MACE included: No pretreatment (Odds Ratio (OR) 3.5. p < 
0 001) and acute Ml (OR 2.2, p = 0.03). Other multivariable predictors included: EF (OR 
0.9, p = 0.1) and 3 vessel disease (OR 1.8, p = .07). Conclusions: Pretreatment with 
either T or C is associated with an improved safety profile for stenting This association 
holds up following muitiiogistic regression analysis. 
Ticlopidine or Clopidogrel Treatment Patterns (Unadjusted) 
Day Prior PCI Day of PCI Day Following PCI 
N=972 N=1701 N=364 P-value 
Death, Ml, Urgent PCI 1.7% 1.4% 3.3% 0.034 
Death 0.5% 0.4% 0.3% 0.92 
Ml 1 .4% 0.5% 1 1% 0.04 
urgent PCI 1.3% 0.9% 3.0% 0.01 
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1123-29 Fewer Bleeding Complications With Comparable Efficacy 
With the Transradial Approach in Coronary Artery Stenting: 
An Analysis of the ESPRIT Trial 
John Conor O’Shea, TiH Mann, Anne Hellkamp, Eric Cohen, Robert Chisholm, Warren J. 
Cantor, Ian Gilchrist, William Meengs, Michael M. Kitt, Todd J. Lorenz, James E. Tcheng 
Duke Clinical Research Institute, Durham, NC 
Background: The benefits of the transradial approach for coronary stenting have previ- 
ously been demonstrated by single centers committed to this technique. The present 
study evaluated fhe safety and efficacy of the transradial approach in the large muti- 
center ESPRIT trail. Methods: In ESPRIT, 2064 patients from 92 centers in the US and 
Canada were randomized to double-blind eplifibatide (180 pglkg double b&s, with 
boluses separated by 10 minutes, with a 2.0 pglkg-min infusion for 18-24 hours) or pla- 
cebo therapy, with study drug being given as an adjunct to planned elective coronary 
stent Implantation. The route of axe?& was at the discretion of the cardiologist. Safety 
and efficacy data were prospectively collected and outcomes following radial and femoral 
approaches were determined. Mutivariable regression was used io adjust for important 
clinical variables previously shown to be predictive of outcome. Results: Data were 
available on 2030 patients: 144 patients (7.6%) from 20 sites underwent transradial coro- 
nary stenting. Eptifibatide was utilized in 48% of the transradial patients and 50% of the 
femoral patients. Procedural outcomes and incidence of endpoints were the .same in both 
groups. 
Femoral (n=1886) Radial (n=144) P Value 
De&h/Ml 151 (8.0%) 15 (10.4%) 0.326 
Urgent TVR 28 (1.4%) 1 (0.7%) 0.274 
Thrombotic Bailout 30 (1.6%) 0 0.09 
Any Bleed 338 (17.9%) 17 (11.8%) 0.05 
Access Site Bleed 268 (14.2%) 9 (6.3%) 0.003 
Access Site Complication 125 (6.6%) 1 (0.7%) 0.14 
Multivariable regression analysis Indicated that the radial approach was associated with 
a significantly reduced risk of access site bleeding (OR 0.41:95%CI 0.2, 0.79, p=O.O09). 
Conclusion: The transradial approach for coronary stent Implantation is associated with 
primary success rates comparable to the femoral approach and access site bleeding 
complications are rare. This approach may be particularly desirable in patients undergo- 
ing glycoprotein Ilb/illa platelet InhibItion therapy to minimize the risk of access site com- 
plications. Interventional cardiologists should consider using this alternative access site. 
1124-31 Staged Versus Non Staged Approach for Multivessel 
Percutaneous Coronary Interventions 
Andrea S. Abizaid, Roxana Mehran. Alexandre Abizaid, George Dangas, Luis Gruberg, 
Augusta D. Pichard, Ron Waksman, Lowell F. Satler, Kenneth M. Kent, Alexandra J. 
Lansky, Gregg W. Stone, Martin B. Leon. Cardiovascular Research Foundation, New 
York, NY, Washington Hospifal Center, Washington, DC 
Background: A strategy of “staging” in’rerventional therapies within the same hospital- 
ization has been adopted in patlents with mulbvessel coronary disease in an attempt to 
decrease acute complications. However, superiority of this strategy to a “single proce- 
dure” approach has not been documented. 
Methods: We compared the acute and long-term clinical outcomes in 2990 consecutive 
pts undergoing multivessel percutaneous coronary intervention. Patients were divided 
into two groups according to the strategies of I) Staged (two procedures in the same 
hospilalization, n=307) and 2) Non-staged (multivessel coronary Intervention 1” a single 
procedure, n=2683). 
Resuhs: Patients in the staged group had more post Ml angina (19.1% versus 11.3%; 
p=O.OOZ), diabetes (40.1% ver.su$ 32.2%; p=O.Ol), peripheral vascular disease (36.5% 
veraus 19%; p=O.OOOl) and chrome renal insufficiency (17.2% versus 8.8%; p=O.OOOl) 
compared to patients in the non-staged group. In-hospital and one-year results are 
shown: 
Staged Non-staged p Value 
In-hospital non Q-wave Ml (%) 29 15.5 0.0001 
In-hospital death (%) 1.8 0.4 0.03 
In-hospital MACE (%) 2.9 21 0.38 
l-year death (%) 11.3 4.9 0.0007 
l-year MI (%) 3.2 0.8 0 008 
l-year target lesion revascularlzation (%) 14.9 19.2 0.06 
I-year MACE (%) 31.5 26.2 0.05 
By multivariate analysis, diabetes (p=O.OOOl; OR=2.06), chronic renal insufficiency 
(p=O.OOOl; ORz3.79) and strategy of “staginr (p=O.Ol: ORz1.68) were independent 
predictors of early and late mortality. 
Conclusions: in patients with multivessel disease referred for PCI, “staging” within ihe 
same hospitalization IS strongly associated with higher early and late clinical events even 
after correcting for baseline differences. These data discourage the implementalion of 
this strategy for percutaneous treatment of patients with multivessel coronary disease. 
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1124-32 Better Procedural Results in Coronary Thrombosis Are 
Obtained With Delayed Percutaneous Coronary Intervention 
Carlos Cafri, Ron Svirsky, Hare1 Gilutz, Julian Zelingher, Reuben Ike. Soroka Medical 
Center, Seer She@ Israel, Faculty of Health Sciences, Ben Gurion University, Beer 
Sheva, lsrael 
Background: Coronary thrombus has been associated with procedural complications dur- 
ing percutaneous coronary intervention (PCI). Appropriate treatment strategy for throm- 
boiic lesions has not yet been defined. Our aim was to compare procedural results and 
clinical outcomes of immediate PCI (IPCI) versus delayed PCI (DPCI) in thrombolic 
lesions. Methods: in 106 pts with coronary thrombus, the clinical, angiographic and pro- 
cedural characteristics and hospital outcome were retrospectively studied. Results: Clini- 
cal and angiographic characteristics were comparable between the two groups. Time to 
DPCI was 4.9idays after diagnosis catheterization. Pretreatment before DPCI: heparin 
(86%) abciximab (36%) and enoxaparin (29%). During PCI, abciximab was used in 49% 
of the IPCI orouo and in 39% of the DPCI orouo INS). Coronarv stent was deoloved in - 1 I 
69% of IPCI “s 75% of DPCI (NS). Results: 
IPCI (82 pts) DPCI (24 pts) p value 
Residual thrombus % 17 0 0.03 
Distal embolism % 6.5 0 NS 
Non reflow % 7.5 0 NS 
Acute closure % 10 0 NS 
Acute stent thrombosis % 1.3 4.2 NS 
Combined end point % (residual throm- 27 4.2 0.018 
bus, distal embolism, non reflow, acute 
closure, acute stent thrombosis) 
Angiographic success % 92 100 NS 
AMYDeath % 7.7 8.9 NS 
Conclusions: In coronary thrombolic lesions, delayed PCI after pharmacological treat- 
ment decreases the complication rate associated with the procedure. 
1124-33 Directional Coronary Atherectomy in Unprotected Left Main 
Coronary Artery: Initial and Long-Term Results of 101 
Procedures 
Kunihiko Kosuga, Hideo Tamai, Eisho Kyo, Tatsuhiko Hata, Masaharu Okada, Takuji 
Nakamura, Hidenori Komori, Takafumi Tsuji, Shinsak” Takeda, Seiichiro Motohara, 
Hirom” Uehata. Shiga Medical Center for Adults. Moriyama, Japan 
Background: Angioplasty in unprotected left main coronary artery (LMCA) has been 
controversial. Recent several studies suggest that new devices such as directional coro- 
nary atherectomy (DCA) and stent may change the situation. Although there are many 
reports of unprotected LMCA stenting, there are few reports of DCA in this lesion. Meth- 
ods: Between April 1986 and March 2000, DCA was performed in 101 patients for de 
nova lesion in unprotected LMCA in our hospital. Scheduled angiographic follow-up was 
routinely performed, and all patients were clinically followed up for more than 5 months 
after DCA. Their initial and long-term results were evaluated. Results: There were 86 
male (85%) and 15 female patients (from 22 to 87 years old, mean age of 671-10 years 
old) in this study. Fifteen procedures (15%) including 3 for acute myocardial infarction 
(MI) were performed emergently, and 86 procedures (85%) were performed electively. 
There were 44% of coronary artery bypass grafting (CABG) high-risk patients in this 
study. Technical success was achieved in 99.0%, and in-hospital results were as follows: 
cardiac death, 2.0%: noncardiac death, 4.0%; QMI, 1.0%; non-QMI, 8.9%; CABG, 0%; 
repeat angioplasty, 4.0%. In-hospital results varied considerably, depending on presen- 
tation and in-hospital mortality were significantly higher in the emergency (pcO.O5), left 
ventricular ejection fractiow35% (~~0.05) and CABG high-risk (p<O.Ol) subgroups. The 
angiographic restenosis rate was 20.4% at follow-up, and its predictor was post-minimal 
lumen diameter by multivariate analysis (p<O.O5). The mean clinical follow-up was 2.8 
years, and the estimated 1 -year and 3-year survival rates were 87.0% and 80.7%. The 3. 
year cardiac survival rate of the CABG low-risk subgroup was significantly higher than 
that of the CABG high-risk subgroup (96.2% vs. 72.5%, p<O.O5). Conclusions: Our data 
show that DCA can be performed safely and effectively in unprotected LMCA with an 
acceptably low restenosis rate and high survival rate. 
1124-34 Direct Stenting Versus Provisional Stenting Guided by 
Fractional Flow Reserve (DSPS Trial) 
Massoud A. Leesar, Tarif Kannan, Anil Sharma, Srini Manchi, Debasis Das, Ronald 
Masden. University of Louisville, Louisville, KY 
Background:Pressure-derived myocardial fractional flow reserve (FFRz0.94) correlates 
significantly with intravascular ultrasound for optimal stent deployment, and a value of 
20.90 after PTCA is associated with an excellent outcome; however, the value of FFR in 
direct stenting (DS) vs. provisional stenting (PS) is unknown. MethodeWe sought to 
compare the impact of DS vs. PS on FFR, and also to determine the cost, procedure 
time, and radiation exposure time associated with achievement of optimal FFR. Accord- 
ingly, we randomized 55 patients with a critical coronary stenosis to DS (n = 26) vs. PS (n 
= 29). The lesion was crossed with a WaveWire and FFR was measured at baseline after 
intracoronary adenosme infusion, In the DS group, a stent was deployed at the lesion 
using a high pressure balloon inflation: if optimal FFR (T0.94) was not achieved after DS, 
high pressure balloon inflation using larger balloon or an additional stent was deployed. 
In the PS group, if optimal FFR (zO.90) was not achieved after PTCA, or in the presence 
of dissection, a stent was deployed. The total cost of the procedure included the 
resources “sad in the catheterization laboratory (CL): equipment, supply, registered 
nurse and technologist times. Results: In the DS group, FFR increased from 0.64 * 0.03 
at baseline to 0.97 + 0.01 after stent deployment, p<O.OOl, and an FFRz0.94 without fur- 
ther balloon inflation was obtained in 86%. In the PS group, an FFRz 0.90 was only 
obtained in 35%, and 65% required stent deployment; FFR increased from 0.64 + 0.02 to 
0.88 + 0.02 after PTCA, and that further increased to 0.99 + 0.01 after stent insertion in 
the remaining cohort, p<O.OOl. Total CL cost was $3065 ? 138 in the DS group vs. $2935 
* 184 in the PS group, p = NS. The procedure time was 56 + 4 min in the DS group vs. 
82 ? 5 min in the PS group, p<O 01. The radiation exposure time was 11 + 1 min in the 
DS group vs. 16 * 1 min in the PS group, p = 0.004. Conclusion: DS with optimal FFR 
was accomplished in all of the patients with no significant additional cost compared to 
PS, and that shortened the procedure time as well as the radiation exposure time. Fur- 
ther studies are needed to determine the impact of optimal DS on long-term clinical out- 
come. 
1124-35 Percutaneous Coronary Intervention for Multivessel 
Coronary Artery Disease: Evolution Since BARI 
V.S. Srinivas, Maria M. Brooks, Katherine M. Detre, Alice K. Jacobs, Spencer 8. King, Ill, 
David 0. Williams. Rhode /s/and HospMand Brown University, Providence, RI 
Background: The Bypass Angioplasty Revascularization Investigation (BARI) described 
the outcomes of patients (pts) with multivessel disease treated by percutaneous coronary 
intervention (PCI). How contemporary PCI compares to the BARI experience is 
unknown. Purpose: We compared the clinical history, procedural and in- hospital out- 
come variables between pts enrolled in WAVE 2 (1999) of the Dynamic Registry who ful- 
filled BARI entry criteria (n=332/1805) to pts randomized to the angioplasty arm of BARI 
(n = 904) enrolled in 1988-91. Results: Compared to BARI pts, Registry pts were older 
(64.2 vs. 61.8 yrs p=.OOl) and included more treated diabetics (25% vs. 19%, p=.O33) 
and hypertensives (65% vs. 49%, p<.OOi). Registry patients had less triple vessel dis- 
ease (30% vs. 39%, p=.OO3) while the number of significant lesions (3.11 vs. 3.18) and 
proportion with total occlusions (31% vs. 29%) were similar (p>.O5). In the Registry, 
attempted lesions were more likely (pc.003) to be calcified (33% vs. 2%), located at a 
bifurcation (12 % vs. 8%) or in a tortuous vessel (31% vs. 13%). Registry pts had angio- 
plasty attempted in fewer lesions (1.6 vs. 2.36 p<.OOl). Balloon alone was used for BARI 
pts while 86% of Registry pts received stents. Mare Registry pts achieved total angio- 
graphic success (90% vs. 71% pcOO1). Major dissection was similar between the groups 
(9.0% vs. 8.9%, p=.92) yet in-lab abrupt closure was lower in Registry pts (0.3% vs. 
9.5% p<.OOl). In-hospital death (0.6% vs. 1.1%) or death /MI (3.6% vs. 3.0%) were not 
(p>.lO) different between the groups although in-hospital CABG was lower (1.8% vs. 
10.2% p=.OOl). The relative risk for CABG in the Registry compared to BARI was 0 17 
(95% C.I.=O.O7, 0.39) after adjustment by logistic regression models. Conclusions: 
Despite more co-morbidity and lesion complexity, BARI-like patients in the Dynamic Reg- 
istry demonstrated superior procedural and clinical outcomes when compared to the orig- 
inal BARI-PTCA subgroup. These results support the use of PCI for selected pts with 
multivessel CAD. 
1124-36 A New and Objective Method for Transradial Approach 
Screening: Comparaison With the Allen’s Test in 1010 
Patients 
Gerald Barbeau, Franc& Arsenault, Louise Dugas, Marie-Ma Lariviere. Quebec Heart 
Institute, Quebec, PQ, Canada 
Background: To avoid ischemic complications of the hand, percutaneous transradial 
approach (PTRA) can only be performed in patients with patent palmar arterial arch, “su- 
ally evaluated with the modified Allen’s test (MAT). This test is a qualitative evaluation of 
time to achieve maximal palmar blush after compression release of the ulnar artery with 
continuing occlusive pressure of the radial artery. Patients with hand blushing in 9 sec- 
onds or less are candidates for PTRA. According to one large series (Bendit et al), only 
73% of patients would qualify for PTRA. Methods: From 06 to 12l99, patients referred to 
the cath lab were prospectively evaluated for patency of the palmar arterial arch with 
MAT, plethysmography (PL) and oxymetry (Ox) tests. The combined PL and Ox sensor 
was applied to the thumb. MAT was recorded in seconds. PL readings during radial 
artery compression (RAC) were divided in 4 types: A- no dampening of pulse tracing; B- 
dampening of pulse tracing; C -loss followed with recovery of pulse tracing within 2 min; 
D- loss of pulse tracing without recovery. Ox was either positive or negative during RAC. 
Patients were considered suitable for PTRA with MAT 9 set or less or PI type A, B C 
and positive Ox readings. Results: Of the 1010 consecutive patients, 32% were female, 
19% were diabetics and 7% had previous coronary artery bypass surgery. Mean age was 
62y (range(r):22-88y) with weight and height of 76kg (r:36-160) and 1.66 meters (r:l.O- 
1.9) respectively. MAT was equal or less than 9 seconds rn 87% and 86% of patients on 
the right and left side, respectively. Positive combined PL and Ox was 96% and 95% of 
patients on the right and left side, respectively. Based on MAT criteria, 6,3% were 
excluded for either right or left PTRA. With PL and Ox only 1.5% of patients were 
excluded for either right or left PTRA. Conclusions: Compared to conventional evalua- 
tion of palmar arterial arch patency with a qualitative test, MAT PL and Ox identified 
more candidates for PTRA, while being more objective. Contrary to results of prevrous 
series, we conclude that only 1.5% of patients are not suitable candidates for PTRA. 
1124-37 The FilterWireY First Evaluation of a New Protection 
Catheter Device for Distal Embolization in Native Coronary 
Arteries and SVGs 
Ulrich Ger~kens, Ralf Miiller, Sascha Rowold, Eberhard Grube. Heart Center Siegburg, 
Siegburg, Germany 
Background: A limitation of catheter interventions in large coronary arteries and SVGs 
is distal embolisation and ‘“no-flow” with the consequence of transient ischemia, CK-rise 
and Ml. The FilterwireTM device provides a method of containing and retrieving embo- 
lised plaque material. We evaluated the effectiveness and safety of the system in 30 
patients. Description of the device: The FilterWireTM consists of a percutaneous 
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guidewire, which incorporates an oval shaped structure that supports a thtn, porous filter 
membrane (pore size 80 urn). The device is delivered through a low profile sheath, which 
allows free rotational movement of the guidewire component. The filter is deployed distal 
to the lesion. At the end of the procedure, the filter can be retrieved to capture throm- 
boembolic created during the intervention Patients: In 30 pts. (22 male, age 51 to 73) 
standard stent placement (mean diameter 3,5 +I-0,5mm; 20 native coronary arteries, 10 
SVGs) was performed over the FitterwireTM gutdewire system. No adverse events were 
recorded and only slight, insignificant rises of CK, GKMB (max 117/22 U/L)) level were 
observed. Results: The FilterwrreTM wire could be placed and retrieved without any com- 
plications; in 28/30 cases macroscopically visible plaque material was found and sent to 
pathology for evaluation. Conclusion: The FilterwireTM system is easy to handle and 
compatible with routine angioplasty procedures with unchanged angiographic guidance 
and normal distal blood-flow. It is capable of containing and retrieving atherosclerotic and 
thrombotic debris and is a very promising device for the prevention of distal emboltzation 
in native coronaries. SVGs and carotid arteries. 
1124-38 The Role of Vessel Size in Determining Debulking Efficiency 
After Directional Coronary Atherectomy 
Issam Moussa. Antonio Colombo, Carlo Di Mario, Yoshio Kobayashi, Michael Collins, 
Milena Adamian, Jeffery W. Moses. Lenox Hi// Heart and Vascular/nstifute, New York, 
NK Cenfro Cuore Columbus, MI/~, /B/y 
Background: Long-term outcome after directional atherectomy (DCA) is related to 
debulking efficiency. DCA has been tradittonally used in large vessels. However. the 
impact of vessel size on debulking efftciency has not been established. Methods: 
Between 1996 and 1998, 128 pts with ischemic CAD underwent DCA prior to stent 
implantation for 168 lesions in native coronary arteries. Mean age was 58+10 yrs, and 
mean vessel size 3.25+0.54 mm. A 7Fr. GTO DCA cutter was used tn 96% of lesions 
performing an average of 14+7 cuts. Intravascular ultrasound was performed after DCA 
in 116 lesions and measurement of residual plaque area was performed at the smallest 
lumen cross sectional area. 
Results: As show in the figure, the 
frequency of achieving a residual 
plaque area ~50% trended to be 
lower in lamer vessels cornoared to 5: 46% 
smaller vessels (p=O.O7). Conclu- VI 
sions: In practice, debulking effi- E 
ciency of DCA may decrease as a :. 
function of vessel size despite 
adhering to DCA cutter sizing rec- 
ommendations. The number of DCA 
cuts and the balloon inflation pres- 
sure used have to be tailored 
aCCording to vessel size and prefer- 
ably under IVUS guidance 
1124-39 Transcatheter Intervention of Thrombotic Lesions: Clinical, 
Anatomic, and Procedural Predictors of Adverse Outcome 
Antonis Pratsos, David Fischman, Stephen Ramee, Kalon Ho. Jeffrey Popma, Richard 
Kuntz. Michael Savage, The VEGAS 2 Investigators. Jefferson Medicai College, 
f’hfladelphia. PA 
Background: Coronary intervention in lesions with large thrombi is problematic due to 
the high risk of ischemic complications. The goal of this study was to identify factors pre- 
dictive of major adverse cardiovascular events (MACE) during intervention of thrombotic 
lesions 
Methods: The study population consisted of 349 patients with significant thrombi 
enrolled in the VEGAS 2 trial (a randomized comparison of AngioJet rheolytic thrombec- 
tomy and intracoronary urokinase). Univariate and multivariate analyses were performed 
to determine factors predictive of 30 day MACE (death, MI, CVA, CABG or TLR). 
Results: High risk features included recent Ml in 53%, class III / IV angina in 87%, 
venous bypass grafts (SVG) in 54% total occlusion in 48%, and large thrombus burden 
(mean thrombus area = 72 i77 mm2 by QCA). In native coronary arteries, MACE was 
7.1% itn the AngioJet group vs 21.8% in the urokinase group. In SVG, MACE was 23.2% 
in the AngroJet group vs 41.8% in the urokinase group. By univariate analysis, clinical 
predictors of MACE included hyperiipidemia (odds ratio [OR] 1.94, pz.01) and age (OR 
1.02, pc.05). Anatomic predictors of MACE included SVG (OR 2.99, p<.OOi) and larger 
vessel size (OR 1.93, p<.OOl). Procedural factors predtctive of MACE included residual 
% stenosis (OR 1.02, p<.OOl) and residual thrombus area (OR 1.02, p<.Oi). Factors 
associated with reduced MACE included use of AngioJet (OR 0.39, p<.Ol), stent use 
(OR 0.50, p<.Ol), final TIMI 3 flow (OR 0.19, p<.OOl) and final MLD (OR 0.72, p=.Ol). 
Multivariable predictors of MACE included: SVG (OR 3.50. pi.001). AngioJet use (OR 
0.47, pi.Ol), stent use (OR 0.49, p=.OZ) and vessel size (OR 1.51, p=.O4). 
Conclusions: lschemic complications are common after intervention in thrombotic 
lesions and can be predicted by baseline features including SVG location and vessel 
size. Use of the AngioJet and stents are associated with improved outcome 
ACCIS2001 (Angiography & Interventional Cardiology) 35A 
POSTER SESSION 
1125 Restenosis: Vascular Remodeling and 
Apoptosis 
Monday, March 19, 2001, Noon-2:00 p.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: Noon-l :00 p.m. 
1125-9 Physical Training Prevented Neointimal Hyperplasia and 
Inward Vascular Remodeling After Balloon Injury and 
Stenting Through Increased NO Signaling 
Daniele Torella, Ciro Indolfi, Carmela Coppola, Antonio Leccia, Antonio Curcio, Or&e 
Arcucci. Alfonsa Pisani, Giovanni Esposito, Mariacristina Falco, Massimo Chiariello. 
University Fe&rim I, Naples, ltaly, La Magna Graecia University Catanzaro. /ta/y 
Background: The effect of physical training on clinical or expecimental restenosis IS 
unknown. The effect of dynamic exercise on neointimal hyperplasia and vascular remod- 
eling after balloon injury (BI) and stenting was assessed. Methods: 81, using the stan- 
dard Clowes method, was performed in: Group I, Sedentary-B1 (SEDEN; N=iO); Group 
II, Swimming-El (SWIMM; N=lO). The effect of chronic administration of L-NMMA after BI 
both in additional SEDEN and SWIMM Groups was also assessed. In the SWIMM 
Groups, rats were trained by swimming (45 min twtce daily) for 14 days before and after 
Bl. Results: At 14 days after 81, a reduction in NeointimaiMedia ratio (from 1.207+0.099 
(SEDEN) to 0.552+0.124; p<O.OOi) was detected in Group SWIMM compared to SEDEN 
group. Physical training (SWIMM Group) prevented vascular negative remodeltng [calcu- 
lated as ratio between External Elastic Lamina (EEL) of right intured and left not-injured 
arteries] after BI Chronic administration of L-NMMA abolished the positive effects of 
physical exercise on neointtmal hyperplasia and vascular inward remodeling after BI (see 
figure). Furthermore, we observed a reduction of neointimal hyperplasia after arterial 
stenttng in 10 exercised rats compared to 10 sedentary rats (N/M ratio from 1.821+0.231 
to 0.709+0.096; p<O.OOl vs. SEDEN). Western blotting analysis showed an evident 
increase in e-NOS protein levels in injured arteries from exercised animals compared to 
sedentary animals. Conclusion: Physical training inhibits neointimal hyperplasia and 
vascular inward remodeling after BI and stenting through increased NO Signaltng. 
1125-l 0 Injury, Adventitial Growth, and Adventitial Collagen Density 
Are Not Related With Remodeling After Balloon Dilation in 
Porcine Arteries 
Freek J. van der Mew, Marion J. Sierevogel, Gerard Pasterkamp, Evelyn Velema, Arjan 
H. Schoneveld, Dominique P. V. de Kleijn, Cornelius Borst. Dept of Cardiology, 
Universify Medical Center Ufrecht, GM-5.23, Heidelberg/an 100, 3584 CX, U&vhf, The 
Netherlands 
Background: It has been suggested that the degree of injury, adventttial growth and 
ahventitial collagen density are important determinants of constrictive remodeling after 
balloon dilation. We examined the relationships between the degree of constrictive 
remodeling and the extent of Injury, adventitial area and collagen density after balloon 
dilation Methods: Seven landrace pigs underwent balloon dilation of the femoral (n=14) 
and internal iliac (n=9) arteries with a balloon/artery ratio of 1.2-1.3. In all arteries, intra- 
vascular ultrasound (IVUS) was performed at all time-points. Arteries were harvested 6 
weeks after dilation and two cross sections per dilated segment were prepared for histo- 
morphometric analysts using El&in van Gieson staining. Collagen density was deter- 
mined by converting a Picrosirius red image into a grayscale image. Collagen density 
was defined as total gray values per cross-sectional area (um2). Measurements of the 
two cross sections were averaged for each artery. The injury score (IS) was based on 
rupture of the internal (IEL) and external (EEL) elastic lamina. I: IEL and EEL intact; II: 
IEL ruptured. EEL intact; Ill: both IEL and EEL ruptured. Remodeling index (RI) was 
deftned as the IVUS ratio of vessel area at follow up over the vessel area post dilation. 
Results: See table, values are in mean + sd. *: ~~0.05 compared with injury score I. Into- 
mal and adventitial area (mm2) increased with increasing injury. Adventitial collagen den- 
sity decreased with tncreasing injury. The RI did not differ among the three Injury groups. 
In regression analysis, RI did not correlate with adventitial area (1=0.30, ~~0.05) or 
adventitial collagen density (r=O.lt, p>O.O5). Conclusion: The extent of injury after bal- 
loon dilation is a determinant of intimal and adventitial growth. Neither the extent of injury 
nor the adventitial area or adventitial collagen density is associated with constrictive 
remodeling after balloon dtlation. 
IS I II Ill 
n 3 8 12 
lntima 0.19 k 0.08 0.74 2 0.47 1.60 & 0.63* 
Adventitia 4.75 2 0.79 3.93 i 1.01 6.48 f 1.43’ 
Adv.coll.content 93.1 * 9.6 83.6 t 20.7 75.5 2 19.0 
RI 0.65 10.17 0.84 f 0.16 0.84 Lk 0.27 
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1125-11 Adventitial Remodeling After Angioplasty is Associated 
with Expression of Tenascin mRNA by Adventitial 
Myofibroblasts 
Kurt Wallner, Behrooz G. Sharifi, Prediman K. Shah, Sumiko Noguchi, Hector &Leon, 
Josiah N. Wilcox. Cedars-Sinai Med. Or., Los Angeles, CA, Emory University: Atlanta, 
GA 
Background: Recent studies suggest that cell migration, in addition to cell proliferation, 
is a critical component of neointima formation following vascular injury. We have previ- 
ously shown that adventitial myofibrablasts synthesize growth factors that contribute to 
the formation of neointima after arterial injury. We have also shown that the extracelluar 
matrix protein tenascin-C regulates cell migration. Consequently, we investigated the 
temporospatial expression of TnC, by myofibroblasts following vascular injury. Methods: 
In situ hybridization and immunohistochemistry were used to investigate the temporospa- 
tial expression of TnC in injured arteries. Northern and Western blots were used to deter- 
mine in vitro expression of TnC. Results: In situ hybridization revealed that the major site 
of TnC expression early after vascular injury was the adventitial myofibroblasts. Immuno- 
histochemical staining demonstrated that TnC expression began in adventitial myofibro- 
blasts 3 days after injury. TnC expression, however, did not persist in this region. Rather, 
it moved progressively across the vascular wall toward the luminal surface. By one week 
TnC expression reached the developing neointima. In vitro, myofibroblasts did not 
express TnC mRNA under basal conditions. In contrast, angiotensin II and PDGF-BB, 
factors that have been implicated in remodeling of balloon-injured arteries, markedly up- 
regulated TnC mRNA. Conclusions: TnC is expressed in response to balloon injury. 
TnC expression begins with adventitial myofibroblasts. Over a period of 7-14 days, 
expression moves progressively across the vessel wall to the neointima. We hypothesize 
that adventitral myofibroblasts are actively involved in the formation of neointima, and 
that TnC facilitates migration of these cells during adventitial remodeling. 
1125-40 Apoptosis and Bcl-2 Modulate Early Vascular Remodeling 
Alexander Jabs, Reng AndriB, Randolph Hutter, Juan J. Badlmon, Valentin Fuster, 
Berndt LDderitz, Gerhard Bauriedel. Department of Cardiology: University of Bonn, Bonn, 
Gerrnanl: Cardiovascular /nstifute, Mounf Sinai Medical Cenfer, New York, NY 
Background: Vascular wall texture post angioplasty may be modulated via pro- and 
anti-apoptotic signals. We sought to investigate the incidence of apoptosis and the 
expression of the anti-apoptotic protooncogene B&2 early post angioplasty. 
Methods: Balloon overstretch injury was performed in rat carotid arteries, while con- 
tralateral vessels served as controls. Arterial cross sections from either Oh, 24h, 5d or 
286 post injury (n=7 per time) were subjected to Bcl-2 immunostaining and TUNEL (Tdt 
mediated dUTP nick end labeling) that indicates apoptosis. 
Results: Early post injury, apoptosis increased rapidly (p<O.Ol) in media(M) and adven- 
titia (A), along with a decrease in cell density. Bcl-2 expression was not detected at Oh 
and also remained low at 24h. On day 5, a dramatic increase in A cell density occured, 
followed by neointima (N) formation. TUNEL labeling was low in N and A, whereas Bcl-2 
expression was maximal. With growing area of N (28d), TUNEL increased, mostly in N 
and M, while B&2 expression decreased in N and A. 
Oh 24h 56 28d 
N - X,8*12,5 5,7*2,5 
Bcl-2 M 0 0,5+0,7 1,7*1,5 1,7+1,9 
(% expression) A 0 0,6+_1,3 11 ,I +5,8 5,1*3,4 
N - 11,3*il,l 23,7*12,3 
TUNEL M 6,2i8,0 20,7*7,2 8,9+6,9 19,7+9,2 
(% expression) A 2,3&1,8 24,8+15,0 10,7t12,0 12,1+8,5 
N 0 0 13,1*1,4 11,3r3,5 
Cells x103/mmd M 4,4*0,8 3,7+0,7 4,1&0,6 4,6+0,7 
A 1,6+0,5 1,4io,5 8,1r3,6 2,2t0,5 
Conclusion: Our data demonstrate that apoptosis effectively modulates cell density in 
early vascular remodeling. High TUNEL labeling without Bcl-2 expression reduces cell 
density at early times post injury. Eel-2 apparently protects vascular cells, and thus may 
be a key contributor to neointlma formation. 
1125-41 Pig Coronary Angioplasty is Followed by the Coordinated 
Upregulation of Tissue-Factor and Caspase-3 
Randolph Hutter, Bernhard Sauter, John T. Fallon, Valentin Fuster, Juan J. Badimon. 
Mount Sinai Medical Center, New York, NY 
Background: Tissue factor (TF) has been implicated in the thrombogenicity of ruptured 
plaques. Cells undergoing apoptosis (programmed cell death) have been postulated as a 
source for TF. However, there is only limited knowledge about the spatiotemporal rela- 
tionship between TF expression and apoptosis after coronary arterial injury. Methods: 
Using the porcine model of coronary balloon angioplasty we performed immunohis- 
tochemical analysis, immunofluorescence double-labelinq and RT-PCR for TF and 
Caspase-3 (CAS) in injured vs. non-injured control arteries. Our data refer to neointrma 
(NI), media (ME) and adventitia (AD) at different time points post injury (n=5 animals/ 
time, expressron in % of cells, mean t SD). Results: 
Time NI ME AD NI ME AD 
Expression Expression Expression Expression Expression Expres- 
TF TF TF CAS CAS sion 
CAS 
Control -- o+o 151 -- oio l+l 
Ih -- li2 l&5 -. 3+1 915 
6h -- 8+5 14&4 -- 617 14+10 
Id -- 1119 12~5 -- 9+6 2025 
7d 24*9 1 Ok6 23tll 2324 1 Ok7 19+3 
146 715 lil iOk6 8i9 213 6+10 
28 d 27210 a5 28?9 16tlO 3+4 18t7 
In non-injured control arteries, TF and CAS expression were absent in the intima and 
media and vary low in the adventitia. Arterial injury leads to a high simultaneous expres- 
sion of TF and CAS in the media which peaks at day 1. Neointima is not yet developed at 
day 1. Expression of TF as well as C+S in the medial layer is largely reduced at week 2 
post injury and remains low also at 4 weeks after angioplasty, On the other hand, neoint- 
imal expression of TF and CAS starts with high levels at day 7, decreases at week 2 and 
regains high levels even 4 weeks after coronary arterial injury. In the adventitia cellular 
TF and CAS expression remains consistently high. lmmunofluorescence double-labeling 
showed almost complete co-localization of TF and GAS expression and RT-PCR also 
showed an increased presence of TF and CAS mRNA in injured arteries. Conclusions: 
TF and CAS respond to arterial trauma in coordinated fashion in all vascular compart- 
ments. TF as primary cell associated activator of the coagulation pathway seems to be 
closely related to apoptotic events thereby pointing to a key role of cell viability in determ- 
ing thrombogenicity of the arterial wall following PTCA. 
1125-42 Time Course of Apoptosis and Proliferation in the lntima 
and Media Following Experimental Brachytherapy With the 
Liquid Beta-Emitter Rhenium-188 
Joachim Kamenz, Markus Wohlfram, Patrick Stiller, Christina Len& Christoph Sadowski, 
Beate Hess, Martin Hoeher, Joerg Kotzerke, Hartmut Hanke. University of U/m 
Department of Cardiology Ulm, Germany University of U/m Department of Nuclear 
Medicine, U/m, Germany 
Endovascular brachytherapy inhibits vascular lesion formation after balloon injury but the 
cellular effects of postinterventlonal irradiation are yet not fully understood. Therefore, 
the aim of our study was to determine the incidence of apoptosis and cellular proliferation 
after vascular injury and endovascular brachytherapy with the liquid beta-emitter Rhe- 
nium-188 (Rh-188). Methods: After endothelial denudation of the carotid artery in 34 
male rabbits, irradiation wtth a Rh-188 filled balloon catheter device was performed with 
a dosage of 30 Gy at the vessel surface (15 Gy in 0.5 mm depth). After 7, 28 and 90 
days, the vessels were excised and histologically analyzed. Corresponding control 
groups without irradiation were also included. The rate of proliferation and apoptosis 
were determined by bromodeoxyuridine labeling and by using the TUNEL-method (TdT- 
mediated d-UTP nick end labeling). Results: Seven days following endovascular irradia- 
tion a significant increase of the apoptotis rate (9.4*8.3(Rh-188) vs. 0.5~0.6 %(control)) 
was found in the medial layer whereas the number of apoptotic cells in the intima did not 
change significantly in comparison to the control group over a period of 90 days. At the 
same time intimal cell proliferation was significantly inhibited (0.8tl.2 vs. 5.213.0 %) 
whereas the proliferation rate in the media was not affected (3.3r4.7 vs. 3.4+2.6 %). 
Consequently, a significant reduction of the total intimal area was observed 90 days after 
brachytherapy (1.16~0.87 vs. 0.44kO.42 mm2). At day 90, however, cellular proliferation 
in the intima and media showed a clear tendency towards an increase suggestmg an 
ongoing vessel wall reaction (intimal proliferation: 4.2 r 3.9 vs. 1.3+1.4%). Conclusion: 
Catheter transmitted endovascular irradiation with Rh-188 after vascular injury is able to 
reduce effectively neointimal hyperplasia by inhibition of intimal proliferation but not by 
induction of apoptosis. However, in the medial layer the proliferation rate was not 
affected whereas the apoptosis rate was significantly increased. This phenomenon per- 
haps can be explained by a decreasing dosage bf beta-radiation dependent on the dis- 
tance to the radiation source. 
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828 Coronary Stents: Predictors of Outcome 
Monday, March 19, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Hall F5 
828-l 
2:oo p.m. 
Post Procedure Chest Pain After Coronary Stenting 
Represents Myonecrosis: Implications on Clinical 
Restenosis 
Samin K. Sharma, Paul Lee, Mary E. Duffy, Paul Andrews, Cristlna A. Mitre, Varinder 
Singh, Nohelia Perez, Mazzulah Kamran. David Reich, Annapoorna S. Kini. The Mound 
Sina, Medical Center, New York, NY 
Background: The significance of post-procedure chest pain (PPCP) after successful 
coronary stenting (CS) in the absence of obvcous procedural complications like side- 
branch closure, dissection, slow-flow, thromboembolism is not known. To elucidate the 
mechanism of PPCP and its implication on cardiac enzyme release and subsequent res- 
tenosis. we prospectively analyzed 1362 consecutive non-acute MI patients undergoing 
CS in 1999. PPCP occurred in 488 (35.8%) patients; of these, some procedural compii- 
cations could be rdentifred in 312 (63.9%) patients and were excluded. Remaining 176 
oattenis with PPCP and without anv orocedural comwlications were cornoared with 874 , 
patients without PPCP Results: Significant variables are shown in the table. 
Variables PPCP (“~176) No PPCP P 
Females (%) 
(n&74) 
27.3 20.0 0.03 
Rest angina/ post-Ml (%) 40.9 12.8 co.oo1 
GP Ilb/llia use (“‘0) 81.8 74.8 0.05 
LAD lesion (%) 52.3 43.2 0.03 
Ref vessel size (mm) 2.83+0.38 2.62?0.41 NS 
inflation pressure (aim) 16+3 13+2 <O.Oi 
Stent:vessel ratio 1.21+0.12 1.08~0.08 0.02 
CK-MB 216 U/L (%) 25.6 9.6 <O.OOl 
Tnl >2 rig/ml (%) 55.7 15.4 co.001 
Clinrcal restenosrs (%) 29.5 16.6 co.01 
Conclusion: Our study suggests that both micro myonecrosis and vessel stretchladven- 
titial irritation can cause PPCP in the absence of procedural complications. PPCP is 
associated with hrgher restenosis perhaps mediated by deep vessel wall injury. There- 
fore, PPCP may identify patients at high risk for developing peri-procedural Ml and clini- 
cal restenosis. 
828-2 
2:15 p.m. 
Fibrinogen After Coronary Stenting as a Risk Factor for 
Restenosis 
Masaya Oisuka, Yasuhiko Hayashi. Hitoshi Fujiwara, Hironori &da, Yasuyuki Tomohiro, 
Yuji Muraoka, Takenori Okada, Yuko Hirai, Kohei Miyaji. Tsuchiya Genera/ Hospital, 
Hiroshima, Japan 
Background: Fibrinogen (F) is considered as a” important factor of coagulation and 
fibrinolytic system, and inflammation. Although F after coronary balloon angioplasty is 
reported as a risk facor for restenosis (R), few clrnical data are available concerning the 
relations between F and R after coronary stenting. Methods: As a prospective study, in 
221 consecutive patients implanting Multi-Link coronary stent (length 15 mm), we mea- 
sured plasma levels of F before stenting and at 6 months of follow-up during the period 
from November 1997 to January 2000. The individual changes of intralumrnal diameter 
were measured by quantitative coronary angiography. R was defined as loss index (late 
loss/acute garn) >0.7. The relations between F and R were assessed univariately, then 
with clinical characteristics, angiographic factors, technical factors included, the relations 
were analyzed multivariately. Results: Angiographic follow-up was obtained in 91% of 
patients with a primary success of stenting. R rate was 25.5%. Although F measured 
before stenting was not increased in restenosis group (RG), F levels measured at follow- 
up were higher in RG than in no restenosis group (NRG) (351+102 mgidl, 317&79 mg/dl, 
P = 0.010, respectively). Patients with a F level >320 mgidl at follow-up had higher R 
rates than patients with a F level ~320 mg/dl (32%, 19% P = 0.022). There was a signifi- 
cant correlation between F level and loss index (I = 0.19, P = 0 004). As other factors, 
age (69#3, 65i10, P = 0.006), left anterior descending coronary artery (LAD) lesion 
(64% 44%, P = 0.007) lesion length (13+7 mm, 9+4 mm, P <O.OOOl) and reference 
diameter (3.1t0.5 mm, 3.2kO.5 mm, P = 0.042) were significantly different between RG 
and NRG. Multivariate analysts confrrmed that F (>320 mgidl) (P = 0.025, odds ratlo = 
2.4, 95% Cl = 1.1 to 5.2) lesion length (0.004, 1.1, 1.0 to 1.2, respectively), reference 
diameter (0.015, 0.3, 0.1 to 0.8, respectively), LAD lesion (0.033, 2.2, 1.1 to 4.7, respec- 
tively) were independent risk factors for Ft. Conclusions: F during follow-up should be 
considered as an independent risk factor for R after coronary stenting which may relate 
to coagulation and fibrinolylic system, and inflammation. 
828-3 
2:30 p.m. 
Persistent High Fibrinogen Levels at Late Follow-Up of 
Percutaneous Coronary Intervention Are Associated With 
Clinical Restenosis 
Jean-Phrlrppe Collet, I. Sotirov, C. Lesty, R. Choussat, A. Ankn, G. Drobinski, D. 
Thomas, G. Montalescot. Pifi&Sa/p&ri&e Hospftal- Department of Cardiology: Paris 
(75013), France 
Background: High fibrinogen level after balloon percutaneous coronary intervention 
(PCI) is a” independent predictor of angiographrc restenosis (AR). However, precise tim- 
ing of the fibrinogen (Fg) increase during the B-month follow-up (FU), the role of stent 
implantation and the relation of fibrinogen to clinical restenosis (CR) remain to be estab- 
lished. We studied 205 consecutive patients who underwent elective balloon-PC (n = 
157) or stent-PC1 (“~58). Plasma Fg level was measured immediately before, 2, 15, 60, 
120 and 180 days after PCI. CR was defined as the composite triple endpoint of death, 
myocardial infarction (Ml) and any repeat revascularization (PC1 or CABG)within 6 
months. In patients with a” event during the S-month FU period, the last Fg concentration 
measured before this event was considered as the final level. CR occurred in 31% and 
29% of the patients without and with stent implantation, respectively (p=ns). Similarly, AR 
did not differ significantly between balloon-PCI and stented patients (47% vs 41%, p=ns). 
Fg level increased abruptly in all patients 48 hours after PCI (3.17kO.08 vs 4.OO-cO.07, 
basekne vs 48 hours, respectively, p<O.OOi), reflecting the inflammatory state and then 
decreased progressively during the 6-month FU. Persistent high Fg levels -at late FU 
identified patients at risk for AR (2 99+0.09 vs 3.41tO.i I for patients without and with 
AR, p<O.OOl), especially if stent was implanted (2.91+0.13 vs 3.75i-0.22 for patients 
without and with AR, p<O.OOi). More interestingly, persrstent high Fg levels identified 
patients at risk for CR in the whole population (3.12+0.07 vs 3.40+0.12, for patients with- 
out and with CR, p = 0.02) and in stented patients (2.97*0.11 vs 3.75?0.2’2, for patients 
without and with CR, p<O.OOl). In a multiparametric analysis, CR in patients without stent 
implantation was related to recurrent angina, a posrtive stress test and the number of 
dilated sites. I” patients wrth implanted stents, the final Fg level had the same positive 
predrctive value as recurrent angina and a positive stress test. Conclusion: The time- 
course of Fg levels is a marker of both AR and CR in patients who undergo PCI. This 
marker is especially relevant to predict in-stent CR. 
828-4 
2:45 p.m. 
Insertion/Deletion Polymorphism of Angiotensin I- 
Converting Enzyme Gene and Risk of Restenosis After 
Directional Coronary Atherectomy Followed by Stent 
Implantation 
Massimiliano Gnecchi, Maurizlo Ferrario, Alessandra Repetto, Umberto Canosi, Ezio 
Bramucci, Luigi Angoli, Maria Luisa Laud&, Francesco Bernardi, Piera Angelica Merlini, 
Diego Ardissino. IRCCS, Policfinico S. Matfeo, Pavia, /fa/y, Department of BioChemiSfry 
and Molecuiar Biolcgl: University of Ferrara, Ferrara, lfaiy 
Background: The renin-angiotensin system is involved in neointlmal hyperplasia in 
response to arterial injury. The insertion/deletion (l/D) polymorphism of the enzyme gene 
largely controls angiotensin converting enzyme (ACE) plasma level, and it has been 
observed that D allele is associated with restenosis after coronary stenting. However, 
plaque remodelling, vessel tearing at the edge of the stent and longitudinal redistributing 
of plaque could remain important determinants of restenosis after PTCA and stent 
implantation; debulking prior stenting eliminates these factors, leaving neointimal hyper- 
plasia as the major mechanism of restenosis. Directional coronary atherectomy (DCA) 
followed by stent implantation therefore represent an ideal model to investigate the rela- 
tionship between ACE l/D polymorphism and restenosis. Methods: We prospectively 
evaluated 113 consecutive patients (102 male, 90%; mean age 57+/- 9 years) who 
underwent successful (residual stenosis ~50%) DCA followed by stent implantation for 
de nova coronary lesion. Angiographic criteria for enrolment include significant stenosis 
(>75%, ~100%) of a tnon-tortuous native vessel with a reference diameter >2.5 mm and a 
lesion length <15mm. Genomic DNA was prepared from peripheral blood leukocytes and 
analysed by means of PCR amplification. Baseline, post-DCA, post-stent and follow-up 
angiograms, performed after 6-12 months, were quantitatively analysed. Subject were 
divided into three groups according to the genotype (DD, ID, II). Results: No significant 
differences were observed among the three groups in terms of acute, late loss, net gain 
or percent of patients developing angiographic restenosis. Conclusions: Our data indi- 
cate that ACE I/D gene polymorphism is not assiciated with the risk of developing rest- 
enosis in a model of plaque debulking plus stent deployment. 
828-5 
3:00 p.m. 
Incidence and Predictors of Total Occlusion Following 
Coronary Stenting 
Pinak B. Shah, Richard E. Kuntz, Kalon K. L. Ho, Elizabeth M. Helper, David R. Holmes, 
Jr.. Brigham and Women’s Hospital, Boston, MA, Mayo Clinic and Mayo Foundation, 
Rochester, MN 
Background: The incidence and predictors for the development of in-stent restenosis 
after coronary stenting have been previously reported, but the incidence and predictors 
for total occlusion (TO) following elective stent placement are not known. Methods: We 
reviewed three randomized stent-versus-stent trials and one stent registry to assess the 
incidence of TO following coronary stenting in 955 coronary lesions with six-month angio- 
graphic follow-up. Angiographic endpoints were determined by an independent core 
quantitative coronary angiography laboratory and were obtained pre-procedure, immedi- 
ately post-procedure, and six months post-procedure. Srepwise multiple logistic regres- 
sion was used to assess the independent determinants of TO. Results: Fifteen of the 
955 stented lesions resulted in TO at six-month follow-up for an incidence of 1.57%. 
Stenting for prior non-stent restenosrs (fxO.001) was a srgnificant clinlcal predictor of TO, 
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whereas diabetes mellitus, female gender, older age, stenting of the left anterior 
descending artery, and stent type were not found to be clinical predictors. Smaller refer- 
ence vessel size (p=O.OZ), longer lesion length (p<O.OOi), smaller pre-procedure mini- 
mum lumen diameter (MLD) (p=O.O04), longer stem length (p<O.OOi), smaller post- 
procedure in-lesion MLD (p=O.O36), and smaller post-procedure in-stent MLD (p=O.O06) 
were significant univariable angiographic predictors of TO. Stepwise multiple logistic 
regression analysis of the univariable clinical and anglographic predictors demonstrated 
that stenting for prior non-stent restenosis (p=O.O04), longer stent length (p<O.OOl), and 
smaller pre-procedure MLD (p=O.OlZ) were the independent predictors of TO. Conclu- 
sion: The incidence of total occlusion six months following coronary stenting is low 
(1.6%). Our analysis suggests that prior non-stent restenosis, small pre-procedure mini- 
mum luminal diameter (which likely inversely reflects the degree of plaque mass), and 
use of long stents are independent determinants of total occlusion. Other risk factors typ- 
ically predictive of in-stent restenosis were not found to be predictors of total occlusion 
following coronary stenting. 
828-6 
3:15 p.m. 
Patient Rather Than Lesion Specific Predisposition for 
Restenosis 
Leslie Cho, Stephen G. Ellis, Derek P. Chew, Eric J. Topol, Marc S. Penn. The Cleveland 
Clinic Foundation, C/eve/and, OH 
Background: There has been much interest in possible genetic predisposition to rest- 
enosis. However, there have been few studies in the current era of stents and Ilb/ llla 
inhibition addressing possible intrapatient correlation of restenosis. We hypothesized that 
if specific patients had a predisposition to restenosis then restenosis in Type C lesion 
would be associated with an increased likelihood of resienosis in Type A lesion in the 
same patient. Methods: Using The Cleveland Clinic Foundation Interventional Database 
from 1996-1999, we identified patients who underwent multivessel intervention with stent 
and abciximab who had follow-up catheterization based on clinical indications. Analyses 
were performed to determine if restenosis in individual vessels was a random event or 
clustered within specific patients. Results: We identified 163 patients who underwent 
multivessel intervention and at ?.ome later date had at least diagnostic coronary angiog- 
raphy. There were 962 lesions treated with an overall restenosis rate of 45.7%. Average 
number of vessel treated were 5.6. We divided patients into three groups: Group 1 (n=69, 
42%): no restenosis in any vessel, Group 2 (n=37, 23%): all vessels had restenosis, or 
Group 3 (n=57, 35%): some vessels restenosed. Demographic and lesion characteristics 
were well matched between the groups. Multivariate analysis based on individual lesions 
demonstrated that the only predictors of restenosis were diabetes (FR1.57) and ACCI 
AHA lesion scores (compared to type A lesions RR: Bl:i .70; 621.64; C: 1.92). However, 
the strongest predictor of restenosis in type A lesions in this population was restenosis in 
the type C lesion (RR 13.1 95% Cl: 6.89. 25.0), followed by lesion length (RR:1.14, 95% 
Cl 1.0-1.3). Conclusion: These findings strongly suggest patient rather than lesion spe- 
cific risk for restenosis, and highlight the influence of genetic factors for modulating 
response to vascular injury. 
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829 Carotid Intervehions I 
Monday, March 19, 2001, 2:00 p.m.-3:30 p.m. 
Orange County Convention Center, Hall F4 
2:00 p.m. 
829-l Carotid Stent-Supported Angioplasty With Distal Neuro- 
Protection Using the GuardwireTM: 30-day Results From the 
Carotid Angioplasty Free of Emboli (CAFE-USA) Trial 
Gary S. Roubin, Roxana Mehran, Edward Diethrich, Lowell F. Satler, Patrick Whitlow, 
Takao Ohki, Lee Guterman, Subbarao Myla, Hassan Faraj, Gishel New, Sriram lyer, 
Martin B. Leon. Lenox Hi// Heart and Vascular institute, New York, NY 
Surgical and interventional carotid revascularization may be complicated by major or 
minor neurologic events due to peri-procedural distal embolization of lesion-associated 
debris. Clinical application of novel guide wire based distal neuro-protection systems 
may reduce embolization and resultant neurologic sequelae. 
Methods and Results: The PercuSurge GuardwireTM system (PGS) consist of a short, 
compliant occlusion balloon (5.5 and 6.0 mm diameters) mounted on a guide wire 
(0.018”) which is inflated distally allowing “protected” carotid intervention, followed by 
aspiration of liberated embolic debris. The CAFg-USA trail is a phase one, 7.center, IOO- 
patient registry to assess feasibility, safety and efficacy of PGS in symptomatic and 
asymptomatic patients undergoing carotid Wallstent therapy. At present, 70 pts are 
enrolled with following characteristics: 64% male, mean age 71 years (16% > 80 years), 
56% symptomatic, 67% contralateral carotid disease, and mean lesion length of 13 mm. 
The PGS was successfully delivered across the lesion site in all patients and prolonged 
distal occlusion (mean time 12.5 min, range 3.4 -35.6 mins) was well tolerated; 5 pts 
require sequential two-steps distal occlusion during problematic stent deliveries. Macro- 
scopic debris were aspirated in all patients and sent for analysis. There were three pro- 
cedure-related neurologic events (4.3%); an ipsilateral retinal artery embolus, a minor 
stroke in apt with prolonged occlusion (18.1 mins) that required an additional stenting for 
adequate lesion coverage (without PSG neuro-protection), and a minor stroke in pt after 
prolonged hypotension. Another pt experienced post-procedure hyper-perfusion syn- 
drome, resulting intra-cerebral hemorrhage and death. At 30.days there were 2 non-neu- 
rologic deaths; no repeat revascularization procedures were required. Conclusion: 
Neuro-protection using PSG during carotid stenting is technically feasible, well tolerated, 
and removes lesion-associated macroscopic debris. PGS efficacy in preventing proce- 
dural neurologic complications will require a larger comparative clinical trial. 
829-2 
2:15 p.m. 
Comparison of Carotid Stenting With and Without Cerebral 
Protection Versus Carotid Endarterectomy in a Single- 
Center Experience 
Edward B. Diethrich, Julio Rodriguez-Lopez, Venkathesh Ram&h, Dawn Olsen, 
Charles Thompson, Leanne D’Mugno. Arizona Heart Institute and Hospital, Phoenix, AZ 
Background: Carotid stenting is being evaluated as an alternative to surgery for primary 
carotid occlusive disease, but neurological complications are a concern. Carotid stenting 
procedures with and without cerebral protection were compared io concurrent carolid 
endarterectomy cases at a single center. Methods: Between June 1998 and August 
2000, 90 consecutive patients received carotid stents, 40 with the PercuSurge protection 
balloon (group 1) and 50 without cerebral protection (group 2). During the same period, 
100 consecutive carotid endarterectomies (group 3) were performed. Periprocedural 
complications (death, transient ischemic atiack, cerebrovascular accident, nerve injuries, 
bleeding, myocardial infarction, bradycardia) and outcomes were analyzed. Results: 
Patients were similar with regard to gender, risk factors, and lesion morphology. Four 
(4.4%) deaths occurred among the stent pattents (1 protected, 3 unprotected) versus 0 in 
the surgical cases. There were significantly more complications in the stent patients than 
the surgical cohort (P=.OO77), particularly in the unprotected group, which had the high- 
est incidence of neurological events (22%, P=.OOO2). Bradycardia during inflation of the 
protection balloon was a common and sometimes severe (5%) phenomenon in group 2 
patients. 
Grout 1 Group 2 All Steni Group 3 
Pro&ted Unprotected Cases (n = Surgery@ 
(n = 40) (n = 50) 90) = 100) 
Transieni ischemic attack (TIA) 2 (5.0%) 5 (10.0%) 7 (7.8%) 1 (1%) 
Cerebrovascular accident (CVA) 3 (7.5%) 6 (12.0%) 9 (10.0%) 2 (2%) 
TIA+CVA 5 (12.5%) 11 (22.0%) 16 (17.8%) 3 (3%) 
Death 1 (2.5%) 3 (5.0%) 4 (4.4%) 0 
Conclusion: Unprotected carotid stenting demonstrated overwhelmingly high neurologi- 
cal sequelae rates in this study and should be seriously reconsidered as a treatment 
option for carotid stenosis. Protective devices seem to decrease the incidence of neuro- 
logical events, but only experienced interventionists should employ this technique. 
Although refinement of the protection device could play an important role in the future, 
the use of carotid stenting for the treatment of primary carotid disease is still a concern. 
Endarteredomy remains the first choice therapy. 
829-3 
2:30 p.m. 
Balloon-Protected Carotid Artery Stenting: Maximum Area 
of Captured Particles Predicts Periprocedural Neurological 
Complications 
Thilo Tuebler, Michael Schlueter, Horst Sievert, llka Boesenberg, Eberhard Grube, 
Juergen Waigand, Olaf Dirsch, Joachim Schafer. Center for Cardiology: Angiologyand 
Vascular Intervention, Hamburg, Germany 
With the intention to prevent embolic complications during carotid artery stenting (CAS), 
temporary distal balloon occlusion of the targeted artery with subsequent aspiration of 
the banked-up volume of blood is increasingly being used during the intervention. Meth- 
ods: Balloon-protected CAS (“GuardWire” system, PercuSurge, Inc.) was performed in 
70 consecutive pts (56 m, 14 f; 70 f 9 years). Blood was aspirated after stent placement 
(mostly Carotid Wall), filtered through a 40 pm mesh and subjected to histologicallcyto- 
logical analysis in 54 pts (77%) with a total of 58 lesions treated. Included in this analysis 
were only’“relevant” particles which were clearly identified upon microscopic examination 
as plaque, organized thrombus or fibrin and whose area exceeded 10,000 square pm 
(0.01 sq mm). Results: No relevant particles were found in the aspirate retrieved from 101 
58 procedures (17%). The remaining 48 aspirates contained between 1 and 32 particles 
(median 6), with a median maximum diameter of 592 pm (range 130-7,301 pm) and a 
mean maximum area of 107,676 sq vrn (range 14,589.2,987,993 sq pm). Three (5.6%) 
of the 54 pts experienced periprocedural neurological complications (1 TIA, 1 PRIND. 1 
stroke). In these, the number of particles, maximum diameter and maximum area were 
all significantly larger than in pts without periprocedural neurological complications (for 
medians and ranges see Table). Multiple regression analysis revealed maximum particle 
area as highly predictive of complications. However, no correlation with lesion morphol- 
ogy could be established. Conclusions: Balloon-protected CAS enables the capture and 
analysis of debris released from the lesion during treatment. Pts in whom the aspirate 
contained both > 9 particles and particles of an excessively large area are prone to 
periprocedural neurological complications, suggesting that particles are released after 
withdrawal of the protection system. 
Comulication No comulication D 
#Of !eslons 3 45 
# of particles 18 (10-24) 5 (l-32) 0.015 
Max. diameter (urn) 2,649 (1,725.7,301) 584 (130.2,846) 0.009 
Max. area (sq pm) 1,844,541 (811,506- 102,852 (14,589. 0.005 
2,987,993) 834,686) 
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829-4 Stent Supported Carotid Artery Angioplasty. The Beneficial 
Effect of Cerebral Protection 
Michel Henry, Christos KLONARIS, Max AMOR, lsabelle HENRY, isabelle MASSON, 
Bernard FOLIGUET, Serge KOWNATOR, Franco~s LUIZY, Edmond LE BORGNE. 
Michele HUGEL. fo/yc/ini9ue d’Essey-/es-Nancy ESSEY-LES-NANCY; France 
Purpose: To prospectively evaluate the safety and efficacy of a new cerebral protection 
technique during stent supported carotid angioplash/ Methods: 164 protected interven- 
tion& procedures with the PercuSurgeTM dewce were attempted in 148 high-risk 
patients (males 116, mean age : 70.5 rt 9.2 y). The mean percent stenosis was 81.7 2 9.2 
and mean lesion length was 14.6 f 6.2 mm. 83 palients were symptomatic (51%). Con- 
tralateral carotid artery was ?&nosed in 34 and occluded in 8 patients. The protection 
dewe consists of a GuardwireTM with a protection balloon incorporated into its distal 
segment and placed distal to the Iwon. The proximal end of the wire incorporates a 
MicrosealTM allowing infiatlon and deflation of the occlusion balloon utilizing a Microse- 
alTM adapter. Angioplasty and stenting are performed under cerebral protection. The 
dilated area is cleaned using an aspiration catheter advanced over the wire, and or by 
flush through the QUidlng catheter, driving the flow towards the ECA. Results: Immediate 
technical success was 99.4%. Carotid flow occlusion was well tolerated in 156 
cases(95.1%). Mean cerebral flow occlusion time was 422 set (125.1479 set). Micrb- 
scopic analysis of the aspirated blood showed different types of particles with mean 
diameter of 250fim. Three periprocedural neurological complications (1.8%) occured one 
ischemlc major stroke, one TIA and one intracerebral hemorrhage. One patient died 3 
weeks after the procedure from unrelated cause. Conclusion: Cerebral protection with 
the PercuSurge GuardwireTM device during stent-suported carotid angioplasty safe and 
effective in protecting the brain from embolic events. It could widen the indications for 
percutaneous procedures in the carotid territory. 
829-5 
3:oo p.m. 
Approach to Carotid Stenosis in Patients Undergoing Open 
Heart Surgery: Stenting or Endarterectomy? 
Khaled M. Ziada, Samir R. Kapadia, Deepak L. Bhatt, Irving Tiong, Fernando A. Cum 
Stephen D. Samples, Kathy Hughes, Derk L. Krieger, Eugene Blackstone, Patrick L. 
Whiilow, Jay S. Yadav. Cleveland Clinic Foundation, Clew/and, OH 
Background: Patients in need of carotid and open heart surgery (OHS) in whom the risk 
of non-cardiac surgery is particulary high are often treated by combined carotid endarter- 
ectomy (CEA)+OHS. However, this combined CEA+OHS approach still has significant 
risks. We explored the role of carotid stenting (CS) prior to OHS as another therapeutic 
option in this patient population. Methods: Patients were evaluated by cardiac and vas- 
cular surgeons. Only patients at a prohibitive risk for CEA undewent CS. Over 3 years, 
CS->OHS was performed in 51 and CEA+OHS in 92 patients. Baseline characteristics 
were compared. Adverse events in the form of stroke. MI, or death were followed from 
the time of CS and up to 30 days post-OHS. Results: Pawants in the CS->OHS group, 
had a higher prevalence of Severe co-morbid conditions. Despite their higher risk profile, 
CS->OHS patients had fewer adverse events (table). 
CS -> OHS CEA + OHS p value 
Baseline Characteristics 
Age (years) 70 +I- II 67+/- 10 0.16 
Male Gender 31 (61%) 60 (65%) 0.58 
Diabetes 36 (71%) 54(59%) 0.16 
Unstable Angina 32 (63%) 17 (19%) <0.0001 
Poor LV function (EF 125%) 6 (12%) 4 (4%) 0.09 
Severe Valvular Aortic Stenosis 12 (24%) 9(10%) 0.03 
Adverse Events 
Peri-Operative MI (CK-MB>100) 4 (8%) 13(14%) 0.27 
Stroke 1 (2%) 6 (7%) 0.22 
Death 2 (4%) 8(9%) 0.11 
Adverse Events 7 (14%) 27 (29%) 0.04 
Conclusions: Carotid stenling followed by OHS is associated with fewer complications 
than CEA+OHS. In a randomized study, this approach may prove to be the treatment of 
choice in patients with severe carotid and cardiac disease. 
3:15 p.m. 
829-6 Immediate Neurovascular Rescue for Stroke Complicating 
Invasive Coronary Procedures 
Nadim Al-Mubarak, Jiri J. Vitek, Sriram S. lyer, lssam Mousa, George Dangas, New 
Gishel, Martin B. Leon, Gary S. Roubin. The Lenox Hi// Heart and Vascular Institute and 
the CardioVascular Research Foundation, New York, NY 
Background. Stroke complicating invasive coronary procedures represents a unique 
opportunity for immediate neurovascular intervention due to the short event-to-interven- 
tion time. We report the feasibility of “Neuro-rescue” for the management of such compli- 
cations In the cardiac catheterization laboratory. 
MethodsBetween January 1998 and September 1999, a total of 7 patients developed 
acute major stroke during an invasive coronary procedure (0.07% of all cases) and 
underwent Neuro-rescue (i.e. immediate cerebral angiography with subsequenl percuta- 
neous revascularization). We report the immediate and follow-up outcome of these 
cases. Results. Patients were 5 men and 2 women; the mean age was 70i10 years. 
Stroke occurred during diagnostic catheterization in 5 patients, during coronary angio- 
plasty in 1 and during direct myocardial revascularizatlon in 1 patient. Atrial fibrillation 
was presumably the cause in 1 patient 25 minutes after completion of coronary angiogra- 
ACCIS2001 (Angiography & Interventional Cardiology) 39A 
phy (while patient was in the recovery area of the laboratory). The mean time from event 
to intervention was 18 * 14 minutes. The right middle cerebral artery (MCA) was be 
totally occluded in 5 patients and the left MCA in 2 patients. A combination of balloon 
angioplasty (all patients), fibrinolytics (6 patients) and platelet glycoproteln llbillla inhibl- 
tars (4 patients) was used. Successful recanalization (residual stenosis of 5 30%) was 
achieved in all 6 patients. Complete neurological improvement occurred immediately 
after Neuro-rescue in 4 patients and withln 60min from Neuro-rescue in 1 patient (i.e. in a 
total of 5 of the 7 stroke patients, 71%). Follow-up at a mean of 2?3 months is awlable 
on 3 of these 5 patients: all 3 patients remained asymptomatic without recurrent events 
or repeat procedures. Two (including the failed procedure) of the 7 stroke patients 
showed no clinical improvement one progressed into coma and expired 3 days later 
from intra-cerebral hemorrhage, while the status of the other remained unchanged. Con- 
clusion lmmedlate neurovascular rescue by experienced operators appears to be a valid 
treatmeni optionfor acute major stroke complicating cardiac procedures in the catheter- 
ization laboratory 
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1155-9 C Reactive Protein Has No Prognostic Impact on 
Thrombotic Events and Target Lesion Reintervention Rate 
After Coronary Stenting 
Bruno Schelier, Benno Hennen, Torsten Markwtrth, Hans-Peter Stall. Unwersityof 
.%&and, Internal Medicine 111, Homburg / Saar, Germany 
Background: By promoting inflammaiion and thrombosis, circulating levels of C-reactive 
protein (CAP) constitute an independent risk factor for cardiovascular disease. The aim 
of the present study was to investigate the association of CRP with the clinical outcome 
after coronary stenting. Methods and patients: We prospectively included 1058 consec- 
utive patients undergoing intracoronary stent implantation at our institution. Blood sam- 
ples were taken immediately before the interventional procedure through the sideport of 
the arterial sheath. Patients were divided in two groups: group I included patients with cir- 
culating CRP levels ~10 mgil (n=799), group II patients with CRP levels of >lO mg/i 
(n=259). There were no differences in baseline da?a between the two groups except age 
(64+10 years in Qroup I vs 66*10 years in group II, p=O.Ol) and the prevalence of acute 
myocardial infarction (3.6% in group I vs 8.9% in group II, p=O.Oi). All patients were 
treated with aspirin and clopidogrel over 4 weeks. Results: The incidence of acute and 
subacute stent occlusion within 30 days was equal in both groups (51799 [0.6%] in group 
I vs 2/259 (0.8%] in group II, ns). There was no influence on target lesion rein@rvention 
rate <I2 months (9.4% I” group I vs 7.7% in group II, ns). Mortality rate ~12 months was 
significantly higher in patients with CRP levels >I0 mgil (0.8% in group I vs 5.4% in group 
II, p=O.Oi). Conclusion: In clinical routine with platelet inhibition using aspirin and clopi- 
dogrel, CRP has no prognostic impact on thrombotic events and target lesion reintewen- 
tion rate after coronary stenting. Elevated CRP levels seem to be associated wth a 
higher mortality rate. 
1155-l 0 In-Stent Restenosis: Predictors of Subsequent Target 
Lesion Revascularization After Repeat Intervention 
Thosaphol Limpijankit, George W. Vetrovec, Michael J. Cowley, Walter N. Malloy, 
Evelyne Goudreau. Medical College of Virginia Campus of Virginia Commonwealth 
University Richmond, VA 
Background: Recurrent in-stent restenosis (ISR) remains the major IImitation of coro- 
nary stems with a wide range of restenosis (30.80%). The purpose of this study was to 
identify predictive variables related to subsequent target lesion revascularization (TLR) 
after repeat intervention 
Methods: One hundred and fourteen ISR lesions in 109 patients who underwent repeat 
percutaneous coronary intervention (PCI) for ISR were prospecfively analyzed to identify 
any possible clinical, anQiOgraphiC, procedural and CICA predictive variables for subse- 
quent TLR. The choice of intervention was left at the operator’s discretion and included 
debulking (RA or ELCA) before balloon angioplasty 55% (63/l 14), POBA 34% (39/i 14). 
and additional stenting 14% (17/114). Adjunct use of Abciximab (ReoProTM) was 9% (lo/ 
114). 
Results: Mean follow-up time was 251 f 214 days. Fifty-three percent of the patient (491 
109) had unstable angina and one patient developed myocardial infarctron. Angio- 
graphic follow-up was available in 46% (521114). Angiagraphic recurrent ISR rate was 
observed in 57% (30/52). Overall, TLR rate was 26% (30/l 14). Univariate predictors of 
TLR were female (64% vs. 34%, P=O.Ol), diabetes mellitus (57% vs. 27%, P=O.OZ), long 
ISR lesion length (16.4212.6 vs. 13.0*11.9. P<O.OOS), and lower stenVlesion length ratio 
(2.0il.5 vs. 2.9k2.6, P=O.O2). On multivariate logistic regression analysis, only diabetes 
mellitus (OR 2.59, 95% Cl 1.06-6.33; P=O.O3), and long ISR lesion length (OR 0.95, 95% 
Cl 0.92-0.98; P=O.Ol) were independently predictors of TLR. Shorter time interval for 
ISR (203+212 days vs. 24&2282 days), higher incidence of dlffuse-pattern ISR (66% vs. 
43%), higher percent of debulklng treatment (74% vs. 49%): and smaller post-rePTCA 
MLD (2.3+0.3 mm vs. 2.6& 0.6 mm) had trend towards correlating with TLR. 
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Conclusion: Diabetes mellitus and long in-stent restenotic lesion are independent pre- 
dictors of TLR after repeat PCI for ISR. These predrctive variables may help to identify 
patrents that could potentially benefit from different treatment modalittes including intrac- 
oronary brachytherapy. 
1155-11 Minor Myocardial Injury After Elective Uncomplicated 
Successful Percutaneous Transluminal Coronary 
Angioplasty With or Without Stenting: Detection by Cardiac 
Troponins 
the restenosis group than in the no restenosis group (50 vs. 22%, P=O.Ol). 2) The levels 
of sCDl4 were significantly higher in restenosis group (3.8 r 0.5 vs. 3.4 i 0.6 pgiml, 
P=O.O07). 3) The concentrations of sCD14 were significantly higher in TIT homozygotes 
(T/T: 3.7 f 0.6, CfT 3.6 * 0.6, C/C: 3.2 ? 0.8 pg/ml, P=O.O07). 4) After adjustment for 
confounding factors, Ti7 homozygotes was an independent predictor for m-stem resteno- 
sis. Conclusions: This study demonstrated that CD14 promoter polymorphism was 
related to the concentrations of sCDl4 and in-stent restenosis. This polymorphism 
appears to be linked to activation of monocytesimacrophages and it may be one of the 
genetrcal risk factors for in-stem restenosis. 
Salam M. Saadeddin, Moh’d A. Habbab, Samia H. Sobki, Gordon A. Ferns. 
Riyadh Armed Forces Hospital and Prince Sultan Cardiac Center, Riyadh, Saudi Arabia 
School of Biological Sciences, University of Surrey Gufldford, United Kingdom 
Background: Cardiac troponins are sensitive and specific markers for the detection of 
minor myocardial injury. However. they have been rarely used to monitor myocardial 
injury after coronary stenting. The purpose of the study was to measure cardiac troponin 
I (cTnl) and cardiac troponin T (cTnT) levels after elective uncomplicated successful per- 
cutaneous transluminal coronary angioplasty (PTCA) with or wtthout coronary stenting 
and to compare their results with serum creatine kinase MB isoenzyme (CKMB). Meth- 
ods: CTnl and cTnT levels were compared with those of CK or CKMB in 98 consecutive 
patients with stable angina undergoing elective uncomplicated successful PTCA with 
stenting (n =71) or without stenting (n = 27). Markers were measured before and 6, 12, 
24, and 48 hours after the procedure. Peak postprocedural levels for each marker were 
compared and related to angiographic and procedural characteristics as well as to the 
occurrence of side-branch occlusion. Results: None of the patients had abnormal mark- 
ers before the procedure Abnormal postprocedural values of one or more markers were 
observed in 28 patients (29%) 23 after stenting and 5 after PTCA alone. The frequencies 
of abnormal cTnl and cTnT levels were significantly higher than that of CKMB after coro- 
nary intervention (26% and 18% vs 7%; p = 0.00016 and 0.015, respectively), with cTnl 
being the most significant. When compared with troponin negative patients, abnormal 
cardiac troponin values were significantly related to total time of inflation (223 ? 128 vs 
170 t 105 set; p = 0.008) and inflation maximal pressure (12.9 i 2.3 vs 12.0 ? 2.7 atm; p 
= 0.04). Small side-branch occlusion was noticed in 36% of the troponin positive patients 
and in 6% of the troponin negative group (p = 0.00047). Conclusions: Minor myocardial 
injury is not uncommon after elective uncomplicated successful PTCA with or without 
stenting. Cardiac troponins, especially cTnl, are more sensitive than CKMB for the detec- 
tion of this minor myocardial injury. Total time of inflation and inflation maximal pressure 
are predictors of postprocedural elevation of cardiac troponins. Side-branch occlusion 
may account for some, but not all, periprocedural minor myocardial injury. 
1155-12 Potential Usefulness of CDllaKD18 for the Prognosis of 
Restenosis After Stent Implantation 
Rainer J. Zotz, Kazem Rahimi, Holger Maerz. Leipzig University Heart Center, Leipzig, 
Germany 
Despite of the progress in coronary stem implantation, clinical suc~e~s is still limited by 
the incidence of restenosis. Previous clinical studies have shown increased activation 
levels of adhesion molecules on leucocytes in patients with restenosts. We wanted to 
know if adhesion molecules directly correspond to restenosis and subsequently can be 
used for the prediction of restenosis before primary stem implantation. Therefore, we 
investigated L-selectin (CD62L), LFA-1 (CDllalCD18), Mac-l (CDllblCDlS), ICAM- 
&X54) and MHC II (HLA-DR) in 31 patients before angiography and compared the 
results to those of a group of healthy volunteers. From 15 patients with a stem implanta- 
bon after angiography, 4 developed a restenosis 4 weeks after stem implantation. In 
addition, 9 patients exhibited a significant progress rn their coronary artery disease. 
While CDllaICD18 was significantly increased on neutrophils and monocytes in all 
patients developing restenosis after implantation, no correlation was found among 
CD62L, CD54 and HLA-DR. The level of CD1 1 b/CD1 8 on neutrophils and monocytes 
was also increased but not significantly. In addition, patients with progress in their coro- 
nary artery disease also showed a signtficantly increased level of CD1 la/CD18 on neu- 
trophils and monwytes. Thus, restenosrs and progress of coronary sclerosis might share 
some processes in the activation of monocytes and neutrophils within the coronary circu- 
lation. Our preliminary results indicate the potential usefulness of CD1 la/CD18 and prob- 
ably CD1 1 b/CD18 as predictors of restenosis before stent implantation 
1155-13 Common Polymorphism in the Promoter of the CD14 
Monocyte Receptor Gene Is the Predictor of Restenosis 
After Elective Coronary Stenting 
Kazunori Shimada, Katsumi Miyauchi, Hiroshi Mokuno, Yoshiro Watanabe, Takeshi 
Kurata, Hitoshi Sate, Satoshi Ohashr, Eriko Seki, Yoshitaka Iwama, Hiroyuki Daida. 
Juntendo University Tokyo, Japan 
Background: &stenosis remains a major clinical problem of coronary angioplasty. 
Monocyteslmacrophages play an important role in the initiation and development of ath- 
erosclerotic process. After coronary intervention, numerws cytokines and growth factors 
produced by macrophages, participate in restenosis process. It is known that monocytes 
are activated by lipopolysaccharide (LPS) via CD14. Recently, It was reported that CD14 
promoter polymorphrsm affects the levels of receptor density. We hypothesized that rest- 
enosis may be linked to CD14 promoter polymorphism associated with monocytesimac- 
rophages activation. Methods: We included 130 consecutive patients undergoing 
elective coronary stenting. We assessed C(-260)T polymorphism in the promoter of the 
CD14 monocyte receptor gene by PCR-RFLP method, and soluble CD14 (sCD14) by 
ELISA at baseline. Follow-up angiography was performed at 6 months after coronary 
stenting. Restenosis was defined as more than 50% stenosis at folloti-up study by quan- 
titative coronary angiography. Results: 1) Genotype distributions conformed to Hardy- 
Weinberg expectations. The frequency of T/T homozygotes was significantly higher in 
1155-14 Glycoprotein la C807T Polymorphism and Risk of 
Restenosis Following Coronary Artery Stenting 
Nicolas “on Beckerath, Werner Koch, Julinda Mehilli, Corinna Biittiger, Siegmund Braun, 
Albert Schomig, Adnan Kastrati. Deutsches Herzzentrum, Munich, Germany 
Background: Platelets are thought to contribute to the formation of restenosis after par- 
cutaneous coronary interventions. The glycoprotein (GP) la/ha complex is an important 
platelet collagen receptor. It has been shown that surface expression of GP laflla is influ- 
enced by two linked, single nucleotide polymorphisms (C807T and G873A) in the GP la 
gene. Stem-induced vessel wall injury allows platelet-collagen interaction. Methods: 
1769 consecutive patients with coronary artery stent placement were genatyped for GP 
la C807T polymorphism with PCR and fluorogenic probes. Follow-up angiography was 
scheduled 6 months following stent implantation and was available tn 82.4% of the 
patients. I-year clinical follow-up was available in all patients. This included recording of 
death, nonfatal myocardial infarction (Ml) and reintervention. Results: The genotype dis- 
tribution was 35.8% CC, 47.6% CT and 16.6 % TT and conformed to Hardy-Weinberg 
equilibrium. Restenosis (diameter stenosis > 50% at follow-up angiography) occurred in 
32.9% of CC, 31.5% of CT and 32.1% of TT patients (P=O.87). Follow-up clinical results 
are displayed inthe table. 
cc CT TT P 
Death,% 1.6 1.5 2.4 0.60 
Nonfatal Ml,% 1.6 1.5 1.7 0.95 
Reinterventron,% 20.2 19.7 19.1 0.93 
Any event,% 21.6 21.7 21.2 0.98 
Conclusion: Carriage of the GP la T807 allele is not associated wrth an mcreased risk of 
restenosis or unfavorable late outcome following coronary stenting. 
1155-15 C-Reactive Protein Serum Levels Are Elevated Even at 6 
Months Follow-Up in Patients With Stent-Restenosis 
Stefan Kriiger, Rainer Hoffmann, Philipp Haager, Jiirgen vom Dahl, Peter Hanrath. 
Medical Clinic I, University Clinic RWTH, 52057Aachen, Germany 
Background: Elevated postprocedural C-reactive protein (CRP) levels are a predictor of 
restenosis after coronary stem placement. Whether CRP-levels remain elevated even 6 
month after stem placement in patients (pat) with restenosis is unknown. Methods: We 
prospectively studied 126 pts (59 ? 9 years, 25 women) who were successfully treated 
with coronary stenting (ACS and Inflow etents). Angiographic follow-up at 5.6 2 1.3 
months was available in 114 pts. 55 pts had i-vessel-, 43 pts P-vessel- and 16 pts 3-ves- 
sel-disease. Stems were implanted in 43 pts with right coronary artery-, 50 pts with left 
anterior descending- and 21 pts with circumflex artery-stenosis. Venous blood samples 
were obtained the day before follow-up angiography and analyzed for CRP concentra- 
tion. CRP-values of > 5 mgll were considered abnormal. Angiographic restenosis was 
defined as > 50 % diameter by quantttative angiography. Results: By 6 months stent- 
restenosis occurred in 26 pts (23 %). 45 pts showed CRP-values > 5 mgil at follow-up. 
The incidence of abnormal CRP-levels was significantly higher in the restenosis group (p 
< 0.01). The negative predictive value of an elevated CRP-level for stemrestenosis was 
high (87%) whereas the positive predictive value was low (38%). 
” CRP < 5 mgil CRP > 5 mgil 
restenosis 26 9 (35%) 17 (65%) 
no restenosis 88 60 (68%) 28 (32%) 
Conclusions: Pts with stem-restenosts show a significantly higher incrdence of abnor- 
mal CRP-values even 6 months after coronary stenting. This suggests that pts with stent- 
restenosis exhibit a higher degree of persistent inflammatory cell activation. 
1155-l 6 Recurrence After Treatment of In-Stent Restenosis: Does 
Diabetes Impact Outcomes in Large Vessels? 
Milena G. Adamian, Roxana Mehran, Yoshio Kobayashi, George Dangas, Issam 
Moussa, Michael B. Collins, Lynn Glasser, Gishel New, Alexandra J. Lansky, Gregg W. 
Stone, Martin B. Leon, Antonio Colombo, Jeffrey W. Moses. Lenox Hi// Heart and 
Vascular Institute, Cardiovascular Research Foundation, New York, NL: Centro Cuore 
Columbus, Milan, /ta/y 
Background: Diabetes mellitus (DM) is a well recognized predictor of clinical and angio- 
graphic recurrence after treatment of in-stent restenosis (ISR). We examined the impact 
of DM on angiographic and clinical recurrence in 259 consecutive pts (355 lesions) 
treated for ISR in large vessels. 
Methods & Results: A total of 259 consecutive pts (355 lesions) treated for ISR with ref- 
erence vessel size > 2.75 mm were divided in 2 groups: DM (55 pts, 69 lesions) and 
Non-DM (204 pts, 286 lesions). There were no differences in baseline clinical, angio- 
graphic characteristics and reetenosrs type (focal/diffuse) between the groups. Among 
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DM pts, 20.6% required insulin therapy and 79.4% were on oral therapy. Clinical and 
angiographic follow-up at 15~12 months was available in 95% and 75% of the patients, 
respectively. 
DM ln=53 f&n!m (n=204) P 
RVD, mm 3.2+ 0.4 3.2f 0.3 NS 
Lesion Length, mm 14.9i 9.4 13.Oi 8.6 NS 
In-hospital MACE 1.8 0 NS 
W) 
Resienosis (%) 34.2 40.4 NS 
TLR (%) 28.3 30.6 NS 
MACE @FU (%) 32.6 31.9 NS 
MVD=multivessel disease: RVD=reference vessel diameter; TLR=target lesion revascu- 
larlzation; MACE=death, myocardial infarction and TLR 
Conclusion: Although diabetes meilitus is an important predictor of outcome after treat- 
ment of ISR, larger vessel size equalizes the risks between DM and non-DM patients. 
1155-19 Validation of a New Score System to Predict Major Adverse 
Cardiovascular Events During Coronary Stenting Using 
Two Large Databases 
David Paniagua, William K. Vaughn, Francisco Loper-Jimenez, Carolyne Ortiz, Ryan 
Lennon, David Holmes, William Weiniraub, David Fish. St. Luke’s Episcopal Hospital/ 
Texas Heart institute, Houston, TX, Brigham and Women’s Hospital, Harvard Medical 
School, and MAVERIC, Boston, MA 
Background: We developed a score to predict in-hospital major adverse cardiovascular 
events defined as death. stroke, acute myocardial Infarction, and urgent coronary artery 
bypass graft in relation to coronary stenting. We sought to validate this score using other 
large databases. Methods: The score was created based on beta coefficients from the 
logistic model of 5441 patients who underwent slent deployment at St Luke s Episcopal 
Hospital&x?& Heart Inslitute, Houston, between January 1994 and December 1998. 
The model assigned a score of -1 for previous coronary artery bypass graft, 1 for unsta- 
ble angina, 2 for urgent procedure, 2 for congestive heart failure, and 6 for shock. A 
score of -1 was associated with a major complication incidence of 0 05% and a score of 
1155-17 Angiotensin Converting Enzyme Genotyping and Coronary 
6, with a 60% incidence. Databases of Emory University Atlanta, and the Mayo Clinic, 
Restenosis 
Rochester, were used to valldate the model. The definition of major adverse cardiovas- 
cular complications and the time uenod studied were the same in all three databases. 
Henning Kelbeek, Erik Jorgensen, Steffen Helqvist, Jens Kastrup, Kari SaunamBki, Jan 
K. Madsen, Gunnar V. H. Jensen, Lene Kbvgaard, Henning Bundgaard, Oie Havndrup, 
Michael ChrisIiansen, Paal S. Andersen, Anton v. Weeri, Hans Reiber. Cardiac Cafh 
Lab, Rigshospihiet, Copenhagen, Denmark 
Background: Recent research in limited series of patients has indicated that presence 
of the deletion (D) rather than the insertion (I) allele in the gene coding for the angio- 
tensin converting enzyme (ACE) predisposes for resrenosis after coronary stent Impian- 
tation. This study evaluaies a possible connection between the ACE genotype and the 
frequency of coronary restenosis 10 a larger patlent material, and to identify subgroups of 
patients at higher risk within Ihe DD genotype. 
Methods: In 369 pailents (25% women, mean age 58 years) undergoing coronary 
angioplasty with stem implantation, genotyping was performed with an established poly- 
merase chain reaction technique. The frequency of the DD, Dl, and II genotypes was 
compared with tie occurrence of > 50% diameter stenosis within the stent evaluated 
angiographically by an independent blinded core lab. 
Results: One third of the patients had multivessel disease and 70% of the lesions were 
complex. There were no differences between Ihe 3 ACE genotypes with regard to age, 
gender, hypercholesterolemia, hypertension, diabetes, prior myocardial infarction or 
treatment with an ACE inhibltor. At 6 months the frequency of patients with restenosis 
was 16%, 1 l%, and 16% in the DD, DI, and II genotype groups, respectively (NS). A 
logistic regression analysis showed that lesion length, minimal lumen diameter after 
stenting and the presence of diabetes but not genotype were independent predictors of 
resienosis. Patlents treated with an ACE inhibitor was at higher risk of developing rest- 
enosis if they had ihe DD genotype (table). 
-ACE + ACE P 
inhibitor inhibitor 
DD, n=l04 Minimal lumen diameter, mm 2.21 1.63 0.03 
Diameter stenosis, % 24 46 0.003 
Restenosis x50%,% 12 40 0.006 
Dl, n=195 Minimal lumen diameter, mm 2.17 2.24 NS 
Diameter sienosis. % 27 29 NS 
Resienosis >50%,% 12 7 NS 
II, n=67 Minimal lumen diameter, mm 2.25 2.23 NS 
Diameter stenosis, % 27 32 NS 
Restenosis >50%,% 15 23 NS 
Conclusion: In general D/l ACE genotyping does not identify patients at higher risk of 
developing restenosis after coronary stent implantation. The higher risk of restenosis in 
DD patients on ACE inhIbitor treatment requires clarificafion. 
1155-l 8 AngiotensinConverting Enzyme Insertion/Deletion 
Polymorphism and Restenosis After Coronary Stenting: A 
Meta-Analysis 
Michael M Zhu, Mahmood Alam. Hal Chadow, Alan Feit. Luther T. Clark. SUNY Health 
Science Center. Brooklyn. NY 
Background: Little is known about ihe genetic risk factors for restenosis after coronary 
steniing (CS). While the anglotensin-converting enzyme (ACE) deletion (D) allele has 
been associated with the risk of restenosis after CS, different studies have generated 
conflicting data. To further axamlne the relation between ACE insertion/deletion (l/D) 
polymorphism and post-CS restenosis. we performed a m&-analysis of all the reported 
studies up to August 2000. Methods: Independent, English-language reports were found 
through searching MEDLINE and the abstract books of the major cardiology meetings. 
Studlas were pooled by using ihe ManteCHaensrel method. Results: Six studies which 
provided post-CS restenosis information for genotypes DD, ID and /I were identified and 
summarized. They enrolled a total of 2,917 patients (876 DD, 1.450 ID and 591 II 
patrants) with successful CS. The overall restenosis rates during the 6monfh follow-up 
period were 29.1% 27.7% and 28.4% for DD, ID and II carriers, respectively. The mean 
odds ratio (OR) for reslenosis for D versus I allele was 1.05 (95% Cl, 0.94-1.18; p [asso- 
elation], 0.40; p [heterogeneity]. 0.1 1). The pooled OR remalned non-significant when DD 
and II homozygotes were compared (OR, 1.06; 95% Cl, 0.84-1.35; p [association], 0.65; 
p [heterogeneiiy], 0.14). Conclusion: This meta-analysis does not support the hypothe- 
sis that the D allele of the ACE gene is associated with the risk of restenosls after CS 
Patients were scored based on the presence or absence of the predictive variables. The 
system’s accuracy for predicting death and major complications was evaluated by 
receiver operator characteristic analysis. Results: The mean patient age was 62 & 11 
years (range 26 to 92), 24% women, 22% diabetic, 71% hypertensive, 20% previous cor- 
onary artery bypass graft, 51% previous myocardlal infarction, 13% prior coronary inter- 
ventions, mean ejection fraction 48%. Major complications occurred in 3.5% of the 
population. We validated the new score system in 8903 patients with comparable demo- 
graphics and comorbid conditions in all three databases. The predictive accuracy of the 
model for death is 0.75 and 0.73 (area under the curve) and 0.64 and 0.65 for major com- 
plications in the Mayo and Emory database respectively. Conclusion: This new score 
with simple clinical variables nsk-stratifies patients who undergo coronary stenring and 
identifies a group of patients with a high complication rate. Despite the difficulties of using 
other databases to test a model, ihe score’s predictive accuracy for death is good and for 
maior complications, borderline. 
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1156-20 Regrowth of Neointimal Effect of In-Stent Restenosis: A 
Volumetric Analysis of the Effects of Radiation 
Manoon Somrantin, Yoshihlro Merino, Thosaphol Limpljankit, Yasuhiro Honda, Gary S 
Minti, Paul G. Yock, Ron Waksman, Peter J. Fitzgerald. Stanforduniversity 
cardiovascular medicine, palo alto, CA 
Background: Initial studies of radiation therapy for insient restenosis (ISR) suggest that 
this therapy can substantially reduce recurrent intimal hyperplasia. However, little IS 
known about how the effect of radiation therapy relates to the characteristics of the ISR 
lesion or the resulis of the pre-radiation intervention. Methods: From the WRIST (Wash- 
ington Radiation for In-Stent reslenosis Trial) cohort, we selected 54 ISR patients (192ir: 
29, placebo: 25) treated with non-stem percutaneous interventions (exclmer laser, rota- 
tional &here&my and/or balloon angloplasty) prior to 192lr- or placebo therapy. Using 
Simpson’s method, serial volumetric IVUS analyses (pre and post-treatment, and 6- 
month follow up) were performed to obtain neointimai volume (NIV), which was adjusted 
for stent length by calculating NIV per mm of stent length. Results: In the placebo group, 
the acute reduction of NIV due to the debulklngldilatlng intervention (- 1.6 i 1.4 mm3/ 
mm) was counteracted by neointlmal regrowth ( 2.1 t 1.7 mm3lmm). The amounl of 
neointimal regrowth correlated directly with the reduction of NIV due to the intervention 
(R=0.76, p<O.OOi). In the 192lr-treated group, neointimal regrowth was signiflcantiy less 
than in the placebo group (-0.3 * 0.1 mm3/mm vs 2.1 e1.7 mm3/mm, p&001) despite a 
similar initial NIV reduction (1.3 + 0.9 mm3imm vs 1.6 i 1.4 mm3/mm, p=NS). No corre- 
lation was found between NIV reduction at the time of the procedure and neomtimal 
regrowth in the 192lr group. Conclusions: In non-radiated instent restenosts segments 
treated without radiation, regrowth of neointima following intervention correlates directly 
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with the extent of acute reduction in neointimal volume due to debulkingldilating. This 
relation is not seen in ISR segments treated with radiation, where neointimal regrowth is 
substantially inhibited. 
1156-21 The Contribution of Mechanical Problems to In-Stent 
Restenosis: An Intravascular Ultrasound Analysis of 1090 
Consecutive InStent Restenosis Lesions 
Marco Castagna. Gary S. Mintz, Neil J. Weissman, Roxana Mehran, August0 D. Pichard, 
Afework G. Gebreeyesus, Lowell F. Satler, Kenneth M. Kent. Wash!ngton Hospital 
&enter, Washington, DC, Cardiovascular Research Foundation, Mew York, NY 
We rewewed the pre-intervention intravascular ultrasound (IVUS) studies of 1090 con- 
secutive patients with in-stent restenosis (ISR) to determine the frequency of mechanical 
complications contributing to this clinical entity. IVUS measurements included stent, min- 
imum lumen, and intimal hyperplasia (IH=stent minus lumen) areas. In 49 patients 
(4.5%), there were mechanical complications which, presumably, occurred during the 
original stent wnplantation procedure. These included (1) missing the lesion, (2) stent 
“crush,“and (3) having the stent stripped off the balloon. An example of a crushed stent is 
shown in the figure. Excluding mechanical complications, stent underexpansion was 
common with 38% of lesions having a minimum stent CSA cfi.OmmZ and 20% of lesions 
having a minimum stent CSA c5.0mm2. IH area measured <4mm2 in 41% of lesions, 
<3mm2 in 15%, and <2mm2 in 3%. Thus, while IH burden (IHistent area) averaged 
66r12%, in 24% of lesions it was less than 60% of minimum stent area. These are 
shown in the figure. 
We conclude: Mechanical complications and/or stent underexpansion contribute impor- 
tantly to ISR: the exact frequency, however, depends on the definition used. These 
mechanical problems are avoidable with better implantation techniques including IVUS 
guidance. 
1156-22 Coronary Artery Vessel Remodelling and Its Relationship 
With Endothelial Function 
AL. McLeod, D B. Northridge, D E. Newby, K A. A. Fox, N G. Uren. Cardiology 
Department, Lothian University Hospitals rrUst, Edinburgh, United Kingdom 
The relationship between endothelial function (EF) and atherosclerotic coronary artery 
remodelling is not well established. This study was done to characterise EF in non- 
remodelled (non-R), adaptively-(adap-R) and adversely-remodelled (ad”-Fi) coronary 
segments following intracoronary (ic)acetylcholine (ACh), adenosine (ADE) and nitro- 
glycerine (NTG). Following diagnostic coronary angiography an IVUS catheter was posi- 
tioned to measure change in epicardial total vessel area (DVA)to ACh at IO-6M and IO- 
4M, ADE at 18.24mcg and NTG 200mcg. Remodelling was calculated as relative VA (VA 
at segment site/mean VA of proximal and distal reference sites). Remodeljing>l.05 was 
adaptive, CO.95 was adverse with non-R between 0.95 and 1.05. Results:45 segments 
were identified (21 non-R, 12 adap-R. 12 adv-R)in 18 patients. Non-R segments had sig- 
nificantly less plaque area than both adap-R and adv-R segments (3.0+/-0.9mm2 vs 
8.2+/-0.4mm2 and 7.0+/-0.6mm2, pcO.O1,p<O.O1). All non-remodelled segments vasodi- 
lated to AChlO-GM. With non-R and adap-R segments there was a significant %DVA with 
AChlO-6M compared to adv-R segments (DVA, 5.3+/-0.7% and 0.73+/-i .9% vs -5.l+/- 
1.9%, ~~0.01, p<O.O5). ACh IO-4M produced a trend toward vasoconstriction in all seg- 
ment types (p=NS). There was a trend towards greater vasodilatation in non-R compared 
with adap-R and adv-R segments to ADE (DVA 6.1 +/-I .4 vs 3.4+/-i .O and 3.2+/-0.6, 
p=NS, p=O.O8). There was significantly more vasodilatation in non-R segments com- 
pared to &v-R types with NTG (OVA 7.4+1-0.9% vs 3.5+/-0.6%, p<O.Ol). There was no 
significant difference between adap-R and adv-R for each ic AChlO-4M, ADE and GTN 
bolus, though they showed significantly more vasodilation to ADE and GTN than with 
AChlO-4M (p<O.OOi ,p<O.OOl ,p<0.001,p<0.001, respectively). Conclusions: These 
results suggest that there is a similar degree of endothelial dysfunction in both adap-R 
and adv-R coronary artery segments, compared with non-R segments. However, recep- 
tor-mediated endothelial-dependant vasodilation to AChlO-GM is generally preserved 
with the increased plaque load in adaptively remodelled segments. 
1156-23 Ultimate Miniaturization of Intravascular Ultrasound 
Transducer: Feasibility of a Novel Guide-Wire Type Catheter 
(Terumo) 
Kenichi Ito, Masakazu Yamagishi, T&u Yamaguchi, Hatsue Ishibashi-&da, Chikao 
Yutani, Hiroyuki Yagami. National Cardiovascular Center, Suita, Japan, Jerumo 
Corporation, Tokyo, Japan 
Background: We developed a new guide-wire type intravascular ultrasound (IVUS) 
imaging catheter that equipped an ultimately miniaturized ultrasound transducer, and 
tested it by using human coronary specimens in vitro to determine suitable element size 
and frequency. Furthermore, we compared IVUS measurements with histological mea- 
surements to assess the accuracy of this IVUS. Methods: The catheter is very flexible 
with a diameter of 0.025 inch. The size of imaging element is 0.3mm or 0.4mm in diame- 
ter 0.025 inch, and rotates at 1,800rpm. In this study, 4 prototype imaging catheters 
which were consisted of imaging element size 0.3mm or 0.4mm, frequency 35MHz or 
25MHz were used. Coronary arterial samples excised in 10mm length were immersed in 
a warmed (35°C) saline bath, and were observed by using motorized IVUS pullback sys- 
tem at a speed 0.5mm/sec. A total of 12 samples were used to obtain IVUS images in 
vitro. Vessel area and lumen area measured by histological microscopic slides and IVUS 
images were compared for 50 human coronary arterial segments. Results: This IVUS 
images clearly described vessel wall morphology and had a similar appearance on con- 
ventional IVUS images. Vessel area and lumen area were identified corresponding to the 
finding of histological microsections. The IVUS imaging with 0.4mm element and 35MHz 
visualized more clearly than that with 0.3mm element and 25MHz. There were excellent 
correlations between IVUS measurements and histological measurements as follows; 
vessel area(y=l.3x-0.4, r=0.89), lumen area(y=l.6x-1.4,r=0.82). Non uniform rotational 
distortion was not observed in all transducers when these were examined with phantom 
model. Conclusions: This guide-wire type IVUS imaging catheter provides an accurate 
qualitative and quantitative information about vessel wall morphology, compared with 
histological measurements. This catheter has great potentials which can be used through 
5Fr size guiding catheter for diagnosis. We suggest the present catheter is useful for the 
evaluation of not only natural atherosclerotic disease but also accelerated transplant vas- 
culopathy that should be carefully and frequently observed after heart transplantation. 
1156-24 Intravascular Ultrasound Predictors of Late Recurrence 
After Stent Implantation in Small Coronary Arteries 
Alexandre Abizaid, Gary S. Mintz, Andrea S. Ablzaid, Roxana Mehran, George Dangas, 
Augusta Pichard, Lowell Salter, lzat Hijazi, Rajshekar Narasimaiah, Alexandra J. Lansky, 
Gregg W. Stone, Martin 6. Leon. Cardiovascular Research Foundation, New York, NY, 
Washington Hospital Center, Washington, DC 
Background: Stent implantation in small coronary arteries is associated with high recur- 
rence rates. Although “bagger is bettel” in vessels >3.0mm. predictors of clinical resteno- 
sis after stenting ‘?xnall” vessels have not been identified. 
Methods: We followed 1411 consecutive patients (1565 lesions) with reference vessels 
5 2.7mm by quantitative angiography (QCA), undergoing intravascular ultrasound 
(IVUS)-guided stent implantation. Patients were divided in two groupi according to the 
final lumen cross sectional area (CSA) achieved by IVUS: <5.0mm* (n=594) and 2 
5.0mm” (n=817). 
Results: Regression 
analysis was used to con- 
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Conclusion: Smaller IVUS final lumen dimensions at the lesion and at reference sites, 
as well as diabetes are predictors of clinical restenosis in pts undergoing small vessel 
stenting. Attempts to safely achieve a final lumen CSA of z-5.0 mm should be imple- 
mented when possible during stenting small vessels under IVUS guidance. 
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115625 An intravascular Ultrasound Classification of Angiographic 
Coronary Artery Aneurysms 
Akiko Maehara, Gary S. Mintz. Javed M Ahmed, Shmuel Fuchs, Neil J. Weissman, 
August D. Pichard, Lowell F. Satier, Ron Waksman, John R. Laird, Jr., Kenneth M. Kent, 
Stephen E. Epstein. Washington Hospifal Center, Washingfon DC, DC 
Background: Three percent of coronary artery lesions have an angiographic appear- 
ance that IS considered aneurysmal. Method: To further classify these lesions, we ana- 
lyzed intravascular ultrasound (IVUS) images of 77 consecutrve patients with an 
aneurysm in a native coronary artery dragnosed by angiography (25% larger than refer- 
ence lumen diameter). True aneurysm was defined as an intact vessel wall and maxi- 
mum lumen area >30% larger than proximal reference lumen area. Pseudoaneurysm 
was defined as loss of vessel wall integrity. Complex plaques were lesions with ruptured 
plaque or spontaneous dissection. Additionally, external elastic membrane (EEM), 
lumen, and plaque&media (P&M=EEM-lumen) cross-sectional area (CSA) at maximum 
aneurysmal lumen CSA and proximal and distal reference site were analyzed. 
Results: 24 (33%) 
lesions were classi- 
fied as true aneu- 
rysm; 3 (4%) were 
classified as 
pseudoaneurysm: 
12 (16%) were 
complex plaques: 
and the other 38 
(40%) were normal 
arterial segment 
adjacent to one or 
more S?“W62 
stenoses. Exam- 
ples are shown in 
the figure. 
The maxmlum 
lumen area withrn the aneurysmal segment was largest for pseudoaneurysm (35.0+10.1 
mm2), 22.3&i mm2 for true aneurysm, and similar for complex plaque (11.3t3.5 mm2), 
and normal segment with adjacent lesions (11.2i3 5 mm2): ANOVA p<O.OOOi. In 24127 
(89%) of true or pseudoaneuryms, there was a signrficant stenosis within the same seg- 
ment. Conclusion: Only one-third of angiographically diagnosed aneurysms had the 
IVUS appearan& of a true or pseudoaneurysm. Instead, the majority are complex 
plaques or normal segments of the artery adjacent to severe stenoses. 
1156-26 Are There Inter-Vendor Differences in Measures of Stent 
Deployment? An Analysis Using Intravascular Ultrasound 
Background: Therapeutic angiogenesis requires the induction and recruitment of new 
blood vessels for the treatment of peripheral vascular and coronary artery disease. Effi- 
cacious applrcation of this new therapy requires optimizing multiple factors including the 
therapeutrc agent, dosing, frequency of administration, and delivery modality. Intramyo- 
cardial injection is evolving as the modality of chorce for local myocardial treatment. In 
this study we examined the distribution pattern and the efficiency of percutaneous 
intramyocardial injection for local protein delivery. Methods: The device applied con- 
sisted of a helical needle infusion system that allowed stable myocardial engagement 
and delivery. 125lodinelabeled albumin (0.4 ml total volume) was delivered in to the pre- 
determined area of left ventricle in 8 swine (single deljvery). Animals were sacrificed 1 
hour later, and 1-2 gram sections of the entire cardiac tissue were examined for radioac- 
tivity. Continuous arterial and coronary sinus samples were collected to monitor the 
“wash-out” and recirculation of the radioactivity after the delivery. Results: Percutane- 
ous intramyocardial delivery resulted in a high concentration of radiolabel at the treat- 
ment siie: 16.4 i 2.1% of delivered activity and 81.4 * 2.6% of the total cardiac activity 
were concentrated at the site of delivery. Continuous coronary srnus and aortic blood 
sampling demonstrated that within 15 minutes following intramyocardral injection the 
majority of unbound protein is found within the coronary sinus. Despite direct intramyo- 
cardial delivery, significant amounts of radioactivity were found in non-targeted organs 
(24.3 f 3.6% rn liver, 11.5 + 3.0% in krdneys, and 6.7 i- 1.9% w the lungs). However, the 
specific activity at the treatment site (radioactivity per gram of tissue) was 115 * 36, 226 
i 55, and 47 rt 10 fold higher compared to liver, lung, and kidney, respectively. Conclu- 
sion: This study indicates that percutaneous intramyocardial Injection is an efficient 
method for local myocardial treatment, and drug levels may be modulated by temporary 
occlusion of coronary sinus drainage during the delivery. 
Warren K. Laskey, Assadour Assadourian, Samuel Yoon, Debra Kelly, William Herzog, 1157-29 Needle-Free Jet Injector Produces Greater Gene Expression 
Jr., J. Lawrence Stafford, Joel Gellman. University of Maryland Medicai System, by Naked Plasmid DNA in Rabbit Hindlimb Muscles 
Balfimore, MD Compared to the Needle Method 
The adequacy of stent deployment has been correlated with short- and long-term clinical 
outcomes. However, these data were obtained from studies rn which the type of stent 
was generally limited to one vendor The current variety of stent types and deployment 
techniques may result rn differences rn the adequacy of deployment. Therefore, using 
intravascular ultrasound we analyzed the following measures of stent deployment in 76 
stents distributed across four vendors (A, B. C, D): in-stent minimal lumen area (ISMLA. 
mm2); average reference lumen area (RLA, mm2); stent Inlet expansion (prox. Stent 
MLA. %): stent outlet expansion (distal stem MLA, %). Ail stents were successfully 
deployed by angiographic criteria (< 30% diameter residual stenosis) by electronic cali- 
per. We found using the MUSIC criteria ( ISMLA > 0.9 RLA) that only 42% stents were 
adequately deployed although this increased to 62% using ISMLA > 0.8 RLA as a crite- 
rion. In addrtion, there was a trend towards greater expansion of the distal stent ( mean 
diff. -5.8%, p c 0.069). Finally, there was no difference rn any measure of stent deploy- 
ment when comparing deployment pressure of < 12 atm and > 12 atm. We conclude that 
I) in the absence of routrne high pressure deployment, most stents are sub-optimally 
deployed using the MUSIC criteria, mespective of vendor; 2) deployment pressure- inde- 
pendent but vendor specific differences exist in proximal stent expansion. These data 
may reflect differences in plaque characterrstics. intrinsic differences in stems them- 
selves or the interaction of these two factors 
Hirami Nishimura, Marianne Kearney, Marcy Silver, David Opie, Robert C. Glines, Diane 
L. Demarais, Jeffrey M. Isner. St. Nizabethk Medic& Center, Boston, MA 
A B C D 
PROX STENT MLA (%)* 94 +/- 13 98 +/- 16 105+/-19 89+/-21 
DISTAL STENT MLA (%) 96 +/- 19 100 +/- 22 105+/- 16 102+24 
MINIMUM STENT AREAIALA (%) 82 ci- 15 85+/- 15 90 +/- 15 85+17 
Background: Gene therapy approaches hold promise for the treatment of a wade variety 
of cardiovascular diseases. However, the transfection efficrency of naked plasmid DNA is 
still limrted compared with that of viral vectors. In this study, we performed in viva experi- 
ments to compare the gene expression efficiency between a novel needle-free jet injector 
(AngioSense Inc.) and needle injection. Methods and Results: The damage of plasmid 
DNA by shear stress in passing through the jet injector micropore or needles was exarr- 
ined. The plasmrd DNA was injected by jet injector at various pressures or a 25 gauge 
needle. After digestion by restriction enzyme, the plasmid DNA damage was quantified 
by the densitometric analysis on gel-electrophoresis. Compared with needle injection 
(1.64 * 0.28, mean * SE, n=3), only plasmrd DNA injected at 4200 psi (2.29 * 0.20) dem- 
onstrated significantly (p c 0.05) intense smears while injection at 1800 psi (1.22 * 0.1 I), 
at 2200 psi (1.54 * 0.01) or at 2600 psi (1.69 + 0.14) did not cause severe damage. Hind- 
limb muscles of New Zealand white rabbits were then transfected with a reporter plasmid 
(pCMV-beta, 100 microgram / limb), expressing beta-galactosidase, delivered from the 
jet injector at the pressure of 2200 psi or by 25 G needle. Five days later, rabbits were 
sacrificed. The hindlimb muscles from each leg were divided into nine pieces. The beta- 
galactosidase activity and protein concentration of each muscle piece were measured. 
To correct sample volume, the beta-galactosidase activity was compared after being 
divided by protein concentration. The average and peak beta-galactosidase activity of 
nine muscle pieces by the jet injector at 2200 psi (91.9 k 18.8 and 217.0 r 35.2, mean i 
SE, n=6) were significantly higher than that by needle injection (38.4 2 4.4 and 78.9 & 
5.0). There was no histologic evrdence of tissue damage related to jet injector activity. 
Conclusion: Gene transfer of plasmrd DNA can be substantially optimized by delivery 
from pressured jet injector compared to needle injection. This observation in physical 
delivery may facilitate use of gene transfer strategies utilizing naked DNA. 
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i 157-28 Percutaneous lntramyocardial Delivery is an Efficient 
Modality for Local Myocardial Treatment 
Mehrdad Rezaee, Alan C. Yeung, Peter Altman, Takeshi Suzuki, Dreter Lubbe, Robert S. 
Schwartz, Simon H. Stertzer, John D. Altman. Stanford University Medical Center, 
Stanford, CA, Mayo Clinic Foundation, Rochester, MN 
1157-30 An In Vivo and In Vitro Assessment of Integrity of Plasmid 
DNA and Cells After Passage Through the NOGA Needle 
Catheter: A Potential Gene Delivery System 
Michael A. Kulisrewski, Michael J. B. Kutryk, David Fitchett, Duncan J. Stewart. Terrence 
Dome//y Heart Center, St. Michael’s Hospital, Toronto, ON, Canada 
The delivery of genetic material for myocardial angiogenesis using the NOGA needle 
injection catheter (Cordis Corp.) is a promising new technique. Unfortunately passage 
through the 1.9m, 27G nitinol needle may expose the cells or DNA to adverse shear 
forces, which could compromise their Integrity. 
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Plaemid DNA (pcDNA3.1) containing beta galactosidase @gal) (0.625mg/mi) was 
passed through the needle at gentle (O.Zml/6Os, 3.0iO.Zkgicm’) and maximal manual 
force (6.3kO.4 kg/cm’). The concentration of the extruded DNA was assessed and trans- 
fection efficiency (TE) determined using cultured rat skin fibroblasts (SFB). The feasibil- 
ity of cell delivery through the NOGA catheter was assessed by passing 1.5~10” SFB 
through the needle at a clinically relevant injection rate of (0.2ml/60s, 3kgicm’). Cells 
were then plated and cultured for 24h, and viable cells were counted. In viva viability was 
determined by using autologous monocytic cells (1.0 x 1Oe SFBlinjection site) labeled 
with the ffuorophore CMTMR and suspended with 5~10~ fluorescent polystyrene (15ym 
diameter) microspheresiml and injected “!a the NOGA catheter Into the left ventricular 
myocardium of 6 Yorkshire pigs (ten sites with 100pl/injectionl30s). 
The TE of DNA passed through the needle at gentle pressure was 81f4%, while at max- 
imum hand pressure it was reduced to 66+4% (p<O.OZ). There was no loss of DNA and 
no evidence of DNA fragmentation, but the supercoiled form was reduced after injection 
as revealed by caprllary electrophoresis. Passage through the needle reduced SFB num- 
ber after 24h in culture by 15% compared with control. On cardiac explant, the injection 
sites were readily discernable and histologic examination showed dense populations of 
robustly labeled monocytic cells after 24h. Cell numbers and density declined markedly 
after 72h, however cells could be identified at greater distances from the needle tract, 
consistent with cell migration. 
These data support the use of the NOGA needle catheter for naked DNA delivery, pro- 
vided that injection pressure is carefully assessed. Moreover viable cells can be deliv- 
ered, suggesting that cell-based therapy using the NOGA injection system is also 
feasible. 
1157-31 Endothelial Cell Function Within Gas-Plasma Treated 3- 
Dimensional Implants 
Steven R. Bailey, Jodie L. Polan, Mauli Agrawal. UTHSCSA, San Antonio, TX 
Background: Stimulation of angiogenesis by endothelial cells transplanted into ischemic 
heart tissue may improve cardiovascular outcomes. We previously showed that human 
aortic endothelial cells (HAECs) exhibit enhanced function on gas-plasma (GP) treated 
bioabsorbable poly-DL-lactic acid (DL-PLA) films. Consequently, we evaluated the ability 
of HAECs to proliferate within 3.dimensional (3D) DL-PLA implants. We examined cellu- 
lar proliferation by fluorescent labeling of beta-tubulin and proliferating cell nuclear anti- 
gen (PCNA). beta-tubulin indicates microtubular formations. PCNA increases with cell 
cycle progression and reaches its peak in G2 & M phases of the cell cycle. Methods: 
Both control and GP treated polymer were analyzed using Electron Spectrometer for 
Chemical Analysis (ESCA). After nine days in vitro, the implants (n=4 par set) were 
immunostained for beta-tubulin and PCNA expression and the subsequent fluorescence 
measured using a BioRad Radiance confocal system. Endothelial densities were verified 
using WSTl ELlSAs. Results: ESCA indicated increased oxides on GP-treated polymer. 
HAECs in both control (A) and GP treated implant (6) had propagated with greater cell 
densities in GP treated implants indicated by immunofluorescence for beta-tubulin and 
the WSTI ELlSAs. beta-tubulin fluorescence was enhanced in HAECs within GP treated 
implants. HAECs in cobblestone morphology expressed less PCNA when density- 
induced contact inhibition occurred. Conclusion: HAECs proliferating in GP treated DL- 
PLA 3D implants are likely to survive transplantation and facilitate myocardial angiogene- 
sis. 
1157-32 Local Delivery of Third-Generation Antisense Drug Inhibits 
Neointimal Formation After Stent Implantation in the 
Porcine Coronary Artery 
Han-Soo Kim, Hamid A. Yazdi, George Dangas, Roxana Mehran, Jana Fournadjiev, 
Rufus Seaborn, Patrick L. Iversen, Martin Leon, Jeffrey Moses, Nicholas Kipshidze. 
Lenox Hill Hospital, New York, NL: Washington Hospifal Center, Washington DC, DC 
Background: The clinical applicability of antisense technology remains limited by a rela- 
tive lack of specificity. Neutrally charged phosphorothioate morpholino oligomers (PMO) 
has been developed to avoid these limiations. We have demonstrated that antisense 
therapy using PM0 with c-myc antisense oligomers (AVI-4126) inhibited the expression 
of c-myc induced by balloon injury in the porcine coronary artery. The purpose of this 
study was to investigate the impact of AVI-4126 on neointimal formation following stent 
implantation. 
Methods and Results: Ten juvenile pigs weighing 30-35kg underwent stem implantation 
in the coronary artery with local AVI-4126 delivery of different doses (Omg,lmg, 5mg and 
10mg) using infiltrator catheter. The animals were sacrificed 30 days after the procedure 
and the hearts are perfusion-fixed. Histomorphometric analysis of the coronary arteries 
was performed for stem strut area (SSA, mm’), intimal area (IA, mm*) and lumen area 
(LA, mm’). There was no abnormal cellular response and no excess of fibrin, thrombus, 
or inflammation in the treated arteries compared to control. Injury score was similar 
among the groups (p=NS). 
Control (n=6) 1 mg (n=8) 5 mg (n=9) 10 mg (n=7) 
SSA (mm”) 7.14*1.04 7.56r1.48 6.86?1 .ll 7.63&l 59 
IA (mm*) 3.88+1.04 2.81+0.46 1.95*0.91’ 2.01+0.66* 
LA (mm’) 3.26t1.77 4.76+1.85 4.91+1.36 5.62*1.40’ 
(* PiO.05) 
Conclusions: Stem implantation with adjunctive local AVI-4126 delivery into porcine cor- 
onary arteries is feasible, safe and associated with significant inhibition of neointimal 
response and larger luminai dimensions at follow-up. Efficacy appeared to be dose- 
dependent. 
1157-33 Inhibition of Balloon Injury Mediated Apoptosis With Local 
Delivery of a Caspase Inhibitor 
Nirat Beohar, Charles J. Davidson, Atman Shah, Norman Wang, Robert Decker, Francis 
J. Klocke. Northwestern Universify Medical School, Chicago, IL 
Mechanical Injury to the arterial wall results in a significant loss of medial smooth muscle 
cells due to apoptosis. Apoptosis plays an important role in restenosis through the regu- 
lation of smooth muscle cell proliferation. Hypothesis: A locally delivered caspase inhib- 
itor (z-VAD) can protect the arterial medial smooth muscle cells from balloon injury 
mediated apoptosis. Methods: Eight New Zealand White rabbits underwent bilateral iliac 
artery angiopiasty using the Remedy 3.5120mm local delivery balloon. Simultaneous with 
the balloon injury, arteries were treated with local infusion of either normal saline into the 
ipsilateral artery (Control) or with z-VAD into the contralateral artery (Treated). High dose 
(n=5), (45,000 ng / animal) or low dose (n=3), (4,500 ng / animal) z-VAD was adminis- 
tered and the animals were sacrificed at 4 hours. Apoptosis was detected using the 
TUNEL assay. 1000 smooth muscle cell nuclei were counted par artery (200 nuclei/ sac- 
tion, 5 sections/ artery). The Apototic Index was calculated (smooth muscle cell nuclei 
positive for apoptosisi 200 smooth muscle cell nuclei counted). 
Results: See Graphs. 
The mean percentage reduction in the Apoptotic Index was 45%, p<O.OOl with high 
dose z-VAD and 33%, ~~0.02 with low dose z-VAD. Conclusions: Local delivery of z- 
VAD significantly inhibits balloon injury mediated apoptosis of the arterial medial smooth 
muscle cells. This could mitigate subsequent medial smooth muscle cell proliferation and 
neointrmal cell formation in response to early apoptotic cell loss. This novel anti-rest- 
enotic strategy is in contradistinction to the conventional approach of causing smooth 
muscle cell death after the onset of cell proliferation, 
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1158-34 Incidence and Reasons of Drop Out in Successive 
Transradial Procedures in One Arm 
Hideaki Sakai, Haruto Ohe, Takashi Harada, Takeshi Yonashiro, Kiyoshi Ozumi, Satoshi 
Ikeda, Shigeru Kohno. Kiiakyushu city Yahata Hospital, Kitakyushu, Japan 
Introduction and Patients: The transradial approach (TRA) has been used for diagnos- 
tic and interventional cardiology. It has not previously been determined how many times 
the Same radial artery can be cannulated without complications. A total of 812 patients 
(502 man and 310 women) underwent angiography or angioplasty via the TRA (total 
1438 procedures). Result: The sheaths were 5.Fr (55%) or 6-Fr (45%)(Tablel). Of the 
502 man who underwent TRA, 304 required no further diagnostic imaging or coronary 
angioplasty. In the remaining 198 men, TRA could not be performed in 7 of these patients 
in the same arm. Dropout rates of 3.5% and 7.9% were found at the second TRA attempt 
in the men and women, respectively(Fig.1) The drop-out rate was higher among female 
than male cases. The drop-out rate increased in both groups each time TRA was par- 
formed. The male drop-out rate gradually increased from the second procedure (3.5%) to 
the fifth procedure (15.6%). The female drop-out rate increased rapidly after the fifth pro- 
cedure to 33.3%. Overall, there were 62 patients who dropped out for s?vere spasm 
(n=4) or a giant hematoma at the time of previous TRA (n=2), a faint radial artery pulse or 
pulseless(n=38), or failed puncture (n=18)(Table 2). Of the 62 TRA failures, 56(90%) 
were due to narrowing or occlusion of the radial artery after the previous TRA procedure. 
Based on the TRA drop-out rates, the succass rate of TRA performed in the same arm 
were calculated for the man and women (Fig.2). Conclusion: TRA was performed in the 
JACC February 2001 ABSTRACTS 
same arm up to three times in 90% of the men and 80% of the women. It was performed 
up to five times in 70% of the tmen and 50% of the women. This was primarily due to the 
vessel narrowing and occlusion occurring as a function of multi& punctures. 
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1158-37 Clinical and Angiographic Outcome After Cutting Balloon 
Angioplasty 
Johann W. Auer, Maurer Edwin, Robert Berent, Herbert Mayr, Christian Punzengruber , 
Bernd Eber. Gen Hasp We/s, We/s, Austria 
Background and Purpose: The cutting balloon is a new device for coronary angioplasty, 
which, by the combination of incision and dilatation of the plaque, is believed to be prom- 
ising for treatment of In-stent restenosis. The purpose of the study was to evaluate the 
safety and efficacy of cutting balloon angcoplasty (CBA). Material and Methods: We 
reviewed immediate and six month follow up angiographic and clinical outcome of 147 
patients (109 men and 38 women) with a mean age of 67,3+10 undergoing this proce- 
dure at 8 interventional cenires in Austria. The target lessons treated with CBA was in- 
stent-restenosis in 61%, stenosis after balloon angioplasty in 8% and native lesions in 
33%. 65% of the patients included had multi-vessel disease. Lesion type was A in 18%, 
Bl in 31% 82 in 39% and C in 12%. The degree of stenosis was 87+9%, the lenghth of 
the target lesion treated with CBA was 8,8+5,1 mm. Target vessel was circumflex artery in 
22, right coronary artery in 36 and left anterior decending artery in 89 cases. Summary 
of Results: The overall procedural sucess was 85%. ,,Stand-alone” CBA was performed 
in 63%. the procedure wai combined wiih coronary stenting in 16% and with balloon 
angioplasty in 21%. Coronary complications occured in 8 cases (5,4%) with coronary dis- 
section in 7 (total dissection rate 4,7%) and urgent bypass surgery in 1 case (0,7%). No 
further complications like death, occlusion or perforation of coronary arteries, embolisa- 
tion or thrombosis were observed. 6 month clinical follow-up (completed in 23,8%) 
revealed q-wave myocardial infarctlo” in 1 (2,7%), aortocoronary bypass surgery in 3 
(8,5%) and repeated percutaneous coronary intervention in 6 (17%; 4 ca?.es with stent- 
ing) cases. 6 month angiographlc follow-up showed target lesion restenosis (x50% diam- 
eter stenosis) m 14%, loss in minimal luminal diameter (~50% diameter stenosis) in 6% 
and progression of ,,other than target”-lesions restenosis (~-50% diameter stenosis) in 
14%. Conclusions: This series demonstrates the safety and efficacy of cutting balloon 
angioplasty I” patients with complex coronary artery disease and in-stent restenosis. 
1158-38 Fiberoptic Guidance System for Treatment of Chronic Total 
Occlusions: A Single Center Experience 
RR Heuser, H Cordero, W Schroeder, BA Weirick, CW Hatler, PL Underwood. Phoenix 
Heart Center, Phoenix, AZ, St. Luke’s Medical Center; Phoenix, AZ 
Background: We report our experience treating chronic total occlusions (CTOs) with a 
forward-looking fiberoptic guidance technology system (Safe-SteerTM System, Intralumi- 
nal Therapeutics, Inc, Carlsbad, CA). The system uses optical coherent reflectometry 
(OCR), which is the reflection of a near infrared light, to determine tissue types. 
Methods: A iota of 13 patients with known CTOs were treated. Initial attempts to cross 
the CT0 were made with a floppy wire. After ten minutes of fluoroscopy, If the CT0 could 
not be crossed, the floppy was exchanged for the fiberoptlc wire. When the CT0 was 
crossed, routine angioplasty was performed with or without a stent. 
Results: The lesion characteristics are described in Table 1. The mean lesson length 
was 25.4mm. CTOs were crossed in 11 cases (85%). In patient #6, the CT0 was 
crossed with the floppy wire after successful navigation into the occlusion with the 
fiberoptic wire. In patient #12, the CT0 was crossed, bui there was no reflow. There was 
no evidence of vessel perforation in any of the cases. 
Conclusion: This system was safe and effective for crossing CTOs. Visualization of 
intraluminal posltion prevented vessel trauma and perforation. Further study in a larger 
trial is needed to confirm device safety and utility. 
1158-35 Intravascular Sonotherapy in Human Coronary Arteries: 
First Results of a Feasibility Trial 
Richard E. Kuntz, Jeffrey W. Moses, Alexander A. C. Abizaid, Nicholas A. F. Chronos, 
Michael R. Mooney, Reginald I. Low, Alan C. Yeung, Douglas W. Losordo, Joseph P 
Carrorra. Neil J. Weissman. Jeffrey J. Popma, Patrick W. Serruys. BrIgham 8 Women’s 
Hospital, Boston, MA 
Introduction: The Sonotherapy for In-Lesion Elimination of Neomtimal Tissue (SILENT) 
Study is a multi-center trial designed to assess the safely of catheter-based Intravascular 
Sonotherapy (IST) for the treatment of newly stented coronary arteries. All patients will 
be followed for a period of nine months post-procedure, and both short and long-term 
clinical endpoints evaluated. Methods: Between January and June 2000, 109 patients 
were enrolled in the SILENT Study at 11 clinical sites, and received a stent(s) at the site 
of a single de nova or non-stent restenosis lesion in a native coronary artery. The aver- 
age length of stent placed per patient was 20.4+6.4mm. Of those patients enrolled, 101 
received 2 or 3 five-minute IST treatments, depending on the length of stent Implanted, 
using the PharmaSonics IJRx’M Intravascular Sonotherapy System. Eight patients were 
unable to be treated due to technical difficulties or inabrlity to cross ihe stenred lesion 
with the study catheter. Patients were released on 60 days of Clopidogrel. Results: Of 
those patients receiving sonotherapy, one underwent a repeat revascularization of the 
target lesion 48 hours post-procedure due to an un-treated small marginal dissection. At 
60 days, no additional repeat interventions, Q-wave MIS, thrombotic events or deaths 
were reported among patients receiving IST treatment. Acute angiographic results are 
listed in the table below. Pre-Procedure Post-Procedure Reference Vessel Diameter 
(mm) 2.9 + 0.5 3.0 + 0.5 Minimal Lumen Diameter (mm) 0.8 -c 0.4 2.9 + 0.5 Lesson 
Length 15.1 + 6.2 Numbers are Mean + SD As assessed by the Angiographic Core Lab- 
oratory Conclusions: Based on 60.day clinical follow-up results, the use of Intravascular 
Sonotherapy for ihe prevention of restenosis in human coronary arteries is believed to be 
feasible and safe, and warrants the conduct of a larger randomized trial to determine effi- 
cacy. The 6.month clinical and angiographic resulis for the SILENT Study will be avail- 
able at the time of presentation. 
1158-36 Initial Results With the Aegis Vortex System, a New Aspiro- 
Atheredomy System With Distal Embolization Protection, in 
the Treatment of Saphenous Vein Grafts 
B F Ureisky, W Kussmaul, III, M Buchblnder, B George, G Braden. University of Texas 
Medical Branch, Galveston, TX 
Background Loosely adherent elements in unstable plaques may embollze during 
saphenous vein graft Intervention. Preventing this event and removing this material may 
improve short- and long- term outcomes. Methods The Aegis Vortex System (AVS) con- 
sists of an over-the-wire aspiro-athereclomy catheter system with a hollow guide wire 
with a distal balloon which is inflated lo prevent embolization. The catheter iip rotates at 
150,000 RPM creating a vortex effect while aspiration of blood and debris is carried out 
through the guide catheter. Results The device has been studied in saphenous vein dis- 
ease in 16 patients in a pilot experience (12 males, age 64.3+ 10.5 years, age of graft 9.9 
i 4.1 years, lesion length 13 _t 6mm). In one patient, the AVS guidewire could not pass 
the lesson. In site-reported data. pre-AVS stenosis was 88 i lo%, post-AVS 60 f 24%, 
and flnal 4 t 6%. In all patients, the final diameter average stenosis was < 40%. Three 
patients showed an increase in CK level 2 3X normal. There was one patlent with angio- 
graphic embolization which occurred during stent implantation and one patient with TIMI 
flow I?& than baseline. Parilcles > 25 microns were found in all patients (mean number 
365, range 67-3869) with 95% of particles being < 50 microns. There were no in-hospital 
repeat revascularizations, Q wave MIS, neurological events, or cardiac deaths. Conclu- 
sion These early data suggested that AVS may be useful adjunciive therapy io decrease 
embolization and improve outcome of saphenous vein graft interventions. 
1 71 M RCA proximal Smm Y!SS Yes NO >30% 2 
2 81 M RCA mid 10mm Yes Yes Yes 0% 3 
3 74 M RCA proximal 15mm Yes Yes NO >30% 2 
4 69 M Dg proximal 20 mm Yes Yes NO >30% 2 
5 63 M RCA proximal 25mm Yes Yt?S Yes 0% 3 
6 76 M RCA proximal 20 mm Yes No Yes 0% 3 
7 65M LADmid 60mm No NO NO 100% 0 
8 68 M LCx proximal 20 mm No YtX Yes 0% 3 
9 70 F RCA proximal 60mm No YES NO <30% 3 
10 64M RCAprox~mal 50mm No NO NO 100% 0 
11 56 F LCxiOM proxi- 20 mm Yes Yes Yes 0% 3 
mal 
12 70M LADmid lOmm No Yes NO 100% 0 
13 39 M RCA distal IOmm Yes Yes No <30% 3 
1158-39 Immediate Protamine Administration and Sheath Removal 
Following Percutaneous Coronary Intervention 
John Ducas, Michael C. Y. Ghan, Anthony Miller, Tarek Kashour. University of Manitoba, 
Winnipeg, MB, Canada 
Background: Standard practice for percutaneous coronary intervention via the femoral 
approach consists of heparinization to an Activated Clotting Time (ACT)>300 seconds. 
Vascular sheath removal occurs 4-6 hours after completion of the procedure when the 
ACT has fallen to sub-therapeutic levels. This is associated with prolonged patient dis- 
comfort and increased groin complications. Previous studies have looked at immediate 
sheath removal following low dose heparinization, but they only Included a selected 
group of stable patients. 
46A ABSTRACTS - ACCIS2001 (Angiography & Interventional Cardiology) JACC February 2001 
Methods: We assessed the safety and feasibility of reversing anticoagulation following 
percutaneous coronary intervention and immediate sheath removal in 429 unselected 
patients. Heparin was given to an ACT > 200 seconds. On completion of the procedure, 
protamine was administered to lower ACT c 160 seconds, the sheath was immediately 
removed and hemostasis achieved. 
Results: A 6 French sheath was employed in 372 patients (87%) 7 French in 10 (2%) 8 
French in 44 (10%) and 9 French in 3 (1%). Stents were used in 364 patients (85%) and 
abciximab was used in 52 patients (12%). The ACT at the end of the procedure was 
208+/-39 seconds and the ACT after protamine administration was 152+/-19 seconds. 
The dose of protamine used was 20+/-6 mg.Time to achieve hemostasis was 40+/-10 
minutes. Minor groin bleeding occurred in 6 patients. One patient required repair of femo- 
ral pseudoaneurysm. Mean creatine kinase at 8 hours and 16 hours post-PC1 were 129~ 
35 and 145 + 32 units respectively. Creatine kinase rose to > 3 ttmes normal in 12 out of 
350 patients (3.4%). Prior to 48 hours, 8 patients (1.9%) required emergency revascular- 
ization. Follow-up at 30 days observed no deaths and only 3 target vessel revasculariza- 
tions (0.7%). 
Conclusion: Immediate reversal of anticoagulation and sheath removal after percutane- 
ous coronary intervention is safe and feasible, and may obviate the need for prolonged 
bed rest and/or femoral closure devices. 
115840 Debulking Using Rotational Atherectomy of Chronic Total 
Coronary Occlusion Leads to High Initial Success and Very 
Low Restenosis Rates 
Gregory A. Braden, Michael A. Kutcher, Kevin M. Rankin, Wendy L. Love, Teresa M. 
Young, Robert J. Applegate. Wake Forest University School of Medicine, Winston-Salem, 
NC 
Background: Chronic total occlusrons (CTO) are composed of fibro-calcific plaque and 
percutaneous treatment has been associated with high acute complication rates and very 
high restenosis rates. High speed rotational atherectomy (RA) will effectively ablate 
fibro-calcific plaque, generally producing smooth lumens. 
Methods: Accordingly, we evaluated the acute and long-term results of RA for CT0 in 
139 consecutive patrents in whom CT0 could be crossed with a guidewire. There were 
94 males and 45 females with a mean age 60.2 + 1 year. The lesions treated include 53 
LAD, 37 CX, and 51 RCA’s There were 2.1 i 0.1 burrs (range l-4) used and patients 
were generally treated with low pressure oversized balloons, however, other adjunctive 
therapy was used, including stents (20%) and DCA (2%). 
Results: By QCA, lumen size increased from 0 to 1.95 i 0.05 mm post procedure with 
only 22% residual stenosis, p < 0.001. Acute complication rates were low: 0 Q-wave MI, 
9 non Q-wave Ml (7.5%) 2 emergency CABG (1.6%) 2 deaths (1.6%), (deaths second- 
ary to a vascular complication and acute renal failure). Late follow-up data was available 
in 122 of 139 (88%) at a mean of 46.2 f 6 months. There have been 7 late deaths (2 car- 
diac, 5 non-cardiac) in the group. Of all patients followed, 23 (19%) had clinical resteno- 
sis which was subsequently confirmed angiographically. All had revascularization: 65% 
were treated percutaneously, 35% were treated with CABG. 
Conclusion: Debulking with RA produced high acute success rates with acceptably low 
complication rates. The acute success of RA of CT0’s led to low rate stenosis and 
should be considered as primary therapy for CTO’s. The optimal strategy post RA, 
including the role of stents needs to be further evaluated. 
1158-41 Comparison of Serial IVUS Findings of DCA Prior to 
Stenting With Stent Implantation Alone 
Akio Kawamura, Yasushi Asakura, Shim Ishikawa, Keiko Asakura, Teruo Okabe, Akiko 
Yamane, Yuichirou Maekawa, Satoshi Ogawa. Keio University, Tokyo, Japan 
Background: It has been reported that DCA prior to stent implantation (DCA/S) is 
advantageous to stent implantation alone (SA) in some situations. But mechanisms and 
serial changes in IVUS findings of DCAIS have not been evaluated. The aim of this study 
is to clarify the difference of initial and follow-up IVUS findings between DCAiS and those 
of SA. Methods: IVUS images were obtained with a motorized pullback at pre-, post- 
intervention, and 6 months follow-up in the consecutive 30 lesions treated by DCAIS. 
Lumen area (LA), vessel area (VA), and plaque area (PA) were measured and vessel 
expansion ratio (post-VA/pre-VA) was calculated. Thirty lesions treated by SA during the 
same period were matched and IVUS findings were compared. Results: Pre-procedural 
VA and LA were not significantly different between the DCAIS group and the SA group 
(VA: 16.1+4.3 vs. 14.5146 mm2, p=O.9, LA: 1.39r0.7 vs. 1.24+0.7 mm2, p=O.4). Post- 
procedural and follow-up LA were larger in the DCAIS group compared to the SA group 
(Post-procedural: 10.6+2.66 vs. 7.69+1.25 mm2, p<O.O5, Follow-up: 8.57e3.05 vs. 
5.48k2.37 mm2, p<O.O5). In the DCA/S group, 78% of the initial lumen gain were due to 
plaque area reduction and 22% were vessel expansion. In the SA group, they were 61% 
and 39%, respectively. There were no significant differences in the vessel expansion ratio 
between the two groups (1.13t0.25 vs. 1.13+0.15, p=O.9). However, the maximum infla- 
tion pressure for stent deployment was lower in the DCAiS group compared to the SA 
group (10.4+3.1 vs. 14.0r2.1 atm, p<O.O5). Conclusion: We were able to expand stents 
with lower pressure and achieve larger lumen by DCA/S than SA. This priority was main- 
tained during the 6 months0 follow-up period. 
1158-42 Contemporary Approach to the Percutaneous 
Revascularization of Branch-Ostial Coronary Lesions 
Shahin Keramati, John S. Douglas, Douglas C. Morris, Jeffrey Marshall, Steven V. 
Manoukian, William S. Weintraub, Trevor Thompson, Ziyad Ghazzal. Emory University 
Hospitaf, Atlanta, GA 
Background: Branch-ostial coronary lesions (ostium of LAD, LCx, PDA, Diagonal and 
OM) continue to present a challenge to the interventional cardiologist. They are thought 
to be associated with lower procedural success, higher complications, and a higher inci- 
dence of restenosis. The aim of the present study is to evaluate the efficacy of percutane- 
ous revascularization of branch-ostial lesions from a large single-center registry. 
Methods: We reviewed the acute results of all interventions on branch-ostial lesions from 
the Emory Cardiovascular databank since 1998. Procedure technique, use of stents or 
other dewces, angtographtc parameters, procedural success and complications were 
recorded. Results: 386 lesions in 370 consecutive patients (mean age =63) were evalu- 
ated. Hyperterxion was common (67%) and 27% of the palients were diabetics.The 
mean ejection fraction was 53%. The lesions were LAD and Diagonal in 46% of patients, 
followed by LCx and OM in 28% and LV branch and PDA in 22%. Calcification was corn- 
t-non (21%) as was diffuse disease (20%) but thrombus was relatively uncommon 
(5.2%). Stents were used in 25 % of lesions but in the subgroup of ostial LAD, stents 
were used in 40% of lesions Rotational atherectomy was used in 7%. Only 2 patients 
had DCA (0.5%) Angiographic success was achieved in 94% of patients. Dissection was 
rare (5.2%). There were 4 acute closures (1.0%). In-hospital complications for the total 
group and for the subgroup of ostial LAD are detailed in the table. 
In-Hospital Complications 
Total Group Ostial LAD Ostial, non-LAD p value 
(rl=370) (n=42) (n=328) 
Mortality 5 (1.4%) 3 (7.1%) 2 (0.6%) 0.012 
Q-wave Ml 1 (0.3%) 0 (0%) 1 (0.3%) ns 
CABG 5 (1.4%) 3 (7.1%) 2 (0.6%) 0.012 
Bleeding 17 (4.6%) 5 (12.2%) 12 (3.7%) 0.03 
Conclusion: Percutaneous interventron on branch-ostial lesions shows favorable short- 
term results with excellent procedural success and low peri-procedure mortality and mor- 
bidity. However, percutaneous intervention in the subgroup of ostial LAD lesions appears 
to show a higher rate of mortatlity and morbidity which may favor surgical revasculariza- 
tion in this patient subset. Long-term clinical follow-up will be presented 
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836-i Experimental Results With a Sirolimus Eluting Stent: A 
Comprehensive Histological Analysis 
Takeshi Suzuki, Gregory Kopia, Lynn R. Bailey, Gerard Llanos, Jennifer Lyons, 
Pallassana Narayan, George Papandreou, Robert Falotico, Fermin Tio, Andrew J. Carter. 
Stanford University Medical Center, Stanford, CA, University Texas San Antonio, San 
Antonio, TX 
Background: Sirolimus (SIR), a potent antiproliferative and immunosuppressive agent, 
is a promising therapy for the prevention of restenosis. The objective of this study was to 
characterize the arterial wall morphology at 28 days after placement of SIR eluting stents 
in the porcine model. Methods: Srxty-four stent and 32 non-stented reference arterial 
sections were evaluated at 28 days after placement of metal stents or SIR (180 i 5 mcg) 
coated stents in coronary arteries. Histological analysis of the arteries was completed in 
a blinded manner to characterize edge effects, neointimal SMC content and fibrin, strut 
associated inflammation and endothelialization for metal and SIR stents. Results: The 
morphology of non-stented reference arterial wall sections, including the vessel area. 
neointimal area and % area stenosis, was similar for the metal and SIR stents. Endothe- 
lialization scores were identical for the metal (2.9 A 0.4) as compared with SIR stents (2.9 
i 0.4, p = 0.66). Neointimal area (mm2) was significantly less for the SIR (2.47 f 1.04) as 
compared with the metal sterns (5.06 t 1.88, p < 0.0001) and associated with a reduced 
SMC content score (2.09 i- 0.30 versus 2.50 i- 0.51 respectively, p = 0.002). Strut associ- 
ated inflammation was significantly reduced for the SIR (0.13 f 0.34) as compared with 
metal stents (0.97 i- 1 .lO, p c 0.0001). lntimal fibrin scores were higher for the SIR (1.09 
+ 0.73) versus metal stents (0.44 t 0.56, p c 0.0001). Conclusions: Stent-based SIR, 
unlike other potent antiproliferative therapies, does not induce “edge” phenomena. Criti- 
cal reparative events, endothelialization and SMC colonization of the neointima, with SIR 
elutrng stents occur in a similar temporal sequence as observed with metal stents. Local 
stent-based delivery of sirolimus profoundly suppresses SMC proliferation and the for- 
eign-body response to stents. 
836-2 
4:15 p.m. 
Stenting in Small Coronary Arteries (SISCA): A Randomized 
Comparison of Heparin Coated beStent and Balloon 
Angioplasty 
Rasmus Moer, Yngvar Myreng, Per Albertsson, Pal Gunnes, Bo Lindvall, Rune Wiseth, 
Per Melstad, Kjetil Ytre-Arne, Swain Golf. F&ring Heart Clinic. Feiring, Norway 
STENTING SMALL CORONARY ARTERIES: 
Background: Stern treatment of small coronary arteries has been controversial, associ- 
ated with a high restenosis rate. Recent advances within stent design might improve the 
outcome. In the present randomized trial, a 15 mm heparin coated (HepamedB) beStent 
was used, investigating angiographic and clinical outcome. 
JACC February 2001 ABSTRACTS - 
Methods: in 5 Scandinavian centers 145 patients were randomized to elective b&tent 
(n = 74) or balloon angioplasty (PTCA, n = 71). Included were denovo lesions ~15 mm in 
native vessels, reference diameter (RD) 2.1-3.0 mm, in patients with stable or unstable 
angma, single or multivessel disease. All patients received aspirin indefinitely. the stent 
arm additional ticlopidin or clopidogrel. Follow-up (FU) angiography was performed after 
6 months. Quantitative coronary angiography (QCA) analysis was performed in a corelab 
(Heartcore, NL). 
Results: Clinical data at 6 months are complete, 1 (stent) refused FU angiography, 1 
(PTCA) was rejected from QCA analysis. There were no significant differences between 
the groups with respect to baseline demographics. In the cohort 35.2% were female, 
13.1% had diabetes, 22.1% had unstable angina, age 62.9 * 10.6 years. Three @tent) 
and IO (PTCA) crossed ovei RD at baseline was 2.44 F 0.35 mm @tent) vs 2.38 3- 0.32 
mm (PTCA) (ns), lesion length 11.9 + 4.5 mm @tent) vs 10.8 i 4.3 mm (PICA) (ns), 
diameter stenosis (DS) 59.4 f 9.9% (stem) vs 57.4 i 8.9% (PTCA) (ns). After interven- 
tion DS was 11.3 i: 8% (stent) vs 25.3 + 13.0% (PTGA) (p c 0.001). Angiographic suc- 
cess rates (DS < 50%) were 100% (stent) vs 95,7% (PTCA) (ns), procedural success 
rates (angiographic success in the absence of crossover or cardiac event) were 94,6% vs 
80% (p = 0.008). During 6 months follow up 9.5% (stent) vs 23.9% (PTCA) patients expe- 
rienced cardiac events (p = 0.025): One myocardial infarctlon in each group, one death 
(PTCA), 6 @tent) and 15 (PTCA) repeat interventions on target lesions I target vessels). 
Conclusions: In small coronary arteries treatment with heparin coated (HepamedB) 
b&tent significantly improves both procedural and 6 months clinical outcome compared 
to balloon angicplasty. Complete angiographic data at follow up will be presented. 
836-3 
4:3D p.m. 
Coronary Restenosis Prevention With a Rapamycin Coated 
Stent 
Benno Rensing, Jeroen Vos, Pieter Smits, David Foley, Marcel van den Brand, Wim de 
Gies, Pim de Feljter, Patrick Serruys. Thoraxcenter, Rotterdam, The Netherlands 
Background: Coronary stenting is still hampered by 15.30% restenosis rate due to 
neointimal hyperplasia. Rapamycin (Rapa) is a macrocyclic lactone agent that interacts 
with cell-cycle regulating proteins and inhibits progression from Gi to Si phase It was 
hypothesized that local delivery of Rapa with an eluting stent can prevent angiographic 
and intravascular ultrasound (IVUS) mstenosis. Methods: Patients (pts) with single ves- 
sel disease were treated with 18 mm Rapa coated BX Velocity stents (Cordis). Minimal 
lumen diameter (MLD) and % diameter stenosis (%DS) were measured before treat- 
ment, immediately after stenting and at 6 months f-up angiography. Percent in-stent vol- 
ume obstruction (PIVO) was meaured with IVUS at f-up. Results: Stenting was 
attempted and successful in ail 15 pts. 10 male, mean age 61 y, 11 unstable angina. 1 pt 
died at day 2 of cerebral hemorrhage. QCA and IVUS f-up is avaIlable for 4 pts. A negitgi- 
ble angiographic late loss and in-stent hyperplasia (PIVO) was observed at f-up No 
edge effect was observed. 
Pre-stent(n=i5) P&t-stent(n=15) 6 mo f-up(n=4) 
MLD (mm) 1.10+0.26 2.43+0 44 2.36t0.46 
%DS 64.2t6.7 16.3r7.1 17 1+5.5 
PIVO (“/) 6.1i2.8 
Conclusion: Implantation of Rapa coated stents seems very promising for prevention of 
restenosis. Complete f-up will be presented 
836-5 
5:oo p.m. 
One Year Follow-Up of Biodegradable Self-Expanding Stent 
Implantation in Humans 
Takafumi Tsuji, ilideo Tam&, Keiji Igakl, Eisho Kyo, Kunihiko Kosuga, Tatsuhiko Hata, 
Masaharu Okada, Takuji Nakamura, Hidenoii Komori, Shinsaku Takeda, Seiichiro 
Motohara, Hiromu Uehata Shiga Medml CenierforAdulis, Moriyama, Japan. lgaki 
Medical Planning Co. Ltd., Kyofo, Japan 
Background: We developed a new biodegradable self-expanding coil stent (Igaki-Tamal 
Stent) made of high molecular weight poly-i-lactic acid (PLLA). After the favorable results 
of this stent in the porcine coronary artery, we started the first human coronary applica- 
tion. Methods: From September 1998 through April 2000, 63 lesions in 50 patients elec- 
tively underwent the stem implantation for coronary artery stenoses. There were 44 male 
and 6 female, and the mean age was 61 + 13 yrs. All target lesions were AHAfACC type 
B and C. Coronary angiography was performed before and immediately after the proce- 
dure. Addltlonal assessment by quantitative coronary angiography was done 1 day, 3, 6 
and 12 months (MO) after the procedure. Restenosis was defined as the percent diame- 
ter stenosis (%DS) Z 50% at follow-up. Results: The reference vessel diameter was 2.95 
t 0.46 mm. The minimal lumen diameter (MLD) was 0.91 f 0.39 mm and the lesion 
length was 13.5 + 5.7 mm before procedure. The %DS decreased from 69% before 
stentmg to 12% after stenting. All PLLA stents were successfully implant&d. Subacute 
thrombosis occurred in one patient (2.0%) at day 5 who had been treated with inade- 
quate heparinization because of gastrorrhagia. No other Ml, CABG 01 death developed 
within the follow-up period. The interim follow-up results are shown in the table. Conclu- 
sions: Our preliminary experience suggests the feasibility, safety, and efficacy of the 
lgaki-Tamal biodegradable stent in humans. 
Pre (n=63) Post (n=63) 6 MO (n=58) 12 MO (n=36) 
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836-6 Comparison Between Sirolimus-Coated and Noncoated 
Stent Implantation in Human Coronary Arteries 
Fausto Feres, Marco A. Costa, Alexandre Abizaid, Andrea S. Abizaid, lbraim M. F. Pinto, 
Ana C. S&as, Rodolfo Staico, Luiz A. P. Mattes, Aurea Chaves, Marinella Centernero, 
Luiz F. L. Tanajura, Robert Falotico, Judith Jaeger, Amanda G. M. R. Sousa, J. Eduardo 
M. R. Sousa. lnsfitufe Dante Pazzanese of Cardiobgv, S.30 Pauio, Brazil 
Background: Sirolimus (Rapamycin) coated stent was proposed as a possible way to 
reduce restenosis. Objective: To assess the safety and efficacy of sirolimus-coated com- 
pared to non-coated (bare) BX Velocity Stents in terms of neointimal proliferation. Meth- 
ods: Forty-five patients underwent elective, single vessel stenting in our institution. 
Sirollmus-coated stents were implanted in 30 patients (15 slow 127 days] release formula- 
tion and 15 fast [I5 days] release of sirolimus) and non-coated stents were Implanted in 
15 pts. All stents were 18mm long and 3.0-3.5 mm in diameter. Angiographic and volu- 
metric IVUS analyses were performed by two experience analysts, after the procedure 
and at 4.month follow-up. Six-month clinical follow-up was also scheduled. Results: All 
stents were successfully deployed after balloon pm-dilatation and pts were discharged 
without complications. High-pressure post-dilatation was performed in all pts. Baseline 
characteristics were similar between groups. Reference vessel diameter was 2.96 r 0.3 
mm (fast release - FR), 2.98 & 0.4 (slow release SR) and 3.0 f 0.5 mm (noncoated stent 
group), p=NS. Late loss was -0.02 * 0.3(FR) and 0.16 + 0.3 (SR), p=NS. lntimal hyper- 
plasia, as detected by volumetric IVUS, was minlmal after either slow or fast release 
sirolimus-coated stenting (2.65 + 4.0 mm3 and 2.45 * 4.21 mm3, p=NS). Follow-up data 
from the non-coated stents are still pending and will be presented at the meeting. Stent 
thrombosis was not observed in any group. No edge restenosis or in-stent restenosis 
was detected by QCA in both groups of sirolimus-coated stent. There were no in-hospital 
and late follow-up MACE. Conclusion: Implantation of Sirolimus-Coated BX-Velocity 
Stent in human coronary arteries is safe. Neointimal proliferation was virtually absent 
after implantation of sirolimus-coated stents, regardless the formulation used (FR vel?.us 
SR). Data from the control group will be available next fall and will be presented at the 
meetmg 
ORAL CONTRIBUTIONS 
844 Therapeutic Angiogenesis Biological and 
Mechanical Approaches 
Tuesday, March 20, 2001, 8:30 a.m.-l 0:OO a.m. 
Orange County Convention Center, Hall F4 
844-l 
8:30 a.m. 
Therapeutic Angiogenesis by Selective Delivery of Basic 
Fibroblast Growth Factor in the Anterior Interventricular 
Vein 
Mehrdad Rezaee, Neil1 A. Herity, Sidney Lo. Takeshi Suzuki, David P Lee, Alan C. 
Yeung, Peter J. Fitzgerald, Andrew J. Carter. Paul G. Yock. Stanford University Medical 
Center, Stanford, CA 
Background: In order to achieve therapeutic angiogenesis, a safe and effective modality 
is required to deliver a critical local concentration of an angiogenic factor. The feasibility 
of using the cardiac venous system for regional, catheter-based delivery of pharmaceuti- 
cal or blological agents to the myocardium has been previously demonstrated. The cur- 
rent study was designed to determine the efficiency and outcome of delivery of an 
angiogenic factor via the anterior interventricular vein (AIV) to ischemic myocardium in a 
porcine model. Methods: In 18 animals chronic myocardial ischemia was created in the 
LAD territory using a copper stent. 1251.labeled basic fibroblast growth factor (bFGF) 
was delivered via a catheter to the myocardium through the AIV to determine regional 
pharmacokinetics. In 10 animals, bFGF (120 mcglanlmal) or placebo was delivered via a 
microporous infusion catheter positioned in the mid AIV. Regional myocardial blood flow 
was assessed using 15 urn microspheres at 21 days after infusion of bFGF or placebo. 
Resu1ts:Tot.a uptake of 1251.labeled bFGF in the myocardium at one hour was 12.3 i 
5.5% (SD) of the dose. After 3 hours, the total cardiac retention of radiolabeled bFGF 
decreased to 9.4 + 1.5%. At this time point, 81.0 * 11 .O% of the total myocardial radioac- 
tive uptake was confined within the ischemic tissue of the LAD territory and was present 
within both the epicardial and endocardial layers of the myocardium. Selective infusion of 
bFGF “!a the AIV resulted in a 16.0 i 2.3% improvement in ischemic zone flow, as com- 
pared to - 4.9 +I- 3.1% decrease in flow in the placebo group (p = 0.05). Conclusions: 
These data demonstrate that selective retrograde catheter-based drug infusion via the 
AIV is feasible and enables efficient delivery of an angiogenlc factor to improve regional 
myocardial blood flow. 
MLD (mm) 0.9lkO.39 2.6850.43 1.76-t-0.75 1.88?0 77 
%DS (%) 69213 liZi8 38*23 33t23 
Restenosis Rate 21% (12158) 19% (7/36) 
TLR Rate 12% (7158) 17% (6/36) 
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844-2 
8:45 a.m. 
Therapeutic Angiogenesis by Bone Marrow-Derived Cell 
Transplantation in Pigs With Coronary Constrictor-Induced 
Chronic Myocardial lschemia 
Takafumi Ueno, Patrick K. Coussement, Toyoaki Murohara, Jianhua Cui, Payam Fallahi, 
Mika Ueno, Stephen Frohwein, Samuel Baldwin, Maria Palasis, Tsutomu Imaizumi, 
Nicolas AF Chronos, Keith A. Robinson. At/an& Cardiovascular Research Institute, 
Norcross, GA, Kurume University School of Medicine, Kurume, Japan 
Background: We showed that bone marrow-derived mononuclear cells (BM-MNCs) 
gave rise to functlonal endothelial progenitor cells (EPCs) that contributed to postnatal 
angiogenesis when injected into rabbit ischemic hindlimb. Methods: We tested the 
hypothesis in a pig model of chronic myocardial ischemia that local transplantation of 
autologous BM-MNCs using endovascular approach may augment neovascularization in 
response to tissue ischemia. One month after ameroid constrictor placement around the 
left circumflex artery, animals were injected with either saline (n=4) or autologous BM- 
MNCs (n=5) into the ischemic area using an intramyocardial Injection catheter (Boston 
Scientific). BM-MNCs were isolated using a density-gradient centrifugation method. Each 
pig received 10 intramyocardial injections of 20 microL. Coronary angiography, dob- 
utamine stress echocardiography and myocardial blood flow measurement using micro- 
sphere injection were performed at the time of treatment and after 4 weeks. Results: At 
follow-up, the reglonal left ventricle wall motion score index at peak stress was improved 
( from 1.21 to 1.06, ~~0.05) in the treated group, as well as, endocardial / epicardial ratio 
of myocardial blood flow in the ischemic region increased at follow-up (from 0.80 to 1.35, 
p<O.Ol), but not in control. The capillary density in ischemic areas was significantly 
higher in treated group than control (46 vs. 38 / field, ~~0.05). Conclusion: BM-MNCs 
transplantation using an intramyocardial injection catheter may contribute to postnatal 
angiogenesis in chronically ischemic myocardium in pigs. 
844-3 
9:oo a.m. 
Arteriogenic Potency of a Growth Factor: Endothelial 
Specificity Versus Activity on Monocyte Adhesion 
Eva E. Katzer, Imo Hoefer, Niels van Royen, Jan Piek, Christoph Bode, Wolfgang 
Schaper, Ivo Buschmann. University Clinic Fretborg, Fretburg, Germany, Max Planck 
Institute, Bad Nauheim, Germany 
Hypoxia IS an important stimulus for capillary growth (anglogenesis) and enhances the 
expression of VEGF within tissue. However larger conductance arteries, such as preex- 
isting collaterai arteries, are necessary for an efficient restoration of physiological blood 
flow into ischemic territories. These arterial conduits are very often found in normoxic 
regions and their growth can be accelerated via the intraarterial infusion of CC-Chemok- 
ines and/or Colony-Stimulating-Factors to selectively attract monocytes. Methods: 18 
New Zealand White Rabbits (NZWR) were subjected to femoral artery occlusion and 
divided into folIowIng groups: 1 first group of 6 NZWR received VEGF (5OOpg), a second 
group (n=6) MCP-1 (31.(g) and a third group (n=6) solvent locally via an osmotic mini- 
pump into the collateral circulation of the hindlimb. The right femoral artery was cannu- 
lated with a catheter, which itself was connected to the minipump (Infusion rate 10 uUh). 
After 7 days of infusion the animals were again anaesthetized and a shunt between the 
carotid artery and the abdominal aortic artery was installed. 6 different perfusion pres- 
?.ures were used (30-90 mmHg) and each one was combined with a single bolus of differ- 
ent microspheres. Peripheral petfusion pressures, and total flow were measured. 
Collateral conductance was calculated via FAGS Analysis. Results: solvent= 3,42+0,8, 
VEGF=7,52*1,3; MCP-1=33,4&2,1, number of collaterals: solvent=l6i-4,1, 
VEGF=19+3.4, MCP-1=28+4,0. Conclusion: Chemoattraction and monocyte survival is 
an important component in arteriogenesis. Growth factors which influence monocyte 
adhesion and attraction thereby may accelerate arteriogenesis rather than endothelial 
specific factors. 
844-4 
9:15 a.m. 
Percutaneous Myocardial Revascularization With a Newly 
Developed High Pressure Saline-Jet System: Evaluation of 
Acute and Chronic Effects in Porcine Hearts 
Christian M. Spaulding, Luis Cesar Guarita Souza, Pascal Richard, Bruno Pouzet, Russ 
Bowden, Bettina Faas, Frederique Tissier, Marie-Cecile Vacher-Lavenu. Co&in Hospital, 
Rene Descartes University Parts, France, EC& de Chirurgte de I’AP-HF: Paris, France 
Background: Percutaneous Myocardial Revascularization (PMR) diminishes angina and 
improves execc~se tolerance in ‘“no-opfion” patients. Current cllnical trials are performed 
with catheter-based laser systems. Up to now, no other source of energy has been clinl- 
caliy tested. High pressure saline-jet technology has been adapted for high-precision 
channel creation and could be an alternative to PMR laser systems. We therefore deter- 
mined in a porcine model the procedural safety, and histological effects of a catheter- 
based saline-jet system that creates channels from within the left ventricular cavity. 
Methods: The CorMedica-Saphi@ jet-system consists of a steerable catheter with a 
fluid lumen that produces a collimated jet of saline. The proximal part is connected to a 
pump that delivers sterile physiologic saline at high pressures. The catheter was Intro- 
duced via a femoral approach into the left ventricular cavity in 32 pigs and positioned 
against the lateral wall or the apex. 6 to 10 pulses of saline were delivered at high pres- 
sures (18 to 22 atm). Pigs were sacrificed immediately (n=&7), 7 (n=8), 14 (n=B) and 21 
days (n=8) after the procedure for histological examination of the heart. Results: The 
procedure was well tolerated in all animals. In samples obtained immediately after appli- 
cation of the water-jet, channels of 3 to 5 mm of depth were visible with a “tear-drop” lon- 
gitudinal cross-section and surrounded by a peripheral layer of disrupted myocardial 
fibers. At day 7, most channels ware obstructed by a clot and encircled by a zone of gran- 
ulation tissue with numerous capillaries and a collagen network. At day 14 and 21, chan- 
nel areas were progressively replaced by fibrous tissue containing thin-walled blood 
vessels. Conclusion: PMR using a high-pressure, saline-jet system is feasible with 
immediate production of channels that are progressively replaced by neovascuiarized tis- 
sue. This system could be a cost-efficient alternative to laser-based PMR and a novel 
method of direct myocardial injection of therapeutic agents. 
844-5 
9:30 a.m. 
Catheter-Based, Direct Myocardial Radiofrequency 
Revascularization Reduces Angina in Patients With End- 
Stages Coronary Artery Disease: The RF-PMR Trial 
Birgit Kantor, Paul S. T&stein, William Knopf, Nicholas Chronos, Jeffrey Moses, Martin 
Leon, Davzd R. Holmes, Jr., Robert S. Schwartz. Mayo Clinic, Rochester, MN 
Transmyocardial laser revascularization (TMR) reduces angina in patients with refractory 
symptoms from end-stage coronary artery disease. Laser TMR has a significant periop- 
erative morbidity and mortality. Currently available percutaneous laser approaches 
(PMR) are expensive and cumbersome to use. Animal studies strongly suggest that 
radiofrequency PMR (RF-PMR) induces comparable myocardial tissue responses to the 
laser. Methods and Results: Phase I of the RF-PMR trial enrolled 12 patients with medi- 
cally refractory Class Ill (45%) and IV (55%) angina with objective evidence of ischemia. 
Patients received 13.9 * 5.7 RF-PMR channels in 1.8 f 0.4 ischemic areas. Average pro- 
cedure time was 24.0 k 10.4 min. There was no morbidity and no mortality associated 
with RF-PMR during the whole 30-day follow-up. Periprocedural CPK and mean ejection 
fraction assessed by left ventriculogram remained unchanged. Ventricular arrhythmias 
assessed by Halter Monitor at baseline and at 30 days decreased significantly (36% vs. 
0%; p<O.O5). Mean angina class decreased by 1.1 CCS classes from 3.6 f 0.52 to 2.5 ? 
1.25 (Table). Conclusions: RF-PMR is a safe, time-efficient, and cost-effective approach 
to percutaneous myocardial revascularization. RF-PMR appears to reduce angina com- 
p&ably to laser TM-R. 
CCS Class Baseline Discharge 30 Days 
No Pain 0% 8% 0% 
I 
II 
Ill 
IV 
Unknown 
0% 0% 0% 
0% 0% 63% 
45% 42% 37% 
55% 17% 0% 
0% 33% 0% 
844-6 
9:45 a.m. 
Percutaneous Myocardial Revascularization Using a 
Myocardial Channeling Device: Procedural Results and 12- 
Month Outcome 
Fayaz Shawl, Upendra Kaul, Syed Mahmood, Cathy Pollock. Washington Adventist 
Hospitai, Takoma Park, MD 
Background: Percutaneous myocardial revascularization (PMR) using laser energy alle- 
viates angina in inoperable pts with coronary ischemm However, lasers are complex and 
expensive We ciescnbe the initial experience with a mechanical myocardial channeling 
device. Methods: In 13 consecutive inoperable (due to diffuse disease) pts (11 men and 
2 women, mean age 61 & 7 years) with Class III (n = 8) or Class IV (n = 5) refractory 
angina, we performed PMR using a 9F percutaneous device that forms channels by com- 
bined mechanical coring and vacuum tissue extraction (AngioTraxTM System). History of 
prior Ml was present in 7 pts, CABG in 4, 3-vessel CAD in 10, P-vessel in 3, and LV ejec- 
tion fraction of > 25% (mean 47 + 7). An average of 10 f 5 channels were created in 
ischemic regions (all had thallium perfusion defects in these regions) - inferior wall: 6, 
anterior: 1, inferolateral: 5, and posterolateral wall: 2. Endomyocardlal tissue was 
extracted as each channel was created. Total procedure time was 32 i 8 minutes and 
total fluoro time was 12.7~ 5.5 min. Results: Left ventriculography performed before and 
after procedure demonstrated unchanged or improved wall motion in the target region. 
Histology of core biopsies in all patients demonstrated myocytes with focal hypertrophy, 
with interstitial scarring in 3, who had wall motion abnormalities on left ventriculography. 
No complications occurred (specifically, no CPK-MB elevations) and all pts were dis- 
charged within 48 hours. Mean angina1 class declined from 3.15 pre-procedure to 1.08 at 
6 months (p < 0.01). In 9 pts B-month exercise time improved to a mean of 319 seconds 
from baseline of 210 sec. (p < 0.05). Complete B-month and 12.month follow-up including 
stress thallium perfusion data will be presented. Conclusions: Mechanical PMR with 
AngioTraxTM system is safe and feasible and may prove to be an inexpensive substitute 
for laser revascularization. Early clinical outcome appears encouraging. Also left ventric- 
ular tissue obtained may provide diagnostic and therapeutic Insights. A randomized effl- 
cacy trial is underway. 
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1187 Restenosis: Cellular Response to Injury 
Tuesday, March 20, 2001, 9:00 a.m.-l 1:OO a.m. 
Orange County Convention Center, Hall A4 
Presentation Hour: 9:00 a.m.-IO:00 a.m. 
1187-9 Absence of Neointimal Thickening Following Arterial Injury 
in M-CSF-Deficient Mice and Its Reversal by Local Delivery 
of M-CSF Highlights the Critical Role of M-CSF in Neointima 
Formation 
Ming Liu. Ning-Ning Char, Arun Shukla, Sanjay Kaul, Prediman K. Shah, Bojan Cercek, 
Tripathi i3. Rajavashisth. Cedars-Sinai Medical Center, Los Angeles, CA 
Background: Our studies using balloon injury model in the rat carotid artery and Ihe rab- 
bit abdominal aorta indicate ihat augmented expression of M-CSF and its receptor may 
contribute to the growth of vascular SMC. 
Methods and Results: To critically test the role of M-CSF in vascular SMC growth, we 
used a murine model of perivascular injury induced by placing a periadventitial collar 
around the carolid arteries in mice lacking M-CSF and/or apoE. In wild type as well as 
apoE null mice with normal M-CSF genotype, arterial injury consistently produced neoin- 
timal thickening at 21 days. In contrast, there was no neointimal thickening after arterial 
injury in M-CSF-deficient mice despite hyperlipidemia. When M-CSF (10e6 M/vessel) 
was locally delivered to the Injured carotid wail through a polymeric gel in MCSF-deficient 
mice, illjury was followed by monocyte-macrophage infiltration and neointimal thickening 
as assessed by histomorphometric analysis. Treatment of injured carotid with perivascu- 
lady delivered M-CSF increased iniimal area (0.011 I 0 002 mm2 vs. 0.002 i 0.0002 
mm2 control, p <O.Oi) and the intima io media ratio (0.407 i 0.012 vs. 0.069 + 0.008 con- 
trol. p ~0.005) These changes occurred without any effect on the levels of the total 
plasma cholesterol and the circulatrng monocytes. 
Background: Macrophage chemotactic protein -1, a C-C chemokine, functions as a 
proinflammatory cytokine and as a chemotactic factor for macropgages. The members of 
MCP family bind and signal through chemokine receptors 2b (CCR 2b) and 5 (CCR 5). 
Though the role of MCP-1 has been well established in the pathogenesis of atherosclero- 
sis, expression of CCR 2b and CCR 5 is not fully known. Hence, in the present investiga- 
tion, we localized the expression of CCR 2b and 5 by immunocytochemlsiry (IHC) in 
human atherectomy lesions. Methods: Expression of CCR 2b and CCR 5 was evaluated 
by IHC using affinity purified polyclonal antibodies in ien primary (mean age: 56, range: 
41.70) and 8 restenotic (mean age: 47; range: 39-58) atherosclerotic lesions obtained by 
directional athereciomy. Lesions were evaluated in a blinded manner. Lesions were char- 
acterized by cellularity. intensity of staining, and whether ii is focal or diffuse. Results: 
Morphometrlc analysis revealed that the primary lesions are more cellular compared to 
restenotic lesions (2.1liO.11 Vs. 1 .OOiO.38, p&05). In primary lesions, CCR 5 immu- 
noreactivity was detected in seven out of ten lessons localized to both cytoplasm and 
membrane components of endotheiial cells as well as to smooth muscle cells. Interest- 
ingly, CCR 2b was also detected in these lesions co-localized with CCR5. However, CCR 
2b immunoreactivity much weaker and more diffuse. In restenotic lesions, only CCR 5 
immunoreactivity, but not of CCR2b, was detected localized to the smooth muscle ceil?.. 
Conclusions: While both CCCR 2b and 5 may be mvolved in the development and pro- 
gression of atherosclerosis, CCR 5 may a play a role in the restenotic process. 
1187-41 Attenuation of Neointimal Formation After Carotid Injury in 
lntegrin Associated Protein (IAP)-Deficient Mice 
Conclusion: These finding suggests a critical role for M-CSF in mediating monocytel David Schwartz, M. Faisal Khan, Kevin Brandstetter, Chris Davis, William A. Frazier, 
macrophage trafficking into the vessel wall and neolntima formation after arterial injury. Dana R. Abendschein. Washington University: St. Louis, MO 
1187-10 Absence of CD40 Signaling is Associated With Increased 
lntimal Thickening Following Acute Arterial Injury 
Mojca Remskar, Hongyan ii, X. Helen Xu, Prediman K. Shah, Kuang-Yuh Chyu, Bojan 
Cercek. Cedars-Sinai Medical Cenfer. Los Angeies, CA 
Background: Immune deficiency has been shown to be associated with increased 
neointlmal thickening after arterial injury Inhibitjon of immune mediator CD40 llgand 
(CD40L) signaling is associated with increased smooth muscle cell (SMC) and collagen 
content of the atherosclerotic plaques. We hypothesized that inhibition of CD40L signal- 
ing is the mechanism of the exuberant iniimal thickening aiter arterial wall injury in 
immune deficient anrmals. Methods: The lntimal area in CD40L-I- mice was compared to 
the intimal area in control 661129 mice, immune deficient RAG-I-/- mice and CD40L-i- 
mice reconstituted with 50-60 million of normal splenocytes (CD40L-I-&x) (n=6 each). 
Arterial injury was induced with a non-occlusive plastic collar placed around carotid 
arterv. The arteries were harvested 21 days after iniurv and intimal and medial area mea- 
Background: Smooth muscle cell (SMC) proliferation and migration are key components 
in vascular lesion formatIon in alherosclerosis and in the arterial response lo injury (rest- 
enosis). IAPiCD47 is a receptor for thrombospondln (TSP), an early response gene pro- 
duced by SMC that has been shown to modulate SMC migration and proliferation in vitro. 
We evaluated the neointimal and medial response to arterial injury in IAP-deficient mice. 
Methods: IAP-deficient (-i-i and competent (+/+) male mice (Cl29 background) fed a 
normal chow diet were anesthetized with ketamineixylazine. The lefi common carotid 
artery was exposed and transiently occluded proximally and dislally. A 30G needle was 
introduced into the external carotid and the occluded segment was hypennflated to 2 
ATM with saline for 5 minutes. Carotid blood flow was restored and hemostasis was 
obtained by ligation of the external carolid artery. Three weeks later, sham control, 
injured, and contralaieral uninjured vessels were perfusion-fixed in situ for morphologic 
and histologic analysis. 
Results: Wild-type mice showed slgnificant’neointimal formation in response to over- 
stretch injury compared to contralateral uninjured and sham control vessels (0.009 i- 
0.005 mm2 injured; 0 + 0 mm* contralateral; 0 + 0 mm* sham conirol [p<O.O5]). The 
neointima was predominately composed of a-actin-positive smooth muscle ceils. IAP- 
deficient mice demonstrated an attenuated neointlmal response to injury. (0.001 ? 0.002 
mm2 , p<O.O3 compared with wild-type animals.) Medial areas of the injured vessels from 
the IAP-knockout animals were not significantly different from those of wild-type animals 
(0.037 f 0.004 mm2 and 0.038 * 0.017 mm*, respectively [p=n.s.]). 
Conclusion: We conclude that IAP-mediated signaling contributes to neointimal forma- 
tion in carotid arteries of mice subjected to overstretch injury. 
sured. Results: 
B6l129 RAG-1 -/- CD40L-I- CD40L-/-Rx 
lntima (mm sq) 0.009+/-0.001 0.021+/-0.007* 0.029+/-0.02’ 0.013+/-0.007 
Media (mm sq) 0.024+/-0.005 0.041+1-0.016 0.04+/-0.016 0.03411-0.008 
MeantSD. * PcO.05 vs B61129, vs CD40L-/-Rec. 
Conclusion: The extent of intimal thickening after arterial injury in the absence of CD40L 
signaling is comparable to the increased intimal thickening in immune deficient mice. 
These findings suggest that CD40L signaling is Important in immune regulation of intimal 
thickenmg after arterial injury. 
1187-I 1 Monocyte/Macrophage Lineage Cells Contribute to 
Neointimal Cellular Mass after Coronary Artery Injury and 
Repair 
Antonio Bayes-Genis, Julie H. Campbell, Giulio Gabbianl, Paula J. Carlson, Paul C. 
Keelan, Debra A. Lewis, David R. Holmes. Jr., Robert S. Schwartz. Mayo Clinic. 
Rochester, MN 
Macrophages participate in the restenosis process through release of cytokines, metallo- 
proteinases, and growth factors. Studies of peritonial granulation tissue suggest that 
macrophages may be precursors of myofibroblasis. This study examinned the coniribu- 
tion of monocytelmacrophage lineage cells to neointimal cellular mass after thermal cor- 
onary artery inJury in pigs (n=ZO). Severe thermal damage was induced in the coronary 
areiry, killing most medial smooth muscle ceils. Neointimal cells formed at these injury 
sites were evaluated over time by light microscopy, electron microscopy, and immunohis- 
tochemistry. At day 3, blood monocytes adhered to and infiltrated the iuminal side of ihe 
acellular. fibrotic media wail. At day 14, 42+-3.9% of neolntimal cells had a monocytlc 
nuclear morphology and stained for monocional antibody DH59B (tissue macrophage). 
Double-label immunohistochemistry revealed that 9.2+-i .8% of ceils were DH59B+ and 
alpha-smooth muscle actIn+, and electron microscopy identified cells with ultrastructural 
characteristics of bolh macrophages and myofibroblasts. Ai day 28, 10.5+-3.5% of ceils 
were DH59B+, and 5.2+-1.8% of cells were both DH59B+ and alpha-smooth muscle 
actln+. These data suggest ihat macrophages and cells with intermediate appearance 
between macrophages and myofibroblasts abundantly populaie the neointima during 
lesion formation. Cells of monocytelmacrophage lineage may thus dlfferentiate into col- 
lagen-secreting myofibroblasts after severe medial injury in coronary arteries. 
1187-40 Differential Expression of C-C Chemokine Receptors CCR 
2b and CCR 5 in Human Primary and Restenotic Lesions 
Bysani Chandrasekar, Jodie Polan-Curtain, Steven R. Bailey. University of Texas Health 
Science Center, San Antonio, TX 
1187-42 Catheter-Based Prostacyclin Synthase Gene Transfer 
Prevents In-Stent Restenosis in Atheromatous Rabbits: A 
Potential Strategy for Therapeutic Angiogenesis via 
Vascular Endothelial Growth Factor 
Mitsunori Harada, Yasushi Numaguchi, Yuklo Toki, Hlroyuki Osanai, Takahito Tomida, 
Michiharu Yamada. Hideo Matsui, Ken]i Okumura. /nterna/MedicineZ, Nagoya University 
School of Medicine, Nagoya, Japan, Children’s Hospital, Harvard !Jniver..itL: Boston, MA 
Background: Overexpression of prostacyclln Induced by prostacyclin synthase (PCS) 
gene transfer accelerates re-endothelializaiion and prevents intimal hyperplasia through 
CAMP in balloon-injured rat arteries. However, its mechanism of angiogenesis is 
unknown. In this study, we hypothesized that PCS gene transfer would induce endothe- 
iium-specific growth factors, which could accelerate the endotheliai recovery and inhibit 
hyperplasia even in the atheromatous stented arteries. Methods: New Zealand White 
Rabbits fed a 0.5% cholesterol diet underwent balloon injury followed by Palmaz-Schatz 
stent implantation in the external iliac arteries. Thereafter, either PCS gene (pPCS. 
2OOvg) or control piasmid carrying LacZ gene (pLac2, 2OOpg) was delivered into the 
injured arterles by the lipotransfection method via Dispatch catheter (n=6 each). 
Results: One week after transfectlon, arterial segments with pPCS produced higher lev- 
els of 6.keto-PGFlalpha than those with pLacZ (10.21-0.2 vs 3.3iO.lngimg tissue, 
~~0.05). The CAMP level was significantly higher in the pPCS-transfecied vessels than in 
the pLacZ-transfecied counterparts (12.1&0.4 vs 7.3+0.5pmol/mg protein, ~~0.05). 
lmmunohistochemical analysis revealed that pPCS-transfecied vessels expressed a 
much higher level of vascular endothelial growth factor (VEGF) than their pLacZ-trans- 
fected counterparts, especially in the adventitia and neolntima. Western blot analysis 
showed that the vessels with pPCS produced l&fold more VEGF protein than those 
with pLacZ (p&05). Two weeks after transfection, stent endotheiialization was signih- 
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cantly greater in the vessels with pPCS than in those with pLacZ as assessed by Evans’ 
blue dye staining (89.4t5.2 vs 41.6+6.1%, p<O.Ol). Four weeks after transfection, PCS 
gene transfer reduced the neointimal area (0.8+0.1 vs 2.lc0.4mm2, ~~0.05) and wid- 
ened the lumen area (4.1i0.4 vs 2.4+0.2mm2, pcO.01). Conclusion: PCS gene transfer 
accelerates the endothelial recovery and prevents restenosis in the atheromatous 
stented arteries probably by VEGF production through CAMP. PCS gene transfer may be 
a potential strategy against in-stent restenosis in atheromatous human coronary arteries. 
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1188-13 The Validity of Duplex Ultrasound as a Diagnostic Modality 
for Internal Carotid Artery Disease. 
Gishel New, Gary S. Roubin, Matthew E. Oetgen, lssam Moussa, Vickram 
Veeramachaneni, Sriram S. lyer, Nadim Al-Mubarak, Mariah Ennis, Christina Barman, 
Kristin Young, Jennifer S&berg, Jiri J. Vitek, George Dangas, Martin 6. Leon, Jeffrey W. 
Moses. Lenox Hill Heart and Vascular Institute of New York, New York, NY 
Background: Carotid endarterectomy is being increasingly performed solely on the 
basis of carotid duplex ultrasound. The aim of our study was to determine the validity of 
duplex carotid ultrasound assessment of the severity of carotid bifurcation disease when 
compared to high-quality digital carotid angiography. Methods: 437 arteries were avail- 
able for analysis. Percent stenosis in the internal carotid artery was measured according 
to NASCET criteria. Results were compared categorically [mild (<40%), moderate (40. 
70%), and severe (>70%)] and numerically (when available) for both angiographic and 
ultrasound results. Results: The sensitivitv, specificitv, and likelihood ratios of the carotid ., 
ultrasound for each lesion category are shown in the table below. 
category Sensitivity Specificity Positive likeli- Negative likeli- 
hood ratio hood ratio 
Mild 54% 95% 10.8 2.1 
Moderate 34% 74% 1.3 1.1 
Severe 93% 67% 2.6 9.6 
ROC &rves demonstrated that if the optimal ultrasound cut-off value of 76% on ultra- 
sound is used to predict >70% stenosis measured angiographically, it would be associ- 
ated with a 29% false positive rate and a false negative rate of 11%. Similarly, if the 
optimal ultrasound cut-off value of 66% on ultrasound is used to predict >60% stenosis 
measured angiographically, it would be associated with a 38% false positive rate and a 
false negative rate of 9%. Conclusion: These data demonstrate that carotid ultrasound 
is an inadequate modality for diagnosing moderate and severs carotid artery stenosis. 
Since duplex ultrasound studies significantly overestimate the degree of severity of 
carotid bifurcation stenoses, practicing physicians should be very cautious in recom- 
mending carotid revascularization solely on the basis of duplex ultrasound. 
1188-14 Review And Management of Neurologic Complications 
Associated With Carotid Artery Stent Placement 
Michael H. Wholey, Mark H. Wholey, Gus Eles, Walter Tan. UNlVERSlTY OF TEXAS 
HEALTH SCIENCE CENTER AT SAN ANTONIO, SAN ANTONIO, TX, PITl-SBURGH 
VASCULAR INSTITUTE, PITTSBURGH, PA 
Background: To review the complicatibns associated with extracranial carotid artery 
stent placement and to preliminarily assess the current techniques in managing these 
complications. Methods: From the 400 patients who underwent successful carotid artery 
angioplasty and stent placement, neurologic complications such as seizures, transient 
ischemic attacks (tia’s), minor and major strokes and deaths were carefully reviewed 
within the 30.day post-procedure period. Management of these complications included 
medical treatment in addition to intraarterial thrombolytic therapy. Results: Of the 400 
patients who underwent carotid artery stent placement, there were 4 cases of seizures 
(1 .O%), all of which r&l&d in no neurologic sequellae. There w&e 12 (3.0%) cases of 
tia’s, 8 (2.0%) minor strokes and 3 (0.8%) major strokes and 4 (1 .O%) procedure-related 
deaths. Total minor and major strokes and procedure-related deaths were 15 (3.8%). All 
of the TIA’s were treated medically and resolved. Of the 8 minor stokes, 3 occurred 
between 1 to 7 days post procedure. All minor strokes were treated with medical therapy 
and 5 resolved completely. Of the 7 procedure-related deaths and major strokes, all 
occurred during or immediately after stent placement except for a groin hem&ma in a 
Jehovah’s witness. Five of the 6 major strokes and deaths received intraarterial throm- 
bolytic therapy. Of the 5 thrombolytic patients, one patient had significant neurologic 
improvement with mild residual motor and sensory deficits. One patient had initial 
improvement but returned to baseline and later died. The other three patients had 
improvement angiographically but not clinically. The patient who received medical treat- 
ment alone required intubation, which was not successful and subsequently died. Con- 
clusions: Neurologic complications occur following carotid stent placment and it is 
imperative that operators are well trained in how to manage such events. The number df 
minor strokes occurring l- 7 days post procedure was surprising and warrants further 
investigtion. Also, the poor results of intraarterial thrombolytic therapy demonstrate the 
destructive nature of embolic plaque and the need for protective devices. 
1188-15 Serial Change of Initial Hyperplasia of Carotid Artery After 
Carotid Stenting 
Keita Odashiro, Hiroyoshi Yokoi, Takeshi Kimura, Hideyukt Nosaka, Masakiyo Nobuyoshi. 
Kokura Memorial Hospital, Kitakyushu, Japan 
Background: Carotid artery stenting (CAS) has evolved as’ a potential alternative to 
carotid endarterectomy. However there was little angiographic follow-up data for patients 
receiving stents at internal carotid arteries. The purpose of this study was to assess the 
serial change of intimal hyperplasia of carotid artery after CAS. Method: Out of 45 
patients with 50 lesions, 1 year follow-up angiography was available in 10 patients with 15 
lesions(l2 Wall stent and 3 Palmaz stent) and 2years follow-up in 6 patients with 10 
lesions(8 Wall and 2 Palmaz). Quantitative angiographic analysis was performed. Stent 
sites were divided into 10 segments. Minimal luminal dianeter(MLD), mean luminal diam- 
eter and % diameter stenosis(%DS) were measured at each segments. ResuI&: lntimal 
hyperplasia became greater at the stenotic lesion after 6 months (MO). Follow-up angiog- 
raphy of 15 lesions at 6 MO, 15 lesions at one year, and 10 lesions at 2 years revealed a 
decrease in MLD from 4.8~0.6 mm immediately after stent implantation to 3.51r0.9 mm 
at 6M0, but no further decrease in diameter at 1 year. Late improvement in luminal diam- 
eter was observed after 6 MO. 
Pre Post 6MO 1Y 2Y 
Lesion studied at lyr ( n=l5) 
MLD 1.67kO.5 4.8~tO.6 3.51r0.9 3.89kO.8 
%DS 69.3i-7.4 11.8e7.3 26.61-10.2 24+8.7 
Lesion studied at 2yr ( n=lO) 
MLD 1.64eO.7 4.710.3 3.5el.O 4.26iO.6 4.3kO.7 
%DS 70.8A9.4 13.2+8.5 28i11.2 20.6k7.0 19.6~6.7 
Conclusion: Angiographic outcomes up to 2 years after GAS were favorable, with a very 
low restenotic rate. Late improvement of intimal hyperplasia appears to occur after 6 
months. 
1188-16 Predictors of Microembolization During Carotid Stenting 
Nadim Al-Mubarak, Gary S. Roubin, Sriram S. lyer, Jiri J. Vitek, Gishel New, George 
Dangas, Roxana Mehran, Martin 6. Leon. The Lenox Hi// Heart and Vascular Institute 
and the Cardiovascular Research Foundation, New York, NY 
Background: Microembolization during carotid stenting (CAS) may serve as a surrogate 
marker for peri-procedural neurological events. We sought to determine the predictors of 
high microembolic load during CAS. 
Methods: Trans-Cranial Doppler was used to assess microembolization during 29 GAS 
procedures performed without distal-occlusion-balloon or filter cerebral protedtion. We 
analyzed the impact of clinicali procedural and morphological factors on the extent of 
microembolization (count of Microembolic Signals, MES) 
Results: The mean age of the patients was 68 t 9, 10% were male, and 35% had neuro- 
logical symptoms attributed to the treated lesion within 3 months of CAS. The mean total 
MES of the entire group was 207 ? 125. MES were observed during all the technical 
stages of CAS: sheath placement and wire cross 36M5, predilation 36+32, stent delivery 
and placement 74*47, and postdilation 3oi27. The median total MES value was 180, 
and MES>160 was considered a high micro-embolic load. Multivariate analysis using dif- 
ferent clinical, procedural and angiographic variables identified age >70 years, pre-CAS 
lesion diameter stenosis >80%, and lesion length 2 15mm as independent predictors of 
high micro-embolic load. Gender, diabetes, hypertension, Hyperlipidimia, symptomatic 
presentation, prior carotid endarterectomy, prior neck radiation, Activated Clotting Time 
(ACT) ~200, lesion ulcer, calcification, and eccentricity were NOT found to be indepen- 
dently predictive of high-embolic load. 
ConclusiowMicroembolization during CAS appears dependent on pre-procedure vari- 
ables, and is increased in older patients, and those with highly obstructive and long 
carotid stenoses. CAS technique should be very careful and likely include distal cerebral 
protection devices to minimize embolization. 
1188-17 Is Simultaneous Bilateral Carotid Artery Stenting Safe? 
Deepak L. Bhatt, Debabrata Mukherjee, Marco Roffi, Samir R. Kapadia, Khaled M. 
Ziada, Derek p. Chew, Jay S. Yadav. Cleveland Cfmic Foundation, C/eve/and, OH 
Background: Percutaneous carotid stenting is increasingly utilized in patients who are 
not candidates for surgical endarterectomy. Patients with severe bilateral carotid stenosis 
have generally not had stenting of both arteries in a single procedure due to concern 
about hemodynamic impairment from stimulation of the carotid sinus baroreflex, as well 
as the risk of cerebral hyperpetiusion syndrome. 
Methods: Only patients at high surgical risk were considered for carotid stenting. 
Patients who had severe carotid stenosis (>70% for symptomatic patients, r80% for 
asymptomatic patients) and were in need of expeditious cartitid revascularization, such 
as those awaiting heart transplantation or other open-heart surgery, received bilateral 
carotid stents during the same procedure. Procedural outcomes of death, stroke, and 
myocardial infarction were examined. 
Results: A total of ten patients underwent simultaneous bilateral carotid stenting. The 
mean diameter stenosis of the lesions was 83%. Lesions were symptomatic in 5120 arter- 
ies. Coronary artery disease was present in 6110 patients. A history of hypertension was 
present in 7110 patients. An intravenous glycoprotein llb/llla antagonist was used in all 
cases. All procedures were technically successful. Four patients required atropine and/or 
norepinephrine after placement of the first carotid stent. Three patients required intrave- 
nous dopamine overnight. One patient with a history of ventricular arrhythmia required 
defibrillation during his hospitalization and went on to have successful open-heart sur- 
gery. There were no deaths, strokes, or myocardial infarctions peri-procedurally, nor were 
there any cases of post-procedural cerebral hyperperfusion syndrome. 
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Conclusion: With careful hemadynamic and neurologic monitoring, bilateral carotid 
stenting can be performed safely in a single procedure in selected patients with critical 
bilateral carotid artery stenosis. 
1188-18 Endovascular Treatment of Atherosclerotic Vertebral Artery 
Stenoses 
Michel Henry, Kyril TZVETANOV, Christos KLONARIS, Max AMOR, lsabelle HENRY: 
Edmond LE BORGNE. Polyclinique d’Essey-/es-Nancy ESSEY-LES-NANC): France 
Purpose: To evaluate the safety and efficacy of percutaneous interventional treatment 
(angioplasty/stenting) in patients with symptomatic vertebral artery stenosis. Materials 
and Methods: 23 procedures were attempted in 22 patients by femoral approach using 
coronary techniques. (M:lZ, F:iO, mean age : 67.7 = 6.9 years (57-80). Right :6 left :17. 
All patients had multivascular diseases (carotid stenosis :18, renal stenosis :2, peripheral 
vascuiar disease :8, coronary disease :13). Indications for angioplasty included : diplopia 
(n=2), vertebra basilar insufficiency (n=22), TIA (n=3). All lesions were ostial. Mean % 
stenosis 79.1 2 7.4% : (70.95). Mean lesion length : 8.3 i 2.4 mm (5-12). Mean arterial 
diameter 4.6 c 0.6 mm (4-6). Results: Technical success :21/23. 2 failures in patients 
with very tortuous calcified arteries. The first 3 patients were treated by angioplasty 
alone, the others with balloon expandable stents (Paimaz : n=9 and other coronary stents 
: n=91. Post stent drug regimen included a combination of Aspirin with Ticlopidine or Clo- 
pidogrei for 30 days Angiographic success , defined as f 20% residual stenosis without 
in hospital emergency surgery, stroke or death : 21123 ies~ons. Post procedure arterial 
diameter. 4.6 i 0.6 mm (4-6). Mean residual stenosis 2 i: 3.6%. Four patients developed 
restenosis during follow-up (31.3 t 26.2 months), among them, one total occlusion was 
treated medically and the 3 stenoses were successfully treated with balloon angioplasty. 
Conclusion: Endoluminal treatment of vertebral artery stenosis can be performed safely 
and effectively with a high technical success rate, a low complication rate and a durable 
clinical success in patients with symptomatic atherosclerotic vertebral artery stenosis. 
1188-l 9 Outcome of Carotid Stenting in Octogenarians Compared to 
Non-Octogenarians: Acute and Long Term Outcome 
Fayaz Shawl, John Hakim, Syed Mahmood, Elizabeth Humphreys, Cathy Pollock. 
Washington Adventist Hos@a/, Takoma Park. MD 
Background: With the increase in life span, mcxe octogenarians are presenting with 
carotid stenosis. Most carotid endarterectomy (CEA) trials (NASCET and ACAS) have 
excluded these patients. Methods: Patients undergoing carotid stenting (CS) at our insti- 
tution were stratified to < 80 years (225 pts) and > 80 years (74 pts, [including 4 pts > 901) 
in order to assess the impact of age on clinical, in-hospital and long term outcomes. 
Results: Summarized below are the characteristics of the two groups. 
CS in Patients Stratified by Age (years) 
Age < 80 Age 2 80 
(n = 225) (n = 74) 
Age (yrs)/Male (%) 66157 85159 
Prior CABG/PTCA (%) 73 74 
Contralateral OCCluSlO” (%) 7 12 
Prior CEA (%) 7 8 
Refused CEA (%) 10 89 
Procedural s”ccess (%) 99 100 
Complications at 30 days 
Death (%) 0 0 
Minor CVA (%) 3.0 13 
Major CVA (%) 0.9 0 
Mean follow-up at 21 months 
Neuro death (“‘o) 0 0 
Minor CVA (%) 0.8 1.3 
Major CVA (%) 0 0 
Conclusions: Despite a higher incidence of refusal for CEA because of associated 
comorbidities, octogenarians have similar procedural success, complications and long 
term outcome as non-octogenarians. Therefore, advanced age should not exclude 
patients from carotid stenting. 
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1189-20 Elective Stenting of Unprotected Left Main Coronary Artery 
Stenosis: Intravascular Ultrasound Guidanceand Debulking 
Atherectomy Before Stenting 
Seung-Jung Park, Seong-Wook Park, Cheol Whan Lee, Myeong-Ki Hong, Jae-Joong 
Kim. Asan Medical Center, Seoul, South Korea 
Background: The aim of this study was to evaluate 1) the long-term outcomes of the first 
127 cases receiving unprotected left main coronary artery (LMCA) stenting, and 2) the 
impacts of debulking procedure prior to stenting and guidance of intravascular ultrasound 
(IVUS) on their clinical outcomes. Methods: One hundred twenty seven consecutive 
patients with unprotected LMCA stenosis and normal left ventricular function were 
treated by elective stenting. The long-term outcomes were compared between 2 groups; 
IVUS- (n=77) vs. angiography-guided (n=50), and debulking prior to stentlng (n=40) vs. 
stenting alone (n=87). Results: Angiographic restenosis was documented in 19 patients 
(19.0%, 19/100) with target lesion revascularization of 15.0%. Post-stent lumen diameter 
was significantly larger in II/US-guided stenting (p=O.O03). The angiographic restenosis 
rate was significantly lower in debulking + stenting (8.3% vs. 25%, p=O.O34). The refer- 
ence artery size was the only independent predictor of angiographic restenosis 
(O&0.39, 95%CI 0.17-0.87, p=O.OZl). During the follow-up (25.5?16.7 months), there 
were 4 deaths (1 cardiac and 3 non-cardiac), but no nonfatal myocardial infarction 
occurred. The survival rate was 97.0&l .7% at 2 years. Conclusion: Stenting of unpro- 
tected LMCA stenosis ware associated with a favorable long-term outcome in selected 
patients with normal left ventricular function. IVUS-guided procedure should be consid- 
ered to optimize the immediate results. Debulking prior to stenting seems to be effective 
in reducing the restenosis rate. 
1189-21 Multivessel Stenting: Is It Time to Reconsider 
Recommendations for Coronary Artery Bypass Surgery? 
Vasant B. Patei, Steven P. Marso, Philip G. Jones, Steven B. Laster, Kenneth C. Huber, 
Lee V. Giorgi, Warren L. Johnson, Barry D. Rutheriord. Mid America Heart Institute, 
Kansas City, MO 
Background: While there is growing enthwasm for multivessel stenting (MVS), limited 
data are available comparing its efficacy to PTCA or CABG. We sought to assess 
whether stenting was as efficacious as CABG for multivessel CAD. Methods: Consecu- 
tive patients undergoing MVS (N=260) or PTCA (N=308) between 1995 and 1999 were 
identified. Using propensity scoring, a CABG cohort (N=260) was matched to MVS 
group. Patients with acute myocardial infarction (Ml) or prior CABG were excluded. Base- 
line clinical variables were well balanced among the three groups. Angina class Ill or IV 
was present in nearly half of the patients in each group. Resutts: Of the entire cohort, 
85.4%, 83.1%, and 85.1% underwent P-vessel, and 14.6%. 16.9%, and 14.9% had 3- 
vessel revascularization in the CABG, MVS, and PTCA groups, respectively. In-hospital 
MACE (death, Ml, and urgent or target-vessel revascularization) rates were 1.6% and 
1.2% for CABG and MVS groups (P=O.72), and 2.6% for PTCA. One important difference 
in outcomes was increased incidence of stroke in the CABG group compared with MVS 
(3.5% versus O.O%, P<O.OOi) or PTCA (0.3%). At 5.year follow-up, there was no slgnifi- 
cant difference in survival between CABG and MVS; however, both were slightly better 
than PTCA. The rate of repeat revascularization for MVS group was intermediate com- 
pared to PTCA and CABG (figure). Conclusion: In this matched cohort, MVS reduces 
in-hospital stroke while providing similar long-term survival benefit as CABG, and seems 
to be “closing the gap” between PTCA and CABG in the treatment of multivessel CAD 
Months Months 
1189-22 One-Year Outcome of Patients With Unprotected or 
Protected Left Main Coronary Artery Stenting 
Juergen Pache, Adnan Kastrati, Josef Dirschinger, Julinda Mehilli, Helmut Schiihlen, 
Franz-Josef Neumann, Albert Schiimig. Deutsches Herzzentrum Munich, Munich, 
Germany, Klinik rechts der Isar, Munich, Germany 
Background: Left main coronary artery disease (LMCA) has been a great challenge for 
interventionists. The increase use of coronary stenting may have improved the chances 
of the percutaneous approach. The aim of this study was to analyse the clinical and 
angiographic short and long-term outcome of 182 patients (pts) after LMCA stenting. 
Methods: We analysed 182 consecutive pts after left main intraccronary stenting. 94 pts 
had unprotected LMCA (uLMCA) and 59 pts had protected LMCA (pLMCA), respectively. 
Pts (n=29) presenting with acute myocardial infarction (AMI) including 15 pts (52%) with 
cardiogenic shock were analysed separately. Clinical events were recorded at 30 days 
and after 12 months. Follow-up angiography was available in more than 80% of eligible 
pts. 
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Resulb: The procedural success rate was 98% in both groups. MACE rate (death, myo- 
cardial Infarction or target vessel revascularisation) within the first 30 days was 3.4% in 
pts with pLMCA and 8.5% in pts with uLMCA. The restenosis rate at 6 month angio- 
graphic follow up was 29.3% in the pLMCA group and 6.6% in the uLMCA group 
(p<O.OOl). The 1 -year survival was 91.5% in the uLMCA group and 93.2% in the pLMCA 
group (p 0.7). In the AMI and cardiogenic shock pts mortality rate was 27.6% at 30 days 
and 34.5% at 1 year. 
Conclusion: Taking into account the high risk usually presented by uLMCA disease, cor- 
onary stenting in these patients appears to be a safe procedure and with favourable long- 
term results. Especially in a subset of pts with AMI including cardiogenic shock the mor- 
tality rate was low considering the high rusk in this pts group. 
1189-23 Does Stent Deployment During Percutaneous Coronary 
Intervention Save Lives? Results From a Registry of 2,877 
Patients 
YanPing La”, Tami L. Bair, Joseph B. Muhlestein, Robert R. Pearson, Sherman G. 
Sorensen, Dale G. Renlund, Li Zhang, Benjamin D. Home, G. Michael Vincent. LDS 
Hospital, Salt Lake City UT 
Background: The use of stents in percutaneous coronary intervention (PCI) has demon- 
strated significantly improved procedural success and reduced restenosis when com- 
pared to non-stent forms of PCI. However, few studies have had a sufficient sample size 
or adequate follow-up to determine whether this advantage results in a positive effect on 
mdrtality. 
Methods: A total of 2,877 patients (pts) undergoing PCI (stented pts = 1,699, non- 
stented pts [balloon PCI or rotational atherectomy] = 1178) at a single institution between 
1995 and 1999 were followed prospectively for acute and long-term clinical outcomes. Pt 
baseline clinical, and angiographic, and procedural characteristics were also collected 
for comparative purposes. 
Results: Angiographic success (150% residual stenosis) (99.8% vs. 97.0%, p<O.OOi) 
and acute gain (3.05 r 0.64 mm vs. 2.15 r 0.72 mm, p<O.OOi) were both greater for 
stented lesions. Likewise, procedural complications of death (0.0% vs. 0.5%, p<O.O03) 
and dissection (5.5% vs. 7.5%, p=O.O43) were lower in the stent group. Over a mean fol- 
low-up of 31r13 months for the stent group and 35516 months for the non-stent group, 
significantly lower rates of target lesion revascularization (8.3% vs. 13.1%, p<O.OOi), 
CABG (6.4% vs. 11.7%, pcO.001) and mortality (4.2% vs. 8.2%, p<O.OOl) were observed 
in the stent group. No difference in long-term incidence of myocardial infarction (Ml) 
between the two groups (3.3% vs. 4.2%, p=O.22) was seen. In multiple variable Cox 
regression, non-use of stents (Hf?=i .85, p=O.OOZ), age (HR=1.06 per yr, p<O.OOOl), dia- 
betes (HR=2.9, p<O.OOOl), number of treated vessels (H&i .9 per # increase, p=O.OOl), 
previous Ml (HR=1.6, p=O.O2), and family history of MI (HRz1.5, p=O.O4) were all inde- 
pendently and significantly associated with mortality. 
Conclusion: This large prospective study demonstrates that, besides a general improve- 
ment in procedural success and a reduced need for repeat revascularization, the use of 
stents during PCI is also associated with a significant reduction in long-term mortality, 
independent of other clinical and procedural variables. 
1189-24 Procedural Results and Late Clinical Outcomes in Patients 
With Low Lefl Ventricular Ejection Fraction Undergoing 
Stent Implantation in Saphenous Vein Grafts 
Javed M. Ahmed, Augusto D. Pichard, Lowell F. Satler, Gary S. Mintr, Luis Gruberg, 
Hongsheng Wu, John R. Laird, Kenneth M. Kent. Washington Hospital Center, 
Washington, DC 
Background: Previous reports have suggested higher in-hospital complicahons and 
worse late clinical outcomes in patients with depressed left ventricular function undergo- 
ing stent implantation in native coronary arteries. However, the impact of low left ventric- 
ular ejection fraction (LVEF) on clinical outcomes after saphenous vein graft (SVG) 
stenting has not been well established. Methods: A total of 430 consecutive patients 
(732 SVG lesions) undergoing successful stenting procedure were studied. Procedural 
results and one year clinical outcomes were compared among patients with LVEF <30%, 
30.45% and >45%. Results: Baseline clinical and lesion characteristics were similar 
among three groups except for higher incidence of chronic renal insufficiency in patients 
with LVEF ~30% (P=O.O006). Similarly, these patients had more frequent episodes of 
post-procedural pulmonary edema (P=O.O004) and more often required intraaortic bal- 
loon (IABP) support (both emergent and elective, PcO.0001). In-hospital results and one 
year clinical outcomes are shown below. Table MI=myocardial infarction, CABG=coro- 
nary bypass surgery Conclusions: Patients undergoing SVG stenting with LVEF ~30% 
have similar in-hospital outcomes as patients with LVEF >30%. However, these patients 
had significantly higher one year mortality. Thus, the results of this study indicate that 
although the stents appear to equalize the early clinical outcomes in these high-risk 
patients, they do not seem to eliminate the increased risk of late mortality. 
LVEF<30% LVEF30-45% LVEF>45% P 
In-hospital results 
Procedural s”ccess (%) 
Death (%) 
Q-Wave Ml (%) 
CABG (%) 
One year Outcomes 
Death (%) 
Q-wave Ml (%) 
CABG (%) 
Event free survival (%) 
99.1 100 100 NS 
2.3 1.9 1.6 NS 
1.7 1.3 1.6 NS 
0.0 1.3 0.0 NS 
23.3 11.2 8.8 0.001 
1.6 1.5 1.9 NS 
3.1 3.8 6 .5 NS 
62 72 74 0.08 
I 189-25 Gender and PCI Outcome: A Population Based Analysis in 
the Stent Era 
Lauren E. Tobe, Karin H. Humphries, James M. Rankin, Ronald G. Carere, Min Gao, F 
Michael Kiely, Christopher E. Buller. Univei’s~ty of British Columbia, Vancouver, BC, 
Canada, Cenfre for Health Evaluation & Outcome Sciences, Vancouver, EC, Canada 
Background: Conficting data exist regarding the effect of gender on outcome following 
percutaneous coronary interventions (PCI). Comparisons of gender specific outcomes 
following modern PCI have not previously been performed using large, unselected, geo- 
graphically based populations. Methods: All 7880 patients undergolng PCI procedures 
between April 1994 and June 1997 were included. Age, sex procedural characteristics. 
and target vessel revascuiarizatlon were obtained from the British Columbia Cardiac 
Registries, which have prospectively collected data on all cardiac surgical procedures 
since 1991 and all PCI since 1994. Co-morbidlties, death, and in-hospital myocardial inf- 
arction (Ml) were obtained using llnked province-wide health databases. Stent rate was 
calculated as the percentage of procedures in which at least one stent was implanted. 
Major adverse cardiac events at one year (death, in-hospital MI, target vessel revascular- 
ization) were evaluated by the Cox proportional hazards method. Burden of disease was 
assessed using a modified Charlson comorbidity index. Resuk: Overall stent rate 
mcreased from 14.2% to 58.7% of procedures during the period (p<O.OOl). Rate of stent- 
ing did not vary be gender (14.0% to 58.4%(F), 14.3% to 58.8%(M) p=O.63). The 
increase in stent use was associated with a significant reduction in the rate of MACE 
(adlusted relative risk, 0.79; 95% Cl 0.69. 0.90) with women and men benefitting equally 
(~~0.74). This reduction was exclusively due to a significant decrease in TVR (adjusted 
relative risk 0.72; 95% Cl 0.62, 0.83). Rates of myocardial infarction (5.2%(F), 
3.7%(M))and death (4.8%(F), 3.7%(M) did not differ signifcantly and were stable over this 
period. Co-morbidity burden was greater in women (mean co-morbidity index 0.91 versus 
0.78 p<O.OOl). The overall burden of disease remained stable over the study period. 
Conclusion: The rate of coronary artery stenting did not vary by gender and women 
benefitted equally ‘in terms of reduction in target vessel revascularization and MACE, 
despite their greater burden of co-morbid disease. 
1189-26 The Stenting in Small Arteries Study (SISA): Quantitative 
Angiographic Results Per Segment Treated 
Martin J. Schallj, Serge Doucet, LUG Bilodeau, Johan H. C. Reiber, David J. Hilton, Matty 
C. Vrolix. Laden University Medical Center, Leiden, The Netherlands, Montreal Heart 
Institute, Montreal, Canada 
Background: The Stentlng In Small Arteries (SISA) trial is a randomized, multicenter, 
worldwide study where balloon angioplasty (PTCA) is compared to stent in pts with a ref- 
erence diameter (RD) of 2.3-2.9 mm. Angiographlc restenosis at 6 months is the primary 
endpoint. A subanalysis was performed to study the outcome of treatment of lesions in 
main branches (MB) compared to the outcome of side branch (SB) treatment. 
Methods: Between October 1997 and July 1999, 351 pts with stable angina and one de 
now lesion in a native coronary artery were randomized to standard PTCA or Medtronic 
b&tent implantation after on-line quantitative coronary analysis (QCA) measurement 
had confirmed a RD of 2.3-2.9 mm. The QCA results of 252 main vessels and 92 side 
braches were available for this sub-analysis. 
Results: Clinical results for cumulative adverse events are available for 347 pts at 30 
days and 341 pts at 6 months. The Event rate at 6 months was 23% for the PTCA group 
and 18% for the Stent group (NS). The reference diameter (RD) at inclusion was 
2.52(+0.33)mm for the PTCA group and 2.52(+0.37)mm for the. STENT group 
(NS).Quantitative angiographic results are summarized in table 1. The 6 month resteno- 
sis rate in the PTCA group was 28.8% (MB)/ 42.9% (SB) and 29.1%(MB)/ 24.2%(56) in 
the STENT group (NS). 
PRE FUP 
PTCA group 
Main Side Main Side 
MLD mm 0.97(0.27) 0.84(0.31)** 1.46(0.57) 1.16(0.53)* 
RD mm 2.52(0.33) 2.30(0.32)“* 2.53(0.36) 2.22(0.33)* 
DS % 61(10) 63(13) 41(21) 47(25) 
STENT group 
MLD mm 0.95(0.30) 0.85(0.26)*’ 1.47(0.56) 1.31(0.43)* 
RD mm 2.56(0.36) 2.32(0.33)** 2.51(0.38) 2.24(0.39) 
DS % 63(11) 63(10) 41(8) 40(16) 
* PcO.05 ** P<O.O05 MLD: minimal lumen diameter DS: diameter stenosis 
Conclusion: Coronary interventions can be performed successfully in coronary arteries 
with a reference diameter of ~3.0 mm. The restenosis rate was equal between the PTCA 
en STENT group. Although the RD and the MLD of the SB treated were significantly 
smaller than the RD and the MLD of the MB treated, the restenosis rate was identical. A 
trend towards a lower restenosis rate of stented SB compared to PTCA was found 
(p&06). 
1189-27 Stenting Elderly Patients in the New Millennium: Results in 
the Year 2000 
Yoshio Kobayashi, George Dangas, Roxana Mehran, lssam Moussa, Gishel New, 
Octavia B&n, Gary S. Roubin, Sriram lyer, Nadim Al-Mubarak, Nancy Cohen, Gregg W. 
Stone, Martin B. Leon. Lenox Hi// Heart and Vascular Institute, New York, NY, 
Cardiovascular Research Foundation, New York, NY 
Background: Recently coronary stent implantation is routinely performed even in elderly 
patients (X80 years old). However, the outcomes of stenting in elderly patients have not 
been fully evaluated. 
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Methods: Between January and June 2000, stenting was performed in 943 patients with 
1,410 lesions. Patients were classified into three groups according to age: 1) ~70 years 
(476 pts, 893 lesions), 2) 70-79 years (251 pts, 372 lesions), and 3) z 80 years (94 pts, 
145 lesions). 
attempted non-stented lesions (86.9% vs 96.3%, pc.001) and persistent dissection 
(2.0% vs. 0.3%, p<.OOi) and flow reductions (2.0% vs. 1 .O%, pc.05) were more common. 
No differences were observed in in-hospital death or MI although CABG was more com- 
mon among No-ST pts (2.3 vs 0.8%, pc.05). Conclusions: Pts who did not receive a 
stent had a different clinical proflle than ST pts. Attempted non-stented lessons were 
more often total occlusions, located in smaller arteries and were previously treated. 
Inability to achieve an initial balloon dilation and the presence of a previously deployed 
stent (in-stent restenosis) likely influenced stent “sage and may have contributed to the 
higher rate of in-hospital CABG. Rates of in-hospital death or Ml were similar between 
No-ST and ST pts. 
Results: Technical success was similar among all 3 groups. 
<70 70-79 280 p value 
Female (%) 20 34 41 co.01 
Diabetes mellitus (%) 32 31 28 0.68 
Ilb/llla (%) 46 41 35 0.07 
Reference (mm) 2.91t0.48 2.90t0.47 2.88kO.45 0.84 
Pre-MLD (mm) 0.74io.45 0.71kO.43 0.77io.45 0.40 
Post MLD (mm) 2.981-O 51 2.95+0.48 2.95+0.46 0.47 
Proc QWMI (%) 0.5 0.4 0 0.78 
Proc CABG (%) 0.2 0 0 0.75 
Proc death (%) 0.2 0.4 0 0.72 
Bleeding Compl. (%) 0.3 1.6 1.1 0.14 
Vascular CornpI. (%) 1.0 1.6 4.3 0.05 
Stroke (%) 0.5 0.4 0 0.78 
Stent thrombosis (%) 1.1 0.5 0.7 0.59 
30.day CABG (%) 0.2 0 0 0.75 
so-day mortality (%) 0.5 0.8 0 0.65 
MACE at 30 days (%) 1.7 1.6 1.1 0.90 
MLD = minimal lumen diameter, QWMI = Q wave myocardial infarctlon, CABG = core- 
nary artery bypass surgery, CornpI= complication. MACE = major adverse cardiac event. 
Conclusions: Even in elderly patients, stenting IS successfully performed with similar 
stroke, stent thrombosis and MACE rates at 30 days compared to younger patients. How- 
ever, elderly patients have higher vascular complications, underlinIng the need for careful 
monitoring of access site and anticoagulation iegrnen. 
118928 Clinical and Angiographic Results of l-Year Follow-Up After 
Coronary Artery Stenting in Unstable Angina 
Julinda Mehllli, Adnan Kastrati, Josef Dirschinger, Jiirgen Pache, Helmut Schijhlen, 
Franz-Josef Neumann, Albert Schbmlg. Deutsches Herzzentrum, Munch, Germany, 1. 
Med. K/in/k rech:s der lsar der TU MOnchen, Munich, Germany 
Background: The issue of ihe most appropriate treatment strategy for patients with 
unstable angina is still under debate. We assessed the l-year clinical and angiographic 
outcome of patients with unstable angina treated with immediate (within 24h) stenting 
and compared these data with the results achieved in patients with stable angina. 
Methods: After excluding pts with recent (~4 weeks) myocardlal infarction (Ml), a con- 
secutwe series of 3844 pts undergoing stent implantation was divided into 2 groups: 
unstable (UA, 1475 pis) and stable angina (SA, 2369 pts). Protocol included systematic 
CK determination poststenting, routine S-month angiography at 6 months (80%) and clin- 
ical follow-up at 30 days and 1 year. 
Results: UA pts were older, included a greater proportion of women and were more likely 
to have hypertension, hypercholesterolemia, a history of Ml and complex lesions; they 
received more often abciximab periprocedurally (30 vs. 21%). One-year results are 
shown in the table. 
UA SA Odds Ratio (95% Cl) 
Subacute stent thrombosis, % 1.3 1.0 1.31 (0.72-2.45) 
Angiographic restenosis (>50% DS) rate,% 33.2 33.8 0.97 (0.83-l .14) 
Death, % 4.5 4.1 1.13 (0.82-1.55) 
nonfatal Ml (Q-and non-Q-wave), % 4.7 2.8 1.74 (1.23-2.45) 
Q-wave MI, % 1.3 1.2 1.05 (0.59-i .88) 
non-Q-wave Ml, % 3.2 1.7 1.87 (1.22-2.86) 
Target vessel revascularization. % 20.7 18.8 1 .I 3 (0.96-l .33) 
Any adverse clinical event, % 27.5 23.9 1.21 (1.04-i .40) 
Conclusion: In the era of combined antiplatelet therapy, UA pts have a favorable out- 
come l-year after coronary artery stenting. This outcome is comparable to that of SA pts 
except for a higher risk of non-Q-wave Ml. 
118929 Patients Who Are Not Treated With Stents in the Stent Era: 
Who Are They and What is Their Outcome? 
David 0. Williams, Helen Vlachos, Katherine M. Detre, Howard Cohen, Alice K. Jacobs, 
Sheryi F Kelsey. Rhode Island and Brown iJniversi& Providence, RI 
Background: Stent Implan!ation improves In-hospital and late outcome of patients (pts) 
undergolng percutaneous coronary intervention (PCI). However, despite technical reilne- 
men& stents are not used uniformly. We sought to determine factors that influence stent 
“sage and the outcomes of PCI pts not treated with stents. Methods: 2,109 pts from 16 
centers were enrolled in the Dynamic Registry in 1999 and had PCI. One oi more stents 
were deployed in 1,664 pts (ST, 78.9%) and not in 445 pts (No-ST). Results: No-ST pts 
more often had a hx of prior revascularization (56.4% vs. 35.0%, p<.OOl) or diabetes 
(34.5% vs. 27.0%, p<.Ol). No differences were noted in age, gender. hx of CHF, clinical 
presentation or extent of CAD. No-ST pts had fewer lesions attempted (mean: 1.2 vs. 1.4, 
pc.OOl),were less likely to receive GP llbllla antagonist prior to or during the procedure 
(18.4% vs. 35.3%, p<.OOl). Attempted non&en&d lesions were more often in the LCX 
(29.7% vs. 20.0%, p<.OOl), in smaller diameter arteries (2.76mm vs. 3.03mm, pc.OOl), 
total occlusions (16.0% vs. 10.5%, p<.OOi), and not complicated by thrombus (14.6% vs. 
20.1%. pc.01) or ulceration (5.3% vs. 12.8%, p<.OOl). Lesion success was lower among 
II 89-30 Combined Coronary Stent Treatment of Unprotected Left 
Main Disease and Severe Coronary Lesions Located at 
Remote Sites 
Alfonso Medina, Jose Suarez de Lezo, Manuel Pan, Miguel Romero, Enrique Hernandez, 
Djordje Pavlovic, Jose Segura, Juan Ft. Silas, Ricardo Huerta, Soledad Ojeda, Carmen 
Adamuz, Jose R. Ortega. Negrin Hospital, Las PAlmas, Spain, Reina Sofia Hospital, 
Cordoba, Spain 
Background: Isolated left main coronary disease may be treated safely with stents. 
However, associated coronary lesions amenable for stent treatment at remote sites are 
frequent and may increase the complexity of the procedure. Methods: From September 
1992 we selected for stent treatment 107 patients having unprotected left main coronary 
stenosis. The mean age was 61+11 years; 81 (78%) were male. The cl~n~cal condition 
was unstable in 90 (84%). Eighty-four patients (Group A) (79%) needed stent repair of 
remote lesion located in the left system (n=54) and/or the contralateral right coronary 
(n=37). The mean number of treated remote lesions in this group of patients was 2.5~1. 
The remaining 23 patlents (21%) had isolated left ma111 disease (group 6). This study 
compares the immediate and follow-up results between both groups of patients. There 
were no significant differences between groups in terms of angiographic or procedural 
parameters related to the left main site. Results: The table shows the main comparative 
results. 
Primary success In-hospital mortality LM-restenosls Late Mace 
Group A 82(98%) 2(2%) 15/44(34%) 27(37%) 
Group B 21(91%) 2(9%) 3/l 1(27%) 4(20%) 
LM: left main; MACE: major adverse coronary event. Conclusions: The combined stent 
treatment of unprotected left main coronary stenosis and severe lesions located at 
remote sites does not adversely influence initial results. However, a trend to an increased 
rate of late major adverse coronary events is observed, as compared with isolated left 
main treatment. 
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1190-31 32P Deployable Balloon System Reduces Neointimal 
Formation After Balloon Overstretch Injury in Porcine 
Coronary Model 
Han-So0 Kim, Marc K. Kollum, Rosanna C. Ghan, Brett Trauthen, Yves Cottin, Balram 
Bhargava, Jana Fournadjiev, Ron Waksman. Washington Hospital Center, Washington 
Background: lntracoronary radiation has been shown the potential to reduce neointimal 
formation in the porcine models of restenosis. The objective of this study was to investi- 
gate the feasibility, safety and efficacy of a new “deployable balloon” device with the 
radioisotope “P integrated into the balloon material. 
Methods: Ten swine underwent balloon overstretch injury (BI) in 20 coronary arteries 
and were randomized to receive a dose of 0 Gy, 15 Gy, or 20 Gy, prescribed to 1 mm 
from the surface of the radioactive balloon material. The animals were sacrificed 4 weeks 
following the procedure. Vessel parameters (intimal area (IA) and fracture length (FL)) 
and thrombus area (TA) were analyzed by computer-aided histomorphometry. 
Results: Neointimal formation after 81 was reduced in the radiated groups as compared 
to control (p-zO.05) (Table). 
Control (n=5) 15 Gy (n=4) 20 Gy (n=9) 
Vessel area (mm’) 5.83 * 1.11 6.00 i 1.49 6.58 k 1.83 
Lumen area (mm*) 3.68 + 0.81 4.70 f 1.43 5.03 t t .82 
IA (mm’) 1.14+0.22 0.17 + 0.13’ 0.21 t 0.30’ 
IA/FL (mm) 0.70 i 0.12 0.08 i 0.13‘ 0.07 + 0.17. 
Total TA (mm*) 0.00 * 0.00 0.06 f 0.20 0.51 + 0.98’ 
p<o.o5 vs Control 
Vessels treated with 20 Gy underwent vascular remodeling and had an increase in the 
total TA (p<O.O5). 
Conclusion: lntracaronary radiation therapy “sing a new “P deployable balloon system 
is feasible and safe. Radiation doses of 15 Gy were sufficient to inhibit the neointimal 
response in the porcine coronary balloon injury model. 
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1190-32 Predictors of Restenosis Following Gamma Radiation for 
Treatment of In-Stent Stenoses 
S.Chiu Wang, Paul T&stein, Jeffrey Moses, Prabhakor Tripuraneni, Bryan Kluck, Shirish 
Jant, Dean Kereiakes, Barry George, Carol I. Duffy, Martin B. Leon. The New York 
Presbyterian Hospital - Come// Campus, New York, NY; Lenox Hi// Heart and Vascular 
/nstitute, New York, NY 
Background: Previous studies identified both clinical (history of diabetes) and lesion 
(reference vessel size, in-stent lesion length, final stent lumen diameter and % diameter 
stenosis) related factors that influence repeat restenosis following conventional treatment 
for in-stent lesions. lntracoronary radiation therapy (IRT) has recently shown marked effi- 
cacy for treatment of in-stent restenosis. However, predictors for repeat in-stent resteno- 
sis following IRT treatment have yet to be characterized. 
Method: Using the combined GAMMA I and II database, we sought to delineate predic- 
tors of repeat restenosis following Ir “e localized IRT for in-stent restenosis. 
Results: A total of 256 consecutive patients were enrolled in the active treatment arm of 
the GAMMA I and II trials. Baseline patient characteristics included a” average age of 
59+12 years, 75.8% were male, 34.0% had diabetes and 23.4% had rest angina. The 
pre-intervention reference vessel size was 2.7010.51mm, with minimal lumen diameter 
(MLD) of 0.96+0.43mm and % diameter stenosis (DS) of 64.1+14.6%. The mea” lesion 
length was 19.02+10.15mm and 39.4% of target vessels involved the LAD. Post interven- 
tion, the in-stent MLD improved to 2.4i0.5mm with corresponding residual DS of 
12.7+17.7%. Six-month follow-up angiograms were available in 86% of patients. The 
average in-stent MLD was 1.68+0.86mm and DS was 37.3?32.2%. The overall 6-month 
binary in-stent restenosis rate was 25.9%. There were 3 univariate predictors of 6-month 
in-stent r&stenosis: 1) Pre-procedure MLD (O&0.422, P=O.O31), 2) Pre-procedure refer- 
ence vessel diameter (OR~0.522, P=O.O46), and 3) Post-procedure in-stent MLD 
(O&0.529, P=O.O43. However, stepwise logistic regression did not identify any indepen- 
dent predictor for in-stent restenosis at the PcO.05 level of significance. 
Conclusions: Intravascular gamma radiation therapy is a” effective treatment for in-stent 
restenosls. Three univariate predictors were identified as significant predictors of in-stent 
restenosis in pooled data from 2 gamma radiation trials. Gamma radiation effectively 
neutralizes the impact of clinical and lesion factors that usually promote in-stent resteno- 
sis 
1190-33 Treatment of Diffuse In-stent Restenosis With Rotational 
Atherectomy Followed by Radiation Therapy With a ‘s’Re- 
MAGs-Filled Balloon (R4 Trial): QCA Analysis 
Seong-Wook Park, Myeong-Ki Hong, Dae-Hyuk Moo”, Seung-Jut- Oh, Sung-Tae Cho, 
Cheol Wha” Lee, Jae-Joong Kim, Seung-Jung Park. Asan Medical Center, Seou/, South 
Korea 
Background: We evaluated the efficacy of beta radiation therapy with ‘88Re-MAG,-filled 
balloon followrng rotational atherectomy for diffuse in-stent restenosis (ISR) by QCA anal- 
ysis. Methods: QCA comparison between post-radiation and B-month follow-up was 
available in 47 of 50 patients in R4 Trial. Using QCA system (ANCOR V2.0, Siemens), 
measurements of minimal lumen diameter (MLD) were performed in proximal and distal 
i”)ured segment (IS), radiation segment (Rad-S), reference segment (RS) and ISR seg- 
ments. Results: Angiographic restenosis occurred in 5 lesions (2 in ISR segment, 1 I” 
proximal edge and 2 in distal edge). The results of QCA analysis are shown in Table. 
Conclusion: Beta irradiation using “‘Re-MAG, for diffuse ISR shows a” excellent 
angiographic results in radiated segment (ISR segment, IS and R&S). Follow-up (F-U) 
MLD larger than post-radiation MLD in ISR segments was documented in 32% of 47 
lesions. However, there were no significant impacts of radiation therapy on RS. 
seqment Proximal Proxlma, Proximal I6 Ia8 lesion Distal IS Distal Rx- Dcstai RS 
1190-34 lntracoronary Radiation Therapy for Patients With InStent 
Restenosis and Chronic Renal Insufficiency 
Luis Gruberg, Ron Waksman, Roxana Mehran, Han-Soo Kim, Andrew E. Ajani, Lowell F. 
Satler, August0 D. Pichard, Kenneth M. Kent, Alexandra J. Lansky. Washington Hospital 
Center, Washington, DC 
Background: Patients with chronic renal failure (CRF) are at a higher risk for r&en&s 
after percutaneous coronary intervention. lntracoronaty radiation therapy (IRT) for 
patients with in-stent restenosis (ISR) has demonstrated a reduction in the recurrence 
rate. The effect of IRT on restenosis and revascularization for patients with CRF was 
studied. 
Methods: In the WRIST (Washington Radiation for InStent restenosis Trial) studies, 547 
patients were treated with gamma radiation ( “?r). A total of 50 (9.1%) consecutive 
patients presented with CRF (serum creatinine >1.8mg/dL). The clinical and angio- 
graphic outcome of patients with CRF were compared to the patients with normal renal 
function (NRF) at six months. 
Results: Patients with CRF had more diabetes, hypertensron, and history of Ml. There 
were no differences in the revascularization rate between CRF and NRF patients, but 
CRF patients had a higher mortality rate (Table). 
CRF (n=50) NRF (“=497) ,P 
Male gender 66.0% 66.8% 0.91 
Age 70.5*12 62.5?12 <O.OOi 
Diabetes 52.0% 38.3% 0.06 
Hypertension 92.0% 70.0% <O.OOl 
Prior Ml 64.0% 50.9% 0.08 
Prior CABG 57.1% 52.4% 0.52 
Lesion Length (mm) 22.3i8.5 23,1+12.1 0.78 
Final MLD (mm) 2.01+0.47 1.97+0.45 0.74 
Follow-up MLD (mm) 1.64iO.87 1.53+0.81 0.59 
Late Thrombosrs 4.0% 1.2% 0.16 
TLR 14.0% 19.5% 0.34 
TVR 20.0% 25.2% 0.42 
Death 18.0% 3.4% <O.OOl 
MLD=minimal lumen diameter; TLRlarget lesion revasculariratio”; TVRlarget vessel 
revascularization 
Conclusion: Despite higher risk in baseline clinical characteristics, patients with CRF 
who were treated with IRT for ISR had similar restenosis and revascularization rates 
when compared to the NRF population. However equalizing the revascularization rate did 
not alter the higher mortality in patients with CRF. 
1190-35 Predictors of Stent and Stent-Edge Restenosis After Sr-90 
Radiation in the START Trial 
Alexandra J. Lansky, Kartik Desai, Costantino Cost&i+Ortiz, Moha” Suntharalingam, 
Ian Cracker, Kalon Ho, Larry S. Dean, John Lasala, Mark R&man, Richard E. Kuntz, 
Raoul Bona” Martin 8. Leo”. Cardiovascular Research Foundation, New York, NY, 
Lenox Hi// Heart & Vascular Institute, New York, NY 
Background: In the START Trial, Sr-90 reduced restenosis (RS) compared to placebo 
(28% vs 45.2%, p<O.OOi), however 50% of recurrences in radiated pts were located out- 
side the stent edge (Edge RS). 
Method: To gain insight into this phenomenon, we compared the demographics and 
lesion characteristics of pts treated with Sr-90 radiation with no RS (N=140), in-stent RS 
(N=28), and edge RS (n=29). 
Results: Compared to pts with no RS, in-stent RS pts had smaller vessels and longer 
lesions, whereas pts with edge RS had more focal lesions (Table). Using’multivariable 
regression analysis, the predictors of overall restenosis included the vessel size (OR 
0.209, p<O.OOl) and the final procedure minimal lumen diameter (MLD) (OR 0.260, 
p<O.O02). The predictors of in-stent RS were the final procedure MLD (OR 0.081, 
p=O.OOl) and vessel size (OR 0.153, p<O.OOl). The single predictor of edge restenosis 
was the lesion length (per mm) (OR 0.928, p=O.O229). Geographic miss, defined as the 
length of vessel injured in the dose fall-off zones or beyond, was not a predictor of edge 
restenosis (OR 1.039, p=O.560) and there was no interaction between lesion length and 
geographic miss. 
Conclusion: We conclude that among patients treated with Sr-90, vessel size and final 
MLD remain important predictors of restenosis, suggesting that optimizing the final pro- 
cedural results may further improve outcomes after Sr-90 brachytherapy. Treatment of 
more focal lesions in this trial predicted edge restenosis, whereas geographic miss did 
not. Thus a strategy of matching the radiation treatment length to the lesion length may 
further optimize results after Sr-90 therapy. 
No RS Stent RS Edge RS p Value 
Diabetes, % 30.7 42.9 31.0 0.460 
Reference, mm 2.87kO.45 2.47-cO.48 2.6510.39 <O.OOl 
Lesion Length, mm 16.6k7.0 18.357.2 13.6t6.8 0.036 
1190-36 Relationship Between Tensile Stress and Plaque Growth 
After Balloon Angioplasty Followed by lntracoronary 
Radiation 
Ken Kozuma, Marco A. Costa, Mane1 Sabate, Cornelis J. Slager, Eric Boersma, Patnck 
Kay, Johannes P. A. Marijnisse”, Stephane G. Carlier, Jolanda J. Wentzel, Attila Thury, 
Jurge” M. R. Ligthart, Veronique L. M. A. Cow, Peter 6. Levendag, Patrick W. Serruys. 
Thoraxcenter, Rotter&m, The Netherlands, Daniel den Hoed Cancer Center, Rotterdam, 
The Netherlands 
Background: Biophysical factors have “ever been investigated in the field of coronary 
brachytherapy. We investigated the influence of tensile stress on plaque growth after bal- 
loo” angioplasty treated with and without P-radiation therapy. 
Methods: Thirty-one consecutive patients successfully treated with balloon angioplasty 
were analyzed qualitatively and quantitatively by means of ECG-gated 3-dimensional 
intravascular ultrasound (IVUS) post-procedure and at 6-month follow-up. Eighteen 
patients were irradiated with a catheter-based b-radiation system (“Srp”Y bource) and 
13 were not (control). As treated segments were divided into 2-mm sub-segments, 184 
irradiated and 111 non-irradiated sub-segments were the subject of the study. Tensile 
stress was calculated according to Laplace’s law. The radiation dose was calculated by 
means of dose-volume histograms. Linear regression analyses were performed to deter- 
mine the relationship among the change in plaque volume (post-procedure - follow-up), 
IVUS derived quantitative and qualitative variables (plaque morphology, dissection, 
plaque-free wall site, vessel size), actual dose and tensile stress. 
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Results: The change in plaque volume and tensile was positively correlated to tensile 
siress in both the radiation and control groups (rzO.374, p=O.OOOi and rz0.305, p=O.OOi, 
respectively). Low-dose sub-segments (c6Gy) had a significant correlation (r=O.41, 
p=O.OOOl) whereas no correlation was observed in the effective-dose sub-segments 
(t6Gy). Low-dose sub-segments had higher initial tensile stress (p=O.Oll) and higher 
plaque growth (p&002) compared to the other segments. Multivariate analysis identified 
tensile stress as ihe only predictor of plaque increase in non-irradiated sub-segments. 
whereas actual dose and plaque morphology were stronger predictors than tensile stress 
in the irradiated sub-segments. 
Conclusions: Plaque growth is related to tensile stress after balloon angioplasty. Intrac- 
oronary brachytherapy may alter the blophysical process on plaque growth when the pre- 
scribed dose is effectively delivered. 
1190-37 Safety and Efficacy of Vascular Beta-Radiation of In-Stent- 
Restenosis With a 188Re Liquid-Filled PTCA Balloon 
Svstem 
Klaus Reynen, Ulrich Koeckeritz, Johannes Kropp, Gerd Wunderlich, Alexander 
Schmeisser, Ruih H Strasser. Heart Center Dresden, Dresden, Germany. Technical 
University Dresden, Dresden, Germany 
Background: In interventionally treated coronary arteries, irradiation has been sug- 
gested to prevent res~enosis. Aim of this study was to show the feasibility and safety of 
intracoronary radialion by a 188Re liquid-filled PTCA balloon. Due to its characteristics, 
this radionuclide does not require additional shielding in the caih lab and it has been 
shown to provide homogeneous dose distribution. This enables the use of a standard 
PTCA catheter. Methods: From October 1999 to April 2000, 41 patients (mean age 60 +I 
- 10 years, 33 male, 8 female) with in-stent-restenosis and suffering from angina pectoris 
or having signs of ischaemia in stress testing, undeiwent intracoronary brachytherapy. 
Restenosis was mainly located in the LAD (LAD 23, ACX 6, RCA 12). After repeat PTCA, 
a second balloon was directed into the redilated coronary segment and filled with the 
solution conlalning 188Rhenium. Low Inflation pressure (3 bar) was used. Depending on 
the concentration of the radioactlvity and the diameter of the vessel, the balloon was 
inflated for 315 _ 880 seconds (mean 540 +/- 155 set) to reach 28 Gy at 0.5 mm depth. 
Results: In all patients, repeat PTCA was successful (residual stenosis less than 30% In 
diameter). In nine cases, stenting was necessary due to dissection. One procedure had 
to be interrupted due to disconnection of the system filled with the radioactive fluid. NO 
other complications were noted during the procedures. In none of the cases, radioactive 
contamination occurred. During follow-up, one patient underwent late (37 days) and 
another acute and very late (6 months) stent thrombosis. 29 patients were examined 4 to 
6 months after brachytherapy showing no restenosis in 18, but restenosis in six and reoc- 
elusion in five patients. In those cases, repeat PTCA was performed in 5 and coronary 
bypass surgery in 3. Results of the remaining repeat angiographies after 6 months will be 
presented at the meeting. Conclusion: lntracoronary brachytherapy with the 188Re- 
filled balloon system is feasible and safe with little additional time compared to standard 
PTCA. 
Background lntracoronary brachytherapyhas been demonstrated toreduce restenosis 
rate. However long-term efficacy after P-radiation therapy remains to be elucidated, since 
late thrombosiS and late lumen loss after 6 months have been reported. 
Methods From April to December 1997, 31 patients treated with a 9oSr/90Y P-emitting 
source (21 male, mean age of 57) were enrolled in the BERT 1.5 trial.Patients were ran- 
domized to a dose of 12, 14 or 16 Gy. Only single de nova lesions were included. Lesion 
length was 13 ?4 mm. Stenting was performed for recoil or dissection in 8 patients (26%). 
One patient who did not receive radiation was excluded from the analysis. All patients 
were examined by an Interview or clinic visit at 6 months, 1 year and 2 years. End points 
were defined as Death, Ml (Q wave, non-Q wave), Thrombotic cardiac event related to 
target vessel occlusion, Target lesion revascularization (TLR), Target vessel revascular- 
izaiion (TVR), composite MACE (any of death, MI, TVR, thrombollc event). 
Results Two-year follow-up clinical data (mean 2.24 i: 0.26 years)of all 30 irradiated 
patients were obtained. 
6 months 1 year* 2 years* 
Death 0 (0%) 0 (0%) 0 (0%) 
Ml 0 (0%) 3 (10%) 4 (13%) 
Thrombotic event 1 (3%) 4 (13%) 5 (17%) 
TLR 7 (23%) 8 (27%) 10 (33%) 
TVR 7 (23%) 8 (27%) 11 (37%) 
Any MACE 8 (27%) 
* cumulative event rates 
10 (33%) 12 (40%) 
Angiographic and IVUS follow-up study is currently under-way. The data will be pre- 
sented at the meeting. 
Conclusion Event rates for MI, as well as need for revascularization are not negligible 
and still increase up to 2 years after P-radiation therapy. This underscores the need for 
longer follow-up in future trials. 
ORAL CONTRIBUTIONS 
1190-38 Delayed Healing of the Vessel Wall Persists at 6 Months 
Following Endovascular Radiation 
Marco Roffi, Urs 0. H%fali, Khaled M. Ziada, Samir R. Kapadia, Jay P. Cwki. Cleveland 
Clinic Foundation, Cleveland, OH 
852 Strategies for intervention 
Tuesday, March 20,2001, IO:30 a.m.-Noon 
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IO:30 a.m. 
852-I PTCA Versus Bypass Surgery in Patients With Multivessel 
Disease: A Tailored Approach Based on Coronary Pressure 
Measurement 
Background: Long-term effects of endovascular radiation on vessel wall remain Cees-Joost Botman, G. Jan-Willem Beth, Bernard De Bruyne, Hans Bonnier, Jozef 
unknown. Animal data with 6 months follow-up ate rare. Adverse events like late throm- Bartunek, Jacques Koolen, Rolf Michels, Nice Pijls. Catharina Hospital, Eindhoven, The 
bosis may be due to delayed healing of the vascular wall after balloon or stent injury. Netherlands, Cardiovascular Center, A&f, Belgium 
1190-39 Two-Year Follow-up After Catheter-Based Beta-Radiation 
Therapy 
Ken Kozuma, Alexander J. Wardeh, Willem J. van der Giessen, Arie H. M. Knook, 
Veronique L. M. A. Cow, Jurgen M. R. Ligthart, David P Foley, Pim J. de Feyter, Peter C. 
Levendag, Patrick W. Serruys. Thoraxcenter, Rotter&m, The Netherlands, Danielden 
Hoed Cancer Center, Rotterdam, The Netherlands 
Methods: Sixteen mini-pigs underwent balloon overexpansion injury of the left anterior 
descending and left circumflex coronary artery. One artery was than irradiated with a 
Background: In multivessel disease, it is controversial if complete revascularization by 
186Re/188Re source wiih a prescribed dose less or equal than 30 Gy to the external 
bypass surgery (CABG) is superior to PTCA of the culprit lesion(s) only. Fractional flow 
elastic lamina (EEL) as visualized by intravascular ultrasound (IVUS). One vessel acted 
reserve (FFR, calculated from coronary pressure measurement) IS a reliable index to 
as a control. The animals were sacrificed at 6 months and underwent histologic analysis. 
identify whether a stenosis is culprit (i.e. functionally significant). Aim of the present 
The degree of media necrosis was assessed using a semi-quantitative grading scale (0 
study was to compare selective PTCA of culprit lwons only (FFR less than 0.75) to 
none, 1 minimal, 2 mild, 3 moderate, 4 marked, and 5 severe). The endothelialization 
CABG of all stenoses. 
was assessed qualitatively using light and scanning electron microscopy (SEM). 
Methods: In 100 patients, referred for CABG, FFR was determined in 272 coronary 
Results: The arterial segments were exposed to comparable mechanical injury (lacera- 
arteries considered for bypass grafting. If FFR was less than 0.75 in 3 or more &noses 
tion of the internal elastic lamina and media present in 7116 irradiated segments and in 81 
or in 2 type C lesions, CABG was performed (CABG-group). If only 1 or 2 lesions (not 
16 controls). Fibrinoid necrosis of the media persisted at 6 month in the injured and irra- 
both type 6) were culprit, PTCA of those lesions was performed (PTCA-group). 
diated segments (15116) but not in controls segments (1116) (p<O.OOl). The degree of 
Results: Out of 100 patients, 61 classified for CABG-group and 39 for PTCA. At 2-year 
media necrosis of the irradiated arteries did not differ between segments wiih mural lac- 
follow-up, no differences were seen in adverse events (event free survival 74% in CABG- 
eration and no laceration (median score 2.43+/-1.51 vs 2.1 I+/-0.78, respectively; p 
group and 72 % in PTCA-group) and a similar number of patients were free from angina 
bO.06). Media regeneration was a consistent finding in lacerated conirols (7/8) but not in 
(76% in the CABG-group and 77% in the PTCA-group). 
Irradiated vessels (3/7) (p=O.ZO). None of the irradiated segments showed evidence of 
Conclusion: In patients with muliivessel disease, PTCA of culprit lesion(s) only, as iden- 
mechanical failure of the vessels wail (no persistent dissection, no aneurysm formation) 
tified by FFR 5 0.75, yields a similar P-year outcome as bypass surgery. 
or mural thrombus formation. Light microscopy and SEM examination of the endothelium 
showed complete cell coverage both in controls and radiated vessels. Conclusions: 
IO:45 a.m. 
__ 
Delayed healing of ihe vessel wall after endovascular radiation persists at 6 months in pig 852-2 
Multivariate Predictors of Target Lesion Revascularization 
coronary arteries exposed to balloon overexpansion injury. Characteristic features are in the Randomized Trial of PTCA Versus Rotablator for 
persistent fibrinoid media necrosis and inconsistent media regeneration. Importantly, Diffuse In-Stent Restenosis (ROSTER) 
endothelialization was complete in all segments. Samin K. Sharma, Annapoorna S. Kini, Traci King, Felix D. Sterling, Paul Lee, Jonathan 
D. Marmur, David Reich. The Mount Sinai Medical Center, New York, NY 
Background: Intervention of diffuse in-stent restenosis (ISR) is associated with a high 
need for repeat target lesion revascularization (TLR). ROSTER is a randomized trial 
comparing PTCA and rotational atherectomy (PRCA) in the treatment of diffuse ISR in 
200 patients. Inclusion criteria were first time ISR of >I0 mm length, after high-pressure 
23.0 mm stent deployment. Patients with stents found by IVUS to have been originally 
underdeployed (stent CSA of ~60% of mean reference vessel area, n=113) were 
excluded. Methods and results: Clinical and orocedural wccess was attained in 98% in 
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PTCA group and 100% in PRCA group. Restenting was required in 31% after PTCA and 
10% after PRCA (p<O.Ol). 30.day MACE occurred in 3% and 2% respectively. Following 
PTCA, TLR was 45% as opposed to 32% after PRCA (p=O 04). Significant multivariate 
predictors of TLR are. 
Conclusion: Early presentation with ISR as well as MLD at present&n are the two 
most robust predictors of TLR after treatment of ISR. Only the use of PRCA was associ- 
ated with lower TLR &n the ROSTER cohort. Therefore, brachytherapy with or without 
PRCA in treatment of these high risk first time ISR subsets may be warranted. 
852-3 
11 :oo a.m. 
Complete Vessel Revascularization vs. lschemic Vessel 
Revascularization In Patients With Multivessel Disease; 5 
Year Follow-Up in the Multivessel PTCA Multicenter 
Randomized Trial (MRT) 
Katsuya Kitano. Tohru Kobayashi, Hideo Tamai, Takahiko Suzuki, Hideo Nishikawa, 
Osamu Katoh, MRT investigators. Kyofo Katsura Hospital Cardiovascular Center, Kyoto, 
Japan 
Background: It is unknown to make better clinical outcome recanalizing non ischemic 
stenosis in patient with multivessel disease (MVD) by percutaneous coronary interven- 
tion (PCI). Methods: Between February 1992 and February 1995, 586 patients (pts) reg- 
istered (Multwessel PTCA Multicenter Study) MVD [LMT&O% stenosis, equal or more 
than two major vessel stenosis, agei75yo, no prior PCI or CABG] from 4 institutions. 96 
pts had combination of lschemic vessel and non ischemrc vessel by stress Tl-scintigra- 
phy (TI). We compared long term outcome of complete vessel revascularization (CVR) 
regardless of ischemia and only ischemic vessel revascularization (IVR) with MVD. The 
96 pts were randomly assigned to the CVR (49 pts) and the IVR (47 pts). There was no 
device limitation for subsequent revascularization. There were no differences in baseline 
data between the two groups [(CVR: IVR) mean age; 62~0: 61~0, male gender; 72%: 
86%, prior Ml; 67%: 64%, CTO; 52%: 57%, triple vessel disease; 33%: 50%, EF; 54%: 
58%, history of congestive heart failure (CHF): 18%: 28%, unstable angina (UA); 19%: 
24%]. The CVR group had 156 (all 313 lesions were) lesions and IVR group had 157 
lesions. In IVR group, eligible 104 lesions of 157 lesions were defined as the target lesion 
for revascularizatlon. Used devices for the lesion were no different between the CVR and 
IVR group [(CVR: IVR) plain old balloon angioplasiy; 126: 86 lesions, stent; 15: 9 lesions, 
direct coronary athelectomy; 7: 6 lesions, cutting balloon; 8: 3 lesions]. Results: Inter- 
vention ?uccess was defined as target vessel revascularization without major cardiac 
event. were achieved 94% (CVR) and 96% (IVR). Late cardiac events were defined as 
cardiac death, AMI, CABG, UA, CHF. At Syears, clinical follow up (96%), there were no 
differences in late clinical events between the 2 groups [(CVR: IVR) CABG; 6%: 2%, AMI; 
12%: 9%, CHF; 16%: 4%.(p=O.O51), UA; 10%: 1 l%]. At Syears, there were no differ- 
ences between the two groups in free from cardiac death [(CVR: IVR) 94%: 96%] and 
total cardiac event-free ratio [(CVR: IVR) 73%: 81%]. Conclusion: The results have not 
showed an advantage of non ischemic vessel revascularization in multivessel disease. 
852-4 
11:15a.m. 
Debulking Prior to Stenting: Insight Into the Best Technique 
of Use From a Prospective Study 
Javier Betas, Antonio Peleato, Juan Angel, Manuel Gomez Recio, Eulogio Garcia. 
lnocencio Anivarro. Hospital Gregorb Maranon, Madrid, Spain, Hospital Clinico, 
Zaragoza, Spain 
The SOLD trial has shown 
that DCA before stenting 
yields excellent 
res”k 
However, it is unclear what 
is the best technique of use 
to obtain the best results, 
specifically, the role of low 
stent implantation pres- g 
sures, how important it is to 
aggressively debulk if a 
stem is going to be 
implanted anyway, and the 0 .5 1 1.5 2 2.5 
possible role of IVUS. 70 pts DCpl &cute Gain 
were prospectively studied. 
Prespecified targets for opti- 
mal DCA and stenting were < 30 and ~10 % DS respectively, but using the lowest possi- 
ble stent deployment pressure (first Inflation cl0 atm). On 26 pts IVUS guided the 
procedure. QCA and QCU analyses were performed by a core lab. Ref Diam was 3.1+.5 
mm (54%<3 0 mm), and postprocedural MLD 3+0.5 mm. Acute clinical success was 
lOO%, with noMACE, and 4 pts (5.7%) had a CK leak (x2). At the end of f-up all but 7 pts 
were asymptomatic and had a negative stress test (Need TVR 10%). Angiographic f-up 
(93%,) showed an overall 20% restenws rate, 12.5% in the IVUS group and 24% in the 
Angio group (p=ns). As expected, the major predictor of restenosis was Procedural 
Lumen Gain (OR 0.15, ~~0.02). Interestingly, univariate predictors of Procedural Lumen 
Gain were Lumen Gain achieved by DCA (fig:), Stem sizq, and maximum pressure during 
DCA but not during stent placement. By multiple regression analysis the most important 
independent predictor of Procedural lumen Gain was Gain achieved by DCA (B 0.727, 
pcO.OOl), but also Stent size (I? 0.125, ~~0.05) was and independent predictor (whole 
model R&80, p<O.OOOi). Furthermore, there was a negative correlation between Pro- 
cedural lumen Gain and late lumen loss index (I3 -0.351, R -0.35, p<O.Ol) further empha- 
sizing the benefit of maximirlng luminal gain. Conclusions. Debulking with DCA prior to 
stenting is safe and effective. Our data suggest that rather than a moderate degree of 
debulking before stenting an aggressive technique should be used if one is to obtain the 
true benefit from this combined technique. 
852-5 
Ii:30 a.m. 
Population-Based Outcomes for the Invasive Approach to 
Management of Non-Q Wave Myocardial Infarction. 
Harold L. Dauerman, Robert J. Goldberg, Jorge Yarzebski, Dar&n H. Lessard, Cynthia 
Sullivan, Joel M. Gore. UMass Memorial Medica/ Center, Worcester, MA 
Background: The invasive versus conservative approach to management of non-ST ele- 
vation and non-Q wave acute coronary syndromes has been addressed in randomized 
trials. We determined the use and outcomes of an invasive approach to hospital manage- 
ment in a population-based sample of non-Q wave acute myocardial infarctron (AMI) 
patients. Methods: 2,435 patients admitted to area-wide hospitals with non-Q AMI 
between 1990 and 1997 were identifed in the Worcester Heart Attack Study. Patients 
charts were reviewed for clinical, medical treatment and procedural variables as well as 
hospital outcomes. An invasive approach was defined as use of catheterization, percuta- 
neous coronary intervention or bypass surgery during the index hospitalization. A first 
multivariable model identified clinical and procedural predictors of hospital mortality and 
a second multivariable model also controlled for associated medications. Results: The 
non-Q AMI population had a mean age of 71 years; 44% were women, 31% diabetic, and 
5% developed cardiogenic shock. The hospital mortality was 12%. An invasive approach 
was used in 30% of patients and the m-hospital mortality in this group was 5%, as com- 
pared to 15% for those not receiving the invasive approach (p=O.OOl). Multivarrable anal- 
ysis was performed to control for differences between patients receiving and not 
receiving an invasive approach to management. Older age, lack of an invasive approach 
to treatment, occurence of heart failure and shock were independent predictors of hospi- 
tal mortality. In the multivariable model including medical therapy, the same clinical and 
procedural predictors of hospital mortality were identified. 
Independent Predictors of Non Q Wave AMI Mortality 
Variable Prevalence Odds Ratio 95% Confidence 
Interval 
.Cardiogenic Shock 5% 28.0 17.3-45.5 
Age > 75 years 42% 6.8 3.2-14.8 
Lack of Invasive 70% 3.1 2.0-4.7 
Approach 
Congestive Heart 38% 1.5 1.1-1.9 
Failure 
Conclusion : Non Q wave AMI hospital mortality remains high in this representative pop- 
ulation-based sample. Only 30% of patients underwent an invasive approach to hospital 
management. The lack of an invasive approach to management is associated with 
increased hospital mortality, as is cardiogenic shock, heart failure and older age. 
852-6 
11:45 a.m. 
Fractional Flow Reserve (FFR) for the Appropriateness of 
Percutaneous Transluminal Coronary Angioplasty (PTCA) in 
Patients With a Coronary Stenosis but Without Proof of 
Ischemia. Two-Year Follow-Up of the Prospective 
Randomized DEFER Study 
G. Jan Willem Beth, Bernard De Bruyne, Nice H. J. Pijls, Ebo de Muinck, Jan 6. A. 
Hoorntje, Javier Escaned, Pieter R. Stella, Eric Boersma, Jozef Bartunek, Jacques J. 
Koolen, William Wijns. Cathark Hospital/Technical University, Eindhoven, The 
Netherlands, Cardiovascular Center, A&t, Belgium 
Background: PTCA of a coronary stenosis is warranted when objective proof of 
ischemia is obtained. In a number of pabents PTCA is performed despite the absence of 
objective proof of ischemia (non-invasive stress testing negative, inconclusive, or not per- 
formed). In these patients it is unclear whether PTCA is appropriate. Coronary pressure- 
derived FFR is an invasive index of stenosis severity which can be used as a reliable sub- 
stitute of non-invasive stress testing. FFR less than 0.75 clearly identifies stenoses with 
hemodynamic significance. 
Methods: In 325 patients referred for PTCA of a moderate stenosis, FFR was measured. 
if FFR was less than 0.75, PTCA was performed as planned (Reference group; N&144). 
If FFR was more than 0.75 patients were randomly assigned to deferral (Defer group; 
N=91) or performance (Perform group; N=90) of PTCA. Follow-up was obtained at 12 
and 24 months. 
Results: The 3 groups were identical for baseline clmical and angiographic characteris- 
tics. No difference in event-free survival was present between the Defer and Perform 
group: 93% versus 89% at 1 year and 88% versus 83% at 2 years). In the reference 
group event-free survival was lower (81% at 1 year and 78% at 2 years). The number of 
patients free from angina increased significantly in all 3 groups. This increase was similar 
in the Defeiand Petiorm group, but was significantly higher in the Reference group (61% 
50%, and 73% respectively at 2 years). 
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Conclusion: Among patients, scheduled for PTCA but without non-invasive evidence of 
ischemia, coronary pressure measurement identifies those patients with FFR below 0.75 
who beneflt from PTCA from those patients wtth FFR above 0 75 m whom no benefit of 
PTCA was present and in whom the mtervention can be safely deferred. 
ORAL CONTRIBUTIONS 
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853-i 
10:30 a.m. 
Late Stent Malapposition Following lntracoronary 
Radiation: A Serial Intravascular Ultrasound Study 
Hiroyuki Okura, Thosaphol Limpijankit, David P Lee, Sydney Lo, Alan C. Yeung. Ron 
Waksman, Grzegorz L. Kaluza, Nadir M. Ali, Heidi N. Bonneau, Paul G. Yock, Albert E. 
Raizner, Gary S. Mintz, Peter J. Fitzgerald. Stanford Universify Medml Center, Stanford, 
CA, Baylor Coilege of Medicine, Houston, TX 
Background: Incomptete stent apposition at the time of deployment has been well char- 
a&wed by intravascular ultrasound (IVUS) and occurs when stents are undersized or 
when vessels have a high degree of localized ectasia. The development of late stent mal- 
apposition despite adequate initial stent apposition is a recent finding by IVUS, especially 
in vessel segments exposed to mtracoronary radiation (ICR). Method: To determme the 
incidence of late stent malapposition and investigate vessel wall response of stented seg- 
ments following ICR, serial (baseline and 6 months) IVUS examination was performed in 
70 stented lesions treated with either 32P or 192lr source. Ultrasound measurements 
were performed throughout the stented segments at 1 mm increments. Results: At lol- 
low-up, localized stent strut malapposition was observed in 6 vessels (9%). Vessel area 
of these segments increased by 1.7 mm2 (23.0+-7.9 to 24.7+-5.7 mm2, p<O.OOOi), with- 
out changes in stent an?a (S.O+-1.4 to 8.1+-1.4 mm2, p=NS). Overall percent change m 
vessel area of the stented segments showed a negative correlation with baseline plaque 
area (r=-0.40, pcO.0001). These observations suggest that late malappositlon results 
from focal vessel dilatation and is likely to occur in irradiated stent segments with a mini- 
mal amount of underlying plaque burden. Conclusions: Excessive vessel remodeling 
with stem malapposition was documented by serial IVUS examination following ICR. ICR 
dosing may cause positive remodelil-ig of stented vessels, possibly related to the amount 
of preexisting plaque burden. 
853-2 
IO:45 a.m. 
Serial Intravascular Ultrasound Analysis of the Impact of 
Lesion Length on the Efficacy of lntracoronary Gamma 
irradiation for Preventing Recurrent In-Stent Restenosis 
Jawed M. Ahmed, Gaiy S. Mintz, Ron Waksman, Neil J. Weissman, Lowell F. Satler, 
Lanja M. Ahmed, Augusta D. Pichard, Kenneth M. Kent. Washmgfon Hospital Center, 
Washington, DC 
In order to assess the impact of in-stent restenosis (ISR) lesion length on the success of 
vascular brachytherapy, we compared serial (post-intervention and follow-up) intravascu- 
lar ultrasound (IVUS) findings in 66 patients with native coronary artery ISR treated wth 
192-11 (15Gy@2mm from the source). Patients were enrolled in WRIST (Washmgton 
Radiation for InStent restenosis Trial, ISR length=lO-47 mm, n=36) or Long WRIST (ISR 
length=36-80 mm, n=30). Stent, lumen, and intimal hyperplasia (lH=stent minus lumen) 
areas and source-to-target (IVUS catheter-to-adventitia) dtstances were measured. In 
Long WRIST lesions, stent areas were smaller, maximum IH reaccumulation was greater, 
and fol!ow-up minimum lumen areas were smaller. The source-to-target distances were 
more variable and the maximum distances greater in Long WRIST lesions. 
Long WRIST p 
WRIST 
Minimum e-tent xea (mm2) 5.2*1 .o 7.6t2.1 <0.0001 
Maximum source-to-target distance 4.0t0.7 2.8i0.4 <o 0001 
Change in maximum IH area (mm2) 2.4rl.8 l.Oil.3 0.006 
Follow-up minimum lumen area (mm2) 2.9Cl .o 4.2&O 0.0015 
The maximum source-to-target distances correlated directly with ISR length (r=O.547, 
pcO.0001, Left Figure). Importantly, the increase in maximum IH area correlated with the 
maximum source-to-target distance (r=O.523, pcO.0001, Right Figure WRIST lesion are 
open circles/Long WRIST lesions are Xs). 
Conclusions: Serial IVUS analysis showed that brachytherapy is less effective in longer 
ISR lesions treated with the same dose prescription as shorter lesions. Longer source-to- 
target distances affect the dose delivered to the adventitia. The resulting greater IH reac- 
cumulation, superimposed on smaller stent areas, result in smaller follow-up lumen 
areas. 
853-3 
1l:OO a.m. 
Relationship Between Vessel Size and Late Lumen Loss 
Following lntracoronary Beta- and Gamma-Radiation 
Therapy 
Yoshihro Merino, Yasuhiro Honda, Atsushi Takagi, Thosaphol Llmpijankit, Ron Waksman, 
Raw Bonan, Jeffrey J. Popma, Alexandra J. Lansky, Theodore Bass, Paul G. Yock. 
Peter J. Fitzgerald. Stanford Univemty, Stanford, CA 
Background: Recent studies with intracoronary radiation therapy have demonstrated a 
striking reduction in recurrent neointimal formation. However, the optimal dose prescrip- 
tions for gamma- and beta-emitters have not been well established, leading to a wide 
range of dose distribution over the vessel wall. The aim of thts study was to investigate 
the relationship between vessel size and long-term outcomes following intracoronary 
radiation therapy with different radiation sources (gamma vs. beta) under currently used 
prescriptkm protocols. Methods: We evaluated serial (post-intervention and follow-up) 
IVUS in two different radiation trials with similar dose prescription protocols: 110 patients 
(19211: 62, placebo: 48) from WRIST (Washington Radiation for In-stent Restenosis Trial) 
and 40 patients (9OSriY. 24, placebo: 16) from START (STent And Radiation Trial). The 
prescribed dose for the treatment group I” WRIST was 15 Gy at 2.0 mm for reference 
diameter x4.0 mm and 15 Gy at 2.4 mm for reference diameter >4.0 mm. For START 
the prescribed dose was 16 Gy at 2.0 mm for reference diameter ~3.4 mm and 20 Gy at 
2.0 mm for reference diameter x3.4 mm. Percent change m minimum lumen area (late 
lumen area loss, %) during the follow-up period (6 months for WRIST and 8 months for 
START) was calculated by IVUS. Results: Baseline lesion characteristics were similar in 
the two radiation trials. In both trials, the treatment group showed a significant reduction 
in late lumen area loss compared to the placebo group (relative reduction: 89% in WRIST 
and 135% in START). In the treatment group of START, there was a significant positive 
correlatlon between reference diameter and late lumen area loss (rz.42, p=O.O4). In con- 
trast, the treatment group of WRIST showed no significant relationship between refer- 
ence diameter and late lumen area loss (p=O.58). Conclusions: The differences in 
Isotope characteristics such as penetration strength may partially account for the results 
of this study. Appropriate dose prescription protocols based on careful measurement of 
reference vessel size appeared to be critically important particularly for beta-irradiation 
therapy. 
11:15 a.m. 
853-4 The Impacts of Geographic Miss on Adjacent Coronary 
Segments in Diffuse lnstent Restenosis With a “‘Re MAG, 
Radiation Therapy (R4 Trial): Intravascular Ultrasound 
Study 
Myeong-KI Hong, Seong-Wook Park, Dae-Hyuk Moon, Seung-Jun Oh, Cheol Whan Lee, 
Duk-Hyun Kang, Jong-Min Song, Jae-Kwan Song, Jae-Joong Kim. Seung-Jung Park. 
Asan Medica/ Center, Semi, South Korea 
Background: The beta radiation therapy with ‘88Re-MAGa-filled balloon following rota- 
tional atherectomy for diffuse instent restenosis(lSR) (R4 trial) was performed in 50 
patients. We evaluated the impacts of geographic miss(GM) on adjacent segments by 
intravascular ultrasound (IVUS) analysis. Methods: Serial IVUS comparison at the same 
site between post-radiation and 6-month follow-up was available in 44 of 50 patients in 
R4 Trial. IVUS images were acquired at 6 different site in proximal and distal part outside 
of stent, respectively; 4 radiation segments (R-ad-S) just outslde of stent with 1 mm inter- 
val and 2 reference segment (RS) with 2 mm interval. Mean average values oi each seg- 
ment were used in analysis. Results: GM was documented in 48 segments (proximal 
segment in 21 & distal segment I” 27). Table shows the IVUS findings between 2 groups. 
Conclusion: Avoidance of GM were associated with positive remodeling of R&S. GM 
miqht be one of the determinant factors of edge restenosis in beta-radiation therapy. 
EEMexternal elastic membrane, P+M: plaque + media, ’ post vs. follow-up, p=O.OOl 
Segment RS EEM RS RS P+M Rad-S R&S Rad-S 
lumen EEM lumen P+M 
GM Post-radiation 14.0+6 5 7.7r4.2 6.2k3.2 12.8i3.6 6.2&1.8 6.6+2.3 
Follow-up 13.9+6.5 7.6r4.3 6.4k3.3 13.Oe3.6 6.2+1.8 6.822.2 
No GM Post-radiation 14.8~52 8.0+3.1 6.9k3.2 15.4k4.4 7.6t2.6 7822.6 
Follow-up 14.715.0 7.9&?.7 7.1~3.3 15.8+4.4* 8.Ok2.6 7.8+2.6 
853-5 
1 I:30 a.m 
The Cold Edge Effect: Mechanisms of Edge Narrowing 
Following Stenting Without Radiation 
Hiroyuki Okura. Yoshihiro Merino, Katsuhiro Kitamura, Jorge Luna, Ali H. M. Hassan, 
Peter J. Fitzgerald. Paul G. Yock, Yasuhlro Honda. 
Be///and Genera/ Hospital, Sakai, Japan, Stanford University Medical Center, Sianford, 
CA 
Background: Recently, attention has been drawn to “edge effects” in stented segments 
following lntracoronary radiation therapy. Little is known about the remodeling process at 
the stent margins in the absence of radiation. Methods: To investigate the impact of ves- 
sel injury at stent edges, we analyzed 125 stent edges in 64 native coronary lesions 
treated with balloon expandable stents. Intravascular ultrasound (IVUS) imaging with 
automated pullback (0.5 mm/set) was performed immediately after successful Stent 
Implantation and repeated at 6 month follow-up. Vessel, plaque and lumen areas were 
measured at the stent edges (5 mm from stent) at 1 mm Increments, and volumes were 
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calculated by Simbson’s method. Vessel injury (VI) at the stent edge was considered sig- 
nificant when edge tear or dissection was observed immediately following stent implanta- 
tion. Results: At baseline, VI was present in 20 edges (16 %) (VI group) and was absent 
in 105 edges (84%) (non-VI group). Baseline lesion characteristics were similar between 
the two groups. At follow-up, the non-VI group showed a significant decrease in vessel 
volume at the stent edge (74.1+-30.8 to 69.4+-31.6 mm3, ~~0.05) with a minimal change 
in plaque volume (38.3+-18.8 to 38.6+-19.6 mm3, p=NS), indicating that lumen volume 
decrease (36.0+-18.2 to 31.2+-19.5 mm3, ~~0.05) was mainly due to recoil and negative 
arterial remodeling (vessel shrinkage). By contrast, in the VI group, plaque volume signif- 
icantly increased (31.5+-13.5 to 35.5+-12.5 mm3, ~~0.05) without changes in vessel vol- 
ume (66.5k27.4 to 66.51-23.3 mm3, p=NS). Lumen volume decrease (35.0+-l&2 to 
31.0+-17.2 mm3) in this group was a result of increased plaque volume and a lack of 
adaptive arterial remodeling. Conclusions: Edge effects occur following stenting without 
radiation and depend on the type of vascular injury. Following dissection / tear at the 
edges, intimal proliferation is the predominant effect; following stretch alone, narrowing is 
due to recoil and negative remodeling. These findings should be taken into account when 
mechanisms of the “edge effects” after intracoronary radiation therapy are investigated. 
853-6 
11:45 a.m. 
Serial Intravascular Ultrasound Assessment of the Efficacy 
of lntracoronary T-Radiation Therapy for Preventing 
Recurrence in Very Long, Diffuse In-stent Restenosis: A 
Comparison of Two Dose Prescriptions 
&wed M. Ahmed, Gary S. Mint& Ron Waksman, Neil Weissman, Craig M. Allen, Lowell 
F. Satler, Kenneth M. Kent, August0 D. Pichatd. Washington Hospital Center, Washingfon 
D.C, DC 
Background: The efficacy of coronary y-irradiation therapy in preventing recurrent in- 
stent restenosis (ISR) is well established. However, at a dose of 15Gy62mm from the 
sourcs, brachytherapy may be less efficacious in very long, diffuse ISR lesions. Meth- 
ods. To determine whether an increased dosing scheme will improve the effectiveness of 
brachytherapy in diffuse ISR, we compared serial (post-intervention and follow-up) intra- 
vascular ultrasound (IVUS) findings in 30 patients from Long WRIST (Washington Radia- 
tion I&tent restenosis Trial: 15 Gy @ 2mm from the source) and 25 patients from high 
dose (HD) Long WRIST who were received 15 Gy 8 2.5mm from the source. IVUS was 
performed using automated pullback (0.5mmJsec). Stent, lumen, and intimal hyperplasia 
(IH=stent-lumen) and minimal lumen area (MLA) areas were measured at 2mm intervals. 
Results: ISR length was longer in HD Long WRIST lesions (65.6+-16.5mm vs 
55.1*15.4mm vs, p=O.Oi). Post-intervention stent, lumen, IH and MLA were similar in 
both groups (Table). At follow-up, MLA was significantly smaller in Long WRIST lesions 
vs HD Long WRIST lesions because the increase in maximum IH CSA was greater in 
Long WRlSTvs HD Long WRIST lesions (2.4?1.9mm2 vs 0.4r0.7mm2, p<O.OOOl). Con- 
clusion: Serial IVUS analysis shows that y-irradiation appears to be more effective in 
preventing recurrence in patients with very long, diffuse ISR when given at a higher dose. 
Thus, increasing the dose prescription may improve on the results of brachytherapy in 
this difficult to treat patient cohort. 
Long WRIST HD Long WRIST p 
Post-irradiation 
Stent area (mm2) 7.6k2.5 8.0+1.6 0.6 
Lumen area (mm2) 5.9&l .6 6.3~1.7 0.35 
IH area (mm2) 1.8*1.7 1.7kl.3 0.8 
MLA (mm2) 4.2el.2 4.721.2 0.16 
Follow-up 
MLA (mm2) 2.9+1 .o 4.Ok1.4 0.009 
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1008-201 Percutaneous Coronary Interventions Prior to Noncardiac 
Surgery Are Associated With a Low Perioperative Cardiac 
Event Rate 
Robert M. Grohowski, Julian M. Es&ban, Eric R. Bates, Steven W. Werns, Mauro 
Moscucci, Kim A. Eagle. University of Michigan, Ann Arbor, MI 
Background: Percutaneous coronary interventions (PCI) done prior to noncardiac SUP 
gery are believed to reduce perioperative cardiac ischemic events in carefully selected 
patients. However, a recent report suggested that preoperative coronary stenting 
increases p&operative ischemic events. especially when surgery follows PCI by less 
than 3 weeks. 
Methods: In order to further explore this, we identified 90 patients who underwent PCI 
between 6/92 and 12199, prior to noncardiac surgery at our institution. Most patients 
were male (71%), mean age of 67 years. Angina was present in 40% of patients. Stent 
implantation was performed in 31 patients and balloon angioplasty was performed in 59. 
Most noncardiac surgery was performed within 90 days of the PCI (mean 67 days, range 
l-490 days). Type of noncardiac surgery was vascular 43%, abdominal -27%, thoracic 
13%. head and neck - 2%, and miscellaneous procedures -15%. General anesthesia was 
used in 89% of patients. 
Results: There were 6 perioperative cardiac events (6.7%). Two patients developed 
congestive heart failure (2%), 2 developed atrial fibrillation (a%), and 1 patient had tran- 
sient hypotension, all of which were treated medically. One patient developed a myocar- 
dial infarction (1%) 4 days after surgery. There were no cardiac deaths. Perioperative 
events were more frequent in patients who underwent noncardiac surgery wlthin a few 
weeks of PCI (mean delay of 21 days in patients with events compared to 71 days in 
patients without events, p=<O.OOl). No differences were seen in the outcomes following 
stent implantation versus balloon angioplasty alone (6.5% vs 6.8% events p=O.88). 
Conclusions: 1. Successful PCI prior to noncardiac surgery is associated with a low 
risk of adverse perioperative cardiac events in patients with significant coronary artery 
disease undergoing moderate or high-risk surgery. 2. Delaying surgery for 3-4 weeks 
after PCI may further minimize the risk for such events. 
12;12 p.m. 
1008-202 A Comparison of Routine and Symptom-Driven Functional 
Testing Early After Successful Coronary Angioplasty in 
Diabetic and Non Diabetic Patients 
Ubeydullah Deligonul, Mark Eisenberg, Janius Tsang, Thao Hyunh, David Schecter. The 
University of Texas Health Center af Ty/er, Tykx TX 
Background: Diabetics(DM) have increased event rates after coronary angio- 
plasty(PTCA). Whether post-PTCA functional testing (FT)is utilized more often in 
patients with DM is not well known. The effect of such routine testing on the post-PTCA 
outcome in patients with DM is also not documented well. Methods: In a multicenter reg- 
istry, 787 consecutive patients with successful PTCA were followed up prospectively for 
>=6 months. Composite clinical events (death, non-fatal myocardial infarction or unstable 
angina), repeat revascularization, and functional testing utilization patterns were com- 
pared between DM (n=179) and non-diabetic (Non-DM) (n=608) patients. Results: Rou- 
tine, early (2months) post-PTCA functional testing was done in 27% of DM and 30% of 
non-DM patients with similar rates for stress induced ischemia (20% vs. 14%) and for fol- 
low-up catheterization (13% vs. 14%). In patients undergoing routine FT, the incidence of 
composite clinical events (8.5% vs. 5.5%) and repeat revascularization (6.4% vs. 11 .l%) 
were not significantly different in DM and non-DM groups, respectively. Conclusion: 
Routine FT was performed in less than l/3 of the post-PTCA patients regardless of the 
diabetic status. Routine FT in diabetics did not lead to the a higher utilization of repeat 
catheterization and revascularization, and did not identify less favorable outcomes. 
12:24 p.m. 
1008-203 Clinical Outcomes Among Patients Undergoing Elective 
Percutaneous Coronary Intervention at a Hospital Without 
On-Site Cardiac Surgery 
Kirk N. Garratt, Henry H. Ting, Joseph A. Dearani, Ryan Lennon, Jack T. Cusma, 
Katherine L. Boutchee, Douglas L. Wood, David R. Holmes, Jr. Mayo Medical Center, 
Rochesfer, MN, Emmanuel St. Josephk Hospital, Mankafo, MN 
Background: The safety of performing elective percutaneous coronary intervention at 
hospitals without on-site cardiac surgery has not been fully defined. 
Methods: Elective percutaneous coronary intervention was conducted at lmmanuel St. 
Joseph’s Hospital without on-site cardiac surgery. Full consultative support was provided 
by interventions.1 cardiologists and cardiac surgeons at a tertiary-care hospital, St. Marys 
Hospital, 85 miles away who were connected with lmmanuel St. Joseph’s Hospital 
through an advanced telecommunications network. Selection criteria and emergency 
transport protocols were established before beginning coronary interventions at Imman- 
uel St. Joseph’s Hospital. Patient outcomes were measured prospectively and compared 
with outcomes for similar patients treated with percutaneous coronary intervention at St. 
Marys Hospital during the same time period. Expected adverse event rates were mod- 
eled using the New York State angioplasty database risk model. 
Results: 63 patients were treated at l~manuel St. Joseph’s Hospital and 370 matched 
patients were treated at St. Marys Hospital between March 1999 and June 2000. Imman- 
uel St. Joseph’s Hospital patients were significantly more likely to have a history of peptic 
ulcer disease and receive glycoprotein IIB:IIIA inhibitors. All procedures were successful 
at lmmanuel St. Joseph’s Hospital. Clinical adverse event rates were low and similar 
between lmmanuel St. Joseph’s Hospital and St. Marys Hospital except for an increased 
risk of gastrointestinal bleeding among patients at lmmanuel St. Joseph’s Hospital. Pre- 
dicted and observed mortality rates (with 95% confide& intervals) are shown in the 
table. No significant differences in intermediate-term follow up (mean time 278 days 
lmmanuel St. Joseph’s Hospital, 223 days St. Marys Hospital) were found. 
Expected Observed 
St. Marys Hospital 1.9% (0.9-3.9) 1.1% (0.3-2.7) 
lmmanuel St. Joseph’s Hospital 1.1% (0.2-8.3) 0 (O-4.3) 
Conclusions: These data suggest that elective percutaneous coronary intervention can 
be conducted safely at hospitals without on-site cardiac surgery when appropriate patient 
selection criteria and support systems are implemented. 
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1008-204 Left Ventricular Electromechanical Mapping: A New 
Perspective on Immediate Outcomes of Coronary 
Intervention 
Emerson C. Perin, Guiiherme Silva, Rogerio Sarmento-L&e, David Fish, William 
Vaughn, James Ferguson, III Texas Heart Insfitufe, Houston. TX 
Background -Ischemic myocardial dysfunction and its sequelae are still not well under- 
stood. 
Nlethods and Results - To gain further insight into the immediate physiologic conse- 
quences of coronary interventions and to better understand the nature of changes that 
result from such interventio~ns, we analyzed 96 electromechanical maps from 48 patients 
before and after successful, uncomplicated percutaneous coronary inlerventions (PCI). A 
NQGA system was used to construct the map of the endocardial surface. Reproducibility 
was confirmed by constructing 10 additional maps in 5 patients who did not undergo an 
intervening procedure. Discordant areas were defined as a percentage of the total area 
of left ventricular myocardium with preserved unipolar voltage (>7.5 mV) and diminished 
linear local shortening (cl 2.5%). Based on the comparison of the variations in the discor- 
dance values (%) in lhe reproducibility group, patients were considered improved (lower 
values), worsened (higher values), or unchanged. In the reproduciblllty group, the mean 
variation in discordance was 2.18+1.26%, whereas in the PCI group, it was 
21.97+18.47%. In the PCI group, LV discordance values improved in 19 patients (39.6%), 
worsened in 24 patients (50%), and remained the same in 5 (10.4%). Of all variables 
analyzed, only abciximab was significantly associated with post-intervention improve- 
ment in discordance (p=O.O2; odds ratia=0.165, 95% Cl, 0.03-O&3), regardless of the 
type of intervention performed (p=O.61), while heparin alone was strongly associated 
with more discordance following intervention (odds ratio=6.07, 95% Cl, 1.14-32.40). 
Conclusions We quantified the effect of revascularization on LV ischemic dysfunction 
by using discordance values. based on electromechanical mapping. This technique pro- 
vides a unique perspective regarding the wnpact of interventional procedures on myocar- 
dial physiology and has potential as a new diagnostic tool in the clinical evaluation of the 
microvasculature. 
12:48 p.m. 
1008-205 The First Successful Clinical Case of a Novel Catheter- 
Based Coronary Artery Bypass Procedure: Percutaneous 
In-Situ Coronary Venous Arterialization 
Nicolaus Reifart, Eugen Hauptmann, Alan Yeung, Motoya Hayase, Stephen N. Oesterle. 
Krankenhaus der Barmherzigen Bruder, Triec Germany, Massachusetts General 
Hospital, Boslon, MA 
Background: We have previously presented pre-clinical data suggesting the use of the 
coronary venous system es a conduit to revascularize the heart percutaneously. Using a 
novel set of catheters and implantable devices in the porcine model, we have demon- 
strated feasibility of percutaneously creating arterio-venous channels, and blocking the 
venous system between the channel site and the coronary sinus. The combination of 
these two steps will result in arterialized blood being delivered to the myocardium retro- 
grade through the veins. We now report on the first clinical experience with the Percuta- 
neous In-Situ Coronary Venous Arterialzation (PICVA) procedure. Methods: We are 
currently evaluating the safety and feasibility of PICVA under an approved protocol in 
Germany. The study population consists of patients for whom PTCA or CABG are not 
reasonable options. The PICVA procedure is as follows: an AV fistula is created and a 
novel connector is placed between the proximal left anterior descending artery (LAD) and 
the anterior interventricular vein (AIV); subsequently a novel implantable blocker is 
placed in the coronary vein just superior to the fist& site. Study endpolnts are: PICVA 
procedural success, angina1 class, and adverse events at the time of procedure, 6 weeks 
and 3 months post-procedure. Results: This patient is a 53 year old diabetic male that 
presented with severe angina, a previous Ml and three failed attempts to reva~cular~ze a 
chronic occlusion mid-LAD. The PICVA procedure was successfully completed without 
complication, and the results are as follows: 
N=l Pre-Procedure Post-Procedure 6 Weeks 3 Months 
Angina Class - Class iv 0 0 0 
CCS 
AV Graft Flow TIMI il l TIMI Ill 
MACE NOM NOW NOtlS 
There was a significant increase in the patient’s Exercise Tolerance assessed by bicycle 
ergometry. This investigation is currently on-going. An update on the progress and clini- 
cal experience in this trial will be provided at the time of this presentation. Conclusions: 
We have demonstrated that PICVA is clinically feasible and can be accomplished without 
complication. Further study is required to define the safety and efficacy of the procedure 
for patients with ischemic heart disease. 
1008-206 Out-Patient Angioplasty: Is the Future Now? 
1 :oo pm. 
Ambika Bhaskaran, Robert M. Siegel, Charles Jest, Warren Breisblatt, Barbara Barker, 
Alvin Nuttall, Deborah Frazier, Jennifer Vermillion, Sarah Dougherty, Jeffrey Gorow, 
William Orlowski. Advanced Cardiac Speciabts, Gilbert/Phoenix, AZ 
Background: Percutaneous intervention (PCI) is the leading modality of treatment in 
coronary artery disease today. With increasing operator confidence and proficiency, hos- 
pital stay following PCI is becoming shorter, even in direct infarct intervention. However, 
the concept of out-patlent angiopiasty (OPA) is not widely accepted and there is no con- 
sensus among cardiologists on the safety and feasibility of this approach. In the U.S.A., 
Medicare defines an out-patient procedure as one where hospitalization lasts cP4 hours. 
Methods: We retrospectively evaluated our interventional registry experience (1995. 
2000). Of a total of 4,022 patients, 1,262 (31.4%) patients qualified as “OPA” by Medicare 
definition. Mean age was 64 years (33% were 370 years; 65% were in the age range of 
41-69 years); 71% were male. Co-morbidities included diabetes 22%; hypertension 65%: 
prior stroke 2%; prior CHF 3 3%. There was history of prior Ml in 32%, prior CABG in 
22%, prior PCI in 42%. Clinical presentation was acute Ml in 19%, unstable angina in 
45% and positive stress echo in 23%. Transfemoral access was used for the PCI in 
98.4%. Anglographlcally, lesions were ostial/proximal in 48%, ACCIAHA Type BZiC in 
58%; >I5 mm long in 54%. Lesions were located in vein grafts in 5.5% and involved the 
LAD territory in 36%. Mean diameter stenosis was 88.4%. Mean baseline LVEF was 
47.1%. Two or more vessels were treated in 16.7%; stent was deployed in 39.6%. Glyco- 
protein Ilb/llla inhibitors were used in 16.7%. Res&s: Procedural success was obtained 
in 1,238 (98%). The incidence of non flow-limiting dissection was 2.4%. There were no 
access site complications. Hospital stay was uneventful. Subacute stent thrombosis rate 
was 0.4%. At l-year follow-up, the incidence of Ml was 1.5%. The rate of target lesion 
revascularization (TLR) by PTCA was 7.3% and CABG 3%. Mortality was 3.3%, with 
event-free survival seen in 86.5%. Conclusions: This large retrospective series prowdes 
a compelling case for OPA. Out-patient angioplasty is feasible and can be effectively per- 
formed without compromlsing patient safety. This is reinforced by the fact that subacute 
and long-term clinical outcomes are favorable, with high rate of event-free survival. 
I:12 p.m. 
1008-207 Cardiac Catheterization Laboratory Backup for Cardiac 
Surgery 
James L. Orford, Mark R. Adams, Gavin J. Blake, John G. Byrne, Marco V. Wainsteln, 
Jeffrey J. Popma, Andrew P. Selwyn. Brigham and !%men’s Hospital Boston, MA 
Background: Percutaneous coronary intervention (PCI) is generally only performed in 
centers where it is possible for failed interventional procedures to be treated by “rescue” 
coronary artery bypass grafting (CABG). Less attention has been focused on the need 
for “rescue” PGI following failed CABG. In addition, there are several situations where a 
combined approach (hybrid procedure) may be desirable. Methods: We examined the 
changing relationship between CABG and PCI by retrospective chart review at an aca- 
demic tertiary care facility. One hundred and sixty nine patients underwent both CABG 
and PCI during the same hospital adinissian out of 7,529 patients who underwent PCI 
and 6,684 patients who underwent CABG between January 1994 and March 2000. 
These 169 patients were divided into three groups: patients who underwent “rescue” 
CABG following failed PCI (n=lOO), patients who underwent planned hybrid procedures 
involving both GABG and PCI (n=46), and patients who underwent “rescue” PCI following 
failed CABG (n=23). Results: Over the 5-year period, there was a dramatic reduction in 
the need for i’re~cuei’ CABG following falled PCI, both in total numbers and as a percent- 
age of total cases (2.5% in 1994 and 0.22% in 1999). During the same period, there was 
an increase in the utilization of “rescue” PCI following failed CABG (0% in 1994 and 1.6% 
in 2000). There was no significant change in the number of hybrid procedures. There was 
no significant difference in mortality between the 3 groups, although there was a trend 
towards a higher mortality in the third group (p=O.O6). Conclusions: It may now be 
equally common for patients to require “rescue” PCI following CABG as “rescue” CABG 
following PCI. Changing patterns of resource utilization may affect patient triage and hos- 
pital organization. Patients undergoing CABG or PCI can benefit from close cooperation 
between the cardiac surgeon and the interventional cardiologist. 
I:24 P.m. 
1008-208 Assessment of Coronary Collateral Perfusion: Effect of 
Metoprolol 
Michael Billinger, Christian Seiler, Martin Fleisch, Franz R. Eberli, Bernhard Meier, Otto 
M. Hess. Universvy hospifai, Bern, Smfzerland 
Background: The recent advent of ultrathin Doppler angioplasty guidewires has made it 
possible to measure the collateral flow quantitatively. Pharmacologic interventions have 
been shown to influence collateral flow and, thus, to affect myocardiai ischemia. Meth- 
ods: Twenty-five patients with coronary artery disease undergoing PTCA were included 
in the present analysis. The Doppler wire was positioned distal to the stenosis which was 
dilated. Coronary flow velocities were measured in the stenosed vessel during PTCA with 
and without i.v. adenosine (140 vg/kg.min) before and after 5 mg metoprolol i.v., respec- 
tively. The measurements of these signals provides the variables for the calculation of a 
collateral flow index (CFI). CFI was defined as the ratio of flow velocity during balloon 
occlusion divided by resting flow after PTCA. Results: Heart rate and mean aortic pres- 
sure decreased slightly (n.s.) after metoprolol. Collateral flow index was 0.25~tO.12 during 
the first, respectively 0.27+0.14 during the second PTCA, but decreased with mdoprolol 
to 0.1620.08 (p<O.OOOl vs. baseline) during the third PTCA. Conclusions: Coronary col- 
lateral flow increased slightly, but not significantly during maximal vasodilatron with ade- 
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nosine but decreased in 23 of 25 patients after i.v. metoprolol. Thus, there is a reduction 
in coronary collateral flow by metoprolol probably due to an increase in coronary collat- 
eral resistance. 
I:36 p.m. 
1008-209 Time Course of Recovery of Coronary Endothelial Function 
in Patients After Percutaneous Transluminal Coronary 
Angioplasty 
Hassan El-Tamimi, Michael Mansoor, Thomas J. Wargovich, Uma M. Krishnan, Krit 
Jongnaransin, Fade Mahmoud, Carl J. Pepine. Michigan State University E. Lansing, Ml, 
University of Florida, Gainesville, FL 
Background: Recovery of coronary endothelial function after acute injury with balloon 
angioplasty has not been well studied. Methods: The effects of acute balloon vascular 
injury on vasomotor responses of stenotic coronary segments to acetylcholine and nitro- 
glycerin were investigated in 15 patients who underwent successful single left coronary 
artery angioplasty and were receiving no vasoactive medications. After baseline angiog- 
raphy, patients received three sequential two-minute left coronary infusions of acetylcho- 
line (1u6, 10d5 and 10m4 M, 1 mllmin) before and 5 min after coronary artery angioplasty 
followed by 200 micrograms of nitroglycerin. Angiography was repeated after each infu- 
sion. Minimal lumeh diameter (in mm) of target segments was measured by quantitative 
angiography. All patients underwent prospective follow-up angiography at six months 
using the same protocol. Results: All segments showed a reduction in minimal lumen 
diameter in response to acetylcholine before angioplasty (9r3%mean &EM; p < 0.02); 
angioplasty resulted in a significant increase in minimal lumen diameter (120+20%) in all 
segments. After angioplasty, acetylcholine reduced minimal lumen diameter by (13*3%, 
p < 0.03), this response was of similar magnitude (p=ns) to that observed before angio- 
plasty, and nitroglycerin increased minimal lumen diamater by (12+2%, p < 0.001). At six 
months, eight patients showed a vasoconstrictor response to acetylcholine, minimal 
lumen diameter decreased by (12+2%:pcO.O2) versus immediate post angioplasty while 
seven patients showed a vasodilator response to acetylcholine, minimal lumen diameter 
increased by ( &l%; p<O.Ol)versus immediate post angioplasty. Conclusion: The 
results of our study show that in 43 % of patients endothelial function did recover as 
reflected by the vasodilator response to acetylcholine at six months following angioplasty. 
I:48 p.m. 
1008-210 New Insights Into the immediate Changes in Left Ventricular 
Voltage Following PCI 
Guilherme Silva, Rogerio Sarmento-Leite, William Vaughn, Emerson 6. Perin. Texas 
Heart Institute, Houston 
Background: The consequences of myocardial &hernia associated with percutaneous 
coronary intervention (PC0 have been object of interest since the early angioplasty era. 
Balloon inflation triggers a transient impairment of diastolic and systolic left ventricular 
mechanical function. The long-term effect of PCI to electrical function of the myocardium 
has been studied before. However, there is no data on the immediate consequences of 
PC1 to electrical myocardial function. Therefore, we have measured the immediate elec- 
trical consequences of PCI as assessed by NOGA mapping. 
Methods: NOGA maps were performed before and after elective successful PCI. The 
percentage of the left ventricle (LV) with a normal (>12.0 mV) Llnipolar Voltage (UniV) 
was quantified in each map. The variation of those values was compared to a control 
group of five patients that had two consecutive maps without intervening PCI in the same 
clinical setting. The patients were then assigned as better, worse or unaltered in terms of 
uniV changes. ANOVA analysis was applied. 
Results: Of 48 patients (pts) undergoing PCI 38 pts had stent implantation and 10 pts 
rotational atherectamy (RA). UniV variations changed significantly between the controls 
and the PCI group (p=O.O03). Overall 16 pts improved (33%), 21 pts worsened (43%) and 
11 pts remained unaltered (24%). Multivariate statistical analysis using diabetes mellitus, 
hypertension, sex, type of intervention, the use of abciximab, smoking, hyperlipidemia, 
cerebrovascular disease, peripheral vascular disease, EF>40%, prior Ml or prior CABG 
as dependent variables showed that the only variable associated with improvement was 
the presence of prior CABG with an odds ratio of 0.141(0.0032-0.624; Cl 0.95). 
Conclusions: There Is an evident change in UniV in the LV immediately after PCI. This 
was positively influenced by the presence of previous CABG. Interestingly, the majority of 
patients had a worsening of electrical function. Although the reason for these changes 
are presently not clearly understood NOGA mapping affords a unique perspective on the 
functional assessment of the myocardium and could help define new patterns of 
K?SpOnSe to PCI. 
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1221-9 Late Thrombosis After Coronary Radiation May Be 
Eliminated by Longer Antiplatelet Therapy and Reduced 
Stenting: The Scripps Ill Results 
Paul S. Teirstein, Jeffrey W. Moses, Peter J. Casterella, Martin B. Leon, Huan Giap, 
Anuradha Koka, Gerard Huppe, Kathleen Sirkin, Shirish Jani, Mark Grise, Steven Baker, 
Prabhakar Tripuraneni, Alexandra Lansky, Roxanna Mehran. Scripps Cinic, La Jolla, CA, 
Lenox Hill Hospital, New York, NY 
Background: While the efficacy of coronary brachytherapy for the treatment of in-stent 
restenosis has been well established, recent reports of excess late thrombosis, leading to 
myocardial infarction, have raised safety concerns. Previous studies have linked throm- 
botic episodes to new stent implantation and early discontinuation of antiplatelet therapy. 
The objective of this study is to evaluate the impact of both reduced additional stent 
implantation and enhanced adjunctive antiplatelet therapy on late target thrombosis. 
Methods: At two centers (Scripps Clinic and Lenox Hill) vigorous attempts were made to 
avoid implanting new stents prior to treatment of in-stent restenosis with gamma radia- 
tion. Patients who did not receive new stents were discharged on clopidogrel (75 mg per 
day after a 300 mg loading dose) for 6 months and patients who received new stents 
were treated with clopidogrel for 12 months. All patients received aspirin, 325 mg, indefi- 
nitely. Results: To date, 494 patients have been enrolled in this 500 patient registry; 32% 
had diabetes, 12.7% had treatment of a saphenous vein graft and 31% were treated with 
a radiation source wire >=55mm in length. New stents were implanted in 22.8% of study 
patients. Current follow-up time is ~3 months in 359 patients and >=6 months in 227 
patients. To date, one patient who received a new stent sustained an acute stent throm- 
bosis six hours after the index radiation procedure due to distal dissection and one 
patient who received a new stent sustained a stent thrombosis two weeks following radi- 
ation. There have been no late (>=30 day) thromboses. Conclusion: Although follow-up 
is still accruing, it appears that minimizing new stem implantation and treatment with pro- 
longed adjunctive antiplatelet therapy may eliminate late target thrombosis after coronary 
brachytherapy. 
1221-10 Influence of Device Selection for the Treatment of In-Stent 
Restenosis With and Without Radiation. A Subanalysis 
From the Gamma Radiation Trials 
Ron Waksman, Andrew E. Ajani, Marco Zimmarino, Roxana Mehran, Kenneth M. Kent, 
Han-So0 Kim, Lowell F. Satler, Augusto D. Pichard. Washington Hospital Center, 
Washington, DC 
Background: Vascular brachytherapy (VB) has demonstrated efficacy in preventing 
recurrent in-stent restenosis (ISR). The purpose of this study was to compare the differ- 
ent devices utilized for the treatment of ISR with and without VB. 
Methods: We evaluated 467 patients from the radiation trials of ISR who were random- 
ized to gamma radiation (‘921ridium) or placebo following intervention. Devices used 
included balloon (POSA), excimer laser (ELCA), rotational atherectomy (RA), and stent- 
ing. Antiplatelet therapy was continued for 6 months in 106 patients (22.5%). Baseline 
clinical and angiographic characteristics were similar between the VB and placebo 
groups. Thirty-day and B-month clinical outcomes were compared. 
Results: VB reduces the B-month major adverse cardiac event (MACE) rate (ps 0.001) 
and the target lesion and vessel revascularization (TLR, TVR) rates compared to pla- 
cebo. However, VB was associated with a trend toward a higher rate of late total occlu- 
sion (7% vs. O%, p=O.12). Selection of device did not influence TLR and TVR in either the 
placebo or the VB group. 
30 days 6 mth 6 mth 6 mtll 8 mth 6 mt 6 me 
MACE’ Death ,QMl TLR. n/R LTO MACE’ 
N (%) N (%) N (“lo) N (%) N (“Yo) N (%j N (%) N (%) 
Radiation 341 7 (2)  6 (2)  4 (1)  51 (15)  71 (21)  9 (7)  76 (22)  
POEM 33 (10)  0 (0)  0 (0)  0 (0)  4 w 10 (30)  2 (6.0) 10 (30)  
ELCA 61 (18)  0 (0)  2 (3)  0 (0)  5 (8)  12 (PO) 0 (0)  13 (21)  
RA 77 (23)  1 (1)  1 (1)  0 (0)  8 (10) 10(13) 1 (1) 10 (13) 
StS”t 170 (50) 6 (4) 3 (2) 4 (7) 34 (20, 39 (23)  6 (4)  43 (25)  
Placebo 126 11 (9)  4 13)  0 (0)  73 (58)  74 (58)  0 (0)  82 (65)  
POBA 11 (9) 2V8) 1 (9)  0 (0)  4 (36)  4 (39)  0 (0)  5 (46)  
ELCA 17(14)  l(6) 1 (6)  0 (0)  13 (77)  13 (77)  0 (0)  14 (82)  
RA 41 (33, 3 (7)  2 (5)  0 (0)  27 (66)  27 (68)  0 (0)  30 (73)  
%“, 57 (45 )  5 (9)  0 (0)  0 (0)  29 (51)  30 (53)  0 (0)  33 (58, 
*p<O.OOl Radiation vs. Placebo 
Conclusion: The overall recurrence rate of ISR is lower in patients treated with VB using 
‘921ridium. Device selection does not influence late outcomes in either irradiated or non- 
irradiated groups. 
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1221-11 Importance of Three-Dimensional Treatment Planning and 
Dose-Valume Fiistogram Analysis in the Performance and 
Evaluation of Intravascular Brachytherapy 
Louis 8. Harrison. Aktko Maehara, Neil S. Patel, Neil J. Weissman, Ron Waksman, Gary 
S. Mint& Taya L. McMillan, Julianna Pisch, Harry Quon, Nathan Yang, Rosanna Ghan, 
Huchen Xie, Sou-Tung Chiu-Tsao. Department of Radiation Oncology, Beth israe/ 
Medfcal Center & St.Luke’s-Roosevelt Hosprtal Center, Mew York, NL: Cardiovascular 
Research Institute, Wasington Hospital Center, Washington, D.C., DC 
Background: Current intravascular brachytherapy (IVBT) protocols often use fixed 
dosimetry prescriptions. We undertook the current study of 3D treatment planning and 
dose-volume histogram (DVH) analysis to assess the actual radiatton doses delivered 
when fixed dosimetry methods are employed, to provide a basis for evaluation of the 
treatment efficacy. 
Methods : We examtned the tntravascular ultrasound (h/US) measurements of 21 cases 
from the WRIST trial that employed a fixed dosimetry prescription: 15 Gy @ 2mm from 
the source for vessels smaller than 4mm in diameter and 15 Gy @ 2.4mm for larger ves- 
sels. For biological purposes, the adventitia is currently considered the target volume and 
the intima is the tissue at risk for complications. These key anatomical structures were 
contoured using volumetric IVUS. We performed 30 treatment planning with software 
developed specifically for IVBT DVHs, as well as maximum and minimum dose values 
were calculated at the intimal and adventitial layers. 
Results : The actual doses received at the adventitia 
and intima ware very heterogeneous. The table shows 
that the actual doses received by the entire (100%) 
adventitia bears no resemblance to the fixed dosimetry 
prescription. The doses become even more heteroge- 
neous in proximal and distal adventitial segments. 
potentially explaining the edge effect. The figure shows 
an example patient, revealing the heterogeneous doses 
at representative points in the circumference of the 
adventrtq ranging from 6 to 23 Gy. and the intima, with 
a range from 10 to 43 Gy. 
Conclusions : DVH analysis shows that fixed dosimetry prescription results in a wide 
range of actual delivered doses to both the adventitia and the intima. This type of analy 
sis can be very critical to the assessment of success/failure as well as adverse out- 
comes. 
% adventitial volume receiving 15Gy # of patients 
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1221-12 The influence of Reference Vessel Diameter on 
Angiographic Restenosis and Target Vessel 
Revascularization in Gamma Radiation Versus Placebo for 
In-Stent Restenosis 
Andrew E. Ajani, Ron Waksman. Roxana Mehran, Alexandra J. Lansky, Lowell F. Satler, 
August0 D. Pichard. Kenneth M. Kent. Waajhington Hospitaai Center, Wash,ngton, DC 
Background: Vascular brachytherapy (VB) reduces angiographic and clinical restenosts 
in patients with in-stent restenosis (ISR). The impact of the reference vessel dtameter 
(RVD) on recurrent restenosis in patients treated wtth VB is not well established. 
Methods: The influence of RVD I” patients with ISR enrolled in gamma radiation trials 
was studied at &months using QCA analysis and clinical follow-up. Angiographic binary 
restenosis (>50% diameter stenosis at follow-up) and target vessel revascularizatio” 
(TVR) were assessed in 219 patients assigned to gamma radiation therapy and 105 
patients assigned io placebo. Baseline demographic, angiographic, and procedural 
details were similar. 
Results: The VB treated group resulted in reduced binary restenosis in all sized vessels 
with the most benefit see” in small vessels (Figure). 
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60%, pcO.0001). In the VB group, RVD i 2.5 mm was not associated with higher ratee of 
angiographic restenosls (32% vs 30% p=NS) or TVR (39% vs. 36%, p=NS) when com- 
pared to RVDZ5mm. 
Conclusion: Radiation results in a stgnificant reduction of angiographic restenosis com- 
pared to placebo across all sized vessels, this effect is see” predominantly in small ves- 
sels. 
1221-13 Square Shouldered Balloons. The Final Option to Prevent 
Edge Restenosis After Radioactive Stent Implantation 
Alexander J. Wardeh, Arie H. M. Knook, Evelyn Regar, Willem J. van der Giessen, David 
P Foley, Ken Kozuma, Jeroen Kleine, Clemens M. C. Disco, Peter 6. Levendag, Patrick 
W. Serruys. Thoraxcenter Rotterdam, Rotterdam, The Netherlands 
Background: Radioactive stents inhibit in-stent restenosis, however edge restenosis 
occurs in 30-50%, caused by the combination of barotrauma and low radiation dose at 
the edges. Higher radtation dose, Hot-Ends and Cold-Ends PSP-stents did not resolve 
edge restenosis. Methods: The P32 radioactive ACS Multi-Link was implanted with a 
special designed square shouldered balloon, which during inflation remained purely 
within the stem, thereby minimizing trauma at the stem edges. Preferably, dtrect stenting 
was performed. Pts returned for 6.month QCA follow-up (FU) and 1 & 6.month clinical 
FU. QCA measurements were done pre-, post-procedure and at FU. In total 30 pts were 
treated. The pts (77% male, age 37-77 yrs) had either stable (33%) or unstable (67%) 
angina. Risk factors ware previous Ml 41%, diabetes 18%, hyperlipidemia 57%, hyper- 
tension 25%, smoking 42% and family history 42%. Results & Conclusion: 29 of the 30 
pts had a successful PSZ-stem implantatton. See Table for preliminary procedural QCA 
results. At the presentation final 6.month clinical & QCA-results will be available, thereby 
showing whether square shouldered balloons resolve edge restenosis or not. 
preliminary QCA Results 
Ref Diam pre, mm 2.75io.49 
Ref Diam post,mm 3.13t0.37 
MLD pm. mm I.04436 
MLD post, mm 2.64+0 45 
DS pm. % 63t9 
DS post, % 16+7 
1221-14 Final Results Of “Hot Ends” 32 P Radioactive B-Emitting 
Stent Implantation in Patients With CAD. The Milan and 
Rotterdam Experience 
Remo Albtero. Takahtro Nishida, Alexander J. Wardeh, A.H. Marco Knook, Antonio 
Am&o, Ntcola Corvaja, Marco Vaghetti, Goran Stankovic, Carlo Di Mario, Patrick W. 
Serruys, Antonio Colombo. EM0 Centro Cuore Columbus, Milan, ItalK Thoraxcente/ 
Rotterdam, Rotterdam, The Netherlands 
Background: Edge restenosis occurs in > 30% of lesions (les) treated by 32P 0 emitttng 
BX stents wtth activittes up to 21 microci. This is possibly the result of the systematic bal- 
loon injury l-3 mm outside the stent in combtnation wtth a sub-therapeutic level of radia- 
tion at the stent edges. The aim of this study was to evaluate whether radioactive stems 
with a higher activity at the proximal and distal end of the stem (“hot ends”) might dimin- 
ish the problem of “edge restenosis”, by extending the area of irradiation beyond this 
injured area. Methods and Results: The “hot ends” 32 P radioactive &particle-emitting 
stent has a length of 18 mm. The initial radioactivtty level is 2.6 microCi/mm m the proxr- 
mal and distal 2 mm of the stem, and 0.57microCilmm in the central 14 mm of the stem 
The Initial total radioactivity of the stem is -18.5 mrcroCi (10.4 microCi at the ends + 7,98 
micr& in the middle of the stent). From July till Nov 1999, 53 patients (pts) with 56 les 
were treated in Milan (36 pts wtth 39 les) and Rotterdam (17 pts wtth 17 les) by implanta- 
tion of 56 “hot ends” 3zP radioactive stems. Six-month FU angiography was performed in 
51 pts with 54 les (96%). The table shows the results. 
Patients, n 53 
Lesions, n 56 
Radioactivity, microCi 14.0r2 6 
Reference Diam, mm 3.0t.61 
Lesion length, mm 13.9*4.8 
Max pressure, atm 14.4i2.9 
MLD - pm, mm .90r.53 
post, mm 2.95k.56 
Follow-up, lesions n (%) 54 (96%) 
Reference Diam, mm 3.oEh.49 
MLD, mm 2.17k.94 
Restenosis (DS>50%), ” (%) 18 (33%) 
- Proximal edge, n (%) 10 (19%) 
- Proximal + distal edge, n (%) 4 (7%) 
- Distal edge, n (%) 4 (7%) 
Conclusion: “P radioactive “hot ends” stents did not solve the problem of “edge rest- 
enosis”. 
At 6 months, TVR was reduced in the irradiated group compared to placebo (34% vs 
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1221-15 Adverse Edge Effects Are Not Prevented by 32P Beta- 1221-17 Geographic Miss in the Treatment of Long and Diffuse In- 
Emitting Hot-Ends Radioactive Stents Stent Restenosis With lntracoronary Brachytherapy 
Michael C. John, Andrew Farb, Renu Virmani. Arm&Forces Institute of Pathology 
Washington, DC 
Background: Adverse stent edge effects have been observed in clinical trials of P-emit- 
ting radioactive stents in humans. The mechanism of this edge effect is unknown but may 
be secondary to a proliferative effect of radiation dose fall-off away from the stent in an 
area of balloon angioplasty-induced arterial injury. In an effort to prevent this deleterious 
edge effect, a novel “hot-ends” radioactive stent has been developed which has a higher 
radiation dose at the proximal and distal ends of the stent. Sn the present study, we 
sought to determine whether a hot-ends radioactive stent will suppress intimal growth 
within the stent and at the stent borders (non-stented edges). 
Methods: Hot-ends radioactive stents (72 or 96 PCi at the stent ends with 7.6 PCi in the 
stent center) were compared to a uniform 7.6 pCi stent and a non-radioactive control 
stem. Stents were placed in rabbit iliac arteries and analyzed at 6 months (n=8 per 
group). lntimal changes within the stents and in the non-stented edges were measured, 
and arterial remodeling (change in EEL area) was determined. 
Results: Distal non-stented edge measurements are presented in the table (mean i 
SEM). 
Christoph Naber, Christoph A. Kaiser, Yasser Abdel Rahman, Holger Eggebrecht, Peter 
Meusers, Wolfgang Sauerwein, Michael Haude, Raimund Erbel, Dietrich Baumgart. 
University Clinic, Essen, Germany 
EEL Area 
(mm’) 
Neointimal 
Thickness 
Adventitial 
Thickness 
% Stenosis 
Background: Despite the high effectiveness of intracoronary brachytherapy for the treat- 
ment of restenosis, edge or candy wrapper effects mainly determine the recurrence rates 
of restenosis. It has been hypothesized that a discrepancy between balloon injury and 
irradiated area, so called geographic miss, could be responsible for edge restenosls. Pre- 
vious studies have only analyzed stenosis lengths of c20mm. It is thus unclear, how geo- 
graphic miss would effect restenosis rates for lesions >20mm. Methods: A total of 88 
patients with recurrent in-stent restenosis were treated with PTCA and subsequent 
brachytherapy utilizing either a 30mm, 40mm or 60mm @“SR-source, applying a mean 
dose of 21.5+1-4.1 Gy at 2.0mm tissue depth. Geographic miss was analyzed by off-line 
QCA. The influence of lesion length, balloon covered area and source length on geo- 
graphic miss was analyzed using a general linear model. Results: 32 (36.4%) of the 
patients had focal lesions (Type I) according to the Mehran classification of in-stent-rest- 
enosis, 56 (63.6%) had diffuse lesions. Mean balloon covered length was 37X+/- 
19.6mm. Geographic miss was found in 33 patients (37.5%). Lesion length was the only 
independent predictor for the occurrence of geographic miss in a general linear model 
(p=O,OO2). In the mean follow-up period of 5.3+/-l .5 months angiographically significant 
restenosis was observed in 4.5% of the patients (n=4). There was no correlation between 
geographic miss and the occurrence of restenosis. Conclusions: Despite a high inci- 
dence of geographic miss in our population we found no correlation between the occur- 
rence of restenosis and geographic miss. Thus, our data indicate that geographic miss 
might be of less importance for the treatment of patients with in-stent restenosis than 
commonly assumed. 
(mm) (mm) 
Control 2.38+0.10 .020r.010 .106+.01 0.7*0.4 
Uniform 7.6 PCi 2.44*0.33 .058+.030 .120+.02 1.9+0.7 
Hot-ends 72 pCi 1.82?0.19’ .107+.030’ .170t.02* 4.0?1.6* 
Hot-ends 96 BCi 1.77rO.i2’.’ .132r.030’.’ .181+.02’z’ 8.1+1.1’.’ 
There were no significant differences in the non-stented proximal edge segments among 
groups. Both hot-ends stent groups demonstrated significant intimal inhibition within the 
stent, which was maximal at the stent ends. Scanning electron microscopy revealed 
incomplete enddhelialization in the hot-ends stents, 
Conclusion: Despite increased intimal inhibition within the stent, there are persistent 
adverse edge effects associated with hot-ends stems characterized by intimal thickening 
and negative arterial remodeling. 
1221-16 The Incidence and Outcome of Patients Presented With 
Edge Restenosis After lntracoronary Radiation Therapy 
Han-Soo Kim, Andrew E. Ajani, Ron Waksman, Lowell F. Satler, Gary S. Mintz, August0 
D. Pichard, Luis Gruberg, Fiosanna C. Ghan, Kenneth M. Kent. Washington Hospital 
Center, Washington, DC 
Background: lntracoronary radiation therapy (IRT) has demonstrated a reduction in the 
recurrence rate in patients with in&ant restenosis (ISR). However, edge restenosis 
(ERS) following IRT has been reported as a complication and limitation of the technology. 
Methods: To evaluate the incidence and clinical outcome of patients with recurrent edge 
restenosis after intracoronary radiation therapy, we reviewed 506 patients who were 
assigned to IRT including both y(‘@lr) and p (90~) emitters in FDA-approved radiation tri- 
als conducted at the Washington Hospital Center. Angiographic ERS was defined as 
z-50% diameter stenosis by QCA at the edge of the lesion (5 mm). ERS was observed in 
43 pts (8.5%); 19 proximal, 22 distal, and 2 both proximal and distal edges. ERS rates 
were similar across studies regardless of the selection of the isotope (y or p). ERS 
lesions were focal <lOmm and characterized soft by intravascular ultrasound. Patients 
with ERS after IRT were assigned to the following therapy: medical therapy (n=l), CABG 
(n=2), and PTCA (n=40; balloon angioplasty n=19 and stent implantation n=21). 
Results: Clinical follow-up was available at a mean of 355 days (135 to 731) after the 
repeat procedure. Event-free survival was 85 0% and 81.8% at 6 and 12 months, respec- 
tively. During the follow-up period, recurrent events occurred in 8 patients (20%), includ- 
ing 1 myocardial infarction (2.5%) and 7 repeat target vessel revascularizations (17.5%). 
(Figure) 
Conclusion: Edge rester&s is a predominant pattern in patients who failed vascular 
brachytherapy. The outcome following repeat balloon angioplasty or stent implantation for 
the treatment of edge restenosis is favorable and comparable to the reported outcome of 
treated focal ISR lesions. 
1221-18 Shorter Recurrent Lesion Length After Localized 
lntracoronary Radiation in the Gamma I Study: A Partial 
Response to Radiation 
Mark A. Grise, Alexandra Lansky, Martin B. Leon, Jeffrey W. Moses, Richard Kuntz, 
Barry George, James Hermiller, Bryan Kluck, Dennis Donohoe, Prabhakar Tripuraneni, 
Shirish Jani, Paul S. Teirstein. 
Scripps Clinic, La Jolla, CA 
Background: Gamma I was the first multicenter, double-blind trial of intracaronary 
gamma radiation for the treatment of in-stent r&en&s. While gamma radiation signifi- 
cantly reduced target lesion revascularization and decreased binary in-lesion restenosis 
(36~s 57% p<O.Oi), approximately one third of treated patients still develop restenosis. 
The objective of this analysis was to evaluate lesion length and its predictors at 6 month 
follow up. Methods: Of 252 study patients, 131 were randomized to Iridium-192, and 121 
received placebo. Angiography was performed at 6 months in 84.7% of the radiation 
group and 85.1% of the placebo group. 
Reari& 
6 Mm& FIU Rensloos Lengh,ZLn”> 
Conclusion: When failures occur following gamma radiation therapy, the restenotic 
lesion is shorter compared to placebo patients. Multivariable analysis shows that radia- 
tion treatment is an independent predictor of follow up lesion length, even after adjust- 
ment for follow up minimal lumen diameter. This partial response to radiation may render 
these lesions more amenable to further percutaneous intervention. 
1221-19 Differing Patterns of Stent Edge Restenosis With Differing 
Forms of Brachytherapy 
Marco Zimarino, Nail J. Weissman, Ron Waksman, Raffaele De Caterina, Javied M. 
Ahmed, August0 D. Pichard, Gary S. Mintz. Washington Hospital Center, Washington, 
DC, Univ of Chid, Chieti, /k/y 
Background: lntracoronary brachytherapy reduces instent restenosis. However, a dis- 
turbihng incidence of stent edge restenosis has been reported. It is not clear what is the 
mechanism of edge restenosis (ER) and whether it is unique to the form of 
brachytherapy. Methods: In ordet to determine the mechanism of ER across different 
forms of brachytherapy, we identified 45 cases of ER among pts who received Gamma 
(n=14), Beta (n=lZ) pr radioactive lsostent (n =12) treatment or had ER and were in the 
placebo arm (n=7). Volumetric IVUS was performed both at treatment and at follow-up 
throughout the stent and for 10 mm proximal and distal. Results: ER was located proxi- 
mal to the stent in 14 (31%), which was no different across groups (29% of Gamma pts 
proximal, 25% of Beta, 42% of lsostent and 43% of placebo, p=ns). Lumen loss within 
the stent was entirely due to intimal hyperplasia (IH) in all groups while both IH and neg 
remodeling contributed to lumen loss outside the stent in all groups. The extent and dis- 
trlbution of negative remodeling was similar across groups. While the smallest lumen of 
the ER at follow-up was located outside the stent in 30 (67%), the distribution and magni- 
tude of IH differed among forms of brachytherapy (p=O.OOE). Both Beta sources (Beta 
and k&tent) had more IH at the stent edge then Gamma or placebo (p<O.Ol). Gamma 
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and placebo pts had IH equally distributed within and up to 5 mm outside the stent. Beta 
has most IH within the stent, which fell off by 3 mm outside the stent. lsostent has peak 
IH at the last mm wlthin the stent that extends for 5 mm outsIde. Conclusions: Edge 
restenosis after brachytherapy is due primarily to IH within and immediately outslde the 
stent, regardless of the source of radiation. However, the relative contribution and distri- 
bution of IH differs depending on the source of radiation 
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1222-20 Stenting Without Rotational Atherectomy in Lesions With at 
Least Moderate Calcification by IVUS but Insignificant 
Calcification Angiographically 
Yoshio Kobayashi, lssam Moussa, Roxana Mehran, George Dangas, Alexandra J. 
Lansky, Gishel New, Milena Adamian. Alexandre Abiraid, Gary Roubm, Gregg W. Stone, 
Martin B. Leon, Jeffrey W. Moses. ienox Hi// Hearf and Vascular Institute, New York, N): 
Cardiovascular Research Foundation, New York, NH 
Background: Intravascular ultrasound (IVUS) may identify moderate or severe leson 
calcification that is not appreciated angiographlcally. This study evaluated the results of 
stenting without rotational atherectomy in lesions with at least moderate calcification as 
indicated by IVUS, but not appreciated by angiography. 
Methods: Pm-intervention intravascular ultrasound (IVUS) was performed in 193 lesions 
with no or mild calcification by anglography, which subsequently underwent stenting with- 
out rotation& atherectomy. Lesions were classified into two groups according to the 
severity of calcification (degrees of calcium arc): 1) no or mild calcification (<180”, 
n=155) and 2) moderate or severe (2180”, n=38). 
Results: 
Calcification 
Measurments No or Mild ZModerate p value 
QCA 
Ref dlamter 3.02~0.68 2.96+0.48 0.53 
(mm: 
Pre MLD (mm) 0.91kO.49 0.98iO.35 0.34 
Post MLD (mm) 3.07?0.60 3.14+0.48 0.45 
tvus 
Prox ref L CSA 8.7r3.0 8.3r2.0 0.58 
(mm’) 
Distal ref L CSA 7.9r3.1 7.0*1.8 009 
(mm*) 
Pte MLD (mm) 1.5110.2 1.520.3 0.16 
Pre L GSA 2.4co.9 2.210 8 0.12 
(mm’) 
Final MLD (mm) 2.71-0.2 2.5t0.4 0.04 
Final L CSA 7.4e2.3 6.4a1.7 0.02 
(mm”) 
Ref = reference, CSA = cross-sectional area: L = lumen: MLD = minimal L diameter 
Conclusions: Moderate or Severe coronary calcification not identified by angiography is 
associated with smaller lumen dimensions by IVUS after stenting alone, although it is not 
appreciated by anglography. 
1222-21 Total Plaque Burden in Early Atherosclerosis: Can It Be 
Predicted by the Most Severe Lesion? 
Samir R. Kapadia, Khaled M. Ziada, Timothy D. Crow@, Debabrata Mukherjee, Robert E. 
Hobbs, Sieven E. N&en, E. Murat Tuzcu. The Cleveland Clinic Foundation, C/eve/and, 
OH 
Background: Accurate quantification of total atherosclerotic plaque burden is necessary 
to investigate the effects of pharmacological interventions on atherosclerosis. This can 
be difficult and time consuming. On the other hand, an individual plaque can be quanti- 
fied easily. We sought to determine whether the most severe atherosclerotic plaque can 
provide an estimate of the total plaque burden in the coronary arteries. Methods: Intra- 
vascular ultrasound examination was performed in 171 patients within 2 months ot car- 
diac iransplantation. Left anterior descending artery and left main trunk were imaged 
using automated pullback (0.5 mm/s+ All sites, separated exactly by 1 mm were mea- 
sured except for the sites with branches and significant calcification. A total of 7932 sites 
were measured. The mean length of imaged segment was 4&13 mm. In each patient, 
the worst lesion was defined as a site with greatest intimal thickness. Plaque area and 
maximum plaque thickness were measured at this site. Total plaque burden was esti- 
mated by calculating average plaque area from all measured sites in each patient. 
Results: There was a high and statistically significant (p&OOl)correlation between the 
severity bf the worst lesion (plaque thickness and plaque area) and total atherosclerosis 
plaque burden (average plaque area).(Figure) Conclusion: In patients with early athero- 
sclerosis, the severity of the worst lesion correlates with total atheroclerosis plaque bur- 
den 
2.4 
Total plaque burden (mm*) 
1222-22 Mechanisms of Lumen Enlargement Through Rotational 
Atherectomy and PTCA Compared With PTCA Alone in 
Patients With in-Stent Restenosis: intravascular Ultrasound 
Results From the ARTIST Trial 
Philipp K. Haager, Rainer Hoffmann, Birger Horn, Hemrich G. Klues, Francois Schiele, 
Jiirgen vom Dahl. University Hospital RWTH, Aachen, Germany 
Diffuse In-Stem Restenosis (1%) has become a severe problem in interventional cardiol- 
ogy after stent implantation for long and complex lesions was introduced in every days 
practice. Best strategy achieving maximal lumen enlargement using conventional treat- 
ment is still under discussion. High pressure PTCA (PTCA) vs. rotational atherectomy 
(ROTA) with adjunctive low pressure PTCA according to the hypothesis of minimal arte- 
rial trauma ware investigated in the randomized, multicenter, european ARTIST trial. We 
used quantitative intravascular ultrasound (IVUS) before and after intervention and at 6 
month follow-up (FU) within a subgroup to study the mechanisms of cross sectional area 
(CSA) enlargement and plaque ablation. CSA of the treated segment is given as 
mean&SD in the table below: 
1 Pre ROTA (ad].) PTCA 6 month FU 
Vessel PTCA : 16.6i3 4 I%&3 4 *I* 18.&3. s” 
ROTA 14 7i4 6 14.8+4.8 14.7-t4.6 14 9i4.4 
Stent “CA 6.8+1,5 8.0+1.7** 8.ltl.kP 
ROTA 6.2+20 6.25?.0 6.6kl.9 6.6-eZ. 1 
Lumen FWA 3251.3 5.9?1;6* 4.8fl 8 
ROT.4 3.txz1.3 3.9??.1 4 9*1.3 4.2*1 7 
Plaque PKA 13 4a3.7 12.3i3.0”* 13 6*3.2*‘* / ROTA 1.7*  4 10 9*4.2 9.?‘* ,3 0.7zt3.7 
Neointima irA z:g:.z ~ 2,2*, 3 :,yz,z* 3.4C1.4+’ 
2.4fl 0 - 
* p4.05 * pa 01 c* pco.005 
PTCA leads to a significant better acute lumen gain, but no significant difference is seen 
after 6 month. Total plaque area is unchanged at FU after initial decrease. ROTA signifi- 
cantly reduces total plaque by neointimal ablation. Lumen gain was insufficient due to 
unchanged stent and vessel dimensions following low pressure balloon inflation. Late 
loss was less and net gain was same as initally achieved by ROTA alone. Conclusion: 
ROTA and adjunctive low pressure PTCA fails to improve outcome in pts. with severe 
ISR. Further Stent expansion and vessel overstretching are the key mechanism in PTCA. 
ROTA demonstrates true plaque ablation with net nsotintima loss at FU. Results are less 
favorable due to the low pressure strategy used. 
1222-23 Comparison of Vascular Remodeling Between Saphenous 
Vein Grafts and Native Coronary Arteries: An Intravascular 
Ultrasound Analysis 
Charanjit Kapoor, Barry L. Sharaf, George R. McKendall, Thomas R. Drew, Edward S 
Thomas, David 0. Williams. Rhode /s/and Hospital, Brown Universi~ Providence, RI 
Background: Saphenous vein grafts (SVG) and native coronary arteries (NCA) have dif- 
ferent vessel wall composition. Whether these vessels demonstrate different patterns of 
vascular remodeling is unclear. Methods: Pre-intervention intravascular ultrasound was 
performed in 35 saphenous vein graft and 33 native coronary artery lesions. Reference 
vessel cross sectional area (RVCSA) (mean of proximal and distal CSA), lesion vessel 
CSA (LVCSA) and lesion lumen GSA (LLCSA) were measured. Plaque CSA (LVCSA- 
LLCSA), percent area stenosis ([plaque CSAILVCSAplOO) and remodeling index 
(LVCSAIRVCSA) were calculated. Ratios of >l.l, <.9 and .9-1.1 represent positive, neg- 
ative and no remodeling respectively. Results: Baseline clinical and demographic char- 
64A ABSTRACTS - ACCIS2001 (Angiography & Interventional Cardiology) JACC February 2001 
acteristics were similar except for a lower incidence of prior myocardial infarction and 
percutaneous translumlnal wronary angioplasty in the native coronary artery group 
(pc.05). Further cesults are listed in the table. 
Quantitative Analysis of Saphenous Vein Grafts and Native Coronary Arteries 
Saphenous Vein Native Coronary p value 
Grafts (n=35) Arteries (n=33) 
Positive Remodeling 26 (74%) 23 (70%) ns 
Negative Remodeling 8 (23%) 7 (21%) ns 
No Remodeling 1 (3%) 3 (9%) “.S 
Remodeling Index 1.6 1.5 ns 
Area Stenosis(%) 80 81 ns 
Plaque Area (mm2)* 14 9.7 p<.ooo1 
Vessel Cross Sectional Area (mm2)’ 17.9 11.7 p<.ooo1 
*=positive correlation for plaque and vessel cross sectional area in saphenous vein 
grafts and native coronary arteries; wO.9, p<.OOOl ns=not significant 
Conclusion: Saphenous vein grafts and native coronary arteries have similar patterns of 
vascular remodeling. Both groups show a preponderance of positive remodeling at the 
stenosis site. Though plaque area tends to be greater in saphenous vein grafts, compen- 
satory vessel enlargement analogous to that seen in native coronary arteries is 
observed. 
1222-24 Coronary Perforations: Morphologic Assessment by 
Intravascular Ultrasound 
Akiko Maehara, Gary S. Mint& Neil J. Weissman, August D. Pichard, Lowell F. Sadler, 
Ron Waksman, John R. Laird, Jr., William 0. Suddath, Kenneth M. Kant, Stephen E. 
Epstein. Washingfon Hospital Center, Washington DC, DC 
Perforations are rare complications of coronary interventions. Methods: We assessed 
the IVUS morphology of 33 coronary perforations documented by anglograhy during var- 
ious interventions. The site of perforation was compared with the pre-interventional study. 
Results: In 28/33 (85%) lesions, site of perforation could be identified. 57% of perfora- 
tions occurred in the lesion and the other 43% in the adjacent reference segment. The 
site of pelforation was in a healthy part of the artery in 57%, at a diseased site in 25%, 
and involved the junction of an eccentric plaque and the adjacent healthy wall in 18%. 
Eccentric plaque (maximum/minimum plaque thickness >3:1) was found in 67%. 
Although the length of the lesion pre-intervention measured 17.5ill.3mm, the length of 
the perivascular hemorrhage measured 24.5~21.4mm (p=O.O77); and its circumferential 
extent was 2735107”. Characteristic features of perforation are shown in the figure and 
include: (1) free blood flow between the true vessel and a large peri-adventitial space 
[Figure A showing perforation site (a) and blood flow (a’)] or (2) peri-adventitial hem&ma 
(Figures B and C) with or without distinct additional perivascular tissue interface not 
present prwntervention (white arrow b and white arrow c, respectively). 
Major cardiac events (Q-MI, death, CABG, target vessel revascularization) in these 
patients were 6.1% at 24 hours, 9.1% at 1 month, and 24.2% at 1 year. Conclusion: 
Coronary perforation occurs with equal frequency in healthy or diseased coronary artery 
segments at or adjacent to the stenosis being treated. Perforations are more common in 
eccentric lesions. The longitudinal and circumferential extent of the hemorrhage is usu- 
ally greater than that of the original lesion. 
1223 Percutaneous Coronary Intervention in 
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1222-25 Vascular Remodeling in Atherosclerotic Coronary Arteries 1223-28 Is the Long Term outcome of Multivessel PTCA in Diabetic 
in Patients With High Insulin Resistance: An Analysis With Patient Inferior to That of Non Diabetic patient? 5 Year 
Intravascular Ultrasound Imaging Follow-Up in the Multivessel PTCA Multicenter Study 
Takashi Yoshitama, Yoko Kitagawa, Raisuke lijima, Rintaro Nakajima, Takuro Takagi, 
Hitoshi Anzai, Tare Tsunoda, Masato Nakamura, Tetsu Yamaguchi. 
Ohashi Hospital Toho University Faculty of Medicine, Tokyo, Japan 
Katsuya Kitano, Tohru Kobayashi, Hideo Tamai, Takahiko Suzuki, Hideo Nishikawa, 
Osamu K&oh. MRT investigators. Kyoto K&m Hospital Cardiovascular Center, Kyofo, 
Japan 
Background: Insulin resistance (IR) has been shown to be an important initiating factor 
of coronary atherosclerosis. However, the association between insulin resistance and 
coronary vascular remodeling in patients with coronary artery disease are not well- 
understood. The purpose of this study was to evaluate the association between insulin 
resistance and coronary vascular remodeling in patients with coronary artery disease. 
Methods: Twenty-nine patients of 31 coronary arteries underwent preintervention intra- 
vascular ultrasound (IVUS) examination. External elastic membrane (EEM) cross-sac- 
tional area (CSA), lumen CSA and plaque and media (P&M) CSA were evaluated at the 
proximal and distal reference segments and lesion site. Positive remodeling (lesion EEM 
GSA greater than average reference) and intermediate/negative remodeling (lesion EEM 
CSA less than or equal to reference) were also evaluated. Patients were divided into two 
groups based on the homeostasis model assessment of insulin resistance (HOMA IR, a 
surrogate for insulin resistance) levels: group 1: N=12, HOMA IR 21.5; group 2: N=17, 
HOMA IR < 1.5. Results: Baseline clinical characteristics was similar among two groups. 
The data of IVUS measurements was as follows. Conclusion: High insulin resistance is 
associated with positive remodeling of coronary arteries. Therefore we suspect that dif- 
ferent adaptive process may occur among the high IR patients and low IR patients. 
IR = insulin resistance 
Background: Recently, It has been reported that diabetes mellitus (DM) worsen long 
term outcomes in patients (pts) with multivessel disease (MVD). The purose of the study 
is to reveal the influence of DM on long term outcome in pts with MVD by PTCA. Meth- 
ods: The multivessel PTCA multicenter study was conducted to evaluate the long term 
outcome on aggressive angioplasty strategy for MVD that means intensively attempting 
the lesions of chronic total occlusion (CTO). From 4 institutions, every patient with MVD 
revealed by 1st diagnostic angiography was recruted from Feb.1992 to Mar.1995. A total 
of 490 pts met the clinical and angiographical criteria of MVD [without left main disease. 
equal or more than two major diseased, no exception of CTO, no prior intervention and 
no CABG]. The 490 pis were divided into 2 groups [DM (212pts), non DM (278pts)l. 
PTCA success was defined as target vessel revascularization without major cardiac 
event, were achieved 89 % (DM) and 91% (non DM). We compared 5 year-outcome of 
cardiac events (cardiac death, MI, CABG, unstable angina, congestive heart failure) 
between the groups. Results: There were no differences in baseline data between the 
groups [(DM: non DM) mean age; 62~0: 62~0, male gender; 75%: 74%, prior MI; 64%: 
63%, CTO; 48%: 49%, triple vessel disease; 29%: 31%, EF; 52%: 54% history of con- 
gestive heart failure (CHF); 15%: lo%]. 5 years clinlcal follow up was achieved 92% in 
DM and 93% in non DM patinent. The cardiac event-free ratio were 64% in DM and 75% 
Group I (High Group 2 (Low P value 
IR) N=13 IR) N=18 
CKISS- Reference External 18.24.6 15.5L3.7 0.113 
sectional elastic membrane 
area 
WW 
Reference Lumen 7.422.2 9.1+2.4 0.056 
Lesion site External 20.3i6.2 13.3+_3.5 <O.OOl 
elastic membrane 
Lesion site Lumen 1.9kO.7 1.5+0.3 0.065 
Lesion site Plaque & 18.5+5.8 11.8k3.4 <O.OOl 
media 
Positive remodeling 8 (62%) 4 (22%) 0.027 
1222-26 Effect of LDL-Apheresis on Coronary Plaque 
Characteristics in Patients With Familial 
Hypercholesterolemia Assessed by Intravascular 
Ultrasound With Wavelet Analysis 
Takafumi Him, Katsuhiko Hiramori, Akira Kitabatake, Tsutomu Imaizumi, Hi&hi Hishida, 
Masanori Nomura, lchiro Sakuma, Kenichi Fukami, Takashi Honda, Hiroshi Ogawa, 
Takashi Fujii, Masunori Matsuzaki. Yamaguchi University, Ube, Japan 
Background: Wavelet analysis is a new mathematical model for assessing local 
changes of geometrical video-intensity profile. We previously reported that Wavelet anal- 
ysis of intravascular ultrasound (IVUS) images might be useful for detecting lipid-rich 
area within atherosclerotic plaque in viva (Circulation, 100, l-229, 1999). Methods: To 
examine the effect of LDL-apheresis on coronary plaque characteristics in patients with 
familial hypercholesterolem~a (FH), IVUS images at baseline and one-year follow-up 
were compared at 34 plaque segments from 11 patients, as a multicenter trial (The LDL- 
Apheresis Coronary Morphology And Reserve Trial). Wavelet analysis of these IVUS 
images was performed with Daubechies-2 wavelet to obtain the three-dimensional bird’s 
aye view of ihe correlation coefficient with the wavelet reconstructed over the x-y plane of 
the wavelet scale and the distance from IVUS catheter. Results: LDL choleslerol was 
reduced from 213(+/-)25 to 140(+/-)27 mgidl (~~0.05) during the follow-up period. At one 
year follow-up, both plaque area and vessel area were decreased, while lumen area was 
unchanged, compared to ihe baseline (Circulation,iOO, l-82,1999). The Waveiet analysis 
was possible at 12 plaque cross sections to compare the basellne and the follow-up. In 
this analysis, the lipid-rich area within plaque was depicted as an area of a high coeffi- 
cient with a short wavelet scale. At one-year follow-up, 4 segments (33%) among the 12 
segments revealed a decrease in lipid-rich area; six segments (50%) did not show any 
changes; two segments (17%) showed an increase in lipid-rich area, compared to the 
baseline. Conclusions: LDL-apheresis for FH patients over one year generally pre- 
vented the progression of lipld-rich area within coronary plaques, and it might partly 
induce the regression of plaque vulnerability. 
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in non DM (p=O.Ol) respectively. In cardiac death, there was no difference between the 
groups [(DM: non DM) 3%: I?%]. Re-PTCA was performed 67% in DM and 60% in non 
DM (p=O.O4). Subsequent PTCA for restenosis were 64% in DM and 56% in non DM 
(~~0.04). CABG was done in [(DM: non DM) 16%: 8%(p=O.O1)]. Subsequent PTCA for 
new lesions except target lesions were [[(DM: non DM) 17%: 13%]. Conclusion: It was 
suggested that aggressive subsequent revascularization in diabetic pts with MVD, create 
similar late outcome that of non diabetic patients. 
Methods: The DESTINI trial is a prospective randomized evaluation of primary stenting 
(PS=367 pts) compared to Doppler-guided optimal balloon angioplasty (GP=366 
patients) in patients with obstructive CAD. DM was present in 135 pts, while 538 patients 
did not have DM. 
1223-29 The Influence of Diabetes on the In-Hospital Outcome of PCI 
in the ACC-NCDR Database 
Ralph Brindis, Charles McKay, Vernon Anderson, Richard Shaw, William S. Weintraub. 
On Behalf of the ACC-NCDR(TM)/ACC Database Committee, Bethesda, MD 
Background: Patients with diabetes are at increased risk after percutaneous coronary 
intervention (PC& However, there are little data to quantify this increased risk from con- 
temporary, nationally based, multisite registries. The ACC-NCDR is a major registry 
activity of the American College of Cardiology which is designed to assess outcome of 
PCI. 
Methods: Outcome of PCI I” diabetics (n=4380) and non-diabetics (n=12904) was 
examined in the ACC-NCDR database. 45 institutions (l/1/98-6/30/99) with acceptable 
complete data used standardized definitions and identical reporting standards. 
Results: Diabetics were more symptomatic, had more co-morbidity, and had greater 
objective severity of disease (see table). While no difference in non-fatal events was 
noted, diabetics had htgher mortality. 
Results: There were more females in the diabetic group (39% versus 23%, p=O.O04). 
There was no difference in angiographic or procedural characteristics. The clinical out- 
coma of patients at 12 month follow-up after hospital discharge is shown below: 
DM No DM 
GP n=70 PS n=65 GP n=296 PS n=302 
Peri-Procedural 
Death 0 0 0 0 
Ml@ and non-Q) 2(2.9%) 3(4.6%) 9(3%) 7(2.3%) 
CABG 0 0 2(0.7%) 3(1%) 
l-year Follow-up 
Event free survival 49(71%) 46(72%) 245(84%) 236(79%) 
Death 3(4.3%) 0 3(1.05%) 6(2%) 
Ml 0 0 i(O.40~) 0 
CABG 2(2.9%) 6(9.4%) 4(4.1%) 5(1.7%) 
Re-PTCA 14(20%) 11(17%) 39( 13%) 51(17%) 
‘P < 0.05 between patients with and without DM: Ml, myocardial infarction. 
Conclusion: Patients with DM have lower event free survival compared to patients without 
DM irrespective of the type of the catheter-based intervention used. Dedicated clinical tri- 
als are necessary to evaluate the role of adjunct therapeutic modalities (pharmacological 
or brachytherapy) to enhance the clinical outcome of DM patients. 
Diabetics Non-Diabetics P-Value 
Age 64*11 63il3 <0.0001 
Hypertension 75% 58% <0.0001 
Female 40% 31% <0.0001 
CHF 18% 8.8% <0.0001 
Prior CABG 25% 17% <0.0001 
Angio Success 33% 32% 0.60 
Q Wave MI 0.43% 0.46% 0.89 
In-hospital CABG 2.20% 2.29% 0.78 
Death, All Cases 2.26% 1 .45% 0.0004 
Death, Elective Cases Only 0.86% 0.50% 0.04 
LOS (days) 2.76zt4.09 2.42i3.12 <0.0001 
Corrected for baseline differences, diabetics still had higher mortality than non-diabetics 
(OR 1.45, 95% Cl 1.10 to 1.91). 
Conclusions: The ACC-NCDR database reveals that diabetics are at increased risk of 
in-hospital death after PCI. While diabetics are sicker, this increased risk remains after 
correction for baseline differences. The broadly representative nature of the ACC-NCDR 
offers a nationally based registry to examine in-hospital outcome of PCI in the United 
States, with sufficient data to examine critical subgroups such as diabetics. 
1223-30 Preprocedurally Increased Platelet Reactivity in Diabetic 
Compared With Non Diabetic Patients Undergoing 
Percutanous Coronary Interventions 
Samer S. Kabbani, Edward F. Terrien, Matthew W. Watkins, Burton E. Sobel, David J. 
Schneider. University of Vermont, Burlington, VT 
Background: Diabetic patients have an increased incidence of cardiac events compared 
with non-diabetic subjects after percutaneous coronary interventions (PCI). We sought to 
determine whether the known differential benefit conferred by treatment with glycoprotein 
(GP) Ilb-llla inhibitors in diabetic compared with non-diabetic patients could be explained 
by amelioration of higher initial platelet reactivity. Methods: Platelet reactivity was char- 
acterized before PCI with the use of flow cytometry in 45 diabetic and 83 non-diabetic 
subjects. Activation of platelets was quantified with respect to surface expression of P- 
selectin and activation of GP Ilb-llla (fibrinogen binding) in response both to adenosine 
diphosphate (ADP) and to thrombin receptor agonist peptide (TRAP). Results: Platelet 
reactivity was increased in the patients with diabetes. The percentage of platelets with 
activation of GP Ilb-llla in response to 0.2 pM ADP was 36 lt19% in the diabetic and 27 k 
18% in the non-diabetic subjects (p<O.Ol). Corresponding differences with 1 iM ADP 
ware 71 i 19% (diabetic subjects) and 61 f 22% (non-diabetic, p= 0.01). With 25 iM 
TRAP they were 74 f 20% and 66 * 23% (p= 0.05). P-selectin expression in response to 
0.2 or 1 iM ADP was increased analogously in diabetic compared with non-diabetic sub- 
jects (~~0.05). Conclusion: Diabetic patients undergoing PCI have increased preproce- 
dural platelet reactivity compared with that in non-diabetic patients. Accordingly, long- 
term therapy following PCI with potent antiplatelet agents is likely to reduce the subse- 
quently increased incidence of cardiac events associated with diabetes. 
1223-31 Long-Term Outcome of Patients With Versus Without 
Diabetes Mellitus in the DESTINI Trial 
lssam Moussa, Antonio Colombo, Carlo Di Mario, Yoshio Kobayashi, Milena Adamian, 
Roxana Mehran, Edward M. Kreps, Hassan Faraj, Alexandra J. Lansky, Michael B. 
Collins, George Dangas, Jeffrey W. Moses, On Behalf of the DESTINI-CFR Study Group. 
Lenox Hill Heart and Vascular institute, New York, Nv; Centro Cuore Columbus, Milan, 
/ta/y 
Background: Patients with diabetes mellitus (DM) have worse outcome than those with. 
out DM (NoDM)after traditional balloon angioplasty. Whether this remains true after 
stenting and optimal balloon angioplasty remains a subject of debate. The purpose of the 
present analysis iS to compare the 12.month outcome of pts with DM with those without 
DM in the randomized DESTINI Trial. 
1223-32 Gender Differences in Outcomes Among Diabetic Patients 
Undergoing Percutaneous Coronary Interventions 
Aaron D. Kugelmass, Sameer Mehta, April W. Simon, Lynn G. Tarkington, Salvatore 
Battaglia, Steven D. Culler, Edmund Ft. Becker. University of Oklahoma, Oklahoma Citj$ 
OK, Emory University Rollins School of Public Health, Atlanta, GA 
Background: Patients with diabetes mellitus (DM) undergoing percutaneous coronary 
interventions (PCI) experience more adverse outcomes than non-DM patients. Similarly, 
female patients experience more adverse outcomes than males. However, little is known 
about the effect of gender on PCI among DM patients. Methods: In-hospital outcome 
information was analyzed on a total of 723 consecutive DM patients undergoing a PCI in 
five community hospitals during 1999. Approximately 56% (409) of the DM patients were 
male. Findings: Stem PGI dominated the interventions with 80.7% of males and 84.7% 
of females receiving stents (p=ns). There was no significant difference between the pri- 
mary reference vessels (males 3.07mm vs. females 2.98mm), or in the distribution of 
lesion type (A, 61, 82, C). Female DM patients were significantly older than male DM 
patient; despite this female DM patients were significantly (~~0.03) more likely to have a 
clinically successful revascularization procedure than male DM patients. There were no 
significant differences in any PCI complications among DM patients includiung CABG 
and death. Conclusions: Female DM patients have improved outcomes with PCI com- 
pared to male DM patients. Therefore, gender should not bias PCI options for female DM 
patients. 
Males Females p-Value 
Age 63.8 yrs 66.2% 0.006 
Clinical Success 87.5% 32.6% 0.026 
GPllb/llla Use 20.5% 20.4% 1 .oo 
Emergency 0.24% 0.32% 1.00 
Death 1 .96%% 0.96% 1.00 
1223-33 High-Dose Verapamile Against Restenosis After PTCA: The 
European Multicenter VESPA Study 
Hans-Peter Bestehorn, Helmut Roskamm, Peter Stiirzenhofecker, Eberhard Hodenberg, 
Antoine Verdun, Jean P. Monassier. Herz-Zentrum Bad Krozingen, Bad Krozingen, 
Germany 
The possibly beneficial effect of calcium channel blockers (CCB) on restenosis after 
PTCA is still open to question. A promising metaanalysis of 5 smaller studies in 1994 led 
to the claim for a big trial with CCB to defenitely answer this question. The multicentre 
randomzed placebo-controlled PTCA-Restenosis VESPA-Trial (VESPA = Verapamil high 
dose (2x240mg/day),Early administration, Slow release, for Prevention of major cardio- 
vascular events and restenosis after Angioplasty)was started in 2/97. Randomization of 
the scheduled 700 patients was completed in lo/99 and the last control angiography (fol- 
low-up (FU) intervalI: months) took place in 3/2000. Two primary endpoints were pre- 
specified: the change of minimum lumen diameter (QCA, CAAS II-System) and the 
number of patients with major cardiovascular events (MACE). The overall stent-rate was 
83%. Data for clinical FU were available from 94,4% and for the angiographical endpoint 
from 93,7% of all patients. The results are presented in the table: 
Verapamil Placebo Significance 
(rl=321) (ll=335) 
MLD post PTCA (mm;SEM) 2.51 +/-0,03 2.47 +/-0.03 p=o.37 
MLD at follow up (mm;SEM) 1.77 +I-0.04 1.66 +I-0.04 p=o.11 
change of MLD (late loss) (mm;SEM) 0.74 +I-0.04 0.81 +I-0.04 p=o.i 1 
number of Patients with MACE (n/%) 94129 1 126137.6 p=o.oz 
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Restenosis rates (50% diameter stenosis criterion) were 25.5% in the Verapamil and 
32.2% in the placebo group (p=O.O7). Conclusion: With slow release Verapamil, 2x240 
mg/day there were significantly less major cardiovascular events following successful 
PTCA. The effect of slow release Verapamil on inhibition of angiographically defined ras- 
tenosis did not reach statistical significance. 
1223-34 Elevated Baseline CRP Levels Predict Death or MI in 
Diabetic Patients Undergoing Percutaneous Coronary 
Intervention 
Deepak L. Bhatt, Derek P. Chew, Mark A. Robbins, Marco Roffi, Leslie Cho, Jay S. Yadav, 
A. Michael Lincoff, Eric J. Topol, Stephen G. Ellis. Cleveland Clinic Foundation, 
Cleveland, OH 
Background: C-Reactive Protein (CRP) is a marker of inflammation and is able to pre- 
Number of Diabetic Patients With 30-Day Death or MI 
dict the risk of future ischemic events in certain clinical settings. Diabetic patients are at 
Death or Ml 
an increased risk for ischemic events after percutaneous coronary intervention (PCI), 
CRP < 0.3 mgidl 
potentially due, in part, to a heightened inflammatory and prothrombotic state. 
CRP 0.3-2.0 mg/dl 
Methods: As part of a single-center interventional registry, CRP data was collected pro- 
CRP > 2.0 mg/dl 
spectively on all patients at the time of presentation for PCI. Those patients who had a 
history of diabetes mellitus, either diet-controlled or requiring medication, were identified. 
Patients were separated into three groups based on the CRP level (CRP < 0.3 mg/dl, 0.3. 
2.0 mg/dl, > 2.0 mg/dl). The rate of death or myocardial infarction (defined as creatine 
kinase MB > 2x ULN) at 30 days was examined. Patients who had a MI within the prior 7 
days ware excluded from this analysis. 
Results: The 30-day rate of death or Ml in diabetic patients was 11% (23/207). The rate 
was 0% (O/46) in those diabetics in the lowest group of CRP, 10.1% (10199) for patients in 
the middle group, and 21.6% (13160) in the highest group, p=O.O02 (see Table). Though 
the number of events was smaller, mortality alone was also increased with elevated CRP 
p=O.Oll. Multivariate analysis controlling for baseline risk factors and ACC/AHA lesion 
score confirmed the independent prognostic value of CRP elevation, with an odds ratio 
for 30.day death or Ml of 1.95 for the lowest CRP group versus the highest, p<O.OOl. 
Interestingly, those diabetics with elevated CRP levels being pretreated with clopidogrel 
before PCI had a marked reduction in death or MI, 16.6% versus 6.4%, pzO.039. 
Conclusions: Baseline CRP elevation is a significant predictor of death or Ml in diabetic 
patients presenting for PCI. Perhaps by interrupting the inflammatory cascade induced 
by thrombosis, pretreatment with clopidogrel appears to diminish some of this excess 
risk. 
lular matrix components. We examined the association between glycemic control deter- 
mined by hemoglobin Ale (Ale) and incidence of target vessel revascularization (TV!?) in 
DM undergoing elective PCI. 
Methods: Baseline laboratory studies including Ale were drawn prior to PCI. Optimal 
glycemic control was defined as Ale < 7, and suboptimal control was defined as Ale z 
7. Followup was performed at 6, 12 and 24 months post index intervention. 
Results: 
NonDM Alcs7 Alo P (DM vs VW 
nonDM) 
N 
insulin 
Ale 
=ge (YN 
male 
smoker 
HTN 
family history 
hyperlipidemia 
BMI 
Tchol I HDL 
LDL 
triglycerides 
death 
Ml 
recurrent angina 
cardiac rehosp 
NR 
60 52 127 
27% 54% 0.001 
6.1&0.8 6.5&0.5 6.6+1.6 
62+11 64+11 63&10 0.596 0.512 
76% 75% 59% 0.036 0.044 
13% 17% 13% 0.633 0.191 
56% 67% 76% 0.015 0.136 
42% 46% 43% 0.683 0.560 
60% 67% 66% 0.363 0.661 
26ti.4 3lk20.1 3lk6.4 0.006 0.959 
4.421 .l 5.0*2.2 4.6~1.7 0.117 0.231 
106i31 106+31 107&65 0.839 0.917 
132k77 162+97 156+104 0.040 0.797 
5% 6% 2% 0.715 0.122 
3% 6% 5% 0.735 0.722 
23% 13% 37% 0.310 0.002 
20% 15% 31% 0.331 0.034 
16% 15% 34% 0.120 0.016 
Univariate analysis revealed Al c > 7 to be a significant predictor of NR (p=O.O16), 
ORc2.615 (95% Cl: 1.216 - 6.510). There was a trend toward higher TVR rates in DM 
treated with insulin compared to oral hypoglycemics (p=O.O63). In a multivariate analy- 
sis, Ale but not insulin use was a significant predictor of NR (p=O.O35 and 0.169 
respectively). 
Conclusions: Diabetics with suboptimal glycemic control have significantly higher rates 
of recurrent angina, cardiac rehospitalization, and ischemia driven TVR. Optimal glyce- 
mic control is associated with rates of NR comparable to the nondiabetic population. 
NO 
Yes 
48 89 47 These data suggest that aggressive treatment of diabetes to achieve hemoglobin Ale 
0 10 13 levels 5 7.0 is beneficial in reducing restenosis post PCI. 
1223-35 Role of a p53 Polymorphism in Luminal Narrowing After 
Coronary Balloon Angioplasty 
Sunao Kojima, Naoharu Iwai, Yoichi Goto, Shinji Yasuno, Shuichi Takagi, Takeshi Baba, 
Hiroshi Nonogi. National Cardiovascular Center, Osaka, Japan 
Backgrounds: p53 is a tumor suppressor protein involved in the control of cell (VSMC) 
proliferation: loss of p53 activity results in growth of VSMC. In addition human cytomega- 
lovirus (HCMV) infection has been reported to predispose to coronary restenosis and 
atherosclerosis, possibly because HCMV IE64 protein binds to p53 and abolishes its 
activity Based on a hypothesis that Arg72Pro polymorphism of p53 may affect its activity 
in restenotic lesions where various infectious agents such as HCMV have been reported 
to be detected, we investigated whether this polymorphism affects the incidence of lumi- 
nal narrowing after coronary balloon angioplasty. Methods: The study population con- 
sisted of 66 consecutive subjects (Arg/Arg: 42 coronary segments in 27 subjects, Arg/ 
Pro: 45 coronary segments in 32 subjects, Pro/Pro: 15 coronary segments in 7 subjects). 
Using an automated edge-detection algorithm and the outer diameter of contrast-filled 
catheters for calibration, the reference lumen diameter (RLD) and the minimal lumen 
diameter (MLD) ware measured on the same view before, immediately after and 3 
months after balloon coronary angioplasty. Results: There were no significant differ- 
ences observed among three genotype groups in terms of RLD, MLDs before and imme- 
diately after angioplasty and other clinical factors. However, ArglArg genotype showed 
significantly different MLD 3 months after angioplasty compared with ArglPro and Pro/ 
Pro genotypes (0.95iO.63 YS 1.4aO.70 vs 1.24+0.61 mm, p=O.O06). Stepwise multiple 
regression analyses, which included the p53 genotype, RLD, MLDs before and immedi- 
ately after angioplasty, age, gender, smoking history, diabetes mellitus, hypertension, 
body mass index (BMI), total cholesterol, high-density lipoprotein cholesterol and triglyc- 
erides as independent variables, indicated that MLD 3 months after angioplasty was 
determined (p=O.OOOl, R-square=0.365) by the genotype of p53 (Arg/Arg=O, Arg/ 
Pro+Pro/Pro=l) (p=O.O027), MLD immediately after angioplasty (p=O.O025), RLD 
(p=O.O066), and BMI (p=O.O025). Conclusions: Arg72Pro polymorphism of p53 can be 
one of the risk factors of coronary luminal narrowing after balloon angioplasty. 
1223-36 Optimal Glycemic Control is Associated With Lower Rates 
of Target Vessel Revascularization in Diabetics Undergoing 
Elective Percutaneous Coronary Intervention 
Roberto A. Corpus, Jr., Peter B. George, Steven C. Ajluni, William H. Devlin, Gerald C. 
Timmis, William W. ONeill. William Beaumont Hospital, Ftoyal Oak, MI 
Background: Diabetics (DM) have higher rates of restenosis after percutaneous coro- 
nary intervention (PCI) compared to nondiabetics (nonDM). This appears to be in part 
due to hyperglycemia and/or hyperinsulinemia which induces endothelial dysfunction, 
production of mitogens, smooth muscle proliferation and increased synthesis of extracel- 
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1224-37 Effect of Endomyocardial Laser Channels on Regional 
Innervation Using l-125 MIBG and Autoradiography 
Sukumaran Thambar, Lynne L. Johnson, Tammy Donahay, Michael W. Dae, David 0. 
Williams. Rhode Island Hospital/Brown University, Providence, RI 
Background: Clinical improvement following percutaneous catheter delivered laser 
energy occurs so early that mechanisms such as acoustic damage causing local dener- 
vation have been proposed. Radioiodinated meta-iodobenzyl guanidine (MIBG) is taken 
up in presynaptic neuronal vesicles and is used to image cardiac sympathetic nervous 
system. The aim of this study was to map regional innervation using l-125 MIBG against 
regional flow using Tc-99m Sestamibi (MIBI) early after laser channel placement in a por- 
cine model. Methods: Two juvenile male swine underwent computer guided endamyo- 
cardial laser revascularization with 20-30 channels to the mid and distal anterior wall of 
the LV. Three days later animals were injected with 1 .O mCi of I-l 25 MIBG followed in 3 hr 
with 30 mCi of Tc-99m MIBI and one hr later sacrificed. Hearts ware removed, perfusion 
fixed and sliced. Slices best showing laser holes ware selected and frozen at -60”. Ten 30 
micron circumferential slices per experiment were cut with a microtome at -20”. Serial 
sections at 10 microns was reserved for H&E staining. The 30 micron section slides ware 
laid out onto a phosphor screen and exposed for 40 hr for Tc-99m and 10 days for t-125. 
Each exposure was scanned and images captured. Images were background subtracted, 
normalized, and registered. The MIBG image was subtracted from the MIBI image and 
vice versa and color tables applied to the difference images which were then overlaid on 
the perfusion image. Results: Twenty sections were analyzed. Regions of acoustic dam- 
age from 17 laser channels were identified on the H&E sections. Reduced MIBG relative 
to regional flow was seen in surrounding tissue corresponding to only one channel. Con- 
clusion: In a porcine model using a high resolution neuronal imaging technique corre- 
lated with microscopic pathology, there is negligible regional denervation 3 days after 
placement of endomyccardial laser channels. 
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1224-38 Sustained Clinical Benefit Two Years After Percutaneous 
Myocardial Laser Revascularization in Patients With End- 
Stage Coronary Artery Disease 
Bernward Lauer, Fabian Stahl, Sophia Bratanow, Gerhard Schuler. University Leipzig, 
Heart Center, Leipzig, Germany 
Background: Catheter-based percutaneous myocardial revascula-rization (PMR) leads 
to significant improvement of clinical symptoms and increased exercise capacity in 
patients with end-stage coronary artery disease. The present study evaluates the long- 
term effect of PMR two years after the intervention. Methods: PMR was performed in 
119 patients (P) (63,7 + 9,4 years) with refractory angina pectoris (CCS Ill - IV) not ame- 
nable to angioplasty or bypass surgery in 172 regions of the heart. ResuBs: PMR was 
successfully performed in all f? 13.1 k 4,5 channels were created per region. A pericar- 
dial effusion requiring pericardiocentesis occured in 2 F? One year follow-up is available in 
78 P two year follow-up in 42 P In the first year after PMR, 2 P died of acute myocardial 
infarction, 1 P died of sudden cardiac death. Another patient died 16 months after PMR 
of a myocardial infarction. Severity of clinical symptoms improved significantly after PMR 
(CCS-class at baseline: 3,3 k 0,5, after 3 month: 1,8 k 0,9 (p<O,O5)) and remained stable 
during follow-up (CCS-class after 1 year: 1,6 f l,O, after 2 years: I,5 f 0,8 (p<O,O5 vs 
baseline, n.s. vs 3 months)) Exercise capacity on standard ergometry also increased sig 
nificantly after PMR (exercise time at baseline: 353 + 141 set, after 3 month: 456 i 189 
set (pcO,O5)) and was unchanged during follow-up (exercise time after 1 year: 451 f 154 
sec. after 2 years: 486 f 175 set (~~0.05 vs baseline, n.s. vs 3 months) Conclusions :In 
P with refractory angina pectoris due to end-stage coronary artery disease, PMR leads 
to significant improvement of clinical symptoms and increased exercise capacity The 
clinical benefit of PMR seems to be sustained during long-term follow-up. 
1224-39 Inability of Computer-Guided Endomyocardial Laser 
Revascularization to Relieve &hernia Acutely: 
Observations From a Porcine Coronary Occlusion Model 
Sukumaran Thambar, Lynne L. Johnson, Lorraine Schofield, Barry L. Sharaf. David 0. 
Williams. Rhode /s/and Hospital and Brown University, Providence, Ri 
Background: Creation of endomyocardial channels by catheter-delivered laser energy 
has resulted in immediate relief of angina in selected patients (pts) with coronary dis- 
ease. The mechanism for this early effect is unclear. Purpose: We investigated the ability 
of laser-created endomyocardial channels to relieve myocardial ischemia and maintain 
regional blood flow during transient coronary occlusion. Methods: Eight juvenile swine 
were anesthetized and instrumented percutaneously. lschemia was created by brief bal- 
loon occlusion of the left anterior descending artery. Endocardial blood flow (EBF) was 
measured by colored microspheres. Anterior interventricular vein and systemic arterial 
lactate concentrations were used to quantitate Ischemia. Three-dimensional, computer 
maps (NOGA) guided the creation of 15-25 Ho:YAG endomyocardiai channels. All ani- 
mals had measurements during an initial control balloon occlusion. Five animals had 
laser (L) before a second balloon occlusion while 3 had repeat balloon occlusion without 
laser (NoL) to exclude preconditioning. Results: Mean EBF (mllgmlmin) in the ischemic 
zone (IZ) decreased following control occlusion in both L (0.75+0.19 to 025~0.20) and 
No-L (0.731-0.13 to 0.04+0.02) animals. Lactate extraction declined in both groups: 
(41.5+15.6% to 8.1+24.1%) and (38.1+11.5% to -1 X+38.7%) respectively. Following 
laser revascularization, IZ EBF again declined (pc.05) with coronary occlusion in both 
groups: L (0.74+0.32 to 0.16+0.14) and No-L (0.43+0.18 to 0.03+0.01). Similar changes 
were observed in lactate extraction: L (30.5+11 .l% to 8.8+19.8%) and No-L (32.1+13.9% 
to 1.9+15.0%). Post-mortem inspection confirmed channels in the IZ for each L animal. 
Conclusions: Balloon occlusion resulted in reduced EBF and metabolic evidence of 
ischemia in the IZ. Endomyocardial channels were successfully created in the IZ but did 
not blunt reduction in EBF or lessen &hernia. Preconditioning was not observed. These 
results do not support the hypothesis that computer-guided laser endomyocardial revas- 
cuiarization is capable of relieving ischemia acutely. 
1224-40 Is The Neoangiogenic Response to Percutaneous 
Myocardial Revascularization Species Dependent? 
John D. Altman, Susan Johnson, Javier Roman-Gonzales, Birgit Kantor, Douglas L. 
Packer, David R. Holmes, Jr., Dieter Lubbe, Antonio Bayes-Genesis, Robert S. Schwartz. 
Mayo Clinic, Rochester, MN 
Background: Percutaneous myocardial revascularization revascularization (PMR) 
relieves angina likely due to neoangiogenesis during the myocardial healing process. 
This study was performed to compare the neoangiogenic response to myocardial injury 
in dogs and pigs. 
Methods: Six dogs and pigs were treated with radiofrequency energy to induce myocar- 
dial injury. Animals were sacrificed 3, 7, 10, and 21 days later. Treatment sites were iso- 
lated and frozen for immunohistochemistry or fixed in paraffin for vessel counting. Mature 
(muscular wall present) and immature vessels (muscular wall absent) were counted in 
the 21 day old samples. A difference was found between species. In addition staining for 
vascular endothelial growth factor (VEGF) and its receptors (VEGFR-1, VEGFRP) and 
basic fibroblastic growth factor (bFGF) and its receptors (bFGFR-1, bFGFRR-2) was per- 
formed on 3, 7, and 10 day old samples. Staining intensity was graded on a scale of 0 to 
3. 
Results: New vessel growth occurred at sites of myocardial injury in both the dog and 
pig. However, the number of mature vessels was significantly greater in the dog (16 +/- 2 
per mm2 vs pig 4 +/- 2 per mm2; pcO.01) while the number of immature vessels was sig- 
nificantly greater in the pig (pig 54 +/- 7 per mm2 vs dog 12 +/- 4 per mm2; p<O.Ol). 
Expression for VEGF, VEGFR-1, VEGFR-2, and bFGF was similar between species, all 
showing intense labeling within the treatment site. However, bFGFR-1 staining was 
greater in pig (pig 2.9 c/- 0.1 vs dog 2.3 +/- 0.3; ~~0.03) while bFGFR-2 was greater in 
the dog (pig 1.0 +/- 0.4 vs dog 2.6 +/- 0.2; pcO.01). 
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Conclusion: The number and maturily of new vessels in response to myocardial injury is 
species dependent. Higher expression of bFGFR-1 and lower expression bFGFR-2 in the 
pig may be associated with the formation of less mature vessels. These findings are sig- 
nificant since immature vessels are not likely functional. 
lmmunohistochemisty (scale O-3) 
VEGF VEGFRI VEGFRP bFGF bFGFR1 bFGFR2 
Pig 3.0 +/- 0 2.7+/-0.1 2.8+/-0.1 2.9+/-0.1 2.9+/-0.1 l.O+/-0.4 
Dog 2.7+/e0.1 2.1 +/-0.3 2.7+/-0.1 2.9+/-0.1 2.3+/-0.3’ 2.6+/-O.?* 
*p<O.O3 vs pig 
‘*pcO.Ol vs pig 
1224-41 Transmyocardial Laser Revascularisation Improves 
Perfusion but Enhances Left Ventricular Remodeling in Rats 
After Myocardial Infarction 
Matthias Nahrendorf, Karl-Heinz Hiller, Dirk The&en, Kai Hu, Christiane Walier, Ralf 
Kaiser, Axe1 Haase, Georg Ertl, Ralf Brinkmann, Wolfgang R. Eauer. Wuerzburg 
University: EP5 and Cardiology Departmenl, Wuerzburg, Germanx Medizinisches 
Laserzenfrum Luebeck, Luebeck, Germany 
Background: The underlying mechanism of symptom improvement in patients recieving 
transmyocardial laser revascularisation (TMR) is not fully understood. Hypertrophy fol- 
lowing MI causes diffuse hypoperfusion of the remote myocardium. We therefore used 
the Ml rat model for assessment of TMR. Methods: 8 weeks after coronary artery liga- 
tion rats had Cine-MRI using a 7 T&a magnet; thereafter TMR was done. A selfdesigned 
Holmium:Yag laser system emitting a wavelength at 2.1 pm (pulse energy 4J, pulse dura- 
tion 1 ms, 365pm fiber diameter) was placed in soft contact to the remote myocardium to 
ablate 4 channels. 4 weeks after TMR a second Cine-MRI including dobutamine-stress 
(10 ~llkglmin via tail vein) was follwed by high resolution spin labeling perfusion imaging 
(pixelsize 140 pm) of the isolated retrogradly perfused heart using an 11 Tesla magnet in 
12 Wistar rats. To locate laser areas histology was used. Results: Lased areas were bet- 
ter perfused than nonlased myocardium (difference of perfusion control vs. lased region 
+3.89+/-0.83mllminlg at rest and +2.29+/-1.06mllminig at nitro stress, p < 0.05 both). 
Results of Cine-MRI 
control TMR 
delta EDV (~1) 24.6+/-16.7 81.7+/-l&7* 
delta LV mass (mg) 54.5+/-l 9.2 124.1+/-30.7’ 
EF at 12 weeks (%) 40+/-2 38~1.2 
Cl at 12 weeks (ml/kg/min) 232.2+/-12.8 242.4+/-12.8 
EF at 12 weeks stress (%) 49.6d5.3 54.4+/-4.9’ 
mean+/-SEM. *p < 0.05 vs control, delta: difference 8 vs 12 weeks after MI. MI-size 27+/- 
2% both groups. Conclusion: Using high resolution perfusion imaging improvement of 
perfusion in channel remnants and their vicinity could be visualized. Due to the retro- 
grade perfusion setting and usage of the spin labeling technique this improvement can 
not be caused by flow from inside the ventricle through open channels. TMR should be 
used with caution in patients undergoing LV remodeling after MI, because dilation and 
hypertrophy was enhanced. 
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860-l 
2:oo p.m. 
Risk-Adjusted Survival After Coronary Artery Bypass 
Surgery Compared to Coronary Stenting 
Rollo P Villareal, Vei-Vei Lee, MacArthur Elayda, Robert J. Hall, James M. Wilson. St. 
Luke’s Episcopal Hospital/Texas Heart Institufe, Ho&on, TX 
Background: The survival expectation for modern coronary artery bypass grafting 
(CABG) compared to coronary stenting is unknown. We sought to compare the 2.year 
risk-adjusted survival in an unselected population of patients undergoing CABG or ~oro- 
nary stenting. Methods: The Texas Heart Institute (THI) Cardiovascular Research Data- 
base was used to identify patients undergoing CABG (n=2292) or stenting (n=2035) as 
their first revascularization procedure from 111195 to 12/31/98. Patients were classified 
into 8 anatomic groups based on the number of vessels diseased and whether there was 
involvement of the proximal left anterior descending (LAD) artery. Mortality rates were 
adjusted using proportional hazards methods to correct for baseline differences in sever- 
iky of disease and comorbidities. Results: CABG patients had a significantly greater in- 
hospital mortality (4.06 vs. 0.69%, OR 8.67 [95% Cl 3.96-18.961, p=O.OOOl). At a mean 
follow-up of 2.0+1.2 years, survival remained higher in the stent group (95.7 vs 90.8%: 
OR 1.57 [95% Cl 1.21-2.041, p=O.O007). When subgroups matched for their anatomic 
estimation of disease severity were compared, patients with 2-vessel disease with LAD 
involvement had improved survival with stenting (97.8 vs. 94.7%, OR 2.47 [95% Cl 1.10. 
5.541, p=O.O29). There were no differences in risk-adjusted survival in the remaining sub- 
groups. Conclusions: CABG is associated with an increased p&procedural mortality in 
comparison to percutaneous revascularization using coronary stents The survival 
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advantage favoring coronary stents persists at 2 years. These data suggest that in 
patients with multivessel disease with lesions that may be treated percutaneously, there 
is no early survival advantage for CABG. 
860-2 
295 p.m. 
Long-Term Outcome of Coronary Stenting: 8-to IO-Year 
Follow-Up After Palmaz-Schatz Stent Implantation in 428 
Consecutive Cases 
Remi Choussat, Catherine Klersy, Alexander Black, Christian Jordan, Jean-Pierre 
Laurent, Bernard Cassagneau, Jean Fajadet, Jean Marco. UC/, Clinique Pa&or, 
Toulouse, France 
Background: Although short-term results of Palmaz-Schatz intra-coronary stenting have 
been promising, with a reduction of both angiographic restenosis and clinical cardiac 
events up to 3 years, longer-term follow-up has not been established. The purpose of this 
single-center study was to evaluate the long-term (>8 years) outcome of Palmaz-Schatz 
intra-coronary stenting and to identify independent predictors of outcome. Methods: We 
analysed clinical outcome in 426 consecutive patients at least 8 years after coronary 
stenting. Demographic, clinical and procedural predictors of restenosis, survival and 
event-free survival, defined as freedom from death, myocardial infarction (MI), coronary 
revasculariation (target stented site, target vessel and any revascularisation) were analy- 
sed. Results: Before discharge, 28 patients (6.6%) sustained at least one major cardio- 
vascular event: 3 deaths (0.7%), 18 Ml (4.2%), 17 repeat revascularization. Surviving 
patients were followed for 8.9 years (interquartile range 8.4-9.4). After discharge, 59 
patients (13.9%) died, 47 (11.1%) sustained a MI, 188 (44.4%) underwent coronary 
revascularization. The 8-year event-free survival (freedom from death, freedom from 
death/Ml/target stented site revascularization and freedom from death/Ml/any coronary 
revascularization) were (mean +-standard error) 86 +- l%, 62 +- 3% and 47 c- 2% 
respectively. Unstable angina, lower left ventricular ejection fraction and saphenous vein 
graft stenting were found to be independent predictors of death during follow-up. Hyper- 
tension, unstable angina, multivessel disease and multiple stent implantation were found 
to be independent predictors of the composite of deathNliany coronary revasculariza- 
tion during follow-up. Conclusion: This study provided a useful assessment of vary long- 
term outcome in terms of survival, event-free survival and predictors of major cardiac 
events 8-10 years after Palmaz-Schatz stent implantation. 
860-3 
2:30 p.m. 
Hemodialysis and Major Adverse Cardiac Events After 
Stenting: Results From the TOPPS Trial 
Morton R. Rinder, Praveen Tamirisa, John Lasala, Howard I. Kurz, Kim Mumm, Megumi 
Taniuchi. Washington University School of Medicine, St Louis, MO 
Background: Patients requiring hemodialysis have a greater than 50% five-year mortal- 
ity, most of which is attributed to cardiac events. Previous reports suggested a higher rata 
of major adverse cardiac events (MACE) after stent placement in dialysis patients. How- 
aver, these reports were mostly small case report studies. In order to determine whether 
patients on hemodialysis are at increased risk of MACE, we reviewed the TOPPS data- 
base for patients on hemodialysis and compared their nine-month rate of adverse events 
to those who were not on hemodialysis. Methods: After completion of the stent implanta- 
tion, patients were randomized to receive either ticlopidine 250 mg twice daily for two 
weeks or clopidogrel 75 mg once daily. Patients were followed prospectively for in-hospi- 
tal events. Telephone follow-up was performed at 30 days and at 9 months. Reports of 
repeat hospitalization were reviewed for cardiac versus non-cardiac cause as well as 
confirmation of Ml. All repeat PCl’s were reviewed to determine whether the same vessel 
underwent revascularization. Results: Of the 1016 patients randomized 27 were under- 
going hemodialysis. Sixty-three percent of these patients were diabetic compared to 29% 
of the overall TOPPS population. 
Hemodialysis No-Hemodialysis p-value 
n 27 989 
Diabetes 63% 28% <O.OOl 
MACE 29.6% 20.9% 0.33 
Conclusions: These data indicate that at 9 months follow-up after intracoronary stent 
implantation, hemodialysis patients have only a slightly higher rate of MACE, despite a 
significantly higher prevalence of diabetes. Stent implantation as opposed to balloon 
angioplasty appears to be associated with a more favorable outcome in hemodialysis 
patients. 
860-4 
2:45 p.m. 
One-Year Results After Multivessel Stenting in Diabetic vs. 
Non Diabetic Patients 
Alexandre Abizaid, George Dangas, Roxana Mehran, Yoshio Kobayashi, Andrea S. 
Abizaid, Gary S. Mintz, Milena G. Adamian, Rajshekar Narasimaiah, Cristian Cioara, 
August0 D. Pichard, Gregg W. Stone, Martin 8. Leon. Cardiovascular Research 
Foundation, New York, NY, Washington Hospital Center, Washington, DC 
Backgroud: Although long-term outcome after multivesssel coronary angioplasty in 
patients with diabetes mellitus (DM) is significantly worse compared to non-DM pts, the 
clinical outcome of DM pts after multivessel stenting is not known. 
Methods: We evaluated 755 consecutive pts (195 DM with 497 treated lesions vs. 560 
non-DM with 1428 treated lesions) undergoing elective, multivessel, native coronary 
stenting of 1,925 lesions. Baseline pt and lesion characteristics were similar between the 
2 groups, except that DM pts had more chronic renal insufficiency, and smaller reference 
vessel size than non-DM pts. Eighty two pts (41%) in the DM group required insulin ther- 
apy. 
Results: Procedural success was similar between groups (97% vs. 98%, p=NS).Angio- 
graphic and clinical results: 
DM Non-DM P 
QCA: Reference diameter, mm 2.89+0.58 3.03eO.67 0.009 
Final MLD, mm 2.65+0.66 2.80-t0.76 0.01 
Final diameter stenosis (%) 8+10 7ta 0.60 
In-hospital: Death 3 (1.5%) 9 (1.6%) 0.92 
Emergent CABG 2 (1 .O%) 1 (0.2%) 0.27 
Q-wave Ml 1 (0.5%) 1 (0.2%) 0.57 
l-year FU: Death 24 (12.5%) 23 (4.1%) 0.001 
Q-wave Ml 17 (8.6%) 28 (5.1%) 0.11 
TLR 17.7% 9.1% 0.004 
MACE 68 (34.8%) 107 (19.2%) <O.OOl 
MLD= minimum lumen diameter, MI= myocardial infarction, TLR= Target lesion rsvascu- 
larization, MACE = death, MI, or TLR 
By multivariate analysis, independent predictors of l-year MACE included DM (OR: 2.31, 
p<O.OOOi) and ostial lesion location (OR: 2.31, pcO.0001). 
Conclusions: Multivessel stenting in DM pts is associated with high procedural success 
and similar in-hospital events compared to non-DM pts. However at one year, DM 
patients require more revascularizations and have higher overall cardiac event rate. 
Careful case selection, as well as maximizing adjunct pharmacotherapy, both peri-pro- 
cedure and long-term, should be implemented in diabetic pts referred for multivessel 
intervention. 
860-5 
3:00 p.m. 
The Effect of lntracoronary Radiation on the Long-Term 
Outcome of Diabetic Patients With In-Stent Restenosis 
Luis Gruberg, Ron Waksman, Roxana Mehran, Alexandra J. Lansky, R. Lawrence White, 
Rosanna C. Ghan, Bill G. Bass, Lowell F Satler, Gary S. Mintz, August0 D. Pichard, 
Kenneth M. Kent. Washington Hospital Center, Washington, DC 
Background: Diabetic patients are known to have excessive neointimal hyperplasia and 
a high recurrence rate of in-stent restenosis (ISR) after conventional percutaneous inter- 
vention. lntracoronary radiation therapy (IRT) has shown to reduce the recurrence rate of 
restenosis in-patients with ISR. 
Methods: The impact of IRT on the six-month clinical and angiographic outcome was 
assessed in 227 diabetic patients and compared to 357 non diabetics who were enrolled 
in the WRIST (Washington Radiation for In-Stent restenosis Trial) protocols using p and y 
emitten. 
Results: Clinical and angiographic characteristics B-month outcome and six-month fol- 
low-up are shown in the Table. 
Diabetic (n=227) Non-diabetic (n=357) p 
Age 62.4+11 61.8*12 0.55 
Male gender 59.5% 70.9% 0.005 
Hypertension 81.9% 85.4% <O.OOl 
Prior infarction 53.3% 50.7% 0.54 
Prior CABG 56.4% 50.9% 0.19 
Unstable angina 83.3% 78.4% 0.15 
Lesion length 24.Oill.3 mm 24.k13.2 mm 0.80 
Final MLD 1.85+0.38 mm 1.99*0.46mm 0.02 
g-month Follow-up 
MLD 1.39*0.78 mm 1.56+0.80 mm 0.13 
Late loss 0.54kO.78 mm 0.48tO.75 mm 0.59 
Restenosis 34.2% 33.8% 0.96 
TLR 19.5% 19.2% 0.92 
TVR 24.5% 25.0% 0.90 
Death 5.9% 3.5% 0.17 
MLD=minimal lumen diameter; TLR=target lesion revascularization; TVR=target vessel 
revascularization. 
Conclusions: Despite having worse baseline clinical and angiographic characteristics, 
diabetic patients had similar rates of restenosis and revascularization procedures at 6- 
month follow-up as non-diabetic patients. This data supports that IRT should be used in 
diabetic patients with ISR. 
860-6 
3:15 p.m. 
Stents and Glycoprotein Ilb/llla Blockade Have No Salutory 
Effect on 30.Day Outcome Following Percutaneous 
Interventions of Coronary Bypass Grafts 
Marco Roffi, Deepak L. Bhatt, Debabrata Mukherjee, Derek P. Chew, Khaled M. Ziada, 
Danielle M. Prosper, Stephen G. Ellis, Eric J. TopoLCleveland Clinic Foundation, 
Cleveland, OH 
Background: It remains a source of debate whether stents or glycoprotein (GP) Ilb/llla 
inhibitors are beneficial in percutaneous coronary interventions (PCI) of bypass graft 
lesions. Methods: We performed a pooled analysis of five randomized GP Ilb/llla trials 
(EPIC, EPILOG, EPISTENT, IMPACT II, and PURSUIT) that included PCI of bypass 
grafts. We compared the outcome at 30 days in relation with the use of stents and GP Ilb/ 
llla inhibitors. Results: In aggregate the five mentioned trials enrolled a total of 627 
patients undergoing PCI of bypass grafts. As reported in the table, neither stents nor GP 
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Ilb/llla inhibitors were beneficial in reducing 30-day death, MI (CKMB>3x normal), or 
urgent revascularization in bypass graft interventions. Across the endpoints there was 
even a consistent, albeit non-significant trend towards worst outcome. 
30-Day Endpoints Placebo GP Ilb/llla P 
Death 1.4% 2.6 % 0.32 
MI 9.9 % 14.5 % 0.10 
Death/MI 10.6 % 15.5 % 0.10 
Death/Ml/Urgent 12.7 % 16.3 % 0.21 
Revasc 
30-Day Endpoints Balloon stent P 
Death 2.1 % 3.0 % 0.53 
MI 12.6 % 15.6 % 0.49 
Death/Ml 13.7 % 16.6 % 0.45 
Death/Ml/Urgent 14.6 % 16.6 % 0.36 
Revasc 
Conclusions: Based on these aggregate data of five large randomized trials, stents or 
GP Ilb/llla inhibitors do not appear to improve the 30-day outcome in patients undergoing 
PCI of coronary bypass grafts. 
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1254.9 Hyperinsulinemia Rather Than Hypergiicemia Is 
Responsible for the Exaggerated Neointimal Hyperplasia 
After Experimental Balloon Angioplasty in Diabetic Rats 
Daniele Torella, Ciro Indolfi, Luigi Cavuto, Carmela Coppola, Giovanni Esposito, Antonio 
Rapacciuolo, Emilio Di Lorenzo, Cinzia Perrino, Lorena Belardo, Massimo Chiariello. 
Federico /I UniversifL: Naples, k/y 
Background: The mechanisms underlying exaggerated neointimal hyperplasia after 
PTCA in diabetics are still not well understood. Methods: We first assessed the effects of 
insulin and glucose on VSMC migration and proliferation in vitro. Then, we assessed the 
effect of insulin on the activation of the ras-MAPKs pathway with MAPKs assays. Finally, 
we evaluated the differential role played by insulin and glucose on neointimal hyperplasia 
after balloon injury (81) in viva in hyperglicemic streptozotocin-induced diabetic rats (ST2 
Group) and in hyperinsulinemic diabetic rats (STZ+INS Group). Results: Glucose unaf- 
fected VSMC proliferation and migration in vitro. In contrast, insulin induced a significant 
increase in VSMC proliferation and migration in cell cultures (see figure). Insulin 
increased MAPKs activation. Furthermore, a reduction in neointimal hyperplasia was 
consistently documented after BI in STZ Group (neointimalmedia ratio from 1.123 it 
0.229 to 0.506 f 0.201, pcO.001 vs. Control). Insulin therapy significantly increased 
neointimal hyperplasia after BI in STU+INS Group (n/m ratio= 1.722 + 0.364, pcO.001 
vs. Control). This effect of hyperinsulinemia on neointimal formation was totally abolished 
by transfection on the arterial wall of Nl7H-ras negative mutant (STZ+INS/ras Group)@/ 
m=0.539 * 0.114, p<O.OOi vs. Control and STZ+INS) Conclusions: Our results demon- 
strated that hyperinsulinemia through activation of ras pathway signaling rather than 
hyperglicemia par se is responsible for exaggerated neointimal hyperplasia after balloon 
injury in diabetic rats. 
1254-10 Hyperglycemia Decreases p21 Expression and Enhances S- 
Phase Entry 
Kurt G. Barringhaus, J. William Phillips, John M. Sanders, Sasha Tichotsky, Ann C. 
Czamik, Ian J. Sarembock, Coleen A. McNamara. Universify of Virginia, Cha/ottesvi//e, 
VA 
Background: Diabetics have an increased rate of restenosis after coronary intervention. 
Hyperglycemia may mediate this effect, potentially by enhancing vascular smooth muscle 
cell (SMC) proliferation. The molecular mechanisms responsible for this effect are poorly 
understood. The cyclin dependent kinase inhibitor p21 is a critical regulator of Gl-S tran- 
sition. We have previously shown that high glucose increases expression of the helix- 
loop-helix (HLH) factor ld3, an early response gene that enhances SMC growth and 
inhibits expression of ~21. We thus hypothesized that hyperglycemia would inhibit early 
expression of ~21 following vascular injury and enhance S-phase entry. 
Methods: To determine if hyperglycemia decreased p21 protein expression in response 
to injury in vim, immunohistochemistry using a rabbit polyclonal ~21 antibody was per- 
formed 3 days after carotid ligation injury of C57BU6 mice in the presence and absence 
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of streptozotocin-induced diabetes. To determine if high glucose regulates the expres- 
sion of the ~21 gene and Gl-S progression, transient transfection studies with a 2.3 kb 
p21 promoterlluciferase reporter construct and BrdU-incorporation assays were per- 
formed on SMC chronically cultured in low glucose (LG) or high glucose (HG). 
Results: lmmunohistochemistry as measured by pixel density demonstrated that p21 
protein expression increased 2.75 fold following injury (39.2% injured vs 14.1% unin- 
jured; pc.05). In contrast, p21 expression was barely detectable in diabetic mice (2.9% 
diabetic vs. 39.2% non-diabetic; 93% decrease, p<.OO5). Glucose levels were 336i65 
and 114517 mgldl, respectively. Cell culture studies demonstrated a significant reduction 
in p21 promoter activity in cells cultured in HG relative to LG (33 % reduction, pc.0001). 
Furthermore, cells chronically cultured in HG had a significant increase in BrdU incorpo- 
ration relative to those cultured in LG (62% increase, p<.OOOl). 
Conclusions: Taken together, these results suggest that hyperglycemia may promote 
SMC growth via decreasing p21 expression resulting in enhanced S phase entry. This 
might have important implications for the exaggerated vascular lesion formation in diabe- 
tes. 
1254-11 Platelet Glycoprotein llla Polymorphism Is Not a Risk Factor 
for Target Vessel Revascularization After Percutaneous 
Revascularization 
Kimberly A. Skelding, Demetri Demetriou, Domnita Crisan, Laxmi Mehta, Judith A. 
Boura, Mark C. Pica, Debra A. Guide-Allen, Bohuslav Finta, Robert D. Safian, James A. 
Goldstein, Cindy L. Grines, William W. O’Neill. William Beaumont Hospital Royal Oak, MI 
Background: Genetic isoform differences in the llla component of the platelet Ilb/llla 
complex influence platelet thrombogenicity. Studies have suggested that the PLAP allele 
may increase late restenosis following PCR through platelet aggregation and promotion 
of smooth muscle proliferation. This study was intended to delineate whether the pres- 
ence of PLAP is an independent risk factor for TVR after PCR. Methods: We prospec- 
tively analyzed the presence of FLAi/P!AP through peripheral blood leukocyte testing of 
550 patients undergoing PCR to determine TVR rate at 6 months. Patients were classi- 
fied into three genotype(A2/A2, Al/A2, Al/Al). Clinical history, procedural details, car- 
diac events and mortality data ware collected and analyzed as well. Results: As in 
previous studies, the prevalence of the A2/A2 genotype was low, seen in only 14 patients 
(3%), whereas Al/A2 was present in 130 patients (23%) and Al/Al was present in 406 
patients (74%). There was no difference within groups A2/A2. Al/A2, Al/Al with regard 
to history of diabetes (29% vs 26% vs 26%, p= 0.945), hypertension (57% vs 67% vs 
72%, p=O.260), smoking (43% vs 64% vs 62%, p=O.268) or hyperlipidemia (79% vs 71% 
vs 70%, p=O.606). No difference was seen in age (64 +/-9 vs 66 c/-l1 vs 64+/- 11, 
~~0.507) or female gender (21% vs 25% vs 27%, p=O.SSS). TVR rates were not influ- 
enced by platelet polymorphisms (7% vs 14% vs 15%, p=O.739), nor was a combined 
endpoint of TVR, myocardial infarction or death effected by the polymorphism (7% vs 
15% vs 15%, p=O.706). Conclusions: In contrast to previous data, in this study platelet 
llla polymorphism does not influence NR rates or combined endpoint of NR, myocar- 
dial infarction or death. The platelet polymorphism groups analyzed were hamogenous 
in regard to history of diabetes, hypertension, smoking, lipid status, age, gender and pro- 
cedural details. 
1254-40 D/D Anglotensin Converting Enzyme Genotype Increases 
Target Vessel Revascularization in Diabetic Patients 
Kimberly A. Skelding, Demetris Demetriou, Laxmi Mehta, Mark C. Pica, Domnita Crisan, 
Debra A. Guido-Allen, Judith A. Boura, Bohuslav Finta, Robert D. Safian, James A. 
Goldstein, Cindy L. Grines, William W. O’Neill. William Beaumont Hospital, Royal Oak, MI 
Background: Restenosis is a substantial problem in diabetic patients undergoing percu- 
taneous coronary revascularization (PCR). The mechanisms or risk factors that increase 
the propensity to restenosis in diabetics have not been well delineated. As the ACE gen- 
otype has been associated with adverse outcomes in diabetics and has been suggested 
to increase restenosis rates following PCR, this study was designed to determine 
whether the ACE genotype contributes to the propensity for restenosis in diabetics 
undergoing PCR. Methods: We prospectively analyzed ACE genotype (DD, 01, II) in 214 
diabetics undergoing FCR to determine NR rates at 6 months. We analyzed clinical 
parameters including death and myocardial infarction over a 6 month time period in 
patients with DD (69 patients) vs DI (95 patients) vs II (50 patients). Results: In the DD 
vs DI vs II groups there was no difference in history of hypertension (71% vs 61% vs 
76%, p=NS), hypcrlipidemia (72% vs 69% vs 76%, p=NS) or smoking (57% vs 56% vs 
56%, p=NS). No difference in age (65+/-l 1, 64+/-g, 66+/-10, p=NS) or female gender 
(32% vs 39% vs 32%, p=NS) was seen. No difference in use of ACE inhibitors (33% vs 
32% vs 46%, p=O.203) or Angiotensin receptor blockers (10% vs 16% vs 6%, p=O.325) 
were seen between the groups. However, TVR rates were significantly higher in the DD 
patients when compared to the DI or II (30% vs 16% vs 14%,(p=O.O5). The combined 
endpoint of TVR, myocardial infarction (Ml) or death also occurred more frequently in the 
DD patients when compared to the DI and II patients (32% vs 17% vs 16%, p=O.O36). 
Conclusions: These findings indicate that the DD genotype of the ACE genotype signifi- 
cantly increases the NR rate in diabetics undergoing PCR. The combined risk of TVR, 
MI, and death is also significantly increased in diabetics with the DD genotype. This 
increased risk is independent of clinical history, procedural details or insulin usage. 
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1254-41 Cytomegalovirus, Chlamydia Pneumoniae, and 
Helicobacter Pylori IgG Antibodies and Restenosis 
Poststent Implantation. An Angiographic and Intravascular 
Ultrasound Study 
Francois Schiele, Marie-France Seronde, Mustafa Kemal Batur, Nicolas Meneveau, 
Pradip &woke, Agnes Bassignot, Gerard Couetdic, Fiona Caulfield, Jean-Pierre L. 
Bassand. Universify Hospital Jean-Minjoz, Besancon, France 
Purpose: The aim of this study was to determine the impact of Cytomegalovirus (CMV), 
Chlamydia Pneumoniae (C Pneumonia@ and Helicobacter Pylori (H Pylori) previous 
infection on the neointimal proliferation after coronary angioplasty with stent implantation. 
Methods: 180 patients were submitted to coronary stent implantation with systematic 
angiographic and intravascular ultrasound (IVUS) control at 6 months. Quantitative coro- 
nary angiography was used to assess the late lumen loss. IVUS analysis was performed 
using a computer assisted system from images recorded during a motorized pullback. 
The mean area of neo intimal tissue within the stent and the ratio of neo intimal tissue to 
stent area were assessed every 0.2 mm along the stent and the average value was 
recorded. Prior CMV, C Pneumoniae and H Pylori infection was identified by IgG antibod- 
ies determination. Results: CMV previous infection was detected in 50% of the popula- 
tion; 18% had C Pneumoniae and 33% had H Pylori infection. Average reference 
diameter was 2.94t0.48 mm and average minimal lumen diameter post stem implanta- 
tion was 2.45~0.42 mm. At 6 months, the average late loss was 0.74eO.50 mm, the mean 
neo intimal tissue area was 3.8k1.7 mm2 and the average ratio of neo intimal tissue area 
to stent area was 45218%. None of these variables of restenosis was linked with any of 
the three infectious agents. By multivariate analysis, the lesion length was the best corre- 
lated variable with the mean neo intimal tissue, the ratio of neo intimal tissue on stent 
area and late loss, explaining respectively 31% 39% and 8% of their variability. Conclu- 
sion: This study shows that prior infection with CMV, C Pneumoniae or H Pylori was not 
a contributing factor in the process of restenosis after stent implantation. 
1254-42 Surface Micro Grooves (MG) Improve Endothelialization 
Rate In Vitro and In Vivo 
Cristina Fuss, Eugene A. Sprague, Steven R. Bailey, Julio C. Palmaz. University of Texas 
Health Science Center at San Antonio, San Antonio, TX 
Background: Prevention of subacute stent thrombosis depends on rapid endothelializa- 
tion of the stented surface. The high rate of stent thrombosis after brachytherapy appears 
to be related to delayed endothelialization of the stent surface. So far, stem endothelial- 
ization cannot be directly improved by any measure. The purpose of this study is to eval- 
uate the effect of MG on the inner surface of stents on migration speed of endothelial 
cells (EC). Methods: In-vitro migration speed of EC was evaluated under static condi- 
tions on flat, lxlcm, 316L stainless steel coupons. MG, 7, 10, 15 and 20pm wide, were 
photochemically etched in groups of 5 coupons per groove width, and compared to a flat 
control. The coupons were placed on confluent EC monolayers for 5 days and Giemsa 
stained for measurement of migration distance. 15 Yorkshire pigs received one grooved 
and one plain stent, each. The balloon-expandable, slotted stainless steel stents 20mm 
long, were placed in both carotid arteries with 5mm balloons at 12 Atm. Grooves of 12- 
i5pm ware chosen based on in-vitro results. The specimens were retrieved at 1, 3, and 8 
weeks and analyzed for endothelial coverage, extent of inflammation, and injury score. 
Results: In-vitro studies of migration showed greater speed on all grooved coupons corn- 
pared to flat control. The overall EC coverage was 136.7 EC/mm2 on the control vs. 
242.8, 241.8, 357.2, and 270 EC/mm2 on the 7, 10, 15, and 20 pm coupons, respectively 
(p-value 0.0095, 0.0152, 0.0012, and 0.0015). Maximum endothelial coverage was 
achieved on 15wm grooved surfaces. In-viva: 69% of the stented area was endothelial- 
ized at one week on the grooved stents vs. 36% on the plain stems (p=O.O13). At three 
and eight weeks both grooved and plain stems were completely endothelialized. Injury 
and inflammatory scores were low and not significantly different in grooved vs. plain 
stents (injury score 0.1 vs. 0.07: inflammatory score 0.43 vs.O.32, respectively). Conclu- 
sion: MG increase EC migration speed and is dependent on groove width. Stems with 
grooved inner surfaces have significantly increased endothelialization rate. Faster endot- 
helialization could reduce the period during which a patient is at risk of subacute throm- 
bosis. 
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1255-12 Changes In Primary Angioplasty And Effect On In-hospital 
And Two-year Outcomes From 1996-1998 
Vijay G. Kalaria, lmran Chaudhary, Seth Jacobson, Richard M. Pomerantz, Christopher 
J. Cove, Lori Caufield, Frederick S. Ling, Donald E. Cutlip. University of Rochester 
Medical Center, Rochester, NY 
Background. Several randomized trials have shown superiority of primary PTCA over 
thrombolytic therapy, although these benefits have not been uniformly confirmed by 
unselected “real-world” data. In addition, the practice of primary PTCA has evolved over 
time with increasing use of stems and Ilb/llla inhibitors. The aims of this study are to 
compare procedure characteristics and in-hospital outcomes from 1996.1998, and evalu- 
ate predictors of two-year mortality in an unselected single center population. Methods. 
257 patients were treated with primary PTCA from 1996-1998. Baseline patient and pro- 
cedural characteristics were prospectively collected and patients were followed clinically 
for 2 years. Lesion success was ~50% diameter stenosis and TIMI 3 flow. Procedure suc- 
cess was lesion success without death, MI, or bypass surgery. Two-year mortality predic- 
tors were determined using Cox proportional hazards modeling. Results. Cardiogenic 
shock was present in 16 (6.2%) patients. Procedural results and in-hospital outcomes 
over the 3 years are shown in table. Overall two-year mortality was 10.5% (7.1% among 
non-shock patients, 5.4% among hospital discharge survivors). Target vessel revascular- 
ization (TVR) was required in 16.9% (13.5% vs 19.9%, PzO.17 for stent compared to no 
stent). The independent predictors of two-year mortality and hazards ratios (HR) were: 
age (HR 1.08 per year, P=O.O04), stent use (HR 5.6, P=O.Ol), ejection fraction <40% (HR 
3.3, P=O.O4) and absence of post Ml beta blockers (HR 0.21, P=O.O3). Conclusions. (1) 
Stent and llblllla inhibitor use increased significantly from 1996-1998. (2) llblllla use was 
associated with a non-significant decrease in in-hospital mortality and increase in proce- 
dure succass. (3) Stent use improved late TVR but not acute lesion succsss. (4) In addi- 
tion to advancing age, low ejection fraction, and absence of post Ml beta blockers, stent 
use was associated with an independent increased risk for late death. 
1996 1997 1998 P 
Door to balloon time (min- 102 89 92 NS 
utes, median) 
llbillla inhibitor (%) 63 88 90 0.001 
stent (%) 19 39 73 0.001 
Lesion success 88 93 92 NS 
Procedure success 83 90 87 NS 
In-hospital death(%) 7.8 5.1 4.3 NS 
1255-13 Early Changes in Coronary Flow Reserve of the Culprit 
Vessel After Primary PTCA for Acute Myocardial Infarction 
in Patients With No Regional Contractile Improvement at 
Hospital Discharge - Relationship With Viability 
Philippe Garot, Olivier Pascal, Marc Simon, Emmanuel Teiger, Pascal GuBret, Jean-Luc 
Dub&-Rand& Patrick Dupouy. Hop&l Henri Mondor, Cr&eil, France 
Background: The relationship between changes in coronary flow reserve (CFR) and myo- 
cardial viability after primary PTCA for AMI is unclear. This study aimed to assess early 
changes in CFR of the culprit vessel in pts with stunned and in pts with non viable rnyo- 
cardium after successful primary PTCA for AMI. Methods: We studied 24 pts (aged 60+6 
yrs, admitted < 6 hours after AMI onset, no prior Ml) successfully treated by primary 
PTCA for AMI (TIMI- flow, residual stenosis ~30%) who had no regional contractile 
improvement at D8. Among these pts, 13 had significant contractile reserve during low- 
dose dobutamine echocardiography (VIAB+) whereas 9 had not (VIAB-). All pts had 
>45% left ventricular ejection fraction (LVEF) on admission. A LV and coronary angiogra- 
phy with CFR measurements was scheduled at Dl and 8. The Slager wall motion score 
was used to determine the regional contractility in the dyscontractile area. Results: LVEF 
and Slager wall motion scores were similar in pts with and without inotropic reserve (for 
acute, Dl and D8). Conclusion: In pts with no regional contractile improvement at D8, 
acute CFR was ~2.2 despite successful primary PTCA. Pts with stunned myocardium 
had >2.2 CFR values from Dl while pts with non viable myocardium had q2.2 CFR val- 
ues at DO, Dl and DE. These data suggest that in pts with no regional contractile 
improvement despite successful primary PTCA for AMI, early recovery of >2.2 CFR val- 
ues may be associated with viable and stunned myocardium. 
1255-14 Therapeutic Ultrasound Reduces Restenosis Rates in 
Primary PCI in AMI Patients 
Raimund Erbel, Robert Kuechler, Hylton I. Miller, lzhak Herz, Uri Rosenschein. Tel Aviv 
Medical Center, Tel Aviv, Israel, Universitatsklinikum Essen, Essen, Germany 
Background: We have shown that percutaneous catheter mediated ultrasound throm- 
bolysis (PCUT) successfully restores coronary flow and myocardial perfusion in AMI 
patients. We have shown that in vitro, therapeutic ultrasound inhibits smooth muscle cell 
migration and induces apoptosis. Preliminary in viva experimental data suggested reduc- 
tion in neointimal hyperplasia in stented porcine coronary arteries following application of 
therapeutic ultrasound. The purpose of this study was to retrospectively evaluate the ras- 
tenosis rate in acute myocardial infarction (AMI) patient population treated with PCUT. 
Methods: Patients (n=50) with AMI and TIMI O-1 flow in the native coronary arteries 
were treated by primary PCUT (ACOLYSIS, Angiosonics Inc, Morrisville, NC.). The ultra- 
sound energy (18 W, 41 KHz for l-5 min) was transmitted through a 141.cm long flexible 
probe connected proximally to a piezoelectric transducer. The probe had a 1.6 mm diam- 
eter tip and fit into a 7 Fr angioplasty guide catheter. All patients had clinical and angio- 
graphic follow up at six months. 
Results: Sonic&on induced arterial patency (TIMI 2-3) in 92% of patients. Adjunct PCI 
was used in 77% of the cases (PTCA 76.9%, stents 20.5%). Reference vessel diameter 
was 2.56f0.38 mm. Follow-up angiography at six months revealed restenosis (diameter 
stenosis >50%) in 11 (22%) patients. Intravascular diagnostic ultrasound at six months 
revealed luminal diameter of 2.7hO.3 mm, plaque area of 58ilO% of external elastic lam- 
ina (EEL) area, plaque eccentricity index of 1.07iO.03, and no damage to EEL. 
Conclusion: AMI patients treated with therapeutic ultrasound thrombolysis exhibited a 
lower than expected restenosis rate at six months. Additional data are needed to fully 
identify optimal dosing parameters and clinical merits of therapeutic ultrasound for the 
prevention of restenosis. 
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1255-15 Trans-Radial Coronary lnetrvention for Acute Myocardial 
infarction 
Taiichiroh Meguro, Hidehiko Honda, Norio Endoh, Masayoshi terashima, Hisanao 
Takeda, Yuko Ito, Tatushi Otomo,Shinya Abe,kazunori Ogat, Yasusuke miyazaki, Satomi 
Fujiwara, Osamu Kawashima, Ryuji Kuhara. SendaiKohseiHospiral, sendai, Japan 
(0bjective)We evaluated the feasibility, safety, and efficacy of trans-radial coronary inter- 
vention for the treatment of acute myocardial infarction. (Methods) 262 consecutive 
patients presenting acute myocardial infarction between Jan. 1999~Dec. 1999 were 
enrolled for the study. 25 patients presented cardiogenic shock and treated with intra aor- 
tic balloon pump(lABP). 234 patients(89.3%) were enrolled for trans.radial coronary 
intervention. 226pts(86.2%) were approached from left-trans radial artery, and 
Spts(3.0%) were approached from right trans&dial artery. We used 6F sheath in 230pts 
and 7F in 4pts. The patients presenting Alien test abnormality, chronic hemodialysis 
patients, or the patients presenting no radial artery pulsation were excluded. The num- 
bers of each target lesion was 106 in LAD, 31 in LCX, and 101 in RCA. The procedures 
were stent(199 cases), PTCA(L?Gcases), and Cutting Balloon(9cases). (Results) The pro- 
cedure success rate was 97.4%(228/234) and the cause of procedure failure was no re- 
cross of the guidewire in 5 cases and no-reflow after PTCA in 1 case. There was no com- 
plication related to trans-radial coronary intervention itself. 2 patients out of 228 proce- 
dure success patients, and 1 patient out of 6 unsuccessful procedure patinets died during 
hospitalization. The mortality rate for tram-radial coronary intervention approach AMI 
patients was 1.2%(3/234). The mortality rate for AMI patients who were enrolled for coro- 
nary intervention was 3.2%(9/262). Total in-hospital mortality rate who presented AMI 
during this period was 4.6%(13/279). (Conclusion). Even though we enrolled 25 
patients(9.5%) who presented cardiogenic shock which required IABP, the mortality rate 
of AMI patients aftertrans-radial coronary intervention was 1.2%. The in-hospital result of 
trans-radial coronary intervention for AMI was safe, feasible, and efficient compared with 
conventional trans-femoral approach. 
1255-16 Clinical Value of Early ST-Segment Changes After Primary 
Angioplasty for Acute Myocardial Infarction 
Giovanni M. Santoro, Renato Valenti, Angela Migliorini, Guia Moschi, Mauri& Trapani, 
David Antoniucci. Division of Cardio/ogx Careggi Hospital, Florence, /fa/y 
Background: Although the clinical outcome of patients (pts) with acute myocardial infarc- 
tion (AMI) is improved by the early recanalization of the occluded coronary artery, not all 
pts benefit from successful reperfusion therapy. Electrocardiogram (ECG) may be useful 
to offer an early stratification of the risk. Methods: In 307 consecutive pts with AMI 
treated with successful (TIMI 3) primary PTCA we evaluated early ST-segment elevation 
changes by visual review of the EGG continuously recorded during the procedure. 
Results: One-hundred ninety pts (62%) had ST-segment elevation resolution > 50% 
(group A), 38 (12%) had transient further ST-segment elevation followed by resolution > 
50% (group B) and 79 (26%) had persistent ST-segment elevation (group 6). Group A 
and group B had similar clinical and angiographic features except for a higher rate of TIMI 
O-l before PTCA in the group B (92% versus 72%, p=O.O09). In comparison to group A, 
group C had higher prevalence of female sex (29% versus 15%, p=O.O14), anterior AMI 
(62% versus 40%, pcO.001) and shock at admission (27% versus 4%, p<O.OOi) and 
longer time from symptoms to reperfusion (4.3ki.9 versus 3.7~tl.9, p=O.O45). Group C 
had more extensive myocardial demage as compared to group A (peak CPK 347122881 
IU/I versus 1804+1499 IU/I, pcO.001; LVEF at discharge 4329% versus 48+10%, 
p=O.OOS). Six-month mortality was 3% in group A, 10% in group B (p=O.O22 versus group 
A) and 21% in group C (pcO.001 versus group A); six-month major adverse cardiac event 
rate was 15% in group A, 13% in group 6 and 33% in group C (p<O.OOl versus group A 
and group B). Persistent ST-segment elevation was an independent determinant of 6. 
month mortality with an Odds ratio (OR) of 2.69 (95% Cl 1.05-6.90, p=O.O39). Conclu- 
sion: The evaluation of ST-segment elevation changes occurring during primary PTCA 
allows a very early identification of pts with different clinical outcomes. 
125517 Early Coronary Angioplasty for Acute Myocardial Infarction 
Complicated by Cardiogenic Shock: Have Novel Therapies 
Led to Better Results? 
Ratil Moreno, Eulogio Garcia, Leopold0 Perez de Isla, Manuel Abeytua, Javier Soriano, 
Es&ban Lbpez de Sb, Rafael Fiubio, Jose L. Ldper-Senden. Hospital Gregorio Maraiidn, 
Madrid, Spain 
Patients with acute myocardial infarction (AMI) and cardiogenic shock constitute a very 
high risk subset despite an aggressive management. The objective of this study was to 
evaluate if the results of early PTCA in patients with AMland cardiogenic shock have 
changed over the last years, and to address which role the recent adjuvant therapies 
have plaid in this evolution. Methods: From 3191 to 4199, 94 patients with AMI and cardio- 
genie shock were treated with PTCA < 12 h. after the onset of symptoms. Temporal 
changes of the utilization of adjuvant therapies were studied over these years, as well as 
their impact on the angiographic results and in-hospital outcome. Results: Over the 
years, a progressive and significant increasing on the use of coronary stents and 
c7E3Fab was observed, as well as the number of primary angioplasties performed per 
month has increased. The proportion of patients treated with intraaortic balloon pump did 
not changed significantly over the years. An angiographic successful result (~50% resid- 
ual stenosis and TIMI flow 2 or 3) and a final TIMI grade 3 flow were obtained in 76 
(80.9%) and 61 (64.9%) patients, respectively. The angiographic success rate progres- 
sively increased over the years, from 72.3% in patients treated before 1994 to 94.1% in 
those admitted in 19981999 (p for trend 0.0409). The proportion of patients with a final 
TIMI grade 3 flow also grew progressively over the years: from 36.4% before 1994 to 
76.5% after 1997 (p for trend 0.0209). The overall in-hospital mortality rate was 63.8% 
(60 patients), and there was no significant change in mot-t&y rate over the years. Con- 
clusions: We have observed an increment on the use of coronary stems and c7E3Fab in 
patients with AMI and cardiogenic shock treated with early PTCA. All these factors have 
led to an improvement on the angiographic results, albeit this change has not been tra- 
duced in a significant reduction of mortality 
1255-i 8 Myocardial Perfusion Flow Is A Prognostic Marker In 
Patients With Acute Myocardial Infarction Who Undergo 
Angioplasty. 
Marcelo 0. Bettinotti, Esteban Escolar, Carlos Deluca, Alvaro Sosa Liprandi, Carlos 
Sztejfman. Sanatorio M&e, Buenos Aires, Argentina 
Background: The degree of myocardial contrast opacification (myocardial “blush” opac- 
iv due to contrast in microvessels) has been proposed as a specific and sensitive marker 
of myocardial reperfusion. Our objective was to retrospectively analyze myocardial blush 
in patients (pts) with AMI who were treated with angioplasty (PTCA), to correlate it with 
long-term outcome and to compare it with post-PTCA TIMI flow. Methods: All consecu- 
tive pts (n=69) who underwent emergent PTCA as AMI treatment in 1999 were recruited. 
Post-PTCA TIMI was analyzed by an independent angiographic core laboratory. Blush 
was scored as grade 3: nornal, with rapid filling and washing; 2: reduced; 1: minimal; and 
0: absence of opacity. Mortality at end of follow-up was the end-point of the study. Fourty 
two (61%) primary and 27 (39%) rescue PTCA were performed. Myocardial blush was 
analyzed for 63% of the sample. Results: Mean age was 61&11 years, 79% were male. 
Mean follow-up time was 6 months (25 months). Baseline characteristics included: past 
history of hypertension (64%), diabetes (ll%), dyslipidemia (48%), Ml (31%), heart fail- 
ure (5%), and revascularization (10%); 66% were current smokers. Killip class at admis- 
sion was: I 39 pts (57%), II 10 pts (14%), Ill 6 (9%). IV 14 pts (20%). & table 
(A:myocardial blush and mortality; B: TIMI flow, myocardial blush and mortality). ++ = 
p<O.Ol (c2), # = p 10.1 (c2), TIMI Ill + blush 3 vs. TIMI Ill + blush c3 = p<O.O4(c2) Con- 
clusions: In our high-risk population, microvascular flow --analyzed with myocardial 
“blush” opacity - had a significant correlation with mortality. For TIMI Ill pts the presence 
of blush score 3 was associated with a better prognosis. 
A Blush 3 Blush 2 Blush 1 Blush 0 Blush <3 P value 
(chi- 
square) 
Pts, n(%) 30 (49 12 (18) 7 (9) 9(12) 28 (41) - 
Mortalitv, n (%) 2 (6.6) 5 (41) 4 (58) 3 (33) 12 (44) 0.01’ 
B TIMI Ill TIMI II/l/O 
pts, n (%) 55 14 
Mortality, n (%) 8 (14.5) 6 (45) 
Blush 3 Blush <3 Blush 3 Blush <3 
Pts, n (%) 30(89) 14(31) 0 (0) 14 (100) 
Mortality, n (%) 2 (66)++ 5 (36)# 0 (0) 6 (45)++/ 
# 
1255-l 9 Does Adenosine Limit Myocardial Necrosis After 
Percutaneous Coronary Intervention? Results of the 
ADELINE Pilot Trial 
Walter J. R. Desmet, Joseph Dens, Patrick Coussement, Frans Van de Wed, Zahur 
Zaman. UH Gasthoisberg, LEUVEN, Belgium 
Background: 24% to 44% of patients suffer some myocardial damage as evidenced by a 
significant rise in troponin or creatine kinase-MB after successful percutaneous coronary 
intervention. We examined if preconditioning using intracoronary administration of ade- 
nosine before coronary intervention affected the release of these cardiac markers. 
Methods: We randomized 32 patients to intracoronary administration of adenosine 
(lmgimin in the right and 2 mglmin in the left coronary artery during 10 minutes) or pla- 
cebo preceding elective coronary intervention. The first balloon inflation started 10 min- 
utes after the end of study drug administration and was maintained for 90 seconds. The 
intracoronary electrocardiogram was recorded before the balloon inflation and during the 
last 10 seconds of the inflation. Thoracic pain during the study drug administration and 
balloon inflation was scored on a visual analogue scale. Before and 24 hours after 
uncomplicated coronary intervention troponin I and creatine kinase-MB were measured. 
One patient was excluded because of occlusion of a major side branch and three 
because of missing data. 
Results: In the adenosine-pretreated group (N=l2), mean creatine kinase-MB rose from 
2.08 * 1.29pg/l to 3.23 + 2.02yg/l at 24 hours (P=O.O60), and mean troponin I from 0.86 f 
2.05pg/l to 1.94 + 2.48 pg/l (P~O.189). Mean ST-segment shift was 6.08 + 5.52mm. In the 
control group (N=16), mean creatine kinase-MB rose from 2.04 * l.O5pg/i to 9.41 f 9.86 
pg/l (P=O.Oll) and mean troponin I from 0.23 * 0.5Ofigll to 3.09 t 4.92 pg/l (P=O.O37). 
Mean ST-segment shift was 12.38 f 11.15 mm. There was a significant difference in cre- 
atine kinase-MB increase between the adenosine and the placebo group (1.15 + 1.90 vs. 
7.36 + lO.l2~g/l, P=O.O47). 
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Conclusion: Preconditioning using intracoronary administration of adenosine resulted in 
a limitation of myocardial damage by coronary intervention. Clinical implications and 
applicability and efficacy of a simplified protocol merit further investigation in a larger trial. 
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1256-20 Early Clinical Experience With Pullback Beta-Irradiation in 
In-Stent Restenosis Longer Than 40 mm 
Christoph A. Kaiser, Christoph Naber, Yasser Abdel Rahman, Clemens “on Birgelen, 
Peter Meusers, Wolfgang Sauerwein, Michael Haude, Raimund Erbel, Dietrich 
Baumgart. University Clinic, Essen, Germany 
Background: lntracoronary brachytherapy has been shown to prevent restenosis follow- 
ing angioplasty in restenotic lesions. Because of the limited length of the beta emitting 
souwss currently available, it is not possible to cover lesions longer than 40mm in a sin- 
gle step approach. Thus, alternative strategies, such as pullback irradiation, are required 
to approach longer lesions. Methods: Among a total of 88 patients treated with beta-irra- 
diation following PTCA, brachytherapy was performed as a sequential pullback procs- 
duns in 23 patients (27.3%) including 7 total occlusions (29.2%), utilizing a g”SR-source 
in a hand-held afterloader. The mean applied dose was 21.0+/-3.1 Gy both in the distal 
and in the proximal part of the lesion. Results: In the patients treated with pullback 
brachytherapy the mean length of the balloon-covered vessel segment was 66.9+/- 
86mm. Minimal luminal diameter and reference diameter were 0.73+/-0.51 and 2.50+/- 
0.78mm, respectively. Geographic miss occurred in a total of 13 patients (54.2%). In the 
proximal part of the lesion with a frequency of 12.5% (n=3) and in the distal part with a 
frequency of 375% (n=9). Additional geographic miss was observed in the mid part of 
the lesion in 11 patients (45.8%) resulting from insufficient overlap of the source during 
pullback. No complications occurred during the procedure or within the first 30 days. In 
the follow-up period of 4.9+/-l .3 months no MACE was observed, angiographically signif- 
icant restenosis occurred in 12.5% (“~3) and target vessel revascularisation was psr- 
formed in 4.4% (n=l) of the patients. Conclusions: This initial experience indicates that 
pullback irradiation is a safe, feasible and effective procedure to approach long lesions. 
1256-21 Radioactive Stents Inhibit Neointimal Hyperplasia and 
Induce Expansive Remodeling in a Dose-Dependent Pattern 
Paul Wexberg, Christian Kirisits, Mariann Gyongyosi, Michael Gottsauner-Wolf, Boris 
Pokrajac, Richard Potter, Dietmar Glogar. Division of Cardiology, University of Vienna 
Medical Center, Vier~na, Austria, Departmenf of Radiotherapy and Radiobiologl: 
Universify of Vienna Medical Center, Vienna, Austria 
Background: The clinical application of radioactive stents is limited by per&tent rest- 
enosis. It is unknown whether this phenomenon is dependent on the absorbed dose wih- 
tin these segments. Thus we established a model of determining the dose-distribution in 
a defined artery volume using dose-volume histograms and correlated it with the 6month 
intravascular ultrasound follow up. Methods: Fifteen patients underwent intravascular 
ultrasound after implantation of a radioactive stent and at 6 months follow-up. Based on 
post-implantation intravascular ultrasound measurements at seven defined segments 
(five within the stent, one at 2.5 mm proximal and distal to the stent, respectively), the 
doses delivered to at least 10 (DVlO)and 90% (DV90) of the assumed target volume, i. s. 
the adventitia (defined 0.5 mm thickness outside the external elastic lamina), were cabu- 
lated by an elaborated computer algorithm. Neointimal growth and vascular remodeling 
were correlated with the calculated doses in each segment. Results: There was a nega- 
tive logarithmic correlation for neointimal hyperplasia in the stent body with the dose 
absorbed by at least 10 (r=.456, pc.001) and 90% (r=.466, p<.OOl), whereas there was a 
positive logarithmic correlation for increase of the external elastic lamina (EEL) within the 
stent (rzO.427, pcO.001; r=O.448, prO.OO1, respectively). Neointimal growth was elevated 
by 24% at the stent edges compared to the peri-stent segments, and by 182% compared 
to the stent-body. Conclusion: The analysis of dose-volume histograms after radioactive 
stsnt implantation reveals a dose-dependent reduction of neointimal growth and induc- 
tion of expansive remodeling within the stent. The peri-stent restenosis seems to be 
related to a combination of mechanical and radiation injury. 
1256-22 lntracoronary Gamma Radiation for Patients With Totally 
Occluded InStent Restenotic Lesions: 6 Months Clinical 
and Angiographic Follow-Up 
Han-Soo Kim, Andrew E. Aiani, Lowell F. Satler, Roxana Mehran, Alexandra J. Lansky, 
Gary S. Mintz, Kenneth M. Kent, Augusta D. Pichard, Luis Gruberg, Rosanna C. Chan, 
Ron Waksman. Washington Hospital Center, Washington, DC 
Background: Conventional PTCA of totally occluded coronary arteries with in-stent rss- 
tenosis (ISR) is associated with higher rates of restenosis and reocclusion. The purpose 
of this study was to evaluate the effectiveness of intracoronary y-radiation therapy in 
patients with total occlusion of ISR lesions. 
Methods: Out of 456 patients who were enrolled into the WRIST studies (Washington 
Radiation for InStent Restenosis Trial), 33 patients (68%) presented at entry with total 
occlusion of the target lesion. Thirty of these patients (90.9%) underwent successful 
intervention using balloon, laser angioplasty, or additional stents (7 patients 23%) to 
obtain a good angiographic result (c 30% diameter stenosis). After the intervention, a 
closed end lumen catheter was introduced into the artery, a ribbon with different trains of 
radioactive ‘$*lr seeds (mean ribbon length of 65?23 mm) was then delivered by hand to 
cover the treated site. The prescribed dose was 14 or 15 Gy at a 2 mm radial distance 
from the center of the source. Antiplatelet therapy (Ticlopidine 250 mg BID or Clopidogrel 
75 mg/QD) was prescribed for one or six months in 12 and 18 patients respectively. All 
patients completed &month clinical and angiographic follow-up. 
Results: At 30 days there were no adverse events related to the radiation procedure. 
Angiographic binary restenosis by QCA was 20.0% with a late loss of 0.40i0.7lmm. 
Clinical results at 6 months are shown in table. 
Clinical outcomes 6 months 
Death 1 (3.3%) 
Myocardial infarction 0 (0%) 
Target vessel revascularization (TVR) 7 (23.3%) 
Target lesion revascularization (TLR) 6 (20.0%) 
Late total occlusion 3 (10.0%) 
MACE (Death, MI, TVR) 8 (26.6%) 
Conclusions: Total occlusion of ISR lesions at entry to the WRIST studies is not infre- 
quent and has a successful recanalization rate with conventional percutaneous coronary 
intervention. lntracoronary rradiation therapy for totally occluded ISR is feasible, safe, 
and associated with comparable event rates to patients who are treated with pradiation 
for non-occlusive ISR lesions. 
1256-23 Late Effects of Low-Energy Gamma Emitting Stents in a 
Rabbit Iliac Injury Model 
Bradley H. Strauss, Chris Li, Heather A. Whittingham, Fermin 0. Tio, Michael J. B. 
Kutryk, John D. Sparkes, Todd Turnlund, William L. Sweet. St. Michael’s Hospital, 
Toronto, ON, Canada, University of Texas Health Science Center, San Antonio, TX 
Background: Human coronary artery studies have shown that radioactive beta-emitting 
(32P) stents potently inhibit in-stent hyperplasia but are limited by narrowing at stent 
edges. The objective of this study was to determine the long-term dose response of 
novel, low dose gamma-emitting stents in a rabbit iliac artery model. Methods: Control 
(n=24) and 1 .O to 4.0 mCi Palladium-103 (103Pd) (n=36) stents were implanted in the 
iliac arteries of 30 New Zealand rabbits and sacrificed at 26 weeks. Stents were evalu- 
ated by intravascular ultrasound (immediately post procedure and prior to sacrifice) and 
by histomorphometry. Results: Twenty-eight rabbits survived to sacrifice with no evi- 
dence of stent thrombosis. In the body of the stent there was a dose response relation- 
ship with significant inhibition of intimal cross-sectional area (CSA) at the highest activity 
compared to control stents (0.21*.12 mm2 vs 0.50r.16mm2,p<0.01) and a significant 
increase in intimal CSA at the lowest activity (0.96kO.51 mm2 vs 0.5ti.16 mm2 pcO.01). 
However, at the stent edges there was a significant reduction of lumen CSA at all activity 
levels compared to control stents. This reduction in lumen CSA was most prominent 
immediately proximal to the stent where control stents had late lumen gain (0.70 mm2), 
while all activity stents had significant late lumen loss (range 1.00-1.90 mm2). The neoin- 
tima of higher activity stents demonstrated immature features (persistent fibrin and 
inflammatory cells, matrix proteoglycans, low smooth muscle cell content). Conclu- 
sions: Continuous low-dose-rate irradiation by gamma emitting 103Pd stents is feasible 
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with reduction of hyperplasia in the stent body in a dose-related manner. However, signif- 
icant narrowing at the stent edges, stimulation of in-stent hyperplasia at lower activities 
and persistence of an immature neointima at higher activities are significant limitations. 
1256-24 Local Delivery of 17-Beta-Estradiol Significantly Reduces 
Collagen Expression and Restenose Formation After 
Coronary Stenting 
Pedro Geraldes, Martin G. Sirois, Jean-Francois Tanguay. Montreal Heart Institute, 
Montreal, PQ, Canada 
Background: Extracellular matrix (ECM) of which collagen formation is a maior compo- 
nent .seems to play an important role in restenosis after balloon angioplasty (PTCA). It 
has been demonstrated that estrogen administration reduces type I and type III collagen 
synthesis by vascular smooth muscle cell in vitro. In previous studies. we have shown 
that local delivery of i7-beta-estradiol (17p) prevents restenosis following angioplasty by 
improving reendothelialization, endothelial function and vascular healing. We hypothe- 
sized that local 170 may influence collagen expression after coronary stenting. 
Methods: Each coronary artery of a juvenile swine (n = 27) underwent PTCA and was 
randomly assigned to treatment (2 and 4 mg of 17p) delivered locally or placebo and 
each vessel was stented. At 28 days, the animals were euthanized, the tissues were fixed 
and red Sirius stained. Each segment was analyzed under polarized light to evaluate 
type I and Ill collagen. The area of pixels of each collagen type in the media and neoint- 
ima divided by the total area of each respective region determined % collagen expres- 
sion. Mean histological injury scores and neointimal thicknesses were evaluated. 
Results: 
Conclusion: Local delivery of 17p decreases type I collagen expression in the media 
and neointima after stenting in a porcine coronary artery model. This reduction in extra- 
cellular matrix formation using 176 may partially explain the reduction of in-stent rest- 
enosis. 
1256-25 Gold Coating of Coronary Stents Increases Neointimal 
Proliferation Following Stent Implantation: A Prospective 
Randomized Multicenter Trial With Quantitative 
Intravascular Ultrasound at 6 Months 
Juergen vom Dahl, Phillip K. Haager, Eberhard Grube, Michael Gross, Eckhard P. 
Kramer, Christian W. Hamm, Rainer Hoffmann, Thorsten Reinecke, Heir&h G. Klues. 
Medizinische Klinik 1, University Hospital Aachen, Aachen, Germany 
Background: Gold coating of stainless steel stents improves fluoroscopic visibility and 
reduces thrombogenecity and tissue proliferation in vitro. This prospective multicenter 
trial sought to evaluate the impact of gold coating on neointimal tissue proliferation in 
patients undergoing elective stent implantation. Methods: Primary endpoint was the in- 
stent neointimal tissue proliferation measured by intravascular ultrasound (IVUS) at six 
months comparing stents of identical design with or without coating (InflowTM). Two hun- 
dred and four patients (pts) were randomized to receive uncoated (group A, n=lOl) or 
gold coated (B, r-1=103) stems. Results: Baseline parameters did not differ between the 
groups. Stent length and balloon size ware comparable, while inflation pressure was 
slightly higher in group A (14*3 vs 13&3 atm, p=.Ol3). Procedural success was similar 
(a: 97%; 8: 96%). The acute angiographic result was better in group B (remaining steno- 
sis 4t12% vs. lOi- l%, p=O.OOZ). IVUS as well as quantitative angiographic analysis 
revealed significantly more neointimal proliferation in group B. Neointimal volume within 
the stent was 47e25mm3 vs 41+23mm3 (~~04) with a ratio of neointimal volume to stem 
volume of 0.45r0.12 vs 0.40+0.12 (p=.OO3). Concordantly, the angiographic minimal 
luminal diameter was significantly smaller in group B (1.47*.57mm vs 1.69t.70mm, 
p=.O4) with a higher late luminal loss of 0.82+0.56mm vs 1.17~0.51mm as compared to 
group A (p=O.OOi). Restenosis was 36% in group B and 24% in group A resp. (p=.13) 
with a need for reintervention in 28% and 18% resp. Conclusions: Gold coating of the 
tested stent type resulted in more neointimal tissue proliferation. Studies evaluating other 
stent types are necessary to elucidate if this is gold related or a result of the coating pro- 
cess. 
1256-26 Elective Placement of Stent Graft in Native Coronary 
Arteries: Acute Results and 6 Month Follow-Up 
Edmund Sovik, Magne Brekke, Nils-Einar Klow, Sindre Stavnes. U//eva/Hospita/, Oslo, 
Norway 
Background: The Jomed Coronary Stent Graft consists of polytetrafluoroethylene graft 
material placed between two stents in a sandwich design. Using stem graft may reduce 
restenosis by preventing neointimal cell ingrowth, and the graft may also be used to seal 
off aneurysms and procedure related perforations. The purpose of the study was to 
assess the feasibility of placing stent grafts into native coronary arteries and evaluate 
restenosis and complications. Methods: 50 patients with stable angina pectoris were 
included, 11 women and 39 men. Significant stenosis in native coronary arteries >3 mm 
and no side branches 22 mm that were closer than 5 mm from the stenosis were 
included. The initial 31 patients were given ticlopidine 250 mg twice daily for 30 days and 
the next 19 for 90 days. All patients were followed clinically for 6 months. Quantitative 
angiography and intravascular ultrasound were performed after stem placement and at 
the follow-up angiography after 6 months. Additional angiography was performed before 
6 months in 12 patients resulting in PTCA in five. Results: The stent grafts ware suc- 
cessfully placed in all. One patient had two grafts placed in the same artery and eight 
patients had a standard steel stent placed in the same vessel. During follow-up there 
were four occlusions, one probably within the first 24 hours, and the other after 75, 76 
and 165 days, giving an occlusion rate of 8 %. All late occlusions were found in the initial 
31 patients treated with ticlopidine for 30 days. There was one early occlusion in the 
group of 19 patients treated with ticlopidine for 90 days. Restenosis (n=7) and occlusion 
(n=4) of the artery treated with stem graft was 20 %. Two patients had restenosis within 
the stent graft, three outside and two both. Conclusion: Stent graft can be placed SUG- 
cessfully into native coronary arteries. The restenosis rate was low. The high balloon 
pressure needed for expansion of the graft may contribute to restenosis at the edges of 
the graft. The occlusion rate was high for patients with short time of antiplatelet therapy 
and the time of antiplatelet therapy should be extended to at least three months. 
1256-27 Ticlid or Plavix Post-stent (TOPPS): No Difference in Clinical 
End-Points at 9 Months Follow-Up 
Morton R. Rinder, Praveen Tamirisa, John Lasala, Kim Mumm, Howard I. Kurz, Megumi 
Taniuchi. Washington University School of Medicine, St Louis, MO 
Background: Post-procedural treatment with aspirin and a thienopyridine derivative has 
become standard therapyu following percutaneous coronary intervention (PCI) to prevent 
sub-acute stent thrombosis (SAT). Clopidogrel offers the potential advantages over ticlo- 
pidine of once per day dosing, lower cost, and a lower reported incidence of TrTp. We 
have previously reported that at 30 days, there is improved tolerance to clopidogrel com- 
pared to ticlopidine, with similar occurrence of MACE, SAT, and cardiac death. We now 
report the nine-month follow-up examining differences in target vessel revascularization 
(NR), cardiac death, or myocardial infarction (Ml). Methods: Patients ware randomized 
to receive ticlopidine 250 mg twice daily for two weeks versus clopidogrel 75 mg once 
daily. Patients were followed prospectively for in-hospital events. Telephone follow-up was 
petformed at 30 days and at 9 months. Reports of repeat hospitalization were reviewed 
for cardiac versus non-cardiac cause as well as confirmation of Ml. All repeat PCl’s were 
reviewed to determine whether the same vessel undetwent revascularization. Results: A 
total of 1016 patients were randomized; 494 to the clopidogrel arm and 522 to the ticlopi- 
dine arm. The mean age of the group was 64 years, with 60% males and 29% diabetics. 
Forty-one percent of patients were treated within one week of an acute Ml. Forty-eight 
percent received an intravenous gp Ilb/llla inhibitor. 
Ticlopidine Clopidogrel P Value 
N 522 494 
Cardiac Death 2.1% 1.4% 0.63 
NR 13.8% 15.8% 0.37 
Ml 4.5% 4.7% 0.91 
MACE 20.5% 21.9% 0.59 
Conclusions: These data indicate that at nine months follow-up, a short course of ticlo- 
pidine or clopidogrel are similar with regard to preventing adverse events following stent 
placement. Along with previous reports of improved tolerability and ease of dosing, our 
study provides further evidence that clopidogrel is the ADP-antagonist of choice after 
stenting. 
1256-28 Effect of Balloon Oversizing in Stenting Small Vessels 
Goran R. Stankovic, Takahiro Nishida, Nicola Corvaja, Massimo Ferraro, Marco Vaghetti, 
Remo Albiero, Carlo Di Mario, Leo Finci, Antonio Colombo. EM0 Centro Cuore 
Columbus, Milan, /ta/y 
The aim of present study was to evaluate whether the placement of coronary stents using 
3.0 mm balloon size in the vessels with the reference diameters2.8 mm favorable affects 
clinical and angiographic outcome. Methods: Data from 509 consecutive patients with 
610 lesions, with the reference diameter < 2.8 mm determined by QCA, in whom stent 
was implanted ware analyzed. According to final balloon diameter two groups were cre- 
ated, Group I (124 pts) - with the balloon size < 3.0 mm and Group II (385 pts) - with the 
balloon size 3.0 mm. Two groups were comparable for clinical and procedural character- 
istics, as well as the incidence of complex lesions (58.9% vs. 65.2%, p = ns). The refer- 
ence vessel size was 2.15+0.33 mm and 2.43& 0.29 mm ( p<O.Ol), the balloon-artery 
ratio 1.19*0.2 and 1.25+0.16 (pcO.002) in Group I and II, respectively. Clinical follow-up 
was obtained for all patients after 12 + 9 months. All patients had angiographic follow-up 
after 6 f 4 months by protocol. Results: Two groups had similar incidence of in-hospital 
complications (non-Q-MI 4.0% vs. 3.7%, and Q-MI 1.6% vs. 2.9%, p = ns for both). There 
were no in-hospital CABG or deaths. Two patients in both groups (1.6% vs. 0.5%) had 
acute stent thrombosis, whereas subacute stem thrombosis occurred in 3 patients (2.4%) 
in Group Ij and in 1 patient (0.3%) in Group II, p = ns. Long term outcome: Recurrence of 
angina was similar in two groups (26.6% vs. 25.5%, p = ns). Long-term MACES (myocar- 
dial infarction, CABG and deaths) were not different in two groups (8.8% vs. 7.6%, p = 
ns). Angiographlc restenosis rate was 41.1 % in group I and 37.4 % in group II, p = ns. 
Target lesion revascularization rate (TLR) was 35.5 % in group I and 37.4 % in group II, p 
= ns, and target vessel revascularization rate (TVR) was 41.9 % in group I and 40.8 % in 
group II, p = ns. Conclusions: Despite the presence of more favorable baseline character- 
istics due to a larger reference vessel size, balloon oversizing in small vessel stenting 
does not seem to lower the incidence of angiographic restenosis or to improve clinical 
outcome. 
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1256-29 Methylprednisolone Coated Stents Decrease Neointimal 
Hyperplasia In A Porcine Coronary Model 
Qiang Bei Ping, Huang Yanming, Lan Wang, Ineke Vermeire, Eric Verbeken, Etienne 
Schacht, Ivan K. De Scheerder. UH GASJHUfSBERG KUL, LEUVEN, Belgium 
Corticosteroids possess potent anti-inflammatory and immunosuppressive effects, they 
have been shown to decrease migration and functional capability of the cells of inflamma- 
tion and they may stabilize lysosomal cell membranes. This study aims to evaluate the 
efficacy of methylprednisolone coated stents to decrease neointimal hyperplasia in a por- 
cine coronary model. Methods: Stainless steel balloon expandable coronary stents were 
spraycoated with 10% (g/g) methylprednisolone (MP) impregnated in a polyfluoroalkoxy 
phosphazene polymer (PFM-P75). To slow down the MP-release a 1% (g/v) PFM-P75 
barrier coating was added. The stents were examined with SEM and in-vitro MP-release 
curves were performed. MP-loaded stents and control coated stents were randomly 
implanted in the right coronary artery of 20 pigs. Histopathologic and morphometric anal- 
ysis were performed at 4 weeks follow-up. Results: Total MP-amount incrusted in a stent 
was 126 + 14 pg. In-vitro release showed a 50% MP-release within 33 days. Histopatho- 
logic analysis at 4 weeks showed a significant decreased inflammatory response sur- 
rounding the stent filaments in the MP-coated stents (0.46 + 054 vs 2.34 + 0.75 
pcO.001). Morphometric analysis showed a significant decreased neointimal hyperplasia 
in the MP-coated stents (2.53 + 0.85 vs 4.29 + 1.28 mm2). Conclusion: Methylpredniso- 
lone coated stents result in a significantly decreased neointimal hyperplasia after implan- 
tation in healthy porcine coronary arteries. 
1256-30 Inhibition of In-Stent Restenosis by the Quanam Drug 
Eluting Polymer Stent; Two Year Follow-Up 
Eberhard Grub@ Ulrich Gerckens, Sascha Rowold, Ralf Miiller, Guido Selbach, J6m 
Stamm, Manfred Staberock. Heart Center Siegburg, Siegburg, Germany 
Background: The Quanam drug delivery stent (Q-DL) is a non-biodegradable propri- 
etary polymer, seamlessly ensheathing a Quanam metal stent (Q-M), and loaded in its 
matrix with a slow release microtubule inhibitor. Kinetic studies have shown drug release 
up to 180 days into subjacent tissues. The metal stent scaffold is a specially designed 
slotted tube stent made of 316L steel. Methods: 14 drug delivery (Q-DL) stents were 
implanted in a randomized safety trial in 13 patients. 18 control bare metal stents (Q-M) 
were placed in 14 patients. Stent sizes ranged from 3.0 to 3.5 mm diameter and from 13 
to 17 mm in length. Patient cohorts and lesions were clinically comparable, 46% type A 
(AHA/ACC), and 54% types 82 and C. All 28 patients will be examined following a clinical 
score protocol two years post procedure. In addition, the 14 patients with the DL stents, a 
stress test (ETT) and a re-angio will be performed. Results: Results are pending and will 
be available at time of presentation. Conclusions: The present data are the first two year 
follow-up data in a small cohort of patients treated with the Quanam Drug eluting stent. 
The data indicate that drug elution from a polymer stent is safe, shows non side-effect 
and an extremely low amount of in-stent restenosis and TLR. All patients treated with the 
Q-DL stent have been asymptomatic with no TLR (0%). 
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1257-31 Acute Late Occlusion After Angioplasty of the Lower Limb 
Arteries in Patients Receiving Stent and Brachytherapy: The 
Need for More Intense and Prolonged Antithrombotic 
Prevention 
Andreas Blatter, Michael Llamas, Agostino Faggiotto, Jeanne-Marie Segatto, Mario 
Alerci, Kurt Jaeger, Felix Mahler, August0 F. Gallino. Augusta Gal/i/m, Be//inzona, 
Switzerland 
Background: The occurrence of late acute occlusions after intracoronary stent and 
brachytherapy is known in patients undergoing coronary revascularization. These events 
have been associated with incomplete reendoethelization or insufficient secondary anti- 
thrombotic prevention. No data are as yet available on late acute thrombotic occlusions in 
the peripheral arteries. Recently, we evaluated the interim analysis of the multicenter trial 
on prevention of restenosis after angioplasty of the femoro-popliteal arteries, carried out 
by three Swiss angiology centers. Methods: Patients with symptomatic peripheral arte- 
rial disease (Fontaine stage Ila and Ilb) were assigned randomly to receive angioplasty 
alone or angioplasty plus brachytherapy (Gamma 14 Gy at 2 mm depth). In case of arte- 
rial dissection or incomplete arterial dilatation, the protocol allowed the insertion of a 
stent. All patients receiving a stent were treated with acetylsalicylic acid (ASA) (lOOmg/ 
day) and 75mgiday of clopidogrel for 4 weeks and subsequently with ASA alone. 
Results: So far, 89 patients were randomized to receive brachytherapy, 29 of which 
received a stent. 60 patients were treated with angioplasty without brachytherapy, 40 of 
which received a stent. Four patients from the group treated with brachytherapy and 
stenting developed an acute occlusion, while there were no such cases among the group 
treated with angioplasty and stenting. The occlusions occurred 2 months +/- 10 days 
after revascularization. These patients had continued to receive IOOmg of ASA daily. In 
all four cases the diagnosis was made with Doppler ultrasound and confirmed angiogra- 
phycally. Three patients required a second angioplasty. The fourth patient needed a suc- 
cessful 24 hour-long intravascular thrombolysis with r-TPA. At discharge, these patients 
resumed the previous double antiplatelet therapy. Conclusion: Late acute arterial occlu- 
sions represent a well-know occurrence in coronary disease. The cases reported above 
suggest that similar events can occur in peripheral arteries, as well. 
1257-32 The Effect of Brachytherapy on Restenosis at 6 Months 
After Angioplasty of the Lower Limb Arteries: An 
Intermediate Analysis 
Agostino Faggiotto, Andreas Blatter, Michael Llamas, Jeanne-Marie Segatto, Felix 
Mahler, Kurt Jaeger, Luca Cozzi, Jacques Bernier, Augusto F. Gallino. August0 Gallino, 
Be//inzona, Switzerland 
Background: In the femoro-popliteal arteries restenosis after angioplasty occurs at an 
incidence of approximately 40%. Among the strategies tested for the prevention of rest- 
enosis only a few seem to maintain their potential value, among which the antioxidant 
drug probucol and intravascular brachytherapy. Methods: Aim of this prospective ran- 
domized semi-blinded multicenter trial is to determine the impact of probucol (lgld pre- 
scribed from 1 month before, to 6 months after angioplasty), brachytherapy or both in 
reducing restenosis after femoro-popliteal angioplasty compared to acetylsalycilic acid 
(ASA) alone (100mgJd). This study consists of the following four treatment arms, with 80 
randomised patients each: ASA alone, ASA + brachytherapy, ASA + probucol, ASA + 
brachytherapy + probucol. The prescribed gamma-radiation dose is 14 Gy to a 2mm 
radial distance from a non-centered 6Fr closed endoluminal catheter. Restenosis was 
defined as >50% reduction of luminal diameter by duplex ultrasound performed on day 1, 
and at 3 and 6 months after angioplasty. Results: So far, a total of 180 patients have 
beeen randomized. Drop out rate due to angioplasty failure or failure to place the catheter 
was 9.5%. Todate, neither major side effects nor complication?. have been reported. 
Analysis of the first 75 patients who completed the study (31 with brachytherapy and 44 
without brachytherapy) indicated that the incidence of restenosis was 9.7% in the brachy- 
therapy group and 36.4% in the group without brachytherapy (p=O.O08). No information is 
as yet available on the effect of probucol, as the study on this respect remains blinded. 
Conclusions: This preliminary report on the role of brachytherapy on restenosis sug- 
gests that endoluminal gamma-radiation is a safe and effective measure to control the 
occurrence of restenosis at 6 months following angioplasty. The influence of probucol will 
be known at the end of the study. 
1257-33 Percutaneous Treatment of Traumatic Arterial Injuries With 
the Wallgraft Endoprosthesis 
Marcus H. Howell, Zvonimir Krajcer, Edward Diethrich, Amir Motarjeme, Michael 
Bacharach, Bart Dolmatch, Craig Walker. Texas Heart Institute, Houston, TX 
Purpose: Arterial injuries from penetrating trauma or invasive vascular procedures can 
result in AV fistulas, pseudoaneurysms, or perforations. Standard treatment is usually 
surgical repair or reconstruction of the injured vessel, which is often performed emer- 
gently. This study evaluated the safety and efficacy of the Wallgraft Endoprosthesis for 
the percutaneous treatment of traumatic arterial injuries in vessels 5-l 1 mm in diameter. 
The Wallgraft Endoprosthesis is a self-expanding cobalt super alloy stent covered with 
polyethylene terephthalate graft material. Methods: From October 1, 1997 to April 1, 
2000, 28 patients with 29 traumatic arterial injuries were treated with the Wallgrafl 
Endoprosthesis. Twenty (71%) were males, average age was 62.7, 15 (53%) had angina, 
20 (71%) had hypertension, 7 (25%) had COPD, and 8 (28%) had diabetes. The loca- 
tions of the lesions were iliac 15 (52%) femoral 10 (34%) upper extremity 3 (10%) and 
carotid 1 (4%). Patients were followed at one month, six months and yearly with duplex 
ultrasound or computed tomography. Results: Acute procedural success, defined as 
complete exclusion of the vessel injury or perforation, was 97%. The prosthesis was suc- 
cessfully placed in 100% of patients, there were no device failures. Thirty-day exclusion 
rate was 91%. One-year exclusion rate was 100%. Thirty-day patency rate was 100%. 
The one-year primary and secondary patency rates ware 88% and 100% respectively. 
There were no device or procedure related deaths. Conclusions: Percutaneous treat- 
ment of traumatic peripheral arterial injuries with the Wallgraft Endoprosthesis is safe and 
effective. This device provides a percutaneous option for the treatment of these lesions, 
which are often associated with significant morbidity. Further follow-up is needed to 
determine the long term patency and exclusion rates with this device. 
1257-34 Intravascular Ultrasound Assessment of Abdominal Aortic 
Aneurysm 
Marco T. Castagna, Neil J. Weissman, John R. Laird, Nancy E. McCarthy, Gerard Finet, 
Daniella Claus, Lowell F. Satler, Augusto D. Pichard, Kenneth M. Kent, Gary S. Mintz. 
Washington Hospital Center, Washington, DC 
Abdominal aortic aneurysms (AAA) and the surrounding non-AAA aorta are routinely 
assessed using abdominal ultrasound, computed tomography and aortography. Aortog- 
raphy is limited to an assessment of aortic lumen size. Intravascular ultrasound (IVUS) 
has a higher resolution than either abdominal ultrasound or CT and may provide more 
information about aortic dimensions and associated plaque distribution and morphology. 
We therefore performed pre-intervention IVUS (12.5 MHz, 6F SciMediBSC) in 76 
patients referred to the catheterization laboratory for evaluation of AAA for possible 
endoluminal stenting between September 1997 and April 2000. Slow continuous pullback 
was performed and images at the aortic neck, AAA, distal aorta prior to the bifurcation 
and common iliac were digitized and planimetered to determine lumen, plaque and ves- 
sel (EEM) area and diameter. Results: Maximum lumen diameter, lumen cross sectional 
area (CSA), plaque CSA and EEM CSA for the none-AAA areas are listed below. 
Lumen Diame- Lumen CSA Plaque CSA EEM CSA (cm2) 
ter (cm) (cm2) (CM 
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Acrtic neck 2.2kO.3 32.3h9.4 10.4k3.8 42.&10.8 
Distal Aorta 2.3kO.6 34.9-ti6.3 14.3~7.6 49.lrt22.4 
Common iliac 1.4*0.4 13.7A9.1 6.1*3.1 19.1&.9 
Dstuse, ‘ang~ograpmcally sllenr plaque was common I” me aornc necK (ii4./f/.S”/o 
cross-sectional narrowing [CSN]), distal aorta (29.1+8.1% CSN) and common iliac 
(32.6-tlO.l% CSN). The plaque often had fibrotic (94.2%) and calcific (48.9%) elements. 
When present, calcium was more often superficial (91.3%) and extensive (mean arc of 
calcium 49+28 degrees to 105191 degrees). Dissections were also common (13.3%) in 
the non-AAA areas. None of AAA had renal artery involvement. In the pts in whom we 
could visualize the entire wall of the AAA segment, plaque and thrombus occupied 
23.&22.0% of the vessel area. AAA often had mural thrombus (58.0%). Conclusions: 
As in coronary arteries, the aorta has diffuse, often calcified plaque in the non-aneurys- 
mal areas. IVUS can make precise measurements and be used to assess plaque burden 
and morphology in the aorta which may help advance our understanding and treatment 
of aortic disease. 
1257-35 Efficacy and Safety of Treatment of latrogenic Femoral 
Artery Pseudoaneurysm Percutaneously by Biodegradable 
Collagen 
Karim Hamraoui, Sjef M. P. G. Ernst, Thijs H. W. Plokker, Johannes C. Kelder, Jurriln M. 
ten Berg, Els R. M. Marques, Ma&en-Jan Suttorp, Wybren Jaarsma. St Anfonius 
Hospifai, Nieuwegein, The Netherlands 
Background: Femoral artery pseudoaneurysm (FAP) is an infrequent but important 
complication of the arterial puncture site. If ultrasound-guided compression (UGC) fails, 
vascular surgery is indicated. We have developed a less invasive method to close FAPs 
percutaneously with collagen by inducing clotting within the aneurysm. Methods: Via a 9 
French needle with sheath, a biodegradable adhesive bovine collagen paste is injected 
percutaneously into the FAP, guided by ultrasound or angiography from the contralateral 
site. Results: From January 1993 to August 1999, compression and UGC had failed to 
obliterate 110 FAPs. These patients have been treated by injecting collagen. Mean age of 
the pts was 65.6 * 10.2 yrs with a range of 32 to 85 yrs and 50% were woman. The delay 
between the arterial puncture and the procedure was 11.1 f 12.8 days, with a median of 
8 days. Immediate closure of the FAP was achieved in 1071110 pts (97.3%) without any 
complication or adverse affect of collagen. Only one pt had partial obliteration of the FAP, 
and needed a second successful session of collagen injection. In one pt the collagen 
could not be applied due to unfavorable anatomy of the FAP cavity. In one case too much 
collagen was applied with protrusion and compression of the femoral artery, which 
needed surgical intervention. The overall success rate was 108/l 10 (98%). Among the 
pts with successful procedures, there ware no recurrences. Conclusions: The percuta- 
neous treatment of iatrogenic FAP, using biodegradable collagen paste, is an effective 
and safe strategy, permitting early ambulation and discharge. This method provides a 
therapeutic alternative to the traditional surgical management, 
1257-36 Comparison of Percutaneous Intervention With Surgery in 
the Treatment of Total Occlusion of Abdominal Aorta 
Won-Heum Shim, Seung-Hyuk Choi, Byoung-Kwon Lee, Donghoon Choi, Yangsoo Jang, 
Byung-Chul Chang, Seung-Yun Cho. Yonsei University Seoul, South Korea 
Background: Total occlusion of the infrarenal abdominal aorta is rare in clinical practice. 
Surgical treatment has been recommended as the treatment of choice for these lesions. 
However, there was relatively high surgical mortality and morbidity associated with aorto- 
bifemoral bypass graft The purpose of this study was to retrospectively compare the 
safety and efficacy of percutaneous intervention with surgery for the treatment of total 
occlusion of infrarenal abdominal aorta. Methods: Thirty-three patients (28 male, mean 
age 58 years) with total occlusion of infrarenal abdominal aorta were treated with percu- 
taneous intervention and surgery. Seventeen patients were treated by local infusion of 
low dose urokinase(mean 1.2million U) , and then balloon angioplasty or stent implanta- 
tion was performed according to the results of follow-up angiography. Sixteen patients 
were performed aorta-bifemoral bypass graft or endaterectomy. Twenty-eight patients 
were followed up for 21 months (range 3- 84months). Follow-up data were derived from 
clinical assessments and angiographic results. Results: Of 17 patients who underwent 
local infusion of “rokinase, effective clot lysis and visualization of common iliac artery 
was accomplished in 13(76.5%). In these pate&, except one who had melena after 
urokinase infusion, recanalization and dilatation proceed uneventfully in the other 
patients. So initial technical success rate in effective lysis group was 92.3%. There ware 
no serious complications such as cerebral hemorrhage and death. In surgery group, one 
patient died due to postoperative sepsis. And the other patient necessitated BK amputa- 
tion because of distal embolization. During the follow-up periods, Revascularization was 
performed in 3 patients, respectively, both group. There were two non-cardiac deaths, but 
no amputation during the follow-up. Conclusion: Our experience suggests that percuta- 
neous intervention may be considered an alternative to conventional surgery in the 
patients who had effective clot lysis after local infusion of fibrinolytic agent for infrarenal 
aortic occlusion 
1257-37 Abdominal Aortic Aneurysm Repair With the AneuRx Stent 
Graft in Cardiology Practice 
Marcus H. Howell, Neil Strickman. Kathy Dougherty, Charles Hallman, Zvonimir Krajcer. 
Texas Heart Insfilule, Houston, 7X 
Background: The “se of endovascuiar stent graft prosthesis for treating infra-renal 
abdominal aortic aneurysms (AAA) is gaining acceptance as an alternative to standard 
surgical repair. This study evaluated the safety and clinical effectiveness of the Medtronic 
AneuRx stent graft in patients with infra-renal AAA’s treated in the cardiac catheterization 
lab. Methods and Results: Between November 1998 thr” July 2000, 168 patients (151 
males, mean age 71+8 years) underwent AAA exclusion. Most (86%) were hypertensive, 
67% had a history of smoking, (66%) had multi-vessel coronary disease with 55% of 
those having undergone prior coronary revascularization. Diabetes was present in 15%, 
23% had CHF, 38% had COPD and 89% were classified Grade Ill or higher by the Amer- 
ican Society of Anesthesiologist. Procedural success was 99.4%. One (0.6%) patient had 
elective open repair because the device could not be delivered. There were no procedure 
related deaths or ruptures, 1 patient suffered a myocardial infarction and 11 (6.5%) 
patients required transfusion. Mean length of stay was 2.01 days, 99 patients (59%) were 
discharged within 24 hours. Six month and 1 year follow-up is available in 87 (52%) and 
52 (31%) patients, respectively. There were 6 late deaths, all due to co-morbid condi- 
tions. Coil embolization of Type II collateral endoleaks was required in 7 patients and 3 
patients had extension cuffs placed to repair Type I endoleaks. No patient had enlarge- 
ment of their aneurysm and mean aneurysm diameter was reduced at 6 months and 1 
year from 54+12 mm to 51+12 mm and 46+12 mm, respectively. Conclusion: Endovas- 
cular infra-renal AAA repair can be accomplished in the catheterization lab with low pro- 
cedural morbidity and mortality. Continued follow-up is necessary to determine long-term 
efficacy of endoluminal treatment to prevent rupture and death due to &IA!?. 
ORAL CONTRIBUTIONS 
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870- 1 
4:oo p.m. 
Creatine Kinase-MB Elevation After Percutaneous Coronary 
Intervention is a Predictor of Long-Term Mortality in 
Patients With Renal Dysfunction 
Allen Jeremias, Abdulhay Albirini, Khaled M. Ziada, Derek P Chew, Marco Roffi, Paul 
Schoenhagen, Sorin J. Brener, Stephen G. Ellis, Eric J. Topol. Cleveland Clinic 
Foundation, Cleveland, OH 
Background: The relationship between creatine kinase-MB isoenzyme (CK-MB) eleva- 
tion after percutaneous coronary intervention and late mortality has been well estab- 
lished. However, since CK-MB is predominantly cleared by the kidney, the clinical 
significance of CK-MB elevation after coronary intervention in patients with chronic renal 
insufficiency is uncertain. Methods: A total of 190 patients with chronic renal insuffi- 
ciency (serum creatinine >2.0 mgidl) undergoing percutaneous coronary intervention at 
the Cleveland Clinic between l/1997 and 3/‘2000 ware followed for a mean duration of 
23.4+1-l 1.2 months (range 6-42 months). Of the total group, 25 patients who underwent 
catheterization for an acute myocardial infarction and/or cardiogenic shock were 
excluded. Univariate and multivariate analysis on various baseline characteristics, proce- 
dural data and subsequent medical therapy were performed. Results: CK-MB elevation 
above the upper limit of normal after intervention was detected in 29 patients (17.6%). 
Baseline characteristics were not significantly different between the CK-MB elevation 
group and the normal CK-MB group. Late mortality, however, was significantly increased 
among patients with post-procedural CK-MB elevation (34.5% versus 16.9%, p=O.O32). 
Other variables at a significance level of ~~0.1 in the univariate analysis were New York 
Heart Association (NYHA) class and lipid-lowering therapy after the index procedure. 
Age, cardiovascular risk factors, degree of renal insufficiency and the “se of a glycopro- 
tein Ilb-llla inhibitor ware not associated with outcome. Multivariate analysis revealed 
post-procedural CK-MB elevation and NYHA class as only predictors of mortality 
Multivariate Analysis 
Parameter Odds Ratio Confidence Interval p 
CK-MB Elevation 2.75 1.083-6.992 0.033 
NYHA Class 1.40 1.014-1.935 0.041 
Conclusion: Despite renal dysfunction and with adjustment for all important co-vari- 
ables, CK-MB elevation after percutaneous coronary intervention is associated with a 
significantly increased late mortality. 
870-2 
4:15 p.m. 
Incidence and Prognostic Importance of Worsening Renal 
Function Following Percutaneous Coronary interventional 
Procedures 
Charanjit S. Rihal, Diane Grill, Steven T. Textor, Malcolm R. Bell, Peter B. Berger, Patricia 
J. Best, Verghese Mathew, Henry H. Ting, David Ft. Holmes, Jr.. Mayo Clinic and 
Foundation, Rochester, MN 
Background: Renal insufficiency is an important prognostic indicator following percuta- 
neous coronary intervention or coronary artery bypass graft surgery. The incidence of 
renal insufficiency following percutaneous coronary intervention in the modern era is 
unknown. 
Methods: Retrospective analysis of the Mayo Clinic Coronary Intervention Registry to 
determine incidence, risk factors for, and prognostic implications of renal insufficiency fol- 
lowing coronary intervention (defined as a rise in serum creatinine >0.5 mgldl from 
baseline). Ail patients undergoing percutaneous coronary intervention from January 
1996 through May 2000 were included. No patient subsets were excluded. 
Results: 209 of 5861 patients (3.6%) experienced a rise in creatinine >0.5 mgidl. These 
patients ware older (mean 68.9 v 65.2 years, pcO.0001) and more often had acute myo- 
cardial infarction (25.4% v 16.9%. p=O.OOOS), shock (13.5% v 4.1%, p<O.OOOl), history of 
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Congestive heart failure (39.9% v 14.1%, p<O.OOOl), hypertension (77.3% v 60.0%, 
p<O.OOOi), or diabetes (39.7% v 22.1%, pcO.0001). Stratified by baseline creatinine, the 
risk of worsening renal function was: 
Creatinine mg/dl Risk, All Patients Risk, Diabetic Risk, Nondiabetic 
O-l.1 2.2 % (N2894) 3.3% (N=608) 1.9% (N=2286) 
1.2-l .9 2.7% (N=2685) 4.8% (NSOO) 2.1% (N=2085) 
2.0-2.9 21.8% (N=l70) 20.6% (N=63) 22.4% (N=107) 
13.0 32.1% (N=ll2) 36.8% (N=57) 27.3% (N=55) 
In multivariate analysis, creatinine rise >0.5 was associated with baseline creatinine, 
acute myocardial infarction, or shock but not with contrast volume. 21.5% of patients with 
creatinine rise>0.5 died in-hospital, versus only 1.1% of the remainder (p<O.OOOl). After 
adjustment, creatinine rise>0.5 was strongly associated with death (odds ratio 20, 
p=O.O14). Among hospital survivors with a creatinine rise, 1- and 5.year estimated mor- 
tality was 14.4% and 49.6%, much greater than 4.3% and 15.3% mortality without creati- 
nine elevation (p<O.OOOl). 
Conclusions: Incidence of creatinine rise >0.5 mgldl is significant following percutane- 
ous coronary intervention in patients with baseline creatinine>2.0 and is highly correlated 
with death, both in-hospital and long-term. 
870-3 
4:30 p.m. 
Even Mild Renal Insufficiency is Associated With Increased 
Mortality After Percutaneous Coronary Interventions 
Patricia J. M. Best, Ryan Lennon, Henry H. Ting, Malcolm R. Bell, Charanjit S. Rihal, 
David R. Holmes, Jr., Peter 8. Berger. n/lay0 Clinic, Rochester, MN 
Background: End-stage renal disease (ESRD) is associated with a high mortality from 
coronary artery disease. Percutaneous coronary interventions (PCI) in patients (pts) with 
ESRD are associated with an increased complication rate and worse long-term outcome. 
The outcome of PCI in pts with less severe renal insufficiency is not known. Methods: All 
pts undergoing successful PCI at the Mayo Clinic from 1194-8199 [w&031] were categor- 
ised by estimated creatinine clearance (z-70 ml/min [n=2,558], 50-69 ml/min [n=1,458], 
30-49 ml/min [n=828], ~30 ml/min [n=l41], or requiring dialysis [n=46]) “sing the Cock- 
raft-Gault formula. Kaplan-Meier curves of all cause mortality in the years following dis- 
charge were determined for each group. Risk ratios of death and cardiac death were 
determined for creatinine clearance analyzed as a continuous variable after adjustment 
for variables significantly associated with mortality on “nivariate analysis. Results: Renal 
insufficiency, even when mild, was associated with a significantly increased mortality 
Using creatinine clearance as a continuous variable, the increased risk associated with 
renal insufficiency was best described by a quadratic equation and the risk ratios (RR), 
with 95% confidence intervals for mortality were determined through the range of 
observed values. Compared to pts with a creatinine clearance of 90 ml/min, the RR for 
pts with a creatinine clearance of 70 ml/min was 1.5 (1.3, 1.6); for 50 mlimin, the RR was 
2.3 (1.8,2.9), and for a creatinine clearance of 30 mlimin, the RR was 3.7 (2.5, 5.5). Dial- 
ysis was associated with a RR of 8.9 (5.3, 15.0), which was higher than any other clinical 
or angiographic variable, including diabetes. The results were similar when just cardiac 
mortality was analyzed. Conclusions: Renal insufficiency is independently associated 
with a marked increase in mortality in a dose-dependent fashion in pts following success- 
ful PCI. 
870-4 
4:45 p.m. 
Troponin I Predicts Adverse Outcome After Percutaneous 
Coronary Intervention in Patients With Chronic Renal 
Failure 
Luis Gruberg, Shmuel Fuchs, Roxana Mehran, Lowell F. Satler, Augusta D. Pichard, 
Kenneth M. Kent, Rakefet Einav-Gruberg, Natalie Gevorkian, Hongsheng W”, Ron 
Waksman. Washington Hospital Center, Washington, DC 
Background: An elevated serum level of cardiac troponin I (Tn I) after percutaneous cor- 
onary intervention (PCl)is a marker with high specificity for myocardial injury that corre- 
lates with late events. The purpose of this study was to detect the frequency of Tn I 
elevation after percutaneous coronary intervention and its influence in the long-term out- 
come of patients with chronic renal failure (CRF). 
Methods: We analyzed the long-term outcome of 116 consecutive patients with CRF 
(serum creatinine >I .8 mg/dL, not on dialysis) who had normal Tn I baseline levels and 
underwent elective PCI. Tn I levels were measured at baseline, at 6 and 18-24 hours 
after intervention. 
Results: Of 116 patients with CRF and normal baseline Tn I, elevated Tn I levels (20.15 
ngiml) were found in 50 patients (43%, Group 1) and normal values in 66 patients (57%, 
Group 2). Baseline clinical characteristics including left ventricular function and serum 
creatinine levels were similar between the two groups, except for age (higher in Group 1, 
p=O.O04). Platelet glycoprotein Ilb/llla inhibitor “se was similar between the two groups 
(2.2% and 2.3%, respectively). Procedural and clinical success rates were similar 
between the two groups. At 12-month follow-up, target lesion and vessel revasculariza- 
tion and Ml rates were comparable between the two groups. However, mortality was sig 
nificantly higher in patients with elevated serum levels of Tn I (28.0% vs. 9.9%, p=O.O02). 
Cox multivariate regression analysis detected CK-MBx3 normal values (OR:2.86, 
p=O.O32) and Tn I elevation (OR32.58, p=O.O42) as the only independent correlates for 
death. 
Conclusions: 1) Patients with CRF have a high frequency of Tn I elevation after PCI. 2) 
Elevation of Tn I levels after PCI is an important and powerful predictor of long-term prog- 
nosis in patients with CRY? 
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1293-9 High-Dose Eptifibatide (Integrilin8) in Coronary Stent 
Implantation: 1 Year Results of the ESPRIT Trial 
James E. Tcheng, John Conor O’Shea, Eric A. Cohen, Christopher E. Buller, A. Michael 
Lincoff, Diane Joseph, Paul S. T&stein, Cynthia M. Pacchiana, Gail Hafley, Todd J. 
Lorenz, Michael M. Kitt, Robert M. Califf. Duke Clinical Research Institute, Durham, NC 
Background. Platelet glycoprotein (GP) Ilb/llla receptor blockade improves clinical out- 
comes following percutaneous coronary intervention (PCI). Pharmacodynamic studies 
have identified a regimen of eptifibatide that systematically achieves >90% inhibition of 
platelet aggregation. The ESPRIT trial was conducted to determine the efficacy and 
safety of this novel, higher dose regimen of eptifibatide as an adjunct to non-acute coro- 
nary stenting. Methods. ESPRIT was intended to enroll 2400 patients at 100 sites in the 
US and Canada. Randomization was to double-blind eptifibatide (two 180 Kg/kg boluses 
separated by 10 minutes, with a 2.0 pglkg-min infusion for 18-24 hours) or placebo, with 
study drug started immediately before PCI. All patients received aspirin, heparin, and a 
thienopyridine. The primary endpoint was the composite of death, myocardial infarction 
(Ml), urgent target vessel revascularization (TVR), or bailout GP Ilb/llla inhibitor therapy 
for thrombosis within 48 hours, with the key secondary endpoint being death, MI, or 
urgent TVR at 30 days. Follow-up is currently ongoing to 1 year. Results. ESPRIT was 
terminated early (n=2064) for efficacy on February 4, 2000. The incidence of the primary 
endpoint was reduced from 10.6% to 6.6% (p=O.O015) with eptifibatide. The key 30 day 
endpoint was reduced from 10.5% to 6.8% (p=O.O034). There was a consistent treatment 
effect across all components of the endpoint; 38% relative reduction in the incidence of 
death or Ml (p=O.O016), 36% reduction in Ml (p=O.O031), and insignificant 35% and 33% 
reductions in urgent TVR and mortality at 30 days were seen. These outcome improve- 
ments were also consistent across patient subgroups. Conclusion. Analysis of 48 hour 
and 30 day outcomes documents the efficacy of eptifibatide in coronary stenting. The 1 
year data will provide additional insight about the utility of eptifibatide treatment in this 
indication. 
1293-10 Robust Benefit of Platelet GP Ilb-llla Inhibition With 
Eptifibatide in Patients Undergoing Stent PCI With Hot or 
Cold Presentation 
Bleakley Chandler, John Conor O’Shea, Sally Greenberg, James Slater, James M. 
Kirshenbaum, Joseph B. Muhlestein, Cindy M. Pacchiana, Todd J. Lorenz, Kristin 
Raffetto, Michael M. Kitt, James E. Tcheng. University Hospital, Augusta, GA, Duke 
Clinical Research Institute, Durham, NC 
Background: The beneficial effects of platelet glycoprotein Ilb-llla inhibition in patients 
with acute coronary syndromes who undergo stent implantation are particularly pro- 
nounced in the setting of unstable angina (within 48 hours) or acute ST elevation Ml 
(within 7 days) (“hot” patients). The benefits of GP Ilb-llla inhibition in “cold” patients 
(those patients with unstable angina or non ST segment elevation MI between 48 hours 
to 6 months, those with chronic stable angina or those with a positive functional study) 
are not as well known. We evaluated the treatment effect of eptifibatide in both “hot” and 
“cold” patients in the ESPRIT trial. Methods: The ESPRIT trial randomized 2,064 
patients undergoing stent implantation to placebo or the platelet glycoprotein Ilb-llla 
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inhibitor, eptifibatide. Patients were grouped and analyzed according to clinical presenta- 
tion as either “hot’ or “cold” as defined above. Results: 11.8% of hot patients and 2.8% 
of cold patients had thrombus present in the index lesion at the start of the intervention. A 
highly significant reduction in the endpoint of death, MI, urgent target vessel revascular- 
ization (TVR), or need for thrombotic bail-out therapy at 48.hours was observed in both 
“hot” and “cold” groups of patients. The beneficial effect of eptifibatide was maintained at 
30 days, with cold patients showing a 30.9% reduction and hot patients showing a 48.4% 
reduction in events. 
46 hour Death, MI, Urgent TVR and Thrombotic Bailout by Clinical Presentation 
Placebo Eptifibatide RRR P Value 
COld Patients 77 (9.2%) 53 (6.2%) 33% 0.019 
(n=1692) 
Hot Patients 31 (16.4%) 16 (8.7%) 47% 0.026 
(n=372) 
Conclusions: Treatment with eptifibatide reduced the occurrence of ischemic events in 
patients undergoing elective stent implantation regardless of clinical presentation, or 
presence of thrombus in the index lesion. This benefit was mantained at 30 days. 
1293-11 Stents and Glycoprotein Ilb/llla Inhibitors Do Not Improve 
30-Day Outcome in Bypass Graft Percutaneous 
Interventions: A Retrospective Registry-Based Analysis 
Marco Roffi, Albert Chan, Derek P. Chew, Marc A. Robbins, Debabrata Mukherjee, 
Deepak L. Bhatt, Abdulhay Albirini, Leslie Gho, Ramtin Agah, Eric J. Topol, Stephen G. 
Ellis. C/eve/and C/in/c Foundafion, C/eve/and 
Background: Percutaneous coronary interventions (PCI) of saphenous vein grafts 
(SVG) are associated with increased incidence of adverse outcome. Despite widely use 
of stents and glycoprotein (GP) llbillla inhibitors in this setting, limited data exist to sup- 
port their use. Methods: At our institution, the first 1000 patients/year undergoing PGI 
are followed at 30 days in a registry. ‘We performed a retrospective analysis of the 30.day 
outcome following SVG PCI in 278 patients consecutively included in the resistry. Myo- 
cardial infarction (Ml) was defined as CKMB >3x normal. Results: The baseline charac- 
teristics of the patients population were as followed: mean age 67r9.4, 80% male, mean 
ejection fraction 46*13, 7 patients (2.5%) presented with acute Ml. 80% has a hystory of 
MI. Stents were deployed in 76% of ihe patients, GP Ilb/llla inhibitors were administered 
in 64% of cases. The oucomes are demonstrated in the table. Neither stents nor GP llbi 
llla inhibitors improved outcome at 30 days in patients undergoing PCI of SVG lesions. In 
the stented group there was even a trend, albeit not significant, towards increased mci- 
dence of Ml (0=0.09). - 
GP lib/llla n=l77 NO GP ilb/llla n=lOi p 
De& 3 (1.7%) 2 (2.0%) 0.86 
MI 22 (12.5%) 13 (12.9%) 0.91 
Death/Ml 25 (14.1%) 13 (12.9%) 0.77 
Death/MI/Revasc 35 (19.8%) 20 (19.8%) 1.0 
Stent n=206 No Stent n=72 P 
Death 3 (1.5%) 2 (2.8%) 0.47 
Ml 30 (14.6%) 5 (6.9%) 0.09 
Death/Ml 32 (15.5%) 6 (8.3%) 0.13 
DeathiMliRsvasc 42 (20.4%) 13 (18.1%) 0.67 
Conclusions: In our retrospective analysis, neither stents nor GP llbillla inhibitors did 
improve 30.days outcome following PCI of bypass grafts. 
1293-40 Incidence of Thrombocytopenia With the Use of 
Glycoprotein Ilb/llla Inhibitors in Real World 
Arshad Ali, Mustafa Hashem, Lynette Moser, Arshad Rehan, M.D., Theodore Schreiber, 
M.D., N Vikraman. M.D.. Thomas LaLonde, M.D. St Joh Hospitaland Medical Center, 
Detroii, MI 
Background: Safety of platelet glycoprotein Ilb/llla inhibitors has been well-documented 
in large randomized trials. These trials are characterized by carefully designed inclusion 
and exclusion criteria. so they may not always represent real world scenario in clinical 
practice. Thrombocytopenia with the “se of GP Ilb/llla inhibitors was rare in these ran- 
domized trials. The purpose of our study was to evaluate the incidence of thrombocy- 
topenia with the use of GP Ilb/llla inhibitors in every day clinical practice. 
Methods: Clmical records of 1028(65% males, mean age 63.6 * 12.6) patients who 
received GP Ilb/lila inhibitors (abaximab, integrillin, and tirofiban) for percutaneous coro- 
nary intervention were reviewed. Thrombocytopenia (TP) was defined as > 25 % 
decrease in platelet count and severe thrombocytopenia as platelet count of <50,000. 
Results: Thrombocytopenia occurred in 223(21.7 %) and severe thrombocytopenia 
occurred in 45 (4.4%) oateints. lncldence of maior thrombocvtooenia with different GP 
11 b/l 1 la inhibitors is shown in tabulated form: 
, 
Major TP 
Abciximab n 
11 (2.8%) 
Eptifibatide 
23 (5.8%) 
Tirofiban 
10 (4,7%) 
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1293-41 Effect of AJ-vW2, Humanized Monoclonal Antibody Against 
Al Domain of von Willebrand Factor, on Stent Thrombosis 
Shinya Goto, Hiroshi Yamamoto, Shunnosuke Handa. Tokai University School of 
Medicine, /wham, Japan, Ajinomoto Pharmaceutical Co., Ltd., Kawasaki, Japan 
Recent investigations revealed the crucial role of von Willebrand factor (vWF) on platelet 
thrombosis occurring under high shear rates. We have tested the effects of recently 
developed humanized monaclonal antibody against Al domain of vWF (AJ-vW2), block- 
ing vWF interaction with platelet glycoprotein (GP) lb, on stent thrombosis. Whole blood 
anticoagulted by specific antithrombin agent of Argatroban, contaimng platelets rendered 
fluorescinated by mepacrine, were perfused on the immobilized type I collagen under 
constant flow condition (wall shear rate: 1,500 l/s) in a parallel plate flow chamber. Pal- 
maz-Schatz and GFX stents were placed on the collagen surface before starting blood 
perfusion. Platelet thrombi formed around the stents in the presence of various concen- 
tration of AJ-vW2 was visualized and recorded by epi-fluorescent video-microscopy. As 
demonstrated in the figure below, AJ-vW2 inhibited platelet thrombi formed upstream of 
stents. Platelet accumulations in the space between stents and collagen and those 
formed on collagen down stream of stents, however, were not inhibited by AJ-vW2, even 
at higher dose. Our results Indicate that AJ-vW2, humanized monocional antibody block- 
ing vWF interaction with GP lb, is an effective antiplatelet agent for preventing platelet 
thrombi formed at sites exposed to high shear rates, but not an effective agents on plate- 
let accumulation at sites where blood flow was stagnate. Newly developed antiplatelet 
agents of AJ-vW2 may be selective antiplatelet agents inhibiting platelet thrombus forma- 
tion only at sites exposed to high shear rates such as thrombosis occurring in atheroscle- 
rotic stenotic coronary arteries without affecting normal hemostasis 
1293-42 Antithrombin, Antiplatelet Therapy or Both During PCI: A 
Preliminary Randomized Trial 
Neal S. Kleiman, A. Michael Lincoff, Robert A. Harrington, Sheily Sapp, Cathy Wolski, 
Eric J. Topol. Baylor College of Medicine, Houston, TX 
The limitations of heparin (Hep) as an adjunct during percutaneous coronary intervention 
(PCI) are well recognized, and may be obviated by newer anticoagulant molecules. We 
randomized 208 pts undergoing elective PCI to receive either Hep (70 U/kg bolus) with 
abciximab (Ab) (0.25 mgikg b&s/0.125 pg/kg/min infusion) (Group I) or the 20 amino 
acid direct acting thrombin inhibttor bivalirudin (Biv). The first 85 Biv pts (Group II) 
received a bolus of 0.5 mg/kg. The next 59 Biv pts (Group Ill) received a bolus of 0.75 
mgikg. Biv pts also received an infusion of 1.75 mglkglh for the duration of the procedure 
and use of provisional Ab at the discretion of the PCI operator based on protocol guid- 
ance. All patients received aspirin; patients were also treated with a thienopyridine after 
stent placement. Stents were deployed in 1841208 (88%) pts. Abciximab was used m 32 
(24%) pts randomized to Biv. 
Median ACT (Qi, Q3) after the bolus were Group I: 291 sac (262,334), Group II: 302 set 
(273, 335), Group III: 324 set (294, 342) and Group 111111: 311 set (285, 339). 
Clinical outcomes at 7 days were (Table): 
Clinical Outcome Group I Hep/ Group II Biv Group Ill BIV Group ll/lll Biv 
Abn=64 (b&s 0.5 mgi (bolus 0.75 mgi (any) n = 144 
Death 
kg) n = 85 kg) n = 59 
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Death/Ml 1 (1.6%) 3 (3.5%) 0 (0.0%) 3 (2.1%) 
Revascularization 4 (6.3%) 1 (1.2%) 0 (0.0%) 1 (0.7%) 
Death/MI/Revasc 5 (7.8%) 4 (4.7%) 0 (0.0%) 4 (2.8%) 
Major hemorrhage 4 (6.3%) 2 (2.4%) 0 (0.0%) 2 (1.4%) 
Any clinical event’ 9 (14.1%) 5 (519%) 0 (0.0%) 5 (3.5%) 
*P=O.O13 for Hep/Ab “s Groups II + Ill 
These data demonstrate that Biv provides a stable and predictable anticoagulant founda- 
tion during PCI with aspirin, and provisional abciximab. We conclude that BIV merits fur- 
ther study as a foundation anticoagulant in larger randomized trials 
incidence of bleeding was much higher in patients with severe TP (42.2% vs. 14.65% 
pcO.001). The mean aPTl was higher in patients with severe TP (61.7+28.3 versus 
51.5+2&l p=O6). Baseline creatinine was significantly higher in severe TP group (l.O* 
0.6 “s 2.5 k .6. P <O.OOOl) 
Conclusion: Severe TP with the “se of GP Ilb/!lia inhibitors may be more common in 
general population than seen in clinical trials. Judicious use of periprocedural heparin 
and careful patient selection may further reduce the incidence of severe thrombocytope- 
nia. 
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1294-13 P/US Guided PCI 
Anne L. Gaster, Per Thayssen, Knud E. Pedersen, Torben H. Haghfelt, Paul F. Hailund- 
Car&n, Lars Korsholm, Allan H. 0. Johansen. Dept. of Cardiology Odense University 
Hospital, Odense, Denmark 
Aim: The aim of this study was to test the concept of determining whether Intravascular 
ultrasound (IVUS) guided percutaneous coronary intervention (PCI) leads to a better 
result than,PCI based on coronary angiography (GAG) alone. The effect of either form of 
guidance was assessed by CAG, IC-Doppler flow measurements (IC-Doppler) and clini- 
cal evaluation at 6 month follow-up. Methods and results: 121 patients were ran- 
domised to PCI guided by IVUS and GAG or CAG alone. lntra coronary flow 
measurements were performed immediately prior to PCI and at completion of the proce- 
dure. A 6 months repeat angiography, including IVUS and coronary flow measurements 
was performed. Significantly fewer patients in the IVUS guided group experienced a 
relapse of the study lesion defined as an angiographic stenosis of SO%, or more, com- 
bined with a reduced coronary flow reserve (less than 2.5) and the presence of angina. 
(5 patients (11%) vs. 10 patients (20%) ~~0.05 in the angiographically guided group). 
Conclusion: The concept of testing the impact of IVUS guided PCI vs. CAG guided PCI 
in the choseri way was found applicable. On its own, in demonstrating fewer patients in 
the IVUS guided group reaching endpoints of angiographic restenosis, flow parameter 
reduction and angina pectoris, this study justifies a more widespread use of IVUS guided 
PCI.’ 
Recurrence of flow limiting stenosis and angina pectoris. 
Endpoint GAG IVUS significance 
guided guided 
group group 
Angiographic restenosis, N(%) 13(25) 8(16) NS 
Angiographic restenosis, CFFlc2.5 and angina, lO(20) 5(11) PcO.05 
N(%) 
Angiographic restenosis, FFR by flow0.75 and 7(20) 2(5) PiO.05 
angina, N(%) 
Taraet vessel revascularisation, N(%) 18f33) lO(19) PzO.07 
1294-14 New Stent Delivery Systems Do Not Provide Optimal Stent 
Expansion 
Yuzuru Takano, James R. Higgins, Jonathan M. Tobis, Erick Ascencio, Larry Yeatman, 
Kristin Kopelson, Jesse Currier. Urwersity of California, Los Angeles, Los Angeles, CA 
Background: Initial observations with intravascular ultrasound (IVUS) showed that first 
generation stents were not adequately expanded even with their post delivery balloon. It 
has been assumed that the newest generation of stent delivery systems have incorpo- 
rated this information and will provide a stented lumen cross sectional area (CSA) equal 
to the manufacture’s stated size. Methods: To test this assumption, 41 Guidant Tristar or 
AVEiMedtronic 5670 stents were deployed at 14 to 16 atm with their delivery balloon sys- 
tem. The minimum lumen CSA and diameter were measured by IVUS imaging (0.5 mm/ 
set mechanical pullback), and were compared to the manufacture’s stated expected 
stent area and diameter at the maximum pressure used. Results: 
Stent No. 41 
Average Stent Size 3.1kO.4 
Average Expected SD(mm) 3.5+0.4 
IVUS MLD(mm) 2.4+0.5 
% of Expected SD Achieved 70+8% 
Average Expected SA(mm sq) 9.5k2.4 
IVUS MLA(mm sq) 5.9k2.0 
% of Expected SA Achieved 61+9% 
(mean r SD) SD&tent Diameter, MLD=Minimum Lumen Diameter, SA=Stent Area, 
MLA=Minimum Lumen Area Conclusion: For both types of stent, despite moderately 
high pressure inflation (average 15.6+0.8 atm), the mean minimum stent lumen CSA was 
only 61% of expected stent area. To optimize stent deployment, these IVUS observations 
should be considered during coronary artery stenting, especially if using lower pressures 
during deployment. 
1294-15 Role of Routine IVUS Guidance for Stent Implantation 
Among Experienced IVUS Operators 
Javier Betas, Jaime Elizaga, Alicia Barrio, Eulogio Garcia, Javier Soriano, Manuel 
Abeytua, Javier Moreno, Leopoldo Perez Isla. Hosp!tal Gregorio Maraiion, Madrid, Spain 
It’s been suggested that the negative results of the OPTICUS trial maybe due to the large 
IVUS operator experience that might have yielded a more aggressive interpretation of the 
angiograms even in the non IVUS group minimizing the benefit of the IVUS exam. To 
assess the effects of routine IVUS use for stent deployment among experienced IVUS 
operators we prospectively studied two groups of stents: IVUS-B-Gr in whom the IVUS 
exam was perform blinded to the operator, and IVUS-G-Gr in whom the procedure was 
guided by IVUS. Eighty stents were prospectively studied, half in each group. In the 
IVUS-G-Gr balloon sizing was performed according to preintervention IVUS vessel size. 
Baseline QCA variables were not different between both groups. However, by IVUS, “es- 
sels in the IVUS-B-Gr were larger (baseline vessel CSA 15.624.1 vs. 13.1+3.6 mm2, 
~~0.05: average proximal and distal Ref lumen CSA 9.5+3.1 vs. 8.2e2.4 mm2, p=O.O5). 
“lxO.05 QCA B/A IVUS Bi Atm QCA-MLD IVUS-Stent IVUS-% 
ratio 
IVUS-B-Gr l.l&O.l 
IVUS- G- 1.2rO.l 
Gt 
vessel ratio Post Stent CSA (mm2 Expansion 
0.81*0.1 14.5*1.2 2.9kO.4 6.8+1.6 75.6+17 
0.89&l’ 14.lA3.3 zsi-0.4 7.1t2.2 86.4+14’ 
In the IVUS-B-Gr more stents ware severely (~70%) underexpanded (40% vs. 7.7%, 
p<O.O5), and incompletely apposed (20 vs. 3% p<O.O5). There ware no differences in the 
number of balloons used 1.2iO.5 vs. 1.320.5 or fluoro time 33+18 vs. 26rl2 min (p=NS). 
At f-up %DS was 2&14 vs. 30+13, and restenosis was very low 2/33 in the IVUS-B-Gr 
vs. 4/34 in the IVUS-G-Gr. Conclusions: IVUS vessel size should be controlled as a 
potential confounding variable evan in weli matched angiographic series. Even among 
experienced IVUS operators, accustomed to balloon overstzing, routine IVUS guidance 
allows for better stent expansion, particularly decreasing those severely underexpanded. 
However, absolute luminal differences-are small compared to angiographic guiding alone 
suggesting that clinically significant differences may only be observed in selected popula- 
tions. Further increasing balloon size rather than utilizing higher pressures appears to 
confer most of the benefit of the IVUS examination. 
1294-16 Predictors of Side Branch Occlusion Immediately After 
Coronary Stenting, An Intravascular Ultrasound Study 
So-Yew Choi, Seung-Jea Tahk, Han-Soo Kim, Zhe-Xun Lian, Myeong-Ho Yoon. Sang 
Yang Yoo, Sung-Gyun Ahn, Hyuk-Jae Chang, Gyo-Seung Hwang, Joon-Han Shin, 
Byung-il W. Choi. Ajou Universi% Suwon, South Korea 
Previous studies have indicated that side branch occlusion(SB0) remains a significant 
problem in coronary bifurcation lesion during percutaneous intervention. Methods: To 
evaluate the predictors of SBO by intravascular ultrasound(lVUS), 37 patients(31 males, 
mean age 56~11 years) were studied at left anterior descending artery&AD)-diagonal 
branch(DB) bifurcation lesions before coronary intervention for measurement of total 
plaque area( PA of branch-side semicircle, percent area stenosis(%AS) of LAD, pres- 
ence of bull’s eye in DB, diameter of LAD and DB, and LAD-DB angle. SBO was defined 
as persistant reduction of TIMI flow to ~1 at the end of the procedure. Results: Immedi- 
ately after stenting, SBO occurred in 6/37(16.2%). PA of branch-side semicircle, diameter 
of DB, ratio of DB to LAD diameter, and ostial diameter of DB significantly affected SBO. 
Total PA, %AS of LAD and presence of bull’s eye in DB were not related to SBO. Multi- 
variate analysis identified that PA of branch-side semicircle was the only predictor of 
SBO(odds ratio 3.3, 95% confidence interval 1.3 to 8.6, p&014). 
Total PA 
Non-SBO group SBO group 
(n=31) (n=6) 
8.03~3.07 8.93+3.02 
p value 
0.514 
%AS of LAD 59.87k16.53 58.58r6.71 0.854 
PA of branch-side semicircle 2.63&l .12 4.68t1.76 0.001 
DB diameter 2.47kO.43 2.04~0.47 0.033 
DBiLAD diameter ratio 1.641-0.32 2.15kO.46 0.002 
DB ostial diameter 2.59*0.45 2.12kO.47 0.027 
Conclusion: It appears that plaque location and distribution of LAD lesion is major deter- 
minant of SBO. These findings support the theory that plaque shift”snow plow effect”) 
may be the mechanism of SOB following stenting. 
1294-17 Mechanism of Lumen Enlargement During Cutting Balloon 
Angioplasty For In-Stent Restenosis: An Intravascular 
Ultrasound Study 
Javed M. Ahmed, Gary S. Mintz, Marco Castagna, Neil J. Weissman, Lowell F. Satler, 
Kenneth M. Kent, August0 D. Pichard. Washington Hospital Cenfer, Washington, DC 
Background: The cutting balloon (CB) is a novel coronary dilation catheter with 3 or 4 
microtomes mounted on the surface of a balloon. It has been increasingly used to treat 
in-stent restenosis (ISR); however, the mechanism of lumen enlargement during CB 
angioplasty for ISR is unknown. Methods: Pre- and post-CB intravascular ultrasound 
(IVUS, automated pullback @ 0.5 mm&c) was used to study 10 pts with native artery 
ISR. External elastic membrane (EEM), stent, lumen , IH (stent-lumen) and 
plaque&media (P&M) cross-sectional areas (CSA) were measured every 1 mm within the 
stent and in 5 mm long proximal and distal reference segments. Results: IVUS analysis 
(Table) showed that the increase in lumen CSA was due to IH extrusion through the stent 
struts (decrease in IH CSA with an increase in EEM CSA and peri-stent P&m csa): there 
was little or not additonal stent expansion. In, addition, in both the proximal and distal ref- 
erence segments, there was a trend towards a decrease in lumen CSA and an increase 
in P&M GSA suggesting that some of the neointima is redistributed into these reference 
segments. Post-CB lumen CSA was significantly smaller than pre-CB stent CSA (a surro- 
gate for the final lumen CSA of the original stent, p=O.O03). Conclusions: Unlike conven- 
tional balloon angioplasty treatment of ISR, lumen enlargement after CB was almost 
entirdly the result of IH extrusion through stent struts and, in some patients, axial redistri- 
bution of IH into adjacent reference segments. However, similar to conventional balloon 
angioplasty , the lumen of the original stent was not recovered. 
Pre-CB Post-CB P 
Dist reference 
Mean EEM CSA (mm2) 
Mean lumen GSA (mm2) 
11.1*4.9 11.3-+5.0 0.31 
5.9*2 7 5.3tl.9 0.14 
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Mean P&M GSA (mm2) 
ISR lesion 
Mean EEM CSA (mm2) 
Mean stent CSA (mm2) 
Mean P&M CSA (mm2) 
Mean lumen CSA (mm2) 
Mean IH CSA (mm2) 
Pnx reference 
Mean EEM CSA (mm2) 
Mean lumen GSA (mm2) 
Mean P&M CSA (mm2) 
5.2&7 6.0t3.3 0.10 
13.9t4.3 15.1+4.5 0.0006 
7.81-3.0 8.lk2.9 0.15 
6.1+2.3 7.Ok2.4 0.001 
2.8c0.9 5.8?1.6 <0.0001 
4.9i2.4 2321.4 40001 
14.2*5.5 14.525.2 0.23 
6.4t2.6 5.7il.4 0.20 
7.8t4.1 8.7+4.5 0.04 
1294-18 Safety and Feasibility of the IVUS-Balloon Megasonics 
Catheter: A Multicenter Investigation 
Alexandre Abizaid, Andrea S. Abizaid, lbrarm M. Pinto, Marco A. Costa, Rodolfo Starco, 
Fausto Fen&?, Luiz A. P Mattes, Marinella Centernero, Luiz F. L. Tanajura, Aurea Chaves, 
Ana 6. Seixas, Hugo Londero, Amanda G. M. R. Sousa, J. Eduardo M. R. Sousa. 
institute Dante Pazzansse of Cardiology Sao &u/o, Brazil 
Background: The incorporation of the IVUS transducer on a balloon-catheter allow fast 
assessment (by IVUS) of the treated lesion with a single catheter, which may ultrmately 
reduce costs and duration of the procedure. To test the safety and feasibility of the use of 
a single balloon-IVUS combo catheter (Megasonics) to guide stent implantation. Meth- 
ods: The Megasonics catheter combines a 20 mm long semi-compliant balloon and an 
intravascular ultrasound transducer. The device (balloon diameter) was sized according 
to quantitative coronary angiography (QCA) in order to achieve an artery/balloon ratio of 
1.2. After IVUS investigation, a single 15 mm long stent (Crown) was manually crimped 
on the same Megasonrcs balloon and deployed at 8 atmospheres. By protocol, all stents 
were post dilated with 12 and 16 atm using the same catheter. IVUS and QCA was per- 
formed after each inflation. Results: Forty patients (pts) with single native coronary artery 
disease have been enrolled so far. Mean age was 59 + 11 years, 12% of the pts had dia- 
betes, 44% dislipidemia and 58% unstable angina. Lesion type A/B1 was present in 65% 
of the cases. No in-hospital death, myocardial infarction or emergent CABG occurred. All 
procedures were successfully (resrdual DS < 10% by QCA) performed with the use of a 
single Megasonics IVUS-Balloon catheter. There was a significant progressive increase 
in minimal lumen area after each balloon inflation: 
Pre 8 atm 12atm 16 am P Value 
IVUS-MLA 2.4 t 1.1 4.9 L 2.2 5.9 i- 2.3 7.2 t 2.3 0.001 
MLA = minimal lumen area (mm’) Conclusion: IVUS-guided stenting using a single 
Megasonics catheter is safe and feasible. In this series, IVUS interrogation allowed the 
optimization of stent deployment without the need of extra devices (balloon and/or IVUS). 
This strategy may further reduce cost, and seems promrsing for daily practice. A random- 
ized mu!ticenter study is planned to test the efficacy of the premounted stent on the 
Megasonics catheter. 
1294-19 influence of Coronary Atherosclerotic Remodeling and 
Plaque Characteristics on Mechanisms of Lumen 
Enlargement During Stent Implantation 
Gerard Fin@, Neil J. Weissman, Marco T. Castagna, Kenneth M. Kent, Lowell F. Satler, 
John Ft. Laird, Augusto 0. Pichard. Washington Hospital Center, Washington, DC 
Objective: The purpose of this study is to determine wheiher arterial remodeling and 
plaque characteristics affect the extent and mechanism of lumen enlargement with stent 
placement. Methods : Pre-interventional volumetric IVUS was performed in 60 de nova. 
non-calcified native coronary lesions treated with a 13 mm Multilink Duet or Tristar stent. 
Lumen (L), vessel (EEM) and plaque (P+M) were measured throughout the lesion and 5 
mm reference segments (n=450 cross-sections per lesion). Remodeling (R) was deter- 
mined by comparing the mean EEM area at the lesion with mean EEM at the proximal 
and distal references: positive R (+R) was defined as a relative ratio >= 100% and nega- 
tive R (-R) is < 100%. Plaque eccentricity (ECC) was identified when the thinnest plaque 
diameter to the thickest plaque diameter ratio was < 0.5. Plaque composition was charac- 
terized as soft or hard. Post-stent IVUS performed to assess the change in lumen, ves- 
sel, and plaque volumes (L, EEM, P+M val). Results : Mean diameter stent used was 
3.3~0.4 mm, maximun balloon pressure was 13.8t2.7 atm, and stenVs.rtery ratio was 
1.24~28. These procedural variables were no different in the +R and -R groups, the 
ECC and No ECC groups nor the soft versus hard plaque groups. The changes in P+M, 
i and EEM volume were similar in soft and hard plaques but differences were noted for R 
and ECC (See table). 4 vol (mm3, mean&D) are the difference between pre- and post- 
intervention values. 
+R -R ECC No ECC 
k60 21 (35%) 39 (65%) 41 (68%) 19 (22%) 
A P+M vol -22.8t14.8- -16112.5 -19.4114.5 -i&18.5 
4 EEM vof 4O.lk32.4 39.5t31.6 50.7t22.3*’ 34.61t18.6 
A L VOI 62.91-29.1* 55.6t24.6 70.1?26.6** 52.6t22.6 
* ~~0.05 vs R and -R ; “‘~~0.05 vs ECC and No ECC 
Conclusion : In native, de nova. non-calcified lesions, the mechanisms of lumen 
enlargement after stenting are significantly influenced by preintervention lesion remodel- 
ing and by plaque eccentricity. Positive remodekng is assocrated with a higher luminal 
gain due to greater plaque reduction (compressionlembolization). Eccentric lesions are 
also associated with more luminal gain but due to greater vessel expansion. 
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129520 Percutaneous Coronary Intervention of Unprotected Left 
Main Stenosis in High Risk Patients: In-Hospital, 30-Day, 
and One-Year Outcome 
Samin K. Sharma, Annapoorna S. Krni, David Reich, Mazzulah Kamran, Jonathan D. 
Marmur. The Mount Sinai Medicai Center, New York NY 
Elective stenting of the left main coronary artery (LMCA) with normal left ventricular func- 
tion has been reported to have excellent short and long term results, comparable to 
CABG. Outcome of LMCA intervention in patients considered at high risk for CABG due 
to low ejection fraction, comorbid conditions and advanced age, has not been published. 
We report our experience of 100 consecutive patients who underwent LMCA interven- 
tion, deemed unsuitable for CABG. Methods and results: Mean age was 8428 years 
(range 62-98) 40% female and indication for procedure being unstable angina and post 
Ml in 60%, CHF rn 25% and both in 15% patients. Mean LVEF was 32~14% (range 1 l- 
63%) with 42% of patients had LVEF ~25%. Stenosis location was at the ostium in 25% 
in body/distal in 60% and at bifurcation in 15%. All patients underwent stenting: 89% after 
rotational atherectomy @A). GP llb/llla inhibitors were used in 78% of cases and elective 
IABP assistance in 38% of cases. Procedural success was achieved in all patients with- 
out any in-hospital major complications of Q-wave Ml, CABG or death. Major vascular 
complications occurred rn 3.2%. Mean reference vessel diameter was 3.81t0.81 mm 
with MLD pre-procedure 1.12*0.36 mm, post-debufking 2.1110.26 mm and post-proce- 
dure 3.67*0.52 mm with residual of 8%. Slow flow and minor dissection occurred in 8% 
and 13% respectively. Any CK-MB elevation occurred in 21%, with >5x normal in 4%. All 
patients were discharged alive at a mean duration of 6i5 days with 30.day MACE occur- 
ring in 3 patients: one cardiac, two non-cardiac. At a mean follow-up of Ok3 months there 
have been 6 additional deaths: 3 cardiac (2 CHF, one arrhythmia), 3 non-cardiac, while 
12 patients (12%) required target lesion revascularization. Freedom from Q-wave MI, 
repeat intervention and death in first 62 patients who have completed at least one-year 
follow-up is 80%. No patient underwent CABG at follow-up. Conclusion: Unprotected 
LMCA stenting with RA in high-risk subset of patients can be performed with very high 
procedural success and favorable 30.day and one-year outcome. Extremely low inci- 
dence of sudden death at follow-up may obviate the need of routine F/U angiography. 
Long-term follow-up of these patients is ongoing. 
129521 Long term Results of the SISA Study 
Serge Dow& Montreal Heart Institute, Montreal, PQ, Canada, Leiden University 
Medical Center, Leidem The Netheriands 
Background: The Stenting In Small Arteries (SISA) trial was a randomized, multicenter 
study where balloon angioplasty (PTCA) was compared to stent in pts with a reference 
diameter (RD) of 2.3-2.9 mm. Angiographic restenosis (~50%) at 6 months was the pri- 
mary endpoint and a one year clrnical follow-up was also obtained. Methods: Between 
October 1997 and July 1999, 351 pts with stable angina and one de nova lesion in a 
native coronary artery were randomized to standard PTCA or Medtronic b&tent impfan- 
tation after on-line quantitative coronary analysis @CA) measurement had confirmed RD 
of 2.3-2.9 mm. Results: Coronary angiography was repeated a mean (*SD) of 6 +Z 2 
months after initial procedure in 289 of 339 (85.3%) pts eligible for angiographic follow- 
uo. Restenosis rate was 32.4% for PTCA and 28.0% for stern (P=NS). Clinical follow-up 
IS available in 343 pts at 6 months and 327 pts at 1 year. 
6 months 12 months 
PTCA stent PTCA Stent 
N 178 165 171 156 
Death 1 (0,6%) 1 (0,6%) 1 (0,6%) 1 (0,6%) 
Q-wave Ml 3 (1,7%) 2 (1,2%) 4 (2,3%) 2 (1,3%) 
Non Q-wave Ml 12 (6,7%) 5 (3,0%) . 14 (8,9%) 5 (3,2%)“* 
CABG 3 (1,7%) 5 (3,0%) 6 (3,50/e) 7 (4,5%) 
Re-PTCA 33 (18,5%) 25 (15,1%) 39 (228%) 28 (17,9%) 
Pts with any 41 (23,0%) 31 (18,8%) 46 (26,9%) 35 (22,4%) 
events 
* P= 0.14 vs PTGA ” P= 0.05 vs PTCA 
Conclusion: In small arteries between 2.3 and 2.9 mm stenting does not appear to 
reduce angiographic restenosis rate at 6 months. Although there is a trend for less non 
Q-Wave Ml at 6 and 12 months with stent, there is no reduction in total cardiac events or 
re-PTCA. 
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1295-22 Unprotected Left Main Stenting Combined With Multivessel 
PCI: Safety and Feasibility. Left Main Stenting Pilot Study 
(Le Mans) 
Ft. Stefan Kiesz, Pawel Buszman, Jack L. Martin, M. Marius Rozek, Ewa Gaszewska, 
Janusz Drzewiecki, Michal Tendera. Universify of Texas Health Science Center, San 
Antonio, TX, Silesian Medical School, Katowice, Poland 
Background: Unprotected left main (LM) stenting has the potential to become an attrac- 
tive alternative to bypass surgery. A complete comparison with bypass surgery would 
also require including multivessel (MV) stenting during this same procedure. Data 
regarding LM plus MV stenting at the same setting is scarce. Methods: We treated 29 
consecutive pts; 22 males, 7 females, mean age 598~10.1 with LM and MV disease. 
Fifty two percent of pts had HTN, 38% smoked and 24% were diabetic. Ejection fraction 
ranged from 18 to 70 %, EF < 40% occurred in 5 pts (17%). Counterpulsation was used 
in 3 pts (10.3%). In addition to LM, 38 vessels were stented (l&LAD, 9.LCX, 7.RCA, 2. 
Dl, 4.IM). Ten pts with distal LM disease involving bifurcation were treated with novel 
stem designs: 7 pts with NlRside stent and 3 pts with Jomed bifurcation stent. The pri- 
mary endpoints were: clinical outcomes and angiographic restenosis at six months. 
Results: Clinical follow-up was obtained In all pts and six month angiography was 
obtained in all but two pts (93%). There were no deaths, Ml or emergent bypass surgery 
in early (0 to 30 days) follow up. At six month: there were no MI or bypass surgery, 2 pts 
died, 1 pts due to neoplasm (LM stent patent), lpts due to severe peripheral disease. 
Angiographic (binary) LM restenosis was present in 20.7% of patients (6 of 29) and all 
these pts underwent successfully repeat PCI. Thirty three percent of pts (5 of 15) with 
distal LM disease developed restenosis as compared to 7% of pts (1 of 14) with ostiali 
mid LM disease (p=O.OOOl). Conclusion: Unprotected LM plus MV stenting at the same 
setting is feasible and safe. Overall LM restenosis rate is acceptable. Distal LM disease 
involving bifurcation has higher restenosis rate than ostiallmid LM. Routine intraaortic 
counterpulsation is indicated only in patients who present with hemodynamic instability. 
1295-23 A Stepwise Strategy for the Stent Treatment of Bifurcated 
Coronary Lesions 
Manuel Pan, Jose Suarez de Lezo, Alfonso Medina, Miguel Romero, Jose Segura, 
Antonio Ramirez, Djordje Pavlovic, Enrique Hernandez, Soledad Ojeda, Carmen 
Adamuz, Ricardo Huerta, Antonio Delgado. Reina Sofia Hospital, Cordoba, Spain, 
Negtin Hospital, Las Palmas, Spain 
Background: Several observational studies have shown a better late outcome in patients 
with coronary bifurcation lesions treated with stents in whom the side branch was not 
stented. However, it is not always possible, which may lead to provisional stenting for the 
side branch. Methods: We analysed the results of this strategy that led us to a 3 stepped 
phases. First step: balloon angioplasty of the side branch followed by stenting of the par- 
ent vessel. Second step: balloon redilation of the side branch origin across the metallic 
structure of the stent. Third step: stenting of the side branch origin crossing the struts of 
the parent vessel stent. Progression through each phase was triggered by the failure of 
one procedure to achieve a < 50% residual stenosis at the side branch. Following this 
strategy we treated 126 patients, 58*t 1 years old, with major coronary bifurcation steno- 
sis. Bifurcated lesions were located at the left main coronary artery in 14 (11%) left ante- 
rior descending artery in 54 (43%) circumflex artery in 37 (29%) and right coronary 
artery in 21 (17%). The mean follow-up period was 18i7 months. Angiographic re-evalu- 
ation studies were performed in all patients havinq symptoms during this period of time. 
The results are summarized in the table. - 
n Procedural Failure Crossing TVR 
success next step 
First step 126 35(28%) 3 88 5/38(13%) 
Second step 88 76(86%) 7 5 13/83(16%) 
Third step 5 5(100%) - l/5(20%) 
Overall 126 116(92%) 10(8%) 93(74%) 19(15%) 
TVR: Target vessel revascularization. Conclusions: Patients with coronary stenosis at 
major bifurcations may be treated following an unitary stepwise approach regardless of 
morphology and angulation. This attitude may avoid side branch stent implantation in 
most patients, providing better immediate and long-term results. 
Background: Treatment of bifurcation lesions remains one of the major limitations of 
most tubular stents. The V-Flexa stent (Global Therapeutics, Broomfield, CO) was espe- 
cially designed to easy access sidebranches and to allow opening of the stem cells up to 
4 mm without breaking the stem filaments. Methods: Twenty-one bifurcation lesions (14 
LAD, 5 RCA and 2 main stem lesions) have been treated using the double overlapping 
stent technique. First the largest vessel was stented using a 16 to 24 mm stent. After 
placing a guidewire in the sidebranch by crossing the first stent, balloon dilatation of the 
stent cell was performed with an appropriately sized balloon. The proximal part of the 
second stent was located within the first stent and the distal part in the sidebranch. After 
deployment of the second stent, both stents were finally inflated simultaneously with two 
‘kissing’ balloons. Results: Procedural success was 100%. The total procedure duration 
was 54+23 min and the total contrast volume was 260+54 ml. There was one (not Stent 
related) in-hospital death in this study. There were no acute or subacute thrombotic stent 
occlusions, however, 2 pts had a mild CK raise (~300 IU) without ECG changes. Three 
pts had temporarily renal malfunction. All pts are scheduled for control 6m angiographic 
follow-up. Conclusipn: Treatment of bifurcation lesions is feasible and safe with this new 
tubular V-Flexa stent. However, it remains a more challenging technique, requiring a con- 
siderable amount of contrast dye. 
1295-27 Stents for the Treatment of I&tent Restenosis: Long-Term 
Outcome 
1295-24 The impact of Cutting Balloon Angioplasty for the Treatment David R. Holmes, Jr., Peter 8. Berger, Charanjit S. Rihal, Kirk N. Garratt, Malcolm R. Bell, 
of Diffuse In-Stent Restenosis. Comparison With Verg Mathew, John F. Bresnahan, Greg W. Barsness, Diane Grill. Mayo Medical Center, 
Conventional Balloon Angioplasty Rochester, MN 
Raisuke lijima, Masato Nakamura,Yoko Krtagawa,Rintaro NakajimaTakashi 
Yoshitama,Takuro Takagi,Hitoshi Anzai, Tarou Tunoda,Tetsu Yamaguchi. Third 
Department of Internal Medicine Toho University School of Medicine, Tokyo, Japan 
Background: Previous studies have reported that diffuse InStent Restenosis(lSR) was 
an important predictive factor for the recurrence of ISR. The efficacy of Cutting Balloon 
Angioplasty(CBA) for diffuse ISR remains unestablished. Purpose: To define the clinical 
usefulness of CBA for diffuse ISR, the results of CBA for diffuse ISR was compared to 
those of conventional balloon angioplasty (BA). Methods: Consecutive 90 diffuse 
ISR(lesion length>lOmm) treated by CBA or BA were analysed. CBA was used in 50 
lesions and BA in 40 lesions. There was no difference in clinical and lesional characteris- 
tics, Initial success(residual restenosisc50%)was obtained in 100% case. Angiographic 
follow up was obtained in all cases(mean time of 131t93days). Results: Anlaysed data 
Background: The treatment of in-stent restenosis remains difficult with increased recur- 
rence rates. The effect of placement of a new stent in this setting on long-term outcome 
is not well understood. Of 304 patients undergoing initially successful treatment of in- 
stent restenosis, a new stent was placed in 35.5% (Group 1) while the remainder of the 
patients were treated with approaches such as angioplasty and/or ablative techniques 
alone without a new stent (Group 2). Brachytherapy was not performed in either group. 
The baseline characteristics were similar between the two groups in terms of mean age, 
gender, unstable angina, history of prior bypass surgery, congestive heart failure and 
ejection fraction. The mean time from initial stem placement to the repeat procedure for 
are shown in table. Conclusion: Compared to BA, CBA resulted in a reduced restenosis 
rate and a sianificantlv shorter lesion lenath followino the treatement of diffuse ISR. 
These data may suggest that CBA is a useful strategy fir the treatment of diffuse ISR. 
BA CBA p value 
Pre mean reference(mm) 
Pre MLD(mm) 
Post MLD(mm) 
Pre lesion length(mm) 
Lesion length at follow up(mm) 
Restenosis(%) 
2.85i-0.61 2.66~0.56 “6 
0.60~0.48 0.78+0.35 ns 
2.25+0.59 2.28?0.57 ns 
20.26+11.04 20.08+11.53 ns 
16.74*15.50 9.33k11.53 0.0325 
51.8 29.8 0.059 
1295-25 Long Stents: Angiographic Detection of the Area With the 
Highest Lumen Loss After Implantation of Long (r20 mm) 
Stents 
Thomas F M. Konorza. Michael Haude, Martin Diedrich, Carsten Kretz, Christoph Kaiser, 
Heinrich Wieneke, Nikolaos Dagres, Dietrich Baumgart, Christoph Naber, Raimund 
Erbel. University of Essen. Essex, Germany 
Background: New ballon expandable stent designs allow to cover long lesions with one 
long stent. Restenosis pattern in these stems is unclear. Method: One hundred consecu- 
tive patients were treated with one long stent(29 * 7mm). Preinterventional (Pm) minimal 
lumen diameter(MLD)was 0.8 f 0.5mm (72 + 15%).Quantitative coronary angiography 
was performed with the Cardiovascular Measurement System (CMS, MEDIS, Leiden 
,NL)in the proximal, central and distal third of the stem after intervention (Post) and at 6 
months (FU). 
Results: Postinterventional 
in stent MLD decreases 
from proximal to distal.After 
6 month the central part 
showed significantly smaller 
MLDs with a significantly 
higher lumen loss. 
Conclusion: Postinterven- 
tional MLD decreases mod- 
erately from proximal to distal. The central part with the area of the initial biggest plaque 
burden seems to be associated with more intimal hyperplasia. 
1295-26 Treatment of Bifurcation Lesions Using a New Tubular Stent 
Ivan De Scheerder, Joseph Dens, Walter Desmet, Patrick Coussement, Jan Piessens, 
Frans Van de Wed. University Hospitals, Leuven, Belgium 
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in-stent restenosis was 180 days. After successful treatment of the in-stent restenosis, 
mean follow uo was available for i 6 “ears for Grouo 1 and 2.8 veals for Grouo 2. Kaolan 
Meier event rates at 6 and 12 months are 
Group 1 Group 2 
Conclusions: Adverse event rates in the EPISTENT trial were lower in Canada than in 
the U.S. The extent to which these variations are due to differences in patient character- 
istics requires further study. 
6 months 1 year 6 months 1 year P value 
Death 5.3 5.3 3.5 4.1 0.90 
QMI 0 0 06 0.6 0.44 
Any MI 4.2 4.2 4.1 4.1 0.83 
ReProcedure 14.9 21 1 15.5 21.2 0.91 
coronary 8.61 12.3 13.9 17.2 0.60 
bypass 
Severe 24.4 30.7 34.2 45.1 0.38 
angina 
Conclusion: The placement of new stents for treatment of in-stent restenosis does not 
improve outcome compared with other non-stem approaches. New approaches such as 
brachytherapy are required to improve outcome. 
129528 predictors of Diffuse-Type InStent Restenosis After 
Coronary Stent Implantation 
Thcsaphol Limpijankit, George W. Vetrovec, Michael J. Cowley, Walter N. Malloy, Evelyne 
Goudreau. Medical College of Virginia Campus of Virginia Commonwealth University 
Richmond, VA 
Background: Diffuse type in-stent restenosis (ISR) is associated with a high rate of sub- 
sequent revascularization after interventional therapy with currently available treatment 
modalities., The purpose of this study was to evaluate the clinical and angiographic pre- 
dictors related to the angiographic patterns of ISR. 
Methods: One hundred and fourteen ISR lesions in 109 patients who underwent repeat 
PTCA for ISR were analyzed to identify any possible clinical, angiographic, procedural 
and QCA predictive variables for focal (cl0 mm in length, occurring within the stem, 
edges or articulate site) and diffuse (>lO mm in length, covering entire stent length or 
extending outside into the nonstented segment) patterns of ISR in a variety of stent types 
(PS = 34, GR-I and GR-II = 30, ACS-ML and duet = 20, AVE.GFX = 6, others = 24). 
Adjunct use of Abciximab (ReoProT+‘) was 22% (251114). 
Results: Mean time interval to ISR was 230 i 259 days. Fifty-eight lesions (51%) were 
focal ISR and 56 lesions (49%) were diffuse ISR. Univariate predictors of diffuse ISR 
were diabetes mellitus (29% vs. 50%, P=O.OZ), multi-vessel disease (22% vs. 50%, 
P=O.OOZ), lower Ien ventricular ejection fraction (53*10 vs. 48+12, P<O.Ol), long lesion 
length (8.6+9.4 vs. 19.2*12.5, P<O.OOOl), multiple stents in the same lesion (1.2~0.4 vs. 
1.610.8, P=O.O03), long stented length (20.8ilO.i vs. 27.9k13.9, P=O.OOZ, and lower 
stenfflesion length ratio (3.6+2.9 vs. 1.7k1.2, P<O.OOOi). On multivariate logistic regres- 
sion analysis, only diabetes mellitus (OR 3.0, 95% Cl 1.2-8.3: P = 0.02) long lesion 
length (OR 1.2, 95% Cl 1.0-1.23; P ~0.01) and total stented length (OR 1.1, 95% Cl l.O- 
1.21; P c 0.05) independently correlated with diifuse ISR. Other factors not correlating 
with diffuse ISR include stenting without debulking, high inflation pressure (216 atm), 
ReoPrc-” use, reference vessel diameter, and pre and post procedure minimal lumen 
diameter. 
Conclusion: Diabetes, long lesions before stenting and total stented length were corre- 
lated with diffuse ISR. These predictive variables may help to identify patients that could 
potentially benefit from new therapeutic approaches such as intracoronary radiation. 
1295-29 Variations in Event Rates Between Canada and United 
States in the EPISTENT Trial 
Eric A. Cohen, Michael Lincoff, Shelly Sapp. Jeffrey R Burton, James E. Tcheng, Eric 
Topol, EPISTENT Investigators. Sunnybrook & Women’s College Health Sciences 
Centre, University of ioronio, Toronto, ON, Canada, Cleveland Clinic Foundation, 
Cleveland, OH 
Background: Interventional cardiology practice differs between Canada and U.S., with 
more restriction on access but greater regionalization of resources and expertise in 
Canada. We examined Canadian and U.S. event rates in the EPISTENT trial to explore 
whether these differences in organization of care impacied on outcome. 
Methods: In the EPISTENT trial, 959 patients ware enrolled at 13 sites in Canada and 
1440 patients at 50 sites in U.S. This analysis included all patients in the trial, across all 
three treatment allocations. Patient characteristics and composite event rates at 30 days 
and 1 year were compared between the countries. 
Results: Baseline characteristics are shown in the table. Canadian patients were 
younger and had less comorbidity and fewer prior manifestations of coronary disease, 
Following myocardial infarction, US. patients underwent intervention earlier, Event rates 
are shown on the bar graph (P=O.O13 at 30 days. P~O.007 at 1 year). The individual 
components of the composite endpoints (not shown) all varied in the same direction as 
the composites. Target vessel revascularization at 1 year was 13.5% in Canada and 
19.2% in US (PcO.001). 
30 day 1 year 
n Canada n U.S., 
Age (years) 
% Female 
Diabetes (%) 
Prior PCI (%) 
Prior CABG (%) 
Ml < 7 days prior 
Ml > 7 days prior 
Canada us P-value 
60.0 58.0 0.017 
24.8 25.1 0.889 
16.5 23.1 <O.OOl 
11.4 18.1 <O.OOl 
8.0 9.7 0.157 
4.2 24.5 <O.OOl 
46.5 26.7 <O.OOl 
1295-30 Estrogen Use is Associated With Reduced Need for Target 
Lesion Revascularization in Postmenopausal Diabetic 
Women After Coronary Stenting 
Partha Manchikalapudi, Masroor Khan, Ramin Arani, Vijay Misra, Ming Liu, Gregory 
Chapman, Suzanne Oparil, Larry Dean. UAB Medical Center. Birmingham, AL 
Background: Estrogen has been reported to improve survival and reduce adverse car- 
diac events after coronary stenting in post-menopausal women but the effects of estro- 
gen after coronary stenting in post-menopausal diabetic women are unknown. 
Methods: Between 1993.97, post-menopausal women on estrogen who had successful 
coronary stenting at UAB medical center were matched by age and site of stenting with 
women on no estrogen. They were divided into four groups: 1. Diabetic women on estro- 
gen (E+,DM+) n=30 2. Diabetic women on no estrogen (E-, DM+) n=33 3. Non-diabetic 
women on estrogen (E+, DM-) n=35 4. Non-diabetic women on no estrogen (E-,DM-) 
n=35. The occurrence of major clinical events including death(D), myocardial infarc- 
tion(MI), target lesion revascularization(TLR) and major adverse cardiac events(MACE) 
was recorded. 
Results: There were no significant differences in the baseline demographics and angio- 
graphic data among the four groups. The clinical events are shown in the table. 
E+,DM+(BO) E-,DM+(33) E+,DM-(35) E-,DM-(35) 
Death 3(10%) 1(3%) 1(2.8%) 2(5.7%) 
Ml 1(3.3%) 3(9%) 1(2.8%) 2(5.7%) 
TLR 10(33.33%) 21(63.64%)* 9(25.7%) 12(34.3%)” 
MACE 13(43.3%) 21(63.64%) 10(28.5%) 13(37.1%) 
follow up 39.6mos 40.5mos 43.6mos 42.2mos 
‘p<O.O32 compared to E+,DM+: ‘*p=ns compared to E+,DM+ 
Conclusions: Estrogen reduced TLR in both DM+ and DM- women compared to 
patients who were not on estrogen. The decrease in TLR with estrogen use was more 
significant in diabetics, a notoriously high risk group than in non-diabetics. 
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1296-31 Small Coronary Vessel Stenting: Primary Results and Long- 
term Follow-up 
P&r Kala, Jirina Kosova, Petr Jerabek, Otakar Bocek, Petr Neugebauer, Martin Poloczek, 
Borivoj Semrad. lnternai and Cardiological Opt, University Hospital Brno - Bohunice, 
Brno, Czech Republic 
Background: There is evidence that coronary angioplasty (PTCA) with stent implanta- 
tion is better than balloon angioplasty only in selected group of patients. This fact seems 
to be clear in coronary arteries with diameter bigger than 2,75mm. It is still questionnaire 
in smaller arteries where the restenosis and complication rates could be greater. 
Method: Prospective single center analysis of the PTCA procedures performed in 1998. 
Patients managed by small stent implantations with QCA diameter artery 2,75mm or less 
were clinical followed 6 and 12 months after the procedures. All results were averaged +- 
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SD. Angina was classified according to CCS score, dyspnoe according to NYHA score. 
Results: In 1998 we made 417 PTCA overall. In 79 patients (pts) we implanted small 
vessel stems. Averaged age was 60,3 yrs +9,7 with left ventricle ejection fraction 
54,3*10,0, 40 pts (50,6%) were smokers, 57 (72,2%) had hypertension, 26 (32,9%) had 
diabetes, 65 (82,3%) had dyslipidemia, 65 (82,3%) had previous myocardial infarction 
and 31 (39,2%) had positive family history. Three vessel disease was observed in 35 pts 
(44,3%). Angina CCS class at baseline was 2,17r0,77, dyspnoe NYHA 1,5*0,77. Incom- 
plete revascularization was performed in 46 pts (58,2%). Predischarge complication rate 
was 2,53% - once nonQ wave acute myocardial infarction and once puncture site compli- 
cation. Angina resp. dyspnoe was 1,2*1,26 resp. 1,1&l ,19 at 6 months and 1,09+1,02 
resp. 1,23+1,03 at 12 months. 75 pts (94,9%) were less symptomatic at 6 months and 61 
pts (91,5%) at 12 months. 12 patients (152%) were lost from 12.month follow-up. 
Repeated coronary angiography was indicated in 13 pts (16,5%) with significant resteno- 
sis observed in 9 pts (11,4%). Conclusion: Small coronary vessel stenting is safe and 
higly effective in reducing angina and dyspnoe (pcO,OOl) at 6 and 12.month follow-up. 
Periprocedural complications and clinical restenosis rate were very acceptable. 
1296-32 Feasibility, Immediate, and Mid-Term Results of a New 
Fibrin Film Covered Stent in Human Coronary Bypass 
Grafts 
Charles J. McKenna, Allan Ft. Camrud, Rodney Wolff, Thomas Dinh, David R. Holmes, 
Jr., Whyte G. Owen, Robert S. Schwartz. Mayo Foundation, Rochester, MN 
Background: Percutaneous intervention on diseased coronary saphenous vein grafts 
historically results in frequent embolic complications and high restenosis rates. We 
assessed the feasibility of a new fibrin film covered stem (FS) in treating this difficult 
group of patients. 
Methods: Fibrin Film Stems (Medtronic, Inc, Minneapolis) were prepared from donated 
human blood plasma resulting in a 360” film adhered to a small-wave WiktorB stent 
platform. The device was sterilized, screened for viruses, and crimped on standard 
stem delivery balloons. Approval for this safety study was obtained from institutional IRB 
and the FDA. Ten patients (pts) with diseased grafts were stented (1 stent per pt) for this 
study. Typical acute and in-hospital data were recorded. Followup included 1 mo blood 
draws assayed for viral infection and immune response due to the FS, as well as 6 mo 
angiograms and 1 yr clinical assessment. 
Results: Technical and Angiographic Procedural Success was achieved for the FS in all 
pts (100 %). Two pts (20%) exhibited temporary no-reflow due to emboli from the initial 
wire crossing/balloon dilatation procedure with resultant confirmed non-Q wave myocar- 
dial infarction. One mo followup results showed no viral contamination nor immunologi- 
cal response due to the FS (IO/IO negative). Binary restenosis rate at 6 months was 
50% which included 3 occlusions. Three pts had elective CABG and 2 pts were 
restented. Five of 9 pts were completely asymptomatic at 1 yr. There was one sudden 
death unrelated to the FS. 
Conclusions: 1. The FS is feasible and can be safely implanted in diseased coronary 
bypass grafts. 2. Acute and mid-term complications with the FS in this difficult lesion 
subset parallel those of other bypass graft intervention studies to date. 3. These data 
suggest that this biodegradable film stent may be a viable carrier for local drug delivery. 
1296-33 The German IST-Registry: Need of One Year of Clopidogrel 
to Avoid Late/Late Stent Thrombosis 
Sigmund Silber, C Brockhoff, R D&r, A Miigge, I Krischke, T Meinertz. Herzkatheterlabor, 
Munich, Germany 
In Germany, intracoronary brachytherapy (ICBT) is being widely used after having 
received the approval for ist clinical application. The usefulness of routine use of ICBT, 
however, is considerably limited by its risk of late (up to six months) or late/late (after six 
months) stem thrombosis. Although the administration of clopidogrel (CLOP) for at least 
three to six months has shown to reduce the incidence of late stem thrombosis after 
ICBT, the minimum duration for administration of CLOP to avoi late/late stent thrombosis 
is unknown. IST is a new German registry: 212 patients (197 with beta, 15 with gamma 
radiation) underwent ICBT for 228 lesions: 64% in-stem restenosis, 33 % de-nova, and 3 
% restenosis without stents. Mean age was 6Oc9 (36-79) years and LV-EF 57&l 1 (31. 
75)%. For de-nova lesions and restenoses without stems, the dose for coronary vessels 
with a diameter of 2.7-3.35 mm was 14 Gy; for 3.36-4.0 mm 18 Gy. For in-stent resteno- 
sis, the corresponding doses were 16 Gy and 20 - 22 Gy. All pats were enforced to take 
CLOP for 6 months. Results: A total of 7 patients developed delayed stem thrombosis: 
Two patients dicontinued CLOP within the six months time frame with stem thrombosis 
after 4 weeks, (with CLOP discontinued after 2 weeks) and after 5 months (with CLOP 
discontinued after 4 months). All other 5 pats (4 beta and 1 gamma) were reliably taking 
CLOP for 6 months with good results at follow-up angiography. Late/late stem thrombosis 
in these pats occurred at 7 to 8 months. Conclusions: The German IST-Registry shows 
that the official recommendation of prescription of CLOP for 3 to 6 months after ICBT is 
not safe enough. Therefore, the administration of CLOP for at least 1 year is highly rec- 
ommended to avoid late/late stent thrombosis. 
1296-34 Is the Need for Re-Intervention Higher With Percutaneous 
Coronary Interventions or With Coronary Artery Bypass 
Surgery? 
Gishel New, lssam Mousse., Vickram Veeramachaneni, Roxana Mehran, George 
Dangas, Alexandra Lansky, Milena Adamian, Gary S. Roubin, Michael B. Collins, Edward 
Kreps, Sriram S. lyer, Martin B. Leon, Valavanur Subramanium, Mark Connelly, Jeffrey 
W. Moses. Lenox Hi/J Heart and Vascular Institute of New York, New York, NY 
Background: Studies have suggested that with the use of stents, there has been a 
reduction in the need for emergency CABG following percutaneous coronary interven- 
tions (PCI). The frequency of the need for re-intervention with PCI after CABG is 
unknown. The aim of this study was to determine the requirement for re-intervention post 
PCI and CABG, and to compare any changes in this need over time. Methods: Data was 
retrospectively collected and analyzed from the PCI and CABG Lenox Hill Hospital data- 
bases from January 1, 1996 unttl June 30th, 2000. Patients who required m-intervention 
to an artery that was revascularized within 2 weeks were included. Results: There were 
9345 patients undergoing PCI and 3089 patients had CABG in this time period. Of these, 
less pts in the PCI group required m-intervention with CABG compared with the no. of pts 
in the CABG group requiring m-intervention with PCI (24 (0.26%) vs 27 {OX&), for PCI 
vs CABG pts, p c 0.0001). There was also a significant trend in the no. of pts requiring re- 
intervention over the past 5 years in the PCI group but not in the CABG group (p 4 0.001 
for PCI vs p = ns for CABG, Chi Square for Trend). Conclusion: This analysis suggests 
that more patients require m-intervention for failed surgical revascularization than for 
failed PCI. In addition, although there has been a decreasing trend over the past 5 years 
for re-intervention following PCI, this trend was not evident following CABG. 
1296-35 Impact of Stenting Compared to Balloon Angioplasty on In- 
Hospital Outcomes of 44000 Patients. Results From the 
Registry of the Brazilian Society of Interventional 
Cardiology (CENIC) 
Marco A. Costa, Amanda G. M. R. Sousa, Luiz A. P. Mattes, Jamil Saad, Andre Labrunie, 
Fausto Feres, Alexandre Abizaid, Carlos Gottchall, Costantino Costantini, Helio Figuejra. 
Valter Lima, Paula Caramori, Paula Sergio Oliveira, Jose Armando Mangione, J. Eduardo 
M. R. Sousa. Brazilian Society of lnterventional Cardiology CENIC, SZo Paula, Brazil, 
Institute Dante Pazzanese of Cardiology, S& Pauto, Brazil 
Background: The BENESTENT and STRESS trials have demonstrated the benefit of 
coronary stents in selected coronary lesions. Whether stems provide superior immediate 
results compared to balloon angioplasty in unselected patients remains to be demon- 
strated in a large multicenter prospective investigation. Methods: From 1997 to 1999, a 
prospective clinical survey was made in 121 Brazilian Hospitals. In these institutions, 
44111 interventional procedures were performed. Patients were grouped according to 
treatment: stenting (n=23753) and balloon angioplasty (20358). Procedural success was 
defined as residual stenosis < 50% and TIMI 3 flow. Logistic regression analysis was 
used to predict hospital discharge without complications (death, myocardial infarction or 
urgent bypass surgery) in the total population. Results: Patients selected to stem 
implantation have a worse baseline clinical characteristics as compared to patients 
treated with balloon angioplasty. 
Baseline Characteristics and In-Hospital Outcomes 
stent Balloon P 
Age 60.3+11 .O 59.8k10.9 <O.OOl 
Male 67.0% 67.0% NS 
Diabetes 16.0% 16.0% NS 
Unstable Angina 21 .O% 17.9% <O.OOl 
Angiographic Thrombus 19.5% 20.9% <O.OOl 
Angiographic Calcium 19.3% 17.0% <0.001 
Residual Stenosis<l6% 7.1% 41.1% <O.OOl 
success 98.3% 89.7% <O.OOl 
In-Hospital Death 1.1% 1.7% <O.OOl 
In-Hospital Myocardial Infarction 1.3% 1.6% 0.005 
The use of stem was retained in the multivariate mQdel as an independent predictor of 
event-free in-hospital survival (p=O.O05; R=O.lE, 95% CI=l.6-1.4). Conclusions: Stent 
implantation represents half of the interventions performed in Brazil. This large, nationally 
representative, survey has found that stem provides a better immediate outcome com- 
pared to balloon angioplasty in unselected patients. After adjustment for baseline charac- 
teristics and degree of residual stenosis, the use of coronary stems independently 
predicted in-hospital outcome. 
1296-36 Mechanisms of Cutting-Balloon Angioplasty in the 
Treatment of In-Stent Restenosis: A Volumetric 
Intravascular Ultrasound Study 
Thomas M. Schiele, Andreas Kijnig, Johannes Rieber, Monika Baylacher, Hans-Ulrich 
Stempfle, Karl Theisen, Volker Klauss. Opt. of Cardioiogy, Klinikum der Universilt 
Mijnchen-lnnenstadt, Ludwig-Maximilians-Universit~t, Mu‘nich, Germany 
Cutting-balloon-angioplasty (CB) is a favourable method for the treatment of instent-rest- 
enosis (ISR). CB is thought to faciliate plaque redistribution and stem expansion by 
plaque incision. Yet the specific contribution of the several mechanisms have not been 
described precisely. We investigated the mechanisms of CB in ISR by intravascular ultra- 
sound (IVUS) in 34 consecutive patients (PT). Methods: 34 PT (55,14+11,2 y; 27 male) 
underwent CB of ISR with an oversized (0,5mm) balloon. ISR was diffuse in all cases, 
lesion length was 18,1*6,7 mm. All previously implanted stems were of slotted-tube type. 
IVUS was performed pm (pr) and post (PO) intervention by motorized pullback with a 
speed of 0,5mm/sec (Endosonics). Volumetric analysis of the distal reference (IOmm, 
divided into far [Rfpx] and near [En] segment of 5mm each), stent segment (divided into 
proximal and distal stem entrance [Stpx, Stdi] of 5mm each and stent body [St]) and prox- 
imal reference (IOmm, divided into far [Rfdi] and near [Eic] segment of 5mm each) was 
performed in steps of 1 mm. Vessel area (VA), stent area (SA) and lumen area (LA) were 
determined. Plaque area (PA), intimal area (IA) and total plaque area (TA) were calcu- 
lated. All area data are in mm2. Ratio of SAiLARf and LASffLARf were calculated to char- 
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acterize the fina: angioplasty result. Results: There were no significant differences of VA, 
LA or PA at the far reference sites. The table shows significant changes of the respective 
segments. 
Change of Ves- Change of Stent Change of Lumen Change of lntimal 
sel Area Area Area Area 
RfE” +1,44 p=o,o1t3 -- -- +0,76 p=O,O27 -- -- 
stpx +I,60 p=O,O18 +I,72 p=O,O18 +3,07 p=o,o18 -1,35 p=o.o18 
Si +1,42 p=o:o18 +1,49 p=o,o18 +3,45 p=o,o18 -I,96 p=O,O18 
Stdi +1,59 p=O,O28 +1,40 p=O,O18 +2.54 p=O,O18 -1,15 p=o,olE 
RfEx +1,09 p=O,O46 -- -- +0,96 p=O,O42 -- -- 
There were no significant changes of PA or TA. SAfLARf was 1,43 and LAStiLARf was 
0,QQ. Conclusion: Mechanisms of CEi comprise significant compression of neointima, but 
not of residual plaque burden, and significant stent expansion and, consecutively, of the 
total vessel circumference. Extent of acute lumen gain within the stent IS very favourable. 
1296-37 Plaque Composition Predicts Stent Edge Dissections; an 
Intravascular Ultrasound Study 
Fadi A. Matar, Chaival Thakore, Akiko Maehara. Neil J. Weissman. Norida 
Cardkxascular institute, Tampa, FL, Washington Hospitai Centec Washington, DC 
Background: Intravascular ultrasound (IVUS) detects edge dissections (D) in 5-15% of 
coronary arteries after stent implantation. Such dissectrons contnbute to thrombosis and, 
therefore understanding the setting in which they occur is important. Method: We ana- 
lyzed 29 patients (age 65+13 yrs. Males= 22) (14 with D, 15 with No-D) who had IVUS 
(30 MHz, automated pullback at 0.5-l mm/set.) post stent implantation (Stent 
size=3.2&0.4 mm, Post balloon size=3.3*0.5 mm, max. dilation pressure= 14.3~2.9 
atm.). D were identified by IVUS as a discontinuity of the intima (4 superiicial, 10 deep) at 
either stent edges. Plaques at the D sites were classified as either soft (echo signal less 
dense than adventitia) or fibrocalcific @gnat as dense or denser than adventitia * acous- 
tic shadowing). Multiple procedural, ultrasonographic and clinical variables were ana- 
lyzed. Results: 1) Q/14 (65%) of D vessels had soft plaques vs. l/15 (6.7%) of the non-D 
vessels (p=O.O02). 2) D patients were younger than the non-D patients (59*14 vs. 7OklO 
yrs., p=O.O25). 3) Balloon: artery ratio of the D vessels tended to be larger in the D vs. the 
non-D vessels (l.&O.l vs. 1.1+0.2, p=O.l). Conclusion: 1) Soft plaques are prone for 
dissection as they meet the rigid stent struts. 2) Large balloon to artery ratios tend to pro- 
mote stent edge dissections. 3) The effect of age on stent edge dissection may be related 
to a higher prevalence of soft plaques in younger patients. 
1296-38 Effect of Clopidogrel Loading Before Percutaneous 
Coronary intervention in Patients Treated With Glycoprotein 
Ilb/llla Inhibitors 
Abid Assali, Stefano Sdringola, Joseph Salloum, Ali Moustapha, Mohammed Ghan), 
George Schroth, H V. Anderson, Richard W. Smailing, Oscar F&ales. University of 
Texas Medical School, Houston, TX 
Background: Glycoprotein llblllla receptor inhibitors showed a remarkable consistency 
in the reduction of major adverse clinical events (MACE) after native coronary arteries 
angioplasty or stenting (PCI). The additional effect of a pre-procedural loading dose of 
clopidogrel and aspirin (PLCA) has not bee” investigated. We tested the hypothesis that 
PLCA may further reduce in-hospital MACE in patients (pts) undergoing PI and receiving 
either tirofaban or abciximab.Methods: We reviewed our institutional interventional data- 
base and identified consecutive pts who underwent PCI and received either abciximab or 
tirofaban. This population was then divided in two groups: pts who received a pre-proce- 
dural loading dose of 300 mg of clopidogrel and 325 mg of aspirin (Group I) and pts who 
received aspirin alone (Group II). Results: During the study period 299 pts underwent 
PCI and were treated with either tirofaban or abciximab. Group I=235 pts (78%) received 
PLCA.1” hospital MACE were recorded in 13 pts (5.5%) in Group I compared to 9 (14%) 
in Group II (p= 0.03). By multivariate analysis acute coronary syndrome at presentation 
and absence of LCA were found to be a significant predictor of MACE. The probability of 
any side effect (thrombocytopenia, bleeding) was not different in the two groups. Conclu- 
sions: These data suggest that clopidogrel loading prior to PCI in patients receiving tiro- 
faban or abciximab may be safe and effective in further reducing in-hospital MACE. 
1296-39 Comparative Pathologic Studies of Chronic Tissue 
Responses to Successful Stent Implantation and Balloon 
Angioplasty 
Katsumi Inoue, Kenji Ando, Shinichi Shirai, Michio Nakanishl, Hiroyoshi Yokoi, Yoshihisa 
Nakagawa, Naoya Hamasaki, Takeshi Kimura, Hideyuki Nosaka, Masakiyo Nobuyoshi. 
Kokura Memorial Hospital, Kitakyushu, Japan 
We investigated the late vascular responses of postmortem coronary arteries In 88 con- 
secutive patients treated with Palm&z-Schatz stenting (PS, 42 patients) or balloon angio- 
plasty (PTCA, 46 patients) that were patent on angiography at 6 months (M). Although 
arteries without rester&s within 1 year (Y) exhibited significant proliferation of smooth 
muscle cells (SMCs) and deposition of proteoglycans on the intimal side of the affected 
lessons following the use of either method, these SMCs were spindle-shaped and orderly 
arranged aiong the iuminal surface. In the case of stenting, however, apparent T lympho- 
cytes (T ceils), macrophages (Ma) and multinucleated giant cells, was also observed 
around the stent struts. Arteries from patients who died more than 1 Y after PS or PTCA 
exhiblted extremely reduced proteoglycan contents, and intercellular spaces contained 
abundant collagen fibers. Thereafter, SMCs in the neointima gradually became atrophic 
and dwindled more than 3 Y after PS or PICA. Furthermore, at the sites affected by 
either PS or PTCA, the lipid core in the atheroma was covered with and demarcated by 
dense fibrous neointima, which guaranteed plaque stabilization. However. immunohis- 
tochemical studies clearly showed small numbers of helper I inducer T cells and slight 
M@ infiltration adjacent to the stent struts. In arteries more than 5 Y after PS, a heavy 
infiltration of lipid-lade” M0 was observed around the struts. In contrast, it was not until 
more than 7 Y after PTCA that a slight infiltration of lipid-laden Ma was observed in the 
subendothelial spaces, primarily in the shoulder regions. Thus, once a given target lesson 
was safely treated with PS or PTCA and after the 6-M vascular repair period had been 
completed without restenosls, the atheromatous segment was converted to a vascular 
scar that was virtually incapable of future plaque rupture by atherosclerosis for several 
years after PS or PTCA. However, in the affected sites more than 5 Y after stenting, 
residual chrome inflammatory cells around the struts may induce new and indolent ath- 
erosclerotic changes, resulting in plaque vulnerability. 
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IO:30 a.m. 
Lack of Clinical Efficacy of Pharmacologic Treatment of the 
No-Reflow Phenomenon Despite Significant Angiographic 
Improvement 
Marco V. Wainstein, Frederic S. Resnic, Michael K. Y. Lee, Rodrigo V. Wainstein, Dominik 
Behrendt, Lucila Ohno-Machado, James M. Kirshenbaum, Campbell Rogers, Robert N. 
Piana, Jeffrey J. Popma. Brigham and Women’s Hospitai. Bosfon, MA, Vanderbilt 
University Medical Center. Nashville, TN 
Background: Reduction in epicardial coronary blood flow during percutaneous coronary 
interventions (PCI), termed the no-reflow phenomenon, is a” independent predictor of 
post-procedural myocardial infarction and in-hospital mortality. The objective of this 
study was to evaluate the effect of pharmacological treatment of “o-reflow. 
Methods: We evaluated angiographic blood flow changes at the no-reflow episode and 
at the end of the procedure using the TIMI flow rate (TFR) and TIMI frame count (TFC), 
correlating these changes with in-hospital mortality and myocardial infarction (MACE). 
All cases of no reflow among 4,264 procedures performed between l/97 and 12/99 at 
Brigham and Women’s Hospital were analyzed. 
Results: Ninety-four patients of 135 patients who suffered a significant episode of “o- 
reflow which was angiographically documented were included in this study. Mean TFC 
improved from 72.3 ? 2.9 to 47.0 * 2.6 (p<O.OOi) which correlated with a” improvement 
in TFR from 1.43 * 0.07 to 2.52 i 0.06 (pcO.001). Twenty eight patients (30%) received 
intracoronary sodium nitroprusside (SNP) and 36 patients (38%) received intracoronary 
verapamil (VER) No-reflow was highly predictive of MACE (18.1% vs. 4.6%, P<O.OOi), 
however treatment with neither SNP nor VER was associated with improved outcomes. 
SNP, but not VER was associated with a” improvement in TFC compared with untreated 
patients (see table). 
Nitroprusslde Verapamil Control p-“&E 
n 28 36 28 
Change in TFC 41.5 f 0.22% 29.4 f 0.24% 30.7 + 0.22% 0.031* 
Death or Ml 16.1% 22.5% 15.4% 0.674 
* p-value for comparison of SNP vs. control 
Conclusion: No-reflow was associated with a poor prognosis following PCI despite sig- 
nificant angiographic improvement I” blood flow velocity by the completion of the proce- 
dure. SNP significantly improved TFC without clinical benefit. Further investigation into 
prevention and treatment strategies for this condition are warranted. 
885-2 
IO:45 a.m. 
Beta Blockers Do Not Appear to Decrease Creatine Kinase 
lsoenzyme Rise After Percutaneous Coronary Intervention 
Stephen G. Ellis, Russell E. Raymond, Irving France, Patrick L. Whitlow, Jakob P. 
Schneider, Eric J. Topol. The Cleveland Clinic Foundation, Cleveland, OH 
Recently, from a” observational study of 1,675 patients (pts) characterized by large dif- 
ferences in the nature of pts treated with or without beta blockers (BB) and Rotablator 
treatment in the majority, Sharma concluded that BB decrease the incidence of creatinine 
kinase isoenzyme (CK-MB) rise after percutaneous coronary intervention (PCI). We 
sought to verify this finding in a larger study of pts more representative of contemporary 
therapy in the year 2000. Consecutive pts, excluding those presenting with acute MI, 
from l/97-12/99 were studied. CK-MB ware routinely collected 6-8 hours after and the 
morning after PCI. CK-MB were available in 95.2% of the pts. 
BB No BB P value 
Patients 2,926 3,274 
Age (yrs) 63111 64?11 <.OOl 
Male gender (%) 68.5 73.2 c.001 
Diabetes/insulin (%) 10.2 12.4 ,005 
stent (%) 69.5 72.4 .Ol 
Atherectomy (any type) (%) 17.4 16.5 .29 
CK-MB >normal (%) 13.3 13.0 .60 
CK-MB (mean SD) 9.5k25.1 9.0+ 24.6 .25 
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After adjustment for the baseline imbalances between patients treated with and without 
BB using a propensity score there remained no difference in the incidence of CK-MB rise 
between the two groups. Conclusion: These data, although limited by their observational 
nature, do not support the contention that BB decrease CK-MB rise after PCI. 
885-3 
11 :oo a.m. 
Bailout Platelet GP Ilb/llla Inhibition in Coronary Stem 
Implantation: Observations From the ESPRIT Trial 
Warren J. Cantor, Anne S Hellkamp, J. Conor O’Shea, Mina Madan, Robert J. Chisholm, 
Todd J. Lorenz, Mrchael M. Kitt, Henry Lui, David J. Cohen, Robert Feldman, Robert 
Greene, James E. Tcheng. Duke Clinical Research Institute, Durham, NC 
Background: In clinical practice. GP Ilb/llla inhibitors are often reserved as ‘“bailout” 
treatment for thrombotic complications, rather than being used as a pre-treatment. This 
bailout strategy has not been prospectively evaluated. We identified the characteristics & 
outcomes of patients requiring bailout treatment, and compared this strategy to prophy- 
lactic use of GP llbillla inhibitors. 
Methods: The ESPRIT trial randomized 2064 patients (pts) to receive aptifibatide or pla- 
cebo starting immediately prior to percutaneous coronary intervention (PCI). Bailout kits 
contained eptifibatide for pts randomized to placebo and placebo for pts randomized to 
eptifibatide, and could be used in blinded fashion when complications occurred during 
study drug infusion. 
Results: Bailout therapy was used in 77 pts: 43 (4.2%) randomized to placebo and 34 
(3.3%) of pts randomized to eptifibatide (p=O.3). Bailout was started for thrombotic com- 
plications in 32 (42%) pts. Baseline characteristics and procedural data are listed in table. 
Compared to pts treated prophylactically with eptifibatide 8 matched for baseline charac- 
teristics, bailout eptifibatide was associated with higher rates of MI (30% vs 7%, p=O.Oi) 
& urgent PCI (14% vs O%, p=O.O3) at 48 hours. These differences remained significant at 
30 days.The rates of Ml & urgent PCI for patients pretreated with eptifibatide and receiv- 
ing placebo bailout were 21% and 0% respectively. 
Conclusions: Complications requiring bailout are more likely to occur in pts with vary 
stenotic or thrombotic lesions, and in pts not pre-treated with ASA. Pts experiencing such 
complications have poor clinical outcomes despite bailout use of GP Ilb/llla inhibitors. 
Any Bailout No Bailout p-value 
(n=77) (n=1,987) 
Stable Angina 31 (40%) 763 (38%) 0.7 
ASA before procedure 74 (96%) 1972 (99%) 0.025 
Ticlopidine or Clopidogrsl before procedure 41 (53%) 1072 (54%) 0.9 
Initial Heparin Dose 4600 5000 0.3 
Thrombus prior to intervention 15 (20%) 81 (4%) 0.001 
Diameter stenosis t 90% 64 (83%) 1326 (67%) 0.002 
Multiple stents used 42 (55%) 614 (31%) 0.001 
885-4 
1 I:15 a.m. 
Effect of Glycoprotein llblllla Receptor inhibition on In-Lab 
Adverse Events and Subsequent CK-MB Elevation During 
Percutanous Coronary Intervention in ESPRIT 
Fouad A. Bachour, James C. Blankenship, Elias A. Iliadis, Gudaye Tasissa, J C. O’Shea, 
Michael M. Kitt, Todd J. Lorenz, James E. Tcheng.GeisingerMedica/ Center, Danville, 
PA, Duke Clinical Research Institute, Durham, NC 
Background: In ESPRIT, eptifibatide during coronary intervention decreased ischemic 
endpoints by 43% at 48 hours (compared to placebo). The mechanism for this effect has 
not been determined. We hypothesized those decreased in-lab adverse events and sub- 
sequent CK-MB elevations could explain the beneficial effects of eptifibatide. 
Methods: 2062 patients in ESPRIT were analyzed (n=1039 eptifibatide, n=1023 pla- 
cebo). In-lab adverse events (major dissection, distal embolization, residual thrombus, 
abrupt closure, residual stenosis >50%, and side branch occlusion) were prospectively 
recorded by the operator. In 1882 patients (n=939 eptifibatide, n=943 placebo) CK-MB 
levels ware measured after the procedure and every 6 hours for 24 hours. 
Results: The incidence of in-lab adverse events was nonsignificantly lower for eptifi- 
batide than for the placebo group (10.1% vs 12.2% in placebo, p=O.13). In patients with 
in-lab adverse events, CK-MB levels over 3 times normal upper limits occurred with simi- 
lar frequency in eptifibatide (21%) and placebo (22%) patients (p=O.90). In patients with- 
out in-lab adverse events the incidence of CK-MB levels over 3 times normal upper limits 
was lower in eptifibatide (4%) than placebo (7%) patients, (p=O.O03). Patients with in-lab 
adverse events had a higher incidence of clinical ischemic end points at 48 hours (26% 
vs 5% for patients without in-lab adverse events, p=O.OOi). This association persisted at 
30 days. 
Conclusion: In ESPRIT, the reduction in ischemic endpoint events observed with eptifi- 
batide can not be explained by reductions in in-lab adverse events or subsequent CK-MB 
elevations. In patients without in-lab adverse events, eptifibitide significantly decreased 
the incidence of CK-MB elevations. This may be due to prevention of angiographically 
invisible adverse microvascular affects. 
885-5 
II:30 a.m. 
Comparson of Abciximab and Small Molecule Platelet 
Glycoprotein llb/llla Inhibitors in Percutaneous Coronary 
Intervention: A Quantitative Review 
David L. Brown, Cathy SJ Fan”, Chee J Chang. Albert Einstein Colege of Medicine/ 
Montetiore Medical Center, Bronx, NY 
.Background: Three platelet glycoprotein Ilb/llla inhibitors (GPI) have been evaluated in 
randomized clinical trials of patients undergoing percutaneous coronary intervention 
(PCI). Abciximab, a monOclonal antibody, is structurally and pharmacologically quite dif- 
ferent than the small molecule inhibitors @MI), eptifibatide and tirofiban. We conducted a 
meta-analysis to determine whether treatment by the two GPI classes (abciximab vs. 
SMI) was associated with different clinical outcomes. Methods: Prospective, placebo- 
controlled, randomized trials reporting 30.day outcomes following GPI treatment during 
PCI were identified. Odds ratios (OR) were calculated for each study and a random 
effects model was used to combine the individual components of composite outcomes 
used in the studies. Results: Of the 14,644 patients analyzed, 8876 were assigned to 
receive active treatment with a GPI and 5768 received placebo. Of the GPI-treated 
patients, 5022 (57%) received abciximab and 3854 (43%) were treated with a SMI. Mor- 
tality at 30 days was not reduced by either abciximab (OR 0.69, 95% Cl: 0.4-I .9) or SMI 
(OR 0.74, 95% Cl: 0.4-1.3). The incidence of myocardial infarction (Ml) was reduced from 
8.5% in placebo-treated patients to 4.3% in abciximab-treated patients (OR 0.49, 95% 
Cl: 0.4-0.6). Ml was not reduced by treatment with SMI (OR 0.85, 95% Cl: 0.7-1.04). 
Urgent revascularization was reduced from 6.2% in placebo-treated patients to 2.7% in 
patients treated with abciximab (OR 0.42, 95% Cl: 0.34-0.53). Likewise, SMI reduced the 
rate of urgent revascularization from 5.5% in placebo-treated patients to 4.2% (OR 0.76, 
95% Cl: 0.6-0.9). Abciximab-treated pataints experienced a major bleeding rate of 5.5% 
compared to 4.4% in placebo-treated patients (OR 1.53, 95% Cl: 1.24-1.90). Patients 
treated with SMI did not experience an increase in major bleeding (OR 1.19, 95%CI: 
0.94-1.52). Conclusion: In the setting of PCI, significant differences appear to exist 
between the clinical outcomes achieved by abciximab and those achieved by SMI. 
885-6 
II:45 a.m. 
Daily Aspirin Does Not Guarantee Complete Inhibition of 
Platelet Function and Activation During Coronary 
Angioplasty: The Effect of an Additional Bolus of High-Dose 
Aspirin 
Jurrien M. ten Berg, Wim 8. M. Gerritsen, Fred J. L. M. Haas, Johannes C. Kelder, Freek 
W. A. Varheugt, Thijs(H) W. M. Plokker. St. Antonius t-tospital, Nieuwegein, The 
Netherlands 
Background: Platelet activation plays a major role in acute vessel closure after coronary 
angioplasty. Aspirin pretreatment reduces acute closure, but many patients do not 
respond to chronic aspirin treatment. In vitro studies showed that in normal subjects this 
unresponsiveness can be partly overcome by an additional high-dose bolus of aspirin. 
For patients undergoing coronary angioplasty this effect is unknown. Methods and 
Results: First the effect of contrast agent during coronary angiography on platelet func- 
tion and activation was studied in 6 control patients treated with 100 mg aspirin/ day. 
Then, 51 angioplasty patients ware randomized to 100 mg aspirin/day (group A, “~24) or 
to 100 mg aspirin/day plus 1000 mg aspirin given 1 day prior to angioplasty (group B, 
n=27). The operator was blinded for the medication. Platelet response tests ware per- 
formed just before and 2 hours after angioplasty. Platelet function was measured by 
means of collageniepinephrine and collagen/ADP induced aggregation on the PFA- 
100TM analyzer. Based on collagenlepinephrine results, patients ware classified as 
responders to aspirin. Platelet activation status was measured by flow cytometry with 
CD62p and CD63 monoclonal antibodies. In the control group angiography did not affect 
platelet function or activation. At baseline, group A had significantly more activated plate- 
lets than group B (p<O.OOl). Moreover, high-dose aspirin resulted in almost complete 
absence of activated platelets. After angioplasty there was a significant decrease in the 
number of activated platelets in group A, and no change in group 8. Additional high-dose 
aspirin did not lead to a more extensive inhibition of platelet function before angioplasty. 
Conclusion: In patients undergoing coronary angioplasty, an high-dose bolus of 1000 
mg aspirin the day before intervention in addition to daily100 mg aspirin results in a sig- 
nificant lower platelet activation before and after angioplasty than daily 100 mg aspirin 
alone. 
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337-t 
IO:30 a.m. 
lntracoronary Stenting and Angiographic Results: Strut 
Thickness Effect on Restenosis Outcome (ISA&STEREO) 
Trial 
Adnan Kastrati, Julinda Mehiili, Josef Dirschinger, Franz Dotzer, Franz-Josef Neumann, 
He!mut Schuhlen, Martin Fleckenstein, Conrad Pfafferott, Albert Schomig. Deutsches 
Herzzentrum & 1. Med. Klimk rechts der Isar, Munich, GermanN Medizinische Klinik I, 
Garmisch-Partenkirchen, Germany 
Background: The greater coronary lumen gain provided by stenting is not rarely offset 
by increased thrombogenicity and smooth muscle cell proliferative response induced by 
the metal struts. Therefore, it is reasonable to hypothesize that reducing the metal burden 
Of the stent may enhance its advantages. The objective of this randomized, multicenter 
study was to assess whether thinner-strut coronary stems are associated with improved 
follow-up angiographic and clinical results. 
Meihods: A total of 651 patients (pts) with coronary lesions situated in native vessels of 
> 2.8 mm in size were enrolled and randomly assigned to receive either the thin-strut 
MULTI-LINK stem (strut thickness of 0.05 mm), 326 pts, or the thick-strut MULTI-LINK 
DUET stem (strut thickness of 0.14 mm), 325 pts. The protocol included routine rean- 
giography at 6 months and l-year clinical follow-up. Primary end point of the study was 
angiographic restenosis (250% diameter stenosis, DS). Secondary end points were the 
incidence of reinterventions (TVR) due to restenosis-induced ischemia and the combined 
rate of death and myocardial infarctions (Ml) at 1 year. 
Results: There were no significant differences in baseline characteristics. Half of the pts 
in both groups received abciximab. The thin-strut pts had a less favorable final angio- 
graphic result (DS post, 5.7% vs 4.0% in the thick strut group, P=O.O3). Nonetheless, the 
follow-up results were significantly in favor of the thin-strut device (Table), with a 42% 
reduction of the primary end point (RR, 0.58 [95% Cl, 0.39-0.871). 
Thin strut Thick strut P 
Early angiographic stent occlusion, % 0.3 0.6 0.99 
Postprocedural CK elevation +3x), % 3.1 2.8 0.82 
l-year combined rate of death and MI, % 6.4 6.2 0.88 
TVR due to resrenosis-induced ischemia, % 8.6 13.8 0.03 
Late lumen loss, mm 0.94f0.74 1,17i-0.78 0.001 
Angiographic restenosis (~50% DS), % 15.0 25.8 0.003 
Conclusion: The use of a thinner-strut device is associated with a significant reduction 
of angiographic and clinical restenosis after coronary artery stenting. These finding may 
have relevant implications for the strategies aimed at improving the long-term results of 
the percutaneous coronary Interventions. 
887-2 
IO:45 a.m. 
Fractional flow Reserve Compared to Intravascular 
Ultrasound Guidance for Optimal Stent Deployment: Final 
Results of the FUSION Study 
William F. Fearon, Atsushi Takagi, Jorge Luna, Allen Jeremias, Habib Samady, Eric R 
Powers, Ted Feldman, Nabil Dib, E. Murat Tuzcu, Michael W. Cleman, Tony M. Chou, 
David J. Cohen, Alan C. Yeung, Morton J. Kern. Paul G. Yock. Sianford University 
Medical Center, Stanford, CA 
Background: Intravascular ultrasound (IVUS) is the current gold standard method for 
high resolution, anatomrc assessment of stent deployment. Measuring fractional flow 
reserve (FFR) with a coronary pressure wire is a physiologic method of assessing flow 
obstruction that is simpler to perform and interpret, In this prospective, multi-center trial, 
we evaluated measuring FFR to optimize stenting by comparing it to standard IVUS crite- 
ria. 
Methods: Stable patients underwent coronary stent deployment starting at 10 atmo- 
spheres: and increased serially by 2 atmospheres, until the FFR was 2 0.94 or 16 atmo- 
spheres was achieved. IVUS was then performed. The diagnostic characterrstics of a 
FFR 2 0.94 to predict an optimal stent result based on standard IVUS criteria (mean stem 
area > 7 mm2 and/or % area expansion 2 90) were calculated, 
Results: Target enrollment of 100 patients will be completed by the presentation. To 
date. in the 69 patients analyzed, the sensitivity, specificity and predictive accuracy of a 
FFR 2 0.94 to predict optimal stent deployment based on standard IVUS criteria were 
75%, 31%, and 46%. respectively. By increasing the cutoff defining an optimal FFR to > 
0.96, the sensitivity specificity and predictive accuracy of FFR improved to 67%, 64% 
and 65% respectively (~~0.04 for comparison of predictive accuracy). The negative pre- 
dictive value of FFR at this cutoff was 78%. Using less stringent IVUS criteria to define 
optimal stent deployment drd not alter these results. Significantly higher sensitivity and 
specrfici!y were achieved with larger doses of intracoronary adenosine (>30 ugs). 
Subopti- Opiimal IVUS 
mal IVUS 
FFR CO.94 14 6 SWlS spec NPV PPV PA 
FFR>O94 31 18 75% 31% 70% 37% 46% 
Subopti- Optimal IVUS 
mal IVUS 
FFR co.96 29 8 St?llS Spec NPV PPV PA 
FFR 20.96 16 16 67% 64% 78% 50% 65% 
Conausrons: I nese oata suggest that a mgner cutott value ot b u.90 can srgnrrrcanrty 
improve the ability of fractional flow reserve to predict an optimal stent result based on 
standard IVUS criteria. A fractional flow reserve of < 0.96 is a useful predictor of a subop- 
timal stent result and defines the need for additional effort to maximize stem expansion. 
11 :oo a.m. 
887-3 Initial Experience With Intravascular Sonotherapy for 
Prevention of In-Stent Restenosis; Safety and Feasibility 
Attila Thury, George Sianos, Ken Kozuma, Arie M. H. Knook, Alexander J. Wardeh, 
Evelyn Regar, Stephane G. Carlier, Willem J. van der Giessen, David P Foley, Patrick W. 
Serruys. Thoraxcenter, Rotter&m, The Netherlands 
Background: Restenosis after coronary stem implantatron remains unresolved and 
results primarily from neointimal hyperplasia. In porcine model, intravascular sonother- 
apy (IST) has been shown to reduce neointimal hyperplasia within stem by 50% without 
hampering re-endothelialization. The aim of this study was to assess the feasibility and 
the procedural and in-hospital complications of this novel therapy. 
Methods: Twenty-nine consecutive patients underwent IST with the 5F PharmaSonics 
URxTM lnravascular Sonotherapy Catheter, which consists of 3 ultrasound transducers. 
24 (1 bifurcation) de nova lesions in native vessel (< 4.0mm) followed by stenting, 3 in- 
stem restenotic lesions, and 2 restenosis after brachytherapy were treated at the end of 
the procedure. Pre- and post-procedural quantitative coronary angiography and post-pro- 
cedural 3D-IVUS analysis was performed. B-month clinical, angiographic and IVUS fol- 
low-up is scheduled. 
Results: Patients had mean age 57 f 9 years, 68% were males, 37% hypertensive, 11% 
diabetics. 26% of patients had prior myocardial infarction, 42% history of smoking, 13% 
of CABG, 53% presented unstable angina. Reference diameter was 3.27 i 0.37 mm, pre- 
procedural diameter stenosis (DS) 72.1 ? 10.5% the total length of the stented segment 
20.4 i 7.5 mm, 52% of patients received GPllb/llla blocker. Final DS was 11.3 r 3.2%, 
SD-n/US stent volume 127 f 52 mms, total vessel volume 282 i 182, mm3. IST was per- 
formed in 2.14 t 0.38 sequential activation (for max. 300 set each) per vessel to cover 
the stented area and 2-mm edges on both sides. Total dwelling time was 612 * 110 sac 
and total average procedure time 84 i 33 min. There were 3 treatment failures; 1 lesion 
could not have been crossed with the catheter, 1 instrument malfunction and 1 interrup- 
tion of IST due to severe angina. Therefore, IST delivery success rate was 90%. During 
hospital stay there was no death, myocardial infarction or repeat intervention. 
Conclusion: lntracoronary sonotherapy is safe and feasible with high acute procedural 
success. No major sonotherapy-induced in-hospital complication was observed. B-month 
clinical, angiographic and IVUS follow-up will be presented. 
887-4 
11:15 a.m. 
Noninvasive Re-expansion of Implanted Nitinol Stents In 
Vivo. A New Noninvasive Method to Treat Stent Recoil, 
Using Fast Alternating Magnetic Fields 
Leonidas D. Diamantopoulos, Glenn Van Langenhove, David Folley, Pim De Feyter, 
Patrick W. Serruys. Interventional Cardiology Dept, THORAXCENTER, ROTTERDAM, 
The Netherlands 
Today, the only way to treat stem recoil 
is post-stem dilatation with balloon. 
Heating of nitinol stents is well known to 
increase their diameter. Methods: To 
heat the nitinol stents in viva we used a 
new method based on the capabilities of 
metals when placed inside an alternat- 
ing magnetic field. Due to metallic stent 
retentivity, as the magnetizing force peri- 
odically changes. magnetic flux inside 
the stent lags behind. Thus, a reverse 
force is necessary to overcome the 
residual magnetism retained by the stent. The result is a power loss to the magnetic cir- 
cuit, which appears as heat in the metallic stem. Human and animal tissues are immune 
to hysteresis effects and losses, so they remain totally unheated. We constructed a high 
frequency alternating magnetic field generator, power-controlled by a PC computer with 
appropriate software. In a series of in-vitro tests we managed to heat several stents of 
the market in a human coronary artery model.Fresh pork meat was placed around the 
arterial model. 3 Nitinol stems were placed in the coronary artery and were optimized by 
balloon inflation to a final diameter of 3.0, 3.5 and 4mm respectively. Then, manually we 
caused a significant reduction of diameter (recoil) in the center of each stent. Stents were 
then heated using our method to 470C for 30 seconds. All stents increased their diame- 
ters automatically to a maximu,m diameter of 4.0mm while the surrounding meat 
remained totally unheated. The histology of the unheated meat showed no evidence of 
thermal damages. By adjusting the stent temperature and heating time, it was easy to re- 
expand nitinol stents to almost any diameter in between. Conclusions: This non-inva- 
sive method, that uses magnetic energy to heat nitinol stents from a distance, is feasible 
and safe and may be used in the future after coronary stenting with the aim to re-expand 
recoiled nitinol stems. 
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887-5 The Effect of Overlapped P-Emitter by Manual Stepping for 
Diffuse In-Stent Restenosis Lesions: Angiographic and 
IVUS Analysis 
Han-So0 Kim, Ron Waksman, B.&am Bhargava, Chrysoula K. Pappas, Andrew E. Ajani, 
Rosanna C. Ghan, Anh B. Bui, Fi. Lawrence White, Lowell F. Satler, August0 D. Pichard, 
Gary S. Mintz, Petros Okubagzi, Michael Porrazzo, Kenneth M. Kent. Washington 
Hospital Center, Washington, DC 
Background: lntracoronary p radiation has demonstrated effectiveness for the treatment 
of in-stem restenosis (ISR). Longer lesions require stepping of p sources for adequate 
coverage of the lesion and its margins. 
Methods: The effect of overlapping a p emitter by manual stepping on the treated seg- 
ment was evaluated in 16150 patients with diffuse ISR in native coronaries who were 
enrolled in the BETA WRIST (Beta Washington Radiation for In-stent Restenosis Trial). 
Following interventional procedures, a “Y 0.014 wire source (29 mm in length) was auto- 
matically loaded into a centering balloon catheter to deliver a dose of 20.6 Gy prescribed 
at 1 mm from the surface of the balloon. To cover lesions 225 mm and its edges, the radi- 
ation catheter was positioned in 2 steps with an overlap of up to 3 mm in the middle of the 
stented segment. The calculated dose at the overlapped area did not exceed 70 Gy to 
the vessel wall. Serial (post radiation vs. follow-up) of IVUS measurement of stent lumen, 
cross sectional area (GSA) and intimal hyperplasia (IH) and QCA measurement of mini- 
mum lumen diameter (MLD) were used to assess the impact of overlapped irradiated 
segments vs. adjacent treatment areas. 
Results: Mean lesion length was longer in patients with stepping (22.3*11 .l vs 15.3+6.4 
mm, p=O.O4) than without stepping. There was no differences in late total occlusion 
(12.5% vs 11.8%, p=NS) and target lesion revascularization (31.3% vs 26.5%, p=NS) 
between patients with stepping and those without stepping. At 6 months, there was no 
evidence of oerforation or aneurvsm at the overlaooed seoments. Anoioaraohic and 
IVUS results are shown in the tabi (Table). - 
1- 
QCA and IVUS Overlapped seg- Adjacent seg- p value 
ment ment 
QCA results 
Post intervention MLD 
Follow-up MLD 
Late loss (mm) 
2.34r0.75 2.3730.89 0.94 
2.37AO.69 2.02r0.71 0.32 
-0.03eO.28 0.36+0.41 0.04 
IVUS results 
AMean stent CSA 0.13~1.11 0.01*0.96 0.80 
AMean lumen CSA 0.32*0.92 -1.86e0.74 0.006 
AMean IH CSA -0.45+0.57 1.87r0.83 0.004 
Conclusion: Manual stepping and overlapped p-emitters for diffuse ISR is safe and 
associated with further increase in lumen dimension and a reduction in intimal hyperpla- 
sia formation at the overlapped segment. 
887-6 
II:45 a.m. 
Local Drug Delivery of Intramural Ethyl Alcohol for 
Treatment of Diffuse In-Stent Restenosis: The Beaumont 
Alcohol Restenosis Study (BARS) 
John A. Fry, Michael J. Curran, Theodore L. Schreiber, Cindy L. Grines, Steven L. 
Almany, Terry Fi. Bowers, Robert D. Safian, Harold Z. Friedman, William W. ONeill. 
William Beaumont Hospital, Royal Oak, MI 
Background: Diffuse in-stent restenosis (ISR) has a high rate of recurrence despite 
treatment with conventional interventional modalities. Preliminary data show that local 
delivery of dilute ethanol (ETOH) may attenuate the proliferative response of smooth 
muscle cells and reduce neointimal hyperplasia. In this phase 1 study, we evaluated the 
safety and efficacy of intramural ETOH following optimal conventional treatment of diffuse 
ISR. Methods: Patients presenting with clinical evidence of ischemia and diffuse in-stent 
restenosis (reference vessel diameter 2.5-4.0 mm, lesion length < 45mm) were enrolled. 
Coronary intervention was performed using standard techniques. Following PCI, 15 % 
ETOH was delivered using the lnfiltratorTM (Interventional Technologies, San Diego, CA) 
local drug delivery catheter. Results: Thirty-seven patients (30males, 7 females) were 
studied. Vessels treated included LAD (7), LCX (5), Diagonal (I), RCA (I@, and SVG (6). 
Sixty-two percent had undergone at least one prior treatment for ISR. PCI included PTCA 
only (35.1%), rotational atherectomy (40.5%), excimer laser (17.1%), cutting balloon 
(8.1%), and re-stent (5.4%). Procedural success was 100%. Two patients developed type 
B dissection following delivery of the Infiltrator catheter, which were successfully treated 
with additional stent placement. Transient no-reflow developed in one patient following 
ETOH delivery. There were no other procedural complications or major adverse in hospi- 
tal cardiac even@ One patient had a significant post-procedure CK elevation with no MB 
release related to multiple countershocks given for ventricular fibrillation that developed 
following rotational atherectomy. To date, 3 TLR and 4 TVR have occurred within 3 
months of treatment. Conclusions: Local drug delivery with intramural ETOH using the 
Infiltrator catheter in patients with diffuse ISR is safe a’nd feasible. Prelimary findings indi- 
cate that this treatment may be an effective strategy to prevent recurrent ISR. TVR and 
completed angiographic follow-up will be presented. 
al Cardiology) JACC February 2001 
